Clustering O 0 0.0005386110278777778
of O 0 2.0634988686651923e-05
missense O 0 0.0005706620868295431
mutations O 0 0.0001417442545061931
in O 0 4.603642082656734e-06
the O 0 1.8559037926024757e-05
ataxia B-Disease 1 0.9999984502792358
- I-Disease 1 0.9994733929634094
telangiectasia I-Disease 1 0.999944806098938
gene O 0 1.818932287278585e-05
in O 0 1.811579522836837e-06
a O 0 5.0938215281348675e-06
sporadic B-Disease 0 0.0005492875352501869
T I-Disease 1 0.9996028542518616
- I-Disease 1 0.8613963723182678
cell I-Disease 0 0.24857568740844727
leukaemia I-Disease 1 0.9979119896888733
. O 0 0.0001466199173592031

Ataxia B-Disease 1 0.9999994039535522
- I-Disease 1 0.9999982118606567
telangiectasia I-Disease 1 0.9999991655349731
( O 0 0.003991409670561552
A B-Disease 1 0.985721230506897
- I-Disease 1 0.9999932050704956
T I-Disease 1 0.9999971389770508
) O 0 1.2907059954159195e-06
is O 0 2.7832643922920397e-07
a O 0 1.330319150838477e-06
recessive B-Disease 0 0.030621062964200974
multi I-Disease 1 0.9776046872138977
- I-Disease 1 0.9995799660682678
system I-Disease 0 0.04794316738843918
disorder I-Disease 0 0.015950167551636696
caused O 0 3.982406269642524e-06
by O 0 6.796035449951887e-07
mutations O 0 3.525412466842681e-06
in O 0 1.66202653417713e-07
the O 0 3.575281652956619e-07
ATM O 0 9.211163160216529e-06
gene O 0 4.178211838734569e-06
at O 0 1.407103013661981e-06
11q22 O 0 5.809282447444275e-05
- O 0 0.00015745728160254657
q23 O 0 5.9329096984583884e-05
( O 0 2.5223814645869425e-06
ref O 0 8.453425107290968e-05
. O 0 1.8676059880817775e-06
3 O 0 4.476323738344945e-06
) O 0 6.172871053422568e-06
. O 0 1.850909029599279e-05

The O 0 7.06987120793201e-05
risk O 0 0.00011499487300170586
of O 0 3.6560097669280367e-06
cancer B-Disease 0 0.009006130509078503
, O 0 1.1884646937687648e-06
especially O 0 2.1013156583649106e-06
lymphoid B-Disease 0 0.0023027074057608843
neoplasias I-Disease 0 0.02539503388106823
, O 0 8.262585993179528e-07
is O 0 1.9887185942479846e-07
substantially O 0 2.291364808115759e-06
elevated O 0 9.160599802271463e-06
in O 0 1.9800938844127813e-06
A B-Disease 1 0.9941369295120239
- I-Disease 1 0.9999994039535522
T I-Disease 1 1.0
patients O 0 0.02749018743634224
and O 0 1.2394406212479225e-06
has O 0 1.1633655958576128e-06
long O 0 8.788343620835803e-06
been O 0 2.3527916255261516e-06
associated O 0 7.451363671862055e-06
with O 0 1.2876943401352037e-05
chromosomal O 1 0.9996824264526367
instability O 1 0.9736035466194153
. O 0 0.0001260672288481146

By O 0 9.347479499410838e-05
analysing O 0 0.001026054611429572
tumour B-Disease 1 0.9999470710754395
DNA O 0 0.00012375539517961442
from O 0 6.383496383932652e-06
patients O 0 2.1479785573319532e-05
with O 0 1.3184870795157622e-06
sporadic B-Disease 0 0.0001873233268270269
T I-Disease 1 0.9985201954841614
- I-Disease 1 0.5507891178131104
cell I-Disease 0 0.014455247670412064
prolymphocytic I-Disease 1 0.9081427454948425
leukaemia I-Disease 1 0.9997337460517883
( O 0 1.1614406503213104e-05
T B-Disease 0 0.2960622012615204
- I-Disease 0 0.0003810377384070307
PLL I-Disease 0 0.000942311598919332
) O 0 6.633491693719407e-07
, O 0 2.4138054754985205e-07
a O 0 4.559381068247603e-07
rare O 0 2.6198315481451573e-06
clonal B-Disease 0 6.318260420812294e-05
malignancy I-Disease 0 0.004334287252277136
with O 0 4.1487641055937274e-07
similarities O 0 2.0709808268293273e-06
to O 0 6.396235789907223e-07
a O 0 1.4507036212307867e-06
mature B-Disease 0 2.7712590963346884e-05
T I-Disease 1 0.5340777039527893
- I-Disease 0 0.014240031130611897
cell I-Disease 0 0.0005021521355956793
leukaemia I-Disease 0 0.4225253164768219
seen O 0 2.4279449917230522e-06
in O 0 8.123648171931563e-07
A B-Disease 0 0.19660118222236633
- I-Disease 1 0.9988970756530762
T I-Disease 1 0.9998190999031067
, O 0 3.3501120810797147e-07
we O 0 1.840246426354497e-07
demonstrate O 0 3.562966810477519e-07
a O 0 2.0021803948111483e-07
high O 0 4.2021255808322167e-07
frequency O 0 8.308177825711027e-07
of O 0 2.846578581738868e-07
ATM O 0 3.156906313961372e-05
mutations O 0 1.810060530260671e-05
in O 0 5.4653187362418976e-06
T B-Disease 0 0.3210380971431732
- I-Disease 0 0.001335968030616641
PLL I-Disease 0 0.007358542177826166
. O 0 8.557059481972829e-05

In O 0 3.912516694981605e-05
marked O 0 2.1838724933331832e-05
contrast O 0 1.3770470104645938e-05
to O 0 1.1107140380772762e-06
the O 0 1.3137075711711077e-06
ATM O 0 1.3198332453612238e-05
mutation O 0 7.418605946440948e-06
pattern O 0 2.9102416192472447e-06
in O 0 1.4874972293910105e-06
A B-Disease 1 0.9531391263008118
- I-Disease 1 0.9999731779098511
T I-Disease 1 0.999961256980896
, O 0 2.9265382295307063e-07
the O 0 1.6487875598159007e-07
most O 0 2.1052301235613413e-07
frequent O 0 7.956637091410812e-07
nucleotide O 0 2.1966225176583976e-06
changes O 0 9.655150279286318e-07
in O 0 6.879706688778242e-07
this O 0 2.351831426494755e-06
leukaemia B-Disease 1 0.9910795092582703
were O 0 1.153028915723553e-05
missense O 0 0.0003560611221473664
mutations O 0 0.0002473002823535353
. O 0 5.8351102779852226e-05

These O 0 2.4644894438097253e-05
clustered O 0 3.3812331821536645e-05
in O 0 1.6875733308552299e-06
the O 0 6.567517516486987e-07
region O 0 6.681751756332233e-07
corresponding O 0 4.595065945522947e-07
to O 0 1.5381645823708823e-07
the O 0 1.8978511207023985e-07
kinase O 0 1.966439413081389e-06
domain O 0 3.7849028444725263e-07
, O 0 1.3366481255161489e-07
which O 0 7.494042364442066e-08
is O 0 7.477650854070816e-08
highly O 0 1.8509726373849844e-07
conserved O 0 2.514925370178389e-07
in O 0 1.717400408551839e-07
ATM O 0 7.152185844461201e-06
- O 0 4.800062924914528e-06
related O 0 4.6854768243065337e-07
proteins O 0 4.787641501025064e-07
in O 0 2.8675506769104686e-07
mouse O 0 1.0026163181464653e-05
, O 0 1.295348624807957e-06
yeast O 0 2.2048492610338144e-05
and O 0 7.972838830028195e-06
Drosophila O 0 7.805041968822479e-05
. O 0 7.33692868379876e-05

The O 0 4.2446827137609944e-05
resulting O 0 4.612919656210579e-05
amino O 0 2.376841803197749e-05
- O 0 2.693981514312327e-05
acid O 0 4.6003942770767026e-06
substitutions O 0 1.8022656149696559e-06
are O 0 1.9145028318234836e-07
predicted O 0 2.3070206225384027e-06
to O 0 2.885978744870954e-07
interfere O 0 2.121611260008649e-06
with O 0 6.417945428438543e-07
ATP O 0 1.4881319657433778e-05
binding O 0 6.7564092205429915e-06
or O 0 4.872254976362456e-06
substrate O 0 4.647652167477645e-05
recognition O 0 3.185706736985594e-05
. O 0 4.042267028125934e-05

Two O 0 1.805621104722377e-05
of O 0 4.239579084241996e-06
seventeen O 0 2.274197140650358e-05
mutated O 0 0.00021593541896436363
T B-Disease 0 0.02358321100473404
- I-Disease 0 3.156120874336921e-05
PLL I-Disease 0 0.00010760536679299548
samples O 0 3.219490736228181e-06
had O 0 8.399332500630408e-07
a O 0 6.899331879139936e-07
previously O 0 8.407952009292785e-06
reported O 0 8.080565748969093e-05
A B-Disease 1 0.9210305213928223
- I-Disease 1 0.9997252821922302
T I-Disease 1 0.9999580383300781
allele O 0 0.0006670410512015224
. O 0 6.806195597164333e-05

In O 0 3.12378178932704e-05
contrast O 0 3.214840398868546e-05
, O 0 3.189188873875537e-06
no O 0 1.2462916174627026e-06
mutations O 0 4.04301363232662e-06
were O 0 4.838951213059772e-07
detected O 0 1.0929570635198615e-06
in O 0 1.7054856016329722e-07
the O 0 3.310469480766187e-07
p53 O 0 2.882426997530274e-06
gene O 0 2.5212366381310858e-06
, O 0 3.0604635981035244e-07
suggesting O 0 1.3353094345802674e-06
that O 0 2.3449283048648795e-07
this O 0 1.3277866628413904e-06
tumour B-Disease 1 0.9999423027038574
suppressor O 0 0.00010991733142873272
is O 0 3.786354341173137e-07
not O 0 4.414238787830982e-07
frequently O 0 1.6596711702732136e-06
altered O 0 6.248064892133698e-06
in O 0 2.437679995637154e-06
this O 0 1.3693938853975851e-05
leukaemia B-Disease 1 0.9914583563804626
. O 0 8.75236073625274e-05

Occasional O 0 0.0006598997861146927
missense O 0 0.0013464514631778002
mutations O 0 0.00017139609553851187
in O 0 4.471758529689396e-06
ATM O 0 3.0055422030272894e-05
were O 0 1.405512421115418e-06
also O 0 5.114091550240119e-07
found O 0 7.164058501984982e-07
in O 0 1.3671631222678116e-06
tumour B-Disease 1 0.9999134540557861
DNA O 0 4.528760473476723e-05
from O 0 9.151240192295518e-07
patients O 0 4.1259322642872576e-06
with O 0 4.645362139399367e-07
B B-Disease 0 0.001079411362297833
- I-Disease 0 0.004671545699238777
cell I-Disease 0 0.00011632383393589407
non I-Disease 0 1.2894416613562498e-05
- I-Disease 1 0.611970067024231
Hodgkins I-Disease 1 0.9992503523826599
lymphomas I-Disease 0 0.4626954197883606
( O 0 8.497742101098993e-07
B B-Disease 0 3.2296788958774414e-06
- I-Disease 0 2.782252749966574e-06
NHL I-Disease 0 1.3974315606901655e-06
) O 0 1.5081116089277202e-07
and O 0 1.1515815856455447e-07
a O 0 4.6732091618650884e-07
B B-Disease 0 1.6837933799251914e-05
- I-Disease 0 1.909388811327517e-05
NHL I-Disease 0 1.3182104339648504e-05
cell O 0 4.35911315435078e-05
line O 0 4.6701239625690505e-05
. O 0 3.59039731847588e-05

The O 0 3.753902274183929e-05
evidence O 0 8.642864486319013e-06
of O 0 6.313131848401099e-07
a O 0 8.755590670261881e-07
significant O 0 9.005016750052164e-07
proportion O 0 1.238112758983334e-06
of O 0 1.93676001458698e-07
loss O 0 3.733705307240598e-05
- O 0 1.3707213838642929e-05
of O 0 2.3216041711293656e-07
- O 0 0.0001470685238018632
function O 0 7.939876809359703e-07
mutations O 0 1.3612175280286465e-06
and O 0 1.445934003641014e-07
a O 0 1.3692478262328223e-07
complete O 0 3.7372345218500413e-07
absence O 0 3.288167533810338e-07
of O 0 4.136992970416031e-08
the O 0 1.3989740921260818e-07
normal O 0 3.588809249777114e-07
copy O 0 4.0213461716120946e-07
of O 0 7.724941042397404e-08
ATM O 0 3.041039462914341e-06
in O 0 2.2259487764131336e-07
the O 0 1.859933291825655e-07
majority O 0 1.1123506737931166e-06
of O 0 3.8562163240385416e-07
mutated O 0 0.0009763700072653592
tumours B-Disease 1 0.9985905289649963
establishes O 0 4.597517090587644e-06
somatic O 0 8.735159099160228e-06
inactivation O 0 6.729876986355521e-06
of O 0 9.645325604878963e-08
this O 0 1.7060941104318772e-07
gene O 0 9.967493497242685e-07
in O 0 2.1438387420857907e-07
the O 0 4.426345583397051e-07
pathogenesis O 0 6.721307727275416e-06
of O 0 3.545537481386418e-07
sporadic B-Disease 0 8.103699656203389e-05
T I-Disease 1 0.9304783940315247
- I-Disease 0 0.00021516963897738606
PLL I-Disease 0 0.00019764075113926083
and O 0 5.311346171765763e-07
suggests O 0 1.267072320842999e-06
that O 0 2.0853879334481462e-07
ATM O 0 3.923634267266607e-06
acts O 0 1.0715832559071714e-06
as O 0 9.974320391847868e-07
a O 0 1.6721567590138875e-05
tumour B-Disease 1 0.9998804330825806
suppressor O 0 0.004277552478015423
. O 0 9.619813499739394e-05

As O 0 1.6330042853951454e-05
constitutional O 0 1.392928243149072e-05
DNA O 0 1.571030225022696e-05
was O 0 1.3996536836202722e-06
not O 0 3.786599904742616e-07
available O 0 3.6083639542994206e-07
, O 0 1.5104721740044624e-07
a O 0 4.243974274231732e-07
putative O 0 0.00027272035367786884
hereditary O 0 0.150939479470253
predisposition O 0 0.0007980071823112667
to O 0 4.791661012859549e-06
T B-Disease 0 0.18645046651363373
- I-Disease 0 1.787939436326269e-05
PLL I-Disease 0 4.097440614714287e-05
will O 0 4.5036074425297556e-07
require O 0 1.0840824415936368e-06
further O 0 1.0391054274805356e-06
investigation O 0 6.498357834061608e-06
. O 0 4.430659373610979e-06
. O 0 2.3451490051229484e-05

Myotonic B-Disease 1 0.9999890327453613
dystrophy I-Disease 1 0.9999936819076538
protein O 0 0.0011413785396143794
kinase O 0 0.0006152736605145037
is O 0 4.005089976999443e-06
involved O 0 2.6182428882748354e-06
in O 0 3.920332574125496e-07
the O 0 5.105144964545616e-07
modulation O 0 2.921512077591615e-06
of O 0 5.523531285689387e-07
the O 0 2.4666826448083157e-06
Ca2 O 0 0.00014086092414800078
+ O 0 6.754482456017286e-05
homeostasis O 0 0.00012074354890501127
in O 0 1.080793754226761e-05
skeletal O 0 0.011395221576094627
muscle O 0 0.02388944663107395
cells O 0 0.0006030784570612013
. O 0 6.656140612903982e-05

Myotonic B-Disease 1 0.9999990463256836
dystrophy I-Disease 1 0.9999998807907104
( O 1 0.644985020160675
DM B-Disease 1 0.9999997615814209
) O 0 1.560143027745653e-05
, O 0 7.020838097560045e-07
the O 0 5.535665081879415e-07
most O 0 9.495785775470722e-07
prevalent O 0 0.00015666773833800107
muscular B-Disease 1 0.9971729516983032
disorder I-Disease 1 0.8707011342048645
in O 0 3.83555561711546e-06
adults O 0 3.4856620914069936e-05
, O 0 3.9423366615665145e-07
is O 0 3.6896523170071305e-07
caused O 0 1.9681649519043276e-06
by O 0 5.02661976042873e-07
( O 0 8.658463457322796e-07
CTG O 0 1.4022833966009784e-05
) O 0 6.449396323660039e-07
n O 0 1.4230080296329106e-06
- O 0 2.6445470666658366e-06
repeat O 0 1.2017470680802944e-06
expansion O 0 1.0480356422704062e-06
in O 0 2.9581224225694314e-07
a O 0 5.715614292967075e-07
gene O 0 1.77718766281032e-06
encoding O 0 2.4841519916662946e-06
a O 0 1.2237676401127828e-06
protein O 0 4.321251253713854e-06
kinase O 0 1.9767918274737895e-05
( O 0 2.8283934625505935e-06
DM B-Disease 1 0.9695513844490051
protein O 0 3.811478791249101e-06
kinase O 0 1.1261637155257631e-05
; O 0 1.314599785473547e-06
DMPK O 0 3.240288424422033e-05
) O 0 3.8832376958453096e-07
and O 0 2.0455092908377992e-07
involves O 0 7.941732746985508e-07
changes O 0 9.336413882010675e-07
in O 0 7.04496301295876e-07
cytoarchitecture O 0 8.746320236241445e-05
and O 0 6.083803782530595e-06
ion O 0 0.00012556098226923496
homeostasis O 0 0.0007695748354308307
. O 0 6.846882024547085e-05

To O 0 2.457615119055845e-05
obtain O 0 1.7395892427884974e-05
clues O 0 7.877023563196417e-06
to O 0 4.7141799086602987e-07
the O 0 4.848300818593998e-07
normal O 0 1.8017689171756501e-06
biological O 0 7.919723543636792e-07
role O 0 3.6066643360754824e-07
of O 0 1.451582107847571e-07
DMPK O 0 2.8255191864445806e-05
in O 0 4.981774281986873e-07
cellular O 0 3.653597786978935e-06
ion O 0 5.526831955648959e-06
homeostasis O 0 1.6406422219006345e-05
, O 0 3.180448686634918e-07
we O 0 2.280968658396887e-07
have O 0 1.5595912827848224e-07
compared O 0 4.1687331986395293e-07
the O 0 2.6880380232796597e-07
resting O 0 5.59971840630169e-06
[ O 0 3.2313516840076772e-06
Ca2 O 0 9.116205546888523e-06
+ O 0 4.6165237108652946e-06
] O 0 1.9315118606755277e-06
i O 0 3.1236217523655796e-07
, O 0 6.126838769660026e-08
the O 0 8.78850343610793e-08
amplitude O 0 6.944828783161938e-07
and O 0 3.143647404613148e-07
shape O 0 1.8791974980558734e-06
of O 0 2.7595567075877625e-07
depolarization O 0 2.303891596966423e-05
- O 0 0.000527002033777535
induced O 0 4.0046310459729284e-05
Ca2 O 0 3.652379018603824e-05
+ O 0 1.2026908734696917e-05
transients O 0 7.540894330304582e-06
, O 0 2.260769633721793e-07
and O 0 8.032484544173712e-08
the O 0 8.68669403075728e-08
content O 0 1.8823098457687593e-07
of O 0 1.3727911607475107e-07
ATP O 0 3.346750645505381e-06
- O 0 5.27781685377704e-06
driven O 0 1.857472625488299e-06
ion O 0 3.1858419333730126e-06
pumps O 0 4.849687684327364e-06
in O 0 6.400726988431416e-07
cultured O 0 1.2258375136298127e-05
skeletal O 0 8.041124965529889e-05
muscle O 0 2.7378582672099583e-05
cells O 0 2.678498049135669e-06
of O 0 1.639523929952702e-07
wild O 0 1.0665650052033016e-06
- O 0 7.2850675678637344e-06
type O 0 1.1253617913098424e-06
and O 0 6.855545962025644e-07
DMPK O 0 0.00018842105055227876
[ O 0 1.2698117643594742e-05
- O 0 0.0001593201741343364
/ O 0 3.323364580865018e-05
- O 0 6.795624358346686e-05
] O 0 4.65366683783941e-05
knockout O 0 0.0022229414898902178
mice O 0 0.0011848078574985266
. O 0 5.81215244892519e-05

In O 0 7.719525456195697e-05
vitro O 0 0.00035721794120036066
- O 0 0.000315509969368577
differentiated O 0 6.709672015858814e-05
DMPK O 0 0.0004953066818416119
[ O 0 4.2645431676646695e-05
- O 0 0.00026130813057534397
/ O 0 3.1279370887205005e-05
- O 0 2.8671436666627415e-05
] O 0 9.1504616648308e-06
myotubes O 0 9.473857062403113e-06
exhibit O 0 1.4181836149873561e-06
a O 0 6.870409379189368e-07
higher O 0 2.1172593278606655e-06
resting O 0 5.348734248400433e-06
[ O 0 4.455961061466951e-06
Ca2 O 0 1.552665162307676e-05
+ O 0 6.798733011237346e-06
] O 0 1.6976330243778648e-06
i O 0 3.537296890954167e-07
than O 0 9.959988744867587e-08
do O 0 2.8971138021915976e-07
wild O 0 4.4556239231496875e-07
- O 0 6.359495728247566e-06
type O 0 1.556947609060444e-06
myotubes O 0 1.454392167943297e-05
because O 0 2.835080863405892e-07
of O 0 5.2913961212652794e-08
an O 0 1.0929126403880218e-07
altered O 0 1.596781544321857e-06
open O 0 5.157328928362404e-07
probability O 0 5.058937517787854e-07
of O 0 1.5147320198138914e-07
voltage O 0 7.170106073317584e-06
- O 0 0.0008237670408561826
dependent O 0 1.1025161256839056e-05
l O 0 0.0007766977651044726
- O 0 3.4967488318216056e-05
type O 0 7.018025826255325e-06
Ca2 O 0 3.201318031642586e-05
+ O 0 1.0919413398369215e-05
and O 0 2.724094656514353e-06
Na O 0 5.198715007281862e-05
+ O 0 1.8636650565895252e-05
channels O 0 2.2367372366716154e-05
. O 0 2.449110797897447e-05

The O 0 9.777551895240322e-05
mutant O 0 0.0002731400600168854
myotubes O 0 0.00020970743207726628
exhibit O 0 1.0187829502683599e-05
smaller O 0 4.3268350964353886e-06
and O 0 1.5665752925997367e-06
slower O 0 1.5673309462727048e-05
Ca2 O 0 5.777851038146764e-05
+ O 0 1.5953119145706296e-05
responses O 0 2.8834085696871625e-06
upon O 0 9.770882343218545e-07
triggering O 0 9.179961125482805e-06
by O 0 1.265763103219797e-06
acetylcholine O 0 2.6270890884916298e-05
or O 0 4.048751179652754e-06
high O 0 1.2495461305661593e-05
external O 0 7.858478784328327e-05
K O 0 0.00034745261655189097
+ O 0 0.0001574689958943054
. O 0 4.250154597684741e-05

In O 0 2.653273804753553e-05
addition O 0 1.1107522368547507e-05
, O 0 1.8933241108243237e-06
we O 0 6.186409677866322e-07
observed O 0 8.784335818745603e-07
that O 0 2.8319300326984376e-07
these O 0 4.692935817729449e-07
Ca2 O 0 2.7249438062426634e-05
+ O 0 1.7911634131451137e-05
transients O 0 3.0958213756093755e-05
partially O 0 7.364202247117646e-06
result O 0 7.581040790682891e-07
from O 0 1.9061533862441138e-07
an O 0 1.2098432478069299e-07
influx O 0 8.512438967045455e-07
of O 0 1.3653216512921063e-07
extracellular O 0 2.0146812858001795e-06
Ca2 O 0 9.320700883108657e-06
+ O 0 2.3523652998846956e-06
through O 0 3.1634843367100984e-07
the O 0 1.0811563697643578e-06
l O 0 0.005945892538875341
- O 0 0.00015759786765556782
type O 0 1.8677645130082965e-05
Ca2 O 0 8.724637882551178e-05
+ O 0 4.290994183975272e-05
channel O 0 4.6563203795813024e-05
. O 0 2.8804548492189497e-05

Neither O 0 0.00016580922238063067
the O 0 4.624702341970988e-06
content O 0 4.412194812175585e-06
nor O 0 3.339484692332917e-06
the O 0 6.558209975082718e-07
activity O 0 1.0741473488451447e-06
of O 0 7.982371243997477e-07
Na O 0 9.733438491821289e-05
+ O 0 2.8014472263748758e-05
/ O 0 1.1439688023529015e-05
K O 0 1.855188747867942e-05
+ O 0 1.5489707948290743e-05
ATPase O 0 3.181499050697312e-05
and O 0 2.750153498709551e-06
sarcoplasmic O 0 0.0002232819824712351
reticulum O 0 0.0010554947657510638
Ca2 O 0 0.00029839284252375364
+ O 0 6.713807670166716e-05
- O 0 5.4903510317672044e-05
ATPase O 0 5.066790254204534e-05
are O 0 1.307166371589119e-06
affected O 0 3.2644136354065267e-06
by O 0 3.214348907931708e-06
DMPK O 0 0.0019435180583968759
absence O 0 0.00011391732550691813
. O 0 5.475663419929333e-05

In O 0 2.3836355467210524e-05
conclusion O 0 1.599693496245891e-05
, O 0 1.8213601151728653e-06
our O 0 1.4452517689278466e-06
data O 0 1.4148333775665378e-06
suggest O 0 1.333698151029239e-06
that O 0 2.3218123601509433e-07
DMPK O 0 2.941778438980691e-05
is O 0 1.9178287402610295e-07
involved O 0 3.1209032158585615e-07
in O 0 1.5682343246226083e-07
modulating O 0 3.91671028410201e-06
the O 0 4.082243094671867e-07
initial O 0 1.9414289909036597e-06
events O 0 6.655308197878185e-07
of O 0 3.56632540388091e-07
excitation O 0 1.4351169738802128e-05
- O 0 0.0002535162784624845
contraction O 0 7.315633411053568e-05
coupling O 0 3.586564344004728e-05
in O 0 7.510843715863302e-06
skeletal O 0 0.005258906167000532
muscle O 0 0.001490219496190548
. O 0 1.632322346267756e-05
. O 0 4.513454405241646e-05

Constitutional O 0 0.0014403954846784472
RB1 O 1 0.8437467813491821
- O 0 0.04594589024782181
gene O 0 0.00013043305079918355
mutations O 0 7.161017128964886e-05
in O 0 9.200408385368064e-06
patients O 0 5.868548760190606e-05
with O 0 4.942632585880347e-06
isolated O 0 0.0001384333590976894
unilateral B-Disease 0 0.00035595419467426836
retinoblastoma I-Disease 0 0.1372162401676178
. O 0 0.0001531129382783547

In O 0 5.45353141205851e-05
most O 0 2.5767616534722038e-05
patients O 0 5.648101796396077e-05
with O 0 1.6939618490141584e-06
isolated O 0 2.021260115725454e-05
unilateral B-Disease 0 5.1208247896283865e-05
retinoblastoma I-Disease 0 0.12503303587436676
, O 0 1.775229065970052e-05
tumor B-Disease 0 0.00015021178114693612
development O 0 9.16139583750919e-07
is O 0 2.6163309030380333e-07
initiated O 0 1.5014458085715887e-06
by O 0 5.018984552407346e-07
somatic O 0 1.1040890967706218e-05
inactivation O 0 1.5955689377733506e-05
of O 0 2.5385304525116226e-07
both O 0 7.521327347603801e-07
alleles O 0 6.537045010190923e-06
of O 0 7.793921099619183e-07
the O 0 1.007847640721593e-05
RB1 O 0 0.12869705259799957
gene O 0 0.00011602794256759807
. O 0 6.346763984765857e-05

However O 0 4.708021515398286e-05
, O 0 2.2727876967110205e-06
some O 0 2.950824864456081e-07
of O 0 1.908188522747878e-07
these O 0 5.212163500800671e-07
patients O 0 8.868757504387759e-06
can O 0 7.218064297376259e-07
transmit O 0 9.53818471316481e-06
retinoblastoma B-Disease 0 0.0012167883105576038
predisposition O 0 7.240940612973645e-05
to O 0 2.727952733039274e-06
their O 0 1.4225265658751596e-05
offspring O 0 0.00015832687495276332
. O 0 6.24513195361942e-05

To O 0 2.548598604334984e-05
determine O 0 1.0887149983318523e-05
the O 0 9.49254399529309e-07
frequency O 0 2.407116880931426e-06
and O 0 6.125500817688589e-07
nature O 0 6.431118890759535e-07
of O 0 2.3776026125688077e-07
constitutional O 0 6.345573638100177e-06
RB1 O 0 0.21050423383712769
- O 0 0.0004365638014860451
gene O 0 5.598884854407515e-06
mutations O 0 7.795358214934822e-06
in O 0 7.337972078858002e-07
patients O 0 9.081375537789427e-06
with O 0 3.638454870724672e-07
isolated O 0 4.299850388633786e-06
unilateral B-Disease 0 5.1188467296015006e-06
retinoblastoma I-Disease 0 8.593958045821637e-05
, O 0 4.2698547986219637e-07
we O 0 1.7030637877724075e-07
analyzed O 0 8.272717764157278e-07
DNA O 0 1.99013493329403e-06
from O 0 5.841756092195283e-07
peripheral O 0 2.3945285647641867e-05
blood O 0 9.988589226850308e-06
and O 0 1.8610560346132843e-06
from O 0 6.422644673875766e-06
tumor B-Disease 0 0.017395181581377983
tissue O 0 0.001185895293019712
. O 0 7.802296022418886e-05

The O 0 3.055795968975872e-05
analysis O 0 1.8655908206710592e-05
of O 0 3.202190100637381e-06
tumors B-Disease 1 0.9974197149276733
from O 0 1.532958435745968e-06
54 O 0 4.857797648583073e-06
( O 0 9.429924716641835e-07
71 O 0 2.2337562768370844e-06
% O 0 4.0717216620578256e-07
) O 0 1.3892552885863552e-07
of O 0 9.698342751107702e-08
76 O 0 6.951322575332597e-06
informative O 0 2.325053901586216e-05
patients O 0 0.0011343661462888122
showed O 0 1.661782334849704e-05
loss O 0 6.4553132688160986e-06
of O 0 5.00627834298939e-07
constitutional O 0 2.0756508092745207e-05
heterozygosity O 0 0.19671446084976196
( O 0 1.2292041901673656e-05
LOH O 1 0.9951316118240356
) O 0 7.416263997583883e-06
at O 0 5.734774276788812e-06
intragenic O 0 0.00021591378026641905
loci O 0 0.0001720856671454385
. O 0 6.382330320775509e-05

Three O 0 2.947855682577938e-05
of O 0 1.0477723662916105e-05
13 O 0 2.146307633665856e-05
uninformative O 0 0.1388944834470749
patients O 0 0.0013127013808116317
had O 0 1.0484091035323218e-05
constitutional O 0 3.351729901623912e-05
deletions O 0 0.0003126906231045723
. O 0 8.312924182973802e-05

For O 0 3.1286264857044443e-05
39 O 0 2.5795254259719513e-05
randomly O 0 1.3185172065277584e-05
selected O 0 1.1234124031034298e-05
tumors B-Disease 1 0.990448534488678
, O 0 1.656764538893185e-06
SSCP O 0 0.0002301360509591177
, O 0 2.230475956821465e-06
hetero O 0 0.00014165144239086658
- O 0 1.3085635146126151e-05
duplex O 0 1.5254656318575144e-05
analysis O 0 1.433498823644186e-06
, O 0 2.0201790107421402e-07
sequencing O 0 1.1046441841244814e-06
, O 0 1.58461375576735e-07
and O 0 9.936346145877906e-08
Southern O 0 5.897216510675207e-07
blot O 0 1.1057412848458625e-05
analysis O 0 1.3837720871379133e-06
were O 0 4.886261422143434e-07
used O 0 1.108671426663932e-06
to O 0 3.189699782524258e-06
identify O 0 3.347545498399995e-05
mutations O 0 9.897514246404171e-05
. O 0 3.348605605424382e-05

Mutations O 0 0.0009553978452458978
were O 0 2.5917704988387413e-05
detected O 0 2.7645988666336052e-05
in O 0 1.7338848010695074e-06
21 O 0 2.1467901660798816e-06
( O 0 8.14900602108537e-07
91 O 0 1.9593148863350507e-06
% O 0 6.130170504548005e-07
) O 0 3.23155063597369e-07
of O 0 5.600041959041846e-07
23 O 0 0.0008569419151172042
tumors B-Disease 1 0.9999520778656006
with O 0 4.190038816886954e-05
LOH O 1 0.9999467134475708
. O 0 0.00011207379429833964

In O 0 5.001110548619181e-05
6 O 0 1.758993857947644e-05
( O 0 2.588067673059413e-06
38 O 0 1.790351007002755e-06
% O 0 4.245638081101788e-07
) O 0 1.4334835896079312e-07
of O 0 1.3006538779336552e-07
16 O 0 5.400892041507177e-05
tumors B-Disease 1 0.999993085861206
without O 0 6.545197720697615e-06
LOH O 1 0.9996159076690674
, O 0 2.938098475624429e-07
one O 0 2.021952099084956e-07
mutation O 0 1.4839961295365356e-06
was O 0 6.490477630904934e-07
detected O 0 5.113759584673971e-07
, O 0 9.55997521145946e-08
and O 0 8.657796968236653e-08
in O 0 1.8551644132003275e-07
9 O 0 4.059190814587055e-07
( O 0 2.223850401605887e-07
56 O 0 3.9574456422997173e-07
% O 0 1.580179969096207e-07
) O 0 7.101606058768084e-08
of O 0 5.256299928646513e-08
the O 0 6.578683951374842e-06
tumors B-Disease 1 0.9999973773956299
without O 0 9.670959116192535e-06
LOH O 1 0.9996176958084106
, O 0 6.255251037146081e-07
both O 0 9.209215363625844e-07
mutations O 0 7.066717898851493e-06
were O 0 1.9306426111143082e-06
found O 0 8.026609066291712e-06
. O 0 2.3424760001944378e-05

Thus O 0 6.793155625928193e-05
, O 0 4.947730758431135e-06
a O 0 9.283213557864656e-07
total O 0 4.525280132838816e-07
of O 0 2.536492900162557e-07
45 O 0 1.2942978173668962e-06
mutations O 0 4.157550847594393e-06
were O 0 7.335285090448451e-07
identified O 0 3.7558816075033974e-06
in O 0 7.859749530325644e-06
tumors B-Disease 1 0.9995408058166504
of O 0 3.2990651561704e-06
36 O 0 0.00013969787687528878
patients O 0 0.004535511136054993
. O 0 8.674364653415978e-05

Thirty O 0 0.0002675585856195539
- O 0 0.0001482057268731296
nine O 0 4.577218078338774e-06
of O 0 7.436885312017694e-07
the O 0 1.4901279428158887e-06
mutations O 0 7.678237125219312e-06
- O 0 7.995637133717537e-06
including O 0 2.9668805723304104e-07
34 O 0 8.16629267319513e-07
small O 0 4.993465836378164e-07
mutations O 0 1.7830445813160622e-06
, O 0 1.7743295188665797e-07
2 O 0 2.26054524432584e-07
large O 0 2.6401471586723346e-07
structural O 0 4.318046649132157e-06
alterations O 0 9.358750503452029e-06
, O 0 2.882056548969558e-07
and O 0 2.8618762826226884e-07
hypermethylation O 0 2.6851019356399775e-05
in O 0 1.3364279993766104e-06
3 O 0 4.614292265614495e-05
tumors O 1 0.9996501207351685
- O 0 3.756086152861826e-05
were O 0 4.1528687688696664e-07
not O 0 2.567204830938863e-07
detected O 0 9.954269444278907e-07
in O 0 1.867725671900189e-07
the O 0 3.4041087815239734e-07
corresponding O 0 5.948044417891651e-06
peripheral O 0 0.0011036304058507085
blood O 0 0.0004984441911801696
DNA O 0 0.00029119427199475467
. O 0 7.488956180168316e-05

In O 0 5.033954221289605e-05
6 O 0 1.670753954385873e-05
( O 0 3.112615331701818e-06
17 O 0 2.071391691060853e-06
% O 0 4.864886591349205e-07
) O 0 1.0551494966648534e-07
of O 0 5.0844558785456684e-08
the O 0 3.2944763006526046e-07
36 O 0 8.969841474026907e-06
patients O 0 3.502966865198687e-05
, O 0 1.8772473708850157e-07
a O 0 3.528775494032743e-07
mutation O 0 3.4894746931968257e-06
was O 0 1.2338975921011297e-06
detected O 0 9.036882033797156e-07
in O 0 1.4144933402349125e-07
constitutional O 0 6.397522724910232e-07
DNA O 0 1.9769652226386825e-06
, O 0 1.239748712578148e-07
and O 0 6.155512721761625e-08
1 O 0 8.406467344457269e-08
of O 0 3.459284769746773e-08
these O 0 1.4650754565082025e-07
mutations O 0 1.5726944866401027e-06
is O 0 9.139537837654643e-08
known O 0 2.800351808218693e-07
to O 0 2.1393984184214787e-07
be O 0 2.0166140757282847e-07
associated O 0 9.508871698926669e-07
with O 0 1.341515371677815e-06
reduced O 0 5.120746936881915e-05
expressivity O 0 0.10342144966125488
. O 0 0.00012863651500083506

The O 0 2.0248426153557375e-05
presence O 0 4.9873442549142055e-06
of O 0 5.803186695629847e-07
a O 0 7.985173624547315e-07
constitutional O 0 3.6828923839493655e-06
mutation O 0 6.049777766747866e-06
was O 0 2.1293462850735523e-06
not O 0 3.4316451547056204e-07
associated O 0 3.905622065758507e-07
with O 0 1.0594206401037809e-07
an O 0 1.8550230151959113e-07
early O 0 5.741034783568466e-06
age O 0 1.009474271995714e-05
at O 0 9.13695475901477e-06
treatment O 0 0.00015624985098838806
. O 0 4.766127676703036e-05

In O 0 4.714261740446091e-05
1 O 0 1.3277183825266548e-05
patient O 0 2.602643689897377e-05
, O 0 1.5250348042172845e-06
somatic O 0 3.020045733137522e-05
mosaicism O 0 0.0005926094017922878
was O 0 4.3164736780454405e-06
demonstrated O 0 2.0660352220147615e-06
by O 0 3.6433888794817904e-07
molecular O 0 3.537327529556933e-06
analysis O 0 8.132050766107568e-07
of O 0 2.2986306191796757e-07
DNA O 0 4.712427653430495e-06
and O 0 1.0799434448927059e-06
RNA O 0 6.433494945667917e-06
from O 0 2.589897349025705e-06
peripheral O 0 0.0002636507560964674
blood O 0 0.0002480389375705272
. O 0 4.259458728483878e-05

In O 0 7.902507786639035e-05
2 O 0 4.992851972929202e-05
patients O 0 8.381649240618572e-05
without O 0 1.7564760810273583e-06
a O 0 1.7688785192149226e-06
detectable O 0 1.2107440852560103e-05
mutation O 0 9.69029133557342e-06
in O 0 8.300622198476049e-07
peripheral O 0 0.00020847341511398554
blood O 0 3.605425445130095e-05
, O 0 8.934666766435839e-07
mosaicism O 0 7.071867003105581e-05
was O 0 1.778706860022794e-06
suggested O 0 1.0984649634337984e-06
because O 0 2.2862955972868804e-07
1 O 0 1.2622970757547591e-07
of O 0 9.034195613821794e-08
the O 0 1.5142062466111383e-06
patients O 0 0.006156296469271183
showed O 0 0.0038979132659733295
multifocal O 1 0.9999862909317017
tumors B-Disease 1 0.9999983310699463
and O 0 6.798874778723984e-07
the O 0 4.058200033796311e-07
other O 0 3.7485784787349985e-07
later O 0 3.3964731755986577e-06
developed O 0 1.3978733477415517e-05
bilateral B-Disease 0 4.312896999181248e-05
retinoblastoma I-Disease 0 0.24242880940437317
. O 0 6.828767800470814e-05

In O 0 2.663803388713859e-05
conclusion O 0 1.4528562132909428e-05
, O 0 1.2101864967917209e-06
our O 0 1.3314817124410183e-06
results O 0 1.5858456663409015e-06
emphasize O 0 1.707889396129758e-06
that O 0 1.8260230660871457e-07
the O 0 2.7485148734740505e-07
manifestation O 0 1.6948021084317588e-06
and O 0 6.137213404144859e-07
transmissibility O 0 8.609425094618928e-06
of O 0 2.4101299800349807e-07
retinoblastoma B-Disease 0 2.1334062694222666e-05
depend O 0 7.243828008540731e-07
on O 0 1.2410333738444024e-07
the O 0 1.4341877374590695e-07
nature O 0 1.7445353250877815e-07
of O 0 3.956992244980029e-08
the O 0 9.438060999400477e-08
first O 0 3.684996556785336e-07
mutation O 0 1.0299282848791336e-06
, O 0 5.337201613997422e-08
its O 0 5.4728431564399216e-08
time O 0 1.011536951978087e-07
in O 0 8.933595552207407e-08
development O 0 2.0468830541631178e-07
, O 0 8.92668055030299e-08
and O 0 5.261997415573205e-08
the O 0 4.993937352537614e-08
number O 0 5.1156618496861483e-08
and O 0 8.178047039564262e-08
types O 0 1.3568430290433753e-07
of O 0 7.561568082792292e-08
cells O 0 2.192309466408915e-06
that O 0 2.772021900909749e-07
are O 0 5.461518526317377e-07
affected O 0 3.621198857217678e-06
. O 0 3.3591254577913787e-06
. O 0 1.636824345041532e-05

Hereditary B-Disease 1 0.9999712705612183
deficiency I-Disease 1 0.9839731454849243
of I-Disease 0 4.572898888000054e-06
the I-Disease 0 2.205674036304117e-06
fifth I-Disease 0 4.762017852044664e-06
component I-Disease 0 3.4566842259664554e-06
of I-Disease 0 7.046421615086729e-07
complement I-Disease 0 7.664833901799284e-06
in O 0 4.767638984048972e-06
man O 0 9.546487126499414e-05
. O 0 4.294081008993089e-05

I O 0 0.006506133824586868
. O 0 0.0013193279737606645

Clinical O 0 0.003032943233847618
, O 0 3.186272078892216e-05
immunochemical O 0 0.0002551046491134912
, O 0 4.281412657292094e-06
and O 0 4.5553747440862935e-06
family O 0 4.564774644677527e-05
studies O 0 0.00012297427747398615
. O 0 6.147389649413526e-05

The O 0 3.542949343682267e-05
first O 0 8.221828466048464e-06
recognized O 0 4.7785551942070015e-06
human O 0 3.2816494694998255e-06
kindred O 0 0.00015942213940434158
with O 0 1.090717614715686e-05
hereditary B-Disease 1 0.9998530149459839
deficiency I-Disease 0 0.3222423791885376
of I-Disease 0 1.8558544923052978e-07
the I-Disease 0 3.2430818919237936e-07
fifth I-Disease 0 2.826929176080739e-06
component I-Disease 0 1.6943787386480835e-06
of I-Disease 0 3.5291424183014897e-07
complement I-Disease 0 4.28786916017998e-06
( O 0 1.5303846794267884e-06
C5 O 0 5.382890230976045e-05
) O 0 1.0778526302601676e-06
is O 0 1.3940399412604165e-06
described O 0 3.144890069961548e-05
. O 0 3.840186764136888e-05

The O 0 3.0117049391265027e-05
proband O 0 0.00022507186804432422
, O 0 2.9986990739416797e-06
a O 0 1.2641248758882284e-06
20 O 0 1.5515967106694006e-06
- O 0 1.5395427908515558e-05
year O 0 2.499460379112861e-06
- O 0 0.0001165362264146097
old O 0 3.2556828955421224e-05
black O 0 1.9020644685951993e-05
female O 0 1.7607828340260312e-05
with O 0 0.0002806141274049878
systemic B-Disease 1 1.0
lupus I-Disease 1 1.0
erythematosus I-Disease 1 0.9999997615814209
since O 0 0.0003149236727040261
age O 0 5.173277713765856e-06
11 O 0 1.3252806638774928e-06
, O 0 9.313949362876883e-07
lacked O 0 5.295425216900185e-05
serum O 0 0.0060546258464455605
hemolytic O 0 0.17117981612682343
complement O 0 3.7606666865031e-06
activity O 0 2.466221530994517e-06
, O 0 1.2031299547743401e-06
even O 0 4.269938017387176e-06
during O 0 2.3502629119320773e-05
remission O 0 0.0018073508981615305
. O 0 5.469933239510283e-05

C5 O 0 0.005119668785482645
was O 0 7.662145799258724e-05
undetectable O 0 0.00011342792276991531
in O 0 3.6886358429910615e-06
her O 0 6.263683644647244e-06
serum O 0 3.299503805465065e-05
by O 0 1.898430014080077e-06
both O 0 4.1770526877371594e-06
immunodiffusion O 0 0.011349376291036606
and O 0 6.956016295589507e-05
hemolytic O 1 0.9981853365898132
assays O 0 0.008151058107614517
. O 0 7.457321771653369e-05

Other O 0 1.4115481462795287e-05
complement O 0 1.4038932022231165e-05
components O 0 4.8233187044388615e-06
were O 0 7.124350531739765e-07
normal O 0 2.039382479779306e-06
during O 0 1.9735707610379905e-06
remission O 0 5.067273377790116e-05
of O 0 1.5602503253830946e-06
lupus O 1 0.9978027939796448
, O 0 1.3102054481350933e-06
but O 0 1.8040728946289164e-06
C1 O 0 0.005573097616434097
, O 0 6.399475864782289e-07
C4 O 0 9.20136517379433e-06
, O 0 5.34568812327052e-07
C2 O 0 2.799265166686382e-05
, O 0 2.9847791438442073e-07
and O 0 7.909518444648711e-07
C3 O 0 5.320678974385373e-05
levels O 0 8.60101317812223e-06
fell O 0 3.3196338335983455e-05
during O 0 3.2490079320268705e-05
exacerbations O 1 0.5492168068885803
. O 0 7.923605880932882e-05

A O 0 9.849608613876626e-05
younger O 0 8.840654481900856e-05
half O 0 1.396660809405148e-05
- O 0 0.00014631543308496475
sister O 0 1.2722615792881697e-05
, O 0 4.516088552009023e-07
who O 0 5.492712489285623e-07
had O 0 2.143576011803816e-06
no O 0 3.2692801141820382e-06
underlying O 1 0.5413295030593872
disease O 0 0.02134510688483715
, O 0 8.134695690387161e-07
was O 0 2.2050328425393673e-06
also O 0 5.559239184549369e-07
found O 0 6.199036306497874e-07
to O 0 1.4999001223259256e-06
lack O 0 1.4184719475451857e-05
immunochemically O 0 0.011842753738164902
detectable O 0 0.0002010434545809403
C5 O 0 0.0004810016544070095
. O 0 5.3962168749421835e-05

By O 0 0.0002666392829269171
hemolytic O 1 0.9983555674552917
assay O 0 0.004464597441256046
, O 0 6.724193099216791e-06
she O 0 1.88491947028524e-06
exhibited O 0 1.2884282796221669e-06
1 O 0 8.37776497064624e-07
- O 0 3.869817646773299e-06
2 O 0 3.5680130849868874e-07
% O 0 1.249207741693681e-07
of O 0 4.8110848638316384e-08
the O 0 1.6344250752808875e-07
normal O 0 1.6385374692617916e-06
serum O 0 1.328075541096041e-05
C5 O 0 6.654072876699502e-06
level O 0 4.587596151850448e-07
and O 0 2.727541925651167e-07
normal O 0 8.306902827825979e-07
concentrations O 0 1.1243533890592516e-06
of O 0 1.7527952422824455e-07
other O 0 5.015797341911821e-07
complement O 0 6.6745128606271464e-06
components O 0 3.1875486456556246e-05
. O 0 3.624347664299421e-05

C5 O 0 0.0010400920873507857
levels O 0 2.1651921997545287e-05
of O 0 9.314890689893218e-07
other O 0 6.135808803264808e-07
family O 0 1.7566937913215952e-06
members O 0 2.444819813263166e-07
were O 0 1.4768532707876147e-07
either O 0 2.607299336432334e-07
normal O 0 6.029125643181033e-07
or O 0 2.0382789500672516e-07
approximately O 0 1.0471798361777473e-07
half O 0 5.15004501266958e-07
- O 0 1.7501857655588537e-05
normal O 0 1.0067094535770593e-06
, O 0 3.042853506940446e-07
consistent O 0 8.955617545325367e-07
with O 0 1.0001953114624484e-06
autosomal O 0 0.001880191033706069
codominant O 0 0.012263231910765171
inheritance O 0 1.129815609601792e-05
of O 0 4.7315569418060477e-07
the O 0 3.116262632829603e-06
gene O 0 9.692371531855315e-05
determining O 0 0.010107557289302349
C5 B-Disease 1 0.9999957084655762
deficiency I-Disease 1 0.9999914169311523
. O 0 0.0001450043055228889

Normal O 0 0.020353658124804497
hemolytic O 1 0.9992154836654663
titers O 0 0.008187839761376381
were O 0 1.0554706022958271e-05
restored O 0 8.815076398605015e-06
to O 0 1.0690467888707644e-06
both O 0 1.9830986275337636e-06
homozygous O 0 0.011957627721130848
C5 B-Disease 1 0.9999958276748657
- I-Disease 1 0.999962329864502
deficient I-Disease 1 0.9999932050704956
( O 0 4.7120947783696465e-06
C5D B-Disease 1 0.9995948672294617
) O 0 1.2722912288154475e-06
sera O 0 2.4958471840363927e-06
by O 0 1.8519932609706302e-07
addition O 0 4.0554763813815953e-07
of O 0 4.729679972115264e-07
highly O 0 3.3721116778906435e-06
purified O 0 3.223288877052255e-05
human O 0 1.6956759282038547e-05
C5 O 0 0.00032979127718135715
. O 0 4.693501614383422e-05

In O 0 6.187806866364554e-05
specific O 0 2.283056528540328e-05
C5 O 0 0.00011902789265150204
titrations O 0 0.0002922277490142733
, O 0 1.2791358585673152e-06
however O 0 5.304553383211896e-07
, O 0 1.677199321648004e-07
it O 0 8.65933245108863e-08
was O 0 2.475141798186087e-07
noted O 0 1.8433132709105848e-07
that O 0 6.080168191147095e-08
when O 0 2.3226715484270244e-07
limited O 0 2.1664178007085866e-07
amounts O 0 1.5677603926178563e-07
of O 0 8.96225031965514e-08
C5 O 0 3.3651533613010542e-06
were O 0 1.4007684967509704e-07
assayed O 0 1.7293665450779372e-06
in O 0 9.12593378643578e-08
the O 0 1.1726717730198288e-07
presence O 0 1.600634362830533e-07
of O 0 1.0336857059201066e-07
low O 0 1.5468392575712642e-06
dilutions O 0 2.4587239749962464e-05
of O 0 2.735737609782518e-07
either O 0 2.1312193894118536e-06
C5D B-Disease 1 0.9999325275421143
serum O 0 0.0005511955241672695
, O 0 3.2451578135805903e-07
curving O 0 2.0618485905288253e-06
rather O 0 6.381472417160694e-07
than O 0 2.0433958525245544e-07
linear O 0 1.791215140656277e-06
dose O 0 1.0885478332056664e-05
- O 0 4.373823685455136e-06
response O 0 1.0967086154778372e-06
plots O 0 1.374919293084531e-06
were O 0 3.2108638947647705e-07
consistently O 0 1.5629816516593564e-06
obtained O 0 1.3311822613104596e-06
, O 0 5.025527229918225e-07
suggesting O 0 3.3488706776552135e-06
some O 0 1.186899339700176e-06
inhibitory O 0 2.5501203708699904e-05
effect O 0 3.090459358645603e-05
. O 0 3.735628706635907e-05

Further O 0 5.895607318961993e-05
studies O 0 3.3599164453335106e-05
suggested O 0 8.929282557801344e-06
that O 0 1.448531747882953e-06
low O 0 6.491211024695076e-06
dilutions O 0 8.521394192939624e-05
of O 0 1.6018635733416886e-06
C5D B-Disease 1 0.9998154044151306
serum O 0 0.0006005798932164907
contain O 0 1.5358176597146667e-06
a O 0 6.514439405691519e-07
factor O 0 1.5251395097948262e-06
( O 0 2.2466809923571418e-07
or O 0 2.227008337740699e-07
factors O 0 3.349715882450255e-07
) O 0 9.968616865307922e-08
interfering O 0 2.3241074131874484e-07
at O 0 1.0783559645233254e-07
some O 0 4.841157874579949e-08
step O 0 3.5475363802106585e-07
in O 0 2.0044079462877562e-07
the O 0 1.0535612773310277e-06
hemolytic O 1 0.902141809463501
assay O 0 0.000255820486927405
of O 0 4.273179001756944e-07
C5 O 0 2.7581736503634602e-05
, O 0 4.1407361095480155e-07
rather O 0 4.162797893059178e-07
than O 0 3.132308279418794e-07
a O 0 1.3167002634872915e-06
true O 0 1.0057583494926803e-05
C5 O 0 0.0003597938921302557
inhibitor O 0 8.73307726578787e-05
or O 0 9.82029359875014e-06
inactivator O 0 0.0003091024118475616
. O 0 5.458927626023069e-05

Of O 0 3.404555536690168e-05
clinical O 0 0.0016182932304218411
interest O 0 7.183849447756074e-06
are O 0 9.365860478283139e-07
( O 0 4.0269529222314304e-07
a O 0 4.5708222273788124e-07
) O 0 3.43972516247959e-07
the O 0 2.272661134838927e-07
documentation O 0 1.7466024928580737e-06
of O 0 9.026425118463521e-07
membranous O 1 0.9936304688453674
glomerulonephritis B-Disease 1 0.9999997615814209
, O 0 0.011578754521906376
vasculitis B-Disease 1 0.9999971389770508
, O 0 4.203321805107407e-05
and O 0 0.03570311889052391
arthritis B-Disease 1 1.0
in O 0 1.8589984165373608e-06
an O 0 3.8805575286460225e-07
individual O 0 1.3668553719980991e-06
lacking O 0 1.7152187865576707e-05
C5 O 0 4.467148391995579e-05
( O 0 3.2944547001534374e-07
and O 0 9.228084252299595e-08
its O 0 1.3899577311349276e-07
biologic O 0 7.76104297983693e-06
functions O 0 3.339483498621121e-07
) O 0 2.5239501155738253e-07
, O 0 9.985668469880693e-08
and O 0 1.9489311853249092e-07
( O 0 3.056199489037681e-07
b O 0 2.0847367068199674e-06
) O 0 1.4007470383603504e-07
a O 0 1.634521851201498e-07
remarkable O 0 1.018414650388877e-06
propensity O 0 2.4302742531290278e-05
to O 0 4.620311756298179e-06
bacterial B-Disease 1 0.9992169141769409
infections I-Disease 1 0.9984923601150513
in O 0 4.6234760020524845e-07
the O 0 3.1247807896761515e-07
proband O 0 0.000189340251381509
, O 0 1.9021020136733569e-07
even O 0 1.739352200047506e-07
during O 0 3.0537697170984757e-07
periods O 0 5.374578790906526e-07
of O 0 1.1904981533916725e-07
low O 0 4.9835552999866195e-06
- O 0 1.53459968714742e-05
dose O 0 7.090181952662533e-06
or O 0 5.364358912629541e-07
alternate O 0 2.6433774564793566e-06
- O 0 2.685043182282243e-05
day O 0 1.4996889149188064e-05
corticosteroid O 0 0.002806768985465169
therapy O 0 0.00048225707723759115
. O 0 4.9580026825424284e-05

Other O 0 2.4327322535100393e-05
observations O 0 2.9102446205797605e-05
indicate O 0 8.042753506742883e-06
that O 0 6.312042728495726e-07
the O 0 1.0446996157043031e-06
C5D B-Disease 1 0.996299684047699
state O 0 7.78211187935085e-07
is O 0 1.6016514337025e-07
compatible O 0 5.308125992087298e-07
with O 0 2.108400565248303e-07
normal O 0 1.1235580359425512e-06
coagulation O 0 6.236492026800988e-06
function O 0 4.454816746601864e-07
and O 0 1.4567119421826646e-07
the O 0 1.905006570268597e-07
capacity O 0 4.873444936492888e-07
to O 0 3.5946288790000835e-07
mount O 0 8.59834017319372e-06
a O 0 9.172295904136263e-06
neutrophilic O 0 0.3880576491355896
leukocytosis O 0 0.36060070991516113
during O 0 0.00012333669292274863
pyogenic B-Disease 1 0.9750794172286987
infection I-Disease 0 0.02188647724688053
. O 0 2.8015592761221342e-05
. O 0 5.5475335102528334e-05

Susceptibility O 0 0.3050288259983063
to O 0 0.009796125814318657
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
in O 0 0.0004377464356366545
twins O 0 0.05958041176199913
: O 0 1.0130494274562807e-06
the O 0 3.10805404524217e-07
role O 0 7.11966436028888e-07
of O 0 2.267908598696522e-07
genes O 0 2.0602369659172837e-06
, O 0 8.082676004050882e-07
HLA O 0 2.5254303182009608e-05
, O 0 4.098345414149662e-07
and O 0 4.376555011731398e-07
the O 0 2.4915641461120686e-06
environment O 0 2.537259024393279e-05
. O 0 1.7864413166535087e-05

OBJECTIVE O 0 0.0001546105631859973
To O 0 6.771252174075926e-06
determine O 0 3.9295960050367285e-06
the O 0 8.39959682252811e-07
relative O 0 2.981566467497032e-06
effects O 0 2.873986659324146e-06
of O 0 3.2972238273032417e-07
genetic O 0 9.273973773815669e-06
and O 0 1.5508037449762924e-06
environmental O 0 7.156593255785992e-06
factors O 0 1.8177159972765367e-06
in O 0 1.3288001809996786e-06
susceptibility O 0 0.011083809658885002
to O 0 0.050387367606163025
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 0 0.0006610078271478415
AS B-Disease 0 0.014319468289613724
) O 0 1.690667158982251e-05
. O 0 2.2738131519872695e-05

METHODS O 0 0.000520414556376636
Twins O 0 0.0007256443495862186
with O 0 3.415305172893568e-06
AS B-Disease 0 1.4852864296699408e-05
were O 0 7.773322181492404e-07
identified O 0 7.975637004165037e-07
from O 0 2.034253157034982e-07
the O 0 4.6532812802979606e-07
Royal O 0 0.0001371869584545493
National O 0 1.7985852537094615e-05
Hospital O 0 0.0840882956981659
for O 0 0.00023718572629150003
Rheumatic B-Disease 1 0.9999978542327881
Diseases I-Disease 1 0.9759694933891296
database O 0 0.00019367354980204254
. O 0 0.00010889855911955237

Clinical O 0 0.0016959768254309893
and O 0 2.685737308638636e-05
radiographic O 0 0.0035505485720932484
examinations O 0 0.00011401925439713523
were O 0 1.960660711119999e-06
performed O 0 1.2760069694195408e-06
to O 0 4.767975951835979e-07
establish O 0 3.5300784020364517e-06
diagnoses O 0 0.010564296506345272
, O 0 1.6237067939073313e-06
and O 0 1.974662700376939e-05
disease O 0 0.007691089063882828
severity O 0 0.0064869169145822525
was O 0 1.112043082684977e-05
assessed O 0 2.5210322291968623e-06
using O 0 6.985927143432491e-07
a O 0 5.833616683048604e-07
combination O 0 2.266255478389212e-06
of O 0 4.451788697679149e-07
validated O 0 1.5379549950012006e-05
scoring O 0 1.2164522559032775e-05
systems O 0 8.001762034837157e-05
. O 0 5.083545693196356e-05

HLA O 0 0.04019422456622124
typing O 0 0.0006730490131303668
for O 0 3.0251416319515556e-05
HLA O 0 0.0009389154147356749
- O 0 0.00010646063310559839
B27 O 0 5.4036121582612395e-05
, O 0 1.959729615919059e-06
HLA O 0 2.3907632566988468e-05
- O 0 9.956889698514715e-06
B60 O 0 7.633116183569655e-06
, O 0 3.429698551826732e-07
and O 0 5.193318770579936e-07
HLA O 0 0.0001477796904509887
- O 0 7.012348214630038e-05
DR1 O 0 0.0019414103589951992
was O 0 8.67195865339454e-07
performed O 0 3.6409193171493826e-07
by O 0 2.2250128495215904e-07
polymerase O 0 3.414256752876099e-06
chain O 0 4.602474291459657e-06
reaction O 0 1.5158678934312775e-06
with O 0 1.7387003481417196e-07
sequence O 0 6.692357601423282e-07
- O 0 2.2723172605765285e-06
specific O 0 6.166865205159411e-07
primers O 0 6.784652214264497e-06
, O 0 3.2899743018788286e-07
and O 0 4.3491482415447535e-07
zygosity O 0 2.830157791322563e-05
was O 0 3.1424833650817163e-06
assessed O 0 4.643777174351271e-06
using O 0 7.872667083574925e-06
microsatellite O 0 0.0003291602188255638
markers O 0 0.0001246672763954848
. O 0 6.892805686220527e-05

Genetic O 0 0.0010180857498198748
and O 0 1.532122587377671e-05
environmental O 0 1.3089604181004688e-05
variance O 0 2.5920937787304865e-06
components O 0 2.050420562227373e-06
were O 0 3.8254080436672666e-07
assessed O 0 8.907969117899484e-07
with O 0 1.15538554723571e-07
the O 0 4.2361054397588305e-07
program O 0 1.7904636706589372e-06
Mx O 0 8.434736628259998e-06
, O 0 1.3932742604083614e-07
using O 0 1.182278381861579e-07
data O 0 2.65474056959647e-07
from O 0 7.834597681721789e-08
this O 0 6.07108248118493e-08
and O 0 1.1889528650499415e-07
previous O 0 1.6357801086996915e-06
studies O 0 1.8927878500107909e-06
of O 0 4.3271879235362576e-07
twins O 0 0.036322031170129776
with O 0 2.7296937332721427e-06
AS B-Disease 0 0.02942107431590557
. O 0 4.448104664334096e-05

RESULTS O 0 0.0005659047747030854
Six O 0 1.9965922547271475e-05
of O 0 3.677578661154257e-06
8 O 0 9.33511273615295e-06
monozygotic O 0 0.0031095228623598814
( O 0 9.18805380933918e-06
MZ O 1 0.8468422889709473
) O 0 2.6354962301411433e-06
twin O 0 6.486949132522568e-05
pairs O 0 4.573888872982934e-06
were O 0 6.468611900345422e-06
disease O 0 2.6410074497107416e-05
concordant O 0 3.980571636930108e-05
, O 0 8.275108598354564e-07
compared O 0 9.69218149293738e-07
with O 0 1.49082595157779e-07
4 O 0 2.5702669859128946e-07
of O 0 9.683353141554107e-08
15 O 0 5.864765739715949e-07
B27 O 0 3.771502451854758e-05
- O 0 5.5740361858624965e-05
positive O 0 2.6117588731722208e-06
dizygotic O 0 7.253399235196412e-05
( O 0 1.4068909877096303e-06
DZ O 0 0.00026211608201265335
) O 0 8.263941140285169e-07
twin O 0 8.173365131369792e-06
pairs O 0 1.2196234138173168e-06
( O 0 4.2291824797757727e-07
27 O 0 1.0173935152124614e-06
% O 0 3.2013457484936225e-07
) O 0 1.0115697790524791e-07
and O 0 7.246606514854648e-08
4 O 0 1.4234761636089388e-07
of O 0 1.1226246243722926e-07
32 O 0 2.6072470973304007e-06
DZ O 0 0.321733683347702
twin O 0 0.0013896714663133025
pairs O 0 2.230333393526962e-06
overall O 0 3.864728114422178e-06
( O 0 5.09676738147391e-07
12 O 0 5.594010303866526e-07
. O 0 4.1389355942555994e-07
5 O 0 1.8654628775038873e-06
% O 0 3.813078365055844e-06
) O 0 8.287101991300005e-06
. O 0 2.003705048991833e-05

Nonsignificant O 0 0.033141158521175385
increases O 0 6.980423495406285e-05
in O 0 3.3341734706482384e-06
similarity O 0 3.404080416657962e-06
with O 0 4.238154076574574e-07
regard O 0 7.825053103260871e-07
to O 0 4.197007115180895e-07
age O 0 1.967380740097724e-06
at O 0 1.0785750419017859e-05
disease O 0 0.0006354121724143624
onset O 0 0.0027633572462946177
and O 0 3.007187956427515e-07
all O 0 6.861537826807762e-08
of O 0 1.5981389367425436e-07
the O 0 1.7866319467430003e-05
disease O 0 0.039979640394449234
severity O 0 0.005617127753794193
scores O 0 9.477028470428195e-06
assessed O 0 5.65800428375951e-06
were O 0 8.042584909162542e-07
noted O 0 2.8323233891569544e-06
in O 0 1.5836900274734944e-05
disease O 0 0.07620387524366379
- O 0 0.1027558371424675
concordant O 0 0.3333779275417328
MZ O 1 0.999850869178772
twins O 0 0.03979409113526344
compared O 0 1.6748823327361606e-05
with O 0 7.816393917892128e-06
concordant O 0 0.13179834187030792
DZ O 1 0.9981343150138855
twins O 0 0.2534179091453552
. O 0 0.00012890984362456948

HLA O 0 0.34480252861976624
- O 0 0.0015781470574438572
B27 O 0 0.00021590801770798862
and O 0 4.09405129175866e-06
B60 O 0 2.822438364091795e-05
were O 0 8.985834369923396e-07
associated O 0 7.32594571672962e-07
with O 0 2.811467822994018e-07
the O 0 1.966064473890583e-06
disease O 0 0.00016757841513026506
in O 0 3.8832376958453096e-07
probands O 0 0.0007132985629141331
, O 0 2.9475171459125704e-07
and O 0 1.2416512618074194e-07
the O 0 1.842023351628086e-07
rate O 0 9.324934353571734e-07
of O 0 3.14952927737977e-07
disease O 0 3.878603456541896e-05
concordance O 0 6.595068407477811e-05
was O 0 3.4265149224665947e-06
significantly O 0 1.7930917692865478e-06
increased O 0 6.705517989757936e-07
among O 0 7.389447205241595e-07
DZ O 0 0.0972650870680809
twin O 0 0.00042280222987756133
pairs O 0 7.754309194751841e-07
in O 0 2.660219706740463e-07
which O 0 1.494330490459106e-07
the O 0 5.474210524880618e-07
co O 0 0.00367531250230968
- O 0 0.0012419712729752064
twin O 0 0.0003977134183514863
was O 0 1.1466548812677502e-06
positive O 0 5.887135330340243e-07
for O 0 3.0626418379142706e-07
both O 0 1.8142937960874406e-06
B27 O 0 0.00017855521582532674
and O 0 2.9444840038195252e-05
DR1 O 0 0.3879908621311188
. O 0 9.681176743470132e-05

Additive O 0 0.0010345535119995475
genetic O 0 0.00021611439296975732
effects O 0 3.075004860875197e-05
were O 0 1.1740138461391325e-06
estimated O 0 6.634896294599457e-07
to O 0 3.182190368988813e-07
contribute O 0 8.550687198294327e-07
97 O 0 2.653631781868171e-06
% O 0 6.008816626490443e-07
of O 0 2.464779527144856e-07
the O 0 1.4571955944120418e-06
population O 0 6.3322981986857485e-06
variance O 0 3.0109153158264235e-05
. O 0 3.8304944609990343e-05

CONCLUSION O 0 0.00025223748525604606
Susceptibility O 0 0.0003123173082713038
to O 0 7.368965270870831e-06
AS B-Disease 0 1.6025900549720973e-05
is O 0 4.557442139230261e-07
largely O 0 1.1950770613111672e-06
genetically O 0 2.3412821974488907e-06
determined O 0 1.1745447636712925e-06
, O 0 1.3208665450292756e-07
and O 0 1.523916921541968e-07
the O 0 3.206940846212092e-07
environmental O 0 2.5532440304232296e-06
trigger O 0 3.6964538594475016e-06
for O 0 5.880783646716736e-07
the O 0 1.4336369531520177e-05
disease O 0 0.006299739237874746
is O 0 1.8655198346095858e-06
probably O 0 1.374729981762357e-05
ubiquitous O 0 8.231893298216164e-05
. O 0 4.473594526643865e-05

HLA O 0 0.4404202401638031
- O 0 0.0030780171509832144
B27 O 0 0.00019786170742008835
accounts O 0 7.672015271964483e-06
for O 0 8.27704980110866e-07
a O 0 9.97524239210179e-07
minority O 0 2.782849833238288e-06
of O 0 1.9338511947353254e-07
the O 0 9.511755365565477e-07
overall O 0 6.26346591161564e-05
genetic O 0 0.00010344167094444856
susceptibility O 0 0.00022011050896253437
to O 0 8.335937309311703e-06
AS B-Disease 0 0.000993599882349372
. O 0 6.460396980401129e-05

Cell O 0 0.021963000297546387
cycle O 0 0.0007940271752886474
- O 0 0.0006442330777645111
dependent O 0 2.0756864614668302e-05
colocalization O 0 2.942190803878475e-05
of O 0 9.17712668524473e-07
BARD1 O 0 7.855271542211995e-05
and O 0 3.253830300309346e-06
BRCA1 O 0 7.215532968984917e-05
proteins O 0 3.6719538911711425e-06
in O 0 1.828338668019569e-06
discrete O 0 2.098385630233679e-05
nuclear O 0 5.9064066590508446e-05
domains O 0 6.155467417556792e-05
. O 0 4.92438739456702e-05

Germ O 0 0.45523032546043396
- O 0 0.09165402501821518
line O 0 6.249100260902196e-05
mutations O 0 1.4707110494782683e-05
of O 0 5.279873107610911e-07
the O 0 1.3619472838399815e-06
BRCA1 O 0 7.762754830764607e-05
gene O 0 7.907883627922274e-06
predispose O 0 1.498192341387039e-05
women O 0 1.223851654685859e-06
to O 0 3.8127805623844324e-07
early O 0 3.7274851365509676e-06
- O 0 0.041593972593545914
onset O 1 0.9798094034194946
breast B-Disease 1 0.9998929500579834
and I-Disease 1 0.993992269039154
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999760389328003
by O 0 9.928594408847857e-07
compromising O 0 3.3764648833312094e-05
the O 0 1.607585659257893e-06
genes O 0 7.675228516745847e-06
presumptive O 0 0.014360942877829075
function O 0 2.080522335745627e-06
as O 0 1.391872046951903e-06
a O 0 1.187052475870587e-05
tumor B-Disease 0 0.011425137519836426
suppressor O 0 0.001561985001899302
. O 0 0.00013105029938742518

Although O 0 5.704825889552012e-05
the O 0 7.031759650999447e-06
biochemical O 0 3.5558325180318207e-05
properties O 0 2.732399934757268e-06
of O 0 5.018965225644934e-07
BRCA1 O 0 3.1578460038872436e-05
polypeptides O 0 7.301196092157625e-06
are O 0 2.7234480626248114e-07
not O 0 2.488006884959759e-07
understood O 0 6.909168632773799e-07
, O 0 1.186954321497069e-07
their O 0 1.3656706698839116e-07
expression O 0 4.822688310923695e-07
pattern O 0 6.613404934796563e-07
and O 0 3.307225711068895e-07
subcellular O 0 1.1512116543599404e-05
localization O 0 8.833001629682258e-06
suggest O 0 2.2199651539267506e-06
a O 0 4.872115937359922e-07
role O 0 2.0967197542631766e-06
in O 0 1.4516224382532528e-06
cell O 0 0.0006274654879234731
- O 0 0.0039173755794763565
cycle O 0 6.30965078016743e-05
regulation O 0 5.296991002978757e-05
. O 0 4.534988329396583e-05

When O 0 0.00012866401812061667
resting O 0 0.00013147108256816864
cells O 0 4.0757648093858734e-05
are O 0 1.046476540977892e-06
induced O 0 7.530079074058449e-06
to O 0 6.019174634275259e-07
proliferate O 0 5.131413672643248e-06
, O 0 1.7487963077655877e-07
the O 0 1.3891599337512162e-07
steady O 0 1.61888272032229e-06
- O 0 4.360129878477892e-06
state O 0 2.985083824569301e-07
levels O 0 3.4571252172099776e-07
of O 0 1.5701483846441988e-07
BRCA1 O 0 8.29255714052124e-06
increase O 0 4.973243790118431e-07
in O 0 2.637067098021362e-07
late O 0 3.79481639356527e-06
G1 O 0 0.0004683202423620969
and O 0 3.4753063005155127e-07
reach O 0 6.762300017726375e-07
a O 0 5.017893158765219e-07
maximum O 0 2.7026997031498468e-06
during O 0 1.0480793207534589e-05
S O 0 0.0042904154397547245
phase O 0 6.790992483729497e-05
. O 0 4.564413029584102e-05

Moreover O 0 0.0003828052431344986
, O 0 1.8424801965011284e-05
in O 0 5.751649950980209e-06
S O 0 0.00022876195725984871
phase O 0 2.140996184607502e-05
cells O 0 2.7345917260390706e-05
, O 0 1.8094694951287238e-06
BRCA1 O 0 3.673743412946351e-05
polypeptides O 0 1.3385324564296752e-05
are O 0 5.948924126641941e-07
hyperphosphorylated O 0 1.6956306353677064e-05
and O 0 1.2112071772207855e-06
accumulate O 0 6.1930013544042595e-06
into O 0 1.0135759112017695e-06
discrete O 0 1.0199240932706743e-05
subnuclear O 0 0.00012669873831328005
foci O 0 7.619855023222044e-05
termed O 0 6.109693640610203e-05
" O 0 2.2116912077763118e-05
BRCA1 O 0 0.00032388637191616
nuclear O 0 9.24121486605145e-05
dots O 0 0.00020697448053397238
. O 0 8.412043825956061e-05

" O 0 0.0010656872764229774
BRCA1 O 0 0.24892593920230865
associates O 0 0.028798051178455353
in O 0 9.293398761656135e-06
vivo O 0 0.00010150189336854964
with O 0 1.4658484133178717e-06
a O 0 5.901897111471044e-06
structurally O 0 0.004408612381666899
related O 0 3.15632569254376e-05
protein O 0 3.390765778021887e-05
termed O 0 0.0002519711561035365
BARD1 O 0 0.040388450026512146
. O 0 9.406530443811789e-05

Here O 0 3.030079278687481e-05
we O 0 4.128963155380916e-06
show O 0 1.2535831501736538e-06
that O 0 1.9259408645666554e-07
the O 0 1.951276402678559e-07
steady O 0 2.593295448605204e-06
- O 0 7.702812581555918e-06
state O 0 3.0597280442634656e-07
levels O 0 3.5478512927511474e-07
of O 0 1.1148873113597801e-07
BARD1 O 0 1.804373096092604e-05
, O 0 2.680802992927056e-07
unlike O 0 4.96238556024764e-07
those O 0 1.5129778319078468e-07
of O 0 2.2924133702417748e-07
BRCA1 O 0 0.00027724826941266656
, O 0 8.327215823555889e-07
remain O 0 1.0399203347333241e-06
relatively O 0 9.38515597681544e-07
constant O 0 2.797164825096843e-06
during O 0 6.614429366891272e-06
cell O 0 0.00022060783521737903
cycle O 0 0.00020515278447419405
progression O 0 0.00042220993782393634
. O 0 8.434920891886577e-05

However O 0 0.00013862582272849977
, O 0 1.5204983355943114e-05
immunostaining O 0 0.0001549390726722777
revealed O 0 1.7813650629250333e-05
that O 0 1.7814910506785964e-06
BARD1 O 0 0.0001512307208031416
resides O 0 5.797517587780021e-06
within O 0 1.5183447885647183e-06
BRCA1 O 0 2.630761628097389e-05
nuclear O 0 5.76674801777699e-06
dots O 0 5.174219950276893e-06
during O 0 1.3625423207486165e-06
S O 0 1.0054390259028878e-05
phase O 0 8.036635108510382e-07
of O 0 1.313560602511643e-07
the O 0 4.660440424686385e-07
cell O 0 9.594071343599353e-06
cycle O 0 3.3740770959411748e-06
, O 0 3.400578520995623e-07
but O 0 2.2249365372317698e-07
not O 0 2.635594000821584e-07
during O 0 1.3795306585961953e-06
the O 0 3.973112143285107e-06
G1 O 0 0.019571183249354362
phase O 0 0.00010425147775094956
. O 0 4.369293310446665e-05

Nevertheless O 0 0.0003976399020757526
, O 0 2.2873276975587942e-05
BARD1 O 0 0.0001725560869090259
polypeptides O 0 3.861294680973515e-05
are O 0 1.1755286095649353e-06
found O 0 5.645578653457051e-07
exclusively O 0 3.230055938274745e-07
in O 0 1.1806412203441141e-07
the O 0 1.661158108845484e-07
nuclear O 0 6.773711902496871e-07
fractions O 0 6.003077146488067e-07
of O 0 1.318334454936121e-07
both O 0 4.6578009005315835e-07
G1 O 0 0.0013434604043141007
- O 0 1.7608097550692037e-05
and O 0 1.06114316622552e-06
S O 0 0.002164664911106229
- O 0 0.00012610042176675051
phase O 0 2.8611375455511734e-05
cells O 0 7.382490730378777e-05
. O 0 4.490610444918275e-05

Therefore O 0 5.293849972076714e-05
, O 0 5.906046681047883e-06
progression O 0 1.3683221368410159e-05
to O 0 1.8993735011463286e-06
S O 0 0.00013162512914277613
phase O 0 3.71885016647866e-06
is O 0 3.201440392786026e-07
accompanied O 0 8.271227329714748e-07
by O 0 2.2576992364520265e-07
the O 0 4.780761173606152e-07
aggregation O 0 3.5914395084546413e-06
of O 0 9.95995719677012e-07
nuclear O 0 1.4908594494045246e-05
BARD1 O 0 7.324932084884495e-05
polypeptides O 0 3.1981202482711524e-05
into O 0 6.435170234908583e-06
BRCA1 O 0 0.0002976969408337027
nuclear O 0 0.00011201704910490662
dots O 0 0.0002939050318673253
. O 0 8.477029041387141e-05

This O 0 6.643901724601164e-05
cell O 0 0.00041563756531104445
cycle O 0 0.00016802609025035053
- O 0 0.0001818222808651626
dependent O 0 6.330317773972638e-06
colocalization O 0 1.5129046914807986e-05
of O 0 5.207999720369116e-07
BARD1 O 0 0.00011963632277911529
and O 0 1.7968201291296282e-06
BRCA1 O 0 0.00014470265887212008
indicates O 0 2.061813120235456e-06
a O 0 4.6558602662116755e-07
role O 0 6.623175181630359e-07
for O 0 5.143330668033741e-07
BARD1 O 0 0.0013579896185547113
in O 0 9.449610843148548e-06
BRCA1 O 0 0.045293569564819336
- O 0 0.009345514699816704
mediated O 0 0.00029579378315247595
tumor B-Disease 0 0.0008005663403309882
suppression O 0 9.112646512221545e-05
. O 0 7.707867189310491e-05

Ethnic O 0 0.00038444894016720355
differences O 0 0.000154456720338203
in O 0 1.532325586595107e-05
the O 0 1.499032623542007e-05
HFE O 0 0.00430420832708478
codon O 0 0.0001362183247692883
282 O 0 9.246070112567395e-05
( O 0 1.674272607488092e-05
Cys O 0 0.15730296075344086
/ O 0 0.00017740008479449898
Tyr O 0 0.0011662818724289536
) O 0 1.2809517102141399e-05
polymorphism O 0 0.0001487570407334715
. O 0 4.0471113607054576e-05

Recent O 0 0.00018739906954579055
studies O 0 4.057553815073334e-05
have O 0 3.1755375857756007e-06
shown O 0 2.7907326511922292e-06
that O 0 1.4095195183472242e-05
hereditary B-Disease 1 0.9999998807907104
hemochromatosis I-Disease 1 1.0
( O 0 0.0012673783348873258
HH B-Disease 1 0.987400233745575
) O 0 7.072354719639407e-07
is O 0 1.4252285041038704e-07
likely O 0 4.868163046012342e-07
to O 0 1.6540445813006954e-07
be O 0 1.1942871935843868e-07
caused O 0 5.607994353340473e-07
by O 0 2.0998442096242798e-07
homozygosity O 0 3.701715831994079e-05
for O 0 3.2151416462511406e-07
a O 0 8.319785820276593e-07
Cys282Tyr O 0 0.0006524103228002787
mutation O 0 8.948669346864335e-06
in O 0 7.117037057469133e-07
the O 0 1.8389392835160834e-06
HFE O 0 0.006481833290308714
gene O 0 1.4738475329068024e-05
located O 0 6.237860361579806e-06
4 O 0 1.2072276149410754e-05
. O 0 2.7731173759093508e-05

5 O 0 0.0005438106600195169
Mb O 0 0.002899172715842724
telomeric O 0 0.002437387593090534
to O 0 9.456517727812752e-05
HLA O 0 0.00663726357743144
- O 0 0.0008591559599153697
A O 0 9.109901293413714e-05
. O 0 0.00012148754467489198

Population O 0 0.00012351323675829917
studies O 0 2.287901588715613e-05
of O 0 1.6706188716852921e-06
this O 0 1.1470705203464604e-06
polymorphism O 0 1.572919063619338e-05
are O 0 2.7041284056394943e-07
facilitated O 0 7.923893576844421e-07
by O 0 2.424982312732027e-07
the O 0 1.8228564613309572e-07
fact O 0 4.34328740084311e-07
that O 0 1.9754376978653454e-07
the O 0 7.46996590805793e-07
Cys282Tyr O 0 0.0017209583893418312
mutation O 0 1.0070445568999276e-05
creates O 0 3.4855502235586755e-06
a O 0 2.0265169951017015e-06
Rsal O 0 7.151606405386701e-05
restriction O 0 1.338152196694864e-05
site O 0 2.2095558961154893e-05
. O 0 2.5200175514328294e-05

We O 0 7.981596718309447e-05
have O 0 6.55304893371067e-06
studied O 0 6.835028671048349e-06
the O 0 1.474057626182912e-06
codon O 0 1.8717977582127787e-05
282 O 0 2.5324628950329497e-05
( O 0 4.919833827443654e-06
Cys O 0 0.022266121581196785
/ O 0 2.8359989300952293e-05
Tyr O 0 8.767589315539226e-05
) O 0 1.2239870557095855e-06
polymorphism O 0 8.259724381787237e-06
in O 0 8.646440505799546e-07
different O 0 1.5212551716103917e-06
ethnic O 0 8.700689249963034e-06
groups O 0 1.8044849639409222e-05
. O 0 3.331202606204897e-05

In O 0 1.8626027667778544e-05
agreement O 0 7.860903679102194e-06
with O 0 9.015465138872969e-07
previous O 0 1.6060702137110638e-06
observations O 0 1.5422890555782942e-06
the O 0 4.6898756522750773e-07
Tyr O 0 9.338321251561865e-05
allele O 0 8.666982466820627e-06
appeared O 0 1.0370513336965814e-06
to O 0 2.7305713956593536e-07
be O 0 1.888916756342951e-07
rare O 0 5.320816853782162e-07
or O 0 6.093868591960927e-07
absent O 0 3.5461703191685956e-06
in O 0 6.067760409678158e-07
Asiatic O 0 9.779470929061063e-06
( O 0 5.196078518565628e-07
Indian O 0 8.322595022036694e-07
, O 0 4.1079402990362723e-07
Chinese O 0 1.055207349054399e-06
) O 0 2.502522875147406e-06
populations O 0 1.3136274901626166e-05
. O 0 1.732004420773592e-05

The O 0 4.032210563309491e-05
highest O 0 2.8748181648552418e-05
allele O 0 3.8988884625723585e-05
frequency O 0 9.167607458948623e-06
( O 0 9.830625913309632e-07
7 O 0 5.820757564833912e-07
. O 0 1.9273629447980056e-07
5 O 0 4.2667977595556295e-07
% O 0 4.124018744278146e-07
) O 0 2.6661783181225474e-07
was O 0 8.114078582366346e-07
found O 0 1.1227418781345477e-06
in O 0 3.2298175938194618e-06
Swedes O 0 0.01689467579126358
. O 0 6.829816265963018e-05

Saamis O 0 0.009732049889862537
( O 0 6.520116585306823e-05
2 O 0 1.3299322745297104e-05
% O 0 2.331371888431022e-06
) O 0 4.5308419771572517e-07
and O 0 2.1309318753992557e-07
Mordvinians O 0 1.2750005225825589e-05
( O 0 2.976675261834316e-07
1 O 0 2.113111037260751e-07
. O 0 1.3147210609076865e-07
8 O 0 3.398762942197209e-07
% O 0 2.2969432222907926e-07
) O 0 1.4436245976412465e-07
had O 0 4.688766637173103e-07
significantly O 0 1.4869625601932057e-06
lower O 0 1.4003385331307072e-06
frequencies O 0 1.990655164263444e-06
of O 0 5.636443916046119e-07
the O 0 4.913499196845805e-06
Tyr O 0 0.0063280281610786915
allele O 0 0.00022595342306885868
. O 0 5.986451651551761e-05

Comparisons O 0 0.00020240350568201393
with O 0 1.804378189262934e-05
allele O 0 6.817316170781851e-05
frequencies O 0 1.2195165254524909e-05
based O 0 4.326318958192132e-06
on O 0 1.4456115877692355e-06
prevalence O 0 1.8499436919228174e-05
estimates O 0 3.159593916279846e-06
of O 0 6.406045827134221e-07
HH B-Disease 1 0.9671354293823242
showed O 0 3.137464545943658e-06
some O 0 1.3125111308909254e-07
disagreements O 0 1.6297291267619585e-06
with O 0 2.4893572003747977e-07
the O 0 8.38164055494417e-07
RFLP O 0 5.5785571021260694e-05
data O 0 2.5035922135430155e-06
, O 0 1.044795226334827e-06
particularly O 0 3.6343876672617625e-06
in O 0 3.895142981491517e-06
Finns O 0 0.00035798209137283266
. O 0 3.563775680959225e-05

The O 0 6.9112800701987e-05
newly O 0 7.231982453959063e-05
described O 0 2.3373324438580312e-05
HFE O 0 0.006177729927003384
marker O 0 1.5135800822463352e-05
provides O 0 1.743379016261315e-06
a O 0 5.224744654697133e-07
new O 0 6.662630767095834e-07
approach O 0 5.689488489224459e-07
to O 0 1.5149529986047128e-07
the O 0 1.258376443047382e-07
screening O 0 6.152907303658139e-07
of O 0 1.2400502669152047e-07
HH B-Disease 0 0.0039771380834281445
as O 0 1.8420584524392325e-07
well O 0 1.6293702742586902e-07
as O 0 9.760901775734965e-08
studies O 0 2.4506815066160925e-07
of O 0 5.486042908842137e-08
the O 0 2.34245632668717e-07
relationship O 0 1.2283206842766958e-06
between O 0 4.2408831291140814e-07
the O 0 2.124506636391743e-06
HFE O 1 0.5413568615913391
Tyr O 0 0.005212272051721811
allele O 0 2.2970705686020665e-05
and O 0 3.1045576633914607e-06
different O 0 1.0436109732836485e-05
disorders O 1 0.678545355796814
including O 0 0.0003092707775067538
cancer B-Disease 1 0.9738698601722717

Autosomal B-Disease 1 0.9981759786605835
dominant I-Disease 1 0.9843645691871643
neurohypophyseal I-Disease 1 0.9999948740005493
diabetes I-Disease 1 0.9999998807907104
insipidus I-Disease 1 0.9999594688415527
associated O 0 0.000146181570016779
with O 0 3.930870661861263e-06
a O 0 5.9044418776466046e-06
missense O 0 0.00013684126315638423
mutation O 0 2.5563587769283913e-05
encoding O 0 1.697760308161378e-05
Gly23 O 0 0.0012786313891410828
- O 0 0.014319884590804577
- O 0 0.001047594239935279
> O 0 9.809323091758415e-05
Val O 0 0.00038755263085477054
in O 0 8.835099833959248e-06
neurophysin O 0 0.002795442473143339
II O 0 0.001066669006831944
. O 0 4.921391882817261e-05

Autosomal B-Disease 1 0.9982792139053345
dominant I-Disease 1 0.9535323977470398
neurohypophyseal I-Disease 1 0.9999707937240601
diabetes I-Disease 1 0.9999996423721313
insipidus I-Disease 1 0.9999490976333618
( O 0 9.846960165305063e-05
ADNDI B-Disease 0 0.16139286756515503
) O 0 4.218100002617575e-06
is O 0 7.463294195986236e-07
an O 0 1.9975539544248022e-05
inherited B-Disease 1 1.0
disease I-Disease 1 0.9999990463256836
caused O 0 0.0015407518949359655
by O 0 3.931492756237276e-06
progressive O 0 0.23967786133289337
degeneration O 0 0.03876807168126106
of O 0 4.417194929828838e-07
the O 0 1.0771220786409685e-06
magnocellular O 0 0.005239092279225588
neurons O 0 7.479913165298058e-06
of O 0 1.8283301983501588e-07
the O 0 4.5655593794435845e-07
hypothalamus O 0 7.137419743230566e-06
leading O 0 1.1280178568995325e-06
to O 0 2.9066728757243254e-07
decreased O 0 1.235197373716801e-06
ability O 0 9.844700343819568e-07
to O 0 2.82604844414891e-07
produce O 0 8.760534342400206e-07
the O 0 9.383016390529519e-07
hormone O 0 1.4059511158848181e-05
arginine O 0 2.1987098079989664e-05
vasopressin O 0 7.401015318464488e-05
( O 0 6.573917744390201e-06
AVP O 0 0.00011519792315084487
) O 0 9.673339263827074e-06
. O 0 2.5157454729196616e-05

Affected O 0 0.00037026903009973466
individuals O 0 1.1575152711884584e-05
are O 0 1.0721433909566258e-06
not O 0 7.543236506535322e-07
symptomatic O 0 7.194044883362949e-06
at O 0 6.675185773019621e-07
birth O 0 3.737893848665408e-06
, O 0 3.875291270105663e-07
but O 0 1.0603764621919254e-06
usually O 0 4.286315288482001e-06
develop O 0 0.0001639029651414603
diabetes B-Disease 1 0.9941657781600952
insipidus I-Disease 0 0.3941710293292999
at O 0 3.484506578388391e-06
1 O 0 3.292489736850257e-06
- O 0 6.879829743411392e-05
6 O 0 5.89152250540792e-06
yr O 0 0.0002825306146405637
of O 0 2.3010704808257287e-06
age O 0 2.833041435224004e-05
. O 0 3.531631955411285e-05

The O 0 6.61279700580053e-05
genetic O 0 8.734010043554008e-05
locus O 0 6.025908805895597e-05
of O 0 1.909679212985793e-06
the O 0 1.1889399502251763e-05
disease O 0 0.0025503456126898527
is O 0 3.9904244886201923e-07
the O 0 8.659594072923937e-07
AVP O 0 0.0038921781815588474
- O 0 0.0022327543701976538
neurophysin O 0 0.001074896426871419
II O 0 0.00036985872429795563
( O 0 7.79412232532195e-07
NPII O 0 1.4716341866005678e-05
) O 0 2.5972977368837746e-07
gene O 0 5.041704298491823e-07
, O 0 1.0046878173852747e-07
and O 0 1.5636868511137436e-07
mutations O 0 9.416157809027936e-07
that O 0 1.3734656079122942e-07
cause O 0 1.3051136420472176e-06
ADNDI B-Disease 0 0.002772008068859577
have O 0 3.2849516173882876e-07
been O 0 1.656026995533466e-07
found O 0 1.482743812175613e-07
in O 0 9.095921882362745e-08
both O 0 9.497726694007724e-08
the O 0 2.3619634248461807e-07
signal O 0 1.0199756843576324e-06
peptide O 0 1.0667928336260957e-06
of O 0 9.026771863318572e-08
the O 0 7.14805480583891e-07
prepro O 0 0.0039649661630392075
- O 0 0.0011339307529851794
AVP O 0 0.00010360455053159967
- O 0 3.0170691388775595e-05
NPII O 0 2.7805001082015224e-05
precursor O 0 3.6541900954034645e-06
and O 0 1.0500555163162062e-06
within O 0 2.5673421077954117e-06
NPII O 0 0.0002161591110052541
itself O 0 3.868444764520973e-05
. O 0 3.72560643882025e-05

An O 0 4.514186002779752e-05
affected O 0 4.041056672576815e-05
girl O 0 2.9600052585010417e-05
who O 0 1.8785990505421069e-06
presented O 0 7.867209319556423e-07
at O 0 4.6933476482990955e-07
9 O 0 2.8095968218622147e-07
months O 0 2.260148761479286e-07
of O 0 7.931183887421867e-08
age O 0 2.7817674208563403e-07
and O 0 2.221022867843203e-07
her O 0 2.6830537080968497e-06
similarly O 0 1.7867565475171432e-05
affected O 0 2.022389253397705e-06
younger O 0 1.8545218836152344e-06
brother O 0 3.085069238295546e-06
and O 0 1.3447478863781726e-07
father O 0 3.580967131711077e-06
were O 0 1.0113459580907147e-07
all O 0 3.223651745543066e-08
found O 0 1.0517797477405111e-07
to O 0 1.231298085713206e-07
have O 0 2.461155474975385e-07
a O 0 6.934067755537399e-07
novel O 0 1.2335339306446258e-05
missense O 0 4.217089372104965e-05
mutation O 0 1.1057508345402312e-05
( O 0 1.1206504950678209e-06
G1758 O 0 3.1281160772778094e-05
- O 0 0.002962747123092413
- O 0 0.001102345995604992
> O 0 4.175471985945478e-05
T O 0 2.7412756026024e-05
) O 0 3.1179641268863634e-07
encoding O 0 6.46887997390877e-07
the O 0 3.9386199546243006e-07
amino O 0 1.7926096234077704e-06
acid O 0 3.4052493447234156e-06
substitution O 0 2.779205715341959e-06
Gly23 O 0 0.00012529114610515535
- O 0 0.0002667287481017411
- O 0 0.00015474774409085512
> O 0 6.501601455966011e-05
Val O 0 0.00012634065933525562
within O 0 9.007919288706034e-06
NPII O 0 0.0004260751884430647
. O 0 5.321343633113429e-05

The O 0 0.00014818467025179416
mutation O 0 0.0004072148585692048
was O 0 1.871612221293617e-05
confirmed O 0 1.1152259503433015e-05
by O 0 2.657260665728245e-06
restriction O 0 2.155254151148256e-05
endonuclease O 0 0.0003017807612195611
analysis O 0 6.992509588599205e-05
. O 0 5.177965067559853e-05

A O 0 0.0001912745792651549
T1 O 0 0.024467969313263893
- O 0 0.0001435471640434116
weighted O 0 1.53604632942006e-05
magnetic O 0 1.1391851330699865e-05
resonance O 0 2.0942670744261704e-05
imaging O 0 2.6308645828976296e-05
of O 0 8.385422347600979e-07
the O 0 2.9197965432103956e-06
fathers O 0 0.0002778693160507828
pituitary O 0 0.0002755866153165698
gland O 0 3.2939264201559126e-05
demonstrates O 0 7.126775471988367e-06
an O 0 1.6528744026800268e-06
attenuated O 0 0.00022193168115336448
posterior O 0 0.0007495978497900069
pituitary O 0 0.0014395233010873199
bright O 0 0.000111244989966508
spot O 0 6.390478665707633e-05
. O 0 4.3866821215488017e-05

This O 0 4.6225897676777095e-05
mutation O 0 0.00011995984823442996
may O 0 5.332370164978784e-06
be O 0 3.275922608736437e-07
valuable O 0 7.235507837322075e-07
for O 0 2.699330536870548e-07
developing O 0 1.8016897911365959e-06
models O 0 1.5442863059433876e-06
of O 0 6.325860226752411e-07
dominantly B-Disease 0 0.09652071446180344
inherited I-Disease 1 0.9996724128723145
neurodegeneration I-Disease 1 0.9999998807907104
, O 0 1.5788076552780694e-06
as O 0 1.7234677329724946e-07
the O 0 1.7360312654091103e-07
early O 0 1.1071500694015413e-06
age O 0 5.305656145537796e-07
of O 0 2.739293449849356e-07
onset O 0 0.02426600642502308
of O 0 2.114900325977942e-06
symptoms O 0 0.00328300753608346
suggests O 0 3.046699703190825e-06
that O 0 1.6832353821882862e-07
this O 0 2.64911108160959e-07
mutation O 0 6.56582233204972e-06
may O 0 9.64004357228987e-07
be O 0 1.68190041449634e-07
particularly O 0 7.316352252928482e-07
deleterious O 0 4.813279247173341e-06
to O 0 8.018337780413276e-07
the O 0 2.9669361083506374e-06
magnocellular O 0 0.004676204174757004
neuron O 0 0.00038990387110970914
. O 0 2.1337074940674938e-05
. O 0 4.405009531183168e-05

Frequent O 0 0.0011996112298220396
inactivation O 0 0.0016248825704678893
of O 0 4.3677060602931306e-05
PTEN O 0 0.00833943672478199
/ O 0 0.00041437576874159276
MMAC1 O 0 0.007408116944134235
in O 0 6.333124474622309e-05
primary O 1 0.9957823753356934
prostate B-Disease 1 1.0
cancer I-Disease 1 0.9999986886978149
. O 0 0.00019165081903338432

Sporadic B-Disease 1 0.9994651675224304
prostate I-Disease 1 1.0
carcinoma I-Disease 1 1.0
is O 0 5.500231509358855e-06
the O 0 1.2678120810960536e-06
most O 0 1.1104460782007664e-06
common O 0 3.594177087506978e-06
male B-Disease 0 0.0004890604177489877
cancer I-Disease 0 0.008335021324455738
in O 0 1.7541546526445018e-07
the O 0 1.1541730060571354e-07
Western O 0 3.110806119366316e-07
world O 0 4.1772810277507233e-07
, O 0 1.4487844168797892e-07
yet O 0 1.6988269635476172e-07
many O 0 5.012259052250556e-08
of O 0 3.2928738846749184e-08
the O 0 1.5278953924280358e-07
major O 0 8.449586630376871e-07
genetic O 0 1.832622615438595e-06
events O 0 3.945590094645013e-07
involved O 0 3.5162355516149546e-07
in O 0 1.1795113152857084e-07
the O 0 2.2151972700612532e-07
progression O 0 2.0334787222964223e-06
of O 0 1.38474476329975e-07
this O 0 6.286073244154977e-07
often O 0 6.381807179423049e-05
fatal O 1 0.9983530044555664
cancer B-Disease 1 0.9770674705505371
remain O 0 2.949900590465404e-06
to O 0 1.0563430805632379e-06
be O 0 3.0527844501193613e-06
elucidated O 0 0.00029666873160749674
. O 0 3.8253692764556035e-05

Numerous O 0 0.00011597129923757166
cytogenetic O 0 0.0012707174755632877
and O 0 2.412241155980155e-05
allelotype O 0 0.008557761088013649
studies O 0 3.849999120575376e-05
have O 0 4.237808298057644e-06
reported O 0 6.696777290926548e-06
frequent O 0 6.095471235312289e-06
loss O 0 4.224596341373399e-05
of O 0 6.980479270168871e-07
heterozygosity O 0 0.0010939831845462322
on O 0 4.564925347949611e-06
chromosomal O 0 0.00014568091137334704
arm O 0 0.0005599028081633151
10q O 0 0.0004120316298212856
in O 0 2.322350519534666e-05
sporadic B-Disease 1 0.977215588092804
prostate I-Disease 1 1.0
cancer I-Disease 1 0.9999991655349731
. O 0 0.0001978926593437791

Deletion O 0 0.0013129470171406865
mapping O 0 0.0002511728962417692
studies O 0 4.3990949052385986e-05
have O 0 2.2163603716762736e-06
unambiguously O 0 9.280308404413518e-06
identified O 0 3.066674025831162e-06
a O 0 7.127592880351585e-07
region O 0 5.347064870875329e-07
of O 0 2.2075818151279236e-07
chromosome O 0 2.9995628665346885e-06
10q23 O 0 8.467280167678837e-06
to O 0 3.295651822554646e-07
be O 0 1.9892382852049195e-07
the O 0 3.491494737772882e-07
minimal O 0 3.621316409407882e-06
area O 0 1.8277406752531533e-06
of O 0 2.3573013550048927e-06
loss O 0 0.004950003232806921
. O 0 7.992107566678897e-05

A O 0 0.00013277832476887852
new O 0 7.798324077157304e-05
tumor B-Disease 0 0.0007835168507881463
suppressor O 0 0.00013243667490314692
gene O 0 2.0260556993889622e-05
, O 0 3.2194232062465744e-06
PTEN O 0 0.0005545359454117715
/ O 0 4.4438180339057e-05
MMAC1 O 0 0.0006974642165005207
, O 0 5.836226932842692e-07
was O 0 1.0674218628992094e-06
isolated O 0 2.4194782781705726e-06
recently O 0 2.410351271464606e-06
at O 0 3.12843638994309e-07
this O 0 1.2726196985113347e-07
region O 0 3.2683306017133873e-07
of O 0 1.4669795689314924e-07
chromosome O 0 2.224958734586835e-06
10q23 O 0 1.3626744475914165e-05
and O 0 2.466846638071729e-07
found O 0 1.9635632497738698e-07
to O 0 1.4270972314989194e-07
be O 0 1.537315483801649e-07
inactivated O 0 8.494290000271576e-07
by O 0 1.9943612983297498e-07
mutation O 0 2.0506593045865884e-06
in O 0 1.6011579191399505e-06
three O 0 0.0017127481987699866
prostate B-Disease 1 1.0
cancer I-Disease 1 0.9999984502792358
cell O 0 0.022271955385804176
lines O 0 0.00030852301279082894
. O 0 8.926937152864411e-05

We O 0 8.544780575903133e-05
screened O 0 0.00010197222582064569
80 O 0 8.452248584944755e-05
prostate B-Disease 1 0.9998195767402649
tumors I-Disease 1 0.9995853304862976
by O 0 1.984483333217213e-06
microsatellite O 0 0.00014774317969568074
analysis O 0 4.6834447857690975e-06
and O 0 8.321968607560848e-07
found O 0 9.464079084864352e-07
chromosome O 0 2.7546761884877924e-06
10q23 O 0 7.83907398727024e-06
to O 0 3.821258758307522e-07
be O 0 3.3111231800830865e-07
deleted O 0 4.801038357982179e-06
in O 0 1.4132326668914175e-06
23 O 0 6.898924766574055e-06
cases O 0 1.3938239135313779e-05
. O 0 4.201714909868315e-05

We O 0 2.7071031581726857e-05
then O 0 3.450229087320622e-06
proceeded O 0 3.88755734093138e-06
with O 0 4.276122069768462e-07
sequence O 0 6.557096980941424e-07
analysis O 0 6.747497423020832e-07
of O 0 1.7437601229630673e-07
the O 0 8.325881708515226e-07
entire O 0 7.312080470001092e-06
PTEN O 0 0.05190145596861839
/ O 0 6.06112225796096e-05
MMAC1 O 0 0.00027686019893735647
coding O 0 1.7193096937262453e-05
region O 0 1.2924081147502875e-06
and O 0 3.611579302287282e-07
tested O 0 1.988507165151532e-06
for O 0 3.21014738347003e-07
homozygous O 0 7.613705292897066e-06
deletion O 0 2.981123088829918e-06
with O 0 2.784586285997648e-07
new O 0 7.624667546224373e-07
intragenic O 0 6.745084829162806e-05
markers O 0 1.7081662235796102e-06
in O 0 2.9588079542008927e-07
these O 0 2.5825670491030905e-07
23 O 0 8.588952482568857e-07
cases O 0 6.898318929415836e-07
with O 0 6.363581519508443e-07
10q23 O 0 0.0030066806357353926
loss O 0 0.00027520774165168405
of O 0 9.105084245675243e-06
heterozygosity O 0 0.16450758278369904
. O 0 9.501042950432748e-05

The O 0 1.8905411707237363e-05
identification O 0 6.771026164642535e-06
of O 0 5.346698230823677e-07
the O 0 5.41722840807779e-07
second O 0 1.8223852293886011e-06
mutational O 0 8.895334758562967e-05
event O 0 3.782733983825892e-06
in O 0 5.943123255747196e-07
10 O 0 6.954691116334288e-07
( O 0 6.276213184719381e-07
43 O 0 2.7842779672937468e-06
% O 0 1.9902640815416817e-06
) O 0 5.584273822023533e-06
tumors B-Disease 1 0.9925209283828735
establishes O 0 8.866677490004804e-06
PTEN O 0 0.0015904541360214353
/ O 0 1.3011296687182039e-05
MMAC1 O 0 2.1599087631329894e-05
as O 0 2.040346203102672e-07
a O 0 3.492560267659428e-07
main O 0 1.1139620710309828e-06
inactivation O 0 9.61367095442256e-06
target O 0 8.000960178833338e-07
of O 0 2.608764191336377e-07
10q O 0 2.0527395463432185e-05
loss O 0 2.2942685973248444e-05
in O 0 5.547917680814862e-06
sporadic B-Disease 1 0.9941323399543762
prostate I-Disease 1 1.0
cancer I-Disease 1 0.9999992847442627
. O 0 3.920329982065596e-05
. O 0 5.3565807320410386e-05

Risk O 0 0.002042158041149378
reversals O 0 0.00044328690273687243
in O 0 1.7890122762764804e-05
predictive O 0 0.0001748863433022052
testing O 0 0.00013713660882785916
for O 0 0.00022155385522637516
Huntington B-Disease 1 0.9999985694885254
disease I-Disease 1 0.9999030828475952
. O 0 0.00013504273374564946

The O 0 2.7885675081051886e-05
first O 0 1.274271107831737e-05
predictive O 0 5.533631701837294e-05
testing O 0 3.2802341593196616e-05
for O 0 6.799325637985021e-05
Huntington B-Disease 1 0.9999991655349731
disease I-Disease 1 0.9994893074035645
( O 0 2.259276698168833e-06
HD B-Disease 0 2.8536685931612737e-05
) O 0 4.20348811758231e-07
was O 0 2.8543371399791795e-07
based O 0 2.828065248650091e-07
on O 0 1.3225455575138767e-07
analysis O 0 5.344566602616396e-07
of O 0 1.8997924655650422e-07
linked O 0 7.829883543308824e-06
polymorphic O 0 2.1882546207052656e-05
DNA O 0 6.482865046564257e-06
markers O 0 1.7236960729860584e-06
to O 0 4.490107130550314e-07
estimate O 0 1.1401276651668013e-06
the O 0 3.380446855771879e-07
likelihood O 0 1.9270758002676303e-06
of O 0 2.0132203815137473e-07
inheriting O 0 1.0355636732128914e-05
the O 0 1.3450894584821071e-06
mutation O 0 1.384291590511566e-05
for O 0 3.884348188876174e-06
HD B-Disease 0 0.00022985863324720412
. O 0 3.503698462736793e-05

Limits O 0 4.4937933125765994e-05
to O 0 2.823316208377946e-06
accuracy O 0 2.9782415822410258e-06
included O 0 7.558206789326505e-07
recombination O 0 2.6913826332020108e-06
between O 0 2.9955268132653146e-07
the O 0 3.5332271863808273e-07
DNA O 0 1.963106114999391e-06
markers O 0 9.621426215744577e-07
and O 0 1.4863768171835545e-07
the O 0 2.4183952973544365e-07
mutation O 0 2.6641400836524554e-06
, O 0 3.680904967495735e-07
pedigree O 0 5.241690814727917e-06
structure O 0 5.567081302615406e-07
, O 0 1.303002790109531e-07
and O 0 1.1032086177920064e-07
whether O 0 1.9285985786154924e-07
DNA O 0 8.116508638522646e-07
samples O 0 4.4881420535602956e-07
were O 0 1.704240162325732e-07
available O 0 2.7336199082128587e-07
from O 0 5.670199811902421e-07
family O 0 8.710062502359506e-06
members O 0 5.407202479545958e-06
. O 0 2.084364678012207e-05

With O 0 1.4212600035534706e-05
direct O 0 7.555320280516753e-06
tests O 0 4.496107521845261e-06
for O 0 4.7074186682039e-07
the O 0 5.40176699814765e-07
HD B-Disease 0 1.6287520338664763e-05
mutation O 0 2.050271859843633e-06
, O 0 2.746078280324582e-07
we O 0 1.1228431162635388e-07
have O 0 8.362600567579648e-08
assessed O 0 3.059815583128511e-07
the O 0 7.383009403838514e-08
accuracy O 0 4.889421347797906e-07
of O 0 9.784574217519548e-08
results O 0 1.908033482322935e-06
obtained O 0 2.867312787202536e-07
by O 0 1.293879137165277e-07
linkage O 0 1.535070964564511e-06
approaches O 0 9.741257827045047e-07
when O 0 4.089358185410674e-07
requested O 0 3.413243234717811e-07
to O 0 1.52804986441879e-07
do O 0 2.1161804397706874e-07
so O 0 1.2464064980122203e-07
by O 0 2.3927884740260197e-07
the O 0 1.135140223595954e-06
test O 0 1.274448550248053e-05
individuals O 0 8.698299097886775e-06
. O 0 2.315287565579638e-05

For O 0 1.0820541319844779e-05
six O 0 3.893033408530755e-06
such O 0 7.977577070050756e-07
individuals O 0 7.770246952532034e-07
, O 0 2.7052888640355377e-07
there O 0 1.4583645224774955e-07
was O 0 8.863717084750533e-07
significant O 0 9.454237215322792e-07
disparity O 0 3.7506347325688694e-06
between O 0 9.001221883409016e-07
the O 0 3.609238547142013e-06
tests O 0 3.843506419798359e-05
. O 0 3.792619827436283e-05

Three O 0 2.34475992328953e-05
went O 0 9.931901331583504e-06
from O 0 1.1138558875245508e-06
a O 0 9.6579503860994e-07
decreased O 0 2.3345166482613422e-05
risk O 0 3.3271410302404547e-06
to O 0 2.0637870079553977e-07
an O 0 1.547314241179265e-07
increased O 0 1.303332510360633e-06
risk O 0 3.2373604881286155e-06
, O 0 1.387505079719631e-07
while O 0 1.4507656942441827e-07
in O 0 8.763980474668642e-08
another O 0 2.5354867716487206e-07
three O 0 3.4014865946119244e-07
the O 0 2.516350605219486e-06
risk O 0 6.270392623264343e-05
was O 0 2.0951740225427784e-05
decreased O 0 9.287949069403112e-05
. O 0 5.2308452723082155e-05

Knowledge O 0 3.19555911119096e-05
of O 0 1.455767801417096e-06
the O 0 1.0762186093415949e-06
potential O 0 1.071252199835726e-06
reasons O 0 6.621748411816952e-07
for O 0 9.993632943405828e-08
these O 0 7.49325579363358e-08
changes O 0 3.201556353360502e-07
in O 0 1.8826222003553994e-07
results O 0 1.4616216503782198e-06
and O 0 1.945657288615621e-07
impact O 0 3.293999100151268e-07
of O 0 5.0383782479457295e-08
these O 0 1.847942456834062e-07
risk O 0 9.368112046104216e-07
reversals O 0 1.7091439303840161e-06
on O 0 1.7394782503288297e-07
both O 0 5.54758798898547e-07
patients O 0 8.228707883972675e-06
and O 0 1.1451114545479868e-07
the O 0 1.729843575049017e-07
counseling O 0 5.710052846552571e-06
team O 0 3.820653944330843e-07
can O 0 1.1260257792855555e-07
assist O 0 2.0215242102494813e-07
in O 0 1.2059680898346414e-07
the O 0 1.3247975516605948e-07
development O 0 2.2167147051277425e-07
of O 0 7.743941665694365e-08
strategies O 0 1.6078786302387016e-06
for O 0 1.4589531360797992e-07
the O 0 2.7883120878868795e-07
prevention O 0 1.1264655768172815e-06
and O 0 1.4851865159926092e-07
, O 0 8.852348543086919e-08
where O 0 1.209084246056591e-07
necessary O 0 3.7168251765251625e-07
, O 0 1.7388778417171125e-07
management O 0 7.087925268933759e-07
of O 0 1.0137387818076604e-07
a O 0 2.1087396362418076e-06
risk O 0 8.775671631156001e-06
reversal O 0 3.729163381649414e-06
in O 0 2.756694925665215e-07
any O 0 3.659375522602204e-07
predictive O 0 1.3320634025149047e-05
testing O 0 3.2874443149921717e-06
program O 0 4.334678123996127e-06
. O 0 4.465477559278952e-06
. O 0 1.679559500189498e-05

A O 0 0.00019584849360398948
novel O 0 0.00010897524043684825
common O 0 2.948943802039139e-05
missense O 0 0.00015996208821889013
mutation O 0 2.214612322859466e-05
G301C O 0 3.075004860875197e-05
in O 0 7.10998165232013e-07
the O 0 6.58003727949108e-07
N O 0 1.9682665879372507e-05
- O 0 5.005662387702614e-05
acetylgalactosamine O 0 0.00015740653907414526
- O 0 0.00019404989143367857
6 O 0 4.291861387173412e-06
- O 0 3.42210078088101e-05
sulfate O 0 6.520290480693802e-05
sulfatase O 0 0.0002232894184999168
gene O 0 1.6243500795098953e-05
in O 0 9.185223461827263e-06
mucopolysaccharidosis B-Disease 0 0.0007814353448338807
IVA I-Disease 0 0.00107191049028188
. O 0 6.715030031045899e-05

Mucopolysaccharidosis B-Disease 1 0.9263095259666443
IVA I-Disease 1 0.9698644876480103
( O 0 0.001048036850988865
MPS B-Disease 1 0.9999279975891113
IVA I-Disease 1 0.9999116659164429
) O 0 1.0731135262176394e-05
is O 0 1.3307696917763678e-06
an O 0 2.1685316369257635e-06
autosomal B-Disease 1 0.7050591111183167
recessive I-Disease 1 0.997258186340332
lysosomal I-Disease 1 0.9999880790710449
storage I-Disease 1 0.9996459484100342
disorder I-Disease 1 0.9895304441452026
caused O 0 6.694289186270908e-05
by O 0 2.2097017335909186e-06
a O 0 0.0008000374073162675
genetic B-Disease 1 0.9997689127922058
defect I-Disease 1 0.9993607401847839
in O 0 3.343918024256709e-06
N O 0 0.0004385682404972613
- O 0 0.0007059429190121591
acetylgalactosamine O 0 0.0020358513575047255
- O 0 0.0023010997101664543
6 O 0 9.756945473782253e-06
- O 0 0.0001635936350794509
sulfate O 0 0.000307243230054155
sulfatase O 0 0.0028584853280335665
( O 0 1.3464677067531738e-05
GALNS O 0 0.00037192911258898675
) O 0 1.1022281796613242e-05
. O 0 2.4499560822732747e-05

In O 0 3.328840102767572e-05
previous O 0 1.8545944840298034e-05
studies O 0 1.0849308637261856e-05
, O 0 9.13320093332004e-07
we O 0 4.6335753722814843e-07
have O 0 2.0762159635978605e-07
found O 0 2.1796769544835115e-07
two O 0 2.0520977273008612e-07
common O 0 1.4639372238889337e-06
mutations O 0 4.7397315938724205e-06
in O 0 4.823406243303907e-07
Caucasians O 0 5.014094313082751e-06
and O 0 7.568636988253274e-07
Japanese O 0 4.748793799080886e-06
, O 0 2.7380995106796036e-06
respectively O 0 2.089646841341164e-05
. O 0 2.36952710110927e-05

To O 0 4.792288746102713e-05
characterize O 0 0.00012122555199312046
the O 0 7.624204954481684e-06
mutational O 0 0.00013764886534772813
spectrum O 0 2.107775981130544e-05
in O 0 1.3329403145689867e-06
various O 0 5.446060526992369e-07
ethnic O 0 1.1146486258439836e-06
groups O 0 5.86079579534271e-07
, O 0 4.0494472841601237e-07
mutations O 0 1.5088149893927039e-06
in O 0 1.568190981515727e-07
the O 0 2.5233194378415646e-07
GALNS O 0 5.1903636631323025e-05
gene O 0 2.168370428989874e-06
in O 0 7.29867849713628e-07
Colombian O 0 8.337915460288059e-06
MPS B-Disease 1 0.999925971031189
IVA I-Disease 1 0.9999804496765137
patients O 0 0.005028621293604374
were O 0 5.003829528504866e-07
investigated O 0 2.226013521067216e-06
, O 0 2.4614558924440644e-07
and O 0 3.0652481086690386e-07
genetic O 0 2.202725227107294e-06
backgrounds O 0 1.2688160495599732e-06
were O 0 2.3380417246698926e-07
extensively O 0 7.07584888459678e-07
analyzed O 0 1.7352875829601544e-06
to O 0 3.582735814688931e-07
identify O 0 8.914631735024159e-07
racial O 0 9.411983228346799e-07
origin O 0 7.334306246775668e-07
, O 0 3.103137657944899e-07
based O 0 4.837806955038104e-07
on O 0 4.963663400303631e-07
mitochondrial O 0 2.2052530766814016e-05
DNA O 0 3.969222598243505e-05
( O 0 4.583381723932689e-06
mtDNA O 0 2.0246226995368488e-05
) O 0 5.598607458523475e-06
lineages O 0 3.542010017554276e-05
. O 0 2.274568032589741e-05

Three O 0 8.897124644136056e-05
novel O 0 0.00013722451694775373
missense O 0 0.0005269088433124125
mutations O 0 0.00013034390576649457
never O 0 1.8226064639748074e-05
identified O 0 4.252666713000508e-06
previously O 0 1.740461925692216e-06
in O 0 3.695181192142627e-07
other O 0 2.70188820650219e-07
populations O 0 5.439488859337871e-07
and O 0 1.873166297627904e-07
found O 0 2.1639112901539193e-07
in O 0 1.1330599392067597e-07
16 O 0 1.8058408102206158e-07
out O 0 1.426585498620625e-07
of O 0 1.9198854772639606e-07
19 O 0 2.447080532874679e-06
Colombian O 0 1.289912688662298e-05
MPS B-Disease 1 0.9870824813842773
IVA I-Disease 1 0.8396825194358826
unrelated O 0 3.844979437417351e-05
alleles O 0 1.891525971586816e-05
account O 0 6.015088274580194e-06
for O 0 4.0748163883108646e-06
84 O 0 9.712299652164802e-05
. O 0 7.363878830801696e-05

2 O 0 7.884254591772333e-05
% O 0 8.893402991816401e-06
of O 0 7.292632631106244e-07
the O 0 1.4640573908764054e-06
alleles O 0 8.810565304884221e-06
in O 0 1.1461847861937713e-06
this O 0 3.0565072393073933e-06
study O 0 2.873338235076517e-05
. O 0 4.335706034908071e-05

The O 0 0.00014430249575525522
G301C O 0 0.0005603287718258798
and O 0 1.940196489158552e-05
S162F O 0 0.000261223700363189
mutations O 0 5.9053647419204935e-05
account O 0 1.0945186659228057e-05
for O 0 7.53781023377087e-06
68 O 0 0.00011447496945038438
. O 0 8.237468136940151e-05

4 O 0 0.00033385399729013443
% O 0 6.571038102265447e-05
and O 0 1.6482215869473293e-05
10 O 0 2.659655365278013e-05
. O 0 5.221879473538138e-05

5 O 0 7.401085167657584e-05
% O 0 8.121657629089896e-06
of O 0 1.101202542486135e-06
mutations O 0 8.070620424405206e-06
, O 0 4.6626900029878016e-07
respectively O 0 7.862604434194509e-07
, O 0 3.2771225733085885e-07
whereas O 0 5.09400251758052e-07
the O 0 2.51303617915255e-07
remaining O 0 9.007138146444049e-07
F69V O 0 0.0002221787435701117
is O 0 4.236222537201684e-07
limited O 0 6.830615575381671e-07
to O 0 6.042790801075171e-07
a O 0 2.0728323306684615e-06
single O 0 1.2086031347280368e-05
allele O 0 0.0001354241685476154
. O 0 7.072662992868572e-05

The O 0 9.798516111914068e-05
skewed O 0 0.00027647375827655196
prevalence O 0 8.847410208545625e-05
of O 0 2.00294175556337e-06
G301C O 0 2.600958941911813e-05
in O 0 7.179220915531914e-07
only O 0 4.420115260472812e-07
Colombian O 0 4.6335585466295015e-06
patients O 0 1.2855272871092893e-05
and O 0 8.425012651969155e-07
haplotype O 0 1.8183529391535558e-05
analysis O 0 1.200278688884282e-06
by O 0 3.630448190961033e-07
restriction O 0 7.546532287960872e-07
fragment O 0 4.0442400859319605e-06
length O 0 2.067188233922934e-06
polymorphisms O 0 7.422724593197927e-06
in O 0 2.8555786002470995e-07
the O 0 5.235663138591917e-07
GALNS O 0 0.0004210122278891504
gene O 0 3.702514959513792e-06
suggest O 0 1.4541276414092863e-06
that O 0 2.653804074270738e-07
G301C O 0 8.430393791059032e-06
originated O 0 1.4714001963511691e-06
from O 0 4.5261782588568167e-07
a O 0 1.949908892129315e-06
common O 0 1.1059786629630253e-05
ancestor O 0 8.38940468383953e-05
. O 0 4.142690886510536e-05

Investigation O 0 7.098318747011945e-05
of O 0 2.6003810944530414e-06
the O 0 3.416324943827931e-06
genetic O 0 1.0638126695994288e-05
background O 0 2.3267496089829365e-06
by O 0 3.12690303871932e-07
means O 0 4.5964247874508146e-07
of O 0 1.3054467729034513e-07
mtDNA O 0 4.195225301373284e-06
lineages O 0 1.8838987898561754e-06
indicate O 0 5.255297992334818e-07
that O 0 1.0039810405260141e-07
all O 0 1.3952195843103254e-07
our O 0 1.157979340860038e-06
patients O 0 1.5588253518217243e-05
are O 0 3.2009455708248424e-07
probably O 0 1.3560787692767917e-06
of O 0 1.0300481108060922e-06
native O 0 9.38542143558152e-06
American O 0 4.036065365653485e-05
descent O 0 0.0020242820028215647

Low O 0 0.0005324832745827734
frequency O 0 0.00012453134695533663
of O 0 9.157970453088637e-06
BRCA1 O 0 0.0005935262306593359
germline O 0 0.0005760997300967574
mutations O 0 2.5643870685598813e-05
in O 0 1.767667868080025e-06
45 O 0 8.910144060791936e-06
German O 1 0.9647841453552246
breast B-Disease 1 0.9999988079071045
/ I-Disease 1 0.9999985694885254
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
families O 0 0.0008503946592099965
. O 0 0.00014564006414730102

In O 0 1.760245686455164e-05
this O 0 2.2292317680694396e-06
study O 0 2.929513811977813e-06
we O 0 7.240236072902917e-07
investigated O 0 3.884236775775207e-06
45 O 0 4.627076123142615e-06
German O 1 0.5266485214233398
breast B-Disease 1 0.9999879598617554
/ I-Disease 1 0.9999961853027344
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999980926513672
families O 0 1.9068502297159284e-05
for O 0 4.56153929917491e-06
germline O 0 0.10594072937965393
mutations O 0 4.003569119959138e-05
in O 0 2.996514922415372e-06
the O 0 9.94341644400265e-06
BRCA1 O 0 0.001465954352170229
gene O 0 0.00015391656779684126
. O 0 7.035114686004817e-05

We O 0 0.00010307222692063078
identified O 0 3.082400144194253e-05
four O 0 8.556817192584276e-06
germline O 0 0.0005838060169480741
mutations O 0 1.9947825421695597e-05
in O 0 1.4258472447181703e-06
three O 0 1.0960877261823043e-05
breast B-Disease 1 0.9998667240142822
cancer I-Disease 1 0.7705576419830322
families O 0 1.1315972869851976e-06
and O 0 3.612805699049204e-07
in O 0 5.578023092311923e-07
one O 0 0.00010877693421207368
breast B-Disease 1 0.9999990463256836
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
family O 0 3.280205783084966e-05
. O 0 3.5092003258796467e-07
among O 0 1.7490063441982784e-07
these O 0 1.0737319655618194e-07
were O 0 2.2822351297691057e-07
one O 0 4.1239556480832107e-07
frameshift O 0 0.011496189050376415
mutation O 0 7.771085620333906e-06
, O 0 3.032808990610647e-07
one O 0 1.5519147211762174e-07
nonsense O 0 5.977318323857617e-06
mutation O 0 3.4574261462694267e-06
, O 0 2.5246964696634677e-07
one O 0 2.7824415838040295e-07
novel O 0 2.455285766700399e-06
splice O 0 6.369440234266222e-05
site O 0 5.107602191856131e-06
mutation O 0 7.0784608396934345e-06
, O 0 4.832209015148692e-07
and O 0 9.371561304760689e-07
one O 0 5.518089437828166e-06
missense O 0 0.0003742557601071894
mutation O 0 0.0002492387138772756
. O 0 6.195777677930892e-05

The O 0 0.00010145427950192243
missense O 0 0.0010058451443910599
mutation O 0 0.00027105252956971526
was O 0 1.3499236047209706e-05
also O 0 2.7705682441592216e-06
found O 0 2.704855432966724e-06
in O 0 3.067329089390114e-06
2 O 0 1.3206944458943326e-05
. O 0 2.890096220653504e-05

8 O 0 9.576557931723073e-05
% O 0 6.7882638177252375e-06
of O 0 4.7080968101909093e-07
the O 0 3.4518379266046395e-07
general O 0 7.621657687195693e-07
population O 0 4.737082974770601e-07
, O 0 2.3151856964886974e-07
suggesting O 0 1.0850184253285988e-06
that O 0 1.4351687127600599e-07
it O 0 2.63420702140138e-07
is O 0 9.410574079993239e-07
not O 0 1.5979492673068307e-05
disease O 0 0.001593434251844883
associated O 0 3.0260189305408858e-05
. O 0 3.0395458452403545e-05

The O 0 6.33275558357127e-05
average O 0 4.297513805795461e-05
age O 0 9.141591363004409e-06
of O 0 2.3949969545356e-06
disease O 0 0.04155983030796051
onset O 0 0.18879684805870056
in O 0 4.59764851257205e-06
those O 0 4.171567070443416e-06
families O 0 2.5744628146640025e-05
harbouring O 0 0.010386932641267776
causative O 0 0.0003082049370277673
mutations O 0 3.1372223020298406e-05
was O 0 2.809044644891401e-06
between O 0 3.5977093375549885e-06
32 O 0 3.210447175661102e-05
. O 0 3.5377295716898516e-05

3 O 0 0.00033897714456543326
and O 0 9.384616714669392e-05
37 O 0 0.00016875923029147089
. O 0 7.515618926845491e-05

4 O 0 0.00013812507677357644
years O 0 2.6667768906918354e-05
, O 0 2.424011881885235e-06
whereas O 0 2.6466436793270987e-06
the O 0 1.08527933662117e-06
family O 0 7.954459761094768e-06
harbouring O 0 8.231736137531698e-05
the O 0 1.5976238501025364e-06
missense O 0 6.271880556596443e-05
mutation O 0 1.081621758203255e-05
had O 0 1.6747279687479022e-06
an O 0 2.850958082944999e-07
average O 0 3.501675791994785e-06
age O 0 1.1203661642866791e-06
of O 0 6.072438054616214e-07
onset O 0 0.001245275023393333
of O 0 4.025538601126755e-06
51 O 0 0.00014429398288484663
. O 0 6.257686618482694e-05

2 O 0 0.000872264092322439
years O 0 0.00045419554226100445
. O 0 0.00028872204711660743

These O 0 3.087324876105413e-05
findings O 0 2.4208182367146946e-05
show O 0 4.183099918009248e-06
that O 0 8.857767284098372e-07
BRCA1 O 0 3.525400097714737e-05
is O 0 6.737363378306327e-07
implicated O 0 3.775900268010446e-06
in O 0 2.7399883606449293e-07
a O 0 2.3424340156452672e-07
small O 0 3.9453721001336817e-07
fraction O 0 1.323005108133657e-06
of O 0 2.4942362415458774e-06
breast B-Disease 1 0.9999890327453613
/ I-Disease 1 0.9999984502792358
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
families O 0 1.8279260984854773e-05
suggesting O 0 3.613781700551044e-06
the O 0 4.40840381088492e-07
involvement O 0 2.3166510345618008e-06
of O 0 7.019117447271128e-07
another O 0 8.523815267835744e-06
susceptibility O 0 0.0008247544174082577
gene O 0 9.436303662369028e-05
( O 0 2.4663373551447876e-05
s O 0 0.0050218598917126656
) O 0 8.386493573198095e-05

Paternal O 0 0.07672511786222458
transmission O 0 0.07147879898548126
of O 0 0.0012422658037394285
congenital B-Disease 1 0.9999991655349731
myotonic I-Disease 1 0.9999998807907104
dystrophy I-Disease 1 0.9999998807907104
. O 0 0.017413608729839325

We O 0 9.598079486750066e-05
report O 0 3.213086893083528e-05
a O 0 7.54896791477222e-06
rare O 0 1.0382811524323188e-05
case O 0 6.1468640524253715e-06
of O 0 8.512378371960949e-06
paternally O 1 0.9861932396888733
transmitted O 1 0.935900092124939
congenital B-Disease 1 0.9999994039535522
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.43776848912239075
DM B-Disease 1 0.9999992847442627
) O 0 0.00011014899064321071
. O 0 8.566302130930126e-05

The O 0 3.098444358329289e-05
proband O 0 0.00014361849753186107
is O 0 1.496662321187614e-06
a O 0 1.205942112392222e-06
23 O 0 1.2220463077028398e-06
year O 0 1.1019526482414221e-06
old O 0 5.1076338422717527e-05
, O 0 2.6991659979103133e-05
mentally B-Disease 1 0.9999988079071045
retarded I-Disease 1 0.9999876022338867
male O 0 0.002308968920260668
who O 0 0.11232014000415802
suffers O 1 0.9999784231185913
severe O 1 0.9999097585678101
muscular B-Disease 1 0.9999334812164307
weakness I-Disease 1 0.9971556663513184
. O 0 0.0003475950506981462

He O 0 7.730568904662505e-05
presented O 0 3.803133586188778e-05
with O 0 9.57216525421245e-06
respiratory O 0 0.10530228167772293
and O 0 5.0150169954576995e-06
feeding O 0 3.924920019926503e-05
difficulties O 0 0.0005907160812057555
at O 0 2.449890598654747e-05
birth O 0 0.0003690220764838159
. O 0 6.330998439807445e-05

His O 0 0.00016738120757509023
two O 0 8.196893759304658e-05
sibs O 1 0.9795197248458862
suffer O 0 0.28365856409072876
from O 0 5.336919639375992e-05
childhood O 0 0.21944254636764526
onset O 1 0.9998894929885864
DM B-Disease 1 0.9999997615814209
. O 0 0.0004251341742929071

Their O 0 4.1577586671337485e-05
late O 0 3.610059866332449e-05
father O 0 2.377785131102428e-05
had O 0 3.15075976686785e-06
the O 0 5.572329087044636e-07
adult O 0 2.3858485747041414e-06
type O 0 2.1912453576078406e-06
of O 0 8.171107310772641e-07
DM B-Disease 1 0.9999969005584717
, O 0 1.1430115591792855e-06
with O 0 6.09162555065268e-07
onset O 0 0.0001979860826395452
around O 0 1.4749379033673904e-06
30 O 0 3.6133749290456763e-06
years O 0 8.320870620082133e-06
. O 0 1.8837637981050648e-05

Only O 0 1.999314918066375e-05
six O 0 4.816134151042206e-06
other O 0 4.4658676756625937e-07
cases O 0 5.472393809213827e-07
of O 0 2.5053307695088733e-07
paternal O 0 9.88327301456593e-05
transmission O 0 0.0004258484113961458
of O 0 1.0328168173145968e-05
congenital B-Disease 1 0.9999998807907104
DM I-Disease 1 1.0
have O 0 0.00034939878969453275
been O 0 1.534192961116787e-05
reported O 0 7.272412040038034e-05
recently O 0 0.000100655437563546
. O 0 8.240941679105163e-05

We O 0 4.829845784115605e-05
review O 0 2.2534868548973463e-05
the O 0 2.2661454295302974e-06
sex O 0 5.421810783445835e-06
related O 0 3.966849817516049e-06
effects O 0 9.079973096959293e-06
on O 0 1.8170782141169184e-06
transmission O 0 7.364757038885728e-05
of O 0 3.568955435184762e-05
congenital B-Disease 1 0.9999980926513672
DM I-Disease 1 0.9999997615814209
. O 0 0.00035011200816370547

Decreased O 0 0.0020295833237469196
fertility O 0 0.00040989069384522736
of O 0 3.7087702366989106e-06
males O 0 6.629294148297049e-06
with O 0 1.3034567700742627e-06
adult O 0 4.657039971789345e-05
onset O 1 0.9818207621574402
DM B-Disease 1 0.9999996423721313
and O 0 2.8049594220647123e-06
contraction O 0 9.274274816561956e-06
of O 0 2.403523922112072e-07
the O 0 4.927422310174734e-07
repeat O 0 4.767638984048972e-06
upon O 0 6.823545390943764e-07
male O 0 1.1365592627043952e-06
transmission O 0 1.917127747219638e-06
contribute O 0 4.959802026860416e-07
to O 0 1.3798066333947645e-07
the O 0 1.8239137489217683e-07
almost O 0 3.496552949400211e-07
absent O 0 3.3613687264733016e-06
occurrence O 0 2.12796771847934e-06
of O 0 5.705898615815386e-07
paternal O 0 0.0003136254090350121
transmission O 0 0.00023567651805933565
of O 0 5.3482861403608695e-05
congenital B-Disease 1 0.9999992847442627
DM I-Disease 1 0.9999998807907104
. O 0 0.00033804887789301574

Also O 0 3.3320215152343735e-05
the O 0 3.74201681552222e-06
fathers O 0 7.776572601869702e-06
of O 0 3.7523483342738473e-07
the O 0 8.805128572930698e-07
reported O 0 2.3185664758784696e-05
congenitally O 0 0.006874378304928541
affected O 0 7.783710316289216e-06
children O 0 2.185948005717364e-06
showed O 0 1.8233761238661828e-06
, O 0 2.0261543909327884e-07
on O 0 2.0209110118685203e-07
average O 0 1.3476187632477377e-06
, O 0 4.867684992859722e-07
shorter O 0 1.5088960935827345e-05
CTG O 0 5.922536729485728e-05
repeat O 0 6.275043688219739e-06
lengths O 0 7.43524333302048e-06
and O 0 5.059564500697888e-07
hence O 0 3.086926426476566e-06
less O 0 4.371021532278974e-06
severe O 1 0.7286748290061951
clinical O 1 0.9125486612319946
symptoms O 0 0.0008493143250234425
than O 0 7.050077783787856e-07
the O 0 1.1808241424660082e-06
mothers O 0 8.942893146013375e-06
of O 0 7.282686738108168e-07
children O 0 3.755198122235015e-05
with O 0 0.0010807336075231433
congenital B-Disease 1 0.9999992847442627
DM I-Disease 1 0.9999998807907104
. O 0 0.0009372038766741753

We O 0 5.551978392759338e-05
conclude O 0 4.869758049608208e-05
that O 0 2.369470166740939e-06
paternal O 0 3.69985937140882e-05
transmission O 0 6.516261782962829e-05
of O 0 8.251504368672613e-06
congenital B-Disease 1 0.9999998807907104
DM I-Disease 1 1.0
is O 0 4.722266112366924e-06
rare O 0 3.6431249554880196e-06
and O 0 6.173096949169121e-07
preferentially O 0 3.3208202694368083e-06
occurs O 0 6.533602459057875e-07
with O 0 3.4435061024851166e-07
onset O 0 5.303076250129379e-05
of O 0 7.141193236748222e-07
DM B-Disease 1 0.9999308586120605
past O 0 2.1468270006153034e-06
30 O 0 8.860454840942111e-07
years O 0 3.882137775690353e-07
in O 0 3.7961814314257936e-07
the O 0 9.469189308219939e-07
father O 0 7.947276026243344e-05
. O 0 1.1985539458692074e-05
. O 0 4.649612310458906e-05

The O 0 0.00032761614420451224
RB1 O 0 0.05921453237533569
gene O 0 0.0001790569949662313
mutation O 0 8.267860539490357e-05
in O 0 4.778341008204734e-06
a O 0 6.789837243559305e-06
child O 0 6.483634206233546e-05
with O 0 4.498119233176112e-05
ectopic B-Disease 1 0.9998273849487305
intracranial I-Disease 1 0.9999806880950928
retinoblastoma I-Disease 1 0.9936309456825256
. O 0 0.0002816568303387612

The O 0 0.0001752910320647061
RB1 O 0 0.09174136072397232
gene O 0 0.00011837569763883948
mutation O 0 6.383181607816368e-05
was O 0 5.498359314515255e-06
investigated O 0 7.299455774045782e-06
in O 0 5.805068781228329e-07
a O 0 1.499702761975641e-06
child O 0 3.444689355092123e-05
with O 0 7.825762622815091e-06
ectopic B-Disease 1 0.9966817498207092
intracranial I-Disease 1 0.9978419542312622
retinoblastoma I-Disease 0 0.0017284209607169032
using O 0 2.6444388367963256e-06
DNA O 0 5.006992978451308e-06
obtained O 0 1.9223016352043487e-06
from O 0 1.840894157112416e-07
both O 0 1.9657515792914637e-07
the O 0 4.5565991513285553e-07
pineal B-Disease 0 5.3624888096237555e-05
and I-Disease 0 1.962437636393588e-05
retinal I-Disease 1 0.9869502186775208
tumours I-Disease 1 0.9999659061431885
of O 0 2.0563970792863984e-06
the O 0 1.189282465929864e-05
patient O 0 0.0018945634365081787
. O 0 6.91259847371839e-05

A O 0 0.00016208025044761598
nonsense O 0 0.000330090697389096
mutation O 0 9.51660331338644e-05
in O 0 4.3398608795541804e-06
exon O 0 3.605057281674817e-05
17 O 0 3.2493619528395357e-06
( O 0 5.472164161801629e-07
codon O 0 2.879583462345181e-06
556 O 0 2.688960876184865e-06
) O 0 2.424996239369648e-07
of O 0 7.571193805233634e-08
the O 0 5.483380505211244e-07
RB1 O 0 0.0004125372797716409
gene O 0 2.2917079149920028e-06
was O 0 5.844196948601166e-07
found O 0 1.9349101876287023e-07
to O 0 1.1476894457018716e-07
be O 0 1.2105103053272614e-07
present O 0 3.080686781231634e-07
homozygously O 0 1.252002221008297e-05
in O 0 2.9052924332972907e-07
both O 0 2.912260868015437e-07
the O 0 1.0914748145296471e-06
retinal B-Disease 0 0.0031729796901345253
and I-Disease 0 8.130383321258705e-06
the I-Disease 0 2.952246904897038e-05
pineal I-Disease 1 0.6438942551612854
tumours I-Disease 1 0.999983549118042
. O 0 0.00018005304445978254

The O 0 3.000696233357303e-05
same O 0 1.0042019312095363e-05
mutation O 0 1.6759704521973617e-05
was O 0 1.3408118775259936e-06
present O 0 5.940216283306654e-07
heterozygously O 0 1.5375471775769256e-05
in O 0 2.535595626795839e-07
the O 0 2.6135677444472094e-07
DNA O 0 1.3104878462399938e-06
from O 0 1.202715509407426e-07
the O 0 1.3968997336633038e-07
constitutional O 0 9.096596045310434e-07
cells O 0 8.249161851381359e-07
of O 0 5.956770365855846e-08
the O 0 2.903215374772117e-07
patient O 0 1.2027666343783494e-05
, O 0 2.5244409584956884e-07
proving O 0 9.677847856437438e-07
it O 0 1.2430945162122953e-07
to O 0 1.47345446066538e-07
be O 0 2.102565588302241e-07
of O 0 7.595318152198161e-07
germline O 0 0.00026919308584183455
origin O 0 4.239015106577426e-05
. O 0 4.2709940316854045e-05

The O 0 4.111825910513289e-05
initial O 0 5.3502961236517876e-05
mutation O 0 3.375743835931644e-05
was O 0 2.097739752571215e-06
shown O 0 6.938275305401476e-07
to O 0 4.287670378744224e-07
have O 0 5.627763925986073e-07
occurred O 0 2.0048812530149007e-06
in O 0 6.275824375734373e-07
the O 0 3.987065156252356e-06
paternally O 0 0.0007189411553554237
derived O 0 0.0001230803318321705
RB1 O 0 0.02632751874625683
allele O 0 0.0006212302832864225
. O 0 0.00012446830805856735

The O 0 3.839970668195747e-05
mutation O 0 6.239238427951932e-05
is O 0 1.124690129472583e-06
in O 0 3.7452517176461697e-07
an O 0 1.414172317026896e-07
area O 0 1.4244946555663773e-07
of O 0 3.534921688697068e-08
the O 0 1.1366552854497058e-07
gene O 0 5.311994755174965e-07
that O 0 7.188347694864206e-08
encodes O 0 3.0963059316491126e-07
the O 0 1.3495592554590985e-07
protein O 0 5.887237080060004e-07
- O 0 3.1372489956993377e-06
binding O 0 4.757846454594983e-07
region O 0 2.367976321693277e-07
known O 0 1.6482749742863234e-07
as O 0 6.665300134045538e-08
the O 0 1.580125683631195e-07
pocket O 0 0.0001608444727025926
region O 0 5.135664764566172e-07
and O 0 2.093166244776512e-07
has O 0 2.4349657223865506e-07
been O 0 2.7741322128349566e-07
detected O 0 8.674869604874402e-07
in O 0 1.6492278120949777e-07
other O 0 1.1657851217705684e-07
cases O 0 6.811094976910681e-07
of O 0 8.398283171118237e-07
retinoblastoma B-Disease 0 0.01614535041153431
. O 0 1.5495750631089322e-05
. O 0 3.4715732908807695e-05

Low O 0 0.00037362531293183565
levels O 0 1.8540302335168235e-05
of O 0 1.097821950679645e-06
beta O 0 7.89188106864458e-06
hexosaminidase O 0 3.4666136343730614e-05
A O 0 2.0430502445378806e-06
in O 0 1.504051169831655e-06
healthy O 0 7.950523468025494e-06
individuals O 0 7.120418104022974e-07
with O 0 1.2867668601757032e-06
apparent O 1 0.6022061109542847
deficiency O 1 0.5317096710205078
of O 0 1.4070882343730773e-06
this O 0 6.1615191953023896e-06
enzyme O 0 0.00030712815350852907
. O 0 6.489708903245628e-05

Appreciable O 0 0.0014747235691174865
beta O 0 0.00036832355544902384
hexosaminidase O 0 0.0009596056770533323
A O 0 1.3335022231331095e-05
( O 0 2.3170950953499414e-06
hex O 0 1.3840618521498982e-05
A O 0 1.1472247933852486e-06
) O 0 5.697024789697025e-07
activity O 0 3.354863054028101e-07
has O 0 2.2257513876411394e-07
been O 0 2.7163849836142617e-07
detected O 0 6.17157809301716e-07
in O 0 2.941664831723756e-07
cultured O 0 1.5794441424077377e-05
skin O 0 0.00011385174002498388
fibroblasts O 0 2.3202339434647e-05
and O 0 4.9098041927209124e-05
melanoma B-Disease 1 0.9981099367141724
tissue O 0 0.000657862052321434
from O 0 1.050036416927469e-06
healthy O 0 5.449055151984794e-06
individuals O 0 4.561103423839086e-07
previously O 0 3.43559509019542e-06
reported O 0 5.879376203665743e-06
as O 0 1.7200160300490097e-06
having O 0 0.011838099919259548
deficiency B-Disease 0 0.011117231100797653
of I-Disease 0 1.6545999415029655e-07
hex I-Disease 0 1.2204344784549903e-05
A I-Disease 0 4.869932581641478e-07
activity O 0 5.084320378045959e-07
indistinguishable O 0 8.120077268358727e-07
from O 0 1.1647183129070982e-07
that O 0 9.892210783846167e-08
of O 0 3.9939956764101225e-07
patients O 0 0.0008176697883754969
with O 0 0.004369667731225491
Tay B-Disease 1 1.0
- I-Disease 1 0.9999997615814209
Sachs I-Disease 1 1.0
disease I-Disease 1 0.9462721347808838
( O 0 1.913871346914675e-05
TSD B-Disease 0 0.35345080494880676
) O 0 1.555454400659073e-05
. O 0 2.8235852369107306e-05

Identification O 0 0.00015812876517884433
and O 0 1.7208452845807187e-05
quantitation O 0 0.00022474720026366413
of O 0 2.944091420431505e-06
hex O 0 6.244386895559728e-05
A O 0 4.694440576713532e-06
, O 0 1.187983116324176e-06
amounting O 0 3.369090336491354e-06
to O 0 3.0880510166753083e-06
3 O 0 1.3535174730350263e-05
. O 0 2.388803659414407e-05

5 O 0 0.0005931159830652177
% O 0 0.00010174298222409561
- O 0 0.0004565010603982955
6 O 0 6.650049181189388e-05
. O 0 7.488870323868468e-05

9 O 0 0.00015336746582761407
% O 0 8.42214922158746e-06
of O 0 3.97485990788482e-07
total O 0 5.341876203601714e-07
beta O 0 2.466913201715215e-06
hexosaminidase O 0 2.1210134946159087e-05
activity O 0 9.688355930848047e-07
, O 0 2.3817557348593255e-07
has O 0 1.5817057885669783e-07
been O 0 2.4205414206335263e-07
obtained O 0 5.489077921083663e-07
by O 0 6.407805699382152e-07
cellulose O 0 6.844903691671789e-05
acetate O 0 2.122702971973922e-05
gel O 0 0.0001825640647439286
electrophoresis O 0 4.0057118894765154e-05
, O 0 1.634342424949864e-06
DEAE O 0 2.9811839340254664e-05
- O 0 1.0867698620131705e-05
cellulose O 0 1.4658968211733736e-05
ion O 0 8.356288162758574e-06
- O 0 6.054019650036935e-06
exchange O 0 2.1077582914585946e-06
chromatography O 0 1.8805327272275463e-05
, O 0 7.914989623714064e-07
radial O 0 9.092917935049627e-06
immunodiffusion O 0 3.185488094459288e-05
, O 0 1.582680511091894e-06
and O 0 4.482124950300204e-06
radioimmunoassay O 0 0.0005095507367514074
. O 0 5.741945278714411e-05

Previous O 0 0.0003965816576965153
family O 0 9.361806587548926e-05
studies O 0 1.3087582374282647e-05
suggested O 0 2.5793278837227263e-06
that O 0 1.9817531438093283e-07
these O 0 2.464885540121031e-07
individuals O 0 4.776654805027647e-07
may O 0 8.071760362327041e-07
be O 0 1.9006151319445053e-07
compound O 0 1.0656297035893658e-06
heterozygotes O 0 9.479503205511719e-06
for O 0 2.3695079676144815e-07
the O 0 4.83199755763053e-07
common O 0 1.8409782569506206e-06
mutant O 0 4.099183570360765e-05
TSD B-Disease 0 0.00704821664839983
gene O 0 4.864631137024844e-06
and O 0 8.608215011918219e-07
a O 0 1.336579657618131e-06
rare O 0 1.1757879292417783e-05
( O 0 3.930862931156298e-06
allelic O 0 8.640269516035914e-05
) O 0 8.082251042651478e-06
mutant O 0 0.00010775712871691212
gene O 0 0.00011144747259095311
. O 0 5.5683096434222534e-05

Thus O 0 8.973519288701937e-05
, O 0 4.6164796003722586e-06
the O 0 1.4030990769242635e-06
postulated O 0 1.3888667126593646e-05
rate O 0 3.4507622785895364e-06
mutant O 0 6.5364210968255065e-06
gene O 0 1.37207416628371e-06
appears O 0 6.451992931033601e-07
to O 0 1.3446877744627272e-07
code O 0 2.0295638591960596e-07
for O 0 1.0578133924354916e-07
the O 0 1.4537904746703134e-07
expression O 0 3.368642751411244e-07
of O 0 2.1284742501848086e-07
low O 0 3.302370487290318e-06
amounts O 0 1.8663313312572427e-06
of O 0 1.0776215049190796e-06
hex O 0 6.203594239195809e-05
A O 0 1.968289325304795e-05
. O 0 3.2282780011883005e-05

Heterozygotes O 0 0.0026919113006442785
for O 0 2.1013294826843776e-05
the O 0 5.870277618669206e-06
rare O 0 9.827769645198714e-06
mutant O 0 3.578996256692335e-05
may O 0 1.6802167692731018e-06
be O 0 2.421538738417439e-07
indistinguishable O 0 1.9381877791602165e-06
from O 0 6.088745294619002e-07
heterozygotes O 0 8.42978261061944e-06
for O 0 5.822645334774279e-07
the O 0 2.0230179416103056e-06
common O 0 2.3069736926117912e-05
TSD B-Disease 0 0.4002853333950043
mutant O 0 0.0003851732471957803
. O 0 5.552327638724819e-05

However O 0 3.105520227109082e-05
, O 0 2.770605306068319e-06
direct O 0 2.073937594104791e-06
visualization O 0 9.051769666257314e-06
and O 0 1.2116830703234882e-06
quantitation O 0 4.123209146200679e-05
of O 0 4.850122650168487e-07
hex O 0 1.726624759612605e-05
A O 0 5.488627721206285e-07
by O 0 1.759771208753591e-07
the O 0 2.664617682057724e-07
methods O 0 4.061613708472578e-06
described O 0 9.897181371343322e-06
may O 0 1.6291262454615207e-06
prevent O 0 9.225811936630635e-07
false O 0 2.488628979335772e-06
- O 0 0.00034335709642618895
positive O 0 3.3632220493018394e-06
prenatal O 0 0.06325947493314743
diagnosis O 0 0.0006004840251989663
of O 0 6.809685260122933e-07
TSD B-Disease 0 0.04904266446828842
in O 0 3.740382908290485e-06
fetuses O 0 0.0026057567447423935
having O 0 1.0738513083197176e-06
the O 0 5.739155994888279e-07
incomplete O 0 6.200790812727064e-05
hex B-Disease 0 0.1649409383535385
A I-Disease 0 0.00040986508247442544
deficiency I-Disease 0 0.001922912779264152
of O 0 1.024026872187278e-07
the O 0 3.6990809348935727e-07
type O 0 4.937281119055115e-06
described O 0 4.549566256173421e-06
in O 0 6.261398652895878e-07
the O 0 1.2624418559425976e-06
four O 0 1.2230150787218008e-05
healthy O 0 9.691659215604886e-05
individuals O 0 5.032004992244765e-05

The O 0 0.00020232881070114672
tumor B-Disease 0 0.001838679309003055
suppressor O 0 0.0005089701735414565
gene O 0 9.687160491012037e-05
Smad4 O 0 0.00043679276132024825
/ O 0 4.409102621139027e-05
Dpc4 O 0 2.6679977963794954e-05
is O 0 3.1326220550909056e-07
required O 0 3.1982787618289876e-07
for O 0 1.549965276126386e-07
gastrulation O 0 4.982927748642396e-06
and O 0 2.9860404993087286e-07
later O 0 7.92819434991543e-07
for O 0 3.2664829063833167e-07
anterior O 0 1.558655822009314e-05
development O 0 9.553492645864026e-07
of O 0 4.941210249853611e-07
the O 0 2.783221361823962e-06
mouse O 0 0.0001625523145776242
embryo O 0 0.00018329525482840836
. O 0 4.811558028450236e-05

Mutations O 0 0.0014057456282898784
in O 0 2.3633325326954946e-05
the O 0 1.240576875716215e-05
SMAD4 O 0 0.006358196958899498
/ O 0 0.0001750074588926509
DPC4 O 0 0.02336554042994976
tumor B-Disease 0 0.0006259844521991909
suppressor O 0 5.182454697205685e-05
gene O 0 5.502482053998392e-06
, O 0 3.479202916878421e-07
a O 0 2.5551045723659627e-07
key O 0 7.71450061165524e-07
signal O 0 1.6829188780320692e-06
transducer O 0 4.703726062871283e-06
in O 0 2.701395942494855e-07
most O 0 3.8313226013997337e-07
TGFbeta O 0 0.00039907859172672033
- O 0 0.00010487496911082417
related O 0 1.2685316050919937e-06
pathways O 0 1.3937847143097315e-06
, O 0 2.226296942353656e-07
are O 0 1.659441721812982e-07
involved O 0 3.9601792423127335e-07
in O 0 4.6690439603480627e-07
50 O 0 1.698426444818324e-06
% O 0 2.1537869088206207e-06
of O 0 3.4972304092661943e-06
pancreatic B-Disease 1 0.999995231628418
cancers I-Disease 1 0.9889612793922424
. O 0 6.54412287985906e-05

Homozygous O 0 0.007706327363848686
Smad4 O 0 0.008768798783421516
mutant O 0 0.0053557283245027065
mice O 0 0.1246805414557457
die O 0 0.0006696997443214059
before O 0 9.751456673257053e-06
day O 0 1.965756746358238e-05
7 O 0 3.170244235661812e-05
. O 0 4.71747262054123e-05

5 O 0 0.0005154531099833548
of O 0 0.0001253181544598192
embryogenesis O 0 0.0035998602397739887
. O 0 0.00036959664430469275

Mutant O 0 0.0012712469324469566
embryos O 0 0.0002788810234051198
have O 0 8.382404303119984e-06
reduced O 0 8.548733603674918e-06
size O 0 4.72044303023722e-06
, O 0 1.041334598994581e-06
fail O 0 5.446764134831028e-06
to O 0 6.006696366966935e-07
gastrulate O 0 3.295771239208989e-05
or O 0 7.88919351180084e-07
express O 0 1.6139005083459779e-06
a O 0 7.536614248238038e-07
mesodermal O 0 2.953260627691634e-05
marker O 0 9.09366372070508e-06
, O 0 8.605522339166782e-07
and O 0 1.0643965424605994e-06
show O 0 6.2645081015944015e-06
abnormal O 0 3.122885391348973e-05
visceral O 0 8.79408253240399e-05
endoderm O 0 0.006961153820157051
development O 0 5.208997754380107e-05
. O 0 6.836735701654106e-05

Growth B-Disease 1 0.9994515776634216
retardation I-Disease 1 0.9982494711875916
of O 0 3.658451305454946e-06
the O 0 4.4497824092104565e-06
Smad4 O 0 0.08732333779335022
- O 0 0.16106708347797394
deficient O 0 0.00243919575586915
embryos O 0 7.062580607453128e-06
results O 0 2.1251712496450637e-06
from O 0 4.193374252281501e-07
reduced O 0 2.9266402634675615e-06
cell O 0 1.4299092981673311e-05
proliferation O 0 4.760678621096304e-06
rather O 0 1.6877601183296065e-06
than O 0 1.3454230156639824e-06
increased O 0 9.047782441484742e-06
apoptosis O 0 9.019571007229388e-05
. O 0 4.6123037463985384e-05

Aggregation O 0 0.0004310359072405845
of O 0 1.4171833754517138e-05
mutant O 0 0.0001459122431697324
Smad4 O 0 0.0011460366658866405
ES O 0 8.541961142327636e-05
cells O 0 1.3968712664791383e-05
with O 0 1.6969822809187463e-06
wild O 0 7.3175219768018e-06
- O 0 0.00013540375221055
type O 0 1.308032005908899e-05
tetraploid O 0 7.630442269146442e-05
morulae O 0 0.00022856135910842568
rescues O 0 0.00013168840087018907
the O 0 1.7456119167036377e-05
gastrulation B-Disease 0 0.0010937560582533479
defect I-Disease 0 0.0014215260744094849
. O 0 9.955936548067257e-05

These O 0 3.2147268939297646e-05
results O 0 2.1374222342274152e-05
indicate O 0 4.386513865028974e-06
that O 0 5.553643518396711e-07
Smad4 O 0 1.5992984117474407e-05
is O 0 2.849039333341352e-07
initially O 0 9.092857453651959e-07
required O 0 2.386885569194419e-07
for O 0 8.01329491650904e-08
the O 0 7.864301210247504e-08
differentiation O 0 2.7905144861506415e-07
of O 0 6.47846789547657e-08
the O 0 1.5040984635561472e-07
visceral O 0 3.0291432722151512e-06
endoderm O 0 5.664672062266618e-05
and O 0 2.6703159505814256e-07
that O 0 1.1792638332508432e-07
the O 0 3.5975128298559866e-07
gastrulation B-Disease 0 4.5582146412925795e-05
defect I-Disease 0 1.731961492623668e-05
in O 0 3.0132915185276943e-07
the O 0 4.24296246137601e-07
epiblast O 0 0.0010631552431732416
is O 0 3.052232386835385e-07
secondary O 0 1.3358928754314547e-06
and O 0 6.421312832571857e-07
non O 0 4.507277935772436e-06
- O 0 0.00016696339298505336
cell O 0 4.506908589974046e-05
autonomous O 0 2.2076896129874513e-05
. O 0 4.126780913793482e-05

Rescued O 0 0.005810333415865898
embryos O 0 0.0010850431863218546
show O 0 0.00019648403394967318
severe O 0 0.025892674922943115
anterior O 0 0.0018135649152100086
truncations O 0 0.002250832738354802
, O 0 6.5399258346587885e-06
indicating O 0 4.920218543702504e-06
a O 0 7.878246037762437e-07
second O 0 1.1435568012529984e-06
important O 0 4.928051566821523e-07
role O 0 1.3873795978724957e-06
for O 0 9.537988034935552e-07
Smad4 O 0 0.00017468367877881974
in O 0 4.037087819597218e-06
anterior O 0 0.00040463346522301435
patterning O 0 0.0011130149941891432
during O 0 4.6832272346364334e-05
embryogenesis O 0 0.0013752509839832783
. O 0 9.820750710787252e-05

Prevalence O 0 0.0019755898974835873
of O 0 1.8400885892333463e-05
p16 O 0 0.0002148549392586574
and O 0 9.355279871670064e-06
CDK4 O 0 0.0013195944484323263
germline O 0 0.003114989260211587
mutations O 0 4.812273618881591e-05
in O 0 3.2986561109282775e-06
48 O 0 0.0001453502627555281
melanoma B-Disease 1 0.9999382495880127
- O 0 0.4395311176776886
prone O 0 0.0002610678202472627
families O 0 9.307874279329553e-06
in O 0 3.769531986108632e-06
France O 0 3.9336136978818104e-05
. O 0 3.517256845952943e-05

The O 0 0.0002118027477990836
French O 0 0.0014818719355389476
Familial B-Disease 1 0.9958733916282654
Melanoma I-Disease 1 0.9999746084213257
Study O 0 0.000510447658598423
Group O 0 0.00015924651233945042
. O 0 8.325759699800983e-05

Germline O 1 0.7999252676963806
mutations O 0 0.0005803732201457024
in O 0 7.040213858999778e-06
the O 0 2.1739524527220055e-06
p16 O 0 2.0922509065712802e-05
and O 0 1.5399418771266937e-06
CDK4 O 0 0.0015295416815206409
genes O 0 3.294367843409418e-06
have O 0 4.969147653355321e-07
been O 0 4.6218445959311794e-07
reported O 0 1.160837655334035e-06
in O 0 1.2007214422737889e-07
a O 0 2.662996791968908e-07
subset O 0 1.6576749430896598e-06
of O 0 8.835022526909597e-07
melanoma B-Disease 1 0.985088050365448
pedigrees O 0 0.0007126829586923122
, O 0 9.553720019539469e-07
but O 0 8.531652042620408e-07
their O 0 1.0140805670744157e-06
prevalence O 0 3.0007535315235145e-05
is O 0 3.477401548934722e-07
not O 0 5.260914122118265e-07
well O 0 1.888363385660341e-06
known O 0 1.557990071887616e-05
. O 0 3.2361200283048674e-05

We O 0 5.9496578614925966e-05
searched O 0 2.365397995163221e-05
for O 0 1.461931105950498e-06
such O 0 1.405431930834311e-06
germline O 0 0.00031107221730053425
mutations O 0 1.3750917787547223e-05
in O 0 7.47441276871541e-07
48 O 0 5.718281499866862e-06
French O 0 0.00013287812180351466
melanoma B-Disease 1 0.9995656609535217
- O 0 0.13936403393745422
prone O 0 4.317510683904402e-05
families O 0 1.500747316640627e-06
selected O 0 3.981043619205593e-07
according O 0 1.4743569920483424e-07
to O 0 7.920314715192944e-08
two O 0 9.953341617574551e-08
major O 0 5.398625262387213e-07
criteria O 0 9.636734148443793e-07
families O 0 5.081286076347169e-07
with O 0 9.752024254794378e-08
at O 0 2.789078052956029e-07
least O 0 1.6878294673006167e-07
three O 0 3.277519624589331e-07
affected O 0 9.566630296831136e-07
members O 0 3.806447921306244e-07
( O 0 2.5809544013100094e-07
n O 0 2.3548634544567904e-06
= O 0 2.1419516542664496e-06
20 O 0 1.1809699884679503e-07
) O 0 1.13643203292213e-07
or O 0 1.1383269793441286e-07
families O 0 2.1227252489097737e-07
with O 0 6.483190162498431e-08
two O 0 1.876839235137595e-07
affected O 0 6.363459874592081e-07
members O 0 9.751652640943576e-08
, O 0 5.873452835203352e-08
one O 0 3.1970522229585185e-08
of O 0 3.725171282553674e-08
them O 0 8.168101572891828e-08
affected O 0 1.637881439364719e-07
before O 0 1.3537977849864546e-07
the O 0 1.0988845389192647e-07
age O 0 1.8876777119203325e-07
of O 0 6.465827340207397e-08
50 O 0 2.7499123689267435e-07
( O 0 2.6867667202168377e-07
n O 0 2.1266005205689e-06
= O 0 4.464809080673149e-06
28 O 0 3.627637852332555e-07
) O 0 1.1083548656642961e-07
, O 0 6.219217141278932e-08
and O 0 9.537718881347246e-08
one O 0 2.6197363922619843e-07
additional O 0 1.4400388863577973e-06
minor O 0 3.155548984068446e-05
criterion O 0 7.687277684453875e-05
. O 0 3.5899385693483055e-05

Sixteen O 0 0.00022726472525391728
different O 0 3.90680470445659e-05
p16 O 0 0.00048686505760997534
germline O 0 0.052996065467596054
mutations O 0 6.103242048993707e-05
were O 0 1.7011579984682612e-06
found O 0 8.200576644412649e-07
in O 0 5.121988806422451e-07
21 O 0 1.1257900496275397e-06
families O 0 1.5044613519421546e-06
, O 0 3.4299699791517924e-07
while O 0 2.741867888289562e-07
one O 0 4.227375995924376e-07
germline O 0 0.0003207386180292815
mutation O 0 4.619078026735224e-06
, O 0 4.794586629941477e-07
Arg24His O 0 1.2980090104974806e-05
, O 0 3.597396300847322e-07
was O 0 7.985287879819225e-07
detected O 0 1.531532348053588e-06
in O 0 4.953703864885028e-07
the O 0 2.9213169909780845e-06
CDK4 O 0 0.007830494083464146
gene O 0 0.0001541033707326278
. O 0 5.7143708545481786e-05

The O 0 1.654381958360318e-05
frequency O 0 1.7086524167098105e-05
of O 0 1.6790714880698943e-06
p16 O 0 4.2731167923193425e-05
gene O 0 8.839793736115098e-06
mutation O 0 3.554309614628437e-06
in O 0 2.1423672080800316e-07
our O 0 2.933809071237192e-07
sample O 0 8.28774545880151e-07
( O 0 3.997844544301188e-07
44 O 0 5.883801463824057e-07
% O 0 3.5312297086420585e-07
) O 0 1.0901332814228226e-07
is O 0 5.1096936459771314e-08
among O 0 7.137320068295594e-08
the O 0 1.0244331605235857e-07
highest O 0 9.553464224154595e-07
rates O 0 2.6902894205704797e-06
yet O 0 9.426975680071337e-07
reported O 0 9.691331115391222e-07
and O 0 2.781221155601088e-07
the O 0 8.607869972365734e-07
CDK4 O 0 0.051297761499881744
mutation O 0 4.492892458074493e-06
is O 0 2.1192542476455856e-07
the O 0 2.968969567973545e-07
second O 0 3.6328005990071688e-06
mutation O 0 1.3429114915197715e-05
detected O 0 2.3146635612647515e-06
in O 0 4.181266604064149e-07
this O 0 1.006836214401119e-06
gene O 0 2.1338946680771187e-05
worldwide O 0 2.3422706362907775e-05
. O 0 4.440911652636714e-05

In O 0 2.4615299480501562e-05
summary O 0 1.886750033008866e-05
, O 0 2.0448862869670847e-06
our O 0 2.3359095848718425e-06
results O 0 4.101913873455487e-06
show O 0 2.084104608002235e-06
frequent O 0 1.4294987522589508e-06
involvement O 0 1.8539807342676795e-06
of O 0 2.2377213326763012e-07
the O 0 6.891020234434109e-07
p16 O 0 2.4731441953917965e-05
gene O 0 6.468081210186938e-06
in O 0 2.1388161712820875e-06
familial B-Disease 1 0.7381883859634399
melanoma I-Disease 1 0.9987297654151917
and O 0 1.0037815627583768e-06
confirm O 0 1.7146785467048176e-06
the O 0 1.6780056455445447e-07
role O 0 4.588090689594537e-07
of O 0 1.0221886270755931e-07
the O 0 5.552336119762913e-07
CDK4 O 0 0.00178065977524966
gene O 0 3.0169655929057626e-06
as O 0 5.931125315328245e-07
a O 0 6.500483777927002e-06
melanoma B-Disease 1 0.9995259046554565
- O 0 0.010543860495090485
predisposing O 0 6.854969979031011e-05
gene O 0 1.7979609765461646e-05
. O 0 9.237573067366611e-06
. O 0 2.9016233384027146e-05

Progression O 0 0.0011876373318955302
of O 0 3.933958578272723e-05
somatic O 0 0.000555359001737088
CTG O 0 0.0008395151235163212
repeat O 0 8.721259655430913e-05
length O 0 1.8421251297695562e-05
heterogeneity O 0 3.435847975197248e-05
in O 0 2.604411520223948e-06
the O 0 3.858607215079246e-06
blood O 0 0.00019760039867833257
cells O 0 0.00011027459549950436
of O 0 3.525289139361121e-05
myotonic B-Disease 1 0.9999998807907104
dystrophy I-Disease 1 1.0
patients O 1 0.9988688826560974
. O 0 0.00025768656632862985

The O 0 6.372817006194964e-05
genetic O 0 6.586709059774876e-05
basis O 0 1.1429939149820711e-05
of O 0 1.4438367543334607e-05
myotonic B-Disease 1 0.9999998807907104
dystrophy I-Disease 1 1.0
( O 0 0.04309424012899399
DM B-Disease 1 0.9999998807907104
) O 0 1.7375497236571391e-06
is O 0 1.4459560304658226e-07
the O 0 1.37317741177867e-07
expansion O 0 5.024281222176796e-07
of O 0 1.2797602266800823e-07
an O 0 4.2884065010184713e-07
unstable O 0 5.8271034504286945e-05
CTG O 0 6.718905206071213e-05
repeat O 0 5.935328772466164e-06
in O 0 3.3084432971008937e-07
the O 0 3.9780300653546874e-07
34 O 0 1.5737747389721335e-06
UTR O 0 9.93260255199857e-06
of O 0 5.873144459656032e-07
the O 0 3.2340153666154947e-06
DM B-Disease 1 0.9996662139892578
protein O 0 8.143962986650877e-06
kinase O 0 2.2982319933362305e-05
gene O 0 9.98121868178714e-06
on O 0 2.849266820703633e-06
chromosome O 0 5.58312312932685e-05
19 O 0 2.99779640045017e-05
. O 0 3.683429167722352e-05

One O 0 2.436856084386818e-05
of O 0 1.8337450455874205e-06
the O 0 1.0791023896672414e-06
principal O 0 1.6195559737752774e-06
features O 0 5.704407612938667e-07
of O 0 1.9313374366447533e-07
the O 0 4.209379767416976e-06
DM B-Disease 1 1.0
mutation O 0 3.4161595976911485e-05
is O 0 2.0005771261821792e-07
an O 0 1.616835447748599e-07
extraordinarily O 0 8.14973554952303e-06
high O 0 7.972314506332623e-07
level O 0 2.507544252239313e-07
of O 0 1.3319805702849408e-07
somatic O 0 1.052882998919813e-05
mosaicism O 0 0.0003427682677283883
, O 0 4.660324464111909e-07
due O 0 4.1330193312205665e-07
to O 0 2.075297516057617e-07
an O 0 2.2761663842629787e-07
extremely O 0 1.6369475588362548e-06
high O 0 7.461991913260135e-07
degree O 0 8.976481922218227e-07
of O 0 2.7502349553287786e-07
somatic O 0 1.5871464711381122e-05
instability O 0 4.735664788313443e-06
both O 0 2.262328848701145e-07
within O 0 2.3235955382006068e-07
and O 0 3.3138744015559496e-07
between O 0 8.244026048487285e-07
different O 0 3.1100157684704755e-06
tissues O 0 0.00012541617616079748
. O 0 4.153454938204959e-05

This O 0 3.252635360695422e-05
instability O 0 6.016072802594863e-05
appears O 0 1.1189769793418236e-05
to O 0 6.990879342083645e-07
be O 0 1.9323285016525915e-07
biased O 0 5.926285666646436e-07
towards O 0 1.8536188406415022e-07
further O 0 1.2814223282475723e-07
expansion O 0 3.4190946962553426e-07
and O 0 1.1407384903350248e-07
continuous O 0 3.3606079341552686e-07
throughout O 0 1.2696570195203094e-07
the O 0 1.0132091432524248e-07
life O 0 1.4208693244199821e-07
of O 0 3.5538644027610644e-08
an O 0 7.122279299665024e-08
individual O 0 1.6626670173991442e-07
, O 0 1.2343784305812733e-07
features O 0 2.618272958443413e-07
that O 0 2.043966702558464e-07
could O 0 6.948943109819083e-07
be O 0 1.7786581452128303e-07
associated O 0 2.536703220812342e-07
with O 0 1.6702000493751257e-07
the O 0 6.480927936536318e-07
progressive O 0 4.034338053315878e-05
nature O 0 1.8908898482550285e-06
of O 0 1.0854977290364332e-06
the O 0 3.497632860671729e-05
disease O 0 0.019307877868413925
. O 0 5.23837843502406e-05

Although O 0 5.2980412874603644e-05
increasing O 0 1.851480919867754e-05
measured O 0 1.8092960090143606e-05
allele O 0 3.359599213581532e-05
size O 0 6.138499884400517e-06
between O 0 2.12953500522417e-06
patients O 0 0.00030128718935884535
clearly O 0 1.660333055042429e-06
correlates O 0 4.209423877910012e-06
with O 0 3.19465755183046e-07
an O 0 2.286260780692828e-07
increased O 0 1.4056196278033894e-06
severity O 0 0.0003128331445623189
of O 0 1.0813089375005802e-06
symptoms O 0 8.930120384320617e-05
and O 0 3.137148496534792e-07
an O 0 1.005306984325216e-07
earlier O 0 1.2088357834727503e-06
age O 0 6.325226991066302e-07
of O 0 1.910818241412926e-07
onset O 0 0.02049824222922325
, O 0 4.051440782859572e-07
this O 0 1.200845076709811e-07
correlation O 0 5.586898055298661e-07
is O 0 7.602566398645649e-08
not O 0 1.0040499631713828e-07
precise O 0 5.643909730679297e-07
and O 0 2.7120827894577815e-07
measured O 0 1.038524942487129e-06
allele O 0 2.3166908249550033e-06
length O 0 1.043413249135483e-06
cannot O 0 6.25387940544897e-07
be O 0 7.89548764146275e-08
used O 0 9.980412585264276e-08
as O 0 6.565594645735473e-08
an O 0 1.4336025344618974e-07
accurate O 0 3.913477030437207e-06
predictor O 0 2.435239002807066e-05
of O 0 4.067165662036132e-07
age O 0 3.5663565540744457e-06
of O 0 4.176136371825123e-06
onset O 0 0.21406811475753784
. O 0 0.00010076299804495648

In O 0 1.96081764443079e-05
order O 0 4.142381385463523e-06
to O 0 6.839402431069175e-07
further O 0 9.544439762976253e-07
characterize O 0 4.57752366855857e-06
the O 0 1.1168214086865191e-06
dynamics O 0 1.4988338989496697e-05
of O 0 2.3786601559550036e-06
DM B-Disease 1 0.9999719858169556
CTG O 0 0.0004128726723138243
repeat O 0 1.992654870264232e-05
somatic O 0 2.0449040675885044e-05
instability O 0 5.581121968134539e-06
, O 0 5.228198460827116e-07
we O 0 2.6309129452783964e-07
have O 0 1.8850835203920724e-07
studied O 0 1.0447753311382257e-06
repeat O 0 2.5919086965586757e-06
length O 0 6.775688348170661e-07
changes O 0 3.444103811034438e-07
over O 0 2.240407610543116e-07
time O 0 4.823406243303907e-07
in O 0 1.2398816124914447e-06
111 O 0 0.01678740419447422
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 0.06617571413516998
with O 0 8.9669327962838e-07
varying O 0 8.563772098568734e-06
clinical O 0 0.009301074780523777
severity O 0 0.0021883754525333643
and O 0 2.244165671072551e-06
CTG O 0 9.90331027423963e-05
repeat O 0 4.424477992870379e-06
size O 0 4.078052313616354e-07
over O 0 1.3495824191522843e-07
time O 0 2.44760542500444e-07
intervals O 0 5.466682182486693e-07
of O 0 2.1168627029055642e-07
1 O 0 1.8583353948997683e-06
- O 0 2.622345527925063e-05
7 O 0 5.285346560413018e-06
years O 0 8.437213182332925e-06
. O 0 1.772040741343517e-05

We O 0 5.556110045290552e-05
have O 0 3.993434802396223e-06
found O 0 7.964137580529496e-07
a O 0 3.682888802813977e-07
direct O 0 6.373809355864068e-07
progression O 0 2.24900782086479e-06
of O 0 1.3724364578138193e-07
the O 0 3.350802160184685e-07
size O 0 5.7988279422716e-07
heterogeneity O 0 2.0475597466429463e-06
over O 0 2.3197318910206377e-07
time O 0 4.3591887788352324e-07
related O 0 8.618104629931622e-07
to O 0 4.5354335043157334e-07
initial O 0 2.8395879780873656e-06
CTG O 0 4.404446735861711e-05
repeat O 0 5.054316261521308e-06
size O 0 4.214514888190024e-07
and O 0 1.231906452403564e-07
the O 0 1.3347755611903267e-07
time O 0 2.9007659918534046e-07
interval O 0 7.415737854898907e-07
and O 0 2.6271746378370153e-07
always O 0 6.554490710186656e-07
biased O 0 2.189708084188169e-06
towards O 0 1.4917659427737817e-06
further O 0 3.098213255725568e-06
expansion O 0 4.2829240555875e-05
. O 0 4.2884414142463356e-05

Attempts O 0 0.00016852124826982617
to O 0 1.0518312592466827e-05
mathematically O 0 3.0280916689662263e-05
model O 0 3.854363058053423e-06
the O 0 1.1513327535794815e-06
dynamics O 0 1.2823852557630744e-05
have O 0 3.6585174711945e-07
proved O 0 1.0314065548300277e-06
only O 0 1.7739149882345373e-07
partially O 0 1.8107780306308996e-06
successful O 0 1.3458541161526227e-06
suggesting O 0 9.01822545529285e-07
that O 0 1.0058209909402649e-07
individual O 0 1.7217099923527712e-07
specific O 0 3.5508602991285443e-07
genetic O 0 2.3542145299870754e-06
and O 0 1.4323209143185522e-06
/ O 0 6.0973543440923095e-05
or O 0 9.673962040324113e-07
environmental O 0 2.387760332567268e-06
factors O 0 5.425267772807274e-07
also O 0 1.8754506925233727e-07
play O 0 2.7101438604404393e-07
a O 0 5.273562351248984e-07
role O 0 2.036195382970618e-06
in O 0 3.2494917832082137e-06
somatic O 0 0.0001279643620364368
mosaicism O 0 0.007395816966891289
. O 0 2.1472820662893355e-05
. O 0 5.0089292926713824e-05

Aspartylglucosaminuria B-Disease 1 0.9966580867767334
among O 0 0.0004830476827919483
Palestinian O 0 0.0011854678159579635
Arabs O 0 0.0015770114259794354
. O 0 0.0003576549934223294

Aspartylglucosaminuria B-Disease 1 0.9999744892120361
( O 0 0.03032122552394867
AGU B-Disease 1 0.9999922513961792
) O 0 1.7947571905096993e-05
is O 0 9.578498065820895e-07
a O 0 1.848558895289898e-06
rare O 0 3.520132668199949e-05
disorder B-Disease 0 0.0008885745191946626
of I-Disease 0 5.080302685200877e-07
glycoprotein I-Disease 0 8.689962851349264e-05
metabolism I-Disease 0 0.0006721378886140883
caused O 0 2.1593670680886135e-05
by O 0 1.4936138086341089e-06
the O 0 5.262311242404394e-05
deficiency B-Disease 0 0.03962497413158417
of I-Disease 0 6.826812750659883e-07
the I-Disease 0 4.120411631447496e-06
lysosomal I-Disease 1 0.880802571773529
enzyme I-Disease 0 0.001875917543657124
aspartylglucosaminidase I-Disease 0 0.11769988387823105
( O 0 8.961821549746674e-06
AGA O 0 0.0023572281934320927
) O 0 1.6768546629464254e-05
. O 0 2.618477083160542e-05

AGU B-Disease 1 0.999998927116394
is O 0 0.00016441388288512826
inherited O 0 0.27214011549949646
as O 0 4.162375262239948e-06
an O 0 3.782834937737789e-06
autosomal O 1 0.8094488382339478
recessive O 1 0.89274662733078
trait O 0 0.00039410931640304625
and O 0 8.94793458883214e-07
occurs O 0 4.482790814108739e-07
with O 0 1.2071049582118576e-07
a O 0 3.9118174299801467e-07
high O 0 9.023843290378863e-07
frequency O 0 1.613417339285661e-06
in O 0 4.0735471884545404e-07
Finland O 0 3.362869392731227e-06
because O 0 3.732019990820845e-07
of O 0 3.1013564694148954e-07
a O 0 2.3606310151080834e-06
founder O 0 0.00016954794409684837
effect O 0 2.114480230375193e-05
. O 0 3.0478384360321797e-05

While O 0 4.2749830754473805e-05
very O 0 1.5027126210043207e-05
few O 0 1.292914203077089e-05
patients O 0 0.00010146493150386959
with O 0 2.892552402045112e-06
AGU B-Disease 1 0.9999994039535522
have O 0 5.283784503262723e-06
been O 0 1.512141238890763e-06
reported O 0 2.1632108655467164e-06
from O 0 2.603929658562265e-07
non O 0 8.398931754527439e-07
- O 0 1.4722097148478497e-05
Finnish O 0 3.818125605903333e-06
origin O 0 5.713085897696146e-07
, O 0 6.03750265781855e-07
we O 0 3.2359716897190083e-06
diagnosed O 0 0.2386942058801651
the O 0 4.380164682515897e-06
disorder O 0 0.00866707507520914
in O 0 1.1424426702433266e-06
8 O 0 3.0070555112615693e-06
patients O 0 3.3553733373992145e-06
originating O 0 4.0813517898641294e-07
from O 0 1.8434010939927248e-07
3 O 0 3.8469636365334736e-07
unrelated O 0 1.8368325527262641e-06
families O 0 7.600440881105897e-07
, O 0 1.2924263614877418e-07
all O 0 9.892719532444971e-08
Palestinian O 0 2.9617062864417676e-06
Arabs O 0 2.2440458451455925e-06
from O 0 3.8089245890660095e-07
the O 0 4.273105389529519e-07
region O 0 1.5587481811962789e-06
of O 0 2.4686924007255584e-06
Jerusalem O 0 0.00030777123174630105
. O 0 6.880053115310147e-05

The O 0 0.00011391102452762425
clinical O 0 0.4522119164466858
diagnosis O 1 0.898385226726532
of O 0 7.183657999121351e-06
AGU B-Disease 1 0.9999991655349731
is O 0 1.9594158402469475e-06
often O 0 1.0101697398567921e-06
difficult O 0 4.424553480930626e-06
, O 0 1.7750014080775145e-07
in O 0 9.109464826906333e-08
particular O 0 1.9441769438799383e-07
early O 0 5.484337179950671e-07
in O 0 1.0501501179760453e-07
the O 0 1.1258465093533232e-07
course O 0 5.730908583245764e-07
of O 0 1.2247279812527267e-07
the O 0 1.2477574273361824e-05
disease O 0 0.0017415937036275864
, O 0 1.465463839167569e-07
and O 0 6.478616398908343e-08
most O 0 4.983384727097473e-08
of O 0 4.8908020744420355e-08
the O 0 1.7374552498949924e-06
patients O 0 0.0017954276409000158
are O 0 1.3128934597261832e-06
diagnosed O 0 0.07329469174146652
after O 0 8.647033951092453e-07
the O 0 3.081856050357601e-07
age O 0 7.484570119231648e-07
of O 0 3.856411296965234e-07
5 O 0 3.139403816021513e-06
years O 0 1.3842810403730255e-05
. O 0 3.288496736786328e-05

However O 0 8.186536433640867e-05
, O 0 7.661106792511418e-06
since O 0 5.268829681881471e-06
these O 0 2.293772240591352e-06
patients O 0 1.8115095372195356e-05
excrete O 0 1.2696288649749476e-05
early O 0 1.8732963553702575e-06
large O 0 5.308318691277236e-07
amounts O 0 4.65043314079594e-07
of O 0 1.9166328968367452e-07
aspartylglucosamine O 0 1.6978427083813585e-05
in O 0 7.441609568559215e-07
urine O 0 4.170349711785093e-06
, O 0 5.58483634449658e-07
biochemical O 0 6.87343708705157e-06
screening O 0 4.51392861577915e-06
is O 0 3.8931568724365206e-07
easy O 0 1.957544100150699e-06
by O 0 1.2170196441729786e-06
urine O 0 2.2689740944770165e-05
chromatography O 0 0.00019975540635641664
. O 0 1.0067391485790722e-05
. O 0 2.6497969884076156e-05

Detection O 0 0.0003725579590536654
of O 0 1.2178730685263872e-05
heterozygous O 0 5.8997018641093746e-05
carriers O 0 1.0314230166841298e-05
of O 0 9.734590094012674e-07
the O 0 8.738349606574047e-06
ataxia B-Disease 1 0.9999991655349731
- I-Disease 1 0.9999699592590332
telangiectasia I-Disease 1 0.9999943971633911
( O 0 3.573131152734277e-06
ATM O 0 1.4972110875532962e-05
) O 0 7.818190397301805e-07
gene O 0 2.0496072465903126e-06
by O 0 8.547712013751152e-07
G2 O 0 0.001138000632636249
phase O 0 2.192131432821043e-05
chromosomal O 0 5.309452171786688e-05
radiosensitivity O 0 5.865571802132763e-05
of O 0 3.6353442283143522e-06
peripheral O 0 0.0028793965466320515
blood O 0 0.005176524166017771
lymphocytes O 0 0.0841260626912117
. O 0 0.00014874157204758376

In O 0 0.008566146716475487
ataxia B-Disease 1 0.9999992847442627
- I-Disease 1 0.9999934434890747
telangiectasia I-Disease 1 0.9999986886978149
( O 0 0.00017120859411079437
A B-Disease 1 0.9336693286895752
- I-Disease 1 0.999992847442627
T I-Disease 1 0.9999996423721313
) O 0 1.570020685903728e-05
patients O 0 3.191021824022755e-05
, O 0 6.446217639677343e-07
mutations O 0 2.008209094128688e-06
in O 0 1.2596478882187512e-07
a O 0 2.7065843255513755e-07
single O 0 8.341705779457698e-07
gene O 0 2.005196847676416e-06
, O 0 3.4138813020945236e-07
ATM O 0 9.981771654565819e-06
, O 0 5.747294835600769e-07
result O 0 1.9985072867712006e-06
in O 0 4.384744897834025e-06
an O 0 0.027358053252100945
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 7.559136747659068e-07
embraces O 0 2.37135327552096e-06
a O 0 3.6585871043826046e-07
variety O 0 3.4642906143744767e-07
of O 0 2.644970891196863e-07
clinical O 0 0.00011392101441742852
features O 0 2.2187118702277075e-06
and O 0 1.6794318753454718e-06
manifests O 0 1.1554639058886096e-05
extreme O 0 1.1532114513101988e-05
radiosensitivity O 0 0.00022031858679838479
and O 0 5.702667067453149e-07
a O 0 5.837189860358194e-07
strong O 0 2.971455387523747e-06
pre O 0 0.002528050448745489
- O 0 0.0014330169651657343
disposition O 0 3.717925937962718e-05
to O 0 1.610332947166171e-05
malignancy B-Disease 0 0.007550466805696487
. O 0 6.214892346179113e-05

Heterozygotes O 0 0.0015224271919578314
for O 0 1.1851183444377966e-05
the O 0 3.4200018035335233e-06
ATM O 0 4.3256495700916275e-05
gene O 0 8.734058610571083e-06
have O 0 1.0785323638629052e-06
no O 0 5.870232371307793e-07
clinical O 0 3.159741254421533e-06
expression O 0 4.176938546152087e-07
of O 0 2.8026977361150784e-07
A B-Disease 1 0.7075200080871582
- I-Disease 1 0.9999022483825684
T I-Disease 1 0.9999854564666748
but O 0 3.6998817449784838e-06
may O 0 4.847051968681626e-06
be O 0 1.9772103314608103e-06
cancer B-Disease 0 0.02761257067322731
prone O 0 9.052200766745955e-06
with O 0 1.8952937352878507e-07
a O 0 1.3876150433134171e-06
moderate O 0 0.002153295325115323
increase O 0 2.4627761376905255e-06
in O 0 1.5724712056908174e-06
in O 0 5.324305675458163e-06
vitro O 0 0.0007480307831428945
radiosensitivity O 0 0.00325008830986917
. O 0 6.733593909302726e-05

We O 0 5.2332256018416956e-05
performed O 0 2.1468686099979095e-05
a O 0 3.9889587242214475e-06
blind O 0 2.392581336607691e-05
chromosomal O 0 2.6004330720752478e-05
analysis O 0 3.7665924992325017e-06
on O 0 1.4744146028533578e-06
G2 O 0 0.01633397489786148
- O 0 4.839855319005437e-05
phase O 0 5.811838036606787e-06
lymphocytes O 0 1.6189991583814844e-05
from O 0 4.6636236561425903e-07
7 O 0 1.2535629139165394e-06
unrelated O 0 1.1904512575711124e-05
A B-Disease 1 0.9605599045753479
- I-Disease 1 0.9999980926513672
T I-Disease 1 0.9999998807907104
patients O 0 0.0007610745378769934
, O 0 4.779685127687117e-07
13 O 0 4.965457378602878e-07
obligate O 0 1.5458512052646256e-06
A B-Disease 0 0.11103596538305283
- I-Disease 1 0.9919607043266296
T I-Disease 1 0.999708354473114
heterozygotes O 0 3.305298741906881e-05
( O 0 5.059246177552268e-07
parents O 0 5.413117492025776e-07
of O 0 8.451675626020005e-08
the O 0 1.1223671663174173e-06
patients O 0 6.114134885137901e-05
) O 0 1.755302747596943e-07
, O 0 7.599768281352226e-08
and O 0 1.1901167340511165e-07
14 O 0 2.0520018040315335e-07
normal O 0 4.272579872122151e-07
controls O 0 8.902516697162355e-07
following O 0 8.970337148639373e-07
X O 0 1.9257371604908258e-05
- O 0 3.3554179026396014e-06
irradiation O 0 1.6936355677898973e-06
with O 0 2.4502233486600744e-07
1 O 0 6.156370773169328e-07
Gy O 0 8.009930024854839e-05
in O 0 1.9464701495053305e-07
order O 0 2.1510474823571712e-07
to O 0 1.8103723675721994e-07
evaluate O 0 1.4928048130968818e-06
this O 0 1.9368745540759846e-07
cytogenetic O 0 8.157083357218653e-06
method O 0 1.0149872196052456e-06
as O 0 1.8581567928777076e-07
a O 0 3.6807924175263906e-07
tool O 0 2.9444872780004516e-06
for O 0 3.6959565363758884e-07
detection O 0 3.758228331207647e-06
of O 0 1.3962632010589004e-06
ATM O 0 0.0001480852224631235
carriers O 0 7.758240826660767e-05
. O 0 4.301687658880837e-05

Both O 0 0.00025498648756183684
A B-Disease 1 0.6036816835403442
- I-Disease 1 0.9981858134269714
T I-Disease 1 0.9994938373565674
homozygotes O 0 0.0003856898401863873
and O 0 3.861942786897998e-06
heterozygotes O 0 5.725432492909022e-05
showed O 0 6.7773448790831026e-06
significantly O 0 5.041001259087352e-06
increased O 0 1.8188796957474551e-06
levels O 0 1.178161596726568e-06
of O 0 5.747876343775715e-07
radiation O 0 0.000564825430046767
- O 0 0.0012941251043230295
induced O 0 4.3808504415210336e-05
chromatid O 0 0.022895876318216324
damage O 0 4.392094342620112e-05
relative O 0 2.150982936655055e-06
to O 0 3.677077131669648e-07
that O 0 1.9024902542241762e-07
of O 0 4.263897608325351e-07
normal O 0 1.018472175928764e-05
controls O 0 3.387113974895328e-05
. O 0 2.9500659366021864e-05

These O 0 2.632634095789399e-05
results O 0 2.1252108126645908e-05
show O 0 2.736465376074193e-06
that O 0 4.921035383631533e-07
the O 0 8.108214615276665e-07
G2 O 0 0.02392839454114437
- O 0 5.458323721541092e-05
phase O 0 6.7528085310186725e-06
chromosomal O 0 1.6722173313610256e-05
radiosensitivity O 0 4.671046190196648e-05
assay O 0 2.8047188607160933e-05
can O 0 3.734718632131262e-07
be O 0 8.359745606867364e-08
used O 0 1.2951531402904948e-07
for O 0 7.376534938430268e-08
the O 0 2.269996883796921e-07
detection O 0 1.5617956705682445e-06
of O 0 8.1144651176146e-07
A B-Disease 1 0.9490460157394409
- I-Disease 1 0.9999310970306396
T I-Disease 1 0.9999791383743286
heterozygotes O 0 0.003417584113776684
. O 0 7.407574594253674e-05

In O 0 5.156549013918266e-05
combination O 0 4.187893864582293e-05
with O 0 5.317495833878638e-06
molecular O 0 0.0001227210450451821
genetic O 0 2.0951740225427784e-05
analyses O 0 6.7169567046221346e-06
, O 0 4.804418267667643e-07
this O 0 2.0665245870077342e-07
test O 0 3.2804573493194766e-06
may O 0 3.21983009143878e-07
be O 0 2.0661770960828107e-08
of O 0 2.5034291084580218e-08
value O 0 8.288758124308515e-08
in O 0 1.0952477680348238e-07
studies O 0 3.414982074900763e-07
of O 0 8.233028836457379e-08
familial B-Disease 0 1.747094029269647e-05
and I-Disease 0 9.105813774112903e-07
sporadic I-Disease 0 6.896559352753684e-05
cancers I-Disease 0 0.06426423043012619
aimed O 0 1.3385939610088826e-06
at O 0 2.656027220382384e-07
determination O 0 4.897392500424758e-07
of O 0 7.763004106209337e-08
the O 0 1.72235374407137e-07
potential O 0 2.901421680689964e-07
involvement O 0 4.032298477341101e-07
of O 0 2.395062210780452e-07
ATM O 0 3.825376552413218e-05
mutations O 0 1.4716622899868526e-05
in O 0 3.8495654735015705e-06
tumor B-Disease 0 0.232301265001297
risk O 0 2.2145002731122077e-05
or O 0 1.0640393384164781e-06
development O 0 3.0458165838354034e-06
. O 0 4.371713657747023e-06
. O 0 2.2245521904551424e-05

Ataxia B-Disease 1 0.999998927116394
- I-Disease 1 0.9999338388442993
telangiectasia I-Disease 1 0.9999512434005737
: O 0 2.0043091353727505e-05
identification O 0 5.424908522400074e-06
and O 0 1.0218138868367532e-06
detection O 0 2.845649760274682e-06
of O 0 3.5343427384759707e-07
founder O 0 4.671727947425097e-05
- O 0 0.00042081880383193493
effect O 0 1.5569980860163923e-06
mutations O 0 1.4971561768106767e-06
in O 0 2.140247516990712e-07
the O 0 3.786852289522358e-07
ATM O 0 1.2175222764199134e-05
gene O 0 4.961655122315278e-06
in O 0 1.8965606614074204e-06
ethnic O 0 1.2619190783880185e-05
populations O 0 3.599804767873138e-05
. O 0 3.188433402101509e-05

To O 0 1.8063063180306926e-05
facilitate O 0 9.884126484394073e-06
the O 0 1.2309593557802145e-06
evaluation O 0 1.9301676275063073e-06
of O 0 2.610294700389204e-07
ATM O 0 1.00377292255871e-05
heterozygotes O 0 1.0349307558499277e-05
for O 0 2.4561987288507225e-07
susceptibility O 0 4.003642970928922e-06
to O 0 3.3851765124381927e-07
other O 0 3.6735579556079756e-07
diseases O 0 1.0896633284573909e-05
, O 0 8.400712658840348e-08
such O 0 1.0093263824728638e-07
as O 0 5.202248757996131e-06
breast B-Disease 1 0.9975740313529968
cancer I-Disease 0 0.14418072998523712
, O 0 3.117173150712915e-07
we O 0 1.4838147421869508e-07
have O 0 1.0281681284141087e-07
attempted O 0 6.694297667309002e-07
to O 0 1.151451982650542e-07
define O 0 6.166318939904158e-07
the O 0 1.0198808553241179e-07
most O 0 2.0370001152514305e-07
common O 0 1.06047752979066e-06
mutations O 0 2.4146213490894297e-06
and O 0 1.5090353144842084e-07
their O 0 2.426684773126908e-07
frequencies O 0 3.602605147534632e-06
in O 0 8.014921149879228e-06
ataxia B-Disease 1 0.999998927116394
- I-Disease 1 0.9999843835830688
telangiectasia I-Disease 1 0.9999988079071045
( O 0 2.0228162611601874e-05
A B-Disease 1 0.8346831202507019
- I-Disease 1 0.9995511174201965
T I-Disease 1 0.9999222755432129
) O 0 1.6216547464864561e-06
homozygotes O 0 1.5367702872026712e-05
from O 0 6.661036309196788e-07
10 O 0 1.2124760360165965e-06
ethnic O 0 5.2333548410388175e-06
populations O 0 4.3824718886753544e-05
. O 0 5.1556537073338404e-05

Both O 0 9.711299207992852e-05
genomic O 0 0.0003675599582493305
mutations O 0 7.00370073900558e-05
and O 0 2.2242500108404784e-06
their O 0 1.5335697298723971e-06
effects O 0 5.627427981380606e-06
on O 0 1.3957812825537985e-06
cDNA O 0 2.5360106519656256e-05
were O 0 9.591692105459515e-06
characterized O 0 0.00011751375859603286
. O 0 7.871723937569186e-05

Protein O 0 0.00037866513594053686
- O 0 0.000147325947182253
truncation O 0 6.802885764045641e-05
testing O 0 9.57985503191594e-06
of O 0 3.205430232355866e-07
the O 0 4.784030807059025e-07
entire O 0 1.2703754919130006e-06
ATM O 0 6.5963126871793065e-06
cDNA O 0 7.86907912697643e-06
detected O 0 3.868223757308442e-06
92 O 0 4.3976133383694105e-06
( O 0 6.350728085635637e-07
66 O 0 2.0147735995124094e-06
% O 0 6.813232289459847e-07
) O 0 6.948684472263267e-07
truncating O 0 1.37777351483237e-05
mutations O 0 6.915893663972383e-06
in O 0 9.712446171761258e-07
140 O 0 8.534657354175579e-06
mutant O 0 4.970045483787544e-05
alleles O 0 6.64715189486742e-05
screened O 0 8.557370165362954e-05
. O 0 5.136388062965125e-05

The O 0 4.989610533812083e-05
haplotyping O 0 0.00017999109695665538
of O 0 5.744928785134107e-06
patients O 0 6.509654485853389e-05
with O 0 6.768868274775741e-07
identical O 0 0.000177610621904023
mutations O 0 5.396577398641966e-05
indicates O 0 1.4586888710255153e-06
that O 0 9.166178216446497e-08
almost O 0 7.192654294385648e-08
all O 0 3.147937022163205e-08
of O 0 5.7900855665593554e-08
these O 0 9.629020780721476e-08
represent O 0 2.488253585397615e-07
common O 0 7.059389304231445e-07
ancestry O 0 3.6770422866538865e-06
and O 0 4.3621747636279906e-07
that O 0 4.4563716983248014e-07
very O 0 1.5554397805317421e-06
few O 0 3.848875621770276e-06
spontaneously O 0 2.3415603209286928e-05
recurring O 0 6.62444144836627e-05
ATM O 0 0.0002901384432334453
mutations O 0 0.00010418560123071074
exist O 0 3.719124651979655e-05
. O 0 4.8332738515455276e-05

Assays O 0 0.0007058049668557942
requiring O 0 4.925298344460316e-05
minimal O 0 2.420324381091632e-05
amounts O 0 4.1116736611002125e-06
of O 0 1.0357416613260284e-06
genomic O 0 1.223220351675991e-05
DNA O 0 7.021239071036689e-06
were O 0 3.5084241289951024e-07
designed O 0 7.89711236848234e-07
to O 0 1.5685320420288917e-07
allow O 0 4.5284664906830585e-07
rapid O 0 1.7160363086077268e-06
screening O 0 2.924079126387369e-06
for O 0 1.0681712865334703e-06
common O 0 5.1248989620944485e-06
ethnic O 0 2.0460121959331445e-05
mutations O 0 0.00025882243062369525
. O 0 4.951279697706923e-05

These O 0 4.035156962345354e-05
rapid O 0 6.752440822310746e-05
assays O 0 0.00017748482059687376
detected O 0 4.134398841415532e-05
mutations O 0 2.2526788598042913e-05
in O 0 1.2810916132366401e-06
76 O 0 7.798273145454004e-06
% O 0 5.793167474621441e-07
of O 0 1.5038891376661923e-07
Costa O 0 2.080133526760619e-06
Rican O 0 1.818014970922377e-05
patients O 0 1.7592805306776427e-05
( O 0 2.4470617177030363e-07
3 O 0 2.0665245870077342e-07
) O 0 8.083217295506984e-08
, O 0 5.654707280200455e-08
50 O 0 1.2579936026213545e-07
% O 0 1.1129920807206872e-07
of O 0 7.868787577081093e-08
Norwegian O 1 0.7144554257392883
patients O 0 0.00029206424369476736
( O 0 1.749970692799252e-07
1 O 0 9.85355015359346e-08
) O 0 8.277604734985289e-08
, O 0 5.013769666106782e-08
25 O 0 1.2855522868449043e-07
% O 0 1.081579696915469e-07
of O 0 1.2208238331368193e-07
Polish O 0 0.05579768493771553
patients O 0 0.00030662957578897476
( O 0 2.4140496179825277e-07
4 O 0 3.109518900146213e-07
) O 0 9.236748610419454e-08
, O 0 5.4286999784380896e-08
and O 0 1.1292389956452098e-07
14 O 0 2.450480280913325e-07
% O 0 1.9813242602140235e-07
of O 0 1.1996294801974727e-07
Italian O 0 0.008123510517179966
patients O 0 0.0011599797289818525
( O 0 3.47078866980155e-07
1 O 0 2.0671947709161032e-07
) O 0 8.74788099736179e-08
, O 0 4.365978512055335e-08
as O 0 6.057653223479065e-08
well O 0 1.2182941588889662e-07
as O 0 1.4840269102478487e-07
in O 0 4.816529894924315e-07
patients O 0 4.914234523312189e-06
of O 0 4.041006320676388e-07
Amish O 0 7.422542694257572e-05
/ O 0 3.447723065619357e-05
Mennonite O 0 0.00010301700967829674
and O 0 4.611059011949692e-06
Irish O 0 3.4558732295408845e-05
English O 0 2.8363181627355516e-05
backgrounds O 0 0.00010044754890259355
. O 0 5.247657827567309e-05

Additional O 0 7.569968147436157e-05
mutations O 0 6.894212128827348e-05
were O 0 2.4793851025606273e-06
observed O 0 2.360194230277557e-06
in O 0 6.694087346659217e-07
Japanese O 0 2.211896571679972e-06
, O 0 4.3725580667342e-07
Utah O 0 1.64003199643048e-06
Mormon O 0 3.3751618957467144e-06
, O 0 6.313625817710999e-07
and O 0 1.165146500170522e-06
African O 0 7.31891759642167e-06
American O 0 2.437281364109367e-05
patients O 0 0.0002362792583880946
. O 0 5.029836393077858e-05

These O 0 2.5270106561947614e-05
assays O 0 6.309608579613268e-05
should O 0 2.610526280477643e-06
facilitate O 0 2.337172873012605e-06
screening O 0 5.657443125528516e-06
for O 0 1.5539274045295315e-06
A B-Disease 0 0.048057008534669876
- I-Disease 1 0.9974495768547058
T I-Disease 1 0.9998881816864014
heterozygotes O 0 4.90222082589753e-05
in O 0 1.0323670949219377e-06
the O 0 1.698891537671443e-06
populations O 0 9.612497706257273e-06
studied O 0 2.543388109188527e-05
. O 0 1.2731316928693559e-05
. O 0 3.5906265111407265e-05

The O 0 0.0003117021406069398
von B-Disease 1 0.9869408011436462
Hippel I-Disease 1 0.9988736510276794
- I-Disease 1 0.8404064774513245
Lindau I-Disease 1 0.9976189732551575
tumor I-Disease 0 0.004916658159345388
suppressor O 0 0.0001331353560090065
gene O 0 1.3718447007704526e-05
is O 0 8.620340281595418e-07
required O 0 1.0257133453706047e-06
for O 0 1.0162705166294472e-06
cell O 0 1.9295019228593446e-05
cycle O 0 1.773117583070416e-05
exit O 0 1.4851263586024288e-05
upon O 0 8.32115620141849e-06
serum O 0 0.0006800447008572519
withdrawal O 0 0.00010531963926041499
. O 0 8.121036808006465e-05

The O 0 7.497852493543178e-05
inactivation O 0 0.00019428446830715984
of O 0 4.885282578470651e-06
the O 0 1.4259546333050821e-05
von B-Disease 1 0.9991680383682251
Hippel I-Disease 1 0.9999595880508423
- I-Disease 1 0.9649035334587097
Lindau I-Disease 1 0.9973104000091553
( I-Disease 0 1.1650881788227707e-05
VHL I-Disease 0 0.0543038584291935
) I-Disease 0 3.1380450309370644e-06
tumor I-Disease 0 2.7055184546043165e-05
suppressor O 0 2.1519394067581743e-05
gene O 0 8.656442332721781e-06
predisposes O 0 3.617458787630312e-05
affected O 0 3.280510327385855e-06
individuals O 0 6.327392725324898e-07
to O 0 3.733899802682572e-07
the O 0 1.3928108728578081e-06
human O 0 0.0016136233462020755
VHL B-Disease 1 1.0
cancer I-Disease 1 1.0
syndrome I-Disease 1 0.9999923706054688
and O 0 1.117594933930377e-06
is O 0 3.215994297534053e-07
associated O 0 1.6060639609349892e-06
with O 0 1.9708697891474003e-06
sporadic B-Disease 1 0.971895158290863
renal I-Disease 1 1.0
cell I-Disease 1 0.9999978542327881
carcinomas I-Disease 1 1.0
( O 0 0.00017451254825573415
RCC B-Disease 1 0.9911651015281677
) O 0 7.548650955868652e-06
and O 0 1.2396638339851052e-05
brain B-Disease 0 0.05871348828077316
hemangioblastomas I-Disease 0 0.02921471744775772
. O 0 9.454137762077153e-05

VHL O 1 0.8765396475791931
- O 0 0.04883166402578354
negative O 0 0.00020026537822559476
786 O 0 0.00027928149211220443
- O 0 0.0005432511097751558
0 O 0 1.7079732060665265e-05
RCC B-Disease 0 0.001956763444468379
cells O 0 7.76653723733034e-06
are O 0 4.633363062112039e-07
tumorigenic O 0 1.6037150999181904e-05
in O 0 1.3662989886142896e-06
nude O 0 3.7511606933549047e-05
mice O 0 8.693726704223081e-05
which O 0 3.707847042733192e-07
is O 0 2.7410075631451036e-07
suppressed O 0 1.6307428722939221e-06
by O 0 5.333039325705613e-07
the O 0 1.9178996808477677e-06
reintroduction O 0 4.2536576074780896e-05
of O 0 7.5353877946326975e-06
VHL B-Disease 0 0.40627211332321167
. O 0 7.451869896613061e-05

Remarkably O 0 0.0026899585500359535
, O 0 9.81905668595573e-06
this O 0 1.2421694464137545e-06
occurs O 0 9.142001999862259e-07
without O 0 3.808721089626488e-07
affecting O 0 6.5480367084092e-07
the O 0 1.8788198019592528e-07
growth O 0 1.0703025736802374e-06
rate O 0 7.68980555676535e-07
and O 0 3.6837315064985887e-07
cell O 0 6.840864898549626e-06
cycle O 0 3.538390046742279e-06
profile O 0 2.457618847984122e-06
of O 0 2.6473330194676237e-07
these O 0 8.860505431584897e-07
cells O 0 7.656286470592022e-06
in O 0 2.377392320340732e-06
culture O 0 1.532037822471466e-05
. O 0 2.9064474801998585e-05

The O 0 3.712707257363945e-05
786 O 0 0.0001870320556918159
- O 0 0.00010044295049738139
0 O 0 4.940625331073534e-06
cell O 0 2.801112941597239e-06
line O 0 1.0563047680989257e-06
, O 0 2.0946801271293225e-07
like O 0 5.310606638886384e-07
many O 0 1.2634258155230782e-06
cancer B-Disease 0 0.07754172384738922
cells O 0 5.95028541283682e-06
, O 0 3.5093609085379285e-07
fails O 0 1.8833760577763314e-06
to O 0 1.4394096581327176e-07
exit O 0 1.0169530924031278e-06
the O 0 5.817549890707596e-07
cell O 0 7.293353064596886e-06
cycle O 0 4.908941718895221e-06
upon O 0 3.1954666610545246e-06
serum O 0 0.0002300410415045917
withdrawal O 0 9.59844546741806e-05
. O 0 4.257221371517517e-05

Here O 0 3.7582645745715126e-05
, O 0 4.218188678350998e-06
it O 0 6.908681484674162e-07
is O 0 2.617309178276628e-07
shown O 0 4.265406516879011e-07
that O 0 1.1140880928905972e-07
reintroduction O 0 1.8077756749335094e-06
of O 0 1.0211324763531593e-07
the O 0 4.739184191748791e-07
wild O 0 2.3717332169326255e-06
- O 0 0.00014679391460958868
type O 0 6.9705015448562335e-06
VHL B-Disease 0 0.0003049559018108994
gene O 0 5.748858256993117e-06
restores O 0 7.640560397703666e-06
the O 0 6.104454541855375e-07
ability O 0 1.8427348322802573e-06
of O 0 8.683925329933118e-07
VHL O 0 0.07015766203403473
- O 0 0.0151130435988307
negative O 0 5.442361725727096e-05
RCC B-Disease 1 0.9992197751998901
cancer I-Disease 0 0.22536100447177887
cells O 0 2.594223360574688e-06
to O 0 3.97317734268654e-07
exit O 0 1.6155775028892094e-06
the O 0 6.977844009270484e-07
cell O 0 7.810075658198912e-06
cycle O 0 5.756209702667547e-06
and O 0 1.604444378244807e-06
enter O 0 6.278371984080877e-06
G0 O 0 0.0014283435884863138
/ O 0 2.004949601541739e-05
quiescence O 0 8.439426892437041e-05
in O 0 6.531654435093515e-06
low O 0 0.00011153688683407381
serum O 0 0.0015841525746509433
. O 0 9.210089046973735e-05

Both O 0 0.00022871048713568598
VHL O 0 0.10538352280855179
- O 0 0.0009291272726841271
positive O 0 1.9253440768807195e-05
and O 0 8.032888217712753e-06
VHL O 0 0.052033618092536926
- O 0 0.002662306185811758
negative O 0 2.220328497060109e-05
RCC B-Disease 0 0.02798040211200714
cells O 0 7.598284355481155e-06
exit O 0 3.859516255033668e-06
the O 0 7.700563742218947e-07
cell O 0 1.1095495210611261e-05
cycle O 0 5.640855306410231e-06
by O 0 2.1364389795053285e-06
contact O 0 1.3086184480926022e-05
inhibition O 0 8.80248990142718e-05
. O 0 3.998094689450227e-05

The O 0 0.00020310950640123338
cyclin O 0 0.3076285123825073
- O 0 0.0011071385815739632
dependent O 0 5.4404474212788045e-05
kinase O 0 5.5840922868810594e-05
inhibitor O 0 2.474167922628112e-05
, O 0 1.5199500467133475e-06
p27 O 0 1.935967884492129e-05
, O 0 8.805212132756424e-07
accumulates O 0 2.265309149152017e-06
upon O 0 7.1696013037581e-07
serum O 0 9.233521268470213e-06
withdrawal O 0 2.5996048407250782e-06
, O 0 2.361607585044112e-07
only O 0 7.254654832422602e-08
in O 0 1.0673938533045657e-07
the O 0 1.3376542540299852e-07
presence O 0 2.467505453296326e-07
of O 0 1.536745202201928e-07
VHL B-Disease 0 0.020494388416409492
, O 0 2.5282187721131777e-07
as O 0 1.1499420082827783e-07
a O 0 1.59706331714915e-07
result O 0 4.521630785347952e-07
of O 0 8.718896538084664e-08
the O 0 3.1910124675960105e-07
stabilization O 0 3.7284808058757335e-06
of O 0 4.807177447219146e-07
the O 0 3.894890141964424e-06
protein O 0 3.853543967125006e-05
. O 0 2.8427413781173527e-05

We O 0 5.224648703006096e-05
propose O 0 3.5892742744181305e-05
that O 0 9.832670002651867e-07
the O 0 6.320493071143574e-07
loss O 0 2.3403445084113628e-06
of O 0 2.340732407901669e-07
wild O 0 1.5470162679775967e-06
- O 0 0.00018776519573293626
type O 0 5.881338438484818e-06
VHL B-Disease 0 0.00281813507899642
gene O 0 3.466330326773459e-06
results O 0 1.6596711702732136e-06
in O 0 1.8022433323494624e-07
a O 0 1.963039011343426e-07
specific O 0 5.24305789895152e-07
cellular O 0 2.2335932953865267e-05
defect O 0 2.427883373457007e-05
in O 0 7.374536608040216e-07
serum O 0 0.0012997096637263894
- O 0 0.00029228680068627
dependent O 0 2.4442863377771573e-06
growth O 0 1.0264296861350886e-06
control O 0 1.1527237120390055e-06
, O 0 3.7086110182826815e-07
which O 0 6.054339110050933e-07
may O 0 2.0740444597322494e-06
initiate O 0 1.2533988410723396e-05
tumor B-Disease 0 0.00027300388319417834
formation O 0 2.525411036913283e-05
. O 0 3.247949280194007e-05

This O 0 3.1111587304621935e-05
is O 0 4.649528818845283e-06
corrected O 0 1.0740513971541077e-05
by O 0 4.968674147676211e-07
the O 0 5.355730650080659e-07
reintroduction O 0 5.035591129853856e-06
of O 0 4.992451749785687e-07
wild O 0 3.869164629577426e-06
- O 0 0.0010413714917376637
type O 0 1.3740246686211322e-05
VHL B-Disease 0 0.013544509187340736
, O 0 1.5529467418673448e-06
implicating O 0 1.4496853509626817e-05
VHL B-Disease 0 0.0018744736444205046
as O 0 4.839108100895828e-07
the O 0 2.976661050979601e-07
first O 0 1.913159167088452e-06
tumor B-Disease 0 3.078693043789826e-05
suppressor O 0 8.383652129850816e-06
involved O 0 5.179657591725118e-07
in O 0 1.9608238233104203e-07
the O 0 1.4554815663814225e-07
regulation O 0 5.059130216977792e-07
of O 0 1.474283806146559e-07
cell O 0 9.886719453788828e-06
cycle O 0 5.737006176786963e-06
exit O 0 3.7641827930201543e-06
, O 0 2.793510134324606e-07
which O 0 1.1515201236989014e-07
is O 0 7.814971780817359e-08
consistent O 0 3.494945985949016e-07
with O 0 1.1545066058715747e-07
its O 0 5.247395051810599e-07
gatekeeper O 0 2.3723037884337828e-05
function O 0 1.1645277027128031e-06
in O 0 9.736002084537176e-07
the O 0 8.781397809798364e-06
kidney O 1 0.8911446928977966
. O 0 2.9311930120456964e-05
. O 0 5.0355094572296366e-05

Piebaldism B-Disease 1 0.9996213912963867
with O 0 0.0004602094122674316
deafness B-Disease 1 0.9999966621398926
: O 0 2.8026439395034686e-05
molecular O 0 5.05356838402804e-05
evidence O 0 5.129602868692018e-06
for O 0 2.392702526776702e-06
an O 0 1.0627002666296903e-05
expanded O 0 0.02655872143805027
syndrome O 1 0.9999138116836548
. O 0 0.00016782274178694934

In O 0 4.870918928645551e-05
a O 0 8.924856047087815e-06
South O 0 6.277635293372441e-06
African O 0 4.082183295395225e-06
girl O 0 8.55343841976719e-06
of O 0 7.693664088037622e-07
Xhosa O 0 0.31037381291389465
stock O 0 0.0002460929681546986
with O 0 2.4787043457763502e-06
severe O 0 0.16310210525989532
piebaldism B-Disease 1 0.7197684049606323
and O 0 3.017466406163294e-05
profound O 0 0.28401774168014526
congenital O 1 0.9999997615814209
sensorineural B-Disease 1 0.9999998807907104
deafness I-Disease 1 1.0
we O 0 0.0002899777900893241
identified O 0 5.341567430150462e-06
a O 0 8.399092052968626e-07
novel O 0 4.219145921524614e-06
missense O 0 8.727064596314449e-06
substitution O 0 1.9189387785445433e-06
at O 0 5.790449790765706e-07
a O 0 3.838051725324476e-07
highly O 0 8.977071956906002e-07
conserved O 0 8.544956813238969e-07
residue O 0 1.9314363726152806e-06
in O 0 2.9890833275203477e-07
the O 0 5.600095391855575e-07
intracellular O 0 4.377746336103883e-06
kinase O 0 4.8231622713501565e-06
domain O 0 5.73097963751934e-07
of O 0 2.0077789031347493e-07
the O 0 8.602207799413009e-07
KIT O 0 0.003800458973273635
proto O 0 0.055039774626493454
- O 0 0.0006634690216742456
oncogene O 0 0.000156403097207658
, O 0 8.069743671512697e-06
R796G O 0 0.00018069680663757026
. O 0 4.9922859034268185e-05

Though O 0 0.00018180946062784642
auditory B-Disease 0 0.005259422585368156
anomalies I-Disease 0 0.0011542614083737135
have O 0 3.450880967648118e-06
been O 0 1.1520038469825522e-06
observed O 0 1.260495309907128e-06
in O 0 6.542543360410491e-07
mice O 0 5.778837657999247e-05
with O 0 5.650604180118535e-07
dominant O 0 6.441997538786381e-05
white O 0 0.00019755556422751397
spotting O 0 0.0016513968585059047
( O 0 3.4544434583949624e-06
W O 0 0.019765563309192657
) O 0 4.770504347106908e-07
due O 0 5.942188181506936e-07
to O 0 7.046058385640208e-07
KIT O 1 0.8163654208183289
mutations O 0 5.1682953198906034e-05
, O 0 4.226927103445632e-06
deafness B-Disease 1 0.9999303817749023
is O 0 6.45946670374542e-07
not O 0 7.222002409434936e-07
typical O 0 2.4940316052379785e-06
in O 0 1.9799088022409705e-06
human O 0 9.685154509497806e-06
piebaldism B-Disease 0 0.0041324784979224205
. O 0 6.257567292777821e-05

Thus O 0 0.00010708047921070829
, O 0 5.259105819277465e-06
the O 0 2.7666658297675895e-06
occurrence O 0 6.774985649826704e-06
of O 0 2.14146962207451e-06
sensorineural B-Disease 1 0.9999749660491943
deafness I-Disease 1 1.0
in O 0 1.3335683433979284e-05
this O 0 1.7448460312152747e-06
patient O 0 2.3614153178641573e-05
extends O 0 2.429209416732192e-06
considerably O 0 3.951791313738795e-06
the O 0 4.315212436267757e-07
phenotypic O 0 2.853307478289935e-06
range O 0 4.6525090624527365e-07
of O 0 1.9831655606594722e-07
piebaldism B-Disease 0 3.445993934292346e-05
due O 0 1.5318579471568228e-06
to O 0 7.009184059825202e-07
KIT O 0 0.0014767443062737584
gene O 0 5.234347554505803e-06
mutation O 0 3.983405349572422e-06
in O 0 2.979973032779526e-07
humans O 0 6.429971790566924e-07
and O 0 3.1511936526840145e-07
tightens O 0 9.32902839849703e-05
the O 0 8.131088975460443e-07
clinical O 0 1.6932310245465487e-05
similarity O 0 1.3992532785778167e-06
between O 0 5.751198841608129e-07
piebaldism B-Disease 0 0.00010144751286134124
and O 0 3.2590648402219813e-07
the O 0 2.4590627845100244e-07
various O 0 4.5736391030004597e-07
forms O 0 3.7046272609586595e-06
of O 0 8.911014447221532e-05
Waardenburg B-Disease 1 0.9999998807907104
syndrome I-Disease 1 0.9999969005584717
. O 0 2.823127397277858e-05
. O 0 5.5315580539172515e-05

Cycloheximide O 0 0.0020338778849691153
facilitates O 0 0.000166115743923001
the O 0 1.2473910828703083e-05
identification O 0 6.46127500658622e-06
of O 0 6.207164346960781e-07
aberrant O 0 8.432210961473174e-06
transcripts O 0 6.949771886866074e-06
resulting O 0 2.2439303393184673e-06
from O 0 4.544105252080044e-07
a O 0 5.792449542241229e-07
novel O 0 5.681362381437793e-06
splice O 0 0.0005178995197638869
- O 0 0.00025119323981925845
site O 0 4.4269845602684654e-06
mutation O 0 2.7948822207690682e-06
in O 0 5.233471824794833e-07
COL17A1 O 0 8.781420910963789e-05
in O 0 7.874408538555144e-07
a O 0 2.4890941858757287e-06
patient O 0 6.382227002177387e-05
with O 0 1.3726181350648403e-05
generalized O 0 0.2672061622142792
atrophic B-Disease 1 0.9999760389328003
benign I-Disease 1 0.9979585409164429
epidermolysis I-Disease 1 0.9986568689346313
bullosa I-Disease 1 0.9960700273513794
. O 0 0.00035988754825666547

Patients O 1 0.680940568447113
with O 0 0.0001516434276709333
generalized O 0 0.011419882997870445
atrophic B-Disease 1 0.999940037727356
benign I-Disease 1 0.998371422290802
epidermolysis I-Disease 1 0.9993554949760437
bullosa I-Disease 1 0.9978391528129578
often O 0 3.675243351608515e-05
show O 0 7.89923797128722e-06
decreased O 0 1.0097679478349164e-05
expression O 0 3.1323222628998337e-06
of O 0 8.578073220633087e-07
type O 0 1.681190769886598e-05
XVII O 0 0.07791723310947418
collagen O 0 5.713531936635263e-05
, O 0 1.9988581243524095e-06
a O 0 3.1039239729580004e-06
transmembrane O 0 2.009053059737198e-05
hemidesmosomal O 0 5.767936454503797e-05
protein O 0 5.7935267250286415e-06
encoded O 0 4.740779786516214e-06
by O 0 7.719145287410356e-06
COL17A1 O 0 0.0008049001335166395
. O 0 0.0001019821283989586

This O 0 4.192580672679469e-05
report O 0 2.1978417862555943e-05
documents O 0 7.723813723714557e-06
a O 0 2.374222503931378e-06
novel O 0 1.276477451028768e-05
splice O 0 0.0005697881570085883
- O 0 0.0008134294184856117
site O 0 4.731954049930209e-06
mutation O 0 4.305865786591312e-06
in O 0 6.381107482411608e-07
COL17A1 O 0 0.0002923849388025701
in O 0 8.763392997934716e-07
a O 0 1.3813960322295316e-06
patient O 0 3.7388359487522393e-05
with O 0 2.598650553409243e-06
generalized O 0 0.006708592642098665
atrophic B-Disease 1 0.9999569654464722
benign I-Disease 1 0.9857600331306458
epidermolysis I-Disease 1 0.9936460256576538
bullosa I-Disease 1 0.9465363025665283
, O 0 2.2344893295667134e-06
and O 0 6.660229132648965e-07
applies O 0 8.680099199409597e-07
a O 0 4.945283080814988e-07
new O 0 6.57142038562597e-07
methodology O 0 2.737204113145708e-06
to O 0 3.433720792145323e-07
define O 0 1.5084539199961e-06
and O 0 6.447440910051228e-07
characterize O 0 4.8501224227948114e-06
the O 0 1.0110757102665957e-06
resulting O 0 7.352006832661573e-06
mRNA O 0 1.7163642041850835e-05
splice O 0 0.0001341828319709748
variants O 0 5.4916541557759047e-05
. O 0 3.7949499528622255e-05

Mutational O 0 0.006092686206102371
analysis O 0 0.00013268593465909362
of O 0 9.431360922462773e-06
COL17A1 O 0 0.0005143877933733165
identified O 0 1.3670478438143618e-05
a O 0 3.952485258196248e-06
maternally O 0 0.00010084103996632621
inherited O 0 0.0026107633020728827
G O 0 0.0006777087692171335
- O 0 3.409640703466721e-05
to O 0 9.635668902774341e-07
- O 0 0.00014298595488071442
T O 0 0.00010260965063935146
transversion O 0 9.008237611851655e-06
at O 0 4.3163728946638e-07
the O 0 3.074980554629292e-07
- O 0 4.773581167683005e-06
1 O 0 9.257053648070723e-07
position O 0 1.0292271781509044e-06
of O 0 1.0188382475462276e-06
exon O 0 5.0336369895376265e-05
32 O 0 2.2227861336432397e-05
. O 0 2.9338945751078427e-05

This O 0 3.1830528314458206e-05
acceptor O 0 0.00013297394616529346
splice O 0 0.00037487351801246405
- O 0 0.00031392756500281394
site O 0 4.746163540403359e-06
mutation O 0 4.933581294608302e-06
led O 0 8.978759069577791e-07
to O 0 2.2097198382198258e-07
the O 0 1.9886464031060314e-07
formation O 0 5.080937057755364e-07
of O 0 1.4213463828127715e-07
aberrant O 0 3.0632716061518295e-06
transcripts O 0 2.3095522010407876e-06
present O 0 9.505733942205552e-07
at O 0 1.3580342965724412e-06
extremely O 0 7.0565079113293905e-06
low O 0 3.385195668670349e-05
levels O 0 2.222629336756654e-05
. O 0 2.668623892532196e-05

Based O 0 6.960124301258475e-05
on O 0 5.120189598528668e-06
our O 0 3.294452881164034e-06
recent O 0 3.1334486720879795e-06
finding O 0 2.8684169137704885e-06
that O 0 1.2176604968772153e-06
cycloheximide O 0 0.00022143179376143962
stabilized O 0 0.0002422873512841761
mutant O 0 2.9364306101342663e-05
COL17A1 O 0 4.768678263644688e-05
transcripts O 0 6.284997652983293e-06
in O 0 8.346511890522379e-07
keratinocytes O 0 1.6106569091789424e-05
homozygous O 0 1.1847929272335023e-05
for O 0 3.538450528139947e-07
a O 0 1.3454332474793773e-06
frameshift O 0 0.00359027786180377
mutation O 0 5.446919658425031e-06
, O 0 2.8989765610276663e-07
the O 0 2.2643017416612565e-07
effects O 0 1.0886680001931381e-06
of O 0 9.933200573186696e-08
the O 0 3.630517255714949e-07
splice O 0 0.001531535410322249
- O 0 0.00047910516150295734
site O 0 1.3018939171161037e-06
mutation O 0 8.972767204795673e-07
on O 0 1.584196667181459e-07
splicing O 0 1.9532978967617964e-06
of O 0 2.401118592842977e-07
COL17A1 O 0 2.1168971215956844e-05
transcripts O 0 2.3359655187960016e-06
were O 0 3.975599156547105e-07
determined O 0 6.895003821227874e-07
using O 0 4.5886508814874105e-07
reverse O 0 6.145768111309735e-06
transcriptase O 0 3.316058428026736e-05
polymerase O 0 1.372712358715944e-05
chain O 0 5.687194516212912e-06
reaction O 0 1.31912338474649e-06
of O 0 1.9057735300975764e-07
total O 0 6.602238613595546e-07
RNA O 0 2.8251529329281766e-06
from O 0 1.0080716492666397e-06
keratinocytes O 0 2.492122439434752e-05
incubated O 0 1.9151038941345178e-05
for O 0 3.299858235550346e-06
2 O 0 1.3972176930110436e-05
. O 0 2.6396732209832408e-05

5 O 0 0.00010258215479552746
h O 0 0.00015773212362546474
in O 0 2.1384205410868162e-06
the O 0 8.383519229937519e-07
presence O 0 9.25125618778111e-07
or O 0 6.312234859251475e-07
absence O 0 1.4735909417140647e-06
of O 0 6.993852821324253e-07
10 O 0 2.1956759610475274e-06
microg O 0 0.00010050159471575171
cycloheximide O 0 0.00012396917736623436
per O 0 1.5109840205695946e-05
ml O 0 0.00031208634027279913
. O 0 3.079051384702325e-05

Using O 0 5.3769854275742546e-05
this O 0 6.413505616365001e-06
approach O 0 8.987087312561926e-06
, O 0 1.0739834124251502e-06
an O 0 4.6175577494977915e-07
abnormally O 0 1.3059853699814994e-05
spliced O 0 1.9371054804651067e-05
transcript O 0 8.248858648585156e-05
was O 0 5.904835688852472e-06
identified O 0 7.04010744811967e-07
that O 0 4.766820538293359e-08
contains O 0 9.424425684301241e-08
an O 0 6.864038226694902e-08
extra O 0 5.012325914321991e-07
264 O 0 1.364848230878124e-06
bases O 0 5.854857363374322e-07
upstream O 0 8.945101512836118e-07
from O 0 3.061248605717992e-07
exon O 0 2.7499777388584334e-06
32 O 0 6.813628488089307e-07
, O 0 2.625817216994619e-07
resulting O 0 9.469721931054664e-07
in O 0 4.810570999325137e-07
a O 0 1.619355202819861e-06
premature O 0 6.972919072723016e-05
termination O 0 3.557958916644566e-05
codon O 0 1.569610321894288e-05
27 O 0 5.981127287668642e-06
bp O 0 1.4694772289658431e-05
downstream O 0 3.94944436266087e-06
from O 0 7.26186669908202e-07
the O 0 2.3321813387156e-06
cryptic O 0 6.245644181035459e-05
splice O 0 0.0005398494540713727
site O 0 6.437746924348176e-05
. O 0 5.464521746034734e-05

Three O 0 2.417666655674111e-05
other O 0 3.3489250199636444e-06
splice O 0 4.0770166378933936e-05
variants O 0 5.463838533614762e-06
, O 0 4.3073100641777273e-07
including O 0 1.8527104828081065e-07
one O 0 1.387505079719631e-07
derived O 0 3.7559465226877364e-07
from O 0 1.1424957335748331e-07
the O 0 1.214291245332788e-07
skipping O 0 9.163169352177647e-07
of O 0 1.7939967733582307e-07
exon O 0 4.503780473896768e-06
32 O 0 1.2394548321026377e-06
, O 0 6.247727242225665e-07
were O 0 9.1538407787084e-07
also O 0 1.9346605313330656e-06
identified O 0 1.8064150935970247e-05
. O 0 2.781523835437838e-05

These O 0 3.043766446353402e-05
results O 0 2.0396963009261526e-05
indicate O 0 4.352859377831919e-06
the O 0 5.915680958423764e-07
usefulness O 0 2.892814563892898e-06
of O 0 4.2845394432333705e-07
cycloheximide O 0 0.0010848203673958778
treatment O 0 1.272172994504217e-05
in O 0 5.539927201425598e-07
evaluating O 0 2.991409701280645e-06
the O 0 4.490381400046317e-07
abnormal O 0 2.442599452479044e-06
processing O 0 7.103123493834573e-07
of O 0 1.4747675436410645e-07
mRNA O 0 1.1864840416819789e-06
due O 0 6.724063155161275e-07
to O 0 3.8000354152245563e-07
splice O 0 4.705996616394259e-05
- O 0 5.119546767673455e-05
site O 0 1.3076651157462038e-06
mutations O 0 1.7249803931917995e-06
, O 0 2.2478317873719789e-07
because O 0 3.344997878684808e-07
( O 0 2.099043285852531e-07
i O 0 7.049217174426303e-07
) O 0 3.29177254343449e-07
aberrant O 0 1.9932310806325404e-06
splicing O 0 4.959199941367842e-06
often O 0 9.412584063284157e-07
generates O 0 1.436649426977965e-06
a O 0 1.59144678946177e-06
premature O 0 2.5497167371213436e-05
termination O 0 1.1286709195701405e-05
codon O 0 5.378525202104356e-06
, O 0 5.973290058136627e-07
( O 0 4.7106658485063235e-07
ii O 0 2.8727315566356992e-06
) O 0 3.9319996858466766e-07
transcripts O 0 8.839826932671713e-07
with O 0 2.7756513532040117e-07
premature O 0 2.01135735551361e-05
termination O 0 5.587608939094935e-06
codons O 0 4.008548330602935e-06
can O 0 3.215837693915091e-07
occur O 0 3.2812945960358775e-07
at O 0 2.492238593276852e-07
low O 0 1.4382807194124325e-06
or O 0 4.481910025333491e-07
undetectable O 0 3.6562887544278055e-06
levels O 0 5.743218594034261e-07
due O 0 4.316595152431546e-07
to O 0 3.0315803201119707e-07
nonsense O 0 3.669409124995582e-06
- O 0 2.9832103791704867e-06
mediated O 0 1.6614322930763592e-06
mRNA O 0 1.033868556987727e-06
decay O 0 1.457846110497485e-06
, O 0 1.6543063452445494e-07
and O 0 2.0394631405906694e-07
( O 0 2.1338215105970448e-07
iii O 0 1.954507297341479e-06
) O 0 7.309908767183515e-08
the O 0 4.565446332094325e-08
levels O 0 1.381776684183933e-07
of O 0 2.99352187482782e-08
these O 0 1.0261032201697162e-07
transcripts O 0 1.1273253903709701e-06
can O 0 3.574361073788168e-07
be O 0 2.0454916693779523e-07
increased O 0 1.406194769515423e-06
by O 0 3.855267550534336e-06
cycloheximide O 0 0.003219116246327758
. O 0 7.183066918514669e-05

A O 0 0.0002142745506716892
deletion O 0 0.0004582731344271451
mutation O 0 0.00014214558177627623
in O 0 4.130574325245107e-06
COL17A1 O 0 0.00018023066513706
in O 0 1.624112428544322e-06
five O 0 2.071960579996812e-06
Austrian O 0 0.0008962054271250963
families O 0 8.814338798401877e-06
with O 0 2.954977162517025e-06
generalized O 0 0.022299805656075478
atrophic B-Disease 1 0.9999866485595703
benign I-Disease 1 0.9991064667701721
epidermolysis I-Disease 1 0.9982284903526306
bullosa I-Disease 1 0.6489253640174866
represents O 0 8.251079634646885e-06
propagation O 0 7.59247450332623e-06
of O 0 1.0388062037236523e-06
an O 0 2.1237610781099647e-06
ancestral O 0 7.171506877057254e-05
allele O 0 0.0002969893685076386
. O 0 5.3085812396602705e-05

Patients O 0 0.434574156999588
with O 0 8.445858838967979e-05
generalized O 0 0.030535008758306503
atrophic B-Disease 1 0.9999806880950928
benign I-Disease 1 0.9996681213378906
epidermolysis I-Disease 1 0.9998225569725037
bullosa I-Disease 1 0.9994766116142273
, O 0 2.267194213345647e-05
a O 0 3.2744035252108006e-06
usually O 0 3.089573965553427e-06
nonlethal O 0 1.998377229028847e-05
form O 0 6.181318440212635e-06
of O 0 2.9175030249461997e-06
junctional B-Disease 1 0.5504191517829895
epidermolysis I-Disease 1 0.9985830783843994
bullosa I-Disease 1 0.9815036058425903
, O 0 4.047589300171239e-06
have O 0 1.09624841115874e-06
generalized O 0 9.231865988112986e-06
blistering B-Disease 0 0.00039743565139360726
, O 0 1.0808041224663612e-05
nail B-Disease 1 0.9996771812438965
dystrophy I-Disease 1 0.9997996687889099
, O 0 3.494475095067173e-05
patchy B-Disease 1 0.9779841303825378
alopecia I-Disease 1 0.9999895095825195
, O 0 1.7678634321782738e-05
and O 0 7.480354543076828e-05
dental B-Disease 1 0.9999136924743652
abnormalities I-Disease 1 0.9995192289352417
. O 0 0.0001600179384695366

Skin B-Disease 1 0.9991637468338013
fragility I-Disease 0 0.42019546031951904
in O 0 9.87460316537181e-06
most O 0 2.5078074941120576e-06
cases O 0 1.4258362170949113e-06
is O 0 2.879762348584336e-07
due O 0 9.191614367409784e-07
to O 0 7.751248176646186e-07
mutations O 0 3.028317223652266e-06
in O 0 2.1283280204897892e-07
the O 0 5.311711106514849e-07
gene O 0 4.913897100777831e-06
encoding O 0 1.0427912457089406e-05
type O 0 5.584033715422265e-05
XVII O 0 0.13336163759231567
collagen O 0 0.00027629960095509887
( O 0 1.2603267350641545e-05
COL17A1 O 0 0.0005599297001026571
) O 0 1.943351890076883e-05
. O 0 2.7574531486607157e-05

Recently O 0 0.0004990304005332291
, O 0 1.2229147614561953e-05
we O 0 4.964248546457384e-06
reported O 0 4.473327862797305e-06
five O 0 1.7261585298911086e-06
Austrian O 0 8.721192716620862e-05
families O 0 1.4033335901331156e-05
with O 0 5.860572855453938e-06
generalized O 0 0.014437759295105934
atrophic B-Disease 1 0.9999709129333496
benign I-Disease 1 0.9916889071464539
epidermolysis I-Disease 1 0.9968588352203369
bullosa I-Disease 1 0.9982993006706238
who O 0 5.6779546866891906e-05
share O 0 1.3397418115346227e-05
the O 0 3.5293344353704015e-06
same O 0 1.537101525173057e-05
COL17A1 O 0 0.2312726080417633
mutation O 0 0.0006480177398771048
. O 0 0.00011455392086645588

Affected O 0 0.000233463040785864
individuals O 0 7.6103515311842784e-06
in O 0 9.994544143410167e-07
three O 0 5.75183548789937e-07
families O 0 1.1832760264951503e-06
are O 0 1.738682158247684e-07
homozygous O 0 3.5635073345474666e-06
for O 0 2.666671718998259e-07
4003delTC O 0 8.36300114315236e-06
, O 0 2.987285085964686e-07
whereas O 0 6.502931455543148e-07
those O 0 2.4830620759530575e-07
in O 0 1.7499658611086488e-07
two O 0 3.7527095742007077e-07
others O 0 2.556928620833787e-06
are O 0 1.1709702221196494e-06
compound O 0 3.3752738090697676e-05
heterozygotes O 0 0.0006793913780711591
. O 0 3.783501961152069e-05

To O 0 3.315201320219785e-05
determine O 0 1.110514858737588e-05
if O 0 1.5913725519567379e-06
the O 0 3.19005096116598e-07
occurrence O 0 8.829059652271098e-07
of O 0 2.0364970509945124e-07
4003delTC O 0 1.9950470232288353e-05
in O 0 3.928615228687704e-07
these O 0 2.7240014333074214e-07
unrelated O 0 7.598313004564261e-06
families O 0 1.3178610061004292e-06
signifies O 0 7.021394026196504e-07
propagation O 0 7.1650356403552e-07
of O 0 1.349868199440607e-07
an O 0 1.284632986653378e-07
ancestral O 0 3.070372713409597e-06
allele O 0 5.546928605326684e-06
or O 0 5.443920940706448e-07
a O 0 5.654377446262515e-07
mutational O 0 3.7963032809784636e-05
hot O 0 6.0836878219561186e-06
spot O 0 2.517094799259212e-06
, O 0 3.013785772054689e-07
haplotypes O 0 3.7370241443568375e-06
were O 0 5.016328827878169e-07
determined O 0 1.8472497913535335e-06
for O 0 5.938154572504573e-07
polymorphisms O 0 8.675500794197433e-06
both O 0 8.04200169568503e-07
within O 0 9.512027645541821e-07
and O 0 3.6523506423691288e-06
flanking O 0 0.000307241192786023
COL17A1 O 0 0.11441569775342941
. O 0 8.045051072258502e-05

Five O 0 0.00013551484153140336
intragenic O 0 0.0005285630468279123
polymorphisms O 0 0.0002066223241854459
were O 0 4.5574693103844766e-06
chosen O 0 2.597937054815702e-06
based O 0 2.1695452687708894e-06
on O 0 1.7379439896103577e-06
their O 0 7.67957044445211e-06
informativeness O 0 0.003368576057255268
. O 0 6.44820393063128e-05

One O 0 1.3383806617639493e-05
of O 0 1.0338478659832617e-06
these O 0 5.621177479042672e-07
, O 0 4.3603861854535353e-07
not O 0 3.245145308028441e-07
previously O 0 1.2543927141450695e-06
reported O 0 1.192474542222044e-06
, O 0 2.0420360158368567e-07
was O 0 6.018015028530499e-07
2988 O 0 7.517343419749523e-06
A O 0 6.414690005840384e-07
or O 0 8.365629469153646e-07
C O 0 5.047437753091799e-06
that O 0 1.003757006401429e-07
introduces O 0 4.708402059350192e-07
a O 0 2.0288401003654144e-07
new O 0 5.446553359433892e-07
restriction O 0 9.504673244009609e-07
site O 0 1.5523100955761038e-06
for O 0 1.1156056416439242e-06
Eco0109 O 0 5.9963302192045376e-05
I O 0 3.3579301089048386e-05
. O 0 3.0137161957100034e-05

All O 0 1.4122078937361948e-05
the O 0 6.453324658650672e-06
4003delTC O 0 6.505061901407316e-05
alleles O 0 2.2905105652171187e-05
showed O 0 3.3105307011283003e-06
the O 0 4.326940654664213e-07
same O 0 6.256706797103107e-07
haplotype O 0 1.5384888683911413e-05
for O 0 6.439071853492351e-07
these O 0 5.485524638970674e-07
five O 0 2.5624208319641184e-06
polymorphic O 0 0.00011524306319188327
markers O 0 8.261335460701957e-05
. O 0 4.991714740754105e-05

Fourteen O 0 0.00034530911943875253
microsatellite O 0 0.001258500968106091
polymorphisms O 0 0.00030493465601466596
were O 0 3.466660700723878e-06
selected O 0 1.4091576758801239e-06
based O 0 6.724358172505163e-07
on O 0 1.8703458692925778e-07
their O 0 4.525202541572071e-07
high O 0 2.263577243866166e-06
heterozygosity O 0 3.981178815593012e-05
and O 0 3.7168680933064024e-07
their O 0 4.853445148000901e-07
location O 0 1.7616966943023726e-06
within O 0 1.4897530036250828e-06
10q23 O 0 9.337305527878925e-05
- O 0 0.00019020936451852322
q25 O 0 0.00018933592946268618
near O 0 3.968965029343963e-05
COL17A1 O 0 0.0012398542603477836
. O 0 6.612815195694566e-05

Three O 0 6.56747943139635e-05
families O 0 2.9846118195564486e-05
shared O 0 1.3034323274041526e-05
microsatellite O 0 0.00012229148705955595
polymorphisms O 0 3.1960375054040924e-05
covering O 0 2.6699035515775904e-06
at O 0 6.870009769954777e-07
most O 0 2.0526067601167597e-07
19 O 0 7.10258177605283e-07
cM O 0 2.4985642994579393e-06
, O 0 1.5337964498485235e-07
whereas O 0 2.643467951202183e-07
the O 0 1.2228326795593603e-07
others O 0 2.652958812632278e-07
shared O 0 5.083380187898001e-07
smaller O 0 1.0355402082495857e-06
regions O 0 3.5292535471853625e-07
consistent O 0 5.047612603448215e-07
with O 0 9.768835695922462e-08
cross O 0 9.246086847269908e-07
- O 0 2.332394842596841e-06
over O 0 1.250313630407618e-07
events O 0 2.0572237247051817e-07
during O 0 2.1748638801000197e-07
passage O 0 3.767070211324608e-07
of O 0 1.0122973748138975e-07
this O 0 2.266998251343466e-07
mutation O 0 2.533601445975364e-06
through O 0 1.1672462960632402e-06
several O 0 3.85269459002302e-06
generations O 0 5.212163523538038e-05
. O 0 4.2381179810035974e-05

These O 0 2.695739567570854e-05
results O 0 3.677319182315841e-05
indicate O 0 5.763944045611424e-06
that O 0 8.49452533202566e-07
4003delTC O 0 2.8373082386679016e-05
occurs O 0 1.067633547791047e-06
on O 0 4.2860108351305826e-07
a O 0 1.4666790093542659e-06
single O 0 7.65611093811458e-06
ancestral O 0 4.8489328037248924e-05
allele O 0 0.00013609809684567153
. O 0 1.9094979506917298e-05
. O 0 4.021013592137024e-05

The O 0 0.00022498065663967282
haptoglobin O 0 0.002479899674654007
- O 0 0.00045573580428026617
gene O 0 9.507858339929953e-05
deletion O 0 0.00013291716459207237
responsible O 0 3.97355506720487e-05
for O 0 2.2368993086274713e-05
anhaptoglobinemia B-Disease 0 0.003479599254205823
. O 0 0.00011311069829389453

We O 0 7.060169446049258e-05
have O 0 6.1492032727983315e-06
found O 0 2.3502798285335302e-06
an O 0 7.02663896845479e-07
allelic O 0 1.138127572630765e-05
deletion O 0 7.75136777519947e-06
of O 0 2.666035925358301e-07
the O 0 7.122258693925687e-07
haptoglobin O 0 0.00013632694026455283
( O 0 1.0180475555898738e-06
Hp O 0 4.2969559217453934e-06
) O 0 2.797650324737333e-07
gene O 0 7.777259725116892e-07
from O 0 2.184713281394579e-07
an O 0 3.300404216588504e-07
individual O 0 2.0594432044163113e-06
with O 0 3.866018232656643e-06
anhaptoglobinemia B-Disease 0 0.11333862692117691
. O 0 7.338124851230532e-05

The O 0 0.00012446203618310392
Hp O 0 0.00024507864145562053
gene O 0 4.257748878444545e-05
cluster O 0 9.574767318554223e-06
consists O 0 1.5651355624868302e-06
of O 0 6.433706971620268e-07
coding O 0 1.3322209269972518e-05
regions O 0 1.1999753724012407e-06
of O 0 1.8956515646095795e-07
the O 0 3.4108094837392855e-07
alpha O 0 4.07354173148633e-06
chain O 0 3.53234486283327e-06
and O 0 4.1597741073928773e-07
beta O 0 1.6462954590679146e-06
chain O 0 1.2942706462126807e-06
of O 0 1.7374357241806138e-07
the O 0 4.863903200202913e-07
haptoglobin O 0 2.366857552260626e-05
gene O 0 2.7023620532418136e-06
( O 0 4.190567892692343e-07
Hp O 0 1.8661888816495775e-06
) O 0 1.7095534587951988e-07
and O 0 6.105840100190107e-08
of O 0 5.1622002672502276e-08
the O 0 1.9269494089257933e-07
alpha O 0 1.654427819630655e-06
chain O 0 1.965794581337832e-06
and O 0 3.032120901025337e-07
beta O 0 1.1976122777923592e-06
chain O 0 9.775169473869028e-07
of O 0 1.1623658480175436e-07
the O 0 4.998750000595464e-07
haptoglobin O 0 0.00011913575872313231
- O 0 8.154451643349603e-05
related O 0 2.20534207073797e-06
gene O 0 4.081895440322114e-06
( O 0 7.831473567421199e-07
Hpr O 0 1.9163646356901154e-05
) O 0 4.334820857820887e-07
, O 0 1.4073296483729791e-07
in O 0 2.0437191494693252e-07
tandem O 0 2.372339395151357e-06
from O 0 4.388035392821621e-07
the O 0 9.740273299030378e-07
5 O 0 3.3072994938265765e-06
side O 0 1.6045656593632884e-05
. O 0 3.109200770268217e-05

Southern O 0 0.00026915152557194233
blot O 0 0.0003500779566820711
and O 0 1.0141957318410277e-05
PCR O 0 8.779067866271362e-05
analyses O 0 1.7509470126242377e-05
have O 0 1.3119272352923872e-06
indicated O 0 2.1846810795977945e-06
that O 0 1.4655840629984596e-07
the O 0 1.5653355944778014e-07
individual O 0 1.746956002079969e-07
with O 0 1.9969286313425982e-07
anhaptoglobinemia B-Disease 0 0.00011324992374284193
was O 0 1.825053232096252e-06
homozygous O 0 3.254814146202989e-06
for O 0 1.6012664616482652e-07
the O 0 2.6885325610237487e-07
gene O 0 1.0439447351018316e-06
deletion O 0 2.5808583359321347e-06
and O 0 2.2788987052990706e-07
that O 0 8.375354099143806e-08
the O 0 1.8220396214019274e-07
gene O 0 1.300366420764476e-06
deletion O 0 2.5040960736077977e-06
was O 0 4.126878820898128e-07
included O 0 1.7596789803064894e-07
at O 0 1.999531917817876e-07
least O 0 8.83184085864741e-08
from O 0 7.313018102195201e-08
the O 0 1.172150732031696e-07
promoter O 0 2.817039103319985e-06
region O 0 5.246724299468042e-07
of O 0 2.0993837779315072e-07
Hp O 0 6.6261845859116875e-06
to O 0 6.04000206294586e-07
Hpr O 0 2.708874671952799e-05
alpha O 0 2.635277496665367e-06
but O 0 2.7244689704275515e-07
not O 0 3.2614337897030055e-07
to O 0 8.881672215466097e-07
Hpr O 0 0.00011969007755396888
beta O 0 2.088819928758312e-05
( O 0 4.430482022144133e-06
Hpdel O 0 8.651663665659726e-05
) O 0 9.408417099621147e-06
. O 0 1.8259746866533533e-05

In O 0 2.043722997768782e-05
addition O 0 4.773303771798965e-06
, O 0 9.72492102846445e-07
we O 0 4.535796733762254e-07
found O 0 2.675174357591459e-07
seven O 0 1.713817283643948e-07
individuals O 0 1.0225747359982051e-07
with O 0 6.987612977127355e-08
hypohaptoglobinemia B-Disease 0 3.7256275390973315e-05
in O 0 2.689602069949615e-07
three O 0 2.5649924850768e-07
families O 0 7.966719977048342e-07
, O 0 1.0173008035962994e-07
and O 0 7.55061506652055e-08
the O 0 1.5917868267933954e-07
genotypes O 0 2.5844542506092694e-06
of O 0 4.955839472131629e-08
six O 0 9.800712064134132e-08
of O 0 3.004412718610183e-08
the O 0 1.235360542750641e-07
seven O 0 2.7345583930582507e-07
individuals O 0 2.0883889817469026e-07
were O 0 1.7074940217298717e-07
found O 0 2.257062163835144e-07
to O 0 3.293370980372856e-07
be O 0 1.1455979347374523e-06
Hp2 O 0 0.001097023137845099
/ O 0 8.937941311160102e-05
Hpdel O 0 0.0003631291911005974
. O 0 4.7533099859720096e-05

The O 0 6.500957533717155e-05
phenotypes O 0 0.00017013905744533986
and O 0 4.851843186770566e-06
genotypes O 0 2.1689722416340373e-05
in O 0 2.59740176034029e-07
one O 0 9.843068937698263e-08
of O 0 5.300537608832201e-08
these O 0 6.248681216902696e-08
three O 0 1.3186462410885724e-07
families O 0 8.605998687016836e-07
showed O 0 7.670674335713557e-07
the O 0 1.5972018729826232e-07
father O 0 3.3245339636778226e-06
to O 0 3.0777030701756303e-07
be O 0 3.065055125262006e-07
hypohaptoglobinemic B-Disease 0 1.7108193787862547e-05
( O 0 3.7445764178301033e-07
Hp2 O 0 4.244797764840769e-06
) O 0 2.3058738918280142e-07
and O 0 2.0052647187185357e-07
Hp2 O 0 2.373455572524108e-05
/ O 0 3.983028818765888e-06
Hpdel O 0 7.283018021553289e-06
, O 0 1.2833277196477866e-07
the O 0 1.1671957622638729e-07
mother O 0 1.6198617913687485e-06
to O 0 1.4018456795383827e-07
be O 0 1.721657412190325e-07
Hp2 O 0 6.2153189901437145e-06
- O 0 2.621000930957962e-06
1 O 0 3.43272546388107e-07
and O 0 2.676041788163275e-07
Hp1 O 0 1.0006494449044112e-05
/ O 0 2.7812579901365098e-06
Hp2 O 0 6.36532013231772e-06
, O 0 9.441409787314115e-08
one O 0 3.0812266516022646e-08
of O 0 3.174369922476217e-08
the O 0 9.36836528353524e-08
two O 0 1.3123934650138835e-07
children O 0 4.803355295734946e-07
to O 0 1.6065267516296444e-07
be O 0 1.601767394276976e-07
hypohaptoglobinemic B-Disease 0 6.3399843384104315e-06
( O 0 3.106086410298303e-07
Hp2 O 0 3.5262662549939705e-06
) O 0 1.7397437090949097e-07
and O 0 1.2000207050277822e-07
Hp2 O 0 1.7120253687608056e-05
/ O 0 2.7344983664079336e-06
Hpdel O 0 5.883369340153877e-06
, O 0 1.0770712322027975e-07
and O 0 5.1989481164582685e-08
the O 0 6.123357110254801e-08
other O 0 5.429145488733411e-08
child O 0 4.4515127228805795e-07
to O 0 1.4737805997810938e-07
be O 0 1.2098570323360036e-07
Hp1 O 0 4.319043000577949e-06
and O 0 5.027463885198813e-07
Hp1 O 0 9.106408833758906e-05
/ O 0 9.547959052724764e-06
Hpdel O 0 2.3749522370053455e-05
, O 0 3.9502890558651416e-07
showing O 0 9.889679404295748e-07
an O 0 2.1545726269778243e-07
anomalous O 0 8.82991935213795e-06
inheritance O 0 4.848281605518423e-06
of O 0 4.027609747936367e-07
Hp O 0 0.0007039678166620433
phenotypes O 0 5.03376686538104e-05
in O 0 4.904721322418482e-07
the O 0 7.904519065959903e-07
child O 0 6.147948624857236e-06
with O 0 4.625474048225442e-06
Hp1 O 0 0.032410476356744766
. O 0 5.554287417908199e-05

The O 0 6.2243350839708e-05
Hp2 O 0 0.001211885130032897
/ O 0 0.00012970564421266317
Hpdel O 0 0.00011530506890267134
individuals O 0 1.8184287000622135e-06
had O 0 1.450224885957141e-06
an O 0 2.666826901531749e-07
extremely O 0 2.0548720840452006e-06
low O 0 1.8871714928536676e-06
level O 0 4.071551131801243e-07
of O 0 1.9088930969246576e-07
Hp O 0 1.390280704072211e-05
( O 0 6.438372111006174e-07
mean O 0 2.856177161447704e-06
+ O 0 1.685821007413324e-05
/ O 0 7.248067959153559e-06
- O 0 1.5938443539198488e-05
SD O 0 3.379441477591172e-05
= O 0 9.689921171229798e-06
0 O 0 1.5199383369690622e-06
. O 0 8.456914315502218e-07
049 O 0 6.880486034788191e-05
+ O 0 1.5965279089869e-05
/ O 0 5.9026797316619195e-06
- O 0 5.20090952704777e-06
0 O 0 1.2821207064916962e-06
. O 0 6.257250220187416e-07
043 O 0 2.3072489057085477e-05
mg O 0 2.4598075469839387e-05
/ O 0 6.1889159042038955e-06
ml O 0 8.894506208889652e-06
; O 0 5.769019253420993e-07
n O 0 1.9448073089733953e-06
= O 0 2.13781709135219e-06
6 O 0 1.8110286248429475e-07
) O 0 8.944422091872184e-08
, O 0 5.174828388021524e-08
compared O 0 1.4274347392984055e-07
with O 0 6.306416366896883e-08
the O 0 1.426053586328635e-07
level O 0 3.1785205578671594e-07
( O 0 1.8672128021535173e-07
1 O 0 1.6170852745744924e-07
. O 0 1.5076027182203688e-07
64 O 0 9.354167218589282e-07
+ O 0 5.180465905141318e-06
/ O 0 3.539385716067045e-06
- O 0 2.1140494936844334e-06
1 O 0 3.5016552146771573e-07
. O 0 3.003141273438814e-07
07 O 0 7.106780230969889e-06
mg O 0 2.5503393771941774e-05
/ O 0 4.4364687710185535e-06
ml O 0 6.929189567017602e-06
) O 0 2.0431268410447956e-07
obtained O 0 2.2361064111464657e-07
from O 0 1.6173349592918385e-07
52 O 0 1.6312404795826296e-06
healthy O 0 1.8476972627468058e-06
volunteers O 0 1.7462427877035225e-06
having O 0 2.6804018489201553e-06
phenotype O 0 0.00014546130842063576
Hp2 O 0 3.069785816478543e-05
, O 0 2.846339555162558e-07
whereas O 0 5.666659035341581e-07
the O 0 4.7429415417354903e-07
serum O 0 3.487849608063698e-05
Hp O 0 5.634258741338272e-06
level O 0 2.918550023878197e-07
of O 0 9.360113750744858e-08
an O 0 1.2933880100263195e-07
individual O 0 3.5526383612705104e-07
with O 0 8.565296525375743e-07
Hp1 O 0 0.00996560137718916
/ O 0 3.971592741436325e-05
Hpdel O 0 0.00012959809100721031
was O 0 1.3331206901057158e-05
0 O 0 2.3053618861013092e-05
. O 0 2.6351055566919968e-05

50 O 0 0.00015421654097735882
mg O 0 0.0011500908294692636
/ O 0 0.0001878169277915731
ml O 0 0.00010142545943381265
, O 0 5.21330719038815e-07
which O 0 1.9459466216176224e-07
was O 0 2.2836458413166838e-07
approximately O 0 7.818863423381117e-08
half O 0 1.2831220885800576e-07
the O 0 1.2669113402807852e-07
level O 0 2.3219098466142896e-07
of O 0 1.0314857235016461e-07
Hp O 0 8.246493052865844e-06
in O 0 3.397161947304994e-07
control O 0 1.94230119632266e-06
sera O 0 2.804066070893896e-06
from O 0 1.4677827664399956e-07
the O 0 3.7890163184783887e-07
Hp1 O 0 0.00046327299787662923
phenotype O 0 6.555315485456958e-05
( O 0 3.076224004416872e-07
1 O 0 2.1509326586510724e-07
. O 0 1.9522144611983094e-07
26 O 0 5.558243287850928e-07
+ O 0 2.239225068478845e-06
/ O 0 2.4048497380135814e-06
- O 0 1.6766136923251906e-06
0 O 0 5.59589921067527e-07
. O 0 1.945492016375283e-07
33 O 0 8.090402729976631e-07
mg O 0 1.4086567716731224e-05
/ O 0 7.4029157985933125e-06
ml O 0 2.27679902309319e-05
; O 0 1.0586546750346315e-06
n O 0 5.1224119488324504e-06
= O 0 4.229298156133154e-06
9 O 0 3.7806458408340404e-07
) O 0 1.543881467114261e-07
, O 0 1.0859061205792386e-07
showing O 0 8.315930699609453e-07
a O 0 8.842187639857002e-07
gene O 0 1.1385834113752935e-05
- O 0 0.0002630767412483692
dosage O 0 0.0001465159293729812
effect O 0 3.234681935282424e-05
. O 0 2.9005470423726365e-05

The O 0 3.209173519280739e-05
other O 0 5.195015546632931e-06
allele O 0 4.246071694069542e-05
( O 0 1.9362184957572026e-06
Hp2 O 0 1.3315629985299893e-05
) O 0 3.718902803484525e-07
of O 0 1.3139188581590133e-07
individuals O 0 2.164584032016137e-07
with O 0 2.5989626806222077e-07
Hp2 O 0 0.001564612379297614
/ O 0 1.3757673514191993e-05
Hpdel O 0 3.4675464121392e-05
was O 0 5.866829724254785e-07
found O 0 1.5328605229569803e-07
to O 0 1.2983041131064965e-07
have O 0 1.8766976950246317e-07
, O 0 1.1337873928596309e-07
in O 0 7.031318460803959e-08
all O 0 8.501099557634006e-08
exons O 0 2.9222476314316737e-06
, O 0 3.9338374335784465e-07
no O 0 6.015823714733415e-07
mutation O 0 2.4640069113956997e-06
, O 0 5.501304372046434e-07
by O 0 1.3730716545978794e-06
DNA O 0 2.7056627004640177e-05
sequencing O 0 0.0001046012039296329
. O 0 6.167513492982835e-05

On O 0 8.873917977325618e-06
the O 0 1.1465969009805121e-06
basis O 0 3.1063530059327604e-07
of O 0 9.774221609859524e-08
the O 0 2.9096401021888596e-07
present O 0 4.122709071907593e-07
study O 0 7.687502829867299e-07
, O 0 1.1353920825740715e-07
the O 0 1.0434335706577258e-07
mechanism O 0 3.978599067977484e-07
of O 0 1.1431016844198894e-07
anhaptoglobinemia B-Disease 0 1.841949597292114e-05
and O 0 1.69151476825391e-07
the O 0 1.5832617350497458e-07
mechanism O 0 5.375686100705934e-07
of O 0 1.428750380227939e-07
anomalous O 0 7.487735729228007e-06
inheritance O 0 8.787496881268453e-06
of O 0 6.559035909958766e-07
Hp O 0 0.00019781927403528243
phenotypes O 0 4.732224260806106e-05
were O 0 2.248460987175349e-06
well O 0 4.940771304973168e-06
explained O 0 4.0756247472018003e-05
. O 0 3.295205533504486e-05

However O 0 8.101728599285707e-05
, O 0 5.5232121667359024e-06
the O 0 3.7029565191915026e-06
mechanism O 0 1.049386446538847e-05
of O 0 5.700726887880592e-06
hypohaptoglobinemia B-Disease 0 0.0013170191086828709
remains O 0 9.773982310434803e-05
unknown O 0 0.00017429304716642946

ATM O 0 0.024722982197999954
mutations O 0 0.0007799946470186114
and O 0 2.6007381165982224e-05
phenotypes O 0 0.0006637762999162078
in O 0 3.038679096789565e-05
ataxia B-Disease 1 0.9999991655349731
- I-Disease 1 0.9999847412109375
telangiectasia I-Disease 1 0.9999979734420776
families O 0 1.6554582543903962e-05
in O 0 7.744044978608144e-07
the O 0 5.448408728625509e-07
British O 0 1.3772019883617759e-05
Isles O 0 1.0157251381315291e-05
: O 0 3.010872831055167e-07
expression O 0 1.807198373171559e-07
of O 0 7.758238496080594e-08
mutant O 0 1.7973566173168365e-06
ATM O 0 2.544915332691744e-06
and O 0 2.652589614626777e-07
the O 0 4.58111230727809e-07
risk O 0 4.319331765145762e-06
of O 0 9.754123766470002e-07
leukemia B-Disease 1 0.9999949932098389
, O 0 0.3999657928943634
lymphoma B-Disease 1 1.0
, O 0 7.113964238669723e-05
and O 0 0.003836947726085782
breast B-Disease 1 0.9999626874923706
cancer I-Disease 1 0.9918709993362427
. O 0 8.705756044946611e-05

We O 0 6.800000119255856e-05
report O 0 1.1736484339053277e-05
the O 0 1.4910178833815735e-06
spectrum O 0 3.978723725595046e-06
of O 0 7.756446507301007e-07
59 O 0 8.890579920262098e-06
ATM O 0 0.00014911919424775988
mutations O 0 1.5659774362575263e-05
observed O 0 3.3900787457241677e-06
in O 0 5.034755758970277e-06
ataxia B-Disease 1 0.9999979734420776
- I-Disease 1 0.9999676942825317
telangiectasia I-Disease 1 0.9999995231628418
( O 0 2.4985760319395922e-05
A B-Disease 1 0.8774154782295227
- I-Disease 1 0.9999589920043945
T I-Disease 1 0.9999972581863403
) O 0 5.904666977585293e-06
patients O 0 6.890376880619442e-06
in O 0 4.4889682726534375e-07
the O 0 1.249123556590348e-06
British O 0 3.953963459935039e-05
Isles O 0 0.00036387285217642784
. O 0 5.484636494657025e-05

Of O 0 2.511969614715781e-05
51 O 0 6.447699706768617e-05
ATM O 0 0.00017330865375697613
mutations O 0 4.3579828343354166e-05
identified O 0 4.129727130930405e-06
in O 0 4.6685943289048737e-07
families O 0 7.371871788564022e-07
native O 0 2.3668970072776574e-07
to O 0 1.4104952583693375e-07
the O 0 2.490109807240515e-07
British O 0 2.175993358832784e-06
Isles O 0 5.616383077722276e-06
, O 0 2.8391988848852634e-07
11 O 0 2.3755583811180259e-07
were O 0 2.1767728242139128e-07
founder O 0 6.3221368691301905e-06
mutations O 0 1.6843575849634362e-06
, O 0 1.015085402400473e-07
and O 0 9.05608956713877e-08
2 O 0 1.0007499895436922e-07
of O 0 3.803094728027645e-08
these O 0 1.0236656322604176e-07
11 O 0 4.239973350195214e-07
conferred O 0 1.826066409194027e-06
a O 0 1.6364323300877004e-06
milder O 0 0.3728694021701813
clinical O 1 0.699927568435669
phenotype O 0 0.009720330126583576
with O 0 3.44624282888617e-07
respect O 0 3.737926022040483e-07
to O 0 4.000239641754888e-07
both O 0 1.1781165767388302e-06
cerebellar B-Disease 0 0.21542958915233612
degeneration I-Disease 1 0.7390859723091125
and O 0 5.397650056693237e-06
cellular O 0 6.188603583723307e-05
features O 0 3.119828033959493e-05
. O 0 3.879113864968531e-05

We O 0 4.560840898193419e-05
report O 0 8.296931810036767e-06
, O 0 7.61963747208938e-07
in O 0 4.2628079199857893e-07
two O 0 1.2571219940582523e-06
A B-Disease 1 0.9902442693710327
- I-Disease 1 0.9999959468841553
T I-Disease 1 0.999998927116394
families O 0 3.582083991204854e-06
, O 0 2.39033198567995e-07
an O 0 2.0074114104318141e-07
ATM O 0 1.2981142390344758e-05
mutation O 0 3.7048955618956825e-06
( O 0 4.7448011741835217e-07
7271T O 0 8.949249604484066e-06
- O 0 0.00044655046076513827
- O 0 5.9084119129693136e-05
> O 0 1.0814701454364695e-05
G O 0 1.4877020475978497e-05
) O 0 1.2989556807951885e-07
that O 0 3.807572923619773e-08
may O 0 1.7783392536330211e-07
be O 0 3.655600977481299e-08
associated O 0 1.1150212486654709e-07
with O 0 4.0026051806307805e-08
an O 0 8.747714019818886e-08
increased O 0 1.1682463991746772e-06
risk O 0 7.96564927441068e-06
of O 0 1.3221512062955298e-06
breast B-Disease 1 0.9998382329940796
cancer I-Disease 0 0.4503920078277588
in O 0 5.773262614638952e-07
both O 0 7.922972145024687e-07
homozygotes O 0 0.0003728130250237882
and O 0 1.1084621291956864e-06
heterozygotes O 0 5.5688724387437105e-05
( O 0 6.293493015618878e-07
relative O 0 3.2763152830739273e-06
risk O 0 2.421535100438632e-06
12 O 0 3.5909729945160507e-07
. O 0 2.7981096195617283e-07
7 O 0 7.952525038490421e-07
; O 0 1.4316544820758281e-06
P O 0 0.011502531357109547
= O 0 2.8685986762866378e-05
. O 0 3.9136159557529027e-07
0025 O 0 5.342454824130982e-05
) O 0 1.8584120198283927e-07
, O 0 6.201081959034127e-08
although O 0 1.0700927788320769e-07
there O 0 5.081062326439678e-08
is O 0 8.503078419153098e-08
a O 0 3.7776618455609423e-07
less O 0 3.964429197367281e-06
severe O 1 0.8524029850959778
A B-Disease 1 0.9998252987861633
- I-Disease 1 0.9999988079071045
T I-Disease 1 0.9999997615814209
phenotype O 0 0.00969030149281025
in O 0 2.634689337810414e-07
terms O 0 3.413594811263465e-07
of O 0 1.4999858422015677e-07
the O 0 6.379501087394601e-07
degree O 0 1.3353971553442534e-05
of O 0 1.2550721294246614e-05
cerebellar B-Disease 1 0.9986636638641357
degeneration I-Disease 1 0.9998019337654114
. O 0 0.00032382583594881

This O 0 7.043827645247802e-05
mutation O 0 0.00016423649503849447
( O 0 9.162119567918126e-06
7271T O 0 6.892200326547027e-05
- O 0 0.0005771610303781927
- O 0 0.00016449211398139596
> O 0 2.5302806534455158e-05
G O 0 2.1680147256120108e-05
) O 0 2.904816085447237e-07
also O 0 6.100101046513373e-08
allows O 0 7.653576261645867e-08
expression O 0 1.2852017050590803e-07
of O 0 5.154270255047777e-08
full O 0 2.201642388399705e-07
- O 0 1.0908639751505689e-06
length O 0 5.20336300269264e-07
ATM O 0 1.702009967630147e-06
protein O 0 3.022668408902973e-07
at O 0 1.0213973666850507e-07
a O 0 7.373581212277713e-08
level O 0 1.8717841498983034e-07
comparable O 0 7.151934937610349e-07
with O 0 2.0683148704847554e-07
that O 0 5.279802621771523e-07
in O 0 2.3517281988461036e-06
unaffected O 0 0.00019602557586040348
individuals O 0 1.6211528418352827e-05
. O 0 4.194916255073622e-05

In O 0 1.7521564586786553e-05
addition O 0 5.30147599420161e-06
, O 0 8.974735123956634e-07
we O 0 2.7809983293991536e-07
have O 0 1.865440140136343e-07
studied O 0 1.2724295856969547e-06
18 O 0 1.1570145943551324e-06
A B-Disease 1 0.8589056134223938
- I-Disease 1 0.9999990463256836
T I-Disease 1 1.0
patients O 0 0.00019113454618491232
, O 0 1.7819790798512258e-07
in O 0 1.3721904679186991e-07
15 O 0 2.788881090509676e-07
families O 0 8.37776497064624e-07
, O 0 3.454768773281103e-07
who O 0 5.325890469976002e-06
developed O 0 0.10081888735294342
leukemia B-Disease 1 0.9999969005584717
, O 0 0.13803811371326447
lymphoma B-Disease 1 1.0
, O 0 3.464162318778108e-06
preleukemic O 0 0.4331791400909424
T O 1 0.8581327199935913
- O 0 0.0008412952884100378
cell O 0 1.3649128050019499e-05
proliferation O 0 5.915629571973113e-06
, O 0 2.500953087292146e-06
or O 0 0.02557690069079399
Hodgkin B-Disease 1 1.0
lymphoma I-Disease 1 1.0
, O 0 4.504149728745688e-06
mostly O 0 4.439050371729536e-06
in O 0 9.436462278245017e-06
childhood O 0 0.0015883059240877628
. O 0 0.00010097306221723557

A O 0 9.845458407653496e-05
wide O 0 2.6681045710574836e-05
variety O 0 6.1786781770933885e-06
of O 0 1.403511305397842e-06
ATM O 0 6.449680222431198e-05
mutation O 0 1.4419212675420567e-05
types O 0 1.48178992276371e-06
, O 0 3.350495489939931e-07
including O 0 5.157019131729612e-07
missense O 0 3.092658880632371e-05
mutations O 0 5.055395831732312e-06
and O 0 3.8474112784570025e-07
in O 0 4.494862935189303e-07
- O 0 9.348796993435826e-06
frame O 0 6.2048247855273075e-06
deletions O 0 3.768367150769336e-06
, O 0 3.70439721564253e-07
were O 0 2.576579163360293e-07
seen O 0 7.745078391963034e-07
in O 0 8.728627562959446e-07
these O 0 4.955961230734829e-06
patients O 0 0.00033405720023438334
. O 0 2.572298217273783e-05

We O 0 2.327734364371281e-05
also O 0 2.014725623666891e-06
show O 0 1.3783037502435036e-06
that O 0 2.598536639197846e-07
25 O 0 3.1839996950111527e-07
% O 0 1.2105934388273454e-07
of O 0 5.237036049265953e-08
all O 0 2.481461933712126e-07
A B-Disease 1 0.9287267327308655
- I-Disease 1 0.9999979734420776
T I-Disease 1 0.9999998807907104
patients O 0 0.0005127043696120381
carried O 0 7.436020155182632e-07
in O 0 3.154567025376309e-07
- O 0 6.039718300598906e-06
frame O 0 4.990722572983941e-06
deletions O 0 7.100364655343583e-06
or O 0 1.104457737710618e-06
missense O 0 1.7171369108837098e-05
mutations O 0 3.272599087722483e-06
, O 0 1.3670623388861713e-07
many O 0 6.148695774754742e-08
of O 0 4.083760885009724e-08
which O 0 1.6899362265121454e-07
were O 0 3.298985120636644e-07
also O 0 3.750366488475265e-07
associated O 0 5.728574592467339e-07
with O 0 1.9785107951975078e-07
expression O 0 7.667470640626561e-07
of O 0 6.503855161099636e-07
mutant O 0 3.522634142427705e-05
ATM O 0 9.130982653005049e-05
protein O 0 5.667655204888433e-05
. O 0 3.9861177356215194e-05

The O 0 9.290234447689727e-05
DMPK O 0 0.0010652112541720271
gene O 0 0.00015537935541942716
of O 0 1.4171671864460222e-05
severely O 1 0.8758683204650879
affected O 0 0.06311298906803131
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 1 0.9775367975234985
is O 0 3.7026420613983646e-06
hypermethylated O 0 0.000559478357899934
proximal O 0 0.00013586910790763795
to O 0 2.027321215791744e-06
the O 0 1.635474404793058e-06
largely O 0 9.194294761982746e-06
expanded O 0 2.931788367277477e-05
CTG O 0 0.0007058063056319952
repeat O 0 0.0003186237590853125
. O 0 4.4234686356503516e-05

Using O 0 8.345631795236841e-05
methylation O 0 0.00014620106958318502
- O 0 9.986791701521724e-05
sensitive O 0 1.595839967194479e-05
restriction O 0 4.503557192947483e-06
enzymes O 0 6.334424142551143e-06
, O 0 3.941483441849414e-07
we O 0 3.7751624404336326e-07
characterized O 0 8.067351018326008e-07
the O 0 2.197222812583277e-07
methylation O 0 1.4407133903659997e-06
pattern O 0 1.3301961416800623e-06
on O 0 2.782749390917161e-07
the O 0 2.0482812601585465e-07
5 O 0 2.2913751251962822e-07
side O 0 1.9644699023046996e-07
of O 0 7.880443320118502e-08
the O 0 3.356194326897821e-07
CTG O 0 5.4789437854196876e-05
repeat O 0 2.5331908091175137e-06
in O 0 1.2656408898692462e-07
the O 0 1.686944415268954e-07
DMPK O 0 1.816553958633449e-05
gene O 0 7.326099193960545e-07
of O 0 8.072586155094541e-08
normal O 0 7.18777812380722e-07
individuals O 0 1.7398349427821813e-07
and O 0 1.1235285768407266e-07
of O 0 3.5319439462000446e-07
patients O 0 0.0016306356992572546
affected O 0 8.014997547434177e-06
with O 0 2.0760189727297984e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 0.9999998807907104
, O 0 5.974696705379756e-06
showing O 0 5.568606411543442e-06
expansions O 0 9.143456736637745e-06
of O 0 1.1506565442687133e-06
the O 0 5.459422027342953e-06
repetitive O 0 0.0001956543419510126
sequence O 0 6.436138937715441e-05
. O 0 6.537250010296702e-05

The O 0 5.5214921303559095e-05
gene O 0 7.878828182583675e-05
segment O 0 3.529016248648986e-05
analyzed O 0 2.159037467208691e-05
corresponds O 0 5.330971816874808e-06
to O 0 1.0078852028527763e-06
the O 0 1.1022343642252963e-06
genomic O 0 2.370241236349102e-05
SacI O 0 7.416855078190565e-05
- O 0 2.506437522242777e-05
HindIII O 0 2.18712830246659e-05
fragment O 0 6.614959602302406e-06
carrying O 0 2.35647416957363e-06
exons O 0 2.692966882023029e-05
11 O 0 6.040916559868492e-06
- O 0 2.8413971449481323e-05
15 O 0 1.3638524251291528e-05
. O 0 3.513344199745916e-05

There O 0 3.560731784091331e-05
is O 0 3.770064040509169e-06
constitutive O 0 1.1932701454497874e-05
methylation O 0 8.460225217277184e-06
in O 0 7.923878797555517e-07
intron O 0 1.5107680155779235e-05
12 O 0 8.394583801418776e-07
at O 0 2.8953957098565297e-07
restriction O 0 3.62603287840102e-07
sites O 0 2.074874032587104e-07
of O 0 8.780227034321797e-08
SacII O 0 4.997128144168528e-06
and O 0 4.2287831547582755e-07
HhaI O 0 9.71551526163239e-06
, O 0 3.172076503688004e-07
localized O 0 1.6971490595096839e-06
1 O 0 2.812224124681961e-07
, O 0 1.2263831195014063e-07
159 O 0 1.1106441206720774e-06
- O 0 5.415181021817261e-06
1 O 0 3.526356806560216e-07
, O 0 1.562005564892388e-07
232 O 0 1.1052911759179551e-06
bp O 0 2.8386998565110844e-06
upstream O 0 6.030470558471279e-07
of O 0 1.1007284683728358e-07
the O 0 3.262578616158862e-07
CTG O 0 9.992552804760635e-06
repeat O 0 1.6596031855442561e-06
, O 0 9.284792668040609e-08
whereas O 0 2.1059106813936523e-07
most O 0 5.551399340220087e-08
, O 0 7.024294035318235e-08
if O 0 7.723202344322999e-08
not O 0 3.312647933739754e-08
all O 0 2.2180081771239202e-08
, O 0 3.439455298348548e-08
of O 0 1.9037566190149846e-08
the O 0 5.127589375319985e-08
other O 0 4.981379575497158e-08
sites O 0 1.1135993105426678e-07
of O 0 1.149968369418275e-07
SacII O 0 1.1761693713197019e-05
, O 0 3.227768274882692e-07
HhaI O 0 6.6166999204142485e-06
, O 0 1.8413032876196667e-07
and O 0 1.62706299988713e-07
HpaII O 0 9.048282663570717e-06
in O 0 1.603736023980673e-07
this O 0 1.5854359958211717e-07
region O 0 4.827943484997377e-07
are O 0 1.3966332801373937e-07
unmethylated O 0 5.81419953959994e-06
, O 0 2.221236883315214e-07
in O 0 2.0199323103042843e-07
normal O 0 6.68652660351654e-07
individuals O 0 3.0961319907873985e-07
and O 0 2.295892045367509e-07
most O 0 3.089569133862824e-07
of O 0 6.959056690902798e-07
the O 0 2.2971649741521105e-05
patients O 0 0.006411717738956213
. O 0 6.551753904204816e-05

In O 0 1.7906168068293482e-05
a O 0 2.7484204565553227e-06
number O 0 5.024980396228784e-07
of O 0 2.8261939633011934e-07
young O 0 1.9774968222918687e-06
and O 0 1.7277018287131796e-06
severely O 0 0.11599225550889969
affected O 0 6.411720823962241e-05
patients O 0 6.363562715705484e-05
, O 0 1.8047423111511307e-07
however O 0 2.7330412422088557e-07
, O 0 9.540611500824525e-08
complete O 0 2.0406264411576558e-07
methylation O 0 5.59079467166157e-07
of O 0 9.392984878786592e-08
these O 0 9.000743972364944e-08
restriction O 0 2.976391613174201e-07
sites O 0 2.868373769615573e-07
was O 0 4.448567381132307e-07
found O 0 2.778967598260351e-07
in O 0 3.572183686628705e-07
the O 0 1.5999413562894915e-06
mutated O 0 8.577238622820005e-05
allele O 0 0.00020389184646774083
. O 0 4.16428993048612e-05

In O 0 2.3300615794141777e-05
most O 0 3.1358192700281506e-06
of O 0 5.741345603382797e-07
these O 0 1.8945721649288316e-06
patients O 0 2.0792904251720756e-05
, O 0 3.4183057096015546e-07
the O 0 6.112674668656837e-07
onset O 0 0.0017618428682908416
of O 0 1.1864127600347274e-06
the O 0 0.0025614409241825342
disease O 1 0.9615007042884827
was O 0 0.4586879014968872
congenital O 1 0.9999606609344482
. O 0 0.00024453969672322273

Preliminary O 0 0.0002759160415735096
in O 0 2.6934139896184206e-05
vivo O 0 0.0001724797475617379
footprinting O 0 0.0006914129480719566
data O 0 5.8557734519126825e-06
gave O 0 1.7407905943400692e-06
evidence O 0 8.743657531340432e-07
for O 0 2.781231671633577e-07
protein O 0 1.5075148667165195e-06
- O 0 9.856153155851644e-06
DNA O 0 2.192671217926545e-06
contact O 0 9.224773407368048e-07
in O 0 3.4580980923237803e-07
normal O 0 1.360145688522607e-06
genes O 0 1.781929427124851e-06
at O 0 4.140763678606163e-07
an O 0 4.776231321557134e-07
Sp1 O 0 9.796740414458327e-06
consensus O 0 1.126338815993222e-06
binding O 0 9.573356010150746e-07
site O 0 6.095095272939943e-07
upstream O 0 4.6590358238063345e-07
of O 0 7.251639289052036e-08
the O 0 2.192452512872478e-07
CTG O 0 1.0045380804513115e-05
repeat O 0 2.1450014173751697e-06
and O 0 1.4696877315145684e-07
for O 0 1.1115643161474509e-07
a O 0 1.4418331772958481e-07
significant O 0 3.3482405115137226e-07
reduction O 0 5.244553449301748e-07
of O 0 7.561943249356773e-08
this O 0 1.4546142779181537e-07
interaction O 0 5.30511954366375e-07
in O 0 5.719802516068739e-07
cells O 0 3.299565378256375e-06
with O 0 6.162767931527924e-07
a O 0 2.8028414362779586e-06
hypermethylated O 0 0.0034591008443385363
DMPK O 0 0.0034186304546892643
gene O 0 5.252894698060118e-05
. O 0 1.194307242258219e-05
. O 0 3.7062261981191114e-05

The O 0 0.00027414190117269754
hemochromatosis B-Disease 1 0.9998656511306763
gene O 0 0.00023249433434102684
product O 0 2.3394486561301164e-05
complexes O 0 8.133377377816942e-06
with O 0 6.073961458241683e-07
the O 0 1.2002465155092068e-06
transferrin O 0 7.405237556667998e-05
receptor O 0 7.773101970087737e-06
and O 0 1.1669391142277163e-06
lowers O 0 1.647926001169253e-05
its O 0 7.733078177807329e-07
affinity O 0 4.91656919621164e-06
for O 0 1.912677589643863e-06
ligand O 0 2.1601785192615353e-05
binding O 0 5.146419061929919e-05
. O 0 5.271542613627389e-05

We O 0 0.00011676268331939355
recently O 0 4.9068083171732724e-05
reported O 0 5.588141448242823e-06
the O 0 8.952646339821513e-07
positional O 0 8.200318006856833e-06
cloning O 0 6.004937858961057e-06
of O 0 3.0733622224943247e-07
a O 0 1.1372466133252601e-06
candidate O 0 2.235114880022593e-05
gene O 0 2.9735916541540064e-05
for O 0 0.00010401277540950105
hereditary B-Disease 1 0.9999996423721313
hemochromatosis I-Disease 1 1.0
called O 0 0.17080938816070557
HFE O 1 0.998111367225647
. O 0 0.0002660947502590716

The O 0 2.1755951820523478e-05
gene O 0 3.484000626485795e-05
product O 0 7.095917680999264e-06
, O 0 9.338106110590161e-07
a O 0 3.9386350181302987e-07
member O 0 3.95392220298163e-07
of O 0 1.273673575497014e-07
the O 0 3.080833437252295e-07
major O 0 1.151899368778686e-06
histocompatibility O 0 0.0003675809421110898
complex O 0 2.4435128125332994e-06
class O 0 3.156847469654167e-06
I O 0 2.6051195618492784e-06
- O 0 3.990990535385208e-06
like O 0 4.009428948847926e-07
family O 0 6.503340728158946e-07
, O 0 1.413964696439507e-07
was O 0 4.007609391010192e-07
found O 0 1.6606861663603922e-07
to O 0 1.5288530619272933e-07
have O 0 2.2247243691708718e-07
a O 0 4.349181494944787e-07
mutation O 0 6.003219823469408e-06
, O 0 1.0404163504063035e-06
Cys O 0 0.0005786670371890068
- O 0 2.626004243211355e-05
282 O 0 1.3377769391809124e-05
- O 0 0.0006590763805434108
- O 0 5.826786582474597e-05
> O 0 1.2053639693476725e-05
Tyr O 0 3.197638216079213e-05
( O 0 6.459078463194601e-07
C282Y O 0 3.4351689919276396e-06
) O 0 1.813009049556058e-07
, O 0 1.2156770878846146e-07
in O 0 2.5131870984296256e-07
85 O 0 2.0642921754188137e-06
% O 0 1.0317174883311964e-06
of O 0 9.502217039880634e-07
patient O 0 6.295982893789187e-05
chromosomes O 0 7.262155850185081e-05
. O 0 4.945121690980159e-05

This O 0 3.988201206084341e-05
mutation O 0 9.691114246379584e-05
eliminates O 0 3.1316201784648e-05
the O 0 1.7491644257461303e-06
ability O 0 2.304065446878667e-06
of O 0 4.1254267557633284e-07
HFE O 0 0.0006134660798124969
to O 0 7.959961294545792e-07
associate O 0 1.6639344266877742e-06
with O 0 3.8803909774287604e-07
beta2 O 0 0.0054632495157420635
- O 0 0.0013217246159911156
microglobulin O 0 0.00014325535448733717
( O 0 6.436493436012825e-07
beta2m O 0 4.200068360660225e-06
) O 0 2.693318776891829e-07
and O 0 2.6021027110800787e-07
prevents O 0 3.0210421755327843e-06
cell O 0 4.954439282300882e-05
- O 0 5.3390118409879506e-05
surface O 0 1.1473077393020503e-05
expression O 0 2.2172011085785925e-05
. O 0 2.6905205231742002e-05

A O 0 5.923519711359404e-05
second O 0 2.960646088467911e-05
mutation O 0 3.654531974461861e-05
that O 0 7.423535635098233e-07
has O 0 3.83981642926301e-07
no O 0 3.0690739549754653e-07
effect O 0 5.669761549143004e-07
on O 0 4.2613768869159685e-07
beta2m O 0 5.969326593913138e-05
association O 0 1.454754624319321e-06
, O 0 2.9672256118828955e-07
H63D O 0 9.255977056454867e-05
, O 0 3.5848890433953784e-07
was O 0 3.551893144049245e-07
found O 0 1.5257577956617752e-07
in O 0 6.656813411609619e-08
eight O 0 1.4181618723796419e-07
out O 0 9.781700072153399e-08
of O 0 1.196558088167876e-07
nine O 0 3.615574087234563e-06
patients O 0 5.780424544354901e-05
heterozygous O 0 4.48652963314089e-06
for O 0 5.729585836888873e-07
the O 0 2.0990005396015476e-06
C282Y O 0 0.0002950674097519368
mutant O 0 0.00018227116379421204
. O 0 4.2798867070814595e-05

In O 0 4.8123565647983924e-05
this O 0 7.316279607039178e-06
report O 0 4.081833139935043e-06
, O 0 9.298240684074699e-07
we O 0 6.366713023453485e-07
demonstrate O 0 1.401529061695328e-06
in O 0 6.551059641424217e-07
cultured O 0 1.3097096598357894e-05
293 O 0 2.160637995984871e-05
cells O 0 1.7768856196198612e-05
overexpressing O 0 8.031177276279777e-05
wild O 0 3.2492500849912176e-06
- O 0 7.0577734732069075e-06
type O 0 2.0538982425932772e-06
or O 0 6.266129730647663e-07
mutant O 0 7.232531970657874e-06
HFE O 0 7.37171430955641e-05
proteins O 0 5.784489189863962e-07
that O 0 1.0564745167584988e-07
both O 0 1.1624600659843054e-07
the O 0 2.0897078911730205e-07
wild O 0 8.247942560046795e-07
- O 0 1.199723919853568e-05
type O 0 1.2784187219949672e-06
and O 0 5.753853997703118e-07
H63D O 0 0.008562988601624966
HFE O 0 0.09099701046943665
proteins O 0 1.8666908090381185e-06
form O 0 1.4622796697949525e-06
stable O 0 3.7192546642472735e-06
complexes O 0 1.1593693898248603e-06
with O 0 3.332760627472453e-07
the O 0 2.4233231670223176e-06
transferrin O 0 0.002272191224619746
receptor O 0 7.193890633061528e-05
( O 0 6.993238457653206e-06
TfR O 0 0.0001633509382372722
) O 0 1.4988110706326552e-05
. O 0 1.5877913028816693e-05

The O 0 6.715497875120491e-05
C282Y O 0 0.0006308152223937213
mutation O 0 0.00013548615970648825
nearly O 0 1.14540434879018e-05
completely O 0 9.930216037901118e-06
prevents O 0 5.561807483900338e-06
the O 0 8.106607083391282e-07
association O 0 1.224895527229819e-06
of O 0 1.9949834495491814e-07
the O 0 1.0667562264643493e-06
mutant O 0 4.4838710891781375e-05
HFE O 0 0.0025837337598204613
protein O 0 5.5237123888218775e-06
with O 0 1.5081475339684403e-06
the O 0 8.568837984057609e-06
TfR O 0 0.0017318939790129662
. O 0 4.8167272325372323e-05

Studies O 0 0.00021920408471487463
on O 0 1.4776276657357812e-05
cell O 0 0.00011579890997381881
- O 0 5.992134174448438e-05
associated O 0 2.5532635845593177e-06
transferrin O 0 1.5639685443602502e-05
at O 0 8.3519347526817e-07
37 O 0 8.828141631056496e-07
degrees O 0 1.9941380742238835e-06
C O 0 3.361585913808085e-05
suggest O 0 1.1033934015358682e-06
that O 0 1.8245573585318198e-07
the O 0 5.441927442007e-07
overexpressed O 0 1.22140900202794e-05
wild O 0 2.8735453270201106e-06
- O 0 1.827446794777643e-05
type O 0 2.6321279165131273e-06
HFE O 0 0.0001304314355365932
protein O 0 1.4159093097987352e-06
decreases O 0 1.1967856607952854e-06
the O 0 2.066225164298885e-07
affinity O 0 7.753355362183356e-07
of O 0 2.7867594099006965e-07
the O 0 1.644873691475368e-06
TfR O 0 0.00018058846762869507
for O 0 1.1588650522753596e-05
transferrin O 0 0.0023765291552990675
. O 0 8.420600352110341e-05

The O 0 6.477948772953823e-05
overexpressed O 0 0.0003287694707978517
H63D O 0 0.00028094477602280676
protein O 0 1.6268893887172453e-05
does O 0 2.3651468836760614e-06
not O 0 4.071473256317404e-07
have O 0 1.504170228372459e-07
this O 0 9.556310942571145e-08
effect O 0 2.8468392088143446e-07
, O 0 9.876958273480341e-08
providing O 0 9.368400810672028e-08
the O 0 6.348560788183022e-08
first O 0 1.3750290861480607e-07
direct O 0 1.9342533619237656e-07
evidence O 0 4.5910758217360126e-07
for O 0 1.355733161290118e-07
a O 0 5.10356699123804e-07
functional O 0 3.4114771096938057e-06
consequence O 0 3.0828662147541763e-06
of O 0 5.134680236551503e-07
the O 0 4.31082526120008e-06
H63D O 0 0.36847051978111267
mutation O 0 0.0002694272552616894
. O 0 4.374346463009715e-05

Addition O 0 7.510877185268328e-05
of O 0 9.980095455830451e-06
soluble O 0 9.255518671125174e-05
wild O 0 3.04709465126507e-05
- O 0 0.0002462934353388846
type O 0 4.9877275159815326e-05
HFE O 0 0.10890594124794006
/ O 0 4.962089951732196e-05
beta2m O 0 6.833986117271706e-05
heterodimers O 0 5.2860512369079515e-05
to O 0 1.580452817506739e-06
cultured O 0 2.153875720978249e-05
cells O 0 8.03685725259129e-06
also O 0 4.3602284449661965e-07
decreased O 0 9.89371756077162e-07
the O 0 3.059693085560866e-07
apparent O 0 2.1939888483757386e-06
affinity O 0 1.0324881714041112e-06
of O 0 1.2691049278146238e-07
the O 0 2.5996718022724963e-07
TfR O 0 1.0262035175401252e-05
for O 0 1.0688585661000616e-07
its O 0 1.1153573353794854e-07
ligand O 0 6.447502869377786e-07
under O 0 2.74983619874547e-07
steady O 0 1.9478977719700197e-06
- O 0 2.1419520635390654e-05
state O 0 2.867214448087907e-07
conditions O 0 1.3528493809644715e-06
, O 0 1.0949804618576309e-07
both O 0 1.6190357143841538e-07
in O 0 3.478997143702145e-07
293 O 0 6.44292003926239e-06
cells O 0 8.328301191795617e-06
and O 0 2.1586376988125267e-06
in O 0 4.572340458253166e-06
HeLa O 0 0.01636890321969986
cells O 0 0.00015324058767873794
. O 0 4.265926327207126e-05

Furthermore O 0 0.00017014391778502613
, O 0 6.378579200827517e-06
at O 0 1.632638259252417e-06
4 O 0 1.1733233122868114e-06
degrees O 0 2.0398649667185964e-06
C O 0 1.2847012840211391e-05
, O 0 2.9842183835171454e-07
the O 0 3.140015962799225e-07
added O 0 1.037504375744902e-06
soluble O 0 3.712166972036357e-06
complex O 0 7.620502060490253e-07
of O 0 3.765210010442388e-07
HFE O 0 0.1673000454902649
/ O 0 2.0828665583394468e-05
beta2m O 0 1.6025012882892042e-05
inhibited O 0 3.134503685942036e-06
binding O 0 7.144401479308726e-07
of O 0 2.4086639882625605e-07
transferrin O 0 1.4496590665658005e-05
to O 0 1.7997596160057583e-06
HeLa O 0 0.00010068528354167938
cell O 0 1.3189322089601774e-05
TfR O 0 2.2827736756880768e-05
in O 0 7.129638674996386e-07
a O 0 2.4381449748034356e-06
concentration O 0 6.039601066731848e-05
- O 0 0.0002199214941356331
dependent O 0 2.7205971491639502e-05
manner O 0 3.31948212988209e-05
. O 0 5.5675664043519646e-05

Scatchard O 0 0.0008527096942998469
plots O 0 4.28869498136919e-05
of O 0 1.7197191937157186e-06
these O 0 7.54815857817448e-07
data O 0 1.3265489542391151e-06
indicate O 0 1.1394330385883222e-06
that O 0 1.569583929494911e-07
the O 0 4.316620163535845e-07
added O 0 1.5030991562525742e-06
heterodimer O 0 1.715447797323577e-05
substantially O 0 6.1343271227087826e-06
reduced O 0 1.7028444290190237e-06
the O 0 6.493783644145878e-07
affinity O 0 4.271392299415311e-06
of O 0 1.527643348708807e-06
TfR O 0 0.00011305937368888408
for O 0 9.58594955591252e-06
transferrin O 0 0.002060378435999155
. O 0 6.054640107322484e-05

These O 0 4.1942086681956425e-05
results O 0 2.093867806252092e-05
establish O 0 6.37567245576065e-06
a O 0 2.4099858819681685e-06
molecular O 0 9.907087587635033e-06
link O 0 5.081080416857731e-06
between O 0 8.170288765541045e-07
HFE O 0 0.006494117900729179
and O 0 4.7498491539954557e-07
a O 0 3.997554927082092e-07
key O 0 7.564091220046976e-07
protein O 0 4.621051346020977e-07
involved O 0 2.9624982289533364e-07
in O 0 1.616265024040331e-07
iron O 0 1.5617299141013063e-05
transport O 0 1.936137095981394e-06
, O 0 1.634044934917256e-07
the O 0 1.4636145806434797e-07
TfR O 0 8.781732503848616e-06
, O 0 1.7000229490804486e-07
and O 0 9.786478472051385e-08
raise O 0 2.485161019194493e-07
the O 0 1.1206136463215444e-07
possibility O 0 4.25880955390312e-07
that O 0 1.4086722899264714e-07
alterations O 0 2.0591683096427005e-06
in O 0 2.571419202013203e-07
this O 0 2.3217680222842318e-07
regulatory O 0 2.848424401236116e-06
mechanism O 0 1.1316727750454447e-06
may O 0 3.6701263184113486e-07
play O 0 1.3559839828758413e-07
a O 0 1.3724967118378117e-07
role O 0 4.991642299501109e-07
in O 0 4.335478251960012e-07
the O 0 1.3709872064282536e-06
pathogenesis O 0 0.00537824584171176
of O 0 2.876584585465025e-05
hereditary B-Disease 1 0.9999998807907104
hemochromatosis I-Disease 1 1.0
. O 0 0.001060976879671216
. O 0 0.00014455178461503237

Genomic O 0 0.0015588306123390794
organization O 0 8.14492377685383e-05
of O 0 5.128292286826763e-06
the O 0 9.087638318305835e-06
UBE3A O 0 0.0008688572561368346
/ O 0 8.33228841656819e-05
E6 O 0 4.9857775593409315e-05
- O 0 0.0004423719074111432
AP O 0 4.216775778331794e-05
gene O 0 9.142149792751297e-06
and O 0 4.337394784670323e-06
related O 0 2.90851039608242e-05
pseudogenes O 0 0.00032023689709603786
. O 0 7.193314377218485e-05

The O 0 0.00010957292397506535
UBE3A O 0 0.0013963093515485525
gene O 0 7.889037078712136e-05
encodes O 0 2.7183928978047334e-05
the O 0 3.5567441045714077e-06
E6 O 0 3.0386676371563226e-05
- O 0 7.69116377341561e-05
AP O 0 1.549467197037302e-05
ubiquitin O 0 1.094680465030251e-05
- O 0 7.819883649062831e-06
protein O 0 9.40497500323545e-07
ligase O 0 1.5100443988558254e-06
and O 0 1.8769824805531243e-07
has O 0 1.816349168848319e-07
recently O 0 1.113979124056641e-06
been O 0 1.3837916412740014e-07
shown O 0 1.7638977567457914e-07
to O 0 1.9196144762645417e-07
be O 0 3.6754360621671367e-07
mutated O 0 9.586663509253412e-05
in O 0 0.4138332009315491
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 1 0.871941089630127
who O 0 1.2025956493744161e-05
lack O 0 1.4839401046629064e-05
15q11 O 0 0.0015471148071810603
- O 0 0.00019953364972025156
q13 O 0 7.016876770649105e-05
deletions O 0 2.2977410480962135e-05
or O 0 6.250163096410688e-06
chromosome O 0 3.6579211155185476e-05
15 O 0 1.3487499927578028e-05
paternal O 0 0.0003589245898183435
uniparental B-Disease 1 0.5307233929634094
disomy I-Disease 0 0.09923604875802994
. O 0 0.00012623168004211038

Previous O 0 0.0003103364142589271
UBE3A O 0 0.001204491127282381
cDNA O 0 0.00017359346384182572
analysis O 0 4.7085464757401496e-05
has O 0 4.424642156664049e-06
shown O 0 2.6897250791080296e-06
a O 0 2.138624495273689e-06
coding O 0 2.835806844814215e-05
region O 0 4.6343757276190445e-06
of O 0 1.832416387514968e-06
approximately O 0 6.1240339164214674e-06
2 O 0 1.9678425815072842e-05
. O 0 3.8000049244146794e-05

6 O 0 0.0002709132677409798
kb O 0 0.0021042118314653635
and O 0 5.652826530422317e-06
a O 0 4.1649605009297375e-06
3 O 0 5.678458819602383e-06
- O 0 6.609335832763463e-05
untranslated O 0 4.633468415704556e-05
region O 0 2.931313474618946e-06
( O 0 6.034728130543954e-07
UTR O 0 6.23006008027005e-06
) O 0 1.7441558952668856e-07
of O 0 9.459976268999526e-08
< O 0 1.5375381963167456e-06
50 O 0 2.8022941478411667e-07
bp O 0 3.8053369735280285e-06
, O 0 1.4164884021283797e-07
whereas O 0 4.075634194578015e-07
Northern O 0 3.74408358538858e-07
analysis O 0 7.430986670442508e-07
has O 0 3.136179316243215e-07
indicated O 0 9.399469149684592e-07
mRNA O 0 7.682680802645336e-07
sizes O 0 1.1900231129402528e-06
of O 0 2.6889378546002263e-07
5 O 0 1.899541985039832e-06
- O 0 3.457597267697565e-05
8 O 0 8.563755727664102e-06
kb O 0 0.00048295193118974566
. O 0 3.258049764554016e-05

We O 0 5.4542284487979487e-05
have O 0 4.8248325583699625e-06
analyzed O 0 5.730275461246492e-06
additional O 0 8.48177535317518e-07
cDNA O 0 6.137879154266557e-06
clones O 0 8.353308658115566e-06
and O 0 5.408019774222339e-07
provide O 0 4.959943566973379e-07
evidence O 0 4.84239478737436e-07
for O 0 1.8622654351929668e-07
an O 0 3.390847211903747e-07
additional O 0 2.7597352527664043e-06
0 O 0 2.430329732305836e-05
. O 0 2.718322866712697e-05

5 O 0 0.00010777090938063338
kb O 0 0.00020792589930351824
of O 0 2.24280051952519e-06
5 O 0 4.235040705680149e-06
- O 0 1.4371946235769428e-05
UTR O 0 2.530886558815837e-05
and O 0 1.2830589639634127e-06
> O 0 7.217538950499147e-06
2 O 0 1.1798301784438081e-06
kb O 0 1.6292524378513917e-05
of O 0 8.947482115218008e-07
3 O 0 8.450646419078112e-06
- O 0 0.00012066989438608289
UTR O 0 0.0006234890897758305
. O 0 6.512162508442998e-05

We O 0 4.275178798707202e-05
have O 0 4.3480636122694705e-06
established O 0 2.8181136713101296e-06
the O 0 1.1249873068663874e-06
genomic O 0 9.058833711605985e-06
organization O 0 1.1293310535620549e-06
of O 0 3.905435903561738e-07
UBE3A O 0 4.266503674443811e-05
and O 0 5.778175591331092e-07
the O 0 4.7108724743338826e-07
sequence O 0 1.7117115476139588e-06
of O 0 1.1230117706872988e-06
intron O 0 0.00032676206319592893
- O 0 0.00029223054298199713
exon O 0 0.00016735965618863702
borders O 0 5.303177022142336e-05
. O 0 3.9862850826466456e-05

We O 0 4.549954246613197e-05
have O 0 4.291047389415326e-06
also O 0 9.83925588116108e-07
mapped O 0 5.822939328936627e-06
two O 0 7.646222002222203e-07
highly O 0 1.8831012766895583e-06
homologous O 0 5.1906622502428945e-06
processed O 0 2.308741841261508e-06
pseudogenes O 0 7.107742931111716e-06
, O 0 5.380086918194138e-07
UBE3AP1 O 0 1.361315753456438e-05
and O 0 4.505274375787849e-07
UBE3AP2 O 0 1.6565827536396682e-05
, O 0 1.5896722516117734e-07
to O 0 6.23394313947756e-08
chromosomes O 0 5.863669230166124e-07
2 O 0 1.858986422575981e-07
and O 0 9.664310596235737e-08
21 O 0 2.0043810877723445e-07
, O 0 8.702929221726663e-08
respectively O 0 3.705421818267496e-07
, O 0 1.738954154006933e-07
and O 0 4.142505360960058e-07
determined O 0 2.9229722713353112e-06
their O 0 2.3932227577461163e-06
genomic O 0 5.385390613810159e-05
organization O 0 2.8737655156874098e-05
. O 0 3.3996439015027136e-05

These O 0 2.810314435919281e-05
results O 0 2.2629343220614828e-05
will O 0 8.291634685519966e-07
form O 0 4.4215150296622596e-07
the O 0 1.8250378275297408e-07
basis O 0 2.90182555318097e-07
for O 0 2.4433677481283667e-07
studies O 0 8.025866122807201e-07
of O 0 2.5605908149373136e-07
mutation O 0 6.3606357798562385e-06
and O 0 1.6927538126765285e-06
imprinting O 0 4.407551386975683e-05
of O 0 9.326871804660186e-06
UBE3A O 0 0.0027003376744687557
. O 0 9.271931048715487e-05

Mutation O 0 0.0014128199545666575
spectrum O 0 0.00023178097035270184
and O 0 2.844975642801728e-05
genotype O 0 0.17634883522987366
- O 0 0.40287715196609497
phenotype O 0 0.0076775923371315
analyses O 0 3.2024658139562234e-05
in O 0 9.598372344044037e-06
Cowden B-Disease 1 0.9976431727409363
disease I-Disease 0 0.015469348058104515
and O 0 9.556011718814261e-06
Bannayan B-Disease 1 0.9978671073913574
- I-Disease 1 0.9999810457229614
Zonana I-Disease 1 0.9999932050704956
syndrome I-Disease 1 0.9999309778213501
, O 0 4.131090463488363e-06
two O 0 1.173999953607563e-05
hamartoma B-Disease 1 0.9979288578033447
syndromes I-Disease 1 0.956777811050415
with O 0 4.006766539532691e-05
germline O 1 0.7087202072143555
PTEN O 1 0.8255221843719482
mutation O 0 0.0007888117688708007
. O 0 7.284031016752124e-05

The O 0 0.0004233258659951389
tumour B-Disease 1 0.9997571110725403
suppressor O 0 0.0026181042194366455
gene O 0 0.00028082585777156055
PTEN O 0 0.0017831873847171664
, O 0 5.725953997171018e-06
which O 0 1.3696009091290762e-06
maps O 0 6.033374120306689e-06
to O 0 8.743826583668124e-06
10q23 O 0 0.0002694776048883796
. O 0 5.4962340072961524e-05

3 O 0 5.67362476431299e-05
and O 0 4.062369498569751e-06
encodes O 0 8.010199053387623e-06
a O 0 2.227659251730074e-06
403 O 0 8.675103345012758e-06
amino O 0 4.2076221689058e-06
acid O 0 7.943755917949602e-06
dual O 0 5.335798505257117e-06
specificity O 0 9.762213267094921e-06
phosphatase O 0 0.0026327904779464006
( O 0 2.598343371573719e-06
protein O 0 2.5806023131735856e-06
tyrosine O 0 8.057331797317602e-06
phosphatase O 0 7.160450331866741e-05
; O 0 1.5029386304377113e-06
PTPase O 0 1.1133874977531377e-05
) O 0 3.9808386986806e-07
, O 0 1.6942996694524481e-07
was O 0 2.864729822249501e-07
shown O 0 3.755097282009956e-07
recently O 0 9.596711834092275e-07
to O 0 1.3743566285029374e-07
play O 0 2.4358669747925887e-07
a O 0 4.051502457969036e-07
broad O 0 1.9678047920024255e-06
role O 0 3.935713266400853e-06
in O 0 3.3568774142622715e-06
human O 0 1.4991456737334374e-05
malignancy B-Disease 0 0.22976680099964142
. O 0 6.156507151899859e-05

Somatic O 0 0.0032004958484321833
PTEN O 0 0.005188016686588526
deletions O 0 0.0004212788480799645
and O 0 1.7037578800227493e-05
mutations O 0 4.5820543164154515e-05
were O 0 1.5259746533047291e-06
observed O 0 2.3749835236230865e-06
in O 0 5.959554414403101e-07
sporadic B-Disease 0 3.343538264743984e-05
breast I-Disease 1 0.7781391739845276
, I-Disease 0 3.4113306810468202e-06
brain I-Disease 0 0.008147181011736393
, I-Disease 0 8.469557542412076e-06
prostate I-Disease 1 0.8290857672691345
and I-Disease 0 0.0031223983969539404
kidney I-Disease 1 0.9999746084213257
cancer I-Disease 1 0.9814886450767517
cell O 0 0.0001517854689154774
lines O 0 4.443277248356026e-06
and O 0 3.387075366845238e-07
in O 0 2.693961107524956e-07
several O 0 1.0197072697337717e-06
primary O 0 0.011067816987633705
tumours B-Disease 1 0.9994750618934631
such O 0 1.2868173371316516e-06
as O 0 1.5377025192719884e-05
endometrial B-Disease 1 0.9999700784683228
carcinomas I-Disease 1 1.0
, O 1 0.9883787631988525
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 1 0.8657351136207581
thyroid B-Disease 1 0.9999980926513672
tumours I-Disease 1 0.9999988079071045
. O 0 0.0002803371171467006

In O 0 2.9723241823376156e-05
addition O 0 2.217928704340011e-05
, O 0 3.9158253457571846e-06
PTEN O 0 0.001420362270437181
was O 0 4.802769126399653e-06
identified O 0 1.615588303138793e-06
as O 0 2.8578014621416514e-07
the O 0 5.359481178857095e-07
susceptibility O 0 1.058091947925277e-05
gene O 0 3.871224180329591e-06
for O 0 1.0532750138736446e-06
two O 0 1.1388669008738361e-05
hamartoma B-Disease 1 0.9999834299087524
syndromes I-Disease 1 0.9999949932098389
Cowden B-Disease 1 0.9999973773956299
disease I-Disease 1 0.7168368101119995
( O 0 1.939162302733166e-06
CD B-Disease 0 7.986704986251425e-06
; O 0 5.141538622410735e-06
MIM O 0 0.011759629473090172
158350 O 0 2.9857248591724783e-05
) O 0 7.171024094532186e-07
and O 0 8.568164275857271e-07
Bannayan B-Disease 0 0.004328624345362186
- I-Disease 0 0.012137887068092823
Zonana I-Disease 0 0.0021942704916000366
( I-Disease 0 3.0160622372932266e-06
BZS I-Disease 0 3.102158007095568e-05
) I-Disease 0 1.0518446060814313e-06
or I-Disease 0 1.031089936986973e-06
Ruvalcaba I-Disease 0 0.0003777915262617171
- I-Disease 0 0.019897639751434326
Riley I-Disease 0 0.001765041844919324
- I-Disease 1 0.9821845293045044
Smith I-Disease 1 0.960462212562561
syndrome I-Disease 1 0.9996531009674072
( O 0 1.367736331303604e-05
MIM O 0 0.029503293335437775
153480 O 0 0.0003821670834440738
) O 0 2.1776791982119903e-05
. O 0 2.8299580662860535e-05

Constitutive O 0 0.0007224424043670297
DNA O 0 0.00023418670753017068
from O 0 8.031654942897148e-06
37 O 0 1.213967607327504e-05
CD B-Disease 0 1.0877861313929316e-05
families O 0 4.608671588357538e-06
and O 0 1.1487509254948236e-06
seven O 0 2.9858347261324525e-06
BZS B-Disease 0 0.000203814881388098
families O 0 6.575535280717304e-06
was O 0 3.6542737689160276e-06
screened O 0 1.1353091394994408e-05
for O 0 1.2487610547395889e-05
germline O 0 0.016716957092285156
PTEN O 0 0.1434517651796341
mutations O 0 0.0004769077349919826
. O 0 7.444390212185681e-05

PTEN O 1 0.6183937788009644
mutations O 0 0.0016638711094856262
were O 0 1.523289301985642e-05
identified O 0 6.4171590565820225e-06
in O 0 6.228440270206193e-07
30 O 0 4.244423621457827e-07
of O 0 1.308209789385728e-07
37 O 0 1.785627659955935e-06
( O 0 4.43711911657374e-07
81 O 0 2.8033575745212147e-06
% O 0 5.201943622523686e-07
) O 0 2.1224985857770662e-07
CD B-Disease 0 1.254964672625647e-06
families O 0 8.945443141783471e-07
, O 0 1.6196719343497534e-07
including O 0 3.451222312378377e-07
missense O 0 9.52162554312963e-06
and O 0 5.169176233721373e-07
nonsense O 0 6.375477823894471e-06
point O 0 1.565455022500828e-06
mutations O 0 3.473067408776842e-06
, O 0 3.3813304867180705e-07
deletions O 0 1.689441205598996e-06
, O 0 3.3499810569992405e-07
insertions O 0 3.970577836298617e-06
, O 0 5.353846290745423e-07
a O 0 9.521666015643859e-07
deletion O 0 2.4831173504935578e-05
/ O 0 9.085940291697625e-06
insertion O 0 5.80478626943659e-06
and O 0 3.176255404468975e-06
splice O 0 0.00023959844838827848
site O 0 5.111117206979543e-05
mutations O 0 0.00014615536201745272
. O 0 6.601046334253624e-05

These O 0 4.252331564202905e-05
mutations O 0 5.169428914086893e-05
were O 0 1.764639364409959e-06
scattered O 0 1.054953713719442e-06
over O 0 3.560820118764241e-07
the O 0 2.645596453021426e-07
entire O 0 8.866405210028461e-07
length O 0 9.521230026621197e-07
of O 0 2.507974841137184e-07
PTEN O 0 0.0006112432456575334
, O 0 2.4979993895613006e-07
with O 0 6.957597520340641e-08
the O 0 1.1149596446102805e-07
exception O 0 2.3061311082983593e-07
of O 0 4.612218873489837e-08
the O 0 1.1304879166118553e-07
first O 0 3.202099776444811e-07
, O 0 3.5865372183252475e-07
fourth O 0 2.8132587885920657e-06
and O 0 1.4533761714119464e-06
last O 0 1.1058858035539743e-05
exons O 0 0.00018965936033055186
. O 0 5.8297602663515136e-05

A O 0 8.684329804964364e-05
hot O 0 4.505722608882934e-05
spot O 0 1.2227911611262243e-05
for O 0 1.7966350469578174e-06
PTEN O 0 0.000142853896250017
mutation O 0 7.696343345742207e-06
in O 0 5.134244815963029e-07
CD B-Disease 0 2.333193606318673e-06
was O 0 8.966060818238475e-07
identified O 0 6.057942982806708e-07
in O 0 2.125338340874805e-07
exon O 0 3.301331162219867e-06
5 O 0 2.951083786228992e-07
that O 0 5.2003962025537476e-08
contains O 0 8.34951521255789e-08
the O 0 1.8418688796373317e-07
PTPase O 0 1.0800024938362185e-05
core O 0 2.2829367480881047e-06
motif O 0 1.2799071100744186e-06
, O 0 1.4745593546194868e-07
with O 0 9.015381863264338e-08
13 O 0 2.3209400978885242e-07
of O 0 9.597757610890767e-08
30 O 0 3.907022971816332e-07
( O 0 2.6652426754480985e-07
43 O 0 7.411601359308406e-07
% O 0 3.566730129023199e-07
) O 0 2.2963212131799082e-07
CD B-Disease 0 3.0541239084413974e-06
mutations O 0 4.929170245304704e-06
identified O 0 1.3091612345306203e-06
in O 0 8.074694051174447e-07
this O 0 2.456269157846691e-06
exon O 0 0.00013523059897124767
. O 0 3.57224780600518e-05

Seven O 0 3.372876381035894e-05
of O 0 2.87844932245207e-06
30 O 0 3.2437144454888767e-06
( O 0 8.441347176812997e-07
23 O 0 7.098287824192084e-07
% O 0 2.2274352318163437e-07
) O 0 1.0995743338071406e-07
were O 0 6.213857517423094e-08
within O 0 4.524365238012251e-08
the O 0 7.53091029537245e-08
core O 0 6.086550570216787e-07
motif O 0 7.142889444367029e-07
, O 0 1.6433700977813714e-07
the O 0 1.7514199157631083e-07
majority O 0 8.956933470471995e-07
( O 0 1.2069070010056748e-07
five O 0 5.485509646518949e-08
of O 0 4.5973234108487304e-08
seven O 0 1.239041864664614e-07
) O 0 8.054960431991276e-08
of O 0 3.0680318729991995e-08
which O 0 1.0399466532362567e-07
were O 0 4.14288450656386e-07
missense O 0 2.960392157547176e-05
mutations O 0 4.333343440521276e-06
, O 0 2.7754080633712874e-07
possibly O 0 4.830191073779133e-07
pointing O 0 5.096262043480237e-07
to O 0 1.9582783750138333e-07
the O 0 2.465604893586715e-07
functional O 0 1.4066763469600119e-06
significance O 0 9.556052873449516e-07
of O 0 3.431910329254606e-07
this O 0 2.2979738787398674e-06
region O 0 2.022056287387386e-05
. O 0 3.557066884241067e-05

Germline O 1 0.6837071180343628
PTEN O 1 0.6461392045021057
mutations O 0 0.001655419822782278
were O 0 9.28062763705384e-06
identified O 0 4.287128831492737e-06
in O 0 5.328403176463326e-07
four O 0 3.7455265555763617e-07
of O 0 2.4368705453525763e-07
seven O 0 1.81220309514174e-06
( O 0 1.6822290263007744e-06
57 O 0 1.4321282833407167e-05
% O 0 4.958689260092797e-06
) O 0 4.33857803727733e-06
BZS B-Disease 0 0.0002438630908727646
families O 0 2.3701328245806508e-05
studied O 0 5.1544353482313454e-05
. O 0 4.555068881018087e-05

Interestingly O 0 0.0007057679467834532
, O 0 1.5700685253250413e-05
none O 0 5.60916760150576e-06
of O 0 7.383023330476135e-07
these O 0 9.5215841611207e-07
mutations O 0 5.787352620245656e-06
was O 0 1.135025513576693e-06
observed O 0 1.5741801462354488e-06
in O 0 6.795530111958215e-07
the O 0 2.5495212412351975e-06
PTPase O 0 0.0004376185534056276
core O 0 7.381167233688757e-05
motif O 0 8.581559086451307e-05
. O 0 4.5796037738909945e-05

It O 0 1.4940959772502538e-05
is O 0 1.6370411231036996e-06
also O 0 5.555418738367734e-07
worthy O 0 6.618894303755951e-07
of O 0 1.0761164048744831e-07
note O 0 8.251184340224427e-07
that O 0 9.14808353513763e-08
a O 0 1.7751470693383453e-07
single O 0 5.887068255105987e-07
nonsense O 0 2.0328407117631286e-06
point O 0 5.483516360982321e-07
mutation O 0 1.5919083580229199e-06
, O 0 2.6702497279984527e-07
R233X O 0 6.896885224705329e-06
, O 0 2.538646697303193e-07
was O 0 4.835422373616893e-07
observed O 0 3.939326234103646e-07
in O 0 1.3553943745137076e-07
the O 0 3.8051123851801094e-07
germline O 0 0.00010684792505344376
DNA O 0 3.325498028061702e-06
from O 0 1.9804855355687323e-07
two O 0 2.926750255483057e-07
unrelated O 0 4.2135966396017466e-06
CD B-Disease 0 9.677232810645364e-06
families O 0 2.4236351237050258e-06
and O 0 8.699541922396747e-07
one O 0 4.025077942060307e-06
BZS B-Disease 0 0.0013278534170240164
family O 0 5.474483987200074e-05
. O 0 3.953680788981728e-05

Genotype O 1 0.9017477631568909
- O 1 0.8845605850219727
phenotype O 0 0.015172936953604221
studies O 0 1.2026243894069921e-05
were O 0 7.83804807724664e-07
not O 0 2.9285649816301884e-07
performed O 0 6.591027954527817e-07
on O 0 3.3744206007213506e-07
this O 0 5.890089482818439e-07
small O 0 1.7878837752505206e-06
group O 0 4.737914423458278e-06
of O 0 2.7668213533615926e-06
BZS B-Disease 0 0.0023588526528328657
families O 0 4.4190117478137836e-05
. O 0 4.0980230551213026e-05

However O 0 0.00018231599824503064
, O 0 3.6964527680538595e-05
genotype O 0 0.0015522687463089824
- O 0 0.0030360061209648848
phenotype O 0 0.00022067176178097725
analysis O 0 9.142585440713447e-06
inthe O 0 5.937777677900158e-05
group O 0 1.5768547427796875e-06
of O 0 1.5607429304509424e-07
CD B-Disease 0 3.443694140514708e-06
families O 0 1.7495314068582957e-06
revealed O 0 1.6722478903830051e-06
two O 0 1.8711024551976152e-07
possible O 0 3.79032456976347e-07
associations O 0 4.6000292286407785e-07
worthy O 0 7.108395152499725e-07
of O 0 8.923922933945505e-08
follow O 0 1.0748768772828043e-06
- O 0 1.0436547199788038e-05
up O 0 1.0912478956015548e-06
in O 0 1.2889420304418309e-06
independent O 0 7.48890715840389e-06
analyses O 0 4.812943734577857e-05
. O 0 3.7015037378296256e-05

The O 0 2.125620267179329e-05
first O 0 7.140749403333757e-06
was O 0 3.146951939925202e-06
an O 0 4.89643980472465e-07
association O 0 1.2598092098414782e-06
noted O 0 8.574867251809337e-07
in O 0 2.1960894969197398e-07
the O 0 3.509220221076248e-07
group O 0 5.148561967871501e-07
of O 0 2.2909752317445964e-07
CD B-Disease 0 1.6203028280870058e-05
families O 0 1.878317561931908e-05
with O 0 0.00011187453492311761
breast B-Disease 1 0.9999793767929077
disease I-Disease 1 0.6327002644538879
. O 0 9.156670421361923e-05

A O 0 6.883701280457899e-05
correlation O 0 5.1366623665671796e-05
was O 0 4.981454821972875e-06
observed O 0 1.6254001593551948e-06
between O 0 4.6730801273042744e-07
the O 0 6.79761058108852e-07
presence O 0 1.705691943243437e-06
/ O 0 9.263233550882433e-06
absence O 0 1.322624029853614e-06
of O 0 3.3689605061226757e-07
a O 0 1.8651818436410394e-06
PTEN O 0 0.0182067658752203
mutation O 0 4.154930593358586e-06
and O 0 2.3797190351615427e-07
the O 0 2.8719898637064034e-07
type O 0 1.2989027027288103e-06
of O 0 7.112043363122211e-07
breast O 0 0.1421201527118683
involvement O 0 5.961311762803234e-05
( O 0 6.779051091143629e-06
unaffected O 0 0.00018385605653747916
versus O 0 0.001170366071164608
benign O 0 0.21571703255176544
versus O 0 0.16330593824386597
malignant O 1 0.989770770072937
) O 0 3.664090399979614e-05
. O 0 3.671754166134633e-05

Specifically O 0 3.69715053238906e-05
and O 0 3.008240355484304e-06
more O 0 6.278607997955987e-07
directly O 0 4.825623705073667e-07
, O 0 2.2103985486410238e-07
an O 0 1.140201177918243e-07
association O 0 1.1031828535124077e-06
was O 0 1.7666278608885477e-06
also O 0 3.262435654960427e-07
observed O 0 3.4082211186614586e-07
between O 0 1.1636325325525831e-07
the O 0 1.9609846901857964e-07
presence O 0 2.680879731542518e-07
of O 0 2.0653463650432968e-07
a O 0 3.0925659757485846e-06
PTEN O 1 0.5651815533638
mutation O 0 0.00023400415375363082
and O 0 0.0065054441802203655
malignant B-Disease 1 0.9999973773956299
breast I-Disease 1 0.9999798536300659
disease I-Disease 0 0.44453099370002747
. O 0 0.00011045802239095792

Secondly O 0 0.0011231257813051343
, O 0 1.4832313354418147e-05
there O 0 2.828388005582383e-06
appeared O 0 2.472749883963843e-06
to O 0 5.373948965825548e-07
be O 0 2.985579214964673e-07
an O 0 2.4339905735359935e-07
interdependent O 0 6.8896665652573574e-06
association O 0 7.648176278962637e-07
between O 0 3.6738941844305373e-07
mutations O 0 1.6522345731573296e-06
upstream O 0 5.472602992995235e-07
and O 0 1.7720550715694117e-07
within O 0 1.7058304990769102e-07
the O 0 3.9703667198409676e-07
PTPase O 0 2.0425264665391296e-05
core O 0 2.9738594093942083e-06
motif O 0 1.3090376569380169e-06
, O 0 2.260094760231368e-07
the O 0 1.4318084140541032e-07
core O 0 7.204777148217545e-07
motif O 0 5.395434641286556e-07
containing O 0 2.747838721006701e-07
the O 0 2.206598850307273e-07
majority O 0 7.13129111318267e-07
of O 0 1.1492513607436194e-07
missense O 0 1.3439877875498496e-05
mutations O 0 3.1720023798698094e-06
, O 0 1.2225365253470954e-07
and O 0 8.197709178148216e-08
the O 0 8.047236832453564e-08
involvement O 0 2.770922549188981e-07
of O 0 3.924476388306175e-08
all O 0 7.36471150730722e-08
major O 0 7.836986810616509e-07
organ O 0 0.0002457258233334869
systems O 0 7.476412429241464e-05
( O 0 4.948292939843668e-07
central O 0 5.610797870758688e-07
nervous O 0 3.758307866519317e-05
system O 0 3.011182343470864e-06
, O 0 1.975879513338441e-06
thyroid O 0 0.13793504238128662
, O 0 5.523991603695322e-06
breast O 0 0.4259101152420044
, O 0 1.2534393135865685e-05
skin O 1 0.8186787366867065
and O 0 0.018094772472977638
gastrointestinal O 1 0.999930739402771
tract O 1 0.8735520243644714
) O 0 3.291244865977205e-05
. O 0 4.760822776006535e-05

However O 0 2.7388950911699794e-05
, O 0 1.8426751466904534e-06
these O 0 3.014889671248966e-07
observations O 0 6.7655770408237e-07
would O 0 2.2039236569071363e-07
need O 0 2.3870086351962527e-07
to O 0 1.3832665501922747e-07
be O 0 1.0470220956904086e-07
confirmed O 0 2.6455259671820386e-07
by O 0 1.2166118779077806e-07
studying O 0 7.038771627776441e-07
a O 0 3.9466365819862403e-07
larger O 0 9.449766480429389e-07
number O 0 2.2486743489480432e-07
of O 0 4.792904633177386e-07
CD B-Disease 0 3.8524525734828785e-05
families O 0 4.162630284554325e-05
. O 0 3.38483732775785e-05

Molecular O 1 0.7732554078102112
defects O 0 0.395973265171051
leading O 0 2.3738652089377865e-05
to O 0 2.584010871942155e-06
human O 0 2.4747832867433317e-06
complement B-Disease 0 1.0093876881001052e-05
component I-Disease 0 0.0030065199825912714
C6 I-Disease 1 0.9999996423721313
deficiency I-Disease 1 0.999983549118042
in O 0 1.3225181874076952e-06
an O 0 1.2735183645418147e-06
African O 0 5.761619377153693e-06
- O 0 0.0002497660752851516
American O 0 1.5571537005598657e-05
family O 0 3.644814569270238e-05
. O 0 4.683557926909998e-05

Complement B-Disease 0 0.002155326772481203
component I-Disease 1 0.6762814521789551
C6 I-Disease 1 0.9999994039535522
deficiency I-Disease 1 0.9999951124191284
( O 0 9.047229468706064e-06
C6D B-Disease 0 0.0014299122849479318
) O 0 2.7907112780667376e-06
was O 0 9.556686563882977e-06
diagnosed O 0 0.01053647045046091
in O 0 2.72621548447205e-07
a O 0 4.3324075704731513e-07
16 O 0 1.0635544640535954e-06
- O 0 2.7643724024528638e-05
year O 0 1.7893064523377689e-06
- O 0 1.2838733709941152e-05
old O 0 2.8960912459297106e-06
African O 0 1.0935607406281633e-06
- O 0 9.760799002833664e-06
American O 0 2.5857609671220416e-06
male O 0 6.4053151618281845e-06
with O 0 1.3333115020941477e-05
meningococcal B-Disease 1 0.999997615814209
meningitis I-Disease 1 0.9999935626983643
. O 0 0.0002222953044110909

The O 0 9.807284368434921e-05
patients O 0 0.0015316169010475278
father O 0 2.5100491257035173e-05
and O 0 1.3003453886994976e-06
two O 0 5.521313823919627e-07
brothers O 0 0.0001821667538024485
also O 0 5.659756538989313e-07
had O 0 1.6015122810131288e-06
C6D B-Disease 0 0.005274344701319933
, O 0 3.113296145329514e-07
but O 0 1.1414109479801482e-07
gave O 0 2.635181886034843e-07
no O 0 1.1496612728478794e-07
history O 0 3.802863091095787e-07
of O 0 5.548064336835523e-07
meningitis B-Disease 1 0.9932268261909485
or O 0 4.476494723348878e-06
other O 0 4.156159320700681e-06
neisserial B-Disease 1 0.781440258026123
infection I-Disease 0 0.023706166073679924
. O 0 6.668109563179314e-05

By O 0 4.368493682704866e-05
using O 0 2.9045688279438764e-05
exon O 0 0.00011770395940402523
- O 0 4.206726225675084e-05
specific O 0 3.7441732274601236e-06
polymerase O 0 3.7137866456760094e-05
chain O 0 2.4634624423924834e-05
reaction O 0 7.84026906330837e-06
( O 0 1.546128373774991e-06
PCR O 0 2.1419296899694018e-05
) O 0 1.2285668162803631e-06
/ O 0 2.3117513592296746e-06
single O 0 1.2512040257206536e-06
- O 0 1.1784305570472497e-05
strand O 0 5.996593699819641e-06
conformation O 0 3.4995262012671446e-06
polymorphism O 0 3.7164779769227607e-06
as O 0 1.9371812243207387e-07
a O 0 2.384794584031624e-07
screening O 0 1.0284284144290723e-06
step O 0 6.647322834396618e-07
and O 0 2.1024652596679516e-07
nucleotide O 0 1.0036801540991291e-06
sequencing O 0 8.076904123299755e-07
of O 0 9.410307910684423e-08
target O 0 5.210458766669035e-07
exons O 0 1.8637806533661205e-06
, O 0 1.9006115792308265e-07
we O 0 1.857543878713841e-07
determined O 0 2.1540036243550276e-07
that O 0 3.945740090216532e-08
the O 0 1.1704930358291676e-07
proband O 0 0.00017838538042269647
was O 0 6.507385705845081e-07
a O 0 5.784908125860966e-07
compound O 0 3.0273527045210358e-06
heterozygote O 0 1.956967571459245e-05
for O 0 7.26849066268187e-07
two O 0 2.5655895115050953e-06
C6 O 0 0.0007837325683794916
gene O 0 6.216243491508067e-05
mutations O 0 9.875302930595353e-05
. O 0 4.413621354615316e-05

The O 0 2.8592661692528054e-05
first O 0 9.821829735301435e-06
, O 0 1.8409607491776114e-06
1195delC O 0 1.0666286470950581e-05
located O 0 8.409672318521189e-07
in O 0 3.6268215808377136e-07
exon O 0 3.739441126526799e-06
7 O 0 7.096365379766212e-07
, O 0 1.5905425243545324e-07
is O 0 5.552902848648955e-08
a O 0 1.409978835908987e-07
novel O 0 3.2820187243487453e-06
mutation O 0 2.0571660570567474e-06
, O 0 1.0850489928770912e-07
while O 0 5.831481431073371e-08
the O 0 4.972769573896585e-08
second O 0 2.6377716721981415e-07
, O 0 1.1314079273461175e-07
1936delG O 0 2.093738430630765e-06
in O 0 1.5492972238462244e-07
exon O 0 2.2553717826667707e-06
12 O 0 3.6060313846064673e-07
, O 0 1.124244590755552e-07
has O 0 9.281004054173536e-08
been O 0 1.555171280642753e-07
described O 0 3.688414267344342e-07
before O 0 2.3430908413502038e-07
to O 0 1.6331443930539535e-07
cause O 0 8.945033869167673e-07
C6D B-Disease 0 0.0001269432541448623
in O 0 2.3737962351333408e-07
an O 0 2.821992381996097e-07
unrelated O 0 5.801084171253024e-06
African O 0 3.0252574561018264e-06
- O 0 2.621595558593981e-05
American O 0 4.524176802078728e-06
individual O 0 1.3457359273161273e-05
. O 0 3.0229442927520722e-05

Both O 0 0.00013547568232752383
mutations O 0 0.00041500249062664807
result O 0 3.5395183658692986e-05
in O 0 9.137957022176124e-06
premature O 0 0.0004379111051093787
termination O 0 0.00011085213191108778
codons O 0 8.260799950221553e-05
and O 0 1.8041528164758347e-05
C6 O 0 0.004026568029075861
null O 0 0.0003837968979496509
alleles O 0 0.00027093858807347715
. O 0 9.157700696960092e-05

Allele O 0 0.002299986779689789
- O 0 0.0005227953079156578
specific O 0 1.616801819182001e-05
PCR O 0 0.00010230024781776592
indicated O 0 7.634922440047376e-06
that O 0 5.591429044216056e-07
the O 0 5.195359449317039e-07
probands O 0 4.7530560550512746e-05
two O 0 9.071974886865064e-07
brothers O 0 0.0006029445794411004
also O 0 1.0227731763734482e-06
inherited O 0 4.315773185226135e-05
the O 0 6.522010949083779e-07
1195delC O 0 0.00012219557538628578
mutation O 0 5.404062903835438e-06
from O 0 2.5683459625724936e-07
their O 0 6.492130637525406e-07
heterozygous O 0 8.26881114335265e-06
mother O 0 4.468936822377145e-06
and O 0 2.6263055019626336e-07
the O 0 6.035303385942825e-07
1936delG O 0 6.668052083114162e-05
mutation O 0 6.080126695451327e-06
from O 0 6.511607466563873e-07
their O 0 1.9589299427025253e-06
homozygous O 0 7.358081347774714e-05
father O 0 3.746759830391966e-05
. O 0 1.7013549950206652e-05
. O 0 3.715345519594848e-05

PAX6 O 1 0.8480424880981445
mutations O 0 0.039554376155138016
reviewed O 0 0.004214763641357422
. O 0 0.000854432990308851

Mutations O 0 0.001058028545230627
in O 0 1.5936955605866387e-05
PAX6 O 0 0.0005544080631807446
are O 0 1.2616992535186e-06
responsible O 0 1.4430950159294298e-06
for O 0 3.133160078050423e-07
human O 0 5.572445616053301e-07
aniridia B-Disease 1 0.9991700649261475
and O 0 1.6994731595332269e-06
have O 0 4.5612077315126953e-07
also O 0 3.1490483820562076e-07
been O 0 3.462688482613885e-07
found O 0 5.384501378102868e-07
in O 0 1.7407174937034142e-06
patients O 0 9.354220674140379e-05
with O 0 2.097483729812666e-06
Peters B-Disease 1 0.9999978542327881
anomaly I-Disease 1 0.999958872795105
, O 0 1.1046125109714922e-05
with O 0 0.0001855191367212683
congenital B-Disease 1 0.9999997615814209
cataracts I-Disease 1 0.99998939037323
, O 0 1.6502412108820863e-05
with O 0 8.143511877278797e-06
autosomal B-Disease 1 0.5333956480026245
dominant I-Disease 0 0.003100930480286479
keratitis I-Disease 0 0.3067169785499573
, O 0 3.047493237318122e-06
and O 0 2.5797116904868744e-06
with O 0 9.290279194829054e-06
isolated B-Disease 0 0.0025368360802531242
foveal I-Disease 1 0.9999744892120361
hypoplasia I-Disease 1 0.9999853372573853
. O 0 0.00037391483783721924

No O 0 3.728044612216763e-05
locus O 0 6.652752199443057e-05
other O 0 1.2553573469631374e-06
than O 0 8.314091246575117e-07
chromosome O 0 6.027933523000684e-06
11p13 O 0 2.7348003641236573e-05
has O 0 9.251185133507533e-07
been O 0 5.235098683442629e-07
implicated O 0 5.8638879636419006e-06
in O 0 8.548640835215338e-07
aniridia B-Disease 1 0.9989001750946045
, O 0 4.109303972654743e-07
and O 0 3.4947228755299875e-07
PAX6 O 0 0.0012196956668049097
is O 0 1.8689836167595786e-07
clearly O 0 3.0808422479822184e-07
the O 0 7.496286258401597e-08
major O 0 2.729004222601361e-07
, O 0 1.8582419158974517e-07
if O 0 1.607549080517856e-07
not O 0 1.5680100773352024e-07
only O 0 2.920103838732757e-07
, O 0 1.6517871017640573e-06
gene O 0 1.543591497465968e-05
responsible O 0 3.5669108910951763e-05
. O 0 4.9817423132481053e-05

Twenty O 0 0.00024554313858971
- O 0 0.00038165703881531954
eight O 0 9.672638043412007e-06
percent O 0 5.486312147695571e-06
of O 0 7.773240895403433e-07
identified O 0 4.373356659925776e-06
PAX6 O 0 0.0006277409265749156
mutations O 0 1.9929912014049478e-05
are O 0 9.382614507558174e-07
C O 0 0.000576268881559372
- O 0 0.014100302010774612
T O 0 0.0006826638709753752
changes O 0 1.7462010646340786e-06
at O 0 6.368219374053297e-07
CpG O 0 6.422454589483095e-06
dinucleotides O 0 2.1437504983623512e-05
, O 0 4.968001121596899e-07
20 O 0 4.462496008272865e-07
% O 0 2.2795681786647037e-07
are O 0 4.4888398775810856e-08
splicing O 0 1.8516872160034836e-06
errors O 0 9.332193826594448e-07
, O 0 1.1497698437779036e-07
and O 0 1.3393174924658524e-07
more O 0 9.147787238816818e-08
than O 0 2.129184935029116e-07
30 O 0 4.3199636934332375e-07
% O 0 4.5930025294182997e-07
are O 0 1.7842185684457945e-07
deletion O 0 6.30989688943373e-06
or O 0 1.9132376110064797e-06
insertion O 0 1.5130764040804934e-05
events O 0 1.541220444778446e-05
. O 0 2.8886055588372983e-05

There O 0 2.1307427232386544e-05
is O 0 2.8512374683486996e-06
a O 0 1.6169030914170435e-06
noticeably O 0 1.0810763342306018e-05
elevated O 0 8.193039320758544e-06
level O 0 5.053527161180682e-07
of O 0 1.3207041149598808e-07
mutation O 0 1.77051231275982e-06
in O 0 1.42544308801007e-07
the O 0 1.4293854633251613e-07
paired O 0 1.5872952872086898e-06
domain O 0 5.544625878428633e-07
compared O 0 8.410779059886409e-07
with O 0 1.0347351064865506e-07
the O 0 2.3243957514296198e-07
rest O 0 5.88636055454117e-07
of O 0 4.1041030840460735e-07
the O 0 3.05619255414058e-06
gene O 0 3.068279329454526e-05
. O 0 3.106136136921123e-05

Increased O 0 0.00023051771859172732
mutation O 0 0.00016076670726761222
in O 0 3.675460902741179e-06
the O 0 1.4927650227036793e-06
homeodomain O 0 2.571856566646602e-05
is O 0 5.866874062121497e-07
accounted O 0 1.2192199392302427e-06
for O 0 3.049543977340363e-07
by O 0 7.979281804182392e-07
the O 0 3.115175104539958e-06
hypermutable O 0 0.004815532825887203
CpG O 0 0.00012588058598339558
dinucleotide O 0 7.312091474886984e-05
in O 0 4.984762199455872e-06
codon O 0 5.1222708862042055e-05
240 O 0 4.440721022547223e-05
. O 0 2.6537114536040463e-05

Very O 0 4.8148631321964785e-05
nearly O 0 6.3298230088548735e-06
all O 0 1.3634600009027054e-06
mutations O 0 5.358138878364116e-06
appear O 0 1.0302210284862667e-06
to O 0 3.6736597053277364e-07
cause O 0 2.4641340132802725e-06
loss O 0 1.8497369183023693e-06
of O 0 7.409319380258239e-08
function O 0 1.675017387015032e-07
of O 0 7.85300002803524e-08
the O 0 2.7933955948356015e-07
mutant O 0 5.750843229179736e-06
allele O 0 2.9220357191661606e-06
, O 0 1.2324117903972365e-07
and O 0 6.413527842141775e-08
more O 0 5.1471872097863525e-08
than O 0 1.2125669002216455e-07
80 O 0 4.0000682588470227e-07
% O 0 1.9836534193018451e-07
of O 0 1.413964696439507e-07
exonic O 0 1.6293113731080666e-05
substitutions O 0 4.274562797945691e-06
result O 0 4.605569756677141e-06
in O 0 2.357260882490664e-06
nonsense O 0 8.038878149818629e-05
codons O 0 0.00013031471462454647
. O 0 4.36877271567937e-05

In O 0 3.656065746326931e-05
a O 0 8.705021173227578e-06
gene O 0 8.778057235758752e-06
with O 0 6.564962404809194e-07
such O 0 7.198540856734326e-07
extraordinarily O 0 5.404473267844878e-05
high O 0 2.857247864085366e-06
sequence O 0 7.536477824032772e-07
conservation O 0 5.75477599795704e-07
throughout O 0 2.201046100935855e-07
evolution O 0 6.641353138547856e-07
, O 0 2.2152649137296976e-07
there O 0 1.6119241763590253e-07
are O 0 3.18763937912081e-07
presumed O 0 2.6281590180587955e-05
undiscovered O 0 2.566067450970877e-05
missense O 0 2.2184829504112713e-05
mutations O 0 4.885459020442795e-06
, O 0 1.8510397126192402e-07
these O 0 7.585503425389106e-08
are O 0 7.769981635874501e-08
hypothesized O 0 1.3524031601264141e-06
to O 0 2.32227307606081e-07
exist O 0 3.536588337738067e-07
in O 0 1.3400328668922157e-07
as O 0 5.611600499833003e-07
- O 0 9.735109779285267e-05
yet O 0 4.158522187935887e-06
unidentified O 0 1.1815422112704255e-05
phenotypes O 0 8.747904939809814e-05
. O 0 7.053749413898913e-06
. O 0 2.7016585590899922e-05

Genetic O 0 0.002116207033395767
heterogeneity O 0 0.0008082418353296816
and O 0 2.5158389689750038e-05
penetrance O 0 0.0002973191440105438
analysis O 0 9.126712939178105e-06
of O 0 5.163613536751654e-07
the O 0 1.8005183619607124e-06
BRCA1 O 0 0.0001376100117340684
and O 0 6.151591151137836e-06
BRCA2 O 0 0.0024564876221120358
genes O 0 2.953288822027389e-05
in O 0 5.565357787418179e-05
breast B-Disease 1 0.9995416402816772
cancer I-Disease 1 0.9771514534950256
families O 0 0.0001544084370834753
. O 0 7.836148142814636e-05

The O 0 0.19875381886959076
Breast B-Disease 1 0.9999996423721313
Cancer I-Disease 1 0.9999933242797852
Linkage O 0 0.011171207763254642
Consortium O 0 0.0024372416082769632
. O 0 0.0003566875820979476

The O 0 2.2083508156356402e-05
contribution O 0 1.0150085472560022e-05
of O 0 1.2348770042081014e-06
BRCA1 O 0 7.061448559397832e-05
and O 0 4.815317424800014e-06
BRCA2 O 0 0.09314140677452087
to O 0 0.0009343668934889138
inherited B-Disease 1 1.0
breast I-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999997615814209
was O 0 6.256959022721276e-05
assessed O 0 2.2860392618895276e-06
by O 0 2.480747127719951e-07
linkage O 0 4.289370281185256e-06
and O 0 7.927030765131349e-07
mutation O 0 2.5710858153615845e-06
analysis O 0 5.790063255517452e-07
in O 0 2.139700541192724e-07
237 O 0 1.8695984635996865e-06
families O 0 7.079682973198942e-07
, O 0 1.1617785133921643e-07
each O 0 4.073756443290222e-08
with O 0 6.49586482381892e-08
at O 0 1.7554133080466272e-07
least O 0 1.0147137885496704e-07
four O 0 1.7213849901054346e-07
cases O 0 4.355856049187423e-07
of O 0 1.4013686495673028e-06
breast B-Disease 1 0.9998887777328491
cancer I-Disease 0 0.2866353690624237
, O 0 2.5815722892730264e-07
collected O 0 4.6870275127730565e-07
by O 0 1.0251599178445758e-06
the O 0 0.021886171773076057
Breast B-Disease 1 1.0
Cancer I-Disease 1 0.9999943971633911
Linkage O 0 0.0006389073096215725
Consortium O 0 0.00032900742371566594
. O 0 6.0725713410647586e-05

Families O 0 0.00014921504771336913
were O 0 4.590489879774395e-06
included O 0 1.339588607152109e-06
without O 0 9.691387958810083e-07
regard O 0 1.2238015187904239e-06
to O 0 2.779232772809337e-07
the O 0 2.4698269385226013e-07
occurrence O 0 2.256606649098103e-06
of O 0 2.1009950614825357e-06
ovarian B-Disease 1 0.9975925087928772
or I-Disease 0 9.861324542725924e-06
other I-Disease 0 9.881855476123746e-06
cancers I-Disease 0 0.46978241205215454
. O 0 6.189684063429013e-05

Overall O 0 0.011150668375194073
, O 0 0.0001677392574492842
disease O 0 0.0025388782378286123
was O 0 3.1009121812530793e-06
linked O 0 5.585392045759363e-06
to O 0 7.898242415649293e-07
BRCA1 O 0 5.4603755415882915e-05
in O 0 3.6731793784383626e-07
an O 0 1.821150164005303e-07
estimated O 0 4.199281420369516e-07
52 O 0 1.0990140708599938e-06
% O 0 1.819039425754454e-07
of O 0 8.073710233702514e-08
families O 0 4.807406526197155e-07
, O 0 1.4768929190722702e-07
to O 0 2.0353012075702281e-07
BRCA2 O 0 2.718030009418726e-05
in O 0 1.7583134592769056e-07
32 O 0 4.193518350348313e-07
% O 0 1.1996340276709816e-07
of O 0 4.7431132799147235e-08
families O 0 6.011212576595426e-07
, O 0 1.0105437553420415e-07
and O 0 8.439916143743176e-08
to O 0 1.0028976760168007e-07
neither O 0 6.989965868342551e-07
gene O 0 8.871683121469687e-07
in O 0 3.1715865134174237e-07
16 O 0 6.362416229421797e-07
% O 0 5.603957902167167e-07
( O 0 2.918361019510485e-07
95 O 0 1.0592929129416007e-06
% O 0 8.342461228494358e-07
confidence O 0 1.8654664017958567e-06
interval O 0 4.805637217941694e-06
[ O 0 7.182301487773657e-06
CI O 0 3.048030339414254e-05
] O 0 5.139033419254702e-06
6 O 0 1.069568838829582e-06
% O 0 6.486034749286773e-07
- O 0 1.930917460413184e-05
28 O 0 1.7978451296585263e-06
% O 0 5.405358933785465e-07
) O 0 3.399501906642399e-07
, O 0 2.797165166157356e-07
suggesting O 0 4.610236373991938e-06
other O 0 3.693691041917191e-06
predisposition O 0 0.0002601256419438869
genes O 0 8.36649996927008e-05
. O 0 5.8318342780694366e-05

The O 0 6.0438756918301806e-05
majority O 0 4.611855183611624e-05
( O 0 5.424990831670584e-06
81 O 0 6.1151336012699176e-06
% O 0 7.113278002179868e-07
) O 0 2.1586222942460154e-07
of O 0 1.7936478968749725e-07
the O 0 9.349295396532398e-06
breast B-Disease 1 0.9999972581863403
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
families O 0 4.944660304317949e-06
were O 0 3.178405165726872e-07
due O 0 5.5446474789278e-07
to O 0 4.5386698843685735e-07
BRCA1 O 0 0.00017943180864676833
, O 0 1.4804521697442397e-07
with O 0 8.953433905389829e-08
most O 0 4.4787694264414313e-07
others O 0 2.22109588321473e-06
( O 0 3.679076314710983e-07
14 O 0 6.647962891292991e-07
% O 0 7.101538130882545e-07
) O 0 7.373439530056203e-07
due O 0 2.499851234460948e-06
to O 0 9.636012691771612e-06
BRCA2 O 0 0.006153283640742302
. O 0 8.484306454192847e-05

Conversely O 0 0.0009790699696168303
, O 0 1.576245267642662e-05
the O 0 2.901005927924416e-06
majority O 0 3.817109700321453e-06
of O 0 3.743905097053357e-07
families O 0 1.7113311514549423e-06
with O 0 3.330647757593397e-07
male B-Disease 0 3.2118550734594464e-06
and I-Disease 0 4.893600817013066e-06
female I-Disease 0 0.014342320151627064
breast I-Disease 1 0.9997217059135437
cancer I-Disease 1 0.6773772835731506
were O 0 1.3059801631243317e-06
due O 0 4.1860766941681504e-06
to O 0 3.699670060086646e-06
BRCA2 O 0 0.026133837178349495
( O 0 4.585769147524843e-06
76 O 0 3.101708716712892e-05
% O 0 9.316221621702425e-06
) O 0 7.157370873756008e-06
. O 0 1.585055906616617e-05

The O 0 4.71412276965566e-05
largest O 0 2.9835873647243716e-05
proportion O 0 1.8818316675606184e-05
( O 0 2.0743450477311853e-06
67 O 0 3.561890025594039e-06
% O 0 5.591962235484971e-07
) O 0 1.6050320539306995e-07
of O 0 7.608906571476837e-08
families O 0 6.535247507599706e-07
due O 0 5.054655503045069e-07
to O 0 1.5975889766650653e-07
other O 0 8.657268324441247e-08
genes O 0 3.802457229085121e-07
was O 0 5.722715741285356e-07
found O 0 1.7544626018661802e-07
in O 0 1.3151249333986925e-07
families O 0 3.9253382055903785e-07
with O 0 9.988791305204359e-08
four O 0 2.3101219426280295e-07
or O 0 3.4227485912197153e-07
five O 0 2.359892050662893e-07
cases O 0 5.882544655833044e-07
of O 0 7.50463300391857e-07
female O 0 0.04121319577097893
breast B-Disease 1 0.9999091625213623
cancer I-Disease 1 0.6066185832023621
only O 0 7.0576252255705185e-06
. O 0 2.5004450435517356e-05

These O 0 2.5647343136370182e-05
estimates O 0 1.962611531780567e-05
were O 0 1.478646140640194e-06
not O 0 6.202146778377937e-07
substantially O 0 2.8902086341986433e-06
affected O 0 8.428050364273076e-07
either O 0 2.2559279955203237e-07
by O 0 1.6939185343289864e-07
changing O 0 9.39873473271291e-07
the O 0 4.61750943259176e-07
assumed O 0 1.1384932804503478e-05
penetrance O 0 9.044979378813878e-05
model O 0 3.7702652662119363e-06
for O 0 7.351595741056371e-07
BRCA1 O 0 9.799300460144877e-05
or O 0 6.957198479540239e-07
by O 0 2.4964631961665873e-07
including O 0 6.967749186514993e-07
or O 0 3.0154697014950216e-06
excluding O 0 2.534018494770862e-05
BRCA1 O 0 0.005354768596589565
mutation O 0 0.00010714001837186515
data O 0 4.626510781235993e-05
. O 0 4.641628765966743e-05

Among O 0 5.211079405853525e-05
those O 0 1.1064469617849682e-05
families O 0 8.56895167089533e-06
with O 0 3.074639153055614e-06
disease O 0 0.0016580895753577352
due O 0 1.98231191461673e-06
to O 0 5.405626666288299e-07
BRCA1 O 0 5.639964001602493e-05
that O 0 2.31881614354279e-07
were O 0 2.72799184131145e-07
tested O 0 5.377886509450036e-07
by O 0 4.4070496585391083e-08
one O 0 3.597182995918047e-08
of O 0 3.1244049125689344e-08
the O 0 1.0922916260369675e-07
standard O 0 2.087567736452911e-06
screening O 0 1.5914999949018238e-06
methods O 0 1.0710499509514193e-06
, O 0 3.1438872838407406e-07
mutations O 0 1.1093716238974594e-06
were O 0 2.051675096481631e-07
detected O 0 5.473025908031559e-07
in O 0 1.0061337718525465e-07
the O 0 1.7916373451498657e-07
coding O 0 2.436383056192426e-06
sequence O 0 4.906648882752052e-07
or O 0 2.934323788394977e-07
splice O 0 4.3733730308304075e-06
sites O 0 4.5867082576478424e-07
in O 0 1.325265088780725e-07
an O 0 1.3653814789904573e-07
estimated O 0 6.094844593462767e-07
63 O 0 2.41340580942051e-06
% O 0 5.573901944444515e-07
( O 0 2.3495306322729448e-07
95 O 0 1.047862610903394e-06
% O 0 9.223348342857207e-07
CI O 0 8.46171606099233e-05
51 O 0 3.425603381401743e-06
% O 0 1.7837061250247643e-06
- O 0 0.00036435757647268474
77 O 0 9.853859410213772e-06
% O 0 4.775275101565057e-06
) O 0 4.580514996632701e-06
. O 0 1.4683355402667075e-05

The O 0 4.051127325510606e-05
estimated O 0 1.710403557808604e-05
sensitivity O 0 1.2945500202476978e-05
was O 0 2.5118001758528408e-06
identical O 0 2.1067696707177674e-06
for O 0 4.479619803987589e-07
direct O 0 6.202039912750479e-07
sequencing O 0 5.231862360233208e-06
and O 0 1.0508609875614638e-06
other O 0 1.4763127182959579e-06
techniques O 0 4.118501237826422e-05
. O 0 4.606492802849971e-05

The O 0 6.70297013130039e-05
penetrance O 0 0.00042769688297994435
of O 0 7.083072432578774e-06
BRCA2 O 0 0.0040968949906528
was O 0 5.82877328270115e-06
estimated O 0 9.771143822945305e-07
by O 0 3.186885635386716e-07
maximizing O 0 2.884349214582471e-06
the O 0 6.888208190503065e-07
LOD O 0 0.00033844661084003747
score O 0 2.05808055397938e-06
in O 0 1.5805915154487593e-06
BRCA2 O 0 0.001450943760573864
- O 0 0.0013528191484510899
mutation O 0 8.18593252915889e-06
families O 0 1.1651176237137406e-06
, O 0 1.9259462646914471e-07
over O 0 2.6604837444210716e-07
all O 0 3.6787150747841224e-07
possible O 0 6.419943929358851e-06
penetrance O 0 0.0002683738130144775
functions O 0 2.0782634237548336e-05
. O 0 7.882164936745539e-05

The O 0 3.253575414419174e-05
estimated O 0 1.4577914953406435e-05
cumulative O 0 2.0818615666939877e-05
risk O 0 1.726883238006849e-05
of O 0 2.299003881489625e-06
breast B-Disease 1 0.9979718327522278
cancer I-Disease 0 0.0952419638633728
reached O 0 1.5058481039886829e-06
28 O 0 1.909072807393386e-06
% O 0 5.677380272572918e-07
( O 0 3.1869282679508615e-07
95 O 0 1.0623551816024701e-06
% O 0 1.2453673434720258e-06
CI O 0 4.569922748487443e-05
9 O 0 9.712973678688286e-07
% O 0 5.589408260675555e-07
- O 0 7.4283257163187955e-06
44 O 0 7.457879860339744e-07
% O 0 2.1088831658744311e-07
) O 0 6.096576754544003e-08
by O 0 6.098774463225709e-08
age O 0 3.167137379023188e-07
50 O 0 1.9376855675545812e-07
years O 0 2.3758890677072486e-07
and O 0 3.40048785574254e-07
84 O 0 3.745773028640542e-06
% O 0 5.016524937673239e-07
( O 0 2.436229067370732e-07
95 O 0 9.466110100220249e-07
% O 0 6.794661544518021e-07
CI O 0 1.9996066839667037e-05
43 O 0 2.082670107483864e-06
% O 0 1.0807223134179367e-06
- O 0 1.997243452933617e-05
95 O 0 1.910264018079033e-06
% O 0 7.452106842720241e-07
) O 0 2.581776641363831e-07
by O 0 2.2731596516223362e-07
age O 0 1.8063969946524594e-06
70 O 0 2.9389325391093735e-06
years O 0 1.1855569937324617e-05
. O 0 2.512880200811196e-05

The O 0 0.0003503520565573126
corresponding O 1 0.8050312995910645
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
risks O 0 0.05729087069630623
were O 0 1.8058277419186197e-05
0 O 0 6.627815309911966e-05
. O 0 5.940212940913625e-05

4 O 0 0.00020876979397144169
% O 0 2.6086121579282917e-05
( O 0 3.511718659865437e-06
95 O 0 3.950148766307393e-06
% O 0 2.216956545453286e-06
CI O 0 6.445775943575427e-05
0 O 0 2.777155259536812e-06
% O 0 5.679383434653573e-07
- O 0 6.270258381846361e-06
1 O 0 4.154909163389675e-07
% O 0 1.8849219429739605e-07
) O 0 5.741817332705068e-08
by O 0 5.990003870692817e-08
age O 0 3.325855004732148e-07
50 O 0 1.777203380015635e-07
years O 0 3.323172563796106e-07
and O 0 2.876817006836063e-07
27 O 0 1.2570549188239966e-06
% O 0 3.0004616746737156e-07
( O 0 2.714789673063933e-07
95 O 0 8.017741492949426e-07
% O 0 6.10477513873775e-07
CI O 0 5.99113991484046e-05
0 O 0 1.4484681969406665e-06
% O 0 5.208754600971588e-07
- O 0 1.1452285434643272e-05
47 O 0 1.7543867443237104e-06
% O 0 4.667926418733259e-07
) O 0 1.9632899750376964e-07
by O 0 1.890167453666436e-07
age O 0 2.3694724404776935e-06
70 O 0 2.9566490411525592e-06
years O 0 1.402918769599637e-05
. O 0 1.9353790776222013e-05

The O 0 4.898944098385982e-05
lifetime O 0 0.0003470083756837994
risk O 0 6.868541095172986e-05
of O 0 6.247576493478846e-06
breast B-Disease 1 0.9999849796295166
cancer I-Disease 1 0.9805388450622559
appears O 0 2.297311993970652e-06
similar O 0 6.20172102117067e-07
to O 0 3.422036911615578e-07
the O 0 5.969218364043627e-07
risk O 0 3.0317326036310988e-06
in O 0 3.384614899459848e-07
BRCA1 O 0 0.0001462338404962793
carriers O 0 1.5364946648332989e-06
, O 0 9.977062376265167e-08
but O 0 9.915482479527782e-08
there O 0 5.562612770404485e-08
was O 0 9.225708197391214e-08
some O 0 3.950273352870681e-08
suggestion O 0 3.800107890583604e-07
of O 0 6.678331487819378e-08
a O 0 8.822628956295375e-07
lower O 0 0.0018543669721111655
risk O 0 2.121149009326473e-05
in O 0 1.3659171145263826e-06
BRCA2 O 0 0.00038116888026706874
carriers O 0 6.254253094084561e-06
< O 0 6.273727194638923e-06
50 O 0 7.099019398992823e-07
years O 0 1.171728740700928e-06
of O 0 1.4189236026140861e-06
age O 0 2.189442420785781e-05
. O 0 5.3082771046319976e-05

Eye B-Disease 1 0.9464300274848938
movement I-Disease 0 0.0041398401372134686
abnormalities I-Disease 1 0.5045609474182129
correlate O 0 0.00025608038413338363
with O 0 2.547490475990344e-05
genotype O 1 0.7546337246894836
in O 0 8.106892346404493e-05
autosomal O 1 0.8197386860847473
dominant O 0 0.1433906853199005
cerebellar B-Disease 1 0.9990338087081909
ataxia I-Disease 1 0.9999041557312012
type I-Disease 0 0.20436307787895203
I I-Disease 0 0.0019647288136184216
. O 0 8.87692003743723e-05

We O 0 0.00010356089478591457
compared O 0 5.6787564972182736e-05
horizontal O 0 0.0001014562149066478
eye O 0 0.0004994531045667827
movements O 0 1.3211303667048924e-05
( O 0 2.11181873055466e-06
visually O 0 3.901507625414524e-06
guided O 0 4.770732175529702e-06
saccades O 0 5.55942788196262e-05
, O 0 6.670279049103556e-07
antisaccades O 0 1.2953453733643983e-05
, O 0 2.4314593360941217e-07
and O 0 1.2572093055496225e-07
smooth O 0 1.3896915334044024e-06
pursuit O 0 3.7854981655982556e-06
) O 0 2.6101977823600464e-07
in O 0 1.5157884547534195e-07
control O 0 7.482272508241294e-07
subjects O 0 1.7654523389865062e-06
( O 0 6.055297490092926e-07
n O 0 2.4984926767501747e-06
= O 0 4.540701866062591e-06
14 O 0 2.895199884278554e-07
) O 0 1.500439452684077e-07
and O 0 3.3643982533249073e-07
patients O 0 3.071432956858189e-06
with O 0 9.87744783742528e-08
three O 0 1.980092605435857e-07
forms O 0 6.55533426652255e-07
of O 0 1.3340849136511679e-06
autosomal O 0 0.058725032955408096
dominant O 0 0.0012765596620738506
cerebellar B-Disease 0 0.4173579514026642
ataxias I-Disease 0 0.3980312943458557
type I-Disease 0 4.802866169484332e-05
I I-Disease 0 1.1726280717994086e-05
spinocerebellar B-Disease 0 0.0005255820578895509
ataxias I-Disease 0 0.00033410938340239227
1 I-Disease 0 1.1867725788761163e-06
and I-Disease 0 4.739595453884249e-07
2 I-Disease 0 8.015019830054371e-07
( O 0 5.372160671868187e-07
SCA1 B-Disease 0 2.7609101380221546e-05
, O 0 6.542980486301531e-07
n O 0 4.811250164493686e-06
= O 0 4.533947048912523e-06
11 O 0 4.954516725774738e-07
; O 0 4.4099093088334484e-07
SCA2 B-Disease 0 2.1365989596233703e-05
, O 0 4.315397461596149e-07
n O 0 2.9955435820738785e-06
= O 0 2.7996413791697705e-06
10 O 0 2.4431579959127703e-07
) O 0 1.7405734809017304e-07
and O 0 3.909852068773034e-07
SCA3 B-Disease 1 0.9925893545150757
/ O 0 2.1928130081505515e-05
Machado B-Disease 0 1.3204336937633343e-05
- I-Disease 0 0.0014280694304034114
Joseph I-Disease 0 0.009351732209324837
disease I-Disease 0 0.0015214983141049743
( O 0 2.2143617570691276e-06
MJD B-Disease 1 0.9995067119598389
) O 0 1.2991876019441406e-06
( O 0 9.106144034376484e-07
n O 0 9.92338937066961e-06
= O 0 1.996369792323094e-05
16 O 0 3.7769589198433096e-06
) O 0 4.48660648544319e-06
. O 0 1.3302175830176566e-05

In O 0 6.554140418302268e-05
SCA1 B-Disease 0 0.0005863402620889246
, O 0 6.221368039405206e-06
saccade O 0 9.316279465565458e-05
amplitude O 0 1.5647592590539716e-05
was O 0 3.7040476854599547e-06
significantly O 0 7.352679403993534e-06
increased O 0 2.006954900934943e-06
, O 0 1.2663765573961427e-06
resulting O 0 9.540094652038533e-06
in O 0 8.436665666522458e-06
hypermetria B-Disease 0 0.01822422631084919
. O 0 8.070462354226038e-05

The O 0 6.612058496102691e-05
smooth O 0 0.00015796467778272927
pursuit O 0 0.00037258188240230083
gain O 0 0.0004119866935070604
was O 0 4.7065939725143835e-05
decreased O 0 0.00022016277944203466
. O 0 9.352793858852237e-05

In O 0 0.00010628880409058183
SCA2 B-Disease 0 0.0009599142358638346
, O 0 1.984434129553847e-05
saccade O 0 0.00024140258028637618
velocity O 0 4.9895726988324896e-05
was O 0 1.7453239706810564e-05
markedly O 0 0.0001858736213762313
decreased O 0 0.00026042741956189275
. O 0 6.374300573952496e-05

The O 0 2.691916779440362e-05
percentage O 0 1.1499148058646824e-05
of O 0 5.528173687707749e-07
errors O 0 2.7559269710764056e-06
in O 0 9.565535492583876e-07
antisaccades O 0 0.00010484366794116795
was O 0 1.4285175211625756e-06
greatly O 0 1.2013516652586986e-06
increased O 0 4.4298298007561243e-07
and O 0 4.455836517536227e-07
was O 0 9.449532285543683e-07
significantly O 0 2.9022455692029325e-06
correlated O 0 4.172147782810498e-06
with O 0 8.305420919896278e-07
age O 0 1.6987738490570337e-05
at O 0 5.108086043037474e-05
disease O 0 0.031211398541927338
onset O 1 0.6444424390792847
. O 0 0.00012288450670894235

In O 0 3.820265192189254e-05
addition O 0 1.235339732374996e-05
, O 0 1.760981035658915e-06
a O 0 8.164727205439704e-07
correlation O 0 1.6295923614961794e-06
between O 0 3.141813351703604e-07
smooth O 0 3.1268484690372134e-06
pursuit O 0 1.839344622567296e-05
gain O 0 1.077296201401623e-05
and O 0 2.525517288631818e-07
the O 0 1.9598851963564812e-07
number O 0 2.2309366443096224e-07
of O 0 5.896080779166368e-07
trinucleotide O 0 0.00035740036400966346
repeats O 0 2.3531110855401494e-05
was O 0 1.4268742233980447e-05
found O 0 9.012765985971782e-06
. O 0 3.5195116652175784e-05

In O 0 0.0001768304209690541
SCA3 B-Disease 1 0.9986236095428467
, O 0 1.6108795534819365e-05
gaze B-Disease 0 5.9618003433570266e-05
- I-Disease 0 4.92450017191004e-05
evoked I-Disease 0 3.7945734220556915e-05
nystagmus I-Disease 0 0.00015712162712588906
was O 0 3.70223960999283e-06
often O 0 7.968467343744123e-07
present O 0 4.7286337689911306e-07
as O 0 2.7086605314252665e-07
was O 0 1.173252826447424e-06
saccade O 0 2.014749770751223e-05
hypometria O 0 1.8461947547621094e-05
and O 0 9.434458547730173e-07
smooth O 0 5.409543973655673e-06
pursuit O 0 2.4112128812703304e-05
gain O 0 4.8979680286720395e-05
was O 0 1.1727443052222952e-05
markedly O 0 0.0002507539466023445
decreased O 0 0.00014703781926073134
. O 0 4.0838418499333784e-05

Three O 0 4.806751894648187e-05
major O 0 1.7553107682033442e-05
criteria O 0 1.0944268069579266e-05
, O 0 1.5701708662163583e-06
saccade O 0 2.7379939638194628e-05
amplitude O 0 4.630430794350104e-06
, O 0 1.0036609410235542e-06
saccade O 0 2.1408532120403834e-05
velocity O 0 3.4169147511420306e-06
, O 0 3.3571836866030935e-07
and O 0 1.5905669670246425e-07
presence O 0 2.689565974378638e-07
of O 0 2.659144513472711e-07
gaze B-Disease 0 1.0899252629315015e-05
- I-Disease 0 2.01894454221474e-05
evoked I-Disease 0 7.744185495539568e-06
nystagmus I-Disease 0 1.6357040294678882e-05
, O 0 2.598913226847799e-07
permitted O 0 2.0925835997331887e-07
the O 0 1.506849400811916e-07
correct O 0 9.71005647443235e-07
assignment O 0 4.235487267578719e-07
of O 0 6.040404798568488e-08
90 O 0 2.0537071065973578e-07
% O 0 1.0510618864145727e-07
of O 0 3.429661887821567e-08
the O 0 2.152096101326606e-07
SCA1 B-Disease 0 0.0008029128657653928
, O 0 1.8610599283874762e-07
90 O 0 1.9385598193366604e-07
% O 0 9.645840037819653e-08
of O 0 3.6580704687594334e-08
the O 0 1.2057174103574653e-07
SCA2 B-Disease 0 0.00017135587404482067
, O 0 1.2724692055599007e-07
and O 0 1.2924880365972058e-07
93 O 0 9.327869747721707e-07
% O 0 1.5305553802136274e-07
of O 0 5.507651934522073e-08
the O 0 4.952409540237568e-07
patients O 0 1.3016856428293977e-05
with O 0 2.83438339465647e-07
SCA3 B-Disease 1 0.999624490737915
to O 0 3.3056426218536217e-07
their O 0 4.062234779667051e-07
genetically O 0 3.618761638790602e-06
confirmed O 0 6.0433831094997e-06
patient O 0 1.7741323972586542e-05
group O 0 6.895759838698723e-07
and O 0 2.4601510517641145e-07
, O 0 1.9552815899714915e-07
therefore O 0 2.5255488367292855e-07
, O 0 1.981717332455446e-07
may O 0 3.757841682272556e-07
help O 0 7.319953283513314e-07
orient O 0 9.433429113414604e-06
diagnoses O 0 1.878689909062814e-05
of O 0 2.5392230895704415e-07
SCA1 B-Disease 0 0.00039513272349722683
, O 0 7.023891726021247e-07
SCA2 B-Disease 0 4.0668121073395014e-05
, O 0 2.983404669976153e-07
and O 0 4.107870097413979e-07
SCA3 B-Disease 1 0.9684467315673828
at O 0 8.244639388976793e-07
early O 0 2.2836575226392597e-06
clinical O 0 1.7750666302163154e-05
stages O 0 3.989700871898094e-06
of O 0 5.513542191692977e-07
the O 0 2.1386334992712364e-05
diseases O 0 0.029321031644940376
. O 0 1.1272220035607461e-05
. O 0 3.44891996064689e-05

Genetic O 0 0.00046205203398130834
basis O 0 1.8713517420110293e-05
and O 0 8.309149961860385e-06
molecular O 0 9.52357440837659e-05
mechanism O 0 7.761518645565957e-05
for O 0 0.0005305327940732241
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 0.9999915361404419
fibrillation I-Disease 1 0.9999988079071045
. O 0 0.0020835534669458866

Ventricular B-Disease 1 0.9952704310417175
fibrillation I-Disease 1 0.9915744662284851
causes O 0 0.00018370432371739298
more O 0 2.8824904347857228e-06
than O 0 9.831142051552888e-07
300 O 0 1.678162107054959e-06
, O 0 4.6845204337842006e-07
000 O 0 1.683140339991951e-06
sudden O 0 6.667044090136187e-06
deaths O 0 1.8198772977484623e-06
each O 0 2.11338502253966e-07
year O 0 7.898581202425703e-07
in O 0 6.914284540471272e-07
the O 0 3.0050030090933433e-06
USA O 0 4.227961107972078e-05
alone O 0 2.63260899373563e-05
. O 0 4.18392191932071e-05

In O 0 1.891507963591721e-05
approximately O 0 6.691248927381821e-06
5 O 0 3.5002201457245974e-06
- O 0 1.0355903214076534e-05
12 O 0 5.857979772372346e-07
% O 0 1.2879156940925895e-07
of O 0 3.7631416205385904e-08
these O 0 1.031029412956741e-07
cases O 0 2.9780778731947066e-07
, O 0 1.5092324190391082e-07
there O 0 6.816508602014437e-08
are O 0 8.174288979034827e-08
no O 0 2.882150056393584e-07
demonstrable O 0 4.990376692148857e-05
cardiac O 0 0.23371098935604095
or O 0 3.3374217309756204e-06
non O 0 1.821379737521056e-05
- O 0 0.3203072249889374
cardiac O 0 0.07312802225351334
causes O 0 1.769143409546814e-06
to O 0 1.700081355693328e-07
account O 0 3.0331273137562675e-07
for O 0 1.019190563056327e-07
the O 0 2.2730166904239013e-07
episode O 0 1.5130081010283902e-06
, O 0 2.647888379669894e-07
which O 0 1.2807626603716926e-07
is O 0 1.782363341362725e-07
therefore O 0 1.396038328493887e-06
classified O 0 1.8911347069661133e-05
as O 0 0.0003660990041680634
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 0.9999923706054688
fibrillation I-Disease 1 0.9999992847442627
( O 0 0.0006084582419134676
IVF B-Disease 1 0.9999812841415405
) O 0 4.6674882469233125e-05
. O 0 5.1811257435474545e-05

A O 0 0.00010159252997254953
distinct O 0 3.393223960301839e-05
group O 0 1.0024069524661172e-05
of O 0 2.7671248972183093e-06
IVF B-Disease 1 0.9999998807907104
patients O 1 0.6280615925788879
has O 0 2.013014409385505e-06
been O 0 8.517920377926202e-07
found O 0 3.9533944118375075e-07
to O 0 2.2686506895297498e-07
present O 0 3.6281912230151647e-07
with O 0 6.053166998754023e-07
a O 0 3.5934021980210673e-06
characteristic O 0 4.570358578348532e-05
electrocardiographic O 0 0.1154451072216034
pattern O 0 0.0002786293625831604
. O 0 0.00011228772928006947

Because O 0 3.303515040897764e-05
of O 0 8.431242122242111e-07
the O 0 5.438804464574787e-07
small O 0 5.035226990912633e-07
size O 0 2.8269164431549143e-07
of O 0 6.796930307473303e-08
most O 0 1.5380852858015714e-07
pedigrees O 0 1.6326928744092584e-05
and O 0 3.882259989040904e-07
the O 0 4.4929086584488687e-07
high O 0 4.311659722588956e-06
incidence O 0 1.0339966138417367e-05
of O 0 2.806881411743234e-07
sudden B-Disease 0 3.906409983756021e-05
death I-Disease 0 1.1878950317623094e-05
, O 0 5.176146373742085e-07
however O 0 5.798274287371896e-07
, O 0 5.244763769951533e-07
molecular O 0 1.367673758068122e-05
genetic O 0 2.6029415494122077e-06
studies O 0 9.417971682523785e-07
of O 0 3.02640643212726e-07
IVF B-Disease 1 0.999985933303833
have O 0 1.927743142005056e-06
not O 0 6.446826432693342e-07
yet O 0 1.8728426312009105e-06
been O 0 3.058945367229171e-06
done O 0 1.3775895240542013e-05
. O 0 3.1247232982423156e-05

Because O 0 0.019224559888243675
IVF B-Disease 1 0.9999891519546509
causes O 0 0.13998378813266754
cardiac O 1 0.9937136769294739
rhythm O 0 0.002064242959022522
disturbance O 0 7.65075528761372e-05
, O 0 1.9159106159349903e-06
we O 0 9.138628911387059e-07
investigated O 0 3.0807796065346338e-06
whether O 0 1.9773442545556463e-06
malfunction O 0 1.2182099453639239e-05
of O 0 2.443624111947429e-07
ion O 0 3.5206346638005925e-06
channels O 0 3.2709485822124407e-06
could O 0 2.4396290427830536e-06
cause O 0 3.787917648878647e-06
the O 0 2.0733402834594017e-06
disorder O 0 0.00016136013437062502
by O 0 4.5424977201946604e-07
studying O 0 5.240801328909583e-06
mutations O 0 9.299320481659379e-06
in O 0 7.454196406797564e-07
the O 0 1.99069677364605e-06
cardiac O 0 0.0025906688533723354
sodium O 0 7.052235741866753e-05
channel O 0 7.158032531151548e-05
gene O 0 0.00011753751459764317
SCN5A O 0 0.0037375909741967916
. O 0 0.00010471817222423851

We O 0 9.517963917460293e-05
have O 0 8.678992344357539e-06
now O 0 3.87631780540687e-06
identified O 0 3.2352556900150375e-06
a O 0 1.5839050320209935e-06
missense O 0 8.746595267439261e-05
mutation O 0 1.1348631232976913e-05
, O 0 4.3428232743281114e-07
a O 0 5.827211566611368e-07
splice O 0 0.0016842768527567387
- O 0 0.022567033767700195
donor O 0 1.5616658856743015e-05
mutation O 0 4.158871433901368e-06
, O 0 3.9354884506792587e-07
and O 0 3.337554232984985e-07
a O 0 1.2754766203215695e-06
frameshift O 0 0.009932749904692173
mutation O 0 8.355635145562701e-06
in O 0 4.1384222981832863e-07
the O 0 5.502463977791194e-07
coding O 0 9.307234904554207e-06
region O 0 8.802072670732741e-07
of O 0 2.920777717463352e-07
SCN5A O 0 0.0001663709554122761
in O 0 1.1843304719150183e-06
three O 0 5.8902633099933155e-06
IVF B-Disease 1 0.9999661445617676
families O 0 0.00013618910452350974
. O 0 4.7718858695589006e-05

We O 0 3.683963223011233e-05
show O 0 9.488539035373833e-06
that O 0 1.160508872999344e-06
sodium O 0 2.717524694162421e-06
channels O 0 1.256386212844518e-06
with O 0 3.2570420671618194e-07
the O 0 8.612304327471065e-07
missense O 0 3.086724245804362e-05
mutation O 0 1.0441345693834592e-05
recover O 0 1.792980037862435e-05
from O 0 3.5429482636573084e-07
inactivation O 0 6.803701580793131e-06
more O 0 1.8829132386599667e-07
rapidly O 0 8.920823688640667e-07
than O 0 1.279443040402839e-07
normal O 0 3.7397373375824827e-07
and O 0 1.0379392278991872e-07
that O 0 1.0394647631528642e-07
the O 0 4.283452881281846e-07
frameshift O 0 0.00047106845886446536
mutation O 0 4.589999207382789e-06
causes O 0 8.729759883863153e-07
the O 0 2.1729171351125842e-07
sodium O 0 1.8829038026524358e-06
channel O 0 1.5380838931378094e-06
to O 0 4.392825303511927e-07
be O 0 6.832342478446662e-07
non O 0 3.5665232189785456e-06
- O 0 4.107973290956579e-05
functional O 0 5.6290882639586926e-05
. O 0 2.7297061024000868e-05

Our O 0 9.068617509910837e-05
results O 0 5.65558293601498e-05
indicate O 0 1.3856664736522362e-05
that O 0 1.7739229178914684e-06
mutations O 0 1.0173363079957198e-05
in O 0 1.40394502068375e-06
cardiac O 0 0.0008701165788806975
ion O 0 4.7814151912461966e-05
- O 0 5.006254286854528e-05
channel O 0 3.8580847103730775e-06
genes O 0 1.3793254538541078e-06
contribute O 0 4.132534456857684e-07
to O 0 2.7308163907946437e-07
the O 0 5.436594960883667e-07
risk O 0 2.8971464871574426e-06
of O 0 8.525518637725327e-07
developing O 0 3.0505370887112804e-05
IVF B-Disease 1 0.9997835755348206
. O 0 2.703155951166991e-05
. O 0 4.836998778046109e-05

Molecular O 0 0.0012573518324643373
heterogeneity O 0 0.0006445198087021708
in O 0 3.1395415135193616e-05
mucopolysaccharidosis B-Disease 0 0.000599246530327946
IVA I-Disease 0 0.00022695724328514189
in O 0 2.2495075882034143e-06
Australia O 0 9.815403245738707e-07
and O 0 3.2931163218563597e-07
Northern O 0 7.335565328503435e-07
Ireland O 0 1.6255319224001141e-06
: O 0 4.822329628950683e-07
nine O 0 5.920100534240191e-07
novel O 0 4.193233053229051e-06
mutations O 0 2.5528593141643796e-06
including O 0 2.9993003636263893e-07
T312S O 0 5.778418926638551e-05
, O 0 4.81092911286396e-07
a O 0 5.934361411163991e-07
common O 0 3.143424464724376e-06
allele O 0 1.607767080713529e-05
that O 0 9.329596082352509e-07
confers O 0 1.5352936316048726e-05
a O 0 2.8247892259969376e-05
mild O 1 0.8487187623977661
phenotype O 1 0.9774554967880249
. O 0 0.00010892983118537813

Mucopolysaccharidosis B-Disease 1 0.9262396693229675
IVA I-Disease 1 0.8603863716125488
( O 0 0.0004272072983440012
MPS B-Disease 1 0.9998753070831299
IVA I-Disease 1 0.9999103546142578
) O 0 7.87822591519216e-06
is O 0 9.046918876265408e-07
an O 0 3.1988113278202945e-06
autosomal B-Disease 1 0.6187338829040527
recessive I-Disease 1 0.9953866600990295
lysosomal I-Disease 1 0.9999840259552002
storage I-Disease 1 0.9990925788879395
disorder I-Disease 1 0.9877946376800537
caused O 0 1.9704943042597733e-05
by O 0 1.3236524409876438e-06
a O 0 6.279529770836234e-05
genetic B-Disease 1 0.9993880987167358
defect I-Disease 1 0.9976077079772949
in O 0 3.0188477921910817e-06
N O 0 0.00025563471717759967
- O 0 0.0015523695619776845
acetylgalactosamine O 0 0.0031739077530801296
- O 0 0.0008791537256911397
6 O 0 1.1837018973892555e-05
- O 0 0.00020821535144932568
sulfate O 0 0.0003594502341002226
sulfatase O 0 0.0023842384107410908
( O 0 8.422502105531748e-06
GALNS O 0 0.0002182258467655629
) O 0 1.3068462976661976e-05
. O 0 2.166745616705157e-05

Previous O 0 0.000172244748682715
studies O 0 2.9545875804615207e-05
of O 0 2.607761871331604e-06
patients O 0 4.493111919146031e-05
from O 0 6.074836278457951e-07
a O 0 8.593319762439933e-07
British O 0 7.314063986996189e-05
- O 0 0.0083643002435565
Irish O 0 1.0642926099535543e-05
population O 0 2.6808848474502156e-07
showed O 0 4.932161346005159e-07
that O 0 9.109551513120095e-08
the O 0 2.5496350986031757e-07
I113F O 0 0.0005117144901305437
mutation O 0 3.215888000340783e-06
is O 0 1.0961547758370216e-07
the O 0 9.838245063065187e-08
most O 0 1.4803956105424732e-07
common O 0 7.588628250232432e-07
single O 0 2.564679334682296e-06
mutation O 0 2.4621214834041893e-05
among O 0 7.727674528723583e-06
MPS B-Disease 1 0.9999920129776001
IVA I-Disease 1 0.9999988079071045
patients O 0 0.025635093450546265
and O 0 1.3071912690065801e-06
produces O 0 8.900293323677033e-06
a O 0 3.913281761924736e-05
severe O 1 0.9963733553886414
clinical O 1 0.9916805624961853
phenotype O 1 0.9924517273902893
. O 0 0.0002282841451233253

We O 0 5.904069257667288e-05
studied O 0 3.272291723988019e-05
mutations O 0 1.922995397762861e-05
in O 0 8.248209724115441e-07
the O 0 6.545452038153599e-07
GALNS O 0 5.3496019972953945e-05
gene O 0 2.964204213640187e-06
from O 0 4.899616214970592e-07
23 O 0 1.3556468729802873e-06
additional O 0 2.7628768748400034e-06
MPS B-Disease 1 0.9998708963394165
IVA I-Disease 1 0.9999830722808838
patients O 0 0.0031297868117690086
( O 0 4.597499128067284e-07
15 O 0 1.8304307047856128e-07
from O 0 4.962631194871392e-08
Australia O 0 9.092019581657951e-08
, O 0 6.867782786912358e-08
8 O 0 9.828604419226394e-08
from O 0 5.9496510829148974e-08
Northern O 0 2.482659624547523e-07
Ireland O 0 8.091467975646083e-07
) O 0 1.7291147003106744e-07
, O 0 6.664932072908414e-08
with O 0 6.04397740744389e-08
various O 0 4.007372353953542e-07
clinical O 0 0.1767740398645401
phenotypes O 0 0.34727099537849426
( O 0 5.523649178940104e-06
severe O 0 0.007374441716820002
, O 0 1.1535913699844969e-06
16 O 0 4.253589622749132e-07
cases O 0 3.995615145413467e-07
; O 0 5.50784022834705e-07
intermediate O 0 1.6502945072716102e-06
, O 0 3.067646048293682e-07
4 O 0 4.475264461234474e-07
cases O 0 6.220616342034191e-07
; O 0 4.699596502177883e-06
mild O 0 0.0023914691992104053
, O 0 1.5282014373951824e-06
3 O 0 3.5190100788895506e-06
cases O 0 4.963098490406992e-06
) O 0 9.127513294515666e-06
. O 0 1.8932478269562125e-05

We O 0 3.554658906068653e-05
found O 0 6.6405195866536815e-06
two O 0 9.963672482626862e-07
common O 0 1.7242484773305478e-06
mutations O 0 3.808099791058339e-06
that O 0 2.292194665187708e-07
together O 0 3.4715003494056873e-07
accounted O 0 6.171054565129452e-07
for O 0 2.0880624163055472e-07
32 O 0 1.0917475492533413e-06
% O 0 2.3527145742718858e-07
of O 0 6.805284158417635e-08
the O 0 2.5621125132602174e-07
44 O 0 1.993394562305184e-06
unrelated O 0 1.4747515706403647e-05
alleles O 0 1.7448628568672575e-05
in O 0 3.471491027084994e-06
these O 0 1.1083681783929933e-05
patients O 0 0.0004471078282222152
. O 0 6.26666733296588e-05

One O 0 3.0735827749595046e-05
is O 0 3.956708951591281e-06
the O 0 2.384049366810359e-06
T312S O 0 7.709919009357691e-05
mutation O 0 1.923237505252473e-05
, O 0 7.075639700815373e-07
a O 0 6.792478188799578e-07
novel O 0 1.0598148037388455e-05
mutation O 0 8.837500899971928e-06
found O 0 9.436905656912131e-07
exclusively O 0 2.796033868435188e-06
in O 0 3.876879418385215e-06
milder O 1 0.5377049446105957
patients O 0 0.06440488994121552
. O 0 6.976391159696504e-05

The O 0 2.4403210773016326e-05
other O 0 3.2235216167464387e-06
is O 0 1.0094435083374265e-06
the O 0 6.409247816918651e-07
previously O 0 3.189535618730588e-06
described O 0 6.106951332185417e-06
I113F O 0 8.2853039202746e-05
that O 0 1.298029701501946e-06
produces O 0 6.091200248192763e-06
a O 0 2.8960223062313162e-05
severe O 1 0.9589219689369202
phenotype O 1 0.9801944494247437
. O 0 0.0001500069338362664

The O 0 3.7886577047174796e-05
I113F O 0 0.00025005440693348646
and O 0 4.685986823460553e-06
T312S O 0 5.837281423737295e-05
mutations O 0 1.55183624883648e-05
accounted O 0 1.9971128040197073e-06
for O 0 4.1807084016909357e-07
8 O 0 6.287919518399576e-07
( O 0 3.0463957045867573e-07
18 O 0 3.7669303765142104e-07
% O 0 2.061642874195968e-07
) O 0 1.3756994121649768e-07
and O 0 1.7730592105635878e-07
6 O 0 4.201849037599459e-07
( O 0 1.8793896572333324e-07
14 O 0 2.824684770530439e-07
% O 0 2.362431956726141e-07
) O 0 8.410171403738786e-08
of O 0 9.06006292211714e-08
44 O 0 9.86075747277937e-07
unrelated O 0 7.334498604905093e-06
alleles O 0 1.7825441318564117e-05
, O 0 4.281559995433781e-06
respectively O 0 3.147020470350981e-05
. O 0 3.514755007927306e-05

The O 0 4.873084253631532e-05
relatively O 0 3.880459917127155e-05
high O 0 9.821173989621457e-06
residual O 0 2.0831623260164633e-05
GALNS O 0 9.76257142610848e-05
activity O 0 3.6067683595319977e-06
seen O 0 2.3587990654050373e-06
when O 0 1.0981947298205341e-06
the O 0 7.182296144492284e-07
T312S O 0 1.3891077287553344e-05
mutant O 0 5.761009560956154e-06
cDNA O 0 6.5060530687333085e-06
is O 0 4.3245518099865876e-07
overexpressed O 0 4.147828349232441e-06
in O 0 4.4674780497189204e-07
mutant O 0 8.577013431931846e-06
cells O 0 2.9931534299976192e-06
provides O 0 2.070932083597654e-07
an O 0 1.0048238863191727e-07
explanation O 0 5.716595978810801e-07
for O 0 2.1346011180867208e-07
the O 0 1.4263735010899836e-06
mild O 1 0.7615052461624146
phenotype O 1 0.987676739692688
in O 0 3.247831409680657e-05
patients O 0 9.322234836872667e-05
with O 0 1.5350767625932349e-06
this O 0 7.375250334007433e-06
mutation O 0 0.00019365102343726903
. O 0 4.98754670843482e-05

The O 0 1.7627959095989354e-05
distribution O 0 5.979860816296423e-06
and O 0 1.1189428050784045e-06
relative O 0 1.423823846380401e-06
frequencies O 0 9.31624185795954e-07
of O 0 1.0722154542008866e-07
the O 0 2.4052437197497056e-07
I113F O 0 8.643903129268438e-06
and O 0 4.78850893159688e-07
T312S O 0 2.211136779806111e-05
mutations O 0 1.7630630964049487e-06
in O 0 1.1310950753795623e-07
Australia O 0 1.519948682471295e-07
corresponded O 0 3.3566584534128197e-07
to O 0 1.0601483779737464e-07
those O 0 8.198318823815498e-08
observed O 0 1.87627364311993e-07
in O 0 6.426066079256998e-08
Northern O 0 1.7356404669044423e-07
Ireland O 0 4.6267354036899633e-07
and O 0 1.2152968054124358e-07
are O 0 4.0070890605647946e-08
unique O 0 7.692975856343764e-08
to O 0 5.8808179659308735e-08
these O 0 5.190298324464493e-08
two O 0 1.326205705254324e-07
populations O 0 6.994720251896069e-07
, O 0 1.340711719421961e-07
suggesting O 0 3.992167876276653e-07
that O 0 6.512650685408516e-08
both O 0 2.5748596499397536e-07
mutations O 0 1.913693722599419e-06
were O 0 1.5479326975764707e-07
probably O 0 3.9309796306952194e-07
introduced O 0 3.661735661353305e-07
to O 0 1.136622742592408e-07
Australia O 0 1.8371778764958435e-07
by O 0 1.59325409754274e-07
Irish O 0 2.8722961360472254e-06
migrants O 0 1.2065403325323132e-06
during O 0 1.1657723462121794e-06
the O 0 1.1696577075781533e-06
19th O 0 1.5729279766674154e-05
century O 0 4.048759728902951e-05
. O 0 4.572285615722649e-05

Haplotype O 0 0.0018935537664219737
analysis O 0 8.073179924394935e-05
using O 0 1.8546723367762752e-05
6 O 0 1.2304696610954124e-05
RFLPs O 0 2.8073038265574723e-05
provides O 0 1.0829716075022588e-06
additional O 0 6.127335723249416e-07
data O 0 6.218671160240774e-07
that O 0 1.4466402831203595e-07
the O 0 4.706947436261544e-07
I113F O 0 0.00011165073374286294
mutation O 0 8.088759386737365e-06
originated O 0 2.4278292585222516e-06
from O 0 6.766273941138934e-07
a O 0 1.5131929558265256e-06
common O 0 9.865161700872704e-06
ancestor O 0 9.735276398714632e-05
. O 0 7.242798164952546e-05

The O 0 1.8261524019180797e-05
other O 0 2.457773689457099e-06
9 O 0 3.2579009712208062e-06
novel O 0 6.1331220422289334e-06
mutations O 0 5.170125859876862e-06
identified O 0 1.2624803957805852e-06
in O 0 1.973690189061017e-07
these O 0 2.327170420812763e-07
23 O 0 3.611087322497042e-06
patients O 0 5.70306519875885e-06
were O 0 1.5163435307385953e-07
each O 0 1.1945195410589804e-07
limited O 0 4.101270008050051e-07
to O 0 3.2638297398079885e-07
a O 0 1.8585338921184302e-06
single O 0 1.4738333447894547e-05
family O 0 0.00012046592746628448
. O 0 4.234425432514399e-05

These O 0 2.8262038540560752e-05
data O 0 1.0919924534391612e-05
provide O 0 1.3661830280398135e-06
further O 0 6.087432780077506e-07
evidence O 0 7.279409146576654e-07
for O 0 3.684870364395465e-07
extensive O 0 2.1813893908984028e-06
allelic O 0 2.4069187929853797e-05
heterogeneity O 0 4.275040191714652e-05
in O 0 3.3580238323338563e-06
MPS B-Disease 1 0.968096911907196
IVA I-Disease 1 0.7704060673713684
in O 0 8.021718826967117e-07
British O 0 3.8677109841955826e-05
- O 0 0.01609203591942787
Irish O 0 8.701655315235257e-05
patients O 0 5.126658834342379e-06
and O 0 1.4449304330810264e-07
provide O 0 1.8112773148004635e-07
evidence O 0 2.2799943621976126e-07
for O 0 1.1115367470893034e-07
their O 0 2.558689118359325e-07
transmission O 0 1.6100648281280883e-06
to O 0 2.5474793119428796e-07
Australia O 0 5.979867410133011e-07
by O 0 5.27069687450421e-07
British O 0 1.5154910215642303e-05
- O 0 0.0003476143174339086
Irish O 0 1.9769369828281924e-05
migrants O 0 1.2152070667070802e-05
. O 0 9.882015547191259e-06
. O 0 3.3359643566654995e-05

Identification O 0 0.00011307920794934034
of O 0 9.092172149394173e-06
constitutional O 0 4.572669058688916e-05
WT1 O 0 0.11357731372117996
mutations O 0 7.860441837692633e-05
, O 0 2.0850588953180704e-06
in O 0 2.1173646018723957e-06
patients O 0 2.1444211597554386e-05
with O 0 1.8630414615472546e-06
isolated O 0 0.0001247432519448921
diffuse B-Disease 1 0.9975005984306335
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
, O 0 3.718523885254399e-06
and O 0 5.818559998260753e-07
analysis O 0 1.6830184677019133e-06
of O 0 6.945027735127951e-07
genotype O 1 0.5078655481338501
/ O 0 0.008360188454389572
phenotype O 0 0.0019729891791939735
correlations O 0 5.93041750107659e-06
by O 0 2.887746290980431e-07
use O 0 3.551642464572069e-07
of O 0 2.965782925912208e-07
a O 0 2.953182729470427e-06
computerized O 0 0.0026561676058918238
mutation O 0 0.0001695384125923738
database O 0 9.466768096899614e-05
. O 0 5.446271461551078e-05

Constitutional O 0 0.0003894349210895598
mutations O 0 0.0001501689403085038
of O 0 2.9642492336279247e-06
the O 0 3.309678504592739e-06
WT1 O 0 0.00029200551216490567
gene O 0 6.907917395437835e-06
, O 0 4.773899604515464e-07
encoding O 0 2.2325486952468054e-06
a O 0 1.4245790680433856e-06
zinc O 0 0.00031525595113635063
- O 0 2.4977374778245576e-05
finger O 0 5.169805717741838e-06
transcription O 0 2.5099418508034432e-06
factor O 0 9.66115635492315e-07
involved O 0 4.7268528646782215e-07
in O 0 1.4064135029911995e-06
renal O 1 0.985686719417572
and O 0 3.053692807952757e-06
gonadal O 1 0.6283571124076843
development O 0 1.8915482087322744e-06
, O 0 3.1126816679716285e-07
are O 0 8.654345862169066e-08
found O 0 1.5919205509362655e-07
in O 0 2.311635967089387e-07
most O 0 1.2735221162074595e-06
patients O 0 1.9058012185269035e-05
with O 0 3.1525992199021857e-06
Denys B-Disease 1 0.9999935626983643
- I-Disease 1 0.9999990463256836
Drash I-Disease 1 0.9999986886978149
syndrome I-Disease 1 0.9999988079071045
( O 0 1.04408882179996e-05
DDS B-Disease 1 0.9999984502792358
) O 0 2.274873850183212e-06
, O 0 9.306775154982461e-07
or O 0 9.504423360340297e-06
diffuse B-Disease 1 0.9780871868133545
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
( O 0 3.3415395591873676e-05
DMS B-Disease 1 0.5251416563987732
) O 0 1.1761330824811012e-06
associated O 0 1.2566702025651466e-06
with O 0 8.154285069394973e-07
pseudohermaphroditism B-Disease 1 0.9998681545257568
and O 0 3.5856817703461275e-05
/ O 0 0.0051708403043448925
or O 0 4.5525066525442526e-05
Wilms B-Disease 1 0.9998877048492432
tumor I-Disease 1 0.6888142824172974
( O 0 4.046540561830625e-05
WT B-Disease 1 0.996788501739502
) O 0 3.926807039533742e-05
. O 0 4.856489977100864e-05

Most O 0 9.418953413842246e-05
mutations O 0 0.000444780191173777
in O 0 6.83645557728596e-05
DDS B-Disease 1 1.0
patients O 1 0.5475705862045288
lie O 0 1.4035289495950565e-05
in O 0 8.579283985454822e-07
exon O 0 7.612165973114315e-06
8 O 0 1.267520701730973e-06
or O 0 5.746099986936315e-07
exon O 0 4.41716292698402e-06
9 O 0 6.84635892866936e-07
, O 0 2.1428044760796183e-07
encoding O 0 1.2167317890998675e-06
zinc O 0 1.1331338100717403e-05
finger O 0 6.839560228399932e-06
2 O 0 7.314649792533601e-07
or O 0 4.102780053472088e-07
zinc O 0 6.7224041231384035e-06
finger O 0 4.226362761983182e-06
3 O 0 3.7060263480270805e-07
, O 0 1.455156706242633e-07
respectively O 0 3.0090870950516546e-07
, O 0 7.027966120176643e-08
with O 0 7.39088648060715e-08
a O 0 3.649401207894698e-07
hot O 0 6.238443347683642e-06
spot O 0 4.387760782265104e-06
( O 0 7.441326488333289e-07
R394W O 0 8.517640708305407e-06
) O 0 7.29098417195928e-07
in O 0 1.5124887795536779e-06
exon O 0 5.342128497431986e-05
9 O 0 2.7074980607721955e-05
. O 0 3.008438397955615e-05

We O 0 5.478520324686542e-05
analyzed O 0 2.5464993086643517e-05
a O 0 1.7793923916542553e-06
series O 0 2.298774006703752e-06
of O 0 9.634979960537748e-07
24 O 0 1.1913280104636215e-05
patients O 0 4.969780275132507e-05
, O 0 4.893368554803601e-07
10 O 0 5.236222477833508e-07
with O 0 6.640929086643155e-07
isolated B-Disease 0 4.114678085898049e-05
DMS I-Disease 1 0.9713385701179504
( O 0 3.934403139282949e-06
IDMS B-Disease 0 0.04577020928263664
) O 0 5.171878569854016e-07
, O 0 1.3159177569832536e-07
10 O 0 1.6030939775646402e-07
with O 0 4.02798633558632e-07
DDS B-Disease 1 0.9999994039535522
, O 0 9.805963827602682e-07
and O 0 4.171731973201531e-07
4 O 0 6.345745759972488e-07
with O 0 8.244631999332341e-07
urogenital B-Disease 1 0.9603500962257385
abnormalities I-Disease 1 0.9945065379142761
and O 0 5.3987499995855615e-05
/ O 0 0.010830365121364594
or O 0 7.346647180384025e-05
WT B-Disease 1 0.9998630285263062
. O 0 5.5900163715705276e-05

We O 0 0.0002057792735286057
report O 0 7.922441727714613e-05
WT1 O 0 0.0013648452004417777
heterozygous O 0 0.00014944429858587682
mutations O 0 2.338355807296466e-05
in O 0 2.4916209895309294e-06
16 O 0 4.4014823288307525e-06
patients O 0 1.4223855032469146e-05
, O 0 3.739227167898207e-07
4 O 0 6.426802201531245e-07
of O 0 3.609933685311262e-07
whom O 0 9.681054507382214e-06
presented O 0 8.485937541991007e-06
with O 0 1.7416045011486858e-05
IDMS B-Disease 1 0.9987469911575317
. O 0 0.0002044455031864345

One O 0 6.525104254251346e-05
male O 0 2.5720970370457508e-05
and O 0 4.747892489831429e-06
two O 0 3.812344175457838e-06
female O 0 9.08113070181571e-05
IDMS B-Disease 1 0.9997531771659851
patients O 0 0.008074344135820866
with O 0 1.3501991816156078e-05
WT1 O 1 0.9647229909896851
mutations O 0 0.0011575050884857774
underwent O 0 0.009480543434619904
normal O 0 0.00016701356798876077
puberty O 0 0.0013222621055319905
. O 0 8.867157157510519e-05

Two O 0 9.688102727523074e-05
mutations O 0 0.00034323634463362396
associated O 0 1.808140405046288e-05
with O 0 2.9268273920024512e-06
IDMS B-Disease 1 0.6608507633209229
are O 0 5.707041168534488e-07
different O 0 2.926739171016379e-07
from O 0 5.243538225840894e-07
those O 0 1.0804801604535896e-06
described O 0 7.976956112543121e-05
in O 0 0.000712971726898104
DDS B-Disease 1 1.0
patients O 1 0.9584886431694031
. O 0 0.0001671075588092208

No O 0 0.00011342370271449909
WT1 O 0 0.008934753946959972
mutations O 0 0.00013604346895590425
were O 0 2.727177616179688e-06
detected O 0 2.866677732527023e-06
in O 0 2.3807632487660157e-07
the O 0 2.2919104480934038e-07
six O 0 6.842233801762632e-07
other O 0 1.3996216239320347e-06
IDMS B-Disease 1 0.9996727705001831
patients O 0 0.00026714205159805715
, O 0 7.469915885849332e-07
suggesting O 0 1.065784726961283e-05
genetic O 0 7.506110705435276e-06
heterogeneity O 0 1.8180444385507144e-05
of O 0 1.7405018297722563e-06
this O 0 3.445820038905367e-05
disease O 0 0.028261616826057434
. O 0 6.627069524256513e-05

We O 0 7.13108092895709e-05
analyzed O 0 0.00013217500236351043
genotype O 0 0.0011019879020750523
/ O 0 0.00017870546435005963
phenotype O 0 0.0003871090884786099
correlations O 0 1.3911361747886986e-05
, O 0 3.4263476322848874e-07
on O 0 1.3923164488005568e-07
the O 0 9.66217328368657e-08
basis O 0 1.2199696186598885e-07
of O 0 6.959734122347072e-08
the O 0 2.1660338234141818e-07
constitution O 0 2.910583702941949e-07
of O 0 1.3531122533549933e-07
a O 0 1.2395211115290294e-06
WT1 O 0 0.0043118540197610855
mutation O 0 4.344905391917564e-06
database O 0 6.336100000225997e-07
of O 0 1.536030254101206e-07
84 O 0 3.6638980418501887e-06
germ O 0 0.0003067623474635184
- O 0 0.0002005581045523286
line O 0 2.9701577659579925e-06
mutations O 0 1.6042347397160484e-06
, O 0 9.441301784818279e-08
to O 0 1.1242724440307938e-07
compare O 0 7.505041139665991e-07
the O 0 7.296522142041795e-08
distribution O 0 2.429213452614931e-07
and O 0 1.7850133815500158e-07
type O 0 5.706257866222586e-07
of O 0 1.4227595102056512e-07
mutations O 0 3.830423793260707e-06
, O 0 2.100941998151029e-07
according O 0 2.565975876223092e-07
to O 0 2.388317739132617e-07
the O 0 1.1756138746932265e-06
different O 0 8.652719770907424e-06
symptoms O 0 0.0005307889659889042
. O 0 6.190510612213984e-05

This O 0 5.5112974223447964e-05
demonstrated O 0 5.845403211424127e-05
( O 0 3.7439376683323644e-06
1 O 0 9.67201572166232e-07
) O 0 2.9346654173423303e-07
the O 0 1.920808472277713e-07
association O 0 5.370731059883838e-07
between O 0 2.867608088763518e-07
mutations O 0 2.2481606265500886e-06
in O 0 3.310248644083913e-07
exons O 0 2.897433887483203e-06
8 O 0 5.71695579765219e-07
and O 0 2.3836780371766508e-07
9 O 0 4.83889095903578e-07
and O 0 3.673578987672954e-07
DMS B-Disease 0 0.13199396431446075
; O 0 6.590091174984991e-07
( O 0 1.6811499392588303e-07
2 O 0 1.945994938523654e-07
) O 0 1.590906748560883e-07
among O 0 2.5308193585260597e-07
patients O 0 5.144986971572507e-06
with O 0 3.4098661672032904e-07
DMS B-Disease 1 0.6646935939788818
, O 0 2.3961453621268447e-07
a O 0 1.5419347221268254e-07
higher O 0 6.512184427265311e-07
frequency O 0 7.178700798249338e-07
of O 0 1.9773261783484486e-07
exon O 0 6.0189499890839215e-06
8 O 0 1.0829602388184867e-06
mutations O 0 1.8615778571984265e-06
among O 0 3.700026525166322e-07
46 O 0 1.6994034695017035e-06
, O 0 2.4072269297903404e-06
XY O 1 0.5485036373138428
patients O 0 2.1023035515099764e-05
with O 0 5.572222789851367e-07
female O 0 6.718013992212946e-06
phenotype O 0 0.0002339024213142693
than O 0 3.464733140390308e-07
among O 0 6.540921617670392e-07
46 O 0 6.860399025754305e-06
, O 0 7.2636789809621405e-06
XY O 1 0.9880870580673218
patients O 0 3.700353408930823e-05
with O 0 2.335594757596482e-07
sexual O 0 5.087929366709432e-07
ambiguity O 0 1.5479239436899661e-06
or O 0 1.4157809573589475e-06
male O 0 4.927938789478503e-06
phenotype O 0 0.00655296491459012
; O 0 1.0294214689565706e-06
and O 0 3.54900180354889e-07
( O 0 2.846491895525105e-07
3 O 0 2.5743537435118924e-07
) O 0 1.6798901469883276e-07
statistically O 0 3.3041047231563425e-07
significant O 0 1.7091100801280845e-07
evidence O 0 3.099464152001019e-07
that O 0 3.3249321518269426e-07
mutations O 0 1.391001433148631e-06
in O 0 1.4674301951345115e-07
exons O 0 1.9475894532661187e-06
8 O 0 4.561220521281939e-07
and O 0 2.1348454026792751e-07
9 O 0 6.229034283933288e-07
preferentially O 0 1.4511989547827397e-06
affect O 0 7.951781526571722e-07
amino O 0 8.715884973753418e-07
acids O 0 9.548436992190545e-07
with O 0 1.734426007260481e-07
different O 0 4.2783247522493184e-07
functions O 0 2.0685549770860234e-06
. O 0 9.274592230212875e-06
. O 0 3.0170662284945138e-05

The O 0 9.122488700086251e-05
185delAG O 0 0.0006061545573174953
BRCA1 O 0 0.0005951276398263872
mutation O 0 3.300113894511014e-05
originated O 0 3.910022769559873e-06
before O 0 6.091602244850947e-07
the O 0 2.578437374722853e-07
dispersion O 0 1.7486673868916114e-06
of O 0 1.4110925405930175e-07
Jews O 0 8.45015847517061e-07
in O 0 1.9388667737985088e-07
the O 0 2.8505121463240357e-07
diaspora O 0 2.295967306054081e-06
and O 0 4.330870524427155e-07
is O 0 3.273280810844881e-07
not O 0 5.570001917476475e-07
limited O 0 3.1072470392246032e-06
to O 0 5.84060308028711e-06
Ashkenazim O 0 0.00036132714012637734
. O 0 6.856833351776004e-05

The O 0 0.00010888714314205572
185delAG O 0 0.0005714368307963014
mutation O 0 0.00012512423563748598
in O 0 5.328226961864857e-06
BRCA1 O 0 0.0001489213900640607
is O 0 1.1804650057456456e-06
detected O 0 3.217538733224501e-06
in O 0 4.243088085331692e-07
Ashkenazi O 0 1.782296021701768e-05
Jews O 0 1.7621050574234687e-06
both O 0 3.685657361529593e-07
in O 0 1.14920567284571e-06
familial B-Disease 0 0.3000723421573639
breast I-Disease 1 0.9997866749763489
and I-Disease 1 0.9994660019874573
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999985694885254
and O 0 1.7632918343224446e-06
in O 0 1.0736987405834952e-06
the O 0 1.883467689367535e-06
general O 0 9.309703273174819e-06
population O 0 1.2180937119410373e-05
. O 0 2.9792539862683043e-05

All O 0 5.538166078622453e-05
tested O 0 0.00017929413297679275
Ashkenazi O 0 0.0003164541267324239
mutation O 0 4.7800607717363164e-05
carriers O 0 1.1364248166501056e-05
share O 0 2.2808476387581322e-06
the O 0 5.768556547991466e-07
same O 0 1.8512315591578954e-06
allelic O 0 2.263331407448277e-05
pattern O 0 1.0677053069230169e-05
at O 0 4.507200628722785e-06
the O 0 9.788241186470259e-06
BRCA1 O 0 0.005432134494185448
locus O 0 0.001127003226429224
. O 0 8.312241698149592e-05

Our O 0 7.82502320362255e-05
previous O 0 2.4744795155129395e-05
study O 0 1.0661557098501362e-05
showed O 0 5.115537987876451e-06
that O 0 3.442908393935795e-07
this O 0 5.455479481497605e-07
Ashkenazi O 0 0.005367619451135397
mutation O 0 6.603116162295919e-06
also O 0 5.519381716112548e-07
occurs O 0 3.0142339824124065e-07
in O 0 2.3001655335974647e-07
Iraqi O 0 9.834002412389964e-07
Jews O 0 1.353313905383402e-06
with O 0 2.989140455156303e-07
a O 0 2.2363824427884538e-06
similar O 0 1.0368216862843838e-05
allelic O 0 0.00033196466392837465
pattern O 0 0.00018936193373519927
. O 0 5.6980516092153266e-05

We O 0 2.8233804187038913e-05
extended O 0 6.613798632315593e-06
our O 0 1.7094146187446313e-06
analysis O 0 1.4109460835243226e-06
to O 0 3.7814825759596715e-07
other O 0 3.5314960200594214e-07
non O 0 1.459658847124956e-06
- O 0 7.310225555556826e-06
Ashkenazi O 0 7.283712420758093e-06
subsets O 0 1.2390057690936374e-06
354 O 0 1.8645663431016146e-06
of O 0 2.0241940035248263e-07
Moroccan O 0 3.853554517263547e-06
origin O 0 8.508737892043428e-07
, O 0 4.232047103869263e-07
200 O 0 6.014773248352867e-07
Yemenites O 0 1.8431814169161953e-05
and O 0 9.814120858209208e-07
150 O 0 2.9037239528406644e-06
Iranian O 0 1.789793896023184e-05
Jews O 0 3.8198428228497505e-05
. O 0 4.7527661081403494e-05

Heteroduplex O 0 0.0021257258486002684
analysis O 0 7.410831312881783e-05
complemented O 0 2.8484510039561428e-05
by O 0 2.6897610041487496e-06
direct O 0 3.880297299474478e-06
DNA O 0 9.52233313000761e-06
sequencing O 0 1.0518402632442303e-05
of O 0 1.3886821079722722e-06
abnormally O 0 4.6253415348473936e-05
migrating O 0 7.168971023929771e-06
bands O 0 1.0512125300010666e-05
were O 0 6.249721991480328e-06
employed O 0 6.163226498756558e-05
. O 0 4.5193555706646293e-05

Four O 0 2.9990256734890863e-05
of O 0 3.2550376545259496e-06
Moroccan O 0 2.8475002181949094e-05
origin O 0 3.432585344853578e-06
( O 0 6.511979790957412e-07
1 O 0 3.221064730496437e-07
. O 0 1.9755694324885553e-07
1 O 0 2.4610710624983767e-07
% O 0 1.9084725977336348e-07
) O 0 6.427169552125633e-08
and O 0 6.618655135071094e-08
none O 0 1.8188728745371918e-07
of O 0 4.347671733739844e-08
the O 0 2.575095550128026e-07
Yemenites O 0 5.2260642405599356e-05
or O 0 3.458019079971564e-07
Iranians O 0 5.169758310330508e-07
was O 0 3.2371394809160847e-07
a O 0 3.4544524396551424e-07
carrier O 0 3.0970377338235267e-06
of O 0 3.3168339541589376e-07
the O 0 3.3868534501380054e-06
185delAG O 0 0.0006940222810953856
mutation O 0 0.0001612147898413241
. O 0 4.301826993469149e-05

BRCA1 O 0 0.0074259997345507145
allelic O 0 0.0007361123571172357
patterns O 0 6.606071110581979e-05
were O 0 4.279233053239295e-06
determined O 0 3.066527824557852e-06
for O 0 2.409159947092121e-07
four O 0 1.8479177299468574e-07
of O 0 7.505772003923994e-08
these O 0 1.463969141468624e-07
individuals O 0 1.4553162941410847e-07
and O 0 7.610444896499757e-08
for O 0 1.5482132198485488e-07
12 O 0 4.2437838487785484e-07
additional O 0 4.2529728716544923e-07
non O 0 2.256395873700967e-06
- O 0 5.862317266291939e-05
Ashkenazi O 0 2.7386575311538763e-05
185delAG O 0 2.005073838518001e-05
mutation O 0 6.639557341259206e-06
carriers O 0 6.875502549519297e-06
who O 0 4.619236733560683e-06
had O 0 0.0018581526819616556
breast B-Disease 1 0.9999791383743286
/ I-Disease 1 0.9999873638153076
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999964237213135
. O 0 0.00021878707048017532

Six O 0 0.00020041015523020178
non O 0 0.0001460599305573851
- O 0 0.005142947658896446
Ashkenazi O 0 0.000356484844814986
individuals O 0 2.329931476197089e-06
shared O 0 1.6168213505807216e-06
the O 0 8.755515068514796e-07
common O 0 4.3113309402542654e-06
Ashkenazi O 0 0.02278536558151245
haplotype O 0 0.000179953858605586
, O 0 7.820099199307151e-07
four O 0 3.901229206348944e-07
had O 0 1.1809964917119942e-06
a O 0 3.121057829957863e-07
closely O 0 1.5148012835197733e-06
related O 0 1.6979795418592403e-06
pattern O 0 1.9569936284824507e-06
, O 0 3.2449409559376363e-07
and O 0 1.8253579980864743e-07
the O 0 2.3259788406448934e-07
rest O 0 1.3131150353729026e-06
( O 0 5.288122224555991e-07
n O 0 6.782569016650086e-06
= O 0 1.4315001862996724e-05
6 O 0 8.138785005940008e-07
) O 0 2.768545357412222e-07
displayed O 0 8.12831331131747e-07
a O 0 2.3402062652166933e-06
distinct O 0 2.2828822693554685e-05
BRCA1 O 0 0.0010052627185359597
allelic O 0 0.0005396022461354733
pattern O 0 0.00034025037894025445
. O 0 0.00022482970962300897

We O 0 3.257872594986111e-05
conclude O 0 2.123735612258315e-05
that O 0 1.1099833727712394e-06
the O 0 1.6049922351157875e-06
185delAG O 0 0.00026892550522461534
BRCA1 O 0 0.001979519845917821
mutation O 0 1.3945897990197409e-05
occurs O 0 1.2379119880279177e-06
in O 0 2.6261503194291436e-07
some O 0 2.265632303988241e-07
non O 0 2.031511257882812e-06
- O 0 0.00019231988699175417
Ashkenazi O 0 0.00011953244393225759
populations O 0 1.6815392882563174e-06
at O 0 5.202013539928885e-07
rates O 0 7.690216534683714e-07
comparable O 0 1.1389170140319038e-06
with O 0 2.8056450673830113e-07
that O 0 4.38033367800017e-07
of O 0 1.5349889963545138e-06
Ashkenazim O 0 0.0006242358358576894
. O 0 3.6562050809152424e-05

The O 0 3.324207864352502e-05
majority O 0 1.641728522372432e-05
of O 0 1.1678297369144275e-06
Jewish O 0 9.08821039047325e-06
185delAG O 0 0.00016062817303463817
mutation O 0 2.4656130335642956e-05
carriers O 0 8.127732144203037e-06
have O 0 5.820563160341408e-07
a O 0 5.556673841056181e-07
common O 0 1.4595070751965977e-06
allelic O 0 1.2337762200331781e-05
pattern O 0 4.3191089389438275e-06
, O 0 5.805965770377952e-07
supporting O 0 6.214497147993825e-07
the O 0 2.726964396515541e-07
founder O 0 3.606971176850493e-06
effect O 0 5.817339001623623e-07
notion O 0 7.068227887430112e-07
, O 0 2.174220981032704e-07
but O 0 2.5124944613708067e-07
dating O 0 6.720716783092939e-07
the O 0 2.46832456696211e-07
mutations O 0 1.146888962466619e-06
origin O 0 1.950911752146567e-07
to O 0 1.1953947876008897e-07
an O 0 8.395234374347638e-08
earlier O 0 7.659358516320935e-07
date O 0 1.4806993249294464e-06
than O 0 9.282275073019264e-07
currently O 0 2.3281900212168694e-06
estimated O 0 1.078776676877169e-05
. O 0 1.9876593796652742e-05

However O 0 7.307699706871063e-05
, O 0 3.0731205242773285e-06
the O 0 9.719794888951583e-07
different O 0 9.408545338374097e-07
allelic O 0 1.5470870494027622e-05
pattern O 0 3.876580194628332e-06
at O 0 1.0448330840517883e-06
the O 0 8.578147117077606e-07
BRCA1 O 0 7.647312304470688e-05
locus O 0 1.4183380699250847e-05
even O 0 6.643418828389258e-07
in O 0 1.4033410877800634e-07
some O 0 1.1538813282641058e-07
Jewish O 0 1.6843447383507737e-06
mutation O 0 2.7857361146743642e-06
carriers O 0 1.1554443517525215e-06
, O 0 1.6546093206670776e-07
might O 0 6.560631504726189e-07
suggest O 0 5.584490168075718e-07
that O 0 1.3687844102605595e-07
the O 0 6.403968768609047e-07
mutation O 0 1.1938825082324911e-05
arose O 0 8.507281563652214e-06
independently O 0 6.569962806679541e-06
. O 0 5.332639830157859e-06
. O 0 2.3428912754752673e-05

Crystal O 0 0.0014859061921015382
structure O 0 5.798633719678037e-05
of O 0 5.090937065688195e-06
the O 0 1.0450201443745755e-05
hemochromatosis B-Disease 1 0.9999790191650391
protein O 0 4.0414961404167116e-05
HFE O 0 0.030076708644628525
and O 0 1.1094562069047242e-06
characterization O 0 5.396070264396258e-06
of O 0 5.799380460302928e-07
its O 0 1.09347308807628e-06
interaction O 0 3.003484380315058e-06
with O 0 3.2064867809822317e-06
transferrin O 0 0.003009434789419174
receptor O 0 0.0002121772849932313
. O 0 6.68221473461017e-05

HFE O 1 0.7475179433822632
is O 0 5.132783917360939e-05
an O 0 8.642074135423172e-06
MHC O 0 0.0009857987752184272
- O 0 0.00011321828787913546
related O 0 2.6958418857248034e-06
protein O 0 1.130178020503081e-06
that O 0 1.4305692275229376e-07
is O 0 2.2513437158977467e-07
mutated O 0 1.9721201169886626e-06
in O 0 3.427740011829883e-07
the O 0 1.8632297269505216e-06
iron B-Disease 1 0.9600035548210144
- I-Disease 1 0.9998842477798462
overload I-Disease 1 0.9995043277740479
disease I-Disease 1 0.9997279047966003
hereditary B-Disease 1 0.9999995231628418
hemochromatosis I-Disease 1 1.0
. O 0 0.0017399364151060581

HFE O 0 0.014889750629663467
binds O 0 0.00028790070791728795
to O 0 2.517725806683302e-05
transferrin O 0 0.00021722333622165024
receptor O 0 3.83307778974995e-05
( O 0 3.053794898733031e-06
TfR O 0 2.0636447516153567e-05
) O 0 5.354142444957688e-07
and O 0 1.83854325541688e-07
reduces O 0 6.351903607537679e-07
its O 0 1.404145706374038e-07
affinity O 0 1.0409314654680202e-06
for O 0 4.0714110127737513e-07
iron O 0 2.293330180691555e-05
- O 0 3.207362169632688e-05
loaded O 0 4.8939646148937754e-06
transferrin O 0 2.8376949558150955e-05
, O 0 2.7537566893443e-06
implicating O 0 5.876792420167476e-05
HFE O 0 0.12702427804470062
in O 0 7.224776254588505e-06
iron O 0 0.0018616261659190059
metabolism O 0 0.001110803452320397
. O 0 9.955689893104136e-05

The O 0 0.00028376647969707847
2 O 0 0.00024452220532111824
. O 0 0.0002641806786414236

6 O 0 0.00022589205764234066
A O 0 2.1928966816631146e-05
crystal O 0 3.094127168878913e-05
structure O 0 5.401460839493666e-06
of O 0 1.4906112255630433e-06
HFE O 0 0.03651348873972893
reveals O 0 8.64261710376013e-06
the O 0 7.91466447935818e-07
locations O 0 1.2659224921662826e-06
of O 0 1.1236909358558478e-06
hemochromatosis B-Disease 1 0.9999990463256836
mutations O 0 6.167789251776412e-05
and O 0 1.0436609727548785e-06
a O 0 1.0311567848475534e-06
patch O 0 4.2462899727979675e-05
of O 0 3.037307294562197e-07
histidines O 0 0.0002541840076446533
that O 0 3.3069511573557975e-07
could O 0 5.359987085284956e-07
be O 0 2.1186278331697395e-07
involved O 0 9.565882237438927e-07
in O 0 1.658013388805557e-06
pH O 0 0.00012924316979479045
- O 0 0.0001365149364573881
dependent O 0 2.2019032257958315e-05
interactions O 0 2.4612296328996308e-05
. O 0 3.129807737423107e-05

We O 0 3.524764542817138e-05
also O 0 3.3452638490416575e-06
demonstrate O 0 4.644477485271636e-06
that O 0 8.894251664059993e-07
soluble O 0 1.2413733202265576e-05
TfR O 0 2.1476324036484584e-05
and O 0 1.1411196965127601e-06
HFE O 0 0.00018005767196882516
bind O 0 3.7380152662080945e-06
tightly O 0 2.603398343126173e-06
at O 0 3.0033874054424814e-07
the O 0 1.8828755798949715e-07
basic O 0 6.577138833563367e-07
pH O 0 1.6221341638811282e-06
of O 0 8.564474285321921e-08
the O 0 2.114477837267259e-07
cell O 0 5.4152483244251925e-06
surface O 0 1.01310934041976e-06
, O 0 2.1039656417087826e-07
but O 0 1.9019024932731554e-07
not O 0 2.686720392830466e-07
at O 0 3.6686390103568556e-07
the O 0 1.0238486538582947e-06
acidic O 0 7.43155978852883e-05
pH O 0 1.763838554325048e-05
of O 0 2.835212399077136e-06
intracellular O 0 7.707822805969045e-05
vesicles O 0 0.0005057980306446552
. O 0 6.850212230347097e-05

TfR O 1 0.6432912945747375
HFE O 1 0.8903788328170776
stoichiometry O 0 0.0014802782097831368
( O 0 3.144140646327287e-05
2 O 0 4.86747103423113e-06
1 O 0 1.4210769450073713e-06
) O 0 6.174892632770934e-07
differs O 0 1.6547434142921702e-06
from O 0 6.244784458431241e-07
TfR O 0 3.1602354283677414e-05
transferrin O 0 4.027944669360295e-05
stoichiometry O 0 1.1006294698745478e-05
( O 0 4.7460002861043904e-07
2 O 0 3.129558194814308e-07
2 O 0 3.0435586495514144e-07
) O 0 1.3145782418177987e-07
, O 0 6.841217015107759e-08
implying O 0 4.639792337002291e-07
a O 0 1.1593036930435119e-07
different O 0 1.0848109610606116e-07
mode O 0 4.689634351962013e-07
of O 0 9.07227146740297e-08
binding O 0 4.7633446342842944e-07
for O 0 3.774654544486111e-07
HFE O 0 0.00033709558192640543
and O 0 5.010041377317975e-07
transferrin O 0 1.35761301862658e-05
to O 0 4.592135383063578e-07
TfR O 0 1.4453962648985907e-05
, O 0 3.8507371868945484e-07
consistent O 0 5.903975193177757e-07
with O 0 1.7468393309627572e-07
our O 0 4.722747632968094e-07
demonstration O 0 9.61883984018641e-07
that O 0 4.06800353403014e-07
HFE O 0 0.00027720830985344946
, O 0 8.080517659436737e-07
transferrin O 0 2.7289877834846266e-05
, O 0 7.447644634339667e-07
and O 0 8.501162938046036e-07
TfR O 0 7.76573215262033e-05
form O 0 3.0194869395927526e-06
a O 0 3.667760893222294e-06
ternary O 0 0.00015274487668648362
complex O 0 0.00010230864427285269
. O 0 7.13435874786228e-05

Identification O 0 7.378057489404455e-05
of O 0 5.3528578973782714e-06
three O 0 3.562821120794979e-06
novel O 0 1.347258785244776e-05
mutations O 0 1.0949916031677276e-05
and O 0 5.455817699839827e-07
a O 0 4.628160752417898e-07
high O 0 6.554290621352266e-07
frequency O 0 6.945332415853045e-07
of O 0 2.0539459910651203e-07
the O 0 8.377285780625243e-07
Arg778Leu O 0 0.0010871192207559943
mutation O 0 1.5148538295761682e-05
in O 0 1.7831262084655464e-06
Korean O 0 2.3430520741385408e-05
patients O 0 5.3555337217403576e-05
with O 0 7.973264473548625e-06
Wilson B-Disease 1 0.6934528946876526
disease I-Disease 0 0.0197078175842762
. O 0 5.909837273065932e-05

Four O 0 7.300678407773376e-05
mutations O 0 0.00024557497818022966
- O 0 0.0004799757443834096
- O 0 6.034845137037337e-05
R778L O 0 2.5054290745174512e-05
, O 0 8.320611186718452e-07
A874V O 0 6.2502049331669696e-06
, O 0 4.5834198658667447e-07
L1083F O 0 3.7054044241813244e-06
, O 0 2.3558580153348885e-07
and O 0 2.4626723416076857e-07
2304delC O 0 1.1453661500127055e-05
- O 0 7.542990351794288e-05
- O 0 3.7887557482463308e-06
in O 0 1.7461266565987899e-07
the O 0 2.5337075726383773e-07
copper O 0 3.7443589917529607e-06
- O 0 5.706111551262438e-06
transporting O 0 1.1649954103631899e-06
enzyme O 0 2.0635245618905174e-06
, O 0 5.868424182153831e-07
P O 0 0.00036256376188248396
- O 0 6.479949661297724e-05
type O 0 4.019423613499384e-06
ATPase O 0 3.3398737286916e-05
( O 0 4.554174779514142e-07
ATP7B O 0 7.587841992062749e-06
) O 0 1.4834311912181875e-07
, O 0 5.8444644679411795e-08
were O 0 1.312731399139011e-07
identified O 0 5.317884301803133e-07
in O 0 4.879611310570908e-07
Korean O 0 1.2497010175138712e-05
Patients O 0 3.638896669144742e-05
with O 0 1.0124302207259461e-05
Wilson B-Disease 1 0.705809473991394
disease I-Disease 0 0.010481225326657295
. O 0 5.3004765504738316e-05

Arg778Leu O 0 0.006634761579334736
, O 0 1.1417268979130313e-05
the O 0 1.8294550727659953e-06
most O 0 1.115465238399338e-06
frequently O 0 3.214584921806818e-06
reported O 0 4.166692633589264e-06
mutation O 0 2.186131496273447e-06
of O 0 1.4096910661010043e-07
this O 0 1.9911610138478864e-07
enzyme O 0 2.8517949886008864e-06
, O 0 4.436412268660206e-07
was O 0 6.000661869620671e-07
found O 0 1.999051306711408e-07
in O 0 1.1641675712326105e-07
six O 0 1.7279441522077832e-07
of O 0 1.3148138577889767e-07
eight O 0 1.0202733164987876e-06
unrelated O 0 0.00022415311832446605
patients O 0 6.661144288955256e-05
studied O 0 2.86001750282594e-06
, O 0 2.544555854910868e-07
an O 0 2.628535469284543e-07
allele O 0 6.892585133755347e-06
frequency O 0 3.61461570719257e-06
of O 0 2.107308091581217e-06
37 O 0 2.683686398086138e-05
. O 0 3.581991040846333e-05

5 O 0 0.0001291845110245049
% O 0 1.1431192433519755e-05
, O 0 9.799044846658944e-07
which O 0 2.941709738024656e-07
is O 0 2.1041442721525527e-07
considerably O 0 1.5345514157161233e-06
higher O 0 8.2396093148418e-07
than O 0 1.7699066745535674e-07
those O 0 1.8392569245406776e-07
in O 0 3.6191750041325577e-07
other O 0 9.122432516051049e-07
Asian O 0 2.270121331093833e-05
populations O 0 4.628854003385641e-05
. O 0 3.0813072953606024e-05

The O 0 3.8476868212455884e-05
novel O 0 4.448409890756011e-05
single O 0 9.613945621822495e-06
nucleotide O 0 1.9291192074888386e-05
deletion O 0 2.3646760382689536e-05
, O 0 1.3265172356113908e-06
2304delC O 0 1.5641266145394184e-05
, O 0 9.829923328652512e-07
was O 0 9.519804962110356e-07
found O 0 1.0141957318410277e-06
in O 0 1.2714929198409664e-06
one O 0 4.683935912908055e-06
patient O 0 0.0002529843186493963
. O 0 7.071786239976063e-05

Since O 0 0.00024056235270109028
a O 0 4.5499673433369026e-05
mutation O 0 7.544738036813214e-05
at O 0 7.604837264807429e-06
cDNA O 0 4.8588935896987095e-05
nucleotide O 0 4.727361738332547e-05
2302 O 0 0.00034959951881319284
( O 0 1.3086756780467113e-06
2302insC O 0 6.34548268863e-06
) O 0 3.9308824284489674e-07
had O 0 2.8886881864309544e-07
been O 0 2.448653617648233e-07
previously O 0 7.156185120038572e-07
described O 0 1.8960326997330412e-06
, O 0 2.415085589291266e-07
this O 0 9.204002537899214e-08
region O 0 2.1322001941825874e-07
of O 0 7.852894867710347e-08
the O 0 4.783826170751126e-07
ATP7B O 0 0.03088553622364998
gene O 0 6.104365638748277e-06
may O 0 1.7228004480784875e-06
be O 0 3.637760812580382e-07
susceptible O 0 4.142792022321373e-06
to O 0 1.264221396013454e-06
gene O 0 1.2509077350841835e-05
rearrangements O 0 0.00017637373821344227
causing O 0 0.0008930217009037733
Wilson B-Disease 0 0.39465492963790894
disease I-Disease 0 0.01558191142976284
. O 0 8.364769018953666e-05

Disruption O 0 0.0005468594026751816
of O 0 1.2125582543376368e-05
splicing O 0 0.00012140601029386744
regulated O 0 2.743561526585836e-05
by O 0 2.3622299067938e-06
a O 0 5.899280949961394e-06
CUG O 0 0.0017130742780864239
- O 0 0.00010927095718216151
binding O 0 1.474167947890237e-05
protein O 0 2.616799611132592e-05
in O 0 4.603607885655947e-05
myotonic B-Disease 1 0.9999904632568359
dystrophy I-Disease 1 0.9999992847442627
. O 0 0.000729881867300719

Myotonic B-Disease 1 0.9999994039535522
dystrophy I-Disease 1 0.9999998807907104
( O 1 0.8878717422485352
DM B-Disease 1 0.9999998807907104
) O 0 2.797276829369366e-05
is O 0 8.071598927017476e-07
caused O 0 2.5161491521430435e-06
by O 0 3.594117856664525e-07
a O 0 9.685750228527468e-07
CTG O 0 2.5300343622802757e-05
expansion O 0 1.1554741377040045e-06
in O 0 1.4941281278879615e-07
the O 0 2.8219415071362164e-07
3 O 0 7.953927934067906e-07
untranslated O 0 1.2011388207611162e-05
region O 0 1.6239545175267267e-06
of O 0 5.718744091609551e-07
the O 0 9.193576261168346e-06
DM B-Disease 1 0.9999853372573853
gene O 0 0.00017415682668797672
. O 0 6.227748235687613e-05

One O 0 4.8259873437928036e-05
model O 0 2.3535645595984533e-05
of O 0 4.4186290324432775e-06
DM B-Disease 1 0.9999868869781494
pathogenesis O 0 0.004726908635348082
suggests O 0 9.252550626115408e-06
that O 0 4.821800985155278e-07
RNAs O 0 2.999482603627257e-06
from O 0 1.1528078402989195e-07
the O 0 1.0195483213237821e-07
expanded O 0 5.697981464436452e-07
allele O 0 2.0035186025779694e-06
create O 0 4.6435593503701966e-07
a O 0 5.042983843850379e-07
gain O 0 4.4597195483220275e-06
- O 0 4.502118372329278e-06
of O 0 1.699581986258636e-07
- O 0 1.0735741852840874e-05
function O 0 5.199592578719603e-07
mutation O 0 9.674064358478063e-07
by O 0 1.2342630384409858e-07
the O 0 1.8908956178620429e-07
inappropriate O 0 6.340512754832162e-07
binding O 0 4.0606545326227206e-07
of O 0 8.555363706364005e-08
proteins O 0 5.086566261525149e-07
to O 0 5.077488367533078e-07
the O 0 2.036467321886448e-06
CUG O 0 0.0005602348246611655
repeats O 0 9.109415259445086e-05
. O 0 5.4507087043020874e-05

Data O 0 0.00011619246652116999
presented O 0 2.098203549394384e-05
here O 0 2.711048182391096e-06
indicate O 0 2.040904064415372e-06
that O 0 2.520120858662267e-07
the O 0 3.9750491964696266e-07
conserved O 0 2.4793569082248723e-06
heterogeneous O 0 7.205683232314186e-06
nuclear O 0 9.384812983626034e-06
ribonucleoprotein O 0 3.0048257031012326e-05
, O 0 7.044627068353293e-07
CUG O 0 2.473981658113189e-05
- O 0 5.829239853483159e-06
binding O 0 1.5194790421446669e-06
protein O 0 1.4526070799547597e-06
( O 0 5.457966949506954e-07
CUG O 0 1.9740677089430392e-05
- O 0 1.2053984391968697e-05
BP O 0 4.211784471408464e-05
) O 0 4.096899886008032e-07
, O 0 2.1792403970266605e-07
may O 0 3.1701409852757934e-07
mediate O 0 1.1208353498659562e-06
the O 0 5.984100539535575e-07
trans O 0 6.866197509225458e-06
- O 0 2.555825085437391e-05
dominant O 0 2.9466448268067325e-06
effect O 0 8.756892952987982e-07
of O 0 2.823553870712203e-07
the O 0 2.815309471770888e-06
RNA O 0 4.375481148599647e-05
. O 0 4.539535439107567e-05

CUG O 0 0.3117366135120392
- O 0 0.13069294393062592
BP O 0 0.00047503283713012934
was O 0 2.796337867039256e-06
found O 0 6.428420533666213e-07
to O 0 2.2441882663315482e-07
bind O 0 1.5909141666270443e-06
to O 0 3.2887132306314015e-07
the O 0 1.1087370239692973e-06
human O 0 6.301297617028467e-06
cardiac O 1 0.8411684632301331
troponin O 1 0.9963524341583252
T O 0 0.21345436573028564
( O 0 1.7319644030067138e-06
cTNT O 0 1.4502011254080571e-05
) O 0 6.787809070374351e-07
pre O 0 6.928905804670649e-06
- O 0 1.130888267653063e-05
messenger O 0 6.5228832681896165e-06
RNA O 0 2.882385842895019e-06
and O 0 3.78919338572814e-07
regulate O 0 2.994652277266141e-06
its O 0 1.9251085632276954e-06
alternative O 0 1.487433928559767e-05
splicing O 0 0.00014340406050905585
. O 0 4.19067800976336e-05

Splicing O 0 0.0009943429613485932
of O 0 3.0892391805537045e-05
cTNT O 0 0.00036003152490593493
was O 0 2.3606449758517556e-05
disrupted O 0 0.00011145204189233482
in O 0 7.252133855217835e-06
DM B-Disease 1 0.9999790191650391
striated O 0 0.008604590781033039
muscle O 0 0.00010807779472088441
and O 0 7.751595489935426e-07
in O 0 6.667054890385771e-07
normal O 0 4.169764906691853e-06
cells O 0 8.334506674145814e-06
expressing O 0 4.4830226215708535e-06
transcripts O 0 1.1583279956539627e-05
that O 0 2.219615453213919e-06
contain O 0 1.4316367014544085e-05
CUG O 0 0.00042006996227428317
repeats O 0 0.00011026975698769093
. O 0 5.5589291150681674e-05

Altered O 0 0.000519586552400142
expression O 0 4.9837522965390235e-05
of O 0 5.360765953810187e-06
genes O 0 2.24439336307114e-05
regulated O 0 1.0243086762784515e-05
posttranscriptionally O 0 3.441977241891436e-05
by O 0 2.6303562208340736e-06
CUG O 0 0.004315953701734543
- O 0 0.0006404045270755887
BP O 0 0.00012511374370660633
therefore O 0 1.9416622762946645e-06
may O 0 2.7795131245511584e-06
contribute O 0 2.505345264580683e-06
to O 0 4.375501248432556e-06
DM B-Disease 1 0.999945878982544
pathogenesis O 0 0.008996346965432167
. O 0 1.599692041054368e-05
. O 0 3.90923123632092e-05

Identification O 0 8.377988706342876e-05
of O 0 5.473571036418434e-06
a O 0 3.911342901119497e-06
novel O 0 1.7709324310999364e-05
nonsense O 0 4.9942187615670264e-05
mutation O 0 1.7133646906586364e-05
and O 0 9.291663900512503e-07
a O 0 1.3332759181139409e-06
missense O 0 1.3780926565232221e-05
substitution O 0 2.5120396003330825e-06
in O 0 8.008266263459518e-07
the O 0 1.0263885314998333e-06
vasopressin O 0 2.0315719666541554e-05
- O 0 6.1324484704528e-05
neurophysin O 0 4.948055720888078e-05
II O 0 1.337090816377895e-05
gene O 0 2.5473389086982934e-06
in O 0 5.586152269643208e-07
two O 0 6.459318910856382e-07
Spanish O 0 7.264621672220528e-06
kindreds O 0 9.111994586419314e-05
with O 0 1.0932417353615165e-05
familial B-Disease 1 0.9903600215911865
neurohypophyseal I-Disease 1 0.9999829530715942
diabetes I-Disease 1 0.9999964237213135
insipidus I-Disease 1 0.9997503161430359
. O 0 0.000290980824502185

Familial B-Disease 1 0.9998918771743774
neurohypophyseal I-Disease 1 0.9999943971633911
diabetes I-Disease 1 0.9999998807907104
insipidus I-Disease 1 0.9999972581863403
( O 0 0.07288142293691635
FNDI B-Disease 1 0.999997615814209
) O 0 1.1052658919652458e-05
is O 0 8.492249321534473e-07
an O 0 1.8406553863314912e-06
autosomal B-Disease 1 0.8761261105537415
dominant I-Disease 1 0.998891294002533
disease I-Disease 1 0.9856334328651428
caused O 0 0.005029012914747
by O 0 0.0007966490811668336
deficiency O 1 0.9509379863739014
in O 0 1.2699102853730437e-06
the O 0 2.308054945387994e-06
antidiuretic O 0 0.0004884041263721883
hormone O 0 2.317297548870556e-05
arginine O 0 1.7738380847731605e-05
vasopressin O 0 2.9731407266808674e-05
( O 0 1.065717015080736e-06
AVP O 0 6.377624686138006e-06
) O 0 2.2846849390134594e-07
encoded O 0 2.3953364802764554e-07
by O 0 1.441376866750943e-07
the O 0 3.4116712299692153e-07
AVP O 0 5.7390225265407935e-05
- O 0 0.0001406543597113341
neurophysin O 0 0.00011937980161746964
II O 0 5.127256372361444e-05
( O 0 1.1363554222043604e-06
AVP O 0 1.9897626771125942e-05
- O 0 3.0762686947127804e-05
NPII O 0 5.1976840040879324e-05
) O 0 9.516836598777445e-07
gene O 0 3.110137640760513e-06
on O 0 2.980406634378596e-06
chromosome O 0 5.40978871867992e-05
20p13 O 0 0.0003074380801990628
. O 0 4.9588918045628816e-05

In O 0 1.9424442143645138e-05
this O 0 2.442525101287174e-06
study O 0 3.196039415342966e-06
, O 0 4.421599442139268e-07
we O 0 2.9897731224082236e-07
analyzed O 0 1.1156098480569199e-06
two O 0 2.2819739342594403e-07
families O 0 7.482329351660155e-07
with O 0 2.8997507683925505e-07
FNDI B-Disease 1 0.6375243663787842
using O 0 5.324014296093083e-07
direct O 0 4.55673813348767e-07
automated O 0 2.7044141006626887e-06
fluorescent O 0 5.056847385276342e-06
, O 0 2.9458365702339506e-07
solid O 0 8.980386496659776e-07
phase O 0 1.3703717058888287e-06
, O 0 3.3042746849787363e-07
single O 0 6.989092753428849e-07
- O 0 6.281965397647582e-06
stranded O 0 1.5133833812797093e-06
DNA O 0 1.7697053635856719e-06
sequencing O 0 2.041511379502481e-06
of O 0 3.7158577015361516e-07
PCR O 0 3.885815021931194e-05
- O 0 2.7091642550658435e-05
amplified O 0 3.439119245740585e-05
AVP O 0 0.0002301858621649444
- O 0 0.00015030747454147786
NPII O 0 0.0003839284763671458
DNA O 0 0.0001582109834998846
. O 0 7.758240826660767e-05

In O 0 2.1154080968699418e-05
one O 0 1.5290718238247791e-06
of O 0 4.800122610504332e-07
the O 0 7.920826305962692e-07
families O 0 3.035676172657986e-06
, O 0 7.055660944388364e-07
affected O 0 1.6088725942609017e-06
individuals O 0 4.18739602991991e-07
presented O 0 7.120431746443501e-07
a O 0 4.0797056044539204e-07
novel O 0 5.342194071999984e-06
nonsense O 0 1.5988867744454183e-05
mutation O 0 5.928427526669111e-06
in O 0 5.080549385638733e-07
exon O 0 4.514828106039204e-06
3 O 0 4.1995855326604214e-07
of O 0 7.920662170590731e-08
the O 0 2.4021352373893023e-07
gene O 0 8.740406087781594e-07
, O 0 1.2731804588383966e-07
consisting O 0 2.1918462778103276e-07
in O 0 2.244783416927021e-07
a O 0 9.039209203365317e-07
G O 0 0.0003034243418369442
to O 0 1.2463201528589707e-06
T O 0 6.496631249319762e-05
transition O 0 2.817517270159442e-06
at O 0 7.298525588339544e-07
nucleotide O 0 3.39922394232417e-06
2101 O 0 1.374399562337203e-05
, O 0 2.7714088446373353e-07
which O 0 1.41793194075035e-07
produces O 0 4.330077558734047e-07
a O 0 3.5022796396333433e-07
stop O 0 1.7150906614915584e-06
signal O 0 2.866825298042386e-06
in O 0 1.0253212394673028e-06
codon O 0 8.930152034736238e-06
82 O 0 1.1328410437272396e-05
( O 0 4.250785423209891e-06
Glu O 0 0.00010444543295307085
) O 0 1.7235054201591993e-06
of O 0 2.106709416693775e-06
NPII O 0 0.0005222666659392416
. O 0 4.261307913111523e-05

The O 0 0.00010294571256963536
premature O 0 0.00041986972792074084
termination O 0 8.82634412846528e-05
eliminates O 0 1.8149696188629605e-05
part O 0 1.3471615147864213e-06
of O 0 2.6644650574780826e-07
the O 0 7.956386411933636e-07
C O 0 0.0010009113466367126
- O 0 0.00021073974494356662
terminal O 0 3.8305001908156555e-06
domain O 0 2.9628995434904937e-07
of O 0 7.929732248612709e-08
NPII O 0 0.00012739459634758532
, O 0 1.8093092535309552e-07
including O 0 9.322412353185427e-08
a O 0 1.2550781036679837e-07
cysteine O 0 5.558105158343096e-07
residue O 0 9.931114846040145e-07
in O 0 1.2943246474605985e-07
position O 0 5.267601181913051e-07
85 O 0 4.570116232116561e-07
, O 0 8.340045098975679e-08
which O 0 7.967330617475454e-08
could O 0 1.2288685979910952e-07
be O 0 6.266309071634169e-08
involved O 0 1.6780296618890134e-07
in O 0 1.8923226718925434e-07
the O 0 4.3908318048124784e-07
correct O 0 1.2753458577208221e-05
folding O 0 1.682063339103479e-05
of O 0 1.2468266277210205e-06
the O 0 9.30986334424233e-06
prohormone O 0 0.016348255798220634
. O 0 6.704332190565765e-05

In O 0 2.3520677132182755e-05
the O 0 5.686175427399576e-06
second O 0 7.0525384217035025e-06
family O 0 3.478643066046061e-06
, O 0 1.8938158063974697e-07
a O 0 1.4257109626214515e-07
G279A O 0 1.976712610485265e-06
substitution O 0 4.439167469172389e-07
at O 0 2.8948466024303343e-07
position O 0 6.062612669666123e-07
- O 0 1.7052625480573624e-06
1 O 0 6.47961755362303e-08
of O 0 2.533049681119337e-08
the O 0 8.360957082231835e-08
signal O 0 6.889600854265154e-07
peptide O 0 1.228669816555339e-06
was O 0 5.13128782131389e-07
observed O 0 5.222831305218278e-07
in O 0 3.1441871328752313e-07
all O 0 7.88245529292908e-07
affected O 0 9.730406418384518e-06
individuals O 0 8.709555913810618e-06
. O 0 2.5193927285727113e-05

This O 0 8.431374590145424e-05
missense O 0 0.0007571100140921772
mutation O 0 0.00014154476230032742
, O 0 3.6253247799322708e-06
which O 0 1.6765113741712412e-06
replaces O 0 2.5318930056528188e-05
Ala O 0 0.00012992499978281558
with O 0 1.2479663382691797e-06
Thr O 0 0.0003489116206765175
, O 0 5.486921850206272e-07
is O 0 1.89501534464398e-07
frequent O 0 1.5480522961297538e-06
among O 0 2.775010898403707e-06
FNDI B-Disease 1 0.9999994039535522
patients O 0 0.003327838843688369
and O 0 4.79781590456696e-07
is O 0 2.442156414872443e-07
thought O 0 6.739907689734537e-07
to O 0 1.4056126929062884e-07
reduce O 0 5.866097012585669e-07
the O 0 2.27111414119463e-07
efficiency O 0 1.435550871065061e-06
of O 0 3.097596561474347e-07
cleavage O 0 1.083855295291869e-05
by O 0 1.4044793488210416e-06
signal O 0 1.8896147594205104e-05
peptidases O 0 0.00018429328338243067
. O 0 1.0771020242827944e-05
. O 0 3.5214590752730146e-05

Genetic O 0 0.000916205404791981
heterogeneity O 0 0.00040820788126438856
of O 0 2.0842970116063952e-05
Saethre B-Disease 1 0.9703271389007568
- I-Disease 1 0.999927282333374
Chotzen I-Disease 1 0.9999589920043945
syndrome I-Disease 1 0.9999709129333496
, O 0 1.3512852774510975e-06
due O 0 1.7980491975322366e-06
to O 0 1.202703288072371e-06
TWIST O 0 8.068438910413533e-05
and O 0 1.7326552551821806e-05
FGFR O 0 0.38034889101982117
mutations O 0 0.0002705021179281175
. O 0 4.842782436753623e-05

Thirty O 0 0.0004257284745108336
- O 0 0.0055992575362324715
two O 0 7.477809958800208e-06
unrelated O 0 0.00010880743502639234
patients O 0 2.7252295694779605e-05
with O 0 2.758582979822677e-07
features O 0 1.3594791425930453e-06
of O 0 9.328973078481795e-07
Saethre B-Disease 1 0.9980660080909729
- I-Disease 1 0.9999316930770874
Chotzen I-Disease 1 0.9999761581420898
syndrome I-Disease 1 0.9999775886535645
, O 0 1.7894428765430348e-06
a O 0 1.8793624576574075e-06
common O 0 3.8197114918148145e-05
autosomal B-Disease 1 0.5205291509628296
dominant I-Disease 0 0.05813061073422432
condition I-Disease 0 0.0009857359109446406
of O 0 1.0851105116671533e-06
craniosynostosis B-Disease 1 0.9979100823402405
and O 0 7.333458779612556e-05
limb B-Disease 1 0.9568586945533752
anomalies I-Disease 0 0.0047453343868255615
, O 0 3.9149449548858684e-07
were O 0 2.5024294814102177e-07
screened O 0 1.2128068647143664e-06
for O 0 4.064280858528946e-07
mutations O 0 2.8668800950981677e-06
in O 0 4.30881385682369e-07
TWIST O 0 2.992528970935382e-05
, O 0 1.4397849099623272e-06
FGFR2 O 0 0.00039538086275570095
, O 0 2.0669949662988074e-06
and O 0 9.22992876439821e-06
FGFR3 O 0 0.008545332588255405
. O 0 7.094034663168713e-05

Nine O 0 0.00012093816621927544
novel O 0 4.538080975180492e-05
and O 0 4.5771439545205794e-06
three O 0 2.924556156358449e-06
recurrent O 0 8.179778524208814e-05
TWIST O 0 0.010191818699240685
mutations O 0 5.2446714107645676e-05
were O 0 1.1094372212028247e-06
found O 0 8.777059292697231e-07
in O 0 1.0529906830925029e-06
12 O 0 5.069000053481432e-06
families O 0 2.5716799427755177e-05
. O 0 4.112120222998783e-05

Seven O 0 6.629914423683658e-05
families O 0 2.3006639821687713e-05
were O 0 1.5983126786522917e-06
found O 0 7.628573257534299e-07
to O 0 3.2842280006661895e-07
have O 0 2.800950369419297e-07
the O 0 3.945567641494563e-07
FGFR3 O 0 0.0012879768619313836
P250R O 0 0.00010728877532528713
mutation O 0 2.8463173293857835e-06
, O 0 1.459775660350715e-07
and O 0 9.544233137148694e-08
one O 0 9.38793434102081e-08
individual O 0 1.758814818231258e-07
was O 0 5.207294293541054e-07
found O 0 2.1345074685541476e-07
to O 0 1.5508732076341403e-07
have O 0 2.653480351000326e-07
an O 0 3.3285013500972127e-07
FGFR2 O 0 0.000836299906950444
VV269 O 0 0.00022641730902250856
- O 0 0.00012199599586892873
270 O 0 6.186042446643114e-05
deletion O 0 0.000208597892196849
. O 0 5.1715102017624304e-05

To O 0 2.2520409402204677e-05
date O 0 1.1844110304082278e-05
, O 0 9.606097819414572e-07
our O 0 8.735839287510316e-07
detection O 0 3.3352580430801027e-06
rate O 0 1.0028132919615018e-06
for O 0 2.8421192155292374e-07
TWIST O 0 1.9761660951189697e-05
or O 0 2.241429911009618e-06
FGFR O 0 0.015297014266252518
mutations O 0 3.699860826600343e-06
is O 0 1.820686463815946e-07
68 O 0 1.2250567351657082e-06
% O 0 3.038593661131017e-07
in O 0 1.995017555600498e-07
our O 0 1.5320860029532923e-06
Saethre B-Disease 0 0.4878424406051636
- I-Disease 1 0.9993410706520081
Chotzen I-Disease 1 0.9999861717224121
syndrome I-Disease 1 0.9999969005584717
patients O 0 6.437845149775967e-05
, O 0 1.8641027565990953e-07
including O 0 1.532810784965477e-07
our O 0 4.308961649712728e-07
five O 0 2.0022273474751273e-06
patients O 0 0.00016430290997959673
elsewhere O 0 6.54601581118186e-06
reported O 0 4.70667919216794e-06
with O 0 1.4567399375664536e-06
TWIST O 0 0.026982147246599197
mutations O 0 0.0004119328805245459
. O 0 5.280206460156478e-05

More O 0 2.1639081751345657e-05
than O 0 4.705188985099085e-06
35 O 0 3.584267687983811e-06
different O 0 1.0378140586908557e-06
TWIST O 0 4.127902866457589e-05
mutations O 0 1.1310316949675325e-05
are O 0 4.228670320571837e-07
now O 0 6.471552183029416e-07
known O 0 7.131420716177672e-07
in O 0 3.908021426468622e-07
the O 0 1.8181182213083957e-06
literature O 0 2.6940355382976122e-05
. O 0 4.677951437770389e-05

The O 0 2.707159728743136e-05
most O 0 3.3706908197927987e-06
common O 0 1.8059008652926423e-06
phenotypic O 0 5.5303012231888715e-06
features O 0 1.0061719422083115e-06
, O 0 3.1899261898615805e-07
present O 0 1.7730727108755673e-07
in O 0 1.0986707366100745e-07
more O 0 5.669037506095265e-08
than O 0 5.5534854936922784e-08
a O 0 1.1715315650917546e-07
third O 0 3.207876773103635e-07
of O 0 1.1790367437924942e-07
our O 0 2.1707994619646342e-06
patients O 0 1.4290490071289241e-05
with O 0 4.4972983914703946e-07
TWIST O 0 0.08479151874780655
mutations O 0 1.7827380361268297e-05
, O 0 3.579716576496139e-07
are O 0 2.1290507845606044e-07
coronal B-Disease 0 3.166751048411243e-05
synostosis I-Disease 0 0.00012005699682049453
, O 0 1.2523177019829745e-06
brachycephaly B-Disease 0 6.519028102047741e-05
, O 0 3.460913148956024e-06
low B-Disease 0 0.00019495435117278248
frontal I-Disease 1 0.9785209894180298
hairline I-Disease 1 0.9999233484268188
, O 0 1.1245034329476766e-05
facial B-Disease 0 0.060189083218574524
asymmetry I-Disease 0 0.0005819097277708352
, O 0 1.3612379916594364e-05
ptosis B-Disease 1 0.9629102945327759
, O 0 2.830916628226987e-06
hypertelorism B-Disease 0 0.00015783970593474805
, O 0 9.285214446208556e-07
broad B-Disease 0 3.3475137115601683e-06
great I-Disease 0 4.932161118631484e-06
toes I-Disease 0 4.7785244532860816e-05
, O 0 3.260978246544255e-06
and O 0 7.65754248277517e-06
clinodactyly B-Disease 0 0.0011377984192222357
. O 0 7.593046029796824e-05

Significant O 0 0.0001744120818329975
intra O 0 0.00024089240469038486
- O 0 0.00040200972580350935
and O 0 4.923757842334453e-06
interfamilial O 0 8.331175922648981e-05
phenotypic O 0 3.2630054192850366e-05
variability O 0 1.721245644148439e-05
is O 0 9.478973765908449e-07
present O 0 8.312188128911657e-07
for O 0 7.206467671494465e-07
either O 0 3.136961822747253e-06
TWIST O 0 0.0009016807889565825
mutations O 0 0.00012654587044380605
or O 0 1.6896356100915e-05
FGFR O 0 0.010156705975532532
mutations O 0 0.00019975272880401462
. O 0 4.4170690671307966e-05

The O 0 3.0213823265512474e-05
overlap O 0 2.576604310888797e-05
in O 0 3.809574536717264e-06
clinical O 0 1.3830748684995342e-05
features O 0 9.987227258534404e-07
and O 0 3.065119358325319e-07
the O 0 1.741362041229877e-07
presence O 0 2.058452395203858e-07
, O 0 9.388775623619949e-08
in O 0 4.462733826926524e-08
the O 0 8.92940548169463e-08
same O 0 2.0064162242761086e-07
genes O 0 3.832770119061024e-07
, O 0 4.8707772037914765e-08
of O 0 6.59996004515051e-08
mutations O 0 5.823155788675649e-07
for O 0 5.997652863243275e-08
more O 0 4.8271704855551434e-08
than O 0 9.539483869502874e-08
one O 0 2.9333111228879716e-07
craniosynostotic B-Disease 0 0.039221446961164474
condition I-Disease 0 5.047937884228304e-05
- O 0 4.441802957444452e-06
such O 0 1.0550125750796724e-07
as O 0 2.49942900154565e-07
Saethre B-Disease 0 3.815383024630137e-05
- I-Disease 0 1.8117823856300674e-05
Chotzen I-Disease 0 7.345166523009539e-06
, I-Disease 0 3.1117497201194055e-07
Crouzon I-Disease 0 5.282227448333288e-06
, I-Disease 0 3.3177451541632763e-07
and I-Disease 0 7.51677418975305e-07
Pfeiffer I-Disease 0 0.0726020485162735
syndromes I-Disease 0 0.06712917238473892
- O 0 4.258764602127485e-05
support O 0 4.918970830658509e-07
the O 0 2.508563170522393e-07
hypothesis O 0 1.521850094832189e-06
that O 0 1.1624656792719179e-07
TWIST O 0 2.752118689386407e-06
and O 0 2.747178484696633e-07
FGFRs O 0 7.408933925034944e-06
are O 0 7.923911482521362e-08
components O 0 1.419940076630155e-07
of O 0 4.0728863837102836e-08
the O 0 1.2086968581570545e-07
same O 0 3.1450389315068605e-07
molecular O 0 4.561878540698672e-06
pathway O 0 1.2647591347558773e-06
involved O 0 2.523312048197113e-07
in O 0 7.87567913107523e-08
the O 0 1.496775041687215e-07
modulation O 0 2.2283052203420084e-06
of O 0 4.657721035528084e-07
craniofacial O 1 0.7880566716194153
and O 0 1.1142851690237876e-05
limb O 0 0.04262217506766319
development O 0 2.181699301218032e-06
in O 0 1.4009664255354437e-06
humans O 0 6.309517630143091e-06
. O 0 5.029457497585099e-06
. O 0 1.7046875655069016e-05

Mutation O 0 0.0032277514692395926
analysis O 0 0.00036873496719636023
of O 0 0.00010731395013863221
UBE3A O 1 0.9876962304115295
in O 1 0.9327940940856934
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 1 0.9970055222511292
. O 0 0.0003450975054875016

Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.003069339320063591
AS B-Disease 0 0.025357665494084358
) O 0 4.319314939493779e-06
is O 0 8.468358601021464e-07
caused O 0 5.3515000217885245e-06
by O 0 1.0499884410819504e-06
chromosome O 0 9.086572390515357e-06
15q11 O 0 0.0001142894325312227
- O 0 2.378297176619526e-05
q13 O 0 2.291120108566247e-05
deletions O 0 4.372622697701445e-06
of O 0 4.5609638732457825e-07
maternal O 0 1.44048653965001e-05
origin O 0 1.5961389863150544e-06
, O 0 4.914994633509195e-07
by O 0 7.375380732810299e-07
paternal O 0 0.0006533221458084881
uniparental B-Disease 1 0.9703238606452942
disomy I-Disease 1 0.8940573930740356
( O 0 6.889062206028029e-06
UPD B-Disease 1 0.9998424053192139
) O 0 1.0618963415254257e-06
15 O 0 4.2984137849089166e-07
, O 0 2.0703198799765232e-07
by O 0 5.447483317766455e-07
imprinting O 0 0.0051139285787940025
defects O 0 0.06231032684445381
, O 0 3.6356937016535085e-07
and O 0 2.90113945311532e-07
by O 0 7.165403985709418e-07
mutations O 0 6.301645953499246e-06
in O 0 1.099585347219545e-06
the O 0 5.1136603360646404e-06
UBE3A O 0 0.0016125183319672942
gene O 0 9.458087879465893e-05
. O 0 4.537665518000722e-05

UBE3A O 0 0.011790325865149498
encodes O 0 0.0005334072629921138
a O 0 6.008740092511289e-05
ubiquitin O 0 0.00018282659584656358
- O 0 6.53576644253917e-05
protein O 0 1.1344443009875249e-05
ligase O 0 1.5603960491716862e-05
and O 0 2.2788342448620824e-06
shows O 0 9.050198968907353e-06
brain O 0 0.0003904032346326858
- O 0 0.0001084813047782518
specific O 0 2.5636778445914388e-05
imprinting O 0 0.000518643471878022
. O 0 0.00010323492460884154

Here O 0 0.00010075645695906132
we O 0 2.493910324119497e-05
describe O 0 4.2340459913248196e-05
UBE3A O 0 0.0008940654806792736
coding O 0 0.0004110957379452884
- O 0 0.0006551696569658816
region O 0 6.349738669086946e-06
mutations O 0 7.765144800941925e-06
detected O 0 1.9810343019344145e-06
by O 0 5.07704271512921e-07
SSCP O 0 3.694768020068295e-05
analysis O 0 2.025494950430584e-06
in O 0 8.925613883548067e-07
13 O 0 2.272995743624051e-06
AS B-Disease 0 0.0001900163188111037
individuals O 0 3.3031765269697644e-06
or O 0 6.153480171633419e-06
families O 0 4.9871472583618015e-05
. O 0 5.9329660871298984e-05

Two O 0 4.708852065959945e-05
identical O 0 7.36603542463854e-05
de O 0 5.453053745441139e-05
novo O 0 3.41352861141786e-05
5 O 0 4.514289685175754e-06
- O 0 1.3468348697642796e-05
bp O 0 9.616494935471565e-06
duplications O 0 6.35122842140845e-06
in O 0 7.81497021762334e-07
exon O 0 1.0524312529014423e-05
16 O 0 2.2756807993573602e-06
were O 0 1.7576859363543917e-06
found O 0 9.000354111776687e-06
. O 0 3.216373443137854e-05

Among O 0 3.445303809712641e-05
the O 0 4.539433120953618e-06
other O 0 1.1725235253834398e-06
11 O 0 1.3586055729319924e-06
unique O 0 1.0607728881950607e-06
mutations O 0 3.914944045391167e-06
, O 0 2.7185618023395364e-07
8 O 0 2.4224718231380393e-07
were O 0 1.437949919136372e-07
small O 0 2.659418214534526e-07
deletions O 0 2.1675123207387514e-06
or O 0 5.263805178401526e-07
insertions O 0 5.59097179575474e-06
predicted O 0 1.2608028555405326e-05
to O 0 6.297701702351333e-07
cause O 0 1.691124111857789e-06
frameshifts O 0 6.155790470074862e-05
, O 0 3.9752313796270755e-07
1 O 0 3.327403135244822e-07
was O 0 3.8481084629893303e-07
a O 0 3.626973636983166e-07
mutation O 0 1.3218510730439448e-06
to O 0 1.4099626355346118e-07
a O 0 1.8997815232069115e-07
stop O 0 5.119044317325461e-07
codon O 0 1.4564786852133693e-06
, O 0 1.4410386484087212e-07
1 O 0 1.7369387705912231e-07
was O 0 2.2812972133579024e-07
a O 0 2.8761365911122994e-07
missense O 0 1.1646171515167225e-05
mutation O 0 1.6534183941985248e-06
, O 0 9.788550414668862e-08
and O 0 1.045533366550444e-07
1 O 0 2.7591249818215147e-07
was O 0 6.002694021844945e-07
predicted O 0 3.0981748295744183e-06
to O 0 1.9246628824021172e-07
cause O 0 4.783643134942395e-07
insertion O 0 7.996421231837303e-07
of O 0 9.514643295460701e-08
an O 0 2.0051422211508907e-07
isoleucine O 0 7.817578443791717e-05
in O 0 2.531698157781648e-07
the O 0 2.730977541887114e-07
hect O 0 5.820696515002055e-06
domain O 0 3.0888648439031385e-07
of O 0 8.487603508910979e-08
the O 0 2.954124624920951e-07
UBE3A O 0 3.094422208960168e-05
protein O 0 1.026965264827595e-06
, O 0 1.097761668233943e-07
which O 0 8.605082513213347e-08
functions O 0 2.53824964602245e-07
in O 0 3.525213685406925e-07
E2 O 0 1.1609622561081778e-05
binding O 0 2.8027507141814567e-06
and O 0 2.275168753840262e-06
ubiquitin O 0 3.233688767068088e-05
transfer O 0 2.89102772512706e-05
. O 0 5.122964648762718e-05

Eight O 0 3.31174123857636e-05
of O 0 2.9331367841223255e-06
the O 0 1.5074630255185184e-06
cases O 0 2.6137024633499095e-06
were O 0 2.833320422723773e-06
familial O 0 0.0003658729256130755
, O 0 7.369980608018523e-07
and O 0 6.576536293323443e-07
five O 0 1.6433699556728243e-06
were O 0 2.658890934981173e-06
sporadic O 0 5.6691194913582876e-05
. O 0 4.0252183680422604e-05

In O 0 3.894752080668695e-05
two O 0 7.812534022377804e-06
familial O 0 0.001352243241854012
cases O 0 5.409312052506721e-06
and O 0 8.113165108625253e-07
one O 0 6.055511221347842e-07
sporadic O 0 4.651413746614708e-06
case O 0 4.869514214078663e-06
, O 0 8.890909839465166e-07
mosaicism O 0 3.9021844713715836e-05
for O 0 9.794111974770203e-07
UBE3A O 0 0.0006076775607652962
mutations O 0 5.011421762901591e-06
was O 0 7.343558650063642e-07
detected O 0 8.465807468382991e-07
in O 0 1.0152287188702758e-07
the O 0 1.504950830621965e-07
mother O 0 1.1811812328232918e-06
of O 0 4.340305892469587e-08
three O 0 2.2382036490853352e-07
AS B-Disease 0 0.00041383274947293103
sons O 0 0.0021802852861583233
, O 0 1.1973709490575857e-07
in O 0 5.821668125349788e-08
the O 0 1.19881278237699e-07
maternal O 0 3.053226919291774e-06
grandfather O 0 4.0708196138439234e-06
of O 0 5.1394565048212826e-08
two O 0 1.255245649645076e-07
AS B-Disease 0 6.07299261901062e-06
first O 0 3.745955154954572e-07
cousins O 0 1.0312067388440482e-05
, O 0 1.4286753469150426e-07
and O 0 1.2707641872111708e-07
in O 0 2.0932422728492384e-07
the O 0 4.0776828313937585e-07
mother O 0 7.760377229715232e-06
of O 0 2.6435938593749597e-07
an O 0 1.897552010632353e-06
AS B-Disease 0 0.37073418498039246
daughter O 0 0.338776171207428
. O 0 9.25218264455907e-05

The O 0 1.460251587559469e-05
frequencies O 0 1.2914944818476215e-05
with O 0 1.1034164799639257e-06
which O 0 4.964505819771148e-07
we O 0 4.543680631741154e-07
detected O 0 1.2555967714433791e-06
mutations O 0 1.7368454336974537e-06
were O 0 2.2121572840205772e-07
5 O 0 2.7462670004752e-07
( O 0 2.016794837800262e-07
14 O 0 2.2318305070712086e-07
% O 0 1.1180559766899023e-07
) O 0 5.376579181870511e-08
of O 0 2.7792689039074503e-08
35 O 0 1.6795218016341096e-07
in O 0 1.35904329567893e-07
sporadic O 0 1.627126266612322e-06
cases O 0 7.153456067499064e-07
and O 0 4.0643504917170503e-07
8 O 0 3.6182501617076923e-07
( O 0 1.4038899109891645e-07
80 O 0 1.6101174082905345e-07
% O 0 1.5736833347546053e-07
) O 0 5.670789704481649e-08
of O 0 4.265199038400169e-08
10 O 0 2.971419519326446e-07
in O 0 6.337320996863127e-07
familial O 0 0.0006476371199823916
cases O 0 1.0943746019620448e-05
. O 0 1.3393061635724735e-05
. O 0 4.6111337724141777e-05

The O 0 0.00029597035609185696
hemochromatosis B-Disease 1 0.9998964071273804
845 O 0 0.014364885166287422
G O 0 0.46328815817832947
- O 0 0.021141843870282173
- O 0 8.295493898913264e-05
> O 0 8.354009878530633e-06
A O 0 6.0187784356458e-07
and O 0 2.907551390762819e-07
187 O 0 4.257332875567954e-06
C O 0 8.220753807108849e-05
- O 0 0.0002700810437090695
- O 0 0.00013670575572177768
> O 0 2.179278999392409e-05
G O 0 9.547270747134462e-05
mutations O 0 5.13491841047653e-06
: O 0 9.058090313374123e-07
prevalence O 0 5.466799393616384e-06
in O 0 1.0009320021708845e-06
non O 0 9.81223456619773e-06
- O 0 0.0006552053382620215
Caucasian O 0 0.00010201247641816735
populations O 0 5.21815090905875e-05
. O 0 3.2696716516511515e-05

Hemochromatosis B-Disease 1 0.9987834095954895
, O 0 0.00042307411786168814
the O 0 0.002714548958465457
inherited B-Disease 1 0.9999998807907104
disorder I-Disease 1 0.9999709129333496
of I-Disease 0 1.6952579926510225e-06
iron I-Disease 0 0.05187136307358742
metabolism I-Disease 0 0.002521551214158535
, O 0 1.1945597861995338e-06
leads O 0 1.6217692291320418e-06
, O 0 5.285253337206086e-07
if O 0 1.7092238522309344e-06
untreated O 0 7.222933345474303e-05
, O 0 4.357173111202428e-07
to O 0 7.84821281740733e-07
progressive O 0 0.00025089000700972974
iron B-Disease 0 0.016161611303687096
overload I-Disease 0 0.006082108709961176
and O 0 1.1225128218939062e-05
premature B-Disease 0 0.002368456218391657
death I-Disease 0 0.0001719369029160589
. O 0 7.540199294453487e-05

The O 0 0.00029139118851162493
hemochromatosis B-Disease 1 0.999852180480957
gene O 0 0.00030437292298302054
, O 0 1.65561923495261e-05
HFE O 0 0.11453671008348465
, O 0 4.82797577205929e-06
recently O 0 1.2018354937026743e-05
has O 0 5.916302256991912e-07
been O 0 5.681766879206407e-07
identified O 0 7.29323062387266e-07
, O 0 1.131163998024931e-07
and O 0 9.058680205953351e-08
characterization O 0 1.3030155514570652e-06
of O 0 1.0729110044849222e-07
this O 0 2.0365436625979783e-07
gene O 0 9.059930334842647e-07
has O 0 1.8323189010516217e-07
shown O 0 1.3820125843722053e-07
that O 0 5.095610688954366e-08
it O 0 3.2673543870487265e-08
contains O 0 7.961253345456498e-08
two O 0 1.3691486344669102e-07
mutations O 0 1.106719309973414e-06
that O 0 1.1569721891646623e-07
result O 0 4.3322918941157695e-07
in O 0 1.9004266960109817e-07
amino O 0 7.829740980014321e-07
acid O 0 1.1749648365366738e-06
substitutions O 0 1.1043366612284444e-06
- O 0 1.562385591569182e-06
cDNA O 0 4.014485512016108e-06
nucleotides O 0 3.949312485929113e-06
845 O 0 1.6194715499295853e-05
G O 0 8.688198431627825e-05
- O 0 4.8422516556456685e-05
- O 0 2.9399498089333065e-05
> O 0 6.69396740704542e-06
A O 0 7.212174182313902e-07
( O 0 4.319898039284453e-07
C282Y O 0 2.474047278155922e-06
) O 0 2.0857062565937667e-07
and O 0 1.595391836417548e-07
187 O 0 3.008845624208334e-06
C O 0 4.033372169942595e-05
- O 0 0.0006518233567476273
- O 0 0.0001446482929168269
> O 0 4.469658597372472e-05
G O 0 0.00011320900375721976
( O 0 4.475179594010115e-06
H63D O 0 0.00018117330910172313
) O 0 9.4422503025271e-06
. O 0 1.947415148606524e-05

Although O 0 0.02635001949965954
hemochromatosis B-Disease 1 0.9999914169311523
is O 0 1.6636307918815874e-05
common O 0 7.494250894524157e-06
in O 0 1.3773930049865157e-06
Caucasians O 0 1.3968498933536466e-05
, O 0 1.1934962458326481e-06
affecting O 0 4.766820893564727e-06
> O 0 2.259339817101136e-05
= O 0 8.08758704806678e-06
1 O 0 6.398133223228797e-07
/ O 0 1.6383280581067083e-06
300 O 0 1.8591104833376448e-07
individuals O 0 5.547482828660577e-08
of O 0 4.487983673584495e-08
northern O 0 3.206616838724585e-07
European O 0 3.079161956520693e-07
origin O 0 2.536139618314337e-07
, O 0 1.2069000376868644e-07
it O 0 6.32660928090445e-08
has O 0 1.2540131422156264e-07
not O 0 1.3514215879695257e-07
been O 0 2.584207834388508e-07
recognized O 0 7.431808626279235e-07
in O 0 6.71581574351876e-07
other O 0 1.6810806755529484e-06
populations O 0 2.082844548567664e-05
. O 0 3.124842623947188e-05

The O 0 2.6355379304732196e-05
present O 0 8.2587312135729e-06
study O 0 3.2032712624641135e-06
used O 0 9.82847041086643e-07
PCR O 0 1.515983876743121e-05
and O 0 5.483082077262225e-07
restriction O 0 1.545370764688414e-06
- O 0 4.661241291614715e-06
enzyme O 0 1.8325509927308303e-06
digestion O 0 2.338965714443475e-06
to O 0 2.274365300536374e-07
analyze O 0 7.862139455028228e-07
the O 0 9.628084285395744e-08
frequency O 0 3.1271983402803016e-07
of O 0 6.16018738242019e-08
the O 0 2.5364300881847157e-07
845 O 0 1.3631657566293143e-05
G O 0 0.006643264554440975
- O 0 0.0003228154091630131
- O 0 2.175744521082379e-05
> O 0 3.0137475732772145e-06
A O 0 3.0839140663374565e-07
and O 0 2.481859553427057e-07
187 O 0 2.3745237740513403e-06
C O 0 1.4159931197355036e-05
- O 0 5.265924846753478e-05
- O 0 2.529793346184306e-05
> O 0 1.5271076335920952e-05
G O 0 3.5550219763536006e-05
mutations O 0 2.5025801733136177e-06
in O 0 4.5933444425827474e-07
HLA O 0 1.2563355085148942e-05
- O 0 2.8141764687461546e-06
typed O 0 2.7515254714671755e-06
samples O 0 1.0522950333324843e-06
from O 0 3.4406502891215496e-07
non O 0 1.0531393854762428e-06
- O 0 1.2281437193450984e-05
Caucasian O 0 6.6815177888202015e-06
populations O 0 1.1867273315147031e-06
, O 0 2.404285055490618e-07
comprising O 0 4.7650573264945706e-07
Australian O 0 1.3143742307875073e-06
Aboriginal O 0 1.402422185492469e-06
, O 0 2.419156714950077e-07
Chinese O 0 3.031559856481181e-07
, O 0 5.927212214373867e-07
and O 0 1.970475068446831e-06
Pacific O 0 2.129093263647519e-05
Islanders O 0 9.938682342180982e-05
. O 0 3.3826265280367807e-05

Results O 0 0.0006462322198785841
showed O 0 2.688953281904105e-05
that O 0 1.6446414292659028e-06
the O 0 1.440927690055105e-06
845 O 0 4.637487654690631e-05
G O 0 0.14051492512226105
- O 0 0.025387069210410118
- O 0 0.0007442253408953547
> O 0 7.475649454136146e-06
A O 0 5.122794846101897e-07
mutation O 0 2.0110956029384397e-06
was O 0 3.6030820638188743e-07
present O 0 1.66557128977729e-07
in O 0 1.3460939385367965e-07
these O 0 2.552425826252147e-07
populations O 0 5.064314905212086e-07
( O 0 1.4017520300058095e-07
allele O 0 6.468417836913432e-07
frequency O 0 5.965297305010608e-07
0 O 0 5.303055559124914e-07
. O 0 1.5219242754938023e-07
32 O 0 2.6828899990505306e-07
% O 0 1.3358528860862862e-07
) O 0 7.28372953062717e-08
, O 0 4.772452300016994e-08
and O 0 6.729452195486374e-08
, O 0 6.909512251240812e-08
furthermore O 0 3.0180106591615186e-07
, O 0 8.875714030409654e-08
it O 0 7.460867834652163e-08
was O 0 2.633855160638632e-07
always O 0 3.160861012929672e-07
seen O 0 3.4296493822694174e-07
in O 0 1.5015460519407497e-07
conjunction O 0 9.628734005673323e-07
with O 0 6.503365170829056e-07
HLA O 0 0.0026981837581843138
haplotypes O 0 1.0980346814903896e-05
common O 0 7.318110419873847e-07
in O 0 4.465331358005642e-07
Caucasians O 0 3.933150310331257e-06
, O 0 2.3717733199646318e-07
suggesting O 0 6.333212354547868e-07
that O 0 1.7860556056348287e-07
845 O 0 6.3937318373064045e-06
G O 0 0.0026563191786408424
- O 0 0.0004561493406072259
- O 0 8.35418322822079e-05
> O 0 5.608461833617184e-06
A O 0 4.189265609966242e-07
may O 0 7.181631644925801e-07
have O 0 7.39438235086709e-08
been O 0 7.719638972503162e-08
introduced O 0 4.2447027226444334e-07
into O 0 3.0276072493506945e-07
these O 0 4.2415021539454756e-07
populations O 0 2.7005660285794875e-06
by O 0 3.2741568247729447e-06
Caucasian O 0 0.00012876636174041778
admixture O 0 0.00032757865847088397
. O 0 6.715626659570262e-05

187 O 0 0.000398568925447762
C O 0 0.000867581635247916
- O 0 0.0003443328314460814
- O 0 0.0001158262966782786
> O 0 2.1292171368259005e-05
G O 0 1.4788683074584696e-05
was O 0 6.165154786685889e-07
present O 0 2.2742828775790258e-07
at O 0 2.1644189018843463e-07
an O 0 1.1826718804286429e-07
allele O 0 3.214606522305985e-06
frequency O 0 2.4665087039466016e-06
of O 0 1.645766474211996e-06
2 O 0 1.1761267160181887e-05
. O 0 3.0651204724563286e-05

68 O 0 0.0005126754986122251
% O 0 1.4680624190077651e-05
in O 0 1.268927235287265e-06
the O 0 5.539731660064717e-07
two O 0 7.288557526408113e-07
populations O 0 3.5489681522449246e-06
analyzed O 0 3.6017534057464218e-06
( O 0 5.476894671119226e-07
Australian O 0 9.575383046467323e-07
Aboriginal O 0 2.8334177386568626e-06
and O 0 9.010050234792288e-07
Chinese O 0 1.6317276276822668e-06
) O 0 3.9657716115470976e-06
. O 0 1.225436517415801e-05

In O 0 1.8685446775634773e-05
the O 0 3.905498033418553e-06
Australian O 0 4.539229848887771e-06
Aboriginal O 0 3.863165602524532e-06
samples O 0 1.4342755321195e-06
, O 0 3.5050831570515584e-07
187 O 0 2.059720145553001e-06
C O 0 1.1752052159863524e-05
- O 0 4.61740892205853e-05
- O 0 2.5952478608815e-05
> O 0 8.226236786867958e-06
G O 0 1.5412409993587062e-05
was O 0 4.7472042297158623e-07
found O 0 1.7151350562016887e-07
to O 0 1.4188383090640855e-07
be O 0 1.537029561404779e-07
associated O 0 6.132848398010537e-07
with O 0 5.224136430115323e-07
HLA O 0 0.002951081609353423
haplotypes O 0 1.865532249212265e-05
common O 0 1.0989333532052115e-06
in O 0 5.109654921398032e-07
Caucasians O 0 6.666458830295596e-06
, O 0 3.432574828821089e-07
suggesting O 0 8.99935002962593e-07
that O 0 9.39517050824179e-08
it O 0 1.4545213389283163e-07
was O 0 5.406183731793135e-07
introduced O 0 2.2153860754769994e-06
by O 0 2.6069485556945438e-06
recent O 0 3.607406324590556e-05
admixture O 0 0.0004001660563517362
. O 0 0.00011882671242346987

In O 0 1.4699047824251465e-05
the O 0 2.67137556875241e-06
Chinese O 0 1.5018639487607288e-06
samples O 0 1.9030615021620179e-06
analyzed O 0 2.3316897568292916e-06
, O 0 5.407792400546896e-07
187 O 0 2.331918722120463e-06
C O 0 9.27929886529455e-06
- O 0 2.070465052383952e-05
- O 0 2.7139427402289584e-05
> O 0 9.153352038993035e-06
G O 0 1.4098233805270866e-05
was O 0 4.278263645574043e-07
present O 0 2.522424438211601e-07
in O 0 1.6160153393229848e-07
association O 0 4.187340323369426e-07
with O 0 8.008436225281912e-08
a O 0 3.1336139727500267e-07
wide O 0 6.538495540553413e-07
variety O 0 4.0971809767142986e-07
of O 0 3.567407134141831e-07
HLA O 0 0.0002749580889940262
haplotypes O 0 8.27048370410921e-06
, O 0 3.742398746453546e-07
showing O 0 7.645069786121894e-07
this O 0 1.4353850019688252e-07
mutation O 0 9.468096209275245e-07
to O 0 1.4555314464814728e-07
be O 0 8.73804211209972e-08
widespread O 0 3.675047253182129e-07
and O 0 3.6872674513688253e-07
likely O 0 8.519390917172132e-07
to O 0 1.6849779171934642e-07
predate O 0 2.5128758807113627e-06
the O 0 1.5421140631133312e-07
more O 0 2.855126695067156e-07
genetically O 0 1.4475692751148017e-06
restricted O 0 1.2084910849807784e-06
845 O 0 2.6764761059894226e-05
G O 0 0.005316989496350288
- O 0 0.002187423873692751
- O 0 0.00012723363761324435
> O 0 2.6900717784883454e-05
A O 0 7.198395906016231e-06
mutation O 0 6.471860251622275e-05
. O 0 4.168986197328195e-05

Genotype O 1 0.9587568044662476
- O 1 0.919559895992279
phenotype O 0 0.10515353828668594
correlations O 0 0.0022573843598365784
in O 0 0.0002933652722276747
attenuated B-Disease 1 0.9727041125297546
adenomatous I-Disease 1 0.999995231628418
polyposis I-Disease 1 0.9999760389328003
coli I-Disease 1 0.9995269775390625
. O 0 0.0008093038923107088

Germ O 0 0.27642086148262024
- O 0 0.008474810980260372
line O 0 7.177986117312685e-05
mutations O 0 2.652337570907548e-05
of O 0 7.42113570595393e-07
the O 0 2.8416470740921795e-06
tumor B-Disease 0 0.001586481579579413
suppressor O 0 0.0005966030876152217
APC O 0 5.453298217616975e-05
are O 0 1.644959866098361e-06
implicated O 0 3.7309324397938326e-05
in O 0 3.3718213671818376e-05
attenuated B-Disease 1 0.997577965259552
adenomatous I-Disease 1 0.9999998807907104
polyposis I-Disease 1 0.9999995231628418
coli I-Disease 1 0.9999914169311523
( O 0 0.0003940153692383319
AAPC B-Disease 1 0.9999923706054688
) O 0 2.6558420813671546e-06
, O 0 8.311228612001287e-07
a O 0 1.9179801711288746e-06
variant O 0 0.0005848639411851764
of O 0 6.46843618596904e-05
familial B-Disease 1 0.9999998807907104
adenomatous I-Disease 1 0.9999998807907104
polyposis I-Disease 1 1.0
( O 0 0.0005919418181292713
FAP B-Disease 0 0.005397256463766098
) O 0 3.0148430596455e-05
. O 0 3.869145439239219e-05

AAPC B-Disease 1 0.9999569654464722
is O 0 4.5031451008981094e-05
recognized O 0 1.318401609751163e-05
by O 0 2.2339543193083955e-06
the O 0 1.407263994224195e-06
occurrence O 0 4.246041044098092e-06
of O 0 8.182227020370192e-07
< O 0 1.4663010006188415e-05
100 O 0 1.1790585858761915e-06
colonic B-Disease 0 0.0007832115516066551
adenomas I-Disease 0 0.00044479864300228655
and O 0 6.239284289222269e-07
a O 0 8.433091238657653e-07
later O 0 5.7772454056248534e-06
onset O 1 0.5557255148887634
of O 0 0.18720202147960663
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
( O 0 5.862635134690208e-06
age O 0 5.532369414140703e-06
> O 0 3.184230445185676e-05
40 O 0 3.460639163677115e-06
years O 0 1.1444926713011228e-05
) O 0 9.169347322313115e-06
. O 0 1.9904631699318998e-05

The O 0 1.7332138668280095e-05
aim O 0 1.4967485185479745e-05
of O 0 4.584670136864588e-07
this O 0 4.563835886983725e-07
study O 0 1.2338246051513124e-06
was O 0 9.67592768574832e-07
to O 0 9.168274459625536e-07
assess O 0 3.277570067439228e-05
genotype O 0 0.02952374331653118
- O 0 0.016543451696634293
phenotype O 0 0.0015938878059387207
correlations O 0 0.00014650168304797262
in O 0 3.100176400039345e-05
AAPC B-Disease 1 0.9999486207962036
families O 0 0.00019667936430778354
. O 0 7.233824726426974e-05

By O 0 7.162833935581148e-05
protein O 0 5.575067552854307e-05
- O 0 5.180221705813892e-05
truncation O 0 5.336130561772734e-05
test O 0 7.779814040986821e-06
( O 0 1.3286328339745523e-06
PTT O 0 8.595536201028153e-06
) O 0 5.495400046129362e-07
assay O 0 2.532635335228406e-06
, O 0 2.2524562837134e-07
the O 0 2.5482859200565144e-07
entire O 0 1.4985847656134865e-06
coding O 0 8.098415491986088e-06
region O 0 5.332398700375052e-07
of O 0 1.384324974651463e-07
the O 0 4.3663700921570126e-07
APC B-Disease 0 6.330088581307791e-06
gene O 0 1.8402586192678427e-06
was O 0 1.0578431783869746e-06
screened O 0 1.7781235328584444e-06
in O 0 2.922482735812082e-07
affected O 0 1.3919968750997214e-06
individuals O 0 4.251237442076672e-07
from O 0 5.773950988441356e-07
11 O 0 6.7853638938686345e-06
AAPC B-Disease 1 0.9998847246170044
kindreds O 0 0.00012390603660605848
, O 0 3.818151412815496e-07
and O 0 2.4339672677342605e-07
their O 0 5.982012112326629e-07
phenotypic O 0 1.2160161531937774e-05
differences O 0 1.2027390766888857e-05
were O 0 5.56337272428209e-06
examined O 0 0.00012029271601932123
. O 0 5.429863085737452e-05

Five O 0 9.85953229246661e-05
novel O 0 0.00014419826038647443
germ O 0 0.0015653661685064435
- O 0 0.00030508326017297804
line O 0 2.785016840789467e-05
APC B-Disease 0 5.084617077955045e-05
mutations O 0 1.3448172467178665e-05
were O 0 1.5023969126559678e-06
identified O 0 4.303406967665069e-06
in O 0 2.5307811029051663e-06
seven O 0 1.6819605662021786e-05
kindreds O 0 0.0020493115298449993
. O 0 8.103753498289734e-05

Mutations O 0 0.0011914422502741218
were O 0 5.956644145044265e-06
located O 0 1.1364562624294194e-06
in O 0 2.1507111114260624e-07
three O 0 2.1445012521326134e-07
different O 0 2.184496423751625e-07
regions O 0 2.6895867222265224e-07
of O 0 7.400901580467689e-08
the O 0 2.800821903292672e-07
APC B-Disease 0 4.534241270448547e-06
gene O 0 9.288899605053302e-07
( O 0 1.9392976469134737e-07
1 O 0 1.2981567465431e-07
) O 0 7.628626264022387e-08
at O 0 8.443264931656813e-08
the O 0 1.337408122026318e-07
5 O 0 2.9070440632494865e-07
end O 0 2.8855876621491916e-07
spanning O 0 7.801834271958796e-07
exons O 0 4.4619869186135475e-06
4 O 0 4.456826445675688e-07
and O 0 1.9071116241775599e-07
5 O 0 2.1696970975426666e-07
, O 0 1.1996591808838275e-07
( O 0 1.1318525139358826e-07
2 O 0 8.110057336807586e-08
) O 0 6.416537701170455e-08
within O 0 5.397221158887078e-08
exon O 0 1.1276069926680066e-06
9 O 0 2.883431307054707e-07
, O 0 6.021367937592004e-08
and O 0 1.0553265639146048e-07
( O 0 9.950323232033043e-08
3 O 0 1.6522882617664436e-07
) O 0 8.06373776640612e-08
at O 0 7.172405958044692e-08
the O 0 9.12649014139788e-08
3 O 0 3.2813383654684003e-07
distal O 0 5.627857262879843e-06
end O 0 1.0008508297687513e-06
of O 0 3.2948472039606713e-07
the O 0 4.181955318927066e-06
gene O 0 6.97844079695642e-05
. O 0 5.287118983687833e-05

Variability O 0 0.0006767658051103354
in O 0 1.4293625099526253e-05
the O 0 3.3005314890033333e-06
number O 0 2.106831971104839e-06
of O 0 2.1025041860411875e-05
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999997615814209
was O 0 8.441261888947338e-05
most O 0 4.1131622197099205e-07
apparent O 0 5.315153430274222e-06
in O 0 7.607090992678422e-07
individuals O 0 4.5800945258633874e-07
with O 0 2.520567932151607e-07
mutations O 0 2.549562623244128e-06
in O 0 2.5912018486451416e-07
region O 0 4.4800043497161823e-07
1 O 0 2.7754398956858495e-07
, O 0 1.853360771519874e-07
and O 0 4.2186246673736605e-07
upper O 0 0.006307827774435282
- O 1 0.6144211888313293
gastrointestinal O 0 0.030233679339289665
manifestations O 0 6.32189539828687e-06
were O 0 7.913910167189897e-07
more O 0 3.954465341848845e-07
severe O 0 0.0004035409656353295
in O 0 2.63867241301341e-06
them O 0 6.056849997548852e-06
. O 0 3.020209987880662e-05

In O 0 4.206967059872113e-05
individuals O 0 5.128571046952857e-06
with O 0 1.747517103467544e-06
mutations O 0 7.393250143650221e-06
in O 0 5.35058461537119e-07
either O 0 5.327569851942826e-07
region O 0 6.114709663052054e-07
2 O 0 2.931135441031074e-07
or O 0 1.845240973352702e-07
region O 0 1.518884999995862e-07
3 O 0 1.4700283657020918e-07
, O 0 4.274156850669897e-08
the O 0 7.853434169646789e-08
average O 0 2.9556125014096324e-07
number O 0 6.450614620234774e-08
of O 0 1.1519924214553612e-07
adenomas B-Disease 0 0.0002741824137046933
tended O 0 2.106167130477843e-06
to O 0 1.0710238740330169e-07
be O 0 7.25761637454525e-08
lower O 0 4.939240625390084e-07
than O 0 7.254737965922686e-08
those O 0 8.515997507174689e-08
in O 0 1.1681267153562658e-07
individuals O 0 1.2048759856497782e-07
with O 0 1.4944700410524092e-07
mutations O 0 1.7136845826826175e-06
in O 0 2.223055020067477e-07
region O 0 4.283677128569252e-07
1 O 0 2.8879665592285164e-07
, O 0 2.2091509777055762e-07
although O 0 7.219262556645845e-07
age O 0 2.1358891899581067e-06
at O 0 3.4172405776189407e-06
diagnosis O 0 0.23445717990398407
was O 0 2.5900757464114577e-05
similar O 0 4.284910028218292e-05
. O 0 7.408047531498596e-05

In O 0 8.589712524553761e-05
all O 0 3.3254505979130045e-05
AAPC B-Disease 1 0.9991305470466614
kindreds O 0 0.0003450143267400563
, O 0 4.568757503875531e-06
a O 0 1.8383221913609304e-06
predominance O 0 1.235188938153442e-05
of O 0 2.043381300609326e-06
right O 0 0.0005782049847766757
- O 1 0.9972788691520691
sided O 1 0.9999991655349731
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999991655349731
and O 0 0.0001612752239452675
rectal B-Disease 1 0.999544084072113
polyp I-Disease 0 0.4767697751522064
sparing O 0 0.00010266730532748625
was O 0 3.173502045683563e-05
observed O 0 4.9263599066762254e-05
. O 0 4.253150837030262e-05

No O 0 0.00047713040839880705
desmoid B-Disease 1 0.9922667145729065
tumors I-Disease 1 0.999992847442627
were O 0 7.355274192377692e-06
found O 0 3.708628810272785e-06
in O 0 1.9876426904374966e-06
these O 0 6.427037533285329e-06
kindreds O 0 0.000796570151578635
. O 0 6.678737554466352e-05

Our O 0 6.04926171945408e-05
data O 0 2.155474248866085e-05
suggest O 0 6.9701891334261745e-06
that O 0 8.588223749939061e-07
, O 0 6.302280439740571e-07
in O 0 1.775112650648225e-06
AAPC B-Disease 1 0.9999922513961792
families O 0 6.3811098698352e-06
, O 0 3.255678677760443e-07
the O 0 2.0013747814573435e-07
location O 0 3.90801403682417e-07
of O 0 1.4154973371205415e-07
the O 0 9.473343993704475e-07
APC B-Disease 0 0.00027854068321175873
mutation O 0 3.1508399843005463e-05
may O 0 8.327094292326365e-06
partially O 0 1.912319021357689e-05
predict O 0 2.888029848691076e-05
specific O 0 5.635328307107557e-06
phenotypic O 0 5.5391697969753295e-05
expression O 0 4.01358884118963e-05
. O 0 4.49517356173601e-05

This O 0 1.7072274204110727e-05
should O 0 7.63397565606283e-06
help O 0 3.0910623536328785e-06
in O 0 4.643360398404184e-07
the O 0 2.424232832254347e-07
design O 0 1.301973384215671e-06
of O 0 4.85455643683963e-07
tailored O 0 0.00178156525362283
clinical O 0 0.061720408499240875
- O 0 0.09955032169818878
management O 0 6.1834525695303455e-06
protocols O 0 5.322701326804236e-06
in O 0 6.413534379134944e-07
this O 0 3.9809523855183215e-07
subset O 0 3.2379966796725057e-06
of O 0 2.6586676540318877e-06
FAP B-Disease 0 0.07585001736879349
patients O 0 0.00031832652166485786
. O 0 1.09010406958987e-05
. O 0 3.529669265844859e-05

Wilms B-Disease 1 0.9984760880470276
' I-Disease 0 0.005075441207736731
tumor I-Disease 0 0.00046251650201156735
1 O 0 3.4649751796678174e-06
and O 0 1.575345550008933e-06
Dax O 0 0.00413402309641242
- O 0 1.1603910934354644e-05
1 O 0 7.610573788952024e-07
modulate O 0 5.857348696736153e-06
the O 0 1.0979580338243977e-06
orphan O 0 2.7575268177315593e-05
nuclear O 0 6.085115728637902e-06
receptor O 0 7.346364327531774e-06
SF O 0 0.0003616501926444471
- O 0 5.15734654982225e-06
1 O 0 4.428224542607495e-07
in O 0 2.0416172219483997e-07
sex O 0 1.8066864413412986e-06
- O 0 7.815111530362628e-06
specific O 0 2.363884277656325e-06
gene O 0 2.1936246412224136e-05
expression O 0 2.3550281184725463e-05
. O 0 3.1031286198413e-05

Products O 0 0.00020809350826311857
of O 0 1.646917371544987e-05
steroidogenic O 0 0.001195305958390236
factor O 0 3.227098932256922e-05
1 O 0 6.086397661420051e-06
( O 0 2.0975855932192644e-06
SF O 0 0.006402586121112108
- O 0 1.1307124623272102e-05
1 O 0 5.815369945594284e-07
) O 0 3.5376712048673653e-07
and O 0 8.90757860361191e-07
Wilms B-Disease 1 0.8914775252342224
tumor I-Disease 0 9.359270916320384e-05
1 O 0 1.3079944665150833e-06
( O 0 4.894926632914576e-07
WT1 O 0 1.7603832020540722e-05
) O 0 2.711387026010925e-07
genes O 0 3.655252953649324e-07
are O 0 6.645485228773396e-08
essential O 0 3.1834468927627313e-07
for O 0 2.602777726679051e-07
mammalian O 0 5.077157311461633e-06
gonadogenesis O 0 3.0726270779268816e-05
prior O 0 3.1492334073845996e-06
to O 0 1.5984026049409295e-06
sexual O 0 6.136468527984107e-06
differentiation O 0 3.2421619835076854e-05
. O 0 2.8643535188166425e-05

In O 0 7.219827239168808e-05
males O 0 3.708931035362184e-05
, O 0 5.228959253145149e-06
SF O 0 0.05348661169409752
- O 0 2.9439393983921036e-05
1 O 0 8.325579869961075e-07
participates O 0 9.508145240033627e-07
in O 0 2.009824981996644e-07
sexual O 0 4.300767102449754e-07
development O 0 3.253797729030339e-07
by O 0 1.9602927636697132e-07
regulating O 0 1.1539345905475784e-06
expression O 0 4.0962004277389497e-07
of O 0 2.3581327468491509e-07
the O 0 1.2476830306695774e-06
polypeptide O 0 5.36746192665305e-05
hormone O 0 4.727749546873383e-05
Mullerian O 0 0.0002072142087854445
inhibiting O 0 4.777795766131021e-05
substance O 0 2.8763102818629704e-05
( O 0 9.840918210102245e-06
MIS O 0 0.00019923267245758325
) O 0 1.0580415619187988e-05
. O 0 2.422070065222215e-05

Here O 0 5.862216494278982e-05
, O 0 6.049875537428306e-06
we O 0 1.9619699287432013e-06
show O 0 2.877035967685515e-06
that O 0 1.6291386373268324e-06
WT1 O 0 0.00026491060270927846
- O 0 8.002104732440785e-05
KTS O 0 0.00013490089622791857
isoforms O 0 1.2346330549917184e-05
associate O 0 3.5993703022541013e-06
and O 0 1.098666075449728e-06
synergize O 0 3.2847823604242876e-05
with O 0 1.6356302694475744e-06
SF O 0 0.2060118168592453
- O 0 1.3324724932317622e-05
1 O 0 7.380031092907302e-07
to O 0 8.581444603805721e-07
promote O 0 5.01849535794463e-06
MIS O 0 0.00011935273505514488
expression O 0 3.0249686460592784e-05
. O 0 3.139286855002865e-05

In O 0 7.807655492797494e-05
contrast O 0 8.370985597139224e-05
, O 0 1.1622074453043751e-05
WT1 O 0 0.0016535224858671427
missense O 0 0.00032185050076805055
mutations O 0 4.576874562189914e-05
, O 0 1.5461637303815223e-06
associated O 0 2.399997129032272e-06
with O 0 1.066400272975443e-06
male B-Disease 0 1.2420637176546734e-05
pseudohermaphroditism I-Disease 1 0.9991129040718079
in O 0 1.0030648809333798e-05
Denys B-Disease 1 0.998710036277771
- I-Disease 1 0.9996998310089111
Drash I-Disease 1 0.9999277591705322
syndrome I-Disease 1 0.9997989535331726
, O 0 2.428723064440419e-06
fail O 0 9.193839105137158e-06
to O 0 1.2519093388618785e-06
synergize O 0 4.517614434007555e-05
with O 0 3.461619598965626e-06
SF O 1 0.9866092801094055
- O 0 0.00044326280476525426
1 O 0 1.2812901331926696e-05
. O 0 3.1897379813017324e-05

Additionally O 0 0.00019379696459509432
, O 0 7.44714452594053e-06
the O 0 2.795585942294565e-06
X O 0 0.00024954258697107434
- O 0 0.00012914584658574313
linked O 0 4.573556907416787e-06
, O 0 5.863859655619308e-07
candidate O 0 2.8800391191907693e-06
dosage O 0 1.625661207071971e-05
- O 0 1.3744650459557306e-05
sensitive O 0 2.4707178454264067e-06
sex O 0 1.3793832067676703e-06
- O 0 4.332748176238965e-06
reversal O 0 3.553130227373913e-06
gene O 0 1.669249172664422e-06
, O 0 4.1572278064450074e-07
Dax O 0 0.0005230617243796587
- O 0 7.414178071485367e-06
1 O 0 4.169687315425108e-07
, O 0 2.4366661932617717e-07
antagonizes O 0 5.0446324166841805e-06
synergy O 0 1.6647470602038084e-06
between O 0 4.6507170736731496e-07
SF O 0 0.0338754802942276
- O 0 6.360781299008522e-06
1 O 0 2.709652733301482e-07
and O 0 2.1115316428677033e-07
WT1 O 0 2.448669147270266e-05
, O 0 2.0400037215040356e-07
most O 0 1.6405201108682377e-07
likely O 0 3.297402884072653e-07
through O 0 1.0663560345847145e-07
a O 0 1.8510220911593933e-07
direct O 0 4.243371165557619e-07
interaction O 0 6.134252430456399e-07
with O 0 2.388562052146881e-06
SF O 1 0.977384626865387
- O 0 0.00016982429951895028
1 O 0 1.3119761206326075e-05
. O 0 2.2857926524011418e-05

We O 0 5.688805686077103e-05
propose O 0 4.700139834312722e-05
that O 0 1.7346919776173308e-06
WT1 O 0 7.198035746114329e-05
and O 0 1.770674430190411e-06
Dax O 0 0.005541428457945585
- O 0 2.8335793103906326e-05
1 O 0 7.721029078311403e-07
functionally O 0 1.8226493239126285e-06
oppose O 0 7.697715318499831e-07
each O 0 9.230988951003383e-08
other O 0 1.2364874635295564e-07
in O 0 3.1445949844055576e-07
testis O 0 1.36881672005984e-05
development O 0 7.335159466492769e-07
by O 0 5.404359058047703e-07
modulating O 0 4.531603190116584e-05
SF O 1 0.8886696696281433
- O 0 5.615170084638521e-05
1 O 0 2.2102919956523692e-06
- O 0 1.558394251333084e-05
mediated O 0 2.6871026420849375e-05
transactivation O 0 0.00013153377221897244
. O 0 1.4219052900443785e-05
. O 0 2.934468284365721e-05

A O 0 0.0002005799178732559
mouse O 0 0.0004963297978974879
model O 0 8.992211223812774e-05
for O 0 5.9917681937804446e-05
Prader B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999990463256836
Willi I-Disease 1 1.0
syndrome I-Disease 1 0.9999945163726807
imprinting O 0 0.022882023826241493
- O 0 0.12673790752887726
centre O 0 0.00011637275747489184
mutations O 0 0.0002327327529201284
. O 0 5.424077244242653e-05

Imprinting O 0 0.0010531332809478045
in O 0 2.7710979338735342e-05
the O 0 7.396452019747812e-06
15q11 O 0 0.00018182313942816108
- O 0 0.00016496884927619249
q13 O 0 3.553472924977541e-05
region O 0 2.239912873847061e-06
involves O 0 1.1599744311752147e-06
an O 0 4.259946990714525e-07
imprinting O 0 1.5290021110558882e-05
centre O 0 4.850113327847794e-06
( O 0 4.4797135956287093e-07
IC O 0 7.248489509947831e-06
) O 0 1.6986923867534642e-07
, O 0 9.743565243525154e-08
mapping O 0 5.108997243041813e-07
in O 0 8.628469316818155e-08
part O 0 2.2705076219153852e-07
to O 0 1.4186758789946907e-07
the O 0 2.527216054204473e-07
promoter O 0 2.7314019916957477e-06
and O 0 5.867495929123834e-07
first O 0 1.446335431865009e-06
exon O 0 2.684146966203116e-05
of O 0 6.729748747602571e-06
SNRPN O 0 0.0032967301085591316
. O 0 4.1637104004621506e-05

Deletion O 0 0.0007515028701163828
of O 0 1.2748035260301549e-05
this O 0 6.796528850827599e-06
IC O 0 0.00014506005391012877
abolishes O 0 8.13233491498977e-05
local O 0 5.772404165327316e-06
paternally O 0 4.6108350943541154e-05
derived O 0 3.0197920750651974e-06
gene O 0 3.9116039260989055e-06
expression O 0 1.18815307814657e-06
and O 0 1.2081719660272938e-06
results O 0 2.31523226830177e-05
in O 0 0.0007170341559685767
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
( O 0 0.0004576414648909122
PWS B-Disease 1 0.9999747276306152
) O 0 4.7100689698709175e-05
. O 0 4.37156850239262e-05

We O 0 4.517433626460843e-05
have O 0 4.850372079090448e-06
created O 0 2.803263896566932e-06
two O 0 1.1337726846250007e-06
deletion O 0 3.8236841646721587e-05
mutations O 0 2.120894168911036e-05
in O 0 1.456677296118869e-06
mice O 0 5.717635212931782e-05
to O 0 1.2294623275010963e-06
understand O 0 1.692620753601659e-05
PWS B-Disease 1 0.9992967844009399
and O 0 6.976107442824286e-07
the O 0 5.099481086290325e-07
mechanism O 0 1.9219039586459985e-06
of O 0 7.966173143358901e-07
this O 0 4.642448857339332e-06
IC O 0 0.0017141845310106874
. O 0 5.558452176046558e-05

Mice O 1 0.8164864778518677
harbouring O 0 0.0042046369053423405
an O 0 2.030508767347783e-05
intragenic O 0 0.0003064069023821503
deletion O 0 5.667644290952012e-05
in O 0 2.0386553387652384e-06
Snrpn O 0 5.631848398479633e-05
are O 0 6.751436103513697e-07
phenotypically O 0 1.9247880118200555e-05
normal O 0 2.725425247263047e-06
, O 0 3.225989644306537e-07
suggesting O 0 2.0231339021847816e-06
that O 0 2.7755774567594926e-07
mutations O 0 1.6096948911581421e-06
of O 0 2.1340902378597093e-07
SNRPN O 0 8.28900228952989e-05
are O 0 3.272257345088292e-07
not O 0 6.592549084416532e-07
sufficient O 0 3.1524248242931208e-06
to O 0 4.800360784429358e-06
induce O 0 0.00014933603233657777
PWS B-Disease 1 0.9993922710418701
. O 0 9.224133827956393e-05

Mice O 0 0.15719442069530487
with O 0 1.045413864630973e-05
a O 0 6.4726846176199615e-06
larger O 0 6.557212145708036e-06
deletion O 0 1.6219197277678177e-05
involving O 0 2.614505092424224e-06
both O 0 8.212606417146162e-07
Snrpn O 0 3.0644627258880064e-05
and O 0 7.30816509530996e-07
the O 0 1.9835108560073422e-06
putative O 0 0.10338110476732254
PWS O 1 0.9999958276748657
- O 0 0.015478377230465412
IC O 0 0.00014923184062354267
lack O 0 2.1799733076477423e-06
expression O 0 7.739186571598111e-07
of O 0 2.2665788890208205e-07
the O 0 7.045399570415611e-07
imprinted O 0 3.7466099456651136e-05
genes O 0 6.908181148901349e-06
Zfp127 O 0 3.5919249057769775e-05
( O 0 1.0513059578443062e-06
mouse O 0 6.955540357012069e-06
homologue O 0 9.612918802304193e-06
of O 0 5.419770445769245e-07
ZNF127 O 0 8.745786908548325e-05
) O 0 1.3096919246891048e-06
, O 0 5.527910502678424e-07
Ndn O 0 2.371609298279509e-05
and O 0 5.071748887530703e-07
Ipw O 0 1.5099354641279206e-05
, O 0 4.3016530071326997e-07
and O 0 5.373390195018146e-07
manifest O 0 4.571668796415906e-06
several O 0 2.040771732936264e-06
phenotypes O 0 0.00013054641021881253
common O 0 1.994984268094413e-05
to O 0 0.00010378312435932457
PWS B-Disease 1 0.9999983310699463
infants O 1 0.805833101272583
. O 0 0.00012553522537928075

These O 0 2.3816406610421836e-05
data O 0 1.0454477887833491e-05
demonstrate O 0 2.560286020525382e-06
that O 0 1.888668208493982e-07
both O 0 1.135532770035752e-07
the O 0 7.623069819828743e-08
position O 0 2.0858732341366704e-07
of O 0 5.565414795682955e-08
the O 0 1.5528682695276075e-07
IC O 0 1.5612949937349185e-05
and O 0 2.2415615319459903e-07
its O 0 1.2635388202397735e-07
role O 0 3.5247393270765315e-07
in O 0 8.110969673680302e-08
the O 0 1.0090030144738193e-07
coordinate O 0 5.44213548892003e-07
expression O 0 3.697754493714456e-07
of O 0 1.0349719303803795e-07
genes O 0 5.654177925862314e-07
is O 0 6.083474346496587e-08
conserved O 0 1.3026622980305547e-07
between O 0 6.201803159910924e-08
mouse O 0 2.1373439267335925e-06
and O 0 2.0049931492849282e-07
human O 0 1.9440768994627433e-07
, O 0 1.2107031466257467e-07
and O 0 1.2776224878052744e-07
indicate O 0 4.840206884182408e-07
that O 0 7.555023273653205e-08
the O 0 1.3871053283764923e-07
mouse O 0 3.2561365514993668e-06
is O 0 9.574682735546958e-08
a O 0 2.797565059609042e-07
suitable O 0 1.2064241445841617e-06
model O 0 1.3975915180708398e-06
system O 0 5.627281325359945e-07
in O 0 9.695254732378089e-08
which O 0 7.335005847153298e-08
to O 0 1.1917749986878334e-07
investigate O 0 5.025565315008862e-07
the O 0 1.305853913891042e-07
molecular O 0 1.561426302032487e-06
mechanisms O 0 5.229001658335619e-07
of O 0 1.437491903288901e-07
imprinting O 0 6.057554401195375e-06
in O 0 3.863232223011437e-07
this O 0 1.9354934011062142e-07
region O 0 5.313737574397237e-07
of O 0 2.1315456422144052e-07
the O 0 1.792934426703141e-06
genome O 0 2.0064033378730528e-05
. O 0 9.277388016926125e-06
. O 0 3.216477489331737e-05

Mutations O 0 0.00045065267477184534
of O 0 3.7865306694584433e-06
the O 0 2.364154624956427e-06
ATM O 0 3.2543044653721154e-05
gene O 0 1.0659025974746328e-05
detected O 0 7.654096407350153e-06
in O 0 1.990579221455846e-06
Japanese O 0 6.44012980046682e-05
ataxia B-Disease 1 0.9999990463256836
- I-Disease 1 0.9999964237213135
telangiectasia I-Disease 1 0.9999998807907104
patients O 0 0.07172280550003052
: O 0 1.1654599347821204e-06
possible O 0 1.1052595709770685e-06
preponderance O 0 5.0784742597898e-06
of O 0 1.5988905488484306e-07
the O 0 5.206490527598362e-07
two O 0 9.62989929575997e-07
founder O 0 0.00022429571254178882
mutations O 0 3.933122206944972e-05
4612del165 O 0 7.986210403032601e-05
and O 0 8.518939466739539e-06
7883del5 O 0 0.0004047216207254678
. O 0 5.5597032769583166e-05

The O 0 5.4279895266518e-05
ATM O 0 0.0006040369044058025
( O 0 2.0494102500379086e-05
A O 0 0.017463302239775658
- O 1 0.9981256127357483
T O 1 0.9997366070747375
, O 0 1.7604504591872683e-06
mutated O 0 6.499442406493472e-06
) O 0 5.904470867790224e-07
gene O 0 1.7795890698835137e-06
on O 0 1.0515988151382771e-06
human O 0 1.1641174751275685e-05
chromosome O 0 9.089422383112833e-05
11q22 O 0 0.00045188143849372864
. O 0 8.064915164140984e-05

3 O 0 8.583318413002416e-05
has O 0 7.684390766371507e-06
recently O 0 1.1730910955520812e-05
been O 0 9.210339158016723e-07
identified O 0 8.12002326711081e-07
as O 0 1.5339338688136195e-07
the O 0 2.3376003355224384e-07
gene O 0 1.2401335425238358e-06
responsible O 0 9.250788366443885e-07
for O 0 3.311966167984792e-07
the O 0 1.6654457795084454e-06
human O 0 0.00011700632603606209
recessive B-Disease 1 0.9999680519104004
disease I-Disease 1 0.9998819828033447
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999983310699463
telangiectasia I-Disease 1 0.9999997615814209
( O 0 0.00011118687689304352
A B-Disease 1 0.9663662314414978
- I-Disease 1 0.9998888969421387
T I-Disease 1 0.9999772310256958
) O 0 2.5066812668228522e-05
. O 0 3.4880125895142555e-05

In O 0 1.9904877262888476e-05
order O 0 5.361512194212992e-06
to O 0 6.889376891194843e-07
define O 0 1.4993481727287872e-06
the O 0 2.997744559252169e-07
types O 0 7.380953661595413e-07
of O 0 9.691959803603822e-07
disease O 0 0.002717547817155719
- O 0 0.0007654020446352661
causing O 0 4.664389507524902e-06
ATM O 0 1.5671979781473055e-05
mutations O 0 3.457515049376525e-06
in O 0 3.305781319795642e-07
Japanese O 0 3.0854250780976145e-06
A B-Disease 1 0.8254890441894531
- I-Disease 1 0.999995231628418
T I-Disease 1 0.9999997615814209
patients O 0 8.55983525980264e-05
as O 0 1.3138124188571965e-07
well O 0 1.5547620080269553e-07
as O 0 9.001137613040555e-08
to O 0 1.1849434145005944e-07
look O 0 4.3997516741001164e-07
for O 0 1.4737159403921396e-07
possible O 0 9.49008153838804e-07
mutational O 0 2.415371454844717e-05
hotspots O 0 4.0306017581315245e-06
, O 0 4.1681369111756794e-07
reverse O 0 5.128776592755457e-06
- O 0 5.471879376273137e-06
transcribed O 0 1.914818312798161e-06
RNA O 0 8.593229381403944e-07
derived O 0 4.7343462483695475e-07
from O 0 1.4095512312906067e-07
ten O 0 4.610882626820967e-07
patients O 0 1.462516706851602e-06
belonging O 0 2.958957736609591e-07
to O 0 1.5868941716234986e-07
eight O 0 2.9515450705730473e-07
unrelated O 0 5.111846348881954e-06
Japanese O 0 1.1432053725002334e-05
A B-Disease 1 0.7416511178016663
- I-Disease 1 0.9998461008071899
T I-Disease 1 0.9999566078186035
families O 0 2.2106059986981563e-06
was O 0 8.940854172578838e-07
analyzed O 0 1.810336016205838e-06
for O 0 4.012045451418089e-07
mutations O 0 2.054660399153363e-06
by O 0 2.384483082096267e-07
the O 0 9.614383316147723e-07
restriction O 0 6.401791324606165e-06
endonuclease O 0 7.863920473027974e-05
fingerprinting O 0 4.083195381099358e-05
method O 0 3.9634811400901526e-05
. O 0 4.828206147067249e-05

As O 0 3.163268047501333e-05
has O 0 6.437797310354654e-06
been O 0 2.4908465547923697e-06
reported O 0 1.8361320144322235e-06
by O 0 3.343116077303421e-07
others O 0 1.1259993470957852e-06
, O 0 4.1380278048563923e-07
mutations O 0 1.8973132682731375e-06
that O 0 1.46638939213517e-07
lead O 0 4.0782117594062584e-07
to O 0 2.031790842238479e-07
exon O 0 2.924505906776176e-06
skipping O 0 5.3836465667700395e-06
or O 0 1.541064420962357e-06
premature O 0 8.669132512295619e-06
protein O 0 1.6888340041987249e-06
truncation O 0 8.283484021376353e-06
were O 0 9.824777862377232e-07
also O 0 6.256265123738558e-07
predominant O 0 4.25421194449882e-06
in O 0 1.6471591379740858e-06
our O 0 8.089037692116108e-06
mutants O 0 0.0002684152568690479
. O 0 5.8897749113384634e-05

Six O 0 4.300280852476135e-05
different O 0 9.857892109721433e-06
mutations O 0 1.684477501839865e-05
were O 0 9.705945558380336e-07
identified O 0 1.0887198413911392e-06
on O 0 1.8669848600438854e-07
12 O 0 2.8656398853854625e-07
of O 0 2.1104868608290417e-07
the O 0 1.23001700558234e-06
16 O 0 7.481169177481206e-06
alleles O 0 7.324373291339725e-05
examined O 0 0.00027425665757618845
. O 0 9.92808272712864e-05

Four O 0 4.56787965958938e-05
were O 0 7.673186701140366e-06
deletions O 0 1.6907897588680498e-05
involving O 0 4.060831543029053e-06
a O 0 1.9292695014883066e-06
loss O 0 1.4700491192343179e-05
of O 0 3.315420258331869e-07
a O 0 6.738352453794505e-07
single O 0 1.6976556480585714e-06
exon O 0 1.3864239008398727e-05
exon O 0 1.1011228707502596e-05
7 O 0 1.7116902881753049e-06
, O 0 3.968685575728159e-07
exon O 0 5.397341737989336e-06
16 O 0 8.501065167365596e-07
, O 0 4.5939313508824853e-07
exon O 0 9.461487024964299e-06
33 O 0 3.249411292927107e-06
or O 0 2.454962441333919e-06
exon O 0 5.1486775191733614e-05
35 O 0 3.143166031804867e-05
. O 0 3.302658296888694e-05

The O 0 4.7163208364509046e-05
others O 0 1.1415157132432796e-05
were O 0 1.4795220977248391e-06
minute O 0 3.1020065307529876e-06
deletions O 0 5.886243343411479e-06
, O 0 6.415583584384876e-07
4649delA O 0 5.814233190903906e-06
in O 0 4.573608407554275e-07
exon O 0 5.870691893505864e-06
33 O 0 1.556552660986199e-06
and O 0 8.448869266430847e-07
7883del5 O 0 2.687615415197797e-05
in O 0 4.782653832080541e-06
exon O 0 8.987067121779546e-05
55 O 0 5.33578495378606e-05
. O 0 6.458529969677329e-05

The O 0 0.00011373400047887117
mutations O 0 0.0001625817531021312
4612del165 O 0 7.73671199567616e-05
and O 0 2.7476287414174294e-06
7883del5 O 0 2.1817284505232237e-05
were O 0 5.54717530576454e-07
found O 0 2.0401438405315275e-07
in O 0 7.148941705281686e-08
more O 0 6.439169908389886e-08
than O 0 6.890350334742834e-08
two O 0 1.0271390493699073e-07
unrelated O 0 3.4387712730676867e-06
families O 0 1.1230309837628738e-06
; O 0 4.342343231655832e-07
44 O 0 4.7598888386346516e-07
% O 0 2.70009536507132e-07
( O 0 1.0524661320232553e-07
7 O 0 9.669492584407635e-08
of O 0 6.096286142565077e-08
16 O 0 2.5528348146508506e-07
) O 0 5.103937184003371e-08
of O 0 2.5367000944243046e-08
the O 0 1.564408762533276e-07
mutant O 0 4.8171264097618405e-06
alleles O 0 2.56708722190524e-06
had O 0 3.5644009699353774e-07
one O 0 7.735069829095664e-08
of O 0 1.0503944736228732e-07
the O 0 7.69354642216058e-07
two O 0 3.703341462824028e-06
mutations O 0 0.00010228639439446852
. O 0 2.7435668016551062e-05

The O 0 6.032463352312334e-05
4612del165 O 0 0.0004894136800430715
mutations O 0 5.843792678206228e-05
in O 0 8.992486755232676e-07
three O 0 3.1792842491995543e-07
different O 0 3.063144049519906e-07
families O 0 7.593456530230469e-07
were O 0 1.1546827494157696e-07
all O 0 4.12861389520458e-08
ascribed O 0 3.7283277265487413e-07
to O 0 1.220698209181137e-07
the O 0 1.6641835998143506e-07
same O 0 1.378218257741537e-06
T O 1 0.7461070418357849
- O 0 0.003940777387470007
- O 0 3.3875952794915065e-05
> O 0 1.948451426869724e-06
A O 0 2.5663334213277267e-07
substitution O 0 6.017625082677114e-07
at O 0 4.250231881997024e-07
the O 0 5.116774559610349e-07
splice O 0 3.195214594597928e-05
donor O 0 8.158562195603736e-06
site O 0 5.620745014311979e-06
in O 0 3.5293580822326476e-06
intron O 0 0.000289266201434657
33 O 0 6.270487938309088e-05
. O 0 6.994536670390517e-05

Microsatellite O 0 0.00491739809513092
genotyping O 0 0.0010918810730800033
around O 0 1.6673222489771433e-05
the O 0 4.227442786941538e-06
ATM O 0 5.1551531214499846e-05
locus O 0 5.414532279246487e-05
also O 0 1.7532277070131386e-06
indicated O 0 2.647146175149828e-06
that O 0 2.2334231175591412e-07
a O 0 7.229334642033791e-07
common O 0 2.723512807278894e-06
haplotype O 0 8.232898107962683e-05
was O 0 3.577308007152169e-06
shared O 0 1.0272600547978072e-06
by O 0 3.677743620755791e-07
the O 0 8.26895586669707e-07
mutant O 0 2.9258755603223108e-05
alleles O 0 1.595509638718795e-05
in O 0 3.1628076158085605e-06
both O 0 1.262677506019827e-05
mutations O 0 0.0001712368248263374
. O 0 6.239381764316931e-05

This O 0 2.2413218175643124e-05
suggests O 0 1.286520819121506e-05
that O 0 6.693327350149048e-07
these O 0 4.4925403130946506e-07
two O 0 4.746389663523587e-07
founder O 0 0.00019358511781319976
mutations O 0 2.5425077183172107e-05
may O 0 1.3691554840988829e-06
be O 0 3.3601750715206435e-07
predominant O 0 3.0926958061172627e-06
among O 0 1.1635098644546815e-06
Japanese O 0 8.222456017392687e-06
ATM O 0 9.653170127421618e-05
mutant O 0 0.00019620732928160578
alleles O 0 0.00016797163698356599
. O 0 5.0294289394514635e-05

W474C O 0 0.0023053926415741444
amino O 0 0.00018808395543601364
acid O 0 8.022742258617654e-05
substitution O 0 2.2214384443941526e-05
affects O 0 1.2764226994477212e-05
early O 0 2.802782773869694e-06
processing O 0 1.0818361033670953e-06
of O 0 1.4351961397096602e-07
the O 0 3.149865506202332e-07
alpha O 0 1.7290367395617068e-06
- O 0 1.7959052911464823e-06
subunit O 0 9.552844630889012e-07
of O 0 2.0914941956107214e-07
beta O 0 2.5837643988779746e-06
- O 0 6.60833893562085e-06
hexosaminidase O 0 7.259967333084205e-06
A O 0 4.1495354707876686e-07
and O 0 2.410322679224919e-07
is O 0 2.6875406433646276e-07
associated O 0 1.2373832305456745e-06
with O 0 2.1846558411198203e-06
subacute O 1 0.9998751878738403
G B-Disease 1 0.9890568852424622
( I-Disease 0 1.0882042261073366e-05
M2 I-Disease 0 0.00014522821584250778
) I-Disease 0 1.2259087270649616e-05
gangliosidosis I-Disease 0 0.00024074269458651543
. O 0 4.2050902266055346e-05

Mutations O 0 0.0013067026156932116
in O 0 1.6818516087369062e-05
the O 0 7.483916306227911e-06
HEXA O 0 0.0012303563999012113
gene O 0 1.6084726667031646e-05
, O 0 7.434438771269924e-07
encoding O 0 2.3811567189113703e-06
the O 0 5.350916012503149e-07
alpha O 0 1.7440158899262315e-06
- O 0 1.902676785903168e-06
subunit O 0 1.2691463098235545e-06
of O 0 1.8363965637036017e-07
beta O 0 2.892497377615655e-06
- O 0 2.085557753161993e-05
hexosaminidase O 0 2.4120983653119765e-05
A O 0 9.962379863281967e-07
( O 0 3.727755313320813e-07
Hex O 0 3.848269898298895e-06
A O 0 6.605513362956117e-07
) O 0 2.539082402108761e-07
, O 0 1.0874212108546999e-07
that O 0 9.578317872183106e-08
abolish O 0 2.3868519747338723e-06
Hex O 0 4.923082087771036e-06
A O 0 5.934599016654829e-07
enzyme O 0 3.5212190141464816e-06
activity O 0 5.270955625746865e-06
cause O 0 0.018271813169121742
Tay B-Disease 1 1.0
- I-Disease 1 0.9999990463256836
Sachs I-Disease 1 1.0
disease I-Disease 0 0.3241317868232727
( O 0 1.7376655705447774e-06
TSD B-Disease 0 0.01390031911432743
) O 0 5.916708119002578e-07
, O 0 1.7299721832841897e-07
the O 0 7.047711960694869e-07
fatal O 0 0.00669592060148716
infantile B-Disease 0 0.0010860746260732412
form I-Disease 0 1.3621253174278536e-06
of I-Disease 0 8.504949846610543e-07
G I-Disease 0 0.014964978210628033
( I-Disease 0 1.1523762850629282e-06
M2 I-Disease 0 1.3082441910228226e-05
) I-Disease 0 1.2901533636977547e-06
gangliosidosis I-Disease 0 1.8278389688930474e-05
, I-Disease 0 1.6765560530984658e-06
Type I-Disease 0 1.2784121281583793e-05
1 I-Disease 0 7.733409802312963e-06
. O 0 2.2809912479715422e-05

Less O 0 0.001970350742340088
severe O 1 0.8373109102249146
, O 0 8.61998341861181e-05
subacute O 1 0.9990887641906738
( O 0 5.490387411555275e-05
juvenile O 1 0.6277843713760376
- O 1 0.8690977692604065
onset O 1 0.8167540431022644
) O 0 4.040904968860559e-06
and O 0 1.876153146440629e-05
chronic O 1 0.9827930927276611
( O 0 1.8861547914639232e-06
adult O 0 1.1462906513770577e-05
- O 0 0.06528528034687042
onset O 0 0.11575013399124146
) O 0 1.4751981325389352e-06
variants O 0 1.7041375031112693e-06
are O 0 2.0190772431760706e-07
characterized O 0 1.093105083782575e-06
by O 0 2.7449681283542304e-07
a O 0 5.132981186761754e-07
broad O 0 2.4019068405323196e-06
spectrum O 0 2.5748254302015994e-06
of O 0 3.32127825686257e-07
clinical O 0 3.300334356026724e-05
manifestations O 0 4.90029742650222e-06
and O 0 9.831563829720835e-07
are O 0 2.2796987764195364e-07
associated O 0 5.469780148814607e-07
with O 0 3.345750769767619e-07
residual O 0 1.3193650374887511e-05
levels O 0 1.4268021004681941e-06
of O 0 4.620694369350531e-07
Hex O 0 3.885637124767527e-05
A O 0 5.5416203394997865e-06
enzyme O 0 3.202350126230158e-05
activity O 0 2.2627293219557032e-05
. O 0 3.081051545450464e-05

We O 0 9.639960626373067e-05
identified O 0 4.3454827391542494e-05
a O 0 1.2366079317871481e-05
1422 O 0 0.0025085993111133575
G O 0 0.04822220280766487
- O 0 0.014575960114598274
- O 0 0.0008145932806655765
> O 0 4.0688097215024754e-05
C O 0 1.3901865713705774e-05
( O 0 5.62263608117064e-07
amino O 0 6.361178179759008e-07
acid O 0 1.322849925600167e-06
W474C O 0 1.9369238088984275e-06
) O 0 9.375336418315783e-08
substitution O 0 1.248631207317885e-07
in O 0 5.6954934990471884e-08
the O 0 5.101017563902133e-08
first O 0 1.221585534949554e-07
position O 0 2.2692348977670918e-07
of O 0 1.1995298621059192e-07
exon O 0 2.2378524136001943e-06
13 O 0 3.804778430094302e-07
of O 0 1.916713188165886e-07
HEXA O 0 6.521261093439534e-05
of O 0 2.2391857612547028e-07
a O 0 6.53891333968204e-07
non O 0 2.261941290271352e-06
- O 0 2.4785415007499978e-05
Jewish O 0 4.1288844840892125e-06
proband O 0 4.856819214182906e-05
who O 0 1.2067681609551073e-06
manifested O 0 7.322059445868945e-06
a O 0 2.827972593877348e-06
subacute O 1 0.7764815092086792
variant O 0 8.857963257469237e-05
of O 0 1.6563159306315356e-06
G B-Disease 0 0.012602796778082848
( I-Disease 0 4.830531452171272e-06
M2 I-Disease 0 8.026875730138272e-05
) I-Disease 0 1.021304342430085e-05
gangliosidosis I-Disease 0 0.0001933407038450241
. O 0 4.412695489008911e-05

On O 0 1.9580316802603193e-05
the O 0 4.9461978051112965e-06
second O 0 6.5106401052617e-06
maternally O 0 8.282095950562507e-05
inherited O 0 0.00033223695936612785
allele O 0 1.4568076039722655e-05
, O 0 7.429838433381519e-07
we O 0 4.2146396594944235e-07
identified O 0 8.770983868089388e-07
the O 0 6.870363336020091e-07
common O 0 2.8802516681025736e-05
infantile O 1 0.9992665648460388
disease O 1 0.7502163648605347
- O 0 0.001068039215169847
causing O 0 6.726258106937166e-06
4 O 0 1.8736840274868882e-06
- O 0 1.008459094009595e-05
bp O 0 1.7243637557839975e-05
insertion O 0 6.1058854043949395e-06
, O 0 1.556805045765941e-06
+ O 0 1.2220496500958689e-05
TATC O 0 8.263100608019158e-05
1278 O 0 0.00010311244113836437
, O 0 9.325859764430788e-07
in O 0 1.6029011931095738e-06
exon O 0 6.240179209271446e-05
11 O 0 1.9554658138076775e-05
. O 0 2.5547356926836073e-05

Pulse O 0 0.002760878764092922
- O 0 0.00367011409252882
chase O 0 0.00011140910646645352
analysis O 0 6.181518983794376e-06
using O 0 2.0456393485801527e-06
proband O 0 2.1570143871940672e-05
fibroblasts O 0 1.2068500836903695e-05
revealed O 0 3.8128021060401807e-06
that O 0 2.296575303262216e-07
the O 0 3.9333346535386227e-07
W474C O 0 1.7390286302543245e-05
- O 0 4.189639639662346e-06
containing O 0 4.6524735353159485e-07
alpha O 0 1.349820990981243e-06
- O 0 1.5649251281502075e-06
subunit O 0 8.645862976663921e-07
precursor O 0 1.009792072181881e-06
was O 0 2.3407234550631983e-07
normally O 0 1.8769573273402784e-07
synthesized O 0 5.24692495673662e-07
, O 0 1.0199781286246434e-07
but O 0 7.184166861406993e-08
not O 0 6.245761596801458e-08
phosphorylated O 0 6.550685043293925e-07
or O 0 2.3302017382320628e-07
secreted O 0 8.873697083799925e-07
, O 0 1.0553527118872807e-07
and O 0 1.1110005004866252e-07
the O 0 4.972940246261714e-07
mature O 0 3.829200068139471e-06
lysosomal O 0 6.635530735366046e-05
alpha O 0 4.013452326034894e-06
- O 0 3.1763131573825376e-06
subunit O 0 2.6295786028640578e-06
was O 0 1.2256854233783088e-06
not O 0 1.3489934644894674e-06
detected O 0 1.3333801689441316e-05
. O 0 1.4774473129364196e-05

When O 0 5.982758739264682e-05
the O 0 9.081773896468803e-06
W474C O 0 4.86245407955721e-05
- O 0 1.0555440894677304e-05
containing O 0 1.6977932091322145e-06
alpha O 0 3.823285169346491e-06
- O 0 3.1714519082015613e-06
subunit O 0 2.086238055198919e-06
was O 0 1.1603506209212355e-06
transiently O 0 1.239329321833793e-05
co O 0 1.2375116057228297e-05
- O 0 4.2071646930708084e-06
expressed O 0 2.942989283383213e-07
with O 0 1.369641040582792e-07
the O 0 3.122576117675635e-07
beta O 0 2.0615025277948007e-06
- O 0 1.6593024838584824e-06
subunit O 0 8.466275289720215e-07
to O 0 2.396085960754135e-07
produce O 0 7.396159844574868e-07
Hex O 0 4.141283170611132e-06
A O 0 6.333611395348271e-07
( O 0 4.524011671946937e-07
alphabeta O 0 7.670611012144946e-06
) O 0 3.8050978901083e-07
in O 0 3.0501371384161757e-07
COS O 0 5.9220343246124685e-05
- O 0 1.7491795006208122e-05
7 O 0 9.585635325493058e-07
cells O 0 1.0599194411042845e-06
, O 0 8.225620007351608e-08
the O 0 1.2890879474980466e-07
mature O 0 6.8690405896632e-07
alpha O 0 6.382361448231677e-07
- O 0 6.411155482055619e-07
subunit O 0 4.0553680946686654e-07
was O 0 1.744335662579033e-07
present O 0 5.8619924914182775e-08
, O 0 5.491529009304941e-08
but O 0 5.18670582039249e-08
its O 0 5.15198053108179e-08
level O 0 1.0917146653355303e-07
was O 0 1.22613045050457e-07
much O 0 8.174912835556825e-08
lower O 0 4.1449081322753045e-07
than O 0 4.913147932938955e-08
that O 0 6.01893361817929e-08
from O 0 8.413605456780715e-08
normal O 0 4.5311230678635184e-07
alpha O 0 8.271447882179928e-07
- O 0 1.3463009054248687e-06
subunit O 0 1.032871296047233e-06
transfections O 0 3.1692204629507614e-06
, O 0 1.2665827853197698e-07
although O 0 1.793952293382972e-07
higher O 0 2.4364894102291146e-07
than O 0 1.240318709960775e-07
in O 0 1.473552799780009e-07
those O 0 4.675255240726983e-07
cells O 0 3.890962489094818e-06
transfected O 0 1.6270834748866037e-05
with O 0 3.215006643131346e-07
an O 0 4.851274866268795e-07
alpha O 0 4.863026333623566e-06
- O 0 7.701850336161442e-06
subunit O 0 6.571710855496349e-06
associated O 0 5.157258328836178e-06
with O 0 7.737807209196035e-06
infantile O 0 0.11238706111907959
TSD B-Disease 1 0.8466120362281799
. O 0 0.00010787299834191799

Furthermore O 0 0.00018393744539935142
, O 0 5.501904979610117e-06
the O 0 1.2871216767962324e-06
precursor O 0 4.521951268543489e-06
level O 0 7.570383786514867e-07
of O 0 1.4290338867795072e-07
the O 0 2.814807658069185e-07
W474C O 0 6.7155669967178255e-06
alpha O 0 2.008971478062449e-06
- O 0 1.452265109946893e-06
subunit O 0 6.026205028319964e-07
was O 0 2.69922765028241e-07
found O 0 1.2591951303875248e-07
to O 0 8.882470581283997e-08
accumulate O 0 1.0897243782892474e-06
in O 0 1.0885293022511178e-07
comparison O 0 4.69350908360866e-07
to O 0 1.3552109123793343e-07
the O 0 2.9517423172364943e-07
normal O 0 2.645783069965546e-06
alpha O 0 5.140592747920891e-06
- O 0 8.867302312864922e-06
subunit O 0 1.4323250070447102e-05
precursor O 0 2.6879075448960066e-05
levels O 0 3.173275035806e-05
. O 0 3.949754318455234e-05

We O 0 5.301563942339271e-05
conclude O 0 2.844688242475968e-05
that O 0 1.3238002338766819e-06
the O 0 1.3382123142946512e-06
1422 O 0 0.0016660650726407766
G O 0 0.00885701086372137
- O 0 0.0013086237013339996
- O 0 0.000283839792245999
> O 0 2.7688893169397488e-05
C O 0 2.995384238602128e-05
mutation O 0 1.6427948139607906e-06
is O 0 9.36947301966029e-08
the O 0 1.8128740464362636e-07
cause O 0 1.2003886240563588e-06
of O 0 3.1821934953768505e-07
Hex B-Disease 0 0.017396915704011917
A I-Disease 0 0.07705153524875641
enzyme I-Disease 1 0.9999986886978149
deficiency I-Disease 1 0.9999938011169434
in O 0 3.231999016861664e-06
the O 0 7.739909960946534e-06
proband O 0 0.019362080842256546
. O 0 7.773926336085424e-05

The O 0 9.827561734709889e-05
resulting O 0 7.679863483645022e-05
W474C O 0 0.00011022958642570302
substitution O 0 2.3210306608234532e-05
clearly O 0 1.0393926459073555e-05
interferes O 0 9.689329999673646e-06
with O 0 8.542960472368577e-07
alpha O 0 2.848234544217121e-06
- O 0 2.1218681922619e-06
subunit O 0 1.4107604329183232e-06
processing O 0 7.018582550699648e-07
, O 0 1.3486804562035104e-07
but O 0 1.2755698719502107e-07
because O 0 1.4901181089044258e-07
the O 0 6.449175060652124e-08
base O 0 2.1008457906646072e-07
substitution O 0 5.125360189595085e-07
falls O 0 2.4450066575809615e-06
at O 0 1.2052575470988813e-07
the O 0 6.45796376375074e-08
first O 0 1.1490628537558223e-07
position O 0 2.6158517130170367e-07
of O 0 9.701840042453114e-08
exon O 0 3.0979738312453264e-06
13 O 0 4.812736733583733e-07
, O 0 1.6297433091949642e-07
aberrant O 0 1.0814987945195753e-06
splicing O 0 6.530203336296836e-06
may O 0 9.227166515302088e-07
also O 0 1.572795014226358e-07
contribute O 0 3.014101821463555e-07
to O 0 2.8336751256574644e-07
Hex B-Disease 0 0.00025335411191917956
A I-Disease 0 3.6987657949794084e-05
deficiency I-Disease 0 0.0038893744349479675
in O 0 8.922286838242144e-07
this O 0 1.9044267673962167e-06
proband O 0 0.002761577256023884
. O 0 1.2588816389325075e-05
. O 0 3.605191523092799e-05

Two O 0 0.0001410088880220428
frequent O 0 0.00044017782784067094
missense O 0 0.009665952995419502
mutations O 0 0.02844541147351265
in O 0 0.007077510468661785
Pendred B-Disease 1 0.9999998807907104
syndrome I-Disease 1 1.0
. O 0 0.0003208013076800853

Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 0.0024059503339231014
an O 0 0.17967595160007477
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 0 0.0880049616098404
by O 0 3.4422922908561304e-05
early O 0 0.1945333182811737
childhood O 1 0.9998412132263184
deafness B-Disease 1 1.0
and O 1 0.924347996711731
goiter B-Disease 1 0.9999998807907104
. O 0 0.0006326630245894194

A O 0 5.5856256949482486e-05
century O 0 1.784527557902038e-05
after O 0 7.423785973514896e-06
its O 0 7.725809609837597e-07
recognition O 0 1.4820668639003998e-06
as O 0 2.5700121568661416e-06
a O 0 3.7455167330335826e-05
syndrome O 1 0.8329426050186157
by O 0 4.7534564373563626e-07
Vaughan O 0 0.00018587097292765975
Pendred O 0 0.0010602878173813224
, O 0 1.0167901791646727e-06
the O 0 2.001692564590485e-06
disease O 0 0.0014531880151480436
gene O 0 6.045319878467126e-06
( O 0 9.481768188379647e-07
PDS O 0 0.0009779427200555801
) O 0 3.1408126233145595e-07
was O 0 4.3060941834482946e-07
mapped O 0 2.8981246487091994e-06
to O 0 1.5779345403643674e-06
chromosome O 0 2.0329303879407234e-05
7q22 O 0 0.00016930369019974023
- O 0 0.00024379750539083034
q31 O 0 0.0004582552064675838
. O 0 6.605605449294671e-05

1 O 0 4.3572137656155974e-05
and O 0 5.591755780187668e-06
, O 0 1.7785270074455184e-06
recently O 0 3.237811142753344e-06
, O 0 5.561699936151854e-07
found O 0 5.313747806212632e-07
to O 0 4.853019390793634e-07
encode O 0 6.357797701639356e-06
a O 0 6.632279564655619e-06
putative O 0 0.0005125978495925665
sulfate O 0 0.010300874710083008
transporter O 0 0.0014621119480580091
. O 0 7.511601143050939e-05

We O 0 6.2966973928269e-05
performed O 0 2.0463789041968994e-05
mutation O 0 1.9116627299808897e-05
analysis O 0 2.462043312334572e-06
of O 0 3.41662087066652e-07
the O 0 7.448078349625575e-07
PDS B-Disease 0 0.019640395417809486
gene O 0 5.542751296161441e-06
in O 0 1.4017374496688717e-06
patients O 0 9.532446711091325e-06
from O 0 2.9302580628609576e-07
14 O 0 7.482650516976719e-07
Pendred B-Disease 0 3.313251363579184e-05
families O 0 6.425490255423938e-07
originating O 0 4.7244327561202226e-07
from O 0 1.5449020906999067e-07
seven O 0 2.1429924856875004e-07
countries O 0 1.4209722110081202e-07
and O 0 5.742495545746351e-07
identified O 0 4.7544990593451075e-06
all O 0 3.3043706935131922e-06
mutations O 0 0.00010727035987656564
. O 0 4.577844083542004e-05

The O 0 5.684054849552922e-05
mutations O 0 6.734236376360059e-05
include O 0 2.49226263804303e-06
three O 0 8.778264941611269e-07
single O 0 1.5970556432876037e-06
base O 0 2.442180402795202e-06
deletions O 0 6.01942110733944e-06
, O 0 8.503530466441589e-07
one O 0 9.47740147694276e-07
splice O 0 7.029320840956643e-05
site O 0 9.33952924242476e-06
mutation O 0 1.617665657249745e-05
and O 0 4.864102265855763e-06
10 O 0 1.1645483027677983e-05
missense O 0 0.00039128982461988926
mutations O 0 0.00032696151174604893
. O 0 6.989056419115514e-05

One O 0 0.00015892161172814667
missense O 0 0.001253653084859252
mutation O 0 0.00025492935674265027
( O 0 1.4711557923874352e-05
L236P O 0 5.5535190767841414e-05
) O 0 1.469745484428131e-06
was O 0 7.430504638250568e-07
found O 0 3.6239103451407573e-07
in O 0 1.551167514435292e-07
a O 0 3.642447268248361e-07
homozygous O 0 4.5456977204594295e-06
state O 0 1.595889358441127e-07
in O 0 1.4304627882211207e-07
two O 0 2.808295107570302e-07
consanguineous O 0 0.00094013282796368
families O 0 1.6116979395519593e-06
and O 0 2.300130432786318e-07
in O 0 1.954099531076281e-07
a O 0 3.6522564528240764e-07
heterozygous O 0 2.753817170741968e-06
state O 0 3.5860483649230446e-07
in O 0 3.2837550634212676e-07
five O 0 4.5509708002100524e-07
additional O 0 2.0927600417053327e-06
non O 0 6.746686722181039e-06
- O 0 0.0002659532183315605
consanguineous O 0 0.0008359962375834584
families O 0 5.405601768870838e-05
. O 0 3.637744521256536e-05

Another O 0 0.0002783964737318456
missense O 0 0.0012199896154925227
mutation O 0 0.0002390225272392854
( O 0 6.3276679611590225e-06
T416P O 0 2.5051087504834868e-05
) O 0 8.992675475383294e-07
was O 0 5.331473289515998e-07
found O 0 2.622290935505589e-07
in O 0 1.0487929102964699e-07
a O 0 3.173292668634531e-07
homozygous O 0 5.169815267436206e-06
state O 0 2.3476604837924242e-07
in O 0 1.5975842870830093e-07
one O 0 2.2109929886937607e-07
family O 0 6.954041396056709e-07
and O 0 1.9424757624619815e-07
in O 0 1.6337753550033085e-07
a O 0 6.457126460190921e-07
heterozygous O 0 4.343537966633448e-06
state O 0 6.925489515197114e-07
in O 0 6.959959364394308e-07
four O 0 3.5396726616454544e-06
families O 0 4.370809983811341e-05
. O 0 4.422320853336714e-05

Pendred B-Disease 1 0.8350666761398315
patients O 0 0.025288857519626617
in O 0 4.794486358150607e-06
three O 0 2.9881991849833867e-06
non O 0 7.313935384445358e-06
- O 0 9.690633305581287e-05
consanguineous O 0 0.000131556109408848
families O 0 3.9444717003789265e-06
were O 0 4.823902486350562e-07
shown O 0 4.2989998405573715e-07
to O 0 3.1928388466440083e-07
be O 0 3.102030916579679e-07
compound O 0 2.7318317279423354e-06
heterozygotes O 0 1.9291155695100315e-05
for O 0 1.3136148027115269e-06
L236P O 0 6.775500514777377e-05
and O 0 1.1633773283392657e-05
T416P O 0 0.0004740815202239901
. O 0 6.590165139641613e-05

In O 0 1.6793175745988265e-05
total O 0 2.871641299861949e-06
, O 0 6.11395137184445e-07
one O 0 2.277755726254327e-07
or O 0 2.3982028096725116e-07
both O 0 6.793910500846323e-08
of O 0 5.141712122735953e-08
these O 0 2.1933810501195694e-07
mutations O 0 2.0616303118004e-06
were O 0 2.0269293088404083e-07
found O 0 1.7181834266466467e-07
in O 0 1.1811614797352377e-07
nine O 0 2.81803380630663e-07
of O 0 1.6720105122658424e-07
the O 0 1.358029066977906e-06
14 O 0 5.7703678066900466e-06
families O 0 1.1372357221262064e-05
analyzed O 0 6.156764720799401e-05
. O 0 3.528222077875398e-05

The O 0 1.2323934242886025e-05
identification O 0 7.0338255682145245e-06
of O 0 7.450841508216399e-07
two O 0 1.0686624136724276e-06
frequent O 0 9.260133083444089e-06
PDS B-Disease 0 0.44372567534446716
mutations O 0 1.1111294043075759e-05
will O 0 3.0055824140617915e-07
facilitate O 0 9.379249945595802e-07
the O 0 1.207224045174371e-06
molecular O 0 0.0027814197819679976
diagnosis O 1 0.9641238451004028
of O 0 0.000651723297778517
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.000355495692929253

Insertional O 0 0.007209456991404295
mutation O 0 0.00028261440456844866
by O 0 6.102956831455231e-06
transposable O 0 0.00012453587260097265
element O 0 7.910350177553482e-06
, O 0 1.8110716837327345e-06
L1 O 0 6.357473466778174e-05
, O 0 4.3900362811655214e-07
in O 0 3.12843638994309e-07
the O 0 1.3639113376484602e-06
DMD B-Disease 1 0.9999969005584717
gene O 0 2.4272445443784818e-05
results O 0 3.173405275447294e-05
in O 0 3.436450242588762e-06
X B-Disease 1 0.9978208541870117
- I-Disease 1 0.9970229268074036
linked I-Disease 1 0.8370217084884644
dilated I-Disease 1 0.9987044334411621
cardiomyopathy I-Disease 1 0.9999923706054688
. O 0 0.00018271034059580415

X B-Disease 1 0.9988763928413391
- I-Disease 1 0.9995771050453186
linked I-Disease 1 0.7472121119499207
dilated I-Disease 1 0.9993733763694763
cardiomyopathy I-Disease 1 0.9999990463256836
( O 0 2.051377305178903e-05
XLDCM B-Disease 0 0.026092570275068283
) O 0 1.4439511915043113e-06
is O 0 2.928408378011227e-07
a O 0 1.3317917364474852e-06
clinical O 0 0.010604564100503922
phenotype O 0 0.0013847225345671177
of O 0 3.830570278751111e-07
dystrophinopathy B-Disease 0 0.04937150329351425
which O 0 5.825922357871605e-07
is O 0 1.959806610329906e-07
characterized O 0 2.1712796751671704e-06
by O 0 8.084232945293479e-07
preferential O 0 3.32476593030151e-05
myocardial B-Disease 1 0.9743525981903076
involvement I-Disease 0 1.0364944500906859e-05
without O 0 1.6189289908652427e-06
any O 0 9.489122589911858e-07
overt O 0 1.0810638741531875e-05
clinical O 0 0.0007032713619992137
signs O 0 2.3243512259796262e-05
of O 0 2.833733378793113e-05
skeletal B-Disease 1 0.9999996423721313
myopathy I-Disease 1 1.0
. O 0 0.002662746934220195

To O 0 2.522820796002634e-05
date O 0 8.866313692124095e-06
, O 0 1.493055492574058e-06
several O 0 1.1827446542156395e-06
mutations O 0 6.657347967120586e-06
in O 0 1.2443914556570235e-06
the O 0 8.832260391500313e-06
Duchenne B-Disease 1 0.9991669654846191
muscular I-Disease 1 0.9893549680709839
dystrophy I-Disease 1 0.9992233514785767
gene O 0 7.263388397404924e-05
, O 0 1.3911321730120108e-05
DMD O 1 0.9999985694885254
, O 0 2.3401257749355864e-06
have O 0 6.109131618359243e-07
been O 0 4.151027610532765e-07
identified O 0 1.6999367744574556e-06
in O 0 1.5479608919122256e-06
patients O 0 2.2637739675701596e-05
with O 0 3.2551631079513754e-07
XLDCM B-Disease 0 0.1291002482175827
, O 0 5.341387350199511e-07
but O 0 2.4475843929394614e-07
a O 0 2.802686935865495e-07
pathogenic O 0 1.5282087133527966e-06
correlation O 0 5.826389042340452e-07
of O 0 1.0796134830570736e-07
these O 0 3.9255701267393306e-07
cardiospecific O 0 0.0018396911909803748
mutations O 0 2.0406185285537504e-05
in O 0 1.2549622852020548e-06
DMD O 1 0.9999816417694092
with O 0 9.300794658884115e-07
the O 0 2.937346607723157e-06
XLDCM B-Disease 1 0.9864730834960938
phenotype O 0 0.3064171075820923
has O 0 2.1733389985456597e-06
remained O 0 3.140955413982738e-06
to O 0 9.187021987600019e-07
be O 0 2.684438413780299e-06
elucidated O 0 0.0001081417067325674
. O 0 4.15613321820274e-05

We O 0 7.079113129293546e-05
report O 0 1.1492109479149804e-05
here O 0 1.2216594313940732e-06
the O 0 4.212116095914098e-07
identification O 0 8.369890451831452e-07
of O 0 2.340772624620513e-07
a O 0 1.1053417665607412e-06
unique O 0 2.4296821266034385e-06
de O 0 5.535113359655952e-06
novo O 0 1.1317351891193539e-05
L1 O 0 3.459348590695299e-05
insertion O 0 3.60118315256841e-06
in O 0 4.131206310376001e-07
the O 0 3.8603189977948205e-07
muscle O 0 6.448876320064301e-06
exon O 0 8.298870852740947e-06
1 O 0 6.797175728934235e-07
in O 0 5.526961786017637e-07
DMD O 1 0.9998219609260559
in O 0 6.827359584349324e-07
three O 0 1.818222244764911e-06
XLDCM B-Disease 1 0.9641331434249878
patients O 0 0.00015891084331087768
from O 0 4.983708663530706e-07
two O 0 8.41649182348192e-07
unrelated O 0 2.435889473417774e-05
Japanese O 0 2.8119873604737222e-05
families O 0 3.9080940041458234e-05
. O 0 3.177402322762646e-05

The O 0 2.6884250473813154e-05
insertion O 0 5.046778096584603e-05
was O 0 6.810128070355859e-06
a O 0 2.2868809992360184e-06
5 O 0 1.617162183720211e-06
- O 0 3.4670047170948237e-06
truncated O 0 4.274224465916632e-06
form O 0 8.877472055246471e-07
of O 0 1.9720251032140368e-07
human O 0 6.432185841731553e-07
L1 O 0 1.3176222637412138e-05
inversely O 0 5.176574632059783e-06
integrated O 0 3.428829131735256e-06
in O 0 3.8345027064679016e-07
the O 0 3.184406693890196e-07
5 O 0 1.0340066864955588e-06
- O 0 6.904334895807551e-06
untranslated O 0 1.0521423064346891e-05
region O 0 8.47264004733006e-07
in O 0 2.641598086938757e-07
the O 0 3.709106124460959e-07
muscle O 0 4.052764779771678e-06
exon O 0 6.214915629243478e-06
1 O 0 4.19413424879167e-07
, O 0 1.1016462764246171e-07
which O 0 1.2523352665994025e-07
affected O 0 2.1977110975512915e-07
the O 0 7.854333006207526e-08
transcription O 0 3.030426967143285e-07
or O 0 1.643221168023956e-07
the O 0 8.794036432391295e-08
stability O 0 3.246271944590262e-07
of O 0 5.565425809095359e-08
the O 0 2.4309747459483333e-07
muscle O 0 2.56980615631619e-06
form O 0 2.085324268819022e-07
of O 0 1.2424852968706546e-07
dystrophin O 0 1.6162468455149792e-05
transcripts O 0 3.774733841055422e-06
but O 0 3.806767381320242e-07
not O 0 7.673646251760147e-08
that O 0 2.7190070639449004e-08
of O 0 4.617835003273285e-08
the O 0 4.242731677095435e-07
brain O 0 0.0001520432997494936
or O 0 7.50163565044204e-07
Purkinje O 0 0.016150053590536118
cell O 0 2.3814702217350714e-05
form O 0 6.027825634191686e-07
, O 0 3.4215474897791864e-07
probably O 0 7.126301397875068e-07
due O 0 4.152674932811351e-07
to O 0 1.9365994319286983e-07
its O 0 2.0277296641779685e-07
unique O 0 5.07521292547608e-07
site O 0 1.428234327249811e-06
of O 0 1.118080945161637e-06
integration O 0 3.262588506913744e-05
. O 0 3.282656325609423e-05

We O 0 7.370104140136391e-05
speculate O 0 4.408190579852089e-05
that O 0 1.000077077151218e-06
this O 0 2.119383708532041e-07
insertion O 0 1.0571513939794386e-06
of O 0 1.3270559406919347e-07
an O 0 2.341183176213235e-07
L1 O 0 2.6493677069083788e-05
sequence O 0 1.2072077879565768e-06
in O 0 1.838844696067099e-06
DMD O 1 0.9999936819076538
is O 0 3.2642748237776686e-07
responsible O 0 4.0249256016977597e-07
for O 0 8.272395746189432e-08
some O 0 4.3289297479987e-08
of O 0 4.18217567244028e-08
the O 0 1.5285307597423525e-07
population O 0 2.1753700707449752e-07
of O 0 2.05690994903307e-07
Japanese O 0 1.564278863952495e-05
patients O 0 1.928105666593183e-05
with O 0 1.9136280116072157e-06
XLDCM B-Disease 0 0.21348868310451508
. O 0 1.5618370525771752e-05
. O 0 3.5341083275852725e-05

Severe O 1 0.9936025738716125
early O 0 0.1567143201828003
- O 1 0.9997844099998474
onset O 1 0.9999667406082153
obesity B-Disease 1 0.9999963045120239
, O 0 0.00038791910628788173
adrenal B-Disease 1 0.9999750852584839
insufficiency I-Disease 1 0.9999985694885254
and O 0 6.770966137992218e-05
red O 0 0.006395758595317602
hair O 1 0.9599438905715942
pigmentation O 1 0.9474465250968933
caused O 0 0.0008069282630458474
by O 0 1.4594623280572705e-05
POMC O 1 0.9862031936645508
mutations O 0 9.52828922891058e-05
in O 0 6.666744866379304e-06
humans O 0 3.0902472644811496e-05
. O 0 3.210725844837725e-05

Sequential O 0 0.0005627868813462555
cleavage O 0 0.00041403676732443273
of O 0 4.8356391744164284e-06
the O 0 2.0193576801830204e-06
precursor O 0 1.0184031452808995e-05
protein O 0 5.400946065492462e-06
pre O 0 6.615906022489071e-05
- O 0 0.0001274927781196311
pro O 0 1.941360824275762e-05
- O 0 0.0001927465491462499
opiomelanocortin O 0 0.000137305396492593
( O 0 2.676149051694665e-06
POMC O 0 0.0001252684451173991
) O 0 7.203801715149893e-07
generates O 0 6.837290129624307e-07
the O 0 4.991289870304172e-07
melanocortin O 0 5.908372259000316e-05
peptides O 0 1.267830975848483e-05
adrenocorticotrophin O 0 7.858882599975914e-05
( O 0 1.97984445549082e-06
ACTH O 0 1.563822297612205e-05
) O 0 5.889157250749122e-07
, O 0 3.6449631579671404e-07
melanocyte O 0 3.058209040318616e-05
- O 0 2.7653848519548774e-05
stimulating O 0 5.623769084195374e-06
hormones O 0 4.899596660834504e-06
( O 0 6.772968390578171e-07
MSH O 0 2.6346382583142258e-05
) O 0 3.0998927513792296e-07
alpha O 0 6.759372581655043e-07
, O 0 9.831229874635028e-08
beta O 0 4.37632138527988e-07
and O 0 8.527440797934105e-08
gamma O 0 7.168288789216604e-07
as O 0 7.667384238629893e-08
well O 0 1.268011402544289e-07
as O 0 1.3106424034958764e-07
the O 0 4.847403829444374e-07
opioid O 0 3.228915375075303e-05
- O 0 3.330018080305308e-05
receptor O 0 1.3573204341810197e-05
ligand O 0 2.4723309252294712e-05
beta O 0 6.474564725067466e-05
- O 0 0.0002747712132986635
endorphin O 0 0.003381336573511362
. O 0 8.75587502378039e-05

While O 0 3.7430600059451535e-05
a O 0 8.257943591161165e-06
few O 0 4.046600679430412e-06
cases O 0 2.3914910798339406e-06
of O 0 1.3862526202501613e-06
isolated O 0 0.009471547789871693
ACTH B-Disease 1 0.9999284744262695
deficiency I-Disease 1 0.9958470463752747
have O 0 2.9657651339221047e-06
been O 0 1.9742483345908113e-06
reported O 0 1.3658344869327266e-05
( O 0 2.7025707822758704e-06
OMIM O 0 0.09935524314641953
201400 O 0 7.593812915729359e-05
) O 0 5.362036858969077e-07
, O 0 1.7261358209452737e-07
an O 0 4.411044756125193e-07
inherited O 0 0.4083784818649292
POMC O 1 0.9977679252624512
defect O 0 0.0032275826670229435
has O 0 9.980561799238785e-07
not O 0 4.846534693569993e-07
been O 0 6.289635052780795e-07
described O 0 3.1115168894757517e-06
so O 0 2.9635314149345504e-06
far O 0 1.2351159057288896e-05
. O 0 2.7294381652609445e-05

Recent O 0 0.000495170010253787
studies O 0 8.148480992531404e-05
in O 0 5.343034899851773e-06
animal O 0 5.208975835557794e-06
models O 0 5.264706032903632e-06
elucidated O 0 1.1001488019246608e-05
a O 0 5.751275580223592e-07
central O 0 3.372609285179351e-07
role O 0 5.630545274470933e-07
of O 0 2.5920618895725056e-07
alpha O 0 3.221855649826466e-06
- O 0 1.971565689018462e-05
MSH O 0 3.619352719397284e-05
in O 0 1.3669345833022817e-07
the O 0 1.127234483533357e-07
regulation O 0 4.6650737317577295e-07
of O 0 1.1571995628401055e-07
food O 0 5.509531888492347e-07
intake O 0 1.6190493852263899e-06
by O 0 1.7147982589449384e-07
activation O 0 7.299876187971677e-07
of O 0 1.622850902549544e-07
the O 0 7.96828487636958e-07
brain O 0 0.0016022849595174193
melanocortin O 0 0.011089780367910862
- O 0 0.0009373601642437279
4 O 0 2.1691168967663543e-06
- O 0 1.0447402019053698e-05
receptor O 0 5.570508164964849e-06
( O 0 1.1402831887608045e-06
MC4 O 0 0.000318194244755432
- O 0 5.578338823397644e-05
R O 0 1.9881352272932418e-05
; O 0 6.094460900385457e-07
refs O 0 3.722902192748734e-06
3 O 0 8.323182782987715e-07
- O 0 2.2699584860674804e-06
5 O 0 2.851164708772558e-07
) O 0 7.452974415400604e-08
and O 0 3.810442805729508e-08
the O 0 5.95105831280307e-08
linkage O 0 7.426325510095921e-07
of O 0 1.4988778218594234e-07
human O 0 8.656357977088192e-07
obesity B-Disease 0 0.042257051914930344
to O 0 3.4585534081088554e-07
chromosome O 0 1.0247082400383078e-06
2 O 0 1.8584793792797427e-07
in O 0 9.829916791659343e-08
close O 0 2.4210399374169356e-07
proximity O 0 3.245135928864329e-07
to O 0 2.1857718479623145e-07
the O 0 4.043107537654578e-07
POMC O 0 0.0007442019996233284
locus O 0 7.828360139683355e-06
, O 0 2.3285713268705877e-07
led O 0 2.3057351938859938e-07
to O 0 1.0764756552816834e-07
the O 0 1.5375367468095646e-07
proposal O 0 9.033072956299293e-07
of O 0 9.953284774155691e-08
an O 0 1.9766022774092562e-07
association O 0 1.0884800758503843e-06
of O 0 6.848324574093567e-07
POMC O 0 0.0541783943772316
with O 0 3.2899974939937238e-06
human O 0 3.6561701563186944e-05
obesity B-Disease 1 0.9859765768051147
. O 0 7.847545202821493e-05

The O 0 2.0029829101986252e-05
dual O 0 2.039824721578043e-05
role O 0 5.039934876549523e-06
of O 0 1.367674258290208e-06
alpha O 0 1.6459031030535698e-05
- O 0 5.3423631470650434e-05
MSH O 0 0.00015135679859668016
in O 0 9.60368879532325e-07
regulating O 0 2.2030128548067296e-06
food O 0 1.0004938530983054e-06
intake O 0 2.6144853109144606e-06
and O 0 4.675941909226822e-07
influencing O 0 1.157838778453879e-05
hair O 0 0.019015541300177574
pigmentation O 0 0.03648995980620384
predicts O 0 0.0007932346779853106
that O 0 4.5669094106415287e-07
the O 0 1.1283547109997016e-06
phenotype O 0 0.27188071608543396
associated O 0 2.146474798792042e-06
with O 0 4.840298970520962e-07
a O 0 3.0367532417585608e-06
defect O 0 0.0011851645540446043
in O 0 1.8187043906436884e-06
POMC O 0 0.09717430919408798
function O 0 1.602847646609007e-06
would O 0 6.998470212238317e-07
include O 0 1.9045338603973505e-06
obesity B-Disease 1 0.5379189252853394
, O 0 1.072055511031067e-06
alteration O 0 7.051287866488565e-06
in O 0 5.695499112334801e-06
pigmentation O 0 0.2586144208908081
and O 0 0.0038100462406873703
ACTH B-Disease 1 0.9989612102508545
deficiency I-Disease 1 0.94754558801651
. O 0 6.83271573507227e-05

The O 0 3.390216443222016e-05
observation O 0 2.3863307433202863e-05
of O 0 1.1471382777017425e-06
these O 0 2.072525830953964e-06
symptoms O 0 1.6310184946632944e-05
in O 0 3.4668818216232467e-07
two O 0 3.1936764344209223e-07
probands O 0 3.306150028947741e-05
prompted O 0 2.5329902655357728e-06
us O 0 6.670584298262838e-07
to O 0 2.4364848627556057e-07
search O 0 1.1472269534351653e-06
for O 0 7.320009558497986e-07
mutations O 0 3.939509497286053e-06
within O 0 6.510675234494556e-07
their O 0 4.858279226027662e-06
POMC O 0 0.14294388890266418
genes O 0 7.498267223127186e-05
. O 0 2.5607088900869712e-05

Patient O 0 0.01684039644896984
1 O 0 1.5217779036902357e-05
was O 0 2.366017724853009e-06
found O 0 5.920896342104243e-07
to O 0 1.874295634252121e-07
be O 0 1.4906609635545465e-07
a O 0 2.830220751093293e-07
compound O 0 1.1214074220333714e-06
heterozygote O 0 9.760407920111902e-06
for O 0 2.05154790933193e-07
two O 0 3.6295062955105095e-07
mutations O 0 1.5136894262468559e-06
in O 0 2.512393848519423e-07
exon O 0 4.043144599563675e-06
3 O 0 5.987308782096079e-07
( O 0 2.8495227866187633e-07
G7013T O 0 3.435070766499848e-06
, O 0 2.384110047159993e-07
C7133delta O 0 8.661231731821317e-06
) O 0 1.3586064540049847e-07
which O 0 1.0479030976284776e-07
interfere O 0 4.309274004299368e-07
with O 0 1.0912233960880258e-07
appropriate O 0 5.28558643964061e-07
synthesis O 0 9.472901183471549e-07
of O 0 7.174074312388257e-07
ACTH O 0 5.876293289475143e-05
and O 0 3.4555043839645805e-06
alpha O 0 4.5993729145266116e-05
- O 0 0.0002505565353203565
MSH O 0 0.0024677328765392303
. O 0 6.076996942283586e-05

Patient O 0 0.02925727888941765
2 O 0 3.334195935167372e-05
was O 0 4.7897697186272126e-06
homozygous O 0 1.0610486242512707e-05
for O 0 6.678789645775396e-07
a O 0 1.1311182106510387e-06
mutation O 0 8.90679621079471e-06
in O 0 1.10305450107262e-06
exon O 0 1.4900122550898232e-05
2 O 0 1.8970273458762676e-06
( O 0 1.3305780157679692e-06
C3804A O 0 2.387869608355686e-05
) O 0 1.7119890571848373e-06
which O 0 3.1013410080049653e-06
abolishes O 0 0.00017830733850132674
POMC O 0 0.005228173919022083
translation O 0 0.0001520611549494788
. O 0 8.853351755533367e-05

These O 0 3.2931948226178065e-05
findings O 0 1.7570744603290223e-05
represent O 0 2.0511872662609676e-06
the O 0 5.614266456177575e-07
first O 0 5.12276074005058e-07
examples O 0 7.29033104107657e-07
of O 0 3.653928501989867e-07
a O 0 0.00013666899758391082
genetic B-Disease 1 0.9993985891342163
defect I-Disease 1 0.9725038409233093
within O 0 6.144077246972302e-07
the O 0 1.1966304782617954e-06
POMC O 0 0.05566614121198654
gene O 0 3.0363739824679215e-06
and O 0 3.470090348400845e-07
define O 0 1.7350326970699825e-06
a O 0 1.2449777386791538e-06
new O 0 7.183751586126164e-05
monogenic B-Disease 1 0.9996383190155029
endocrine I-Disease 1 0.9997015595436096
disorder I-Disease 0 0.03407302871346474
resulting O 0 4.029848241771106e-06
in O 0 9.445117257200764e-07
early O 0 0.0001515396434115246
- O 1 0.9680542349815369
onset O 1 0.9986807703971863
obesity B-Disease 1 0.9999879598617554
, O 0 0.0014907916774973273
adrenal B-Disease 1 0.999932050704956
insufficiency I-Disease 1 0.9999939203262329
and O 0 2.6495799829717726e-05
red O 0 0.0007354406407102942
hair O 1 0.584335446357727
pigmentation O 0 0.3304130733013153
. O 0 3.11027470161207e-05
. O 0 6.162403587950394e-05

A O 0 0.00018025953613687307
European O 0 0.00022369727957993746
multicenter O 1 0.7780417203903198
study O 0 5.464469359139912e-05
of O 0 1.1643805919447914e-05
phenylalanine B-Disease 1 0.9999960660934448
hydroxylase I-Disease 1 0.9999995231628418
deficiency I-Disease 1 0.9999994039535522
: O 0 4.286711828171974e-06
classification O 0 3.602447122830199e-06
of O 0 2.863721988433099e-07
105 O 0 2.2783822259953013e-06
mutations O 0 3.4891420455096522e-06
and O 0 2.3686132522016123e-07
a O 0 3.1318037940764043e-07
general O 0 5.187873739487259e-07
system O 0 1.0864152955036843e-06
for O 0 8.1173442367799e-07
genotype O 0 0.0013111444422975183
- O 0 0.0003618367773015052
based O 0 3.547286269167671e-06
prediction O 0 3.0492688892991282e-05
of O 0 3.4718686947599053e-06
metabolic O 1 0.8000333905220032
phenotype O 1 0.5222748517990112
. O 0 6.74719485687092e-05

Phenylketonuria B-Disease 1 0.9976771473884583
( O 0 0.0006025298498570919
PKU B-Disease 0 0.4152771234512329
) O 0 2.755392051767558e-05
and O 0 1.2501278433774132e-05
mild B-Disease 1 0.9564008116722107
hyperphenylalaninemia I-Disease 1 0.9999998807907104
( O 0 0.0053718979470431805
MHP B-Disease 1 0.9999986886978149
) O 0 3.843395461444743e-06
are O 0 8.507277584612893e-07
allelic B-Disease 0 0.013883374631404877
disorders I-Disease 1 0.8837636113166809
caused O 0 1.191134924738435e-05
by O 0 1.2870908676632098e-06
mutations O 0 7.787838512740564e-06
in O 0 3.8747737107769353e-07
the O 0 1.0922016144832014e-06
gene O 0 1.2910855730297044e-05
encoding O 0 5.72328208363615e-05
phenylalanine O 0 0.18027663230895996
hydroxylase O 1 0.9808027744293213
( O 0 5.6723583838902414e-05
PAH O 1 0.9411709904670715
) O 0 2.2156918930704705e-05
. O 0 2.81475640804274e-05

Previous O 0 0.0002287359966430813
studies O 0 4.7709028876852244e-05
have O 0 3.5665061659528874e-06
suggested O 0 4.685414751293138e-06
that O 0 6.285317795118317e-07
the O 0 1.0862588624149794e-06
highly O 0 5.471435997606022e-06
variable O 0 3.1143586966209114e-05
metabolic O 0 0.4543055295944214
phenotypes O 0 0.010055785067379475
of O 0 4.212130079395138e-05
PAH B-Disease 1 0.9999996423721313
deficiency I-Disease 1 0.986578106880188
correlate O 0 0.000672797323204577
with O 0 0.00016446529480163008
PAH O 1 0.9999686479568481
genotypes O 0 0.051799505949020386
. O 0 0.00012479037104640156

We O 0 5.3785955969942734e-05
identified O 0 2.889277857320849e-05
both O 0 5.381542450777488e-06
causative O 0 6.045616828487255e-05
mutations O 0 3.055300476262346e-05
in O 0 2.5576136977178976e-06
686 O 0 0.00035878430935554206
patients O 0 4.320459993323311e-05
from O 0 1.224378138431348e-06
seven O 0 2.766101260931464e-06
European O 0 1.6505244275322184e-05
centers O 0 4.802389594260603e-05
. O 0 5.293208596413024e-05

On O 0 1.8146043657907285e-05
the O 0 3.6810245092055993e-06
basis O 0 1.3546323316404596e-06
of O 0 3.2031749697125633e-07
the O 0 5.362323918234324e-07
phenotypic O 0 6.260291229409631e-06
characteristics O 0 1.4372194527823012e-06
of O 0 4.0518580135540105e-07
297 O 0 1.130529199144803e-05
functionally O 0 7.825671491445974e-05
hemizygous O 0 0.16118422150611877
patients O 0 4.066366091137752e-05
, O 0 2.0836662883993995e-07
105 O 0 3.1744309580972185e-07
of O 0 8.189754652221382e-08
the O 0 3.238238832636853e-07
mutations O 0 1.7268584997509606e-06
were O 0 1.5900876348950987e-07
assigned O 0 3.566005659649818e-07
to O 0 9.629865616034294e-08
one O 0 1.3330962644886313e-07
of O 0 1.1523352583253654e-07
four O 0 1.0719470537878806e-06
arbitrary O 0 9.772833436727524e-06
phenotype O 0 0.12862113118171692
categories O 0 8.51056829560548e-05
. O 0 5.667509321938269e-05

We O 0 3.865922553814016e-05
proposed O 0 1.409315245837206e-05
and O 0 1.8976388673763722e-06
tested O 0 2.934144049504539e-06
a O 0 3.290215886408987e-07
simple O 0 1.0184710390603868e-06
model O 0 1.9207257082598517e-06
for O 0 4.013583918549557e-07
correlation O 0 2.7889977900485974e-06
between O 0 1.698277401374071e-06
genotype O 0 8.419612277066335e-05
and O 0 4.3804902816191316e-06
phenotypic O 0 5.914415669394657e-05
outcome O 0 0.00011393155000405386
. O 0 5.159834836376831e-05

The O 0 5.7095010561170056e-05
observed O 0 6.356152152875438e-05
phenotype O 0 0.0006240868242457509
matched O 0 3.24315442412626e-05
the O 0 4.137193172937259e-06
predicted O 0 0.0009806411108002067
phenotype O 0 0.00041934839100576937
in O 0 7.054059665279055e-07
79 O 0 4.170326064922847e-06
% O 0 1.7789599837669812e-07
of O 0 5.0202576318270076e-08
the O 0 1.4357917166307743e-07
cases O 0 3.4922504710266367e-07
, O 0 1.1380925002413278e-07
and O 0 5.991855545062208e-08
in O 0 6.240819772074246e-08
only O 0 5.105388112269793e-08
5 O 0 1.005324250513695e-07
of O 0 6.973939292720388e-08
184 O 0 4.777316007675836e-06
patients O 0 3.2256961276289076e-05
was O 0 1.1428502375565586e-06
the O 0 4.4615768501898856e-07
observed O 0 2.0828449578402797e-06
phenotype O 0 1.2266126759641338e-05
more O 0 1.2248239045220544e-07
than O 0 1.0977846898185817e-07
one O 0 1.395890336652883e-07
category O 0 6.417541840164631e-07
away O 0 3.421126564262522e-07
from O 0 2.3391034176256653e-07
that O 0 6.743045446455653e-07
expected O 0 6.738996034982847e-06
. O 0 3.069727245019749e-05

Among O 0 5.18664310220629e-05
the O 0 4.674479896493722e-06
seven O 0 2.5153046863124473e-06
contributing O 0 2.471080733812414e-06
centers O 0 1.0110871926372056e-06
, O 0 1.7548340736084356e-07
the O 0 1.8132925561076263e-07
proportion O 0 7.832190931367222e-07
of O 0 2.545210975313239e-07
patients O 0 1.2852307008870412e-05
for O 0 1.8344921670632175e-07
whom O 0 1.0052665402326966e-06
the O 0 2.584139053851686e-07
observed O 0 1.7279786561630317e-06
phenotype O 0 0.00010799640585901216
did O 0 6.35081278232974e-07
not O 0 1.3899577311349276e-07
match O 0 2.563192822435667e-07
the O 0 3.632553955412732e-07
predicted O 0 0.0001522052043583244
phenotype O 0 0.0005772548611275852
was O 0 1.7822217159846332e-06
4 O 0 1.2878952020400902e-06
% O 0 8.196456633413618e-07
- O 0 7.718165579717606e-05
23 O 0 2.2092867766332347e-06
% O 0 8.147467838170996e-07
( O 0 5.097618327454256e-07
P O 0 3.88755724998191e-05
< O 0 3.979809207521612e-06
. O 0 2.581257092515443e-07
0001 O 0 4.813471605302766e-06
) O 0 1.6778183464793983e-07
, O 0 9.147926505193027e-08
suggesting O 0 4.093502070645627e-07
that O 0 7.747856756168403e-08
differences O 0 4.2706528802227695e-07
in O 0 1.3810178245421412e-07
methods O 0 5.296414542499406e-07
used O 0 3.264776182732021e-07
for O 0 2.2611662586768944e-07
mutation O 0 3.265599843871314e-06
detection O 0 7.511352123401593e-06
or O 0 9.810764822759666e-06
phenotype O 0 0.4264102280139923
classification O 0 0.0003263778635300696
may O 0 1.4241919643609435e-06
account O 0 4.177886694378685e-07
for O 0 1.9297981168620026e-07
a O 0 5.612714062408486e-07
considerable O 0 2.5299507342424477e-06
proportion O 0 5.606456397799775e-06
of O 0 2.168155333492905e-06
genotype O 1 0.8495028614997864
- O 1 0.8208602666854858
phenotype O 0 0.06264014542102814
inconsistencies O 0 0.00033236556919291615
. O 0 8.829062426229939e-05

Our O 0 8.60025393194519e-05
data O 0 3.964523784816265e-05
indicate O 0 9.35102525545517e-06
that O 0 1.2911639259982621e-06
the O 0 2.9923912734375335e-06
PAH O 1 0.9998224377632141
- O 0 0.014029478654265404
mutation O 0 1.7458351067034528e-05
genotype O 0 2.1680683857994154e-05
is O 0 1.9938497075600026e-07
the O 0 1.926918287153967e-07
main O 0 6.415473308152286e-07
determinant O 0 2.5072959033423103e-06
of O 0 4.420798234150425e-07
metabolic O 0 0.3890513479709625
phenotype O 0 0.0748584046959877
in O 0 2.4791204396024114e-06
most O 0 5.6013395806076005e-05
patients O 1 0.5633459091186523
with O 0 0.20541390776634216
PAH B-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9982694387435913
. O 0 6.730441236868501e-05

In O 0 2.9033890314167365e-05
the O 0 4.1575704017304815e-06
present O 0 2.7685346140060574e-06
study O 0 2.4260700683953473e-06
, O 0 4.23742676503025e-07
the O 0 2.3587266184676992e-07
classification O 0 2.040764002231299e-06
of O 0 3.115140430054453e-07
105 O 0 2.1983116312185302e-05
PAH O 1 0.9998503923416138
mutations O 0 1.3473872058966663e-05
may O 0 3.896469991104823e-07
allow O 0 2.421233773475251e-07
the O 0 1.5049135981826112e-07
prediction O 0 2.2305248421616852e-06
of O 0 7.515068745078679e-08
the O 0 4.1021149854714167e-07
biochemical O 0 0.00010838659363798797
phenotype O 0 0.0009819966508075595
in O 0 9.044650823852862e-07
> O 0 6.118032615631819e-06
10 O 0 2.3748651756250183e-07
, O 0 2.0368661068914662e-07
000 O 0 6.313806011348788e-07
genotypes O 0 5.346490524971159e-06
, O 0 1.205816317906283e-07
which O 0 1.2653525516270747e-07
may O 0 2.4485041194566293e-07
be O 0 8.213125113343267e-08
useful O 0 2.1605293909487955e-07
for O 0 1.307294468233522e-07
the O 0 4.6433069655904546e-07
management O 0 3.179965233357507e-06
of O 0 1.492152932769386e-06
hyperphenylalaninemia B-Disease 1 0.999927282333374
in O 0 5.8782603446161374e-05
newborns O 0 0.23666821420192719
. O 0 5.4299049224937335e-05

Somatic O 0 0.0019248750759288669
instability O 0 0.0002540475979913026
of O 0 4.693357368523721e-06
the O 0 4.663597792387009e-06
CTG O 0 0.0001423243375029415
repeat O 0 2.0116891391808167e-05
in O 0 1.700559437267657e-06
mice O 0 1.468977006879868e-05
transgenic O 0 5.011397661291994e-06
for O 0 4.3018417272833176e-07
the O 0 5.960343514743727e-06
myotonic B-Disease 1 0.9999998807907104
dystrophy I-Disease 1 0.9999998807907104
region O 0 1.5312230971176177e-05
is O 0 6.474885481111414e-07
age O 0 9.122728670263314e-07
dependent O 0 6.908233558533539e-07
but O 0 2.739112971994473e-07
not O 0 1.3262031473004754e-07
correlated O 0 1.0418223155284068e-06
to O 0 3.00701856303931e-07
the O 0 3.4903160894828034e-07
relative O 0 3.6383787573868176e-06
intertissue O 0 5.492592026712373e-05
transcription O 0 1.5049240573716816e-05
levels O 0 1.1218214240216184e-05
and O 0 1.2131875337217934e-05
proliferative O 0 0.027039507403969765
capacities O 0 0.0002974557864945382
. O 0 9.160774789052084e-05

A O 0 0.0003564076905604452
( O 0 5.428828444564715e-05
CTG O 0 0.00017355555610265583
) O 0 4.430819899425842e-06
nexpansion O 0 2.421358658466488e-05
in O 0 7.611270689267258e-07
the O 0 7.939642614473996e-07
3 O 0 2.7573098577704513e-06
- O 0 7.0707275881432e-05
untranslated O 0 4.6957087761256844e-05
region O 0 2.2884778445586562e-06
( O 0 5.564671141655708e-07
UTR O 0 6.730787845299346e-06
) O 0 2.0964587577054772e-07
of O 0 8.554189179221794e-08
the O 0 8.242288913606899e-07
DM O 1 0.9998277425765991
protein O 0 4.769294264406199e-06
kinase O 0 9.227921509591397e-06
gene O 0 3.511400564093492e-06
( O 0 8.570485192649357e-07
DMPK O 0 2.2836706193629652e-05
) O 0 4.835638947042753e-07
is O 0 2.5837272232820396e-07
responsible O 0 3.1605129606759874e-06
for O 0 6.83801499690162e-06
causing O 0 0.07320941984653473
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.09669481962919235
DM B-Disease 1 0.9999990463256836
) O 0 6.537923763971776e-05
. O 0 8.985970634967089e-05

Major O 0 0.00019932372379116714
instability O 0 0.00014657125575467944
, O 0 4.15670274378499e-06
with O 0 9.399254281561298e-07
very O 0 1.0366508149672882e-06
large O 0 6.120368425399647e-07
expansions O 0 1.9247120235377224e-06
between O 0 3.4249492841809115e-07
generations O 0 1.319478315053857e-06
and O 0 2.984446041409683e-07
high O 0 1.0064252364827553e-06
levels O 0 5.669675715580524e-07
of O 0 2.4783327035038383e-07
somatic O 0 1.538019387226086e-05
mosaicism O 0 0.0002500713453628123
, O 0 1.4072882095206296e-06
is O 0 1.2098148545192089e-06
observed O 0 6.709152785333572e-06
in O 0 1.2105917448934633e-05
patients O 0 0.0005454263300634921
. O 0 5.115559179103002e-05

There O 0 2.1723153622588143e-05
is O 0 2.2672541035717586e-06
a O 0 1.708265585875779e-06
good O 0 1.5426994650624692e-06
correlation O 0 2.2549847926711664e-06
between O 0 4.651240033126669e-07
repeat O 0 6.245789336389862e-06
size O 0 1.6244161997747142e-06
( O 0 2.919401822509826e-07
at O 0 1.2357942580365489e-07
least O 0 1.4881950960443646e-07
in O 0 2.1762581070561282e-07
leucocytes O 0 7.675499364268035e-05
) O 0 7.466034617209516e-07
, O 0 5.445374995360908e-07
clinical O 0 2.887572736653965e-05
severity O 0 0.00012782742851413786
and O 0 2.4485043468303047e-06
age O 0 5.367825906432699e-06
of O 0 3.21355241794663e-06
onset O 1 0.5669125318527222
. O 0 0.00011238220758968964

The O 0 0.00013239600230008364
trinucleotide O 0 0.004916357807815075
repeat O 0 0.0003082913171965629
instability O 0 4.984855331713334e-05
mechanisms O 0 1.5107017134141643e-05
involved O 0 3.3688622806948842e-06
in O 0 2.6006339339801343e-06
DM B-Disease 1 0.9999947547912598
and O 0 1.9041834775634925e-06
other O 0 1.4628990356868599e-06
human O 0 4.38786628365051e-05
genetic B-Disease 1 0.9999904632568359
diseases I-Disease 1 0.999961256980896
are O 0 5.022622644901276e-06
unknown O 0 2.9226295737316832e-05
. O 0 3.52422684954945e-05

We O 0 6.45277468720451e-05
studied O 0 4.613087003235705e-05
somatic O 0 0.00012222889927215874
instability O 0 2.9961898690089583e-05
by O 0 1.3356278714127257e-06
measuring O 0 5.285190582071664e-06
the O 0 1.2181320698800846e-06
CTG O 0 7.579806697322056e-05
repeat O 0 5.79808147449512e-06
length O 0 1.4849473473077524e-06
at O 0 3.579866927339026e-07
several O 0 1.8441011206959956e-07
ages O 0 8.056194928940386e-07
in O 0 1.1323555781928007e-07
various O 0 1.2564996154651453e-07
tissues O 0 1.4821049489910365e-06
of O 0 2.4868538162081677e-07
transgenic O 0 2.778120142465923e-05
mice O 0 5.426483403425664e-05
carrying O 0 1.1084219977419707e-06
a O 0 9.445063255952846e-07
( O 0 8.081087798927911e-07
CTG O 0 1.9084749510511756e-05
) O 0 6.095274898143543e-07
55expansion O 0 5.716852683690377e-06
surrounded O 0 8.466194572065433e-07
by O 0 2.0275597023555747e-07
45 O 0 5.584842028838466e-07
kb O 0 9.717609827930573e-06
of O 0 1.5215599091789045e-07
the O 0 6.565024932569941e-07
human O 0 3.2834243484103354e-06
DM B-Disease 1 0.9999903440475464
region O 0 1.8409782569506206e-06
, O 0 3.923706515251979e-07
using O 0 1.1795805221481714e-06
small O 0 2.876736971302307e-06
- O 0 6.643641972914338e-05
pool O 0 3.374256630195305e-05
PCR O 0 0.0002919222752097994
. O 0 4.4587643060367554e-05

These O 0 5.406260970630683e-05
mice O 0 0.0009079855517484248
have O 0 2.1596117676381255e-06
been O 0 7.05504191955697e-07
shown O 0 6.136575620985241e-07
to O 0 4.116034517664957e-07
reproduce O 0 3.3118885767180473e-06
the O 0 3.4567165130283684e-07
intergenerational O 0 4.741466909763403e-06
and O 0 4.0387257627116924e-07
somatic O 0 5.264234005153412e-06
instability O 0 1.1675380164888338e-06
of O 0 1.211376456922153e-07
the O 0 3.3566487900316133e-07
55 O 0 1.776631847860699e-06
CTG O 0 2.7682952350005507e-05
repeat O 0 3.419887661948451e-06
suggesting O 0 1.1842830645036884e-06
that O 0 1.0504085423690412e-07
surrounding O 0 4.0712092186367954e-07
sequences O 0 6.250337492019753e-07
and O 0 2.2998979432031774e-07
the O 0 4.0486906982550863e-07
chromatin O 0 9.276804121327586e-06
environment O 0 6.8081217250437476e-06
are O 0 7.30241083601868e-07
involved O 0 2.1412222395156277e-06
in O 0 3.4154486456827726e-06
instability O 0 6.48301574983634e-05
mechanisms O 0 8.581903239246458e-05
. O 0 6.043253597454168e-05

As O 0 1.8724369510891847e-05
observed O 0 9.594364200893324e-06
in O 0 8.264824487014266e-07
some O 0 2.397987941549218e-07
of O 0 1.404996226028743e-07
the O 0 3.7925991591691854e-07
tissues O 0 1.1088428436778486e-05
of O 0 1.78346283519204e-06
DM B-Disease 1 1.0
patients O 0 0.3174927532672882
, O 0 6.492966804216849e-07
there O 0 1.5283137599908514e-07
is O 0 1.368137105828282e-07
a O 0 3.5867427072844293e-07
tendency O 0 1.4634920262324158e-06
for O 0 2.879578175907227e-07
repeat O 0 3.3457615700172028e-06
length O 0 1.1412460025894688e-06
and O 0 4.4615001115744235e-07
somatic O 0 9.217718798026908e-06
mosaicism O 0 3.272828325862065e-05
to O 0 4.3651041892189824e-07
increase O 0 3.8449022099484864e-07
with O 0 1.3680404720162187e-07
the O 0 2.384241781783203e-07
age O 0 6.544028678945324e-07
of O 0 2.62846526766225e-07
the O 0 3.2907882996369153e-06
mouse O 0 0.000443631608504802
. O 0 5.596939809038304e-05

Furthermore O 0 0.00018495006952434778
, O 0 1.1667138096527196e-05
we O 0 2.248602413601475e-06
observed O 0 1.8425345160721918e-06
no O 0 4.276860465779464e-07
correlation O 0 1.2520310974650783e-06
between O 0 2.659311633124162e-07
the O 0 8.619979325885652e-07
somatic O 0 2.60798551607877e-05
mutation O 0 1.7507734810351394e-05
rate O 0 4.188756520306924e-06
and O 0 3.1819765808904776e-06
tissue O 0 0.00020350748673081398
proliferation O 0 6.575199222424999e-05
capacity O 0 2.8261552870390005e-05
. O 0 3.1428153306478634e-05

The O 0 2.9169852496124804e-05
somatic O 0 0.00018636092136148363
mutation O 0 7.721057772869244e-05
rates O 0 1.0200272299698554e-05
in O 0 5.878703177586431e-07
different O 0 3.7996730384293187e-07
tissues O 0 2.6564980544208083e-06
were O 0 1.9430945030762814e-07
also O 0 1.277821155554193e-07
not O 0 9.963788727418432e-08
correlated O 0 6.082418622099794e-07
to O 0 1.0879502099214733e-07
the O 0 2.306085065129082e-07
relative O 0 1.361479917250108e-06
inter O 0 4.3106897464895155e-06
- O 0 0.00011973366781603545
tissue O 0 5.565240826399531e-06
difference O 0 6.0492311604321e-07
in O 0 2.1502128788597474e-07
transcriptional O 0 2.020919964706991e-06
levels O 0 5.529935265258246e-07
of O 0 8.495539560726684e-08
the O 0 2.0853561011335842e-07
three O 0 4.448253605460195e-07
genes O 0 1.5227415133267641e-06
( O 0 3.7291738408384845e-07
DMAHP O 0 1.7857206330518238e-05
, O 0 4.355835301339539e-07
DMPK O 0 2.778748057608027e-05
and O 0 6.714412847941276e-07
59 O 0 2.0620020677597495e-06
) O 0 3.6039617157257453e-07
surrounding O 0 6.746460599060811e-07
the O 0 7.069454568409128e-07
repeat O 0 2.4681656213942915e-05
. O 0 6.6783136389858555e-06
. O 0 2.2948832338443026e-05

A O 0 0.00017670367378741503
novel O 0 0.00017400809156242758
missense O 0 0.0009575593867339194
mutation O 0 0.00021320015366654843
in O 0 1.8866476239054464e-05
patients O 0 0.00018543866463005543
from O 0 1.213100631503039e-06
a O 0 2.67256314145925e-06
retinoblastoma B-Disease 0 0.17425894737243652
pedigree O 0 0.032038334757089615
showing O 0 1.8922874005511403e-05
only O 0 1.2100457524866215e-06
mild O 0 3.9842063415562734e-05
expression O 0 1.7455950001021847e-06
of O 0 8.366315569219296e-07
the O 0 2.210698221460916e-05
tumor B-Disease 1 0.8097342252731323
phenotype O 0 0.10824158787727356
. O 0 7.247060420922935e-05

We O 0 5.261678961687721e-05
have O 0 4.3814638956973795e-06
used O 0 2.1979135453875642e-06
single O 0 2.208966407124535e-06
strand O 0 1.0810412277351134e-05
conformation O 0 7.83420091465814e-06
polymorphism O 0 9.822662832448259e-06
analysis O 0 1.4043707778910175e-06
to O 0 3.3431288670726644e-07
study O 0 5.22051095686038e-07
the O 0 2.0442104187168297e-07
27 O 0 5.50464221760194e-07
exons O 0 1.869035145318776e-06
of O 0 1.5543379561222537e-07
the O 0 6.059676138647774e-07
RB1 O 0 0.007065963465720415
gene O 0 1.699275458122429e-06
in O 0 2.4513639118595165e-07
individuals O 0 2.4612822357994446e-07
from O 0 1.501398543268806e-07
a O 0 6.781662023058743e-07
family O 0 1.4057231965125538e-05
showing O 0 4.930890281684697e-05
mild O 0 0.0008157098782248795
expression O 0 2.909006980189588e-06
of O 0 1.182637447527668e-06
the O 0 1.608553975529503e-05
retinoblastoma B-Disease 1 0.9470458030700684
phenotype O 1 0.8025286197662354
. O 0 0.00013135805784258991

In O 0 3.317007212899625e-05
this O 0 4.396908934722887e-06
family O 0 1.2405910638335627e-05
affected O 0 4.387760782265104e-06
individuals O 0 1.2208068937979988e-06
developed O 0 1.4881547940603923e-05
unilateral B-Disease 0 0.026069169864058495
tumors I-Disease 1 0.9999967813491821
and O 0 1.0451519756315975e-06
, O 0 2.5385060098415124e-07
as O 0 1.3919554930907907e-07
a O 0 2.4086088501462655e-07
result O 0 4.944679403706687e-07
of O 0 1.0756095747410654e-07
linkage O 0 5.086258624942275e-06
analysis O 0 1.7907727851707023e-06
, O 0 5.68068344364292e-07
unaffected O 0 1.4316531633085106e-05
mutation O 0 8.592568519816268e-06
carriers O 0 4.421618086780654e-06
were O 0 5.436491505861341e-07
also O 0 5.208963216318807e-07
identified O 0 1.4957206531107659e-06
within O 0 8.623021017228893e-07
the O 0 5.705360308638774e-06
pedigree O 0 0.00474977120757103
. O 0 4.5657237933482975e-05

A O 0 7.746352639514953e-05
single O 0 1.5934005205053836e-05
band O 0 1.00248535090941e-05
shift O 0 9.35762727749534e-06
using O 0 2.633729764056625e-06
SSCP O 0 0.00015933795657474548
was O 0 2.117637222909252e-06
identified O 0 1.0645670727171819e-06
in O 0 2.554724574110878e-07
exon O 0 5.064709966973169e-06
21 O 0 6.708735327265458e-07
which O 0 2.3431557849562523e-07
resulted O 0 1.3355806913750712e-06
in O 0 3.7225294136078446e-07
a O 0 6.328116910481185e-07
missense O 0 1.580224488861859e-05
mutation O 0 3.166374654028914e-06
converting O 0 1.955409743459313e-06
a O 0 1.2876729442723445e-06
cys O 0 0.011520566418766975
- O 0 0.00017584128363523632
- O 0 1.9155568224960007e-05
> O 0 1.1325363630021457e-05
arg O 0 5.32106696482515e-06
at O 0 4.236788129219349e-07
nucleotide O 0 1.4984361769165844e-06
position O 0 1.3737894732912537e-06
28 O 0 1.7281928421652992e-06
in O 0 7.809128987901204e-07
the O 0 4.322100267017959e-06
exon O 0 0.00020934744679834694
. O 0 6.615703750867397e-05

The O 0 0.00010992476745741442
mutation O 0 0.00021839943656232208
destroyed O 0 4.9244859837926924e-05
an O 0 6.163705620565452e-06
NdeI O 0 0.00025057586026377976
restriction O 0 4.990591332898475e-05
enzyme O 0 0.00010189095337409526
site O 0 5.165161928744055e-05
. O 0 7.547882705694064e-05

Analysis O 0 5.504615910467692e-05
of O 0 2.196526338593685e-06
all O 0 9.350760024062765e-07
family O 0 2.115505594701972e-06
members O 0 5.197322252570302e-07
demonstrated O 0 1.217614112647425e-06
that O 0 1.1295276891587491e-07
the O 0 4.561916853162984e-07
missense O 0 2.6238965801894665e-05
mutation O 0 1.3492054677044507e-05
co O 0 4.236906170262955e-05
- O 0 1.2435143617040012e-05
segregated O 0 1.7296106307185255e-06
with O 0 3.01497578902854e-07
patients O 0 3.908086728188209e-05
with O 0 7.931280379125383e-06
tumors B-Disease 1 0.9999978542327881
or O 0 2.783826630547992e-06
who O 0 1.1586167829591432e-06
, O 0 1.41046569979153e-07
as O 0 6.283639919502093e-08
a O 0 9.833048864038574e-08
result O 0 2.4978683654808265e-07
of O 0 1.0193479482722978e-07
linkage O 0 5.2971195145801175e-06
analysis O 0 2.657780441950308e-06
had O 0 1.658282144489931e-06
been O 0 3.6975606576561404e-07
predicted O 0 3.066030785703333e-06
to O 0 4.352492339876335e-07
carry O 0 2.651759814398247e-06
the O 0 4.378648554848041e-06
predisposing O 0 0.00022523435472976416
mutation O 0 0.0001271546643693
. O 0 5.922237687627785e-05

These O 0 1.1813653145509306e-05
observations O 0 1.023302957037231e-05
point O 0 1.8078292214340763e-06
to O 0 4.2204476358165266e-07
another O 0 5.758300858360599e-07
region O 0 6.596712864848087e-07
of O 0 2.0348353757526638e-07
the O 0 8.067673888945137e-07
RB1 O 0 0.009015647694468498
gene O 0 2.4624237084935885e-06
where O 0 5.398259759203938e-07
mutations O 0 1.2147780807936215e-06
only O 0 1.1690650580931106e-07
modify O 0 8.08054096523847e-07
the O 0 1.1168645386305798e-07
function O 0 1.1606599770175308e-07
of O 0 4.4882746408347884e-08
the O 0 1.1386277520841759e-07
gene O 0 6.359001076816639e-07
and O 0 2.49874489099966e-07
raise O 0 5.417145416686253e-07
important O 0 1.7893663084578293e-07
questions O 0 4.262604704763362e-07
for O 0 2.047218856660038e-07
genetic O 0 3.2717252906877548e-06
counseling O 0 1.1741500202333555e-05
in O 0 5.699943130821339e-07
families O 0 1.1280974376859376e-06
with O 0 3.500870491279784e-07
these O 0 1.1386379128452973e-06
distinctive O 0 5.64899601158686e-05
phenotypes O 0 0.012632184661924839
. O 0 1.6028712707338855e-05
. O 0 4.9938094889512286e-05

Maternal B-Disease 0 0.07971731573343277
disomy I-Disease 1 0.8115019798278809
and O 0 0.20076996088027954
Prader B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
Willi I-Disease 1 1.0
syndrome I-Disease 1 0.9999974966049194
consistent O 0 1.3448942809191067e-05
with O 0 1.8975085822603432e-06
gamete O 0 4.8942842113319784e-05
complementation O 0 0.014340413734316826
in O 0 1.4447584817389725e-06
a O 0 1.037544848259131e-06
case O 0 1.410249183209089e-06
of O 0 4.3294500073898234e-07
familial O 0 0.0012129828101024032
translocation O 0 6.152410060167313e-05
( O 0 1.0917901818174869e-06
3 O 0 9.455355893805972e-07
; O 0 7.742582397440856e-07
15 O 0 3.966044630487886e-07
) O 0 5.100852149553248e-07
( O 0 4.62214444496567e-07
p25 O 0 9.643735211284366e-06
; O 0 1.2323430382821243e-06
q11 O 0 1.4127196664048824e-05
. O 0 9.459757279728365e-07
2 O 0 3.2599771202512784e-06
) O 0 4.616585556505015e-06
. O 0 1.2154734577052295e-05

Maternal B-Disease 1 0.6775004863739014
uniparental I-Disease 1 0.9898764491081238
disomy I-Disease 1 0.9130019545555115
( I-Disease 0 0.00023698026780039072
UPD I-Disease 1 0.9998966455459595
) I-Disease 0 6.4957312133628875e-06
for I-Disease 0 8.334031917911489e-07
chromosome I-Disease 0 4.119535333302338e-06
15 I-Disease 0 5.249972900855937e-07
is O 0 1.4324996300274506e-07
responsible O 0 3.5660602293319243e-07
for O 0 1.419921176193384e-07
an O 0 1.7126718887539027e-07
estimated O 0 7.872193350522139e-07
30 O 0 5.4744509725424e-07
% O 0 2.6018471999122994e-07
of O 0 2.030930801311115e-07
cases O 0 2.6768484531203285e-06
of O 0 6.082377876737155e-05
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
( O 0 0.0005442692781798542
PWS B-Disease 1 0.9999803304672241
) O 0 4.54331238870509e-05
. O 0 4.215304215904325e-05

We O 0 6.009600110701285e-05
report O 0 1.5199269910226576e-05
on O 0 1.0859439498744905e-06
an O 0 3.020029168965266e-07
unusual O 0 1.0621434967106325e-06
case O 0 7.370036883003195e-07
of O 0 3.514827255912678e-07
maternal B-Disease 0 2.8888451197417453e-05
disomy I-Disease 0 0.00495151337236166
15 I-Disease 0 1.247224986400397e-06
in O 0 1.349694798591372e-06
PWS B-Disease 1 0.9999661445617676
that O 0 2.974291533064388e-07
is O 0 7.26099500525379e-08
most O 0 1.415006067873037e-07
consistent O 0 5.062992158855195e-07
with O 0 1.8796406209276029e-07
adjacent O 0 2.157285734938341e-06
- O 0 3.569860928109847e-05
1 O 0 4.6512047902069753e-07
segregation O 0 7.762114364595618e-07
of O 0 1.1363236751549266e-07
a O 0 5.606390232060221e-07
paternal O 0 0.003978555090725422
t O 0 0.03212456777691841
( O 0 6.138161552371457e-07
3 O 0 2.557664515734359e-07
; O 0 2.423895466563408e-07
15 O 0 1.6759248921971448e-07
) O 0 2.1303831942987017e-07
( O 0 2.0948598944414698e-07
p25 O 0 3.683335307869129e-06
; O 0 4.865257778874366e-07
q11 O 0 3.6064895994059043e-06
. O 0 1.6897556065487151e-07
2 O 0 1.767160853205496e-07
) O 0 9.606072381984632e-08
with O 0 1.1641741792800531e-07
simultaneous O 0 2.619127144498634e-06
maternal O 0 3.7167559639783576e-05
meiotic O 0 0.00030846509616822004
nondisjunction O 0 0.001566016231663525
for O 0 4.6064747039054055e-06
chromosome O 0 6.537499575642869e-05
15 O 0 2.1320965970517136e-05
. O 0 4.3902273318963125e-05

The O 0 7.552087481599301e-05
patient O 0 0.0002455377543810755
( O 0 7.037509021756705e-06
J O 0 0.0003875998954754323
. O 0 1.0985907010763185e-06
B O 0 2.7071985186921665e-06
. O 0 1.241613460933877e-07
) O 0 9.797983580028813e-08
, O 0 4.793745134179517e-08
a O 0 1.2162081475253217e-07
17 O 0 4.1433273167967855e-07
- O 0 2.0485345885390416e-05
year O 0 1.2798533362001763e-06
- O 0 0.0001112525278585963
old O 0 1.484877157054143e-05
white O 0 4.400361376610817e-06
male O 0 1.0209206493527745e-06
with O 0 5.346687430574093e-07
PWS B-Disease 1 0.9999861717224121
, O 0 7.662390544282971e-07
was O 0 7.475824190805724e-07
found O 0 2.2749726724669017e-07
to O 0 1.50795344211474e-07
have O 0 1.8817463853793015e-07
47 O 0 8.626837484371208e-07
chromosomes O 0 8.358882723769057e-07
with O 0 1.6989953621759923e-07
a O 0 6.442241442528029e-07
supernumerary O 0 0.0012575340224429965
, O 0 7.296507078535797e-07
paternal O 0 2.0132822101004422e-05
der O 0 0.00014012237079441547
( O 0 2.73787264859493e-07
15 O 0 1.589232567766885e-07
) O 0 6.136077246310379e-08
consisting O 0 4.589158209000743e-08
of O 0 5.3692623680490215e-08
the O 0 1.9160553677011194e-07
short O 0 5.1310953494976275e-06
arm O 0 7.795216515660286e-05
and O 0 2.7240221811553056e-07
the O 0 4.490698302106466e-07
proximal O 0 0.0010067521361634135
long O 0 0.00010541972005739808
arm O 0 2.0880455849692225e-05
of O 0 2.8055217171640834e-07
chromosome O 0 3.5878347262041643e-06
15 O 0 1.0978595810229308e-06
, O 0 9.34888760184549e-07
and O 0 3.468046315902029e-06
distal O 0 0.011285338550806046
chromosome O 0 0.0006665787659585476
arm O 0 0.06144270300865173
3p O 0 0.17129230499267578
. O 0 0.00014847106649540365

The O 0 8.098663238342851e-05
t O 0 0.0007275572279468179
( O 0 1.9108633750875015e-06
3 O 0 5.207885465097206e-07
; O 0 3.463335644937615e-07
15 O 0 2.091889257371804e-07
) O 0 1.1216572914918288e-07
was O 0 1.0698213515070165e-07
present O 0 7.70194574784e-08
in O 0 4.3159939622228194e-08
the O 0 7.1787425781622e-08
balanced O 0 5.469039479066851e-07
state O 0 2.1586964749076287e-07
in O 0 2.1109154602072522e-07
the O 0 1.0590847523417324e-06
patients O 0 0.00012266862904652953
father O 0 1.4822909179201815e-05
and O 0 2.0408592718013097e-06
a O 0 7.041133812890621e-06
sister O 0 0.006338050588965416
. O 0 6.331415352178738e-05

Fluorescent O 0 0.0008562913862988353
in O 0 2.1273317543091252e-05
situ O 0 6.047484930604696e-05
hybridization O 0 2.8728913093800656e-05
analysis O 0 6.8799495238636155e-06
demonstrated O 0 4.801276645594044e-06
that O 0 3.801068260145257e-07
the O 0 1.9784554297075374e-06
PWS B-Disease 1 0.9999759197235107
critical O 0 1.204743512062123e-05
region O 0 1.5610480659233872e-06
resided O 0 2.2787908164900728e-06
on O 0 1.8309405902527942e-07
the O 0 2.0257583344118757e-07
derivative O 0 2.318516408195137e-06
chromosome O 0 1.3758137811237248e-06
3 O 0 2.1173876518787438e-07
and O 0 7.579082961228778e-08
that O 0 8.79910331264e-08
there O 0 7.286925551852619e-08
was O 0 2.717742688673752e-07
no O 0 2.2794638709910942e-07
deletion O 0 1.9942160633945605e-06
of O 0 1.568597838286223e-07
the O 0 1.5037729781397502e-06
PWS B-Disease 1 0.9999240636825562
region O 0 1.2508103282016236e-06
on O 0 2.2900687213223136e-07
the O 0 2.4920436203501595e-07
normal O 0 1.3307252402228187e-06
pair O 0 1.6939990246100933e-06
of O 0 5.114140435580339e-07
15s O 0 4.6656419726787135e-05
present O 0 5.755935490014963e-06
in O 0 1.2209746273583733e-05
J O 0 0.35734254121780396
. O 0 6.341010157484561e-05

B O 0 0.0315253883600235
. O 0 0.00156618922483176

Methylation O 0 0.00036722334334626794
analysis O 0 6.9189234636724e-05
at O 0 7.902244760771282e-06
exon O 0 1.7377455151290633e-05
alpha O 0 3.6143123907095287e-06
of O 0 2.666000398221513e-07
the O 0 5.300952352627064e-07
small O 0 1.5961054486979265e-06
nuclear O 0 8.138908015098423e-06
ribonucleoprotein O 0 0.0001148146329796873
- O 0 3.223184103262611e-05
associated O 0 1.9452004380582366e-06
polypeptide O 0 1.2139466889493633e-05
N O 0 6.212877451616805e-06
( O 0 5.471392228173499e-07
SNRPN O 0 1.1046779036405496e-05
) O 0 4.357551404154947e-07
gene O 0 1.147375769505743e-06
showed O 0 1.2242276170582045e-06
a O 0 3.2650999060024333e-07
pattern O 0 1.207861942020827e-06
characteristic O 0 5.505298190655594e-07
of O 0 1.1867460614212177e-07
only O 0 1.7890045000967802e-07
the O 0 9.746927389642224e-07
maternal O 0 6.729228334734216e-05
chromosome O 0 2.821189809765201e-05
15 O 0 5.746282567997696e-06
in O 0 1.0349742296966724e-05
J O 0 0.36418402194976807
. O 0 6.850512727396563e-05

B O 0 0.03209138289093971
. O 0 0.0025083953514695168

Maternal B-Disease 0 0.07865889370441437
disomy I-Disease 0 0.07445631176233292
was O 0 8.819343202048913e-05
confirmed O 0 1.543688449601177e-05
by O 0 1.7853689087132807e-06
polymerase O 0 2.312696597073227e-05
chain O 0 1.4412697055377066e-05
reaction O 0 5.498485279531451e-06
analysis O 0 1.7833949641499203e-06
of O 0 4.499413535086205e-07
microsatellite O 0 4.6450470108538866e-05
repeats O 0 1.0625999493640848e-05
at O 0 1.0931061069641146e-06
the O 0 7.952373266562063e-07
gamma O 0 1.736756348691415e-05
- O 0 7.132971222745255e-05
aminobutyric O 0 4.674714000429958e-05
acid O 0 1.7396889234078117e-05
receptor O 0 1.6022737327148207e-05
beta3 O 0 3.0187902666511945e-05
subunit O 0 1.693465128482785e-05
( O 0 4.94302912557032e-06
GABRB3 O 0 0.0001261432480532676
) O 0 9.399735063198023e-06
locus O 0 0.00013317026605363935
. O 0 4.893592995358631e-05

A O 0 0.00012474718096200377
niece O 0 0.001064916024915874
( O 0 1.4076025763642974e-05
B O 0 1.4171509064908605e-05
. O 0 8.961230832937872e-07
B O 0 3.1834579203859903e-06
. O 0 1.9190049727058067e-07
) O 0 9.372154607945049e-08
with O 0 5.5897235284874114e-08
45 O 0 1.5356727089965716e-07
chromosomes O 0 4.0899158193496987e-07
and O 0 1.1668996791058817e-07
the O 0 1.2058416132276761e-07
derivative O 0 1.3307532071848982e-06
3 O 0 3.3465613569205743e-07
but O 0 1.910708959940166e-07
without O 0 1.34718803224132e-07
the O 0 3.057059529965045e-07
der O 0 6.92720859660767e-05
( O 0 2.3339872257110983e-07
15 O 0 2.0952674617547018e-07
) O 0 1.844181838350778e-07
demonstrated O 0 5.869084702680993e-07
a O 0 7.906833729975915e-07
phenotype O 0 0.0004535755142569542
consistent O 0 1.2458459650588338e-06
with O 0 2.2759145679174253e-07
that O 0 3.973540856350155e-07
reported O 0 1.832584189287445e-06
for O 0 6.535047987199505e-07
haploinsufficiency O 0 4.840003020945005e-05
of O 0 2.3280701952899108e-06
distal O 0 0.0027415610384196043
3 O 0 4.8486552259419113e-05
p O 0 0.0016138931969180703
. O 0 4.143109617871232e-05

Uniparental B-Disease 1 0.9999668598175049
disomy I-Disease 1 0.9998817443847656
associated O 0 0.00026898758369497955
with O 0 9.916625458572526e-06
unbalanced O 0 0.00013363863399717957
segregation O 0 1.7117379684350453e-05
of O 0 1.0145304258912802e-06
non O 0 3.483283990135533e-06
- O 0 1.6937397958827205e-05
Robertsonian O 0 1.3623885934066493e-05
translocations O 0 8.878015250957105e-06
has O 0 6.5573476604186e-07
been O 0 3.3383372510797926e-07
reported O 0 8.815185879029741e-07
previously O 0 3.9118174299801467e-07
but O 0 1.5027593747163337e-07
has O 0 9.955050472854055e-08
not O 0 1.0563577035327398e-07
, O 0 5.523905954873953e-08
to O 0 5.563334681824017e-08
our O 0 1.2116490211155906e-07
knowledge O 0 2.476260760886362e-07
, O 0 2.711834667934454e-07
been O 0 4.7643757739024295e-07
observed O 0 6.620427939196816e-07
in O 0 5.735260515393747e-07
a O 0 2.5425963485758984e-06
case O 0 1.828414315241389e-05
of O 0 1.3270158888190053e-05
PWS B-Disease 1 0.9999830722808838
. O 0 0.00012383093417156488

Furthermore O 0 0.00011740197078324854
, O 0 6.5299168454657774e-06
our O 0 3.378095470907283e-06
findings O 0 3.6243013710191008e-06
are O 0 3.472463845355378e-07
best O 0 9.789442856344976e-07
interpreted O 0 1.685736378931324e-06
as O 0 7.939960369185428e-07
true O 0 7.345950962189818e-06
gamete O 0 5.670995597029105e-05
complementation O 0 0.0003374610096216202
resulting O 0 2.565705290180631e-05
in O 0 1.542596692161169e-05
maternal B-Disease 0 0.22876442968845367
UPD I-Disease 1 0.9999938011169434
15 I-Disease 0 0.00014862348325550556
and O 0 0.00018631010607350618
PWS B-Disease 1 0.9998574256896973

Schwartz B-Disease 1 0.9935023188591003
- I-Disease 1 0.9997208714485168
Jampel I-Disease 1 0.9995118379592896
syndrome I-Disease 1 0.9999414682388306
type I-Disease 0 2.7429390684119426e-05
2 I-Disease 0 4.199515842628898e-06
and O 0 2.5824956537690014e-06
Stuve B-Disease 1 0.9464153051376343
- I-Disease 1 0.999932050704956
Wiedemann I-Disease 1 0.9999984502792358
syndrome I-Disease 1 0.9999479055404663
: O 0 1.8747476815406117e-06
a O 0 8.165685017047508e-07
case O 0 2.830784296747879e-06
for O 0 9.545977945890627e-07
" O 0 4.260972673364449e-06
lumping O 0 4.984208499081433e-05
" O 0 2.1789714082842693e-05
. O 0 5.109323319629766e-05

Recent O 0 0.0005499132676050067
studies O 0 0.00011436794011387974
demonstrated O 0 1.6709005649317987e-05
the O 0 1.3491491017703083e-06
existence O 0 1.822894546421594e-06
of O 0 3.198892102318496e-07
a O 0 1.2522866654762765e-06
genetically O 0 2.8250856303202454e-06
distinct O 0 1.083965571524459e-06
, O 0 4.901606871499098e-07
usually O 0 3.7389239082585846e-07
lethal O 0 9.643721341490163e-07
form O 0 2.941922900845384e-07
of O 0 1.5728821267657622e-07
the O 0 2.934194299086812e-06
Schwartz B-Disease 1 0.9748585224151611
- I-Disease 1 0.999679446220398
Jampel I-Disease 1 0.9999703168869019
syndrome I-Disease 1 0.9999873638153076
( O 0 1.1139854905195534e-05
SJS B-Disease 0 0.04487070441246033
) O 0 6.577226372428413e-07
of O 0 4.361234857697127e-07
myotonia B-Disease 0 0.31660565733909607
and O 0 4.804726631846279e-05
skeletal B-Disease 1 0.8712238073348999
dysplasia I-Disease 1 0.9836493730545044
, O 0 1.3287051388033433e-06
which O 0 6.10034021519823e-07
we O 0 1.3492006019077962e-06
called O 0 1.4339569133881014e-05
SJS B-Disease 0 0.2603105902671814
type I-Disease 0 1.7110625776695088e-05
2 I-Disease 0 1.1570351489353925e-05
. O 0 1.711966615403071e-05

This O 0 0.0006053740507923067
disorder O 1 0.644023060798645
is O 0 3.6045191791345133e-06
reminiscent O 0 1.2311928003327921e-05
of O 0 8.145928518388246e-07
another O 0 3.1920978926791577e-06
rare O 0 2.5269384423154406e-05
condition O 0 0.0012168330140411854
, O 0 1.2722038036372396e-06
the O 0 3.336756662974949e-06
Stuve B-Disease 1 0.9989718198776245
- I-Disease 1 0.9999868869781494
Wiedemann I-Disease 1 0.9999992847442627
syndrome I-Disease 1 0.999997615814209
( O 0 6.72023770675878e-06
SWS B-Disease 0 0.11023334413766861
) O 0 5.887101792723115e-07
, O 0 1.394551674138711e-07
which O 0 1.269766016775975e-07
comprises O 0 3.327212709791638e-07
campomelia B-Disease 0 6.919609586475417e-05
at O 0 1.342422820016509e-06
birth O 0 1.664161027292721e-05
with O 0 2.4736837076488882e-06
skeletal B-Disease 1 0.9803046584129333
dysplasia I-Disease 1 0.9996275901794434
, O 0 9.627525287214667e-06
contractures B-Disease 0 0.16149988770484924
, O 0 1.6153079513969715e-06
and O 0 1.914407448566635e-06
early B-Disease 0 1.9601931853685528e-05
death I-Disease 0 0.00017749295511748642
. O 0 6.675756594631821e-05

To O 0 3.29520225932356e-05
test O 0 1.4067397387407254e-05
for O 0 8.112166938190057e-07
possible O 0 1.6525041246495675e-06
nosologic O 0 1.5953348338371143e-05
identity O 0 1.4809733102083555e-06
between O 0 4.599349381351203e-07
these O 0 1.003044758363103e-06
disorders O 0 0.003632966661825776
, O 0 3.468826434982475e-07
we O 0 1.302421424043132e-07
reviewed O 0 2.1089314827804628e-07
the O 0 9.281039581310324e-08
literature O 0 3.347205961290456e-07
and O 0 1.3960845990368398e-07
obtained O 0 4.5002755655332294e-07
a O 0 2.2361042795182584e-07
follow O 0 5.557023996516364e-07
- O 0 1.971527808564133e-06
up O 0 1.0488809465414306e-07
of O 0 2.9484665375889563e-08
the O 0 8.047620525530874e-08
only O 0 8.349466895651858e-08
two O 0 4.810094083040894e-07
surviving O 0 0.05899357423186302
patients O 0 0.00018859324336517602
, O 0 1.5491703209136176e-07
one O 0 2.0265659372853406e-07
with O 0 5.624866616926738e-07
SJS B-Disease 0 0.13823047280311584
type I-Disease 0 1.4108061350270873e-06
2 I-Disease 0 2.888847916437953e-07
at O 0 1.5195544733614952e-07
age O 0 1.9524789252045593e-07
10 O 0 8.180902000276546e-08
years O 0 1.214624774092954e-07
and O 0 1.2463732446121867e-07
another O 0 3.4747594668260717e-07
with O 0 7.009484761510976e-07
SWS B-Disease 1 0.8837487101554871
at O 0 2.3990498903003754e-06
age O 0 3.5498514989740215e-06
7 O 0 4.65029143015272e-06
years O 0 1.5067608728713822e-05
. O 0 3.593350265873596e-05

Patients O 1 0.9877463579177856
reported O 0 0.00012918598076794297
as O 0 3.6497219753073296e-06
having O 0 9.111738108913414e-06
either O 0 1.903171323647257e-05
neonatal O 1 0.9999970197677612
SJS B-Disease 1 0.9999873638153076
or O 0 3.028475839528255e-05
SWS B-Disease 1 0.8064998388290405
presented O 0 2.088879909933894e-06
a O 0 6.146532882667088e-07
combination O 0 2.2743486169929383e-06
of O 0 2.690530607196706e-07
a O 0 5.987222721159924e-06
severe O 1 0.6155998706817627
, O 0 0.00015178431931417435
prenatal O 1 0.9999721050262451
- O 1 0.9999936819076538
onset O 1 0.9999974966049194
neuromuscular B-Disease 1 0.9999997615814209
disorder I-Disease 1 0.9990999698638916
( O 0 3.737808356163441e-06
with O 0 4.673713647207478e-06
congenital B-Disease 1 0.9999078512191772
joint I-Disease 0 0.0294909980148077
contractures I-Disease 1 0.9998231530189514
, O 0 0.0005563023150898516
respiratory O 0 0.33129239082336426
and O 0 3.1068618682184024e-06
feeding O 0 9.161070920526981e-06
difficulties O 0 3.873804962495342e-05
, O 0 5.912139613428735e-07
tendency O 0 3.6836302115261788e-06
to O 0 7.745610446363571e-07
hyperthermia B-Disease 0 0.021063387393951416
, O 0 2.5325093133687915e-07
and O 0 1.344100439837348e-07
frequent O 0 8.655961778458732e-07
death O 0 2.0253795810276642e-05
in O 0 2.5816411834966857e-06
infancy O 0 0.14578446745872498
) O 0 5.445146484817087e-07
with O 0 2.677803365713771e-07
a O 0 1.4673422583655338e-06
distinct O 0 1.0570511221885681e-05
campomelic B-Disease 1 0.9294242858886719
- I-Disease 1 0.9280415177345276
metaphyseal I-Disease 1 0.6269171833992004
skeletal I-Disease 1 0.8282943367958069
dysplasia I-Disease 1 0.998580813407898
. O 0 0.00020890637824777514

The O 0 1.615260771359317e-05
similarity O 0 1.4455908058153e-05
of O 0 9.260117508347321e-07
the O 0 1.4829547581030056e-06
clinical O 0 5.5419281125068665e-05
and O 0 2.076605142065091e-06
radiographic O 1 0.6715090870857239
findings O 0 1.9688035536091775e-05
is O 0 2.605519568987802e-07
so O 0 3.1744187367621635e-07
extensive O 0 8.525681209903269e-07
that O 0 3.201080005510448e-07
these O 0 2.480529929016484e-06
disorders O 0 0.15578140318393707
appear O 0 1.9101400994259166e-06
to O 0 4.3597293597485987e-07
be O 0 3.4113395486201625e-07
a O 0 1.6283929653582163e-06
single O 0 1.2854244232585188e-05
entity O 0 6.0447753639891744e-05
. O 0 4.45150799350813e-05

The O 0 2.685365871002432e-05
follow O 0 1.3814481462759431e-05
- O 0 1.3953999769000802e-05
up O 0 6.037814159753907e-07
observation O 0 7.916552249298547e-07
of O 0 8.749933044782665e-08
an O 0 1.2586284015014826e-07
identical O 0 1.714869881652703e-06
and O 0 3.083555384364445e-07
unique O 0 5.935102649345936e-07
pattern O 0 2.8273793759581167e-06
of O 0 1.2956118098372826e-06
progressive O 1 0.993553876876831
bone B-Disease 1 0.9998806715011597
dysplasia I-Disease 1 0.9986841082572937
in O 0 1.0156427379115485e-06
the O 0 4.4307000734988833e-07
two O 0 1.9364733816473745e-06
patients O 0 0.00027628932730294764
( O 0 2.0145265011706215e-07
one O 0 1.991863740613553e-07
with O 0 1.0055589427793166e-06
SJS B-Disease 1 0.8443276286125183
type I-Disease 0 1.8103256707036053e-06
2 I-Disease 0 1.9873306200679508e-07
, O 0 7.566213611198691e-08
one O 0 8.379493010579608e-08
with O 0 4.905904802399164e-07
SWS B-Disease 0 0.18460781872272491
) O 0 5.835431124978641e-07
surviving O 0 2.3446739305654773e-06
beyond O 0 1.7997938357439125e-06
infancy O 0 8.656012505525723e-05
adds O 0 1.5904652173048817e-06
to O 0 1.5202850534024037e-07
the O 0 1.6764828103532636e-07
evidence O 0 4.8429217258672e-07
in O 0 5.55439555682824e-07
favor O 0 2.4056710117292823e-06
of O 0 1.3589113905254635e-06
identity O 0 3.634852691902779e-05
. O 0 4.0834602259565145e-05

The O 0 6.033315003151074e-05
hypothesis O 0 0.00011967614409513772
that O 0 8.391459232370835e-06
SWS B-Disease 0 0.0550391785800457
and O 0 6.784483957744669e-06
SJS B-Disease 0 0.21472427248954773
type I-Disease 0 2.847387122528744e-06
2 I-Disease 0 4.5518299884861335e-07
are O 0 9.439501269525863e-08
the O 0 3.0312708076962736e-07
same O 0 3.5204534469812643e-06
disorder O 0 0.0006976047880016267
should O 0 4.234840957906272e-07
be O 0 2.651221393534797e-07
testable O 0 3.772444870264735e-06
by O 0 7.562186965515139e-07
molecular O 0 1.117822921514744e-05
methods O 0 1.6713627701392397e-05
. O 0 9.916408089338802e-06
. O 0 3.026518243132159e-05

A O 0 0.0002153401728719473
mouse O 0 0.00044253154192119837
model O 0 7.475392339983955e-05
of O 0 1.8361901311436668e-05
severe O 1 0.9999786615371704
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 0.9999998807907104
: O 0 0.0007557670469395816
defects O 1 0.7741562724113464
in O 0 1.9514825908117928e-05
hemostasis O 1 0.9980853796005249
and O 0 0.010304179973900318
thrombosis B-Disease 1 0.9999762773513794
. O 0 0.00013031184789724648

von B-Disease 1 0.9996447563171387
Willebrand I-Disease 1 0.999728262424469
factor I-Disease 0 0.008913262747228146
( I-Disease 0 0.00015615439042448997
vWf I-Disease 1 0.7143483757972717
) I-Disease 0 0.003156464546918869
deficiency I-Disease 1 0.9882389307022095
causes O 0 0.14075304567813873
severe O 1 0.9999960660934448
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 0.9999943971633911
in O 0 5.4432908655144274e-05
humans O 0 8.645626803627238e-05
. O 0 5.762417276855558e-05

We O 0 3.523151463014074e-05
generated O 0 8.79559593158774e-06
a O 0 2.982647174576414e-06
mouse O 0 1.4355112398334313e-05
model O 0 3.368415946169989e-06
for O 0 5.388297381614393e-07
this O 0 1.3548003607866121e-06
disease O 0 1.872344182629604e-05
by O 0 6.782891546208702e-07
using O 0 4.386036835057894e-06
gene O 0 3.8331985706463456e-05
targeting O 0 8.124823943944648e-05
. O 0 6.614190351683646e-05

vWf B-Disease 1 0.9913488030433655
- I-Disease 1 0.99988853931427
deficient I-Disease 1 0.9978735446929932
mice O 0 0.0012423096923157573
appeared O 0 5.8474306570133194e-06
normal O 0 3.214128355466528e-06
at O 0 7.433786208821402e-07
birth O 0 2.890936457333737e-06
; O 0 7.480973636120325e-07
they O 0 4.1571325937184156e-07
were O 0 1.1423707064750488e-06
viable O 0 1.7199494322994724e-05
and O 0 5.2588247854146175e-06
fertile O 0 7.792354881530628e-05
. O 0 5.2194696763763204e-05

Neither O 0 0.002873794175684452
vWf O 0 0.01123780943453312
nor O 0 0.0006770070176571608
vWf O 0 0.003335394198074937
propolypeptide O 0 0.0029201782308518887
( O 0 5.427710129879415e-05
von B-Disease 0 0.09430129081010818
Willebrand I-Disease 1 0.6270607709884644
antigen O 0 0.0002444990968797356
II O 0 0.00028841994935646653
) O 0 6.587445682271209e-07
were O 0 2.2140272903925506e-07
detectable O 0 1.1194765647815075e-06
in O 0 1.3885984628814185e-07
plasma O 0 1.6336723547283327e-06
, O 0 3.887009825120913e-07
platelets O 0 1.2712561328953598e-05
, O 0 3.99774563675237e-07
or O 0 7.648818041161576e-07
endothelial O 0 2.358970778004732e-05
cells O 0 3.830328751064371e-06
of O 0 3.807769815011852e-07
the O 0 3.015317133758799e-06
homozygous O 0 0.00024911470245569944
mutant O 0 0.0005020666867494583
mice O 0 0.000995200709439814
. O 0 8.893747872207314e-05

The O 0 0.00012307448196224868
mutant O 0 0.0017836840124800801
mice O 0 0.020867662504315376
exhibited O 0 0.00013126039993949234
defects O 0 0.19545988738536835
in O 0 4.295161943446146e-06
hemostasis O 0 0.1632249504327774
with O 0 1.023960066959262e-06
a O 0 4.60961655335268e-06
highly O 0 1.4776052012166474e-05
prolonged O 0 0.18379466235637665
bleeding O 0 0.07919275760650635
time O 0 1.0257143685521442e-06
and O 0 7.482857427021372e-07
spontaneous O 0 3.858349828078644e-06
bleeding O 0 0.00015386521408800036
events O 0 9.286038675782038e-07
in O 0 5.153494271326053e-07
approximately O 0 5.873195050298818e-07
10 O 0 1.0612585583658074e-06
% O 0 1.854067477324861e-06
of O 0 2.810486193993711e-06
neonates O 0 0.11648470908403397
. O 0 7.91378115536645e-05

As O 0 1.3755731743003707e-05
in O 0 2.44764532908448e-06
the O 0 2.140530341421254e-06
human O 0 4.19743400925654e-06
disease O 0 2.877758743125014e-05
, O 0 2.162543353279034e-07
the O 0 1.6282038473036664e-07
factor O 0 7.107466899469728e-07
VIII O 0 2.1144562197150663e-05
level O 0 1.9968163655903481e-07
in O 0 1.065162749114279e-07
these O 0 1.6395927104895236e-07
mice O 0 2.2756506950827315e-05
was O 0 4.660547006096749e-07
reduced O 0 3.352880071361142e-07
strongly O 0 4.389341370369948e-07
as O 0 1.1874865180061533e-07
a O 0 1.4928177449746727e-07
result O 0 2.514373704798345e-07
of O 0 9.413754753495596e-08
the O 0 3.406388202620292e-07
lack O 0 1.6289242239508894e-06
of O 0 5.101231295157049e-07
protection O 0 3.650435701274546e-06
provided O 0 6.262381702981656e-06
by O 0 1.233526836585952e-05
vWf O 0 0.0012003411538898945
. O 0 6.182568904478103e-05

Defective O 1 0.9247744679450989
thrombosis B-Disease 1 0.9993937015533447
in O 0 4.179562893114053e-05
mutant O 0 0.0004598991072271019
mice O 0 0.0031288049649447203
was O 0 2.2683314000460086e-06
also O 0 4.2378468378956313e-07
evident O 0 9.95051095742383e-07
in O 0 3.0801402317592874e-07
an O 0 2.557427762894804e-07
in O 0 1.065066840055806e-06
vivo O 0 5.136255640536547e-05
model O 0 6.2240742408903316e-06
of O 0 4.835588242713129e-06
vascular B-Disease 1 0.999666690826416
injury I-Disease 1 0.9729252457618713
. O 0 0.00013124638644512743

In O 0 3.0197577871149406e-05
this O 0 4.1419939407205675e-06
model O 0 8.041902219702024e-06
, O 0 1.0284109066560632e-06
the O 0 1.2670940350290039e-06
exteriorized O 0 0.00010370121890446171
mesentery O 0 0.0005127181066200137
was O 0 3.0578369205613853e-06
superfused O 0 2.9010258003836498e-05
with O 0 5.924680408497807e-07
ferric O 0 0.00010177249350817874
chloride O 0 1.247326781594893e-05
and O 0 5.1461569228195e-07
the O 0 3.1991575610845757e-07
accumulation O 0 1.1739433602997451e-06
of O 0 4.219916149850178e-07
fluorescently O 0 0.0001128054573200643
labeled O 0 3.370319973328151e-05
platelets O 0 8.770765998633578e-05
was O 0 2.213289235442062e-06
observed O 0 4.232449100527447e-06
by O 0 3.2312470921169734e-06
intravital O 0 0.00017786856915336102
microscopy O 0 0.0001748369977576658
. O 0 0.00010014438157668337

We O 0 5.140126813785173e-05
conclude O 0 3.5767952795140445e-05
that O 0 1.7448793414587271e-06
these O 0 1.2113596312701702e-06
mice O 0 2.8908514650538564e-05
very O 0 1.7758238755050115e-06
closely O 0 9.996289008995518e-06
mimic O 0 0.02676999568939209
severe O 1 0.8489037752151489
human O 0 0.0004799800517503172
von B-Disease 1 1.0
Willebrand I-Disease 1 0.9999998807907104
disease I-Disease 1 0.9998977184295654
and O 0 9.4330550837185e-07
will O 0 1.92789613606692e-07
be O 0 9.041608706183979e-08
very O 0 1.3756560690580955e-07
useful O 0 3.0204842005332466e-07
for O 0 1.3103225171562372e-07
investigating O 0 4.313484112117294e-07
the O 0 1.2646805203075928e-07
role O 0 3.650459632353886e-07
of O 0 1.849582105251102e-07
vWf O 0 1.2295288797758985e-05
in O 0 3.6811505310652137e-07
normal O 0 1.5378608395621995e-06
physiology O 0 7.367180842265952e-06
and O 0 1.4374414831763715e-06
in O 0 1.4216694580682088e-05
disease O 0 0.002939568366855383
models O 0 2.9901782909291796e-05
. O 0 1.4547889804816805e-05
. O 0 4.197301677777432e-05

Oral O 0 0.0008203537436202168
contraceptives O 0 0.0018804632127285004
and O 0 1.312924905505497e-05
the O 0 9.227341251971666e-06
risk O 0 5.643455369863659e-05
of O 0 2.1155594367883168e-05
hereditary B-Disease 1 0.9999990463256836
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999995231628418
. O 0 0.00027722472441382706

Hereditary B-Disease 1 0.999991774559021
Ovarian I-Disease 1 0.9999998807907104
Cancer I-Disease 1 0.9999910593032837
Clinical O 1 0.8432778716087341
Study O 0 0.0006066192290745676
Group O 0 0.00037894610431976616
. O 0 0.00016432642587460577

BACKGROUND O 0 0.0011705433716997504
Women O 0 4.882508437731303e-05
with O 0 3.563520976967993e-06
mutations O 0 1.0543710232013837e-05
in O 0 3.7801774510626274e-07
either O 0 4.3988788434035087e-07
the O 0 6.763499982298526e-07
BRCA1 O 0 0.0002828653377946466
or O 0 8.24864287096716e-07
the O 0 6.631404403378838e-07
BRCA2 O 0 0.0002051236224360764
gene O 0 2.166766307709622e-06
have O 0 4.042247780944308e-07
a O 0 7.834460689082334e-07
high O 0 5.362668161978945e-06
lifetime O 0 0.0004851923731621355
risk O 0 0.0009407457546330988
of O 0 0.0025086672976613045
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999984502792358
. O 0 0.00016167678404599428

Oral O 0 0.000987478531897068
contraceptives O 0 0.04694075137376785
protect O 0 0.00022009623353369534
against O 0 0.20882809162139893
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999569654464722
in O 0 7.777171049383469e-07
general O 0 6.563753913724213e-07
, O 0 2.192496424413548e-07
but O 0 1.444428932018127e-07
it O 0 6.3039031772405e-08
is O 0 4.6750766813374867e-08
not O 0 6.593605661464608e-08
known O 0 1.41472000336762e-07
whether O 0 1.7666890528289514e-07
they O 0 1.810061718288125e-07
also O 0 3.0450161148110055e-07
protect O 0 9.881346159090754e-07
against O 0 9.806150274016545e-07
hereditary B-Disease 0 0.0001260867138626054
forms I-Disease 0 8.568028533773031e-06
of I-Disease 0 0.0383850522339344
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999983310699463
. O 0 0.00011247976362938061

METHODS O 0 0.00023583161237183958
We O 0 1.5561472537228838e-05
enrolled O 0 1.745300687616691e-05
207 O 0 1.0368691619078163e-05
women O 0 3.1778401989868144e-06
with O 0 3.800444801527192e-06
hereditary B-Disease 1 0.9999983310699463
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999927282333374
and O 0 4.252835026363755e-07
161 O 0 6.56023075862322e-07
of O 0 8.812018847947911e-08
their O 0 2.3586682118548197e-07
sisters O 0 5.2636114560300484e-06
as O 0 2.4382327978855756e-07
controls O 0 9.346516094410617e-07
in O 0 3.2873018085410877e-07
a O 0 9.089207537726907e-07
case O 0 1.3283948646858335e-05
- O 0 0.007621473167091608
control O 0 2.297083665325772e-05
study O 0 3.059513255720958e-05
. O 0 3.733356425072998e-05

All O 0 2.697403215279337e-05
the O 0 1.4237317373044789e-05
patients O 0 9.980937466025352e-05
carried O 0 4.1587841224099975e-06
a O 0 2.639578497110051e-06
pathogenic O 0 1.5128037375689019e-05
mutation O 0 9.240144208888523e-06
in O 0 8.643867772661906e-07
either O 0 2.2561032437806716e-06
BRCA1 O 0 0.0004810972313862294
( O 0 6.939744139344839e-07
179 O 0 1.798174366740568e-06
women O 0 1.3247902188595617e-06
) O 0 5.769415452050453e-07
or O 0 1.2820888741771341e-06
BRCA2 O 0 0.0006631902069784701
( O 0 2.063219653791748e-06
28 O 0 3.362651341376477e-06
women O 0 4.5663532546313945e-06
) O 0 3.940704573324183e-06
. O 0 1.189600061479723e-05

The O 0 3.281473254901357e-05
control O 0 3.6769612052012235e-05
women O 0 6.092036528571043e-06
were O 0 9.409550330019556e-07
enrolled O 0 2.777043846435845e-06
regardless O 0 5.585896474258334e-07
of O 0 1.0022418450716941e-07
whether O 0 5.993633180878533e-07
or O 0 4.5477429466700414e-07
not O 0 5.012837505091738e-07
they O 0 6.002951522532385e-07
had O 0 2.427331310173031e-06
either O 0 6.867605861771153e-06
mutation O 0 7.591032772324979e-05
. O 0 2.7859146939590573e-05

Lifetime O 0 0.0008589410572312772
histories O 0 0.00015520909801125526
of O 0 5.169179530639667e-06
oral O 0 5.0048987759510055e-05
- O 0 0.001489802380092442
contraceptive O 0 0.0006739531527273357
use O 0 8.192056952793791e-07
were O 0 3.217417372525233e-07
obtained O 0 5.017931812290044e-07
by O 0 1.8490459297026973e-07
interview O 0 2.413281663393718e-06
or O 0 1.7137371344233543e-07
by O 0 1.0310844800187624e-07
written O 0 2.867651858196041e-07
questionnaire O 0 1.3080655207886593e-06
and O 0 1.3172021340324136e-07
were O 0 1.4838330741895334e-07
compared O 0 7.060735924824257e-07
between O 0 4.2187332383036846e-07
patients O 0 2.3894872356322594e-05
and O 0 8.253796863755269e-07
control O 0 2.935227030320675e-06
women O 0 8.570812042307807e-07
, O 0 1.6962624727057118e-07
after O 0 5.371074394133757e-07
adjustment O 0 1.2849042150264722e-06
for O 0 1.9481656465814012e-07
year O 0 5.084402801003307e-07
of O 0 3.224313331884332e-07
birth O 0 2.1728874344262294e-05
and O 0 4.724577138404129e-06
parity O 0 7.432473648805171e-05
. O 0 5.3990690503269434e-05

RESULTS O 0 0.0005507344612851739
The O 0 1.3280275197757874e-05
adjusted O 0 7.290201028808951e-05
odds O 0 0.0002113393711624667
ratio O 0 4.5896023948444054e-05
for O 0 0.18832051753997803
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
associated O 0 2.3071461328072473e-06
with O 0 1.4222710831290897e-07
any O 0 1.4411678250780824e-07
past O 0 2.755070340754173e-07
use O 0 3.2954005746432813e-07
of O 0 2.553530862314801e-07
oral O 0 1.834887734730728e-05
contraceptives O 0 0.03688594698905945
was O 0 1.961879934242461e-05
0 O 0 4.137617725064047e-05
. O 0 2.166551348636858e-05

5 O 0 8.796414476819336e-05
( O 0 1.183383574243635e-05
95 O 0 8.15972907730611e-06
percent O 0 4.279020686226431e-06
confidence O 0 2.6042971512652002e-06
interval O 0 2.6673735646909336e-06
, O 0 3.7355735571509285e-07
0 O 0 5.643587428494357e-07
. O 0 1.5357400684479217e-07
3 O 0 2.3230836632137652e-07
to O 0 1.4385287272489222e-07
0 O 0 1.0640566188158118e-06
. O 0 5.533997295970039e-07
8 O 0 3.3461635666753864e-06
) O 0 6.839599336672109e-06
. O 0 1.9435967260506004e-05

The O 0 8.113767398754135e-05
risk O 0 0.00016535024042241275
decreased O 0 1.1524506589921657e-05
with O 0 5.573987209572806e-07
increasing O 0 6.602994062632206e-07
duration O 0 1.5390228327305522e-06
of O 0 1.832809886082032e-07
use O 0 8.701740057404095e-07
( O 0 6.728707830916392e-07
P O 0 1.2593583051057067e-05
for O 0 2.711498154894798e-07
trend O 0 1.3310425401868997e-06
, O 0 3.048118912829523e-07
< O 0 2.8208376079419395e-06
0 O 0 5.62234617973445e-07
. O 0 2.1718358311773045e-07
001 O 0 1.7385574437867035e-06
) O 0 1.370662801036815e-07
; O 0 7.274108781984978e-08
use O 0 5.60605997179664e-08
for O 0 4.1262680383624684e-08
six O 0 8.643079496550854e-08
or O 0 8.792376604560559e-08
more O 0 5.8569746386183397e-08
years O 0 7.014760967649636e-07
was O 0 1.0097795666297316e-06
associated O 0 2.8553196784741885e-07
with O 0 1.0131859085049655e-07
a O 0 5.907478453082149e-07
60 O 0 1.5725776165709249e-06
percent O 0 7.020388693490531e-06
reduction O 0 6.8950175773352385e-06
in O 0 7.7870363384136e-06
risk O 0 0.0001031654464895837
. O 0 4.4818272726843134e-05

Oral O 0 0.001127154566347599
- O 0 0.005503790453076363
contraceptive O 0 0.00047316623385995626
use O 0 8.31793477118481e-06
protected O 0 1.0855539585463703e-05
against O 0 0.036283574998378754
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.999940037727356
both O 0 4.447014987363218e-07
for O 0 2.960719029942993e-07
carriers O 0 1.1064386171710794e-06
of O 0 1.3992517722272169e-07
the O 0 1.0748840395535808e-06
BRCA1 O 0 0.005545147694647312
mutation O 0 1.8225926396553405e-05
( O 0 9.266911433769565e-07
odds O 0 6.849221335869515e-06
ratio O 0 8.434410574409412e-07
, O 0 1.8342191765441385e-07
0 O 0 3.9183066746772965e-07
. O 0 1.069301092115893e-07
5 O 0 1.3688104161246883e-07
; O 0 1.7397503881966259e-07
95 O 0 2.919037171977834e-07
percent O 0 4.361933747532021e-07
confidence O 0 5.007538561585534e-07
interval O 0 6.053178367437795e-07
, O 0 1.5844746314996883e-07
0 O 0 1.7106820848766802e-07
. O 0 4.7872212860511354e-08
3 O 0 8.088013458973364e-08
to O 0 6.00194383082453e-08
0 O 0 2.0549256873891864e-07
. O 0 7.183632533269702e-08
9 O 0 1.4921573665560572e-07
) O 0 4.254465579833777e-08
and O 0 3.5034680934131757e-08
for O 0 5.537904712582531e-08
carriers O 0 3.209786427760264e-07
of O 0 7.547332359081338e-08
the O 0 9.418779995939985e-07
BRCA2 O 0 0.05882907658815384
mutation O 0 9.189683623844758e-06
( O 0 6.365486910908658e-07
odds O 0 6.010380275256466e-06
ratio O 0 1.098753045880585e-06
, O 0 1.6936262170474947e-07
0 O 0 3.6629162991630437e-07
. O 0 1.0441303999186857e-07
4 O 0 1.6515761558366648e-07
; O 0 1.475584952004283e-07
95 O 0 4.396538599849009e-07
percent O 0 5.40788050784613e-07
confidence O 0 5.968529990241223e-07
interval O 0 7.94655079516815e-07
, O 0 1.596901739731038e-07
0 O 0 3.1414296586262935e-07
. O 0 8.929626460485451e-08
2 O 0 1.379727763151095e-07
to O 0 1.186682681009188e-07
1 O 0 2.7659038437377603e-07
. O 0 4.4497468820736685e-07
1 O 0 2.165621708627441e-06
) O 0 4.2297983782191295e-06
. O 0 1.2677500308200251e-05

CONCLUSIONS O 0 0.0004102105740457773
Oral O 0 0.00015388634346891195
- O 0 0.00048764137318357825
contraceptive O 0 0.0001491146394982934
use O 0 2.626726427479298e-06
may O 0 1.4292247669800417e-06
reduce O 0 1.1058289146603784e-06
the O 0 8.658653314341791e-07
risk O 0 1.1324023944325745e-05
of O 0 0.00011343744699843228
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999994039535522
in O 0 2.7399673854233697e-06
women O 0 2.5682652449177112e-06
with O 0 1.0208096909991582e-06
pathogenic O 0 2.391018824710045e-05
mutations O 0 7.795744750183076e-06
in O 0 1.117949864237744e-06
the O 0 3.706224561028648e-06
BRCA1 O 0 0.004808271303772926
or O 0 9.529298404231668e-05
BRCA2 O 0 0.009049549698829651
gene O 0 0.0008112406358122826

A O 0 0.00012981181498616934
Japanese O 0 9.17693178053014e-05
family O 0 4.84368356410414e-05
with O 0 6.009148364682915e-06
adrenoleukodystrophy B-Disease 1 0.9999639987945557
with O 0 1.0993683190463344e-06
a O 0 1.246733745574602e-06
codon O 0 1.5251455806719605e-05
291 O 0 1.0471660971234087e-05
deletion O 0 1.4323032701213378e-05
: O 0 6.665121645710315e-07
a O 0 5.011083317185694e-07
clinical O 0 2.272616620757617e-05
, O 0 8.239027806666854e-07
biochemical O 0 1.6025504010031e-05
, O 0 8.000540674402146e-07
pathological O 0 1.2354174941719975e-05
, O 0 1.5040769767438178e-06
and O 0 3.5624234442366287e-06
genetic O 0 5.743161091231741e-05
report O 0 6.358673999784514e-05
. O 0 5.5296906793955714e-05

We O 0 0.00011449385056039318
report O 0 2.472642154316418e-05
a O 0 5.3440235205926e-06
Japanese O 0 1.1191435078217182e-05
family O 0 1.6929452613112517e-05
with O 0 9.545901775709353e-06
adrenoleukodystrophy B-Disease 1 1.0
( O 0 0.016282470896840096
ALD B-Disease 1 0.9999995231628418
) O 0 1.217665158037562e-06
with O 0 1.9221425873183762e-07
a O 0 3.656103615412576e-07
three O 0 5.489313252837746e-07
base O 0 1.5763780538691208e-06
pair O 0 4.7776620704098605e-06
deletion O 0 2.8385748009895906e-05
( O 0 1.2935796576130087e-06
delGAG O 0 1.8068198187393136e-05
291 O 0 4.958268164045876e-06
) O 0 1.0572289284027647e-06
in O 0 1.2830062132707098e-06
the O 0 1.2097620128770359e-05
ALD B-Disease 1 0.9999825954437256
gene O 0 0.00015838454419281334
. O 0 8.071362390182912e-05

A O 0 6.875710096210241e-05
variety O 0 1.7208714780281298e-05
of O 0 3.14749195240438e-06
phenotypes O 0 9.576192678650841e-05
were O 0 1.974427277673385e-06
observed O 0 3.674633944683592e-06
within O 0 1.3604700370706269e-06
this O 0 3.4514139315433567e-06
family O 0 7.236259989440441e-05
. O 0 5.0796788855222985e-05

While O 0 3.864105383399874e-05
the O 0 8.323315341840498e-06
proband O 0 0.0003587455430533737
( O 0 4.3649979488691315e-06
patient O 0 1.3111669431964401e-05
1 O 0 8.058692060330941e-07
) O 0 3.168714215462387e-07
was O 0 4.7021646309985954e-07
classified O 0 6.82288145981147e-07
as O 0 1.7211945646522508e-07
having O 0 5.510656251317414e-07
a O 0 6.973352810746292e-07
rare O 0 1.8561213437351398e-06
intermediate O 0 3.455369324001367e-06
type O 0 2.104669192704023e-06
of O 0 2.1516424908440968e-07
adult O 0 8.17840191302821e-06
cerebral O 0 0.07698827236890793
and O 0 2.813693527059513e-06
cerebello O 1 0.920742928981781
- O 1 0.9511387348175049
brain O 0 0.00810147076845169
stem O 0 4.970559075445635e-06
forms O 0 4.0163942571780353e-07
, O 0 2.2051474957152095e-07
his O 0 4.2251028276041325e-07
younger O 0 9.535447134112474e-06
brother O 0 0.0004297556006349623
( O 0 6.562877388205379e-07
patient O 0 3.8359912650776096e-06
2 O 0 3.9607155599696853e-07
) O 0 2.1846278741577407e-07
and O 0 2.67127376218923e-07
nephew O 0 0.001656387816183269
( O 0 8.403659421674092e-07
patient O 0 5.486861482495442e-06
3 O 0 7.25913878341089e-07
) O 0 4.0452403027302353e-07
had O 0 1.9002702629222767e-06
a O 0 1.2615749255928677e-05
childhood O 1 0.863396167755127
ALD B-Disease 1 0.9999996423721313
type O 0 0.007919421419501305
. O 0 7.680573617108166e-05

Another O 0 0.00012655371392611414
nephew O 0 0.0007700392161495984
( O 0 1.3662423043570016e-05
patient O 0 1.6464713553432375e-05
4 O 0 1.6760990320108249e-06
) O 0 4.1094764924309857e-07
of O 0 1.885561857761786e-07
patient O 0 1.8486754925106652e-05
1 O 0 9.937784852809273e-07
was O 0 1.7411425687896553e-06
classified O 0 2.579185093054548e-06
as O 0 4.0898223119256727e-07
having O 0 1.5250974456648692e-06
an O 0 1.5864901570239454e-06
adolescent O 0 0.00018341990653425455
form O 0 2.8757012842106633e-05
. O 0 4.313937824917957e-05

The O 0 3.773351272684522e-05
tau O 0 4.9169968406204134e-05
level O 0 5.684234110958641e-06
in O 0 8.99840642887284e-07
the O 0 1.5949733551678946e-06
cerebrospinal O 0 0.0016307117184624076
fluid O 0 0.00012434815289452672
( O 0 1.8415472595734173e-06
CSF O 0 0.0016731865471228957
) O 0 3.736457472314214e-07
in O 0 1.8388990952189488e-07
patient O 0 2.385878133281949e-06
1 O 0 2.938067780178244e-07
was O 0 2.3662607873120578e-07
as O 0 8.833272602259967e-08
high O 0 1.5583543699904112e-07
as O 0 8.881031021701347e-08
that O 0 1.0851606901951527e-07
of O 0 3.401220567411656e-07
patients O 0 0.0007697773980908096
with O 0 0.0005188208306208253
Alzheimers B-Disease 1 0.9999998807907104
disease I-Disease 1 0.9776870608329773
( O 0 8.006517418834846e-06
AD B-Disease 0 0.0001829620887292549
) O 0 1.2615918421943206e-05
. O 0 2.193231375713367e-05

His O 0 0.00017375507741235197
brain O 0 0.005098034627735615
magnetic O 0 6.79087606840767e-05
resonance O 0 0.00019712166977114975
image O 0 0.0001159522871603258
( O 0 3.7097324820933864e-06
MRI O 0 0.03688545897603035
) O 0 2.598318587843096e-06
showed O 0 4.279070344637148e-05
abnormalities B-Disease 0 0.0017446520505473018
in I-Disease 0 2.4199275117098296e-07
the I-Disease 0 3.385169975445024e-07
bilateral I-Disease 0 1.592767944202933e-06
cerebellar I-Disease 0 0.002265973947942257
hemispheres I-Disease 0 0.0008720945916138589
and O 0 1.285900088987546e-05
brain O 0 0.009281421080231667
stem O 0 7.339102467085468e-06
, O 0 1.6847931760821666e-07
but O 0 1.6379797784793482e-07
not O 0 9.468605099982597e-08
in O 0 1.4388854197022738e-07
the O 0 6.437168735828891e-07
cerebral O 0 0.44185715913772583
white O 0 3.5819877666654065e-05
matter O 0 4.797275892087782e-07
, O 0 1.1252356557633902e-07
where O 0 1.35800291900523e-07
marked O 0 5.307538799570466e-07
reductions O 0 7.420675842695346e-07
of O 0 9.649741627981712e-08
the O 0 5.659206294694741e-07
cerebral O 0 0.22115632891654968
blood O 0 1.3020805454289075e-05
flow O 0 1.619015392861911e-06
and O 0 7.262130452545534e-07
oxygen O 0 4.16274042436271e-06
metabolism O 0 5.3536746236204635e-06
were O 0 5.330700787453679e-07
clearly O 0 9.9662952379731e-07
demonstrated O 0 1.397418259330152e-06
by O 0 6.04650324476097e-07
positron O 0 0.0001682072615949437
emission O 0 1.7026890418492258e-05
tomography O 0 0.0004398045421112329
( O 0 6.320617103483528e-06
PET O 0 5.2061273891013116e-05
) O 0 1.2143844287493266e-05
. O 0 2.1632213247357868e-05

In O 0 9.480898006586358e-05
patients O 0 0.0002157878188882023
2 O 0 3.0083981528150616e-06
and O 0 7.388108542727423e-07
3 O 0 7.782587090332527e-07
, O 0 1.75634426113902e-07
the O 0 4.062413268002274e-07
autopsy O 0 0.006612265482544899
findings O 0 8.370985597139224e-05
showed O 0 2.9925062335678376e-05
massive O 0 5.004221020499244e-05
demyelination B-Disease 1 0.9993023872375488
of I-Disease 0 8.609627002442721e-07
the I-Disease 0 5.487170255946694e-06
cerebral I-Disease 1 0.9745450615882874
white I-Disease 0 2.4560662495787255e-05
matter I-Disease 0 3.2338010669263895e-07
with O 0 1.295607745532834e-07
sparing O 0 1.7620511698623886e-06
of O 0 1.0556829010965885e-07
the O 0 5.003910246159649e-07
U O 0 0.006105947773903608
- O 0 0.007671266328543425
fibers O 0 6.246883276617154e-05
, O 0 2.2444024239121063e-07
compatible O 0 5.504631985786546e-07
with O 0 2.006027841616742e-07
the O 0 8.139608098645112e-07
findings O 0 1.0126243068953045e-05
of O 0 6.168051186250523e-06
childhood O 1 0.739183247089386
ALD B-Disease 1 0.999998927116394
. O 0 0.00021940396982245147

Oleic O 0 0.00838683545589447
and O 0 5.906412479816936e-05
erucic O 0 0.023050274699926376
acids O 0 4.214608634356409e-05
( O 0 2.068253024845035e-06
Lorenzos O 0 9.73351598076988e-06
Oil O 0 1.4308491245174082e-06
) O 0 2.1875361255752068e-07
were O 0 1.141144352345691e-07
administered O 0 3.1253648558049463e-07
to O 0 2.7239286737312796e-07
patients O 0 1.4162415027385578e-06
1 O 0 1.1124954113483909e-07
and O 0 7.527837198040288e-08
4 O 0 2.623111470256845e-07
, O 0 1.390877883977737e-07
but O 0 1.5814809728453838e-07
sufficient O 0 1.2183481885585934e-06
effectiveness O 0 4.855453880736604e-06
was O 0 1.4546297961715027e-06
not O 0 1.4514425856759772e-06
obtained O 0 8.116964636428747e-06
. O 0 2.6704263291321695e-05

The O 0 5.863681508344598e-05
findings O 0 3.4036820579785854e-05
in O 0 1.6650741372359334e-06
this O 0 5.297293910189182e-07
family O 0 1.9306387457618257e-06
suggest O 0 1.6496745729455142e-06
that O 0 2.4227307449109503e-07
delGAG291 O 0 9.642631084716413e-06
is O 0 1.6449835982257355e-07
part O 0 2.227250490705046e-07
of O 0 1.194480887534155e-07
the O 0 7.568550586256606e-07
cause O 0 3.7361619433795568e-06
of O 0 9.382667940371903e-07
Japanese O 0 0.001818688353523612
ALD B-Disease 1 0.9999895095825195
with O 0 4.5940460040583275e-06
phenotypic O 0 0.0001355755957774818
variations O 0 0.00011270104005234316
. O 0 5.9839800087502226e-05

Moreover O 0 0.0002426729624858126
, O 0 7.181055025284877e-06
although O 0 1.604401518306986e-06
the O 0 3.7810207231814275e-07
scale O 0 9.217474143952131e-07
of O 0 7.697276060980585e-08
the O 0 2.3658679992877296e-07
study O 0 7.717503081039467e-07
is O 0 1.3032686752012523e-07
limited O 0 3.6045599927092553e-07
, O 0 9.057126248990244e-08
there O 0 4.561903210742457e-08
is O 0 3.619896205009354e-08
a O 0 1.1707966507401579e-07
possibility O 0 7.452376280525641e-07
that O 0 2.54746481687107e-07
PET O 0 1.6710950148990378e-05
can O 0 7.525403020736121e-07
detect O 0 9.022707672556862e-06
an O 0 3.354447244419134e-07
insidious B-Disease 0 0.0005868629668839276
lesion I-Disease 0 0.0343642421066761
which O 0 4.4783809016735177e-07
is O 0 2.983595379646431e-07
undetectable O 0 2.8618374017241877e-06
by O 0 2.7604673391579126e-07
computed O 0 3.7405043258331716e-06
tomogram O 0 3.1601928640156984e-05
( O 0 9.35659386414045e-07
CT O 0 0.17230886220932007
) O 0 3.0933753691897437e-07
or O 0 2.188068179975744e-07
MRI O 0 6.784428842365742e-05
analysis O 0 5.233291631157044e-07
, O 0 1.0433301156353991e-07
and O 0 6.834761023810643e-08
that O 0 4.74063526212376e-08
the O 0 1.6341883224413323e-07
higher O 0 5.638755737891188e-07
level O 0 2.3083094902176526e-07
of O 0 1.4444964335780242e-07
tau O 0 2.269737706228625e-06
reflects O 0 6.762893463019282e-07
the O 0 3.0807160555923474e-07
process O 0 8.608166126577999e-07
of O 0 1.5876343013587757e-06
neuronal B-Disease 0 0.016661055386066437
degeneration I-Disease 1 0.9978362917900085
in O 0 0.005874059163033962
ALD B-Disease 1 0.9999988079071045
. O 0 0.00020143853907939047

Lorenzos O 0 0.001708391821011901
Oil O 0 7.153775368351489e-05
should O 0 4.983279268344631e-06
be O 0 6.821508122811792e-07
given O 0 3.5269857789899106e-07
in O 0 2.2164989843531657e-07
the O 0 5.13709494498471e-07
early O 0 9.124972166318912e-06
stage O 0 3.602902506827377e-05
. O 0 9.272966053686105e-06
. O 0 3.594048757804558e-05

Nonsense O 0 0.0011378575582057238
mutation O 0 0.00030773336766287684
in O 0 6.454962203861214e-06
exon O 0 2.270996083097998e-05
4 O 0 2.415515155007597e-06
of O 0 4.751054234475305e-07
human O 0 9.497886139797629e-07
complement O 0 2.6552368126431247e-06
C9 O 0 0.002101000165566802
gene O 0 3.918914899259107e-06
is O 0 3.046666279260535e-07
the O 0 4.225070711072476e-07
major O 0 9.905187425829354e-07
cause O 0 3.209436044926406e-06
of O 0 7.952783107612049e-07
Japanese O 0 3.34559845214244e-05
complement B-Disease 0 0.0001813502749428153
C9 I-Disease 1 0.9998660087585449
deficiency I-Disease 1 0.9632524251937866
. O 0 7.178321538958699e-05

Deficiency B-Disease 1 0.9957347512245178
of I-Disease 0 6.6537049860926345e-06
the I-Disease 0 2.3275995317817433e-06
ninth I-Disease 0 7.871240995882545e-06
component I-Disease 0 2.029011511694989e-06
of I-Disease 0 3.53675034148182e-07
human I-Disease 0 5.633434625451628e-07
complement I-Disease 0 1.4199363249645103e-06
( O 0 5.778114768872911e-07
C9 O 0 0.0073034935630857944
) O 0 2.5963021244024276e-07
is O 0 5.987811135810261e-08
the O 0 8.625391956229578e-08
most O 0 3.1650839105168416e-07
common O 0 8.77126967679942e-06
complement B-Disease 1 0.9979405999183655
deficiency I-Disease 1 0.9999791383743286
in O 0 7.888779691711534e-07
Japan O 0 1.4146296507533407e-06
but O 0 4.688981505296397e-07
is O 0 2.2450102221682755e-07
rare O 0 7.018736027930572e-07
in O 0 4.699824387444096e-07
other O 0 1.0695504215618712e-06
countries O 0 4.189803348708665e-06
. O 0 2.660071368154604e-05

We O 0 4.479882773011923e-05
studied O 0 2.0246785425115377e-05
the O 0 1.7657739590504207e-06
molecular O 0 6.26790824753698e-06
basis O 0 1.7796401152736507e-06
of O 0 2.1250393729133066e-06
C9 B-Disease 1 0.9999591112136841
deficiency I-Disease 1 0.6519074440002441
in O 0 7.994485144990904e-07
four O 0 1.0734386250987882e-06
Japanese O 0 2.768250305962283e-05
C9 B-Disease 1 0.9997602105140686
- I-Disease 1 0.9993158578872681
deficient I-Disease 1 0.9916627407073975
patients O 0 0.00026684626936912537
who O 0 1.0712935363699216e-05
had O 0 0.0005121873691678047
suffered O 1 0.9977596998214722
from O 0 0.0004989267326891422
meningococcal B-Disease 1 0.9999995231628418
meningitis I-Disease 1 0.9999969005584717
. O 0 0.00035438817576505244

Direct O 0 8.661899482831359e-05
sequencing O 0 6.42597078694962e-05
of O 0 4.567311407299712e-06
amplified O 0 4.510993312578648e-05
C9 O 0 0.0002612575772218406
cDNA O 0 3.8408754335250705e-05
and O 0 3.464268047537189e-06
DNA O 0 1.138175321102608e-05
revealed O 0 4.510004146141e-06
a O 0 7.736766178823018e-07
nonsense O 0 4.909559720545076e-06
substitution O 0 2.47699335886864e-06
( O 0 1.2137927569710882e-06
CGA O 0 1.3441504961519968e-05
- O 0 0.00030271473224274814
- O 0 4.676974640460685e-05
> O 0 1.3729977581533603e-05
TGA O 0 4.1432282159803435e-05
) O 0 3.730077366981277e-07
at O 0 1.7257012530080829e-07
codon O 0 7.131916959224327e-07
95 O 0 4.367836368146527e-07
in O 0 1.6122747581448493e-07
exon O 0 1.503093471910688e-06
4 O 0 2.731368340391782e-07
in O 0 1.4914259338638658e-07
the O 0 4.014150363218505e-07
four O 0 3.653064823083696e-06
C9 B-Disease 1 0.9986013770103455
- I-Disease 1 0.9837971329689026
deficient I-Disease 0 0.1657685935497284
individuals O 0 2.514913103368599e-05
. O 0 4.026419992442243e-05

An O 0 4.866782182944007e-05
allele O 0 0.0002178702998207882
- O 0 4.1628922190284356e-05
specific O 0 3.075055701629026e-06
polymerase O 0 1.9019194951397367e-05
chain O 0 1.007063747238135e-05
reaction O 0 2.6164582322962815e-06
system O 0 1.3132490721545764e-06
designed O 0 1.5344650137194549e-06
to O 0 3.478526195976883e-07
detect O 0 1.8876611420637346e-06
exclusively O 0 2.289817615519496e-07
only O 0 5.190060647919381e-08
one O 0 3.480509391806663e-08
of O 0 2.4009070287434042e-08
the O 0 1.020503574977738e-07
normal O 0 4.013492116428097e-07
and O 0 2.2923104836536368e-07
mutant O 0 3.6508392895484576e-06
alleles O 0 1.8950202047562925e-06
indicated O 0 6.198138180479873e-07
that O 0 5.223259691433668e-08
all O 0 4.067941006269393e-08
the O 0 1.5763328065077076e-07
four O 0 8.22990216420294e-07
patients O 0 1.0883620234380942e-05
were O 0 2.6985944145963003e-07
homozygous O 0 2.029170445894124e-06
for O 0 1.171422070456174e-07
the O 0 1.4237448908716033e-07
mutation O 0 1.2789187167072669e-06
in O 0 1.8135901314053626e-07
exon O 0 2.6111313218279975e-06
4 O 0 3.2054362009148463e-07
and O 0 9.503978048996942e-08
that O 0 5.791786605868765e-08
the O 0 1.5628133098744001e-07
parents O 0 8.054727800299588e-07
of O 0 3.1963182323124784e-07
patient O 0 1.914026688609738e-05
2 O 0 4.01718989451183e-06
were O 0 4.517080469668144e-06
heterozygous O 0 6.641051004407927e-05
. O 0 3.795072916545905e-05

The O 0 4.144852209719829e-05
common O 0 1.7272473996854387e-05
mutation O 0 2.1666504835593514e-05
at O 0 1.4267667438616627e-06
codon O 0 4.719551725429483e-06
95 O 0 1.4219946251614601e-06
in O 0 4.162670848018024e-07
exon O 0 3.724919451997266e-06
4 O 0 5.671340659318957e-07
might O 0 3.4256092362738855e-07
be O 0 8.035349452484297e-08
responsible O 0 3.22199866786832e-07
for O 0 2.3029465978652297e-07
most O 0 1.8805492345563835e-06
Japanese O 0 0.001996764913201332
C9 B-Disease 1 0.9999833106994629
deficiency I-Disease 1 0.8996483087539673
. O 0 1.0024996299762279e-05
. O 0 2.6113601052202284e-05

BRCA1 O 0 0.005691403988748789
required O 0 3.776811354327947e-05
for O 0 4.3729687604354694e-06
transcription O 0 2.2084288502810523e-05
- O 0 0.000381563906557858
coupled O 0 7.665222074138e-05
repair O 0 0.001136481761932373
of O 0 6.60248042549938e-06
oxidative O 0 0.03288412466645241
DNA O 0 0.0017950269393622875
damage O 0 0.01209288090467453
. O 0 9.849787602433935e-05

The O 0 0.00048776459880173206
breast B-Disease 1 0.9998257756233215
and I-Disease 1 0.9984728693962097
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
susceptibility O 0 0.04596635326743126
gene O 0 0.00013608408335130662
BRCA1 O 0 0.0003368864709045738
encodes O 0 1.8804932551574893e-05
a O 0 6.789254257455468e-06
zinc O 0 0.0001818569580791518
finger O 0 2.5777695555007085e-05
protein O 0 4.678083769249497e-06
of O 0 1.0456974450789858e-06
unknown O 0 1.4460692909779027e-05
function O 0 1.7543115973239765e-05
. O 0 3.493235999485478e-05

Association O 0 0.00015494099352508783
of O 0 5.920336207054788e-06
the O 0 3.97418079955969e-06
BRCA1 O 0 5.517733734450303e-05
protein O 0 2.639855438246741e-06
with O 0 3.3424117873437353e-07
the O 0 9.114814929489512e-07
DNA O 0 1.3468645192915574e-05
repair O 0 0.00029701710445806384
protein O 0 3.636821020336356e-06
Rad51 O 0 4.676301250583492e-05
and O 0 4.800223223355715e-07
changes O 0 4.692815309681464e-07
in O 0 1.5110659035144636e-07
the O 0 1.2778004077063088e-07
phosphorylation O 0 4.568834697238344e-07
and O 0 2.2275456501574808e-07
cellular O 0 1.2129340802857769e-06
localization O 0 1.5863388398429379e-06
of O 0 1.108407658989563e-07
the O 0 2.343309830621365e-07
protein O 0 7.922231475276931e-07
after O 0 9.186338729705312e-07
exposure O 0 2.243033577542519e-06
to O 0 3.4585994512781326e-07
DNA O 0 6.897884759382578e-06
- O 0 6.420849240384996e-05
damaging O 0 7.845341315260157e-06
agents O 0 6.835268777649617e-07
are O 0 1.2094140799945308e-07
consistent O 0 2.784527737276221e-07
with O 0 7.317692762853767e-08
a O 0 3.5144788057550613e-07
role O 0 1.8811124391504563e-06
for O 0 1.8962062995342421e-06
BRCA1 O 0 0.00024824924184940755
in O 0 6.916421170899412e-06
DNA O 0 0.0003780307015404105
repair O 1 0.5011144876480103
. O 0 9.994347055908293e-05

Here O 0 4.480630741454661e-05
, O 0 3.6722447021020344e-06
it O 0 5.142732106833137e-07
is O 0 2.5349163479404524e-07
shown O 0 3.470990463938506e-07
that O 0 2.246175370146375e-07
mouse O 0 1.4564130651706364e-05
embryonic O 0 5.8154011639999226e-05
stem O 0 0.000159981005708687
cells O 0 0.00022080246708355844
deficient B-Disease 0 0.0009373039356432855
in I-Disease 0 6.568099593096122e-07
BRCA1 I-Disease 0 7.840461330488324e-05
are O 0 2.1245763548449759e-07
defective O 0 3.6755873225047253e-06
in O 0 1.1626641338580157e-07
the O 0 1.048175022333453e-07
ability O 0 4.4655186570707883e-07
to O 0 1.2677658389748103e-07
carry O 0 3.9235004578586086e-07
out O 0 2.1732218158376782e-07
transcription O 0 1.7058155208360404e-06
- O 0 1.6628475350444205e-05
coupled O 0 7.267545242939377e-06
repair O 0 6.133148417575285e-05
of O 0 4.5711885832133703e-07
oxidative O 0 0.0015247572446241975
DNA O 0 0.00011729656398529187
damage O 0 9.082473115995526e-05
, O 0 2.4859906488927663e-07
and O 0 1.8369919985161687e-07
are O 0 2.1862346955003886e-07
hypersensitive O 0 7.629623723914847e-06
to O 0 1.6591426401646459e-06
ionizing O 0 4.892035576631315e-05
radiation O 0 2.566471630416345e-05
and O 0 1.5737958847239497e-06
hydrogen O 0 2.4557337383157574e-05
peroxide O 0 0.00093660136917606
. O 0 5.00227470183745e-05

These O 0 4.056632678839378e-05
results O 0 6.470107473433018e-05
suggest O 0 1.717638224363327e-05
that O 0 1.744187215990678e-06
BRCA1 O 0 3.761678090086207e-05
participates O 0 2.2434401216742117e-06
, O 0 2.8548214459078736e-07
directly O 0 2.623741863772011e-07
or O 0 2.4873565962479915e-07
indirectly O 0 8.562168432035833e-07
, O 0 1.6163512839284522e-07
in O 0 1.8934690615424188e-07
transcription O 0 2.69045108325372e-06
- O 0 0.00017457912326790392
coupled O 0 5.018807132728398e-05
repair O 0 0.0011396805057302117
of O 0 1.5695795809733681e-06
oxidative O 0 0.003514210693538189
DNA O 0 0.0006176508613862097
damage O 0 0.004075065720826387
. O 0 1.2201097888464574e-05
. O 0 3.5012933949474245e-05

Truncation O 0 0.0031696634832769632
mutations O 0 0.0008963156142272055
in O 0 1.4257670045481063e-05
the O 0 7.405578799080104e-06
transactivation O 0 0.000106888881418854
region O 0 6.609990123251919e-06
of O 0 1.5742926962047932e-06
PAX6 O 0 0.0025000444147735834
result O 0 1.253012760571437e-05
in O 0 3.788250069192145e-06
dominant O 0 0.00012048431381117553
- O 0 0.019091254100203514
negative O 0 9.529625094728544e-05
mutants O 0 0.00036878028186038136
. O 0 5.482570850290358e-05

PAX6 O 0 0.049107491970062256
is O 0 1.9538067135727033e-05
a O 0 6.1395585362333804e-06
transcription O 0 6.12324538451503e-06
factor O 0 2.672195932973409e-06
with O 0 4.3849229314218974e-07
two O 0 6.632834015363187e-07
DNA O 0 1.366966898785904e-05
- O 0 7.808682858012617e-05
binding O 0 2.60191154666245e-06
domains O 0 1.5656058849344845e-06
( O 0 4.160606863479188e-07
paired O 0 1.8174006299886969e-06
box O 0 2.39864948525792e-06
and O 0 1.0217943327006651e-06
homeobox O 0 0.00011787917901528999
) O 0 7.392040970444214e-07
and O 0 2.4848932866916584e-07
a O 0 6.354302399813605e-07
proline O 0 2.2185337002156302e-05
- O 0 3.038870454474818e-05
serine O 0 1.9791157683357596e-05
- O 0 4.248047844157554e-05
threonine O 0 3.877826384268701e-05
( O 0 2.619581664475845e-06
PST O 0 2.3210528524941765e-05
) O 0 1.4671937833554693e-06
- O 0 1.0601655958453193e-05
rich O 0 1.7708058294374496e-05
transactivation O 0 0.00013122335076332092
domain O 0 4.871095734415576e-05
. O 0 3.528040542732924e-05

PAX6 O 0 0.02361823059618473
regulates O 0 0.0009825985180214047
eye O 0 0.014299673028290272
development O 0 1.2633737242140342e-05
in O 0 1.6512311731275986e-06
animals O 0 1.4977160844864557e-06
ranging O 0 1.2077491646778071e-06
from O 0 4.824394750357897e-07
jellyfish O 0 3.959060450142715e-06
to O 0 4.449500750070001e-07
Drosophila O 0 3.536369376888615e-06
to O 0 2.254372020615847e-06
humans O 0 1.5630976122338325e-05
. O 0 1.9275155864306726e-05

Heterozygous O 0 0.0047456189058721066
mutations O 0 0.0005126218311488628
in O 0 7.802856089256238e-06
the O 0 3.1168867735686945e-06
human O 0 3.842721071123378e-06
PAX6 O 0 0.0013194261118769646
gene O 0 8.359955245396122e-06
result O 0 2.327590664208401e-06
in O 0 3.474047218787746e-07
various O 0 5.097020334687841e-07
phenotypes O 0 5.019036689191125e-05
, O 0 8.50027106480411e-07
including O 0 1.352109165964066e-06
aniridia B-Disease 1 0.9999896287918091
, O 0 0.0002471786574460566
Peters B-Disease 1 0.9999918937683105
anomaly I-Disease 1 0.9999589920043945
, O 0 7.286045729415491e-05
autosomal B-Disease 0 0.005855221301317215
dominant I-Disease 0 0.00026669621001929045
keratitis I-Disease 1 0.5676084160804749
, O 0 1.5342455299105495e-05
and O 0 4.815257852897048e-05
familial B-Disease 1 0.9640589952468872
foveal I-Disease 1 0.9997214674949646
dysplasia I-Disease 1 0.9997982382774353
. O 0 0.00023439066717401147

It O 0 1.8035836546914652e-05
is O 0 2.366198259551311e-06
believed O 0 2.318808355994406e-06
that O 0 4.2800346022886515e-07
the O 0 3.9752387692715274e-07
mutated O 0 7.2344359978160355e-06
allele O 0 5.069473900221055e-06
of O 0 3.933661218979978e-07
PAX6 O 0 0.00019326586334500462
produces O 0 1.622587546989962e-06
an O 0 3.3772471397242043e-07
inactive O 0 2.7785565634985687e-06
protein O 0 9.592539527147892e-07
and O 0 6.558523182320641e-07
aniridia B-Disease 1 0.9864870309829712
is O 0 9.354827739116445e-07
caused O 0 5.815868917125044e-06
due O 0 4.731638000521343e-06
to O 0 6.747935003659222e-06
genetic O 0 9.159307955997065e-05
haploinsufficiency O 0 0.007605177816003561
. O 0 8.069362229434773e-05

However O 0 4.3827018089359626e-05
, O 0 2.789870222841273e-06
several O 0 1.020907006932248e-06
truncation O 0 2.505338125047274e-05
mutations O 0 1.587579390616156e-05
have O 0 6.60157127185812e-07
been O 0 2.5554408011885243e-07
found O 0 1.8531697776325018e-07
to O 0 9.310205228985069e-08
occur O 0 1.411173400356347e-07
in O 0 1.1307735547916309e-07
the O 0 3.3564248269613017e-07
C O 0 0.001194703858345747
- O 0 8.781830547377467e-05
terminal O 0 3.262135578552261e-06
half O 0 2.989271479236777e-07
of O 0 1.9233272041674354e-07
PAX6 O 0 0.003167168004438281
in O 0 2.3831651105865603e-06
patients O 0 1.4706184629176278e-05
with O 0 5.452566824715177e-07
Aniridia B-Disease 1 0.9916113018989563
resulting O 0 1.9316296402394073e-06
in O 0 3.3760329642973375e-07
mutant O 0 3.535843461577315e-06
proteins O 0 4.5720909724877856e-07
that O 0 1.4822703064965026e-07
retain O 0 1.290010686716414e-06
the O 0 3.797492240664724e-07
DNA O 0 6.229953214642592e-06
- O 0 6.9758007157361135e-06
binding O 0 7.471391541002959e-07
domains O 0 7.086289315338945e-07
but O 0 5.591604690380336e-07
have O 0 4.886503575107781e-07
lost O 0 4.237113444105489e-06
most O 0 3.710174496518448e-07
of O 0 3.420666701003938e-07
the O 0 3.070507545999135e-06
transactivation O 0 0.0002343877567909658
domain O 0 3.491617098916322e-05
. O 0 3.568223837646656e-05

It O 0 2.4221346393460408e-05
is O 0 2.867990360755357e-06
not O 0 8.504893003191683e-07
clear O 0 6.954452373975073e-07
whether O 0 2.8325729317657533e-07
such O 0 2.174810020960649e-07
mutants O 0 2.2429834643844515e-05
really O 0 2.1463192751980387e-06
behave O 0 9.918525165630854e-07
as O 0 2.5636720124566637e-07
loss O 0 4.306481969251763e-06
- O 0 4.0745521800999995e-06
of O 0 2.5702425432427844e-07
- O 0 2.3690570742473938e-05
function O 0 1.3781170764559647e-06
mutants O 0 1.5879882994340733e-05
as O 0 1.3168760233384091e-06
predicted O 0 1.4944708709663246e-05
by O 0 8.176468327292241e-06
haploinsufficiency O 0 0.0013920371420681477
. O 0 6.818486144766212e-05

Contrary O 0 8.750517736189067e-05
to O 0 4.007596544397529e-06
this O 0 5.957110715826275e-07
theory O 0 8.805498055153294e-07
, O 0 2.4404425857937895e-07
our O 0 2.849240274827025e-07
data O 0 6.532343945764296e-07
showed O 0 8.933636195251893e-07
that O 0 1.4120968216957408e-07
these O 0 2.731999018124043e-07
mutants O 0 8.295103725686204e-06
are O 0 4.1165134234688594e-07
dominant O 0 5.7611637203081045e-06
- O 0 4.573881233227439e-05
negative O 0 2.2060421542846598e-06
in O 0 4.1637031245045364e-07
transient O 0 5.465131380333332e-06
transfection O 0 0.00016361534653697163
assays O 0 1.776289354893379e-05
when O 0 1.0414786402179743e-06
they O 0 2.8243994165677577e-07
are O 0 2.0102312703329517e-07
coexpressed O 0 7.801672836649232e-06
with O 0 9.428018188373244e-07
wild O 0 1.1540168088686187e-05
- O 0 0.0014036535285413265
type O 0 0.00010118492355104536
PAX6 O 0 0.0139482906088233
. O 0 8.96582132554613e-05

We O 0 5.694254286936484e-05
found O 0 5.6165117712225765e-06
that O 0 8.085297054094553e-07
the O 0 6.856428171886364e-07
dominant O 0 1.3231842785899062e-05
- O 0 0.0029747679363936186
negative O 0 5.988307748339139e-06
effects O 0 3.90535296901362e-06
result O 0 7.227597507153405e-07
from O 0 1.5181609569481225e-07
the O 0 2.1240860803573014e-07
enhanced O 0 2.923463171100593e-06
DNA O 0 5.62990771868499e-06
binding O 0 1.4180606058289413e-06
ability O 0 1.3851663425157312e-06
of O 0 7.043049095045717e-07
these O 0 3.6508115499600535e-06
mutants O 0 0.00015813193749636412
. O 0 4.566995266941376e-05

Kinetic O 0 0.00038830703124403954
studies O 0 4.659688056563027e-05
of O 0 1.8815753719536588e-06
binding O 0 4.265835286787478e-06
and O 0 1.1461049780336907e-06
dissociation O 0 1.2175060874142218e-05
revealed O 0 3.821126938419184e-06
that O 0 1.9272049200935726e-07
various O 0 2.9987052130309166e-07
truncation O 0 6.685610060230829e-06
mutants O 0 1.9599539882619865e-05
have O 0 4.426303519267094e-07
3 O 0 4.132522519739723e-07
- O 0 2.256189191029989e-06
5 O 0 2.808672547871538e-07
- O 0 1.7846742821348016e-06
fold O 0 1.2698401405941695e-06
higher O 0 4.436420795173035e-07
affinity O 0 6.531147960231465e-07
to O 0 1.0663174521141627e-07
various O 0 1.3530517151139065e-07
DNA O 0 2.595450496301055e-06
- O 0 4.010242264484987e-06
binding O 0 3.178969052441971e-07
sites O 0 2.5090130861826765e-07
when O 0 3.697331294461037e-07
compared O 0 4.5526590497502184e-07
with O 0 1.3685468047697213e-07
the O 0 9.699523388917441e-07
wild O 0 7.042832748993533e-06
- O 0 0.000627094239462167
type O 0 9.932893590303138e-05
PAX6 O 0 0.011893058195710182
. O 0 0.00011681614705594257

These O 0 3.0556238925782964e-05
results O 0 2.4220236809924245e-05
provide O 0 2.795148930090363e-06
a O 0 9.521157835479244e-07
new O 0 9.612887197363307e-07
insight O 0 1.653489334785263e-06
into O 0 1.54411253561193e-07
the O 0 2.4717826363485074e-07
role O 0 7.228356366795197e-07
of O 0 4.166626581536548e-07
mutant O 0 2.6639252610038966e-05
PAX6 O 0 0.0007415649015456438
in O 0 5.392685125116259e-06
causing O 0 6.601108907489106e-05
aniridia B-Disease 1 0.9991344809532166
. O 0 2.1388454115367495e-05
. O 0 5.809260255773552e-05

Reversal O 0 0.011899436824023724
of O 0 0.00012457993580028415
severe O 1 0.9999606609344482
hypertrophic B-Disease 1 0.9999881982803345
cardiomyopathy I-Disease 1 0.9999991655349731
and O 0 2.313971890544053e-05
excellent O 0 3.687048956635408e-05
neuropsychologic O 0 0.01301233097910881
outcome O 0 2.5464411010034382e-05
in O 0 1.7693038216748391e-06
very B-Disease 0 9.80429285846185e-06
- I-Disease 0 0.17485827207565308
long I-Disease 0 9.318519732914865e-05
- I-Disease 0 0.0016014918219298124
chain I-Disease 0 8.742677164264023e-05
acyl I-Disease 0 0.0011744167422875762
- I-Disease 0 0.018482498824596405
coenzyme I-Disease 0 0.0004733983369078487
A I-Disease 0 0.00016001761832740158
dehydrogenase I-Disease 0 0.16628070175647736
deficiency I-Disease 0 0.4041837751865387
. O 0 8.434422488790005e-05

Very B-Disease 0 0.0016181407263502479
- I-Disease 1 0.9515786170959473
long I-Disease 0 0.0005686851218342781
- I-Disease 0 0.01520836167037487
chain I-Disease 0 5.557938129641116e-05
acyl I-Disease 0 0.0003392715298105031
- I-Disease 0 0.0001430368283763528
coenzyme I-Disease 0 3.27079433191102e-05
A I-Disease 0 4.662614628614392e-06
dehydrogenase I-Disease 0 5.0569287850521505e-05
( I-Disease 0 3.578516043489799e-06
VLCAD I-Disease 0 0.4614672362804413
) I-Disease 0 0.0003854663809761405
deficiency I-Disease 0 0.015957361087203026
is O 0 4.4077395955355314e-07
a O 0 2.7473931822896702e-06
disorder O 0 0.00077368866186589
of O 0 4.0930726186161337e-07
fatty O 0 7.038604962872341e-05
acid O 0 7.743070455035195e-06
beta O 0 3.750226824195124e-06
oxidation O 0 1.3580873883256572e-06
that O 0 3.758680406917847e-07
reportedly O 0 2.3532670638815034e-06
has O 0 3.740964302778593e-07
high O 0 1.1993221278316923e-06
rates O 0 1.9710575998033164e-06
of O 0 6.577878934876935e-07
morbidity O 0 0.03034747950732708
and O 0 1.795541356841568e-05
mortality O 0 0.0005382915842346847
. O 0 5.8619934861781076e-05

We O 0 5.867143772775307e-05
describe O 0 2.3235023036249913e-05
the O 0 1.7905730373968254e-06
outcome O 0 2.7596563541010255e-06
of O 0 1.6114661605115543e-07
a O 0 4.327221176936291e-07
5 O 0 1.0759179076558212e-06
- O 0 3.943694173358381e-05
year O 0 1.9996932678623125e-06
- O 0 5.218598380452022e-05
old O 0 9.450070137972943e-06
girl O 0 2.425051570753567e-05
with O 0 5.737750598200364e-06
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 0.9999983310699463
who O 0 2.527978040234302e-06
was O 0 4.3820466544275405e-07
first O 0 3.64101623517854e-07
seen O 0 8.777444122642919e-07
at O 0 2.8174451927043265e-07
5 O 0 1.6567378224863205e-07
months O 0 2.923402746546344e-07
of O 0 1.4890113675392058e-07
age O 0 4.497710961004486e-06
with O 0 1.3278880942380056e-05
severe O 1 0.999982476234436
hypertrophic B-Disease 1 0.9999983310699463
cardiomyopathy I-Disease 1 1.0
, O 0 0.06587418168783188
hepatomegaly B-Disease 1 0.9999997615814209
, O 0 0.00023807885008864105
encephalopathy B-Disease 0 0.2101016342639923
, O 0 1.2697535566985607e-05
and O 0 2.7144111300003715e-05
hypotonia B-Disease 0 0.4398631751537323
. O 0 0.00014326354721561074

Biochemical O 0 0.31397923827171326
studies O 0 0.039180707186460495
indicated O 1 0.918245792388916
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
caused O 0 0.00046005629701539874
by O 0 3.886537797370693e-06
a O 0 1.4018782167113386e-05
stable O 0 0.0001530866720713675
yet O 0 4.4855172745883465e-05
inactive O 0 0.00013246167509350926
enzyme O 0 0.00017823306552600116
. O 0 6.408945773728192e-05

Molecular O 0 0.012018687091767788
genetic O 0 0.00016013758431654423
analysis O 0 1.3397405382420402e-05
of O 0 2.2971412363403942e-06
her O 0 2.843809488695115e-05
VLCAD O 0 0.43295231461524963
gene O 0 3.751947951968759e-05
revealed O 0 3.9462753193220124e-05
a O 0 6.566041520272847e-06
T1372C O 0 0.0011990463826805353
( O 0 4.029971478303196e-06
F458L O 0 4.3662275857059285e-05
) O 0 2.2398060082196025e-06
missense O 0 3.1307841709349304e-05
mutation O 0 1.087082000594819e-05
and O 0 1.944390078278957e-06
a O 0 1.0303851013304666e-05
1668 O 1 0.5485400557518005
ACAG O 0 0.1385362595319748
1669 O 0 0.008914238773286343
splice O 0 0.0007363839540630579
site O 0 0.00010217038652626798
mutation O 0 0.00025555919273756444
. O 0 6.588605901924893e-05

After O 0 0.0002926660527009517
initial O 0 8.084782166406512e-05
treatment O 0 2.0303885321482085e-05
with O 0 1.1620172699622344e-06
intravenous O 0 1.2468320164771285e-05
glucose O 0 1.3750406651524827e-05
and O 0 1.0879331284741056e-06
carnitine O 0 6.044959445716813e-05
, O 0 4.124529766613705e-07
the O 0 3.100439869285765e-07
patient O 0 7.253710464283358e-06
has O 0 5.109313860884868e-07
thrived O 0 2.4984879019029904e-06
on O 0 2.671498009476636e-07
a O 0 7.05147670032602e-07
low O 0 4.621677817340242e-06
- O 0 1.5767323930049315e-05
fat O 0 3.5461262086755596e-06
diet O 0 1.3932930187365855e-06
supplemented O 0 7.311413696697855e-07
with O 0 2.3849969466027687e-07
medium O 0 4.335542143962812e-06
- O 0 6.0406632655940484e-06
chain O 0 6.419196779461345e-06
triglyceride O 0 1.78838108695345e-05
oil O 0 3.0794517442700453e-06
and O 0 1.0096130154124694e-06
carnitine O 0 4.01041324948892e-05
and O 0 1.5680489013902843e-06
avoidance O 0 1.1642106983345002e-05
of O 0 3.0847895686747506e-06
fasting O 0 0.00023973120551090688
. O 0 4.896972677670419e-05

Her O 0 0.0011351760476827621
ventricular O 0 0.08379709720611572
hypertrophy O 0 0.017519591376185417
resolved O 0 0.00013446924276649952
significantly O 0 2.3111091650207527e-05
over O 0 1.1374853556844755e-06
1 O 0 7.255961804730759e-07
year O 0 5.668804874403577e-07
, O 0 2.3224612277772394e-07
and O 0 4.0821146285452414e-07
cognitively O 0 0.0071870009414851665
, O 0 4.836783205064421e-07
she O 0 8.938621363085986e-07
is O 0 1.1670287847209693e-07
in O 0 1.5689658994233469e-07
the O 0 3.808441704222787e-07
superior O 0 8.366224392375443e-06
range O 0 1.7007475889840862e-06
for O 0 2.442753384457319e-06
age O 0 1.827169762691483e-05
. O 0 2.881432737922296e-05

Clinical O 0 0.006549786776304245
recognition O 0 0.00011423409159760922
of O 0 7.48939928598702e-05
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 0.9999996423721313
is O 0 1.3931841067460482e-06
important O 0 5.236756805970799e-07
because O 0 3.225774207749055e-07
it O 0 8.32472437650722e-08
is O 0 4.532614283903058e-08
one O 0 2.7521913636974205e-08
of O 0 2.820732269981363e-08
the O 0 1.1658184462248755e-07
few O 0 7.215008395178302e-07
directly O 0 2.3159352622315055e-06
treatable O 1 0.7194249033927917
causes O 0 4.802197054232238e-06
of O 0 1.2872739034719416e-06
cardiomyopathy B-Disease 1 0.9999854564666748
in O 0 1.268999585590791e-05
children O 0 1.6466661691083573e-05
. O 0 1.3248800314613618e-05
. O 0 4.4672251533484086e-05

Cloning O 0 0.0003280799719505012
of O 0 5.392654202296399e-06
a O 0 3.768295300687896e-06
novel O 0 4.659730166167719e-06
member O 0 8.270627063211577e-07
of O 0 1.3094930295665108e-07
the O 0 9.055205509866937e-07
low O 0 3.202301013516262e-05
- O 0 0.00019344838801771402
density O 0 1.6864561985130422e-05
lipoprotein O 0 0.001536250812932849
receptor O 0 9.330878674518317e-05
family O 0 4.9525973736308515e-05
. O 0 4.993371112504974e-05

A O 0 7.204450230346993e-05
gene O 0 5.513762152986601e-05
encoding O 0 1.770258677424863e-05
a O 0 3.543350658219424e-06
novel O 0 9.730518286232837e-06
transmembrane O 0 1.7502557966508903e-05
protein O 0 3.7692298064939678e-06
was O 0 9.98221821646439e-07
identified O 0 8.901854471332626e-07
by O 0 2.742890501394868e-07
DNA O 0 1.6846209973664372e-06
sequence O 0 7.407284101645928e-07
analysis O 0 8.570354452785978e-07
within O 0 3.014326068750961e-07
the O 0 1.0695433729779324e-06
insulin B-Disease 1 0.9297670125961304
- I-Disease 1 0.9995434880256653
dependent I-Disease 1 0.8150591254234314
diabetes I-Disease 1 1.0
mellitus I-Disease 1 0.9999998807907104
( O 0 2.4552304239477962e-05
IDDM B-Disease 0 0.04853445664048195
) O 0 4.192433607386192e-06
locus O 0 4.293516030884348e-05
IDDM4 O 0 0.00025045505026355386
on O 0 5.919337127124891e-06
chromosome O 0 8.987323963083327e-05
11q13 O 0 0.0004907469847239554
. O 0 0.0001010245832731016

Based O 0 7.246092718560249e-05
on O 0 5.7272104641015176e-06
its O 0 2.111142066496541e-06
chromosomal O 0 2.1572530386038125e-05
position O 0 2.1815037598571507e-06
, O 0 3.601155071919493e-07
this O 0 2.022739096219084e-07
gene O 0 1.312915969720052e-06
is O 0 1.8947586966078234e-07
a O 0 4.212091653243988e-07
candidate O 0 2.8599383767868858e-06
for O 0 7.851110126466665e-07
conferring O 0 3.175164238200523e-05
susceptibility O 0 0.0023348424583673477
to O 0 0.00016168126603588462
diabetes B-Disease 1 0.9988314509391785
. O 0 0.00010495930473553017

The O 0 2.7697344194166362e-05
gene O 0 4.766127676703036e-05
, O 0 4.457912382349605e-06
termed O 0 2.1424913938972168e-05
low O 0 3.804421066888608e-05
- O 0 4.299111969885416e-05
density O 0 3.520607606333215e-06
lipoprotein O 0 7.128810102585703e-05
receptor O 0 6.152582500362769e-06
related O 0 1.8299715520697646e-06
protein O 0 1.4556052292391541e-06
5 O 0 5.435273351395153e-07
( O 0 3.031559856481181e-07
LRP5 O 0 1.4079638276598416e-05
) O 0 2.2023228041234688e-07
, O 0 8.515445415469003e-08
encodes O 0 3.6570801853486046e-07
a O 0 1.825852393722016e-07
protein O 0 4.3568741148192203e-07
of O 0 1.3291038669649424e-07
1615 O 0 1.4980509149609134e-05
amino O 0 1.1962550843236386e-06
acids O 0 8.953073233897157e-07
that O 0 7.39328314125487e-08
contains O 0 9.36295236897422e-08
conserved O 0 2.6339407099840173e-07
modules O 0 5.16158991104021e-07
which O 0 7.964823112160957e-08
are O 0 3.9342047841728345e-08
characteristic O 0 1.2934498272443307e-07
of O 0 7.296939230627686e-08
the O 0 4.780104632118309e-07
low O 0 7.447614189004526e-05
- O 0 0.0003163641958963126
density O 0 5.9849730860150885e-06
lipoprotein O 0 0.007961653172969818
( O 0 9.221025720762555e-06
LDL O 0 0.00024224113440141082
) O 0 5.50034201296512e-06
receptor O 0 1.7073689377866685e-05
family O 0 2.008430783462245e-05
. O 0 3.511251270538196e-05

These O 0 2.9634338716277853e-05
modules O 0 2.5465842554694973e-05
include O 0 2.3419922854373e-06
a O 0 1.6073695405793842e-06
putative O 0 9.189307093038224e-06
signal O 0 1.9602643988037016e-06
peptide O 0 1.8018290575128049e-06
for O 0 1.734153016741402e-07
protein O 0 4.461866183191887e-07
export O 0 4.037589746985759e-07
, O 0 2.0696170111023093e-07
four O 0 4.870684620073007e-07
epidermal O 0 7.10161475581117e-05
growth O 0 1.4842541531834286e-05
factor O 0 3.7034367323940387e-06
( O 0 9.995211485147593e-07
EGF O 0 1.98667221411597e-05
) O 0 3.7572181099676527e-07
repeats O 0 9.950244930223562e-07
with O 0 2.0371265918583958e-07
associated O 0 1.3602845001514652e-06
spacer O 0 1.158831855718745e-05
domains O 0 2.4141702397173503e-06
, O 0 6.917040877851832e-07
three O 0 1.0106977015311713e-06
LDL O 0 0.0008079835679382086
- O 0 6.269250297918916e-05
receptor O 0 4.084660304215504e-06
( O 0 4.916110469821433e-07
LDLR O 0 1.1441106835263781e-05
) O 0 3.0186470212356653e-07
repeats O 0 8.354213036909641e-07
, O 0 1.4618514398989646e-07
a O 0 1.5009575804469932e-07
single O 0 6.260514737732592e-07
transmembrane O 0 3.1939980544848368e-06
spanning O 0 1.7151969586848281e-06
domain O 0 1.1199698519703816e-06
, O 0 5.634552167066431e-07
and O 0 5.326350560608262e-07
a O 0 2.5296346848335816e-06
cytoplasmic O 0 4.8019501264207065e-05
domain O 0 3.368096804479137e-05
. O 0 3.50012160197366e-05

The O 0 2.6741368856164627e-05
encoded O 0 2.3423241145792417e-05
protein O 0 1.0598915650916751e-05
has O 0 1.1545740790097625e-06
a O 0 6.043765097274445e-07
unique O 0 9.384815484736464e-07
organization O 0 7.601202014484443e-07
of O 0 3.709948259711382e-07
EGF O 0 6.965834472794086e-05
and O 0 8.920533787204477e-07
LDLR O 0 0.00023109736503101885
repeats O 0 4.055726549268002e-06
; O 0 6.650150226050755e-07
therefore O 0 4.101715944671014e-07
, O 0 4.2881120521087723e-07
LRP5 O 0 0.0016094729071483016
likely O 0 2.3288341708394e-06
represents O 0 5.814138717141759e-07
a O 0 3.6724651408803766e-07
new O 0 5.40880364496843e-07
category O 0 1.0058849966299022e-06
of O 0 3.048136818506464e-07
the O 0 2.913448952313047e-06
LDLR O 1 0.5617425441741943
family O 0 0.00014170682698022574
. O 0 4.6792494686087593e-05

Both O 0 4.005734808743e-05
human O 0 1.0682971151254606e-05
and O 0 3.1515289720118744e-06
mouse O 0 3.49089787050616e-05
LRP5 O 0 0.0003868018393404782
cDNAs O 0 0.00033375027123838663
have O 0 1.478390913689509e-06
been O 0 6.472978384408634e-07
isolated O 0 1.1242375421716133e-06
and O 0 1.698771683322775e-07
the O 0 1.103886404507648e-07
encoded O 0 4.392825303511927e-07
mature O 0 5.072435556030541e-07
proteins O 0 2.2793682319388608e-07
are O 0 7.799500423288919e-08
95 O 0 3.6517201351671247e-07
% O 0 2.2309919245344645e-07
identical O 0 1.2006175893475302e-06
, O 0 4.3603117205748276e-07
indicating O 0 1.5456890878340346e-06
a O 0 4.400024238293554e-07
high O 0 1.4107361039350508e-06
degree O 0 1.6488580740769976e-06
of O 0 8.845333923090948e-07
evolutionary O 0 2.305929228896275e-05
conservation O 0 1.1346509381837677e-05
. O 0 9.81132598099066e-06
. O 0 3.326767182443291e-05

The O 0 4.5381675590761006e-05
APC B-Disease 0 7.878347241785377e-05
variants O 0 1.8155667930841446e-05
I1307K O 0 3.037288479390554e-05
and O 0 1.3724904874834465e-06
E1317Q O 0 1.8187882233178243e-05
are O 0 5.08169819113391e-07
associated O 0 5.28273130839807e-06
with O 0 0.47938451170921326
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 7.05344018570031e-06
but O 0 7.759916229588271e-07
not O 0 3.069243632580765e-07
always O 0 7.385826279460161e-07
with O 0 3.931519643174397e-07
a O 0 3.083692490690737e-06
family O 0 4.107836139155552e-05
history O 0 5.053154018241912e-05
. O 0 6.0849128203699365e-05

Classical O 0 0.12946228682994843
familial B-Disease 1 0.9999978542327881
adenomatous I-Disease 1 0.9999990463256836
polyposis I-Disease 1 0.9999998807907104
( O 0 0.003543582744896412
FAP B-Disease 0 0.014371220022439957
) O 0 5.3905514505458996e-06
is O 0 5.36802247097512e-07
a O 0 1.9155124846292892e-06
high O 0 0.00023945936118252575
- O 1 0.929990291595459
penetrance O 1 0.984302282333374
autosomal B-Disease 1 0.965776264667511
dominant I-Disease 1 0.7301617860794067
disease I-Disease 0 0.004110969603061676
that O 0 3.386926721304917e-07
predisposes O 0 6.353493972710567e-06
to O 0 2.0436178260752058e-07
hundreds O 0 3.155758747652726e-07
or O 0 3.059237769775791e-07
thousands O 0 5.420256457000505e-07
of O 0 5.046388650953304e-06
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999998807907104
and I-Disease 1 0.5734409689903259
carcinoma I-Disease 1 1.0
and O 0 1.8860631598727196e-06
that O 0 4.98596136822016e-07
results O 0 4.4195185182616115e-06
from O 0 6.877449436615279e-07
truncating O 0 4.709579297923483e-05
mutations O 0 2.007846524065826e-05
in O 0 1.68904182373808e-06
the O 0 3.958731667808024e-06
APC B-Disease 0 0.00011980563431279734
gene O 0 5.593183959717862e-05
. O 0 4.994190385332331e-05

A O 0 0.0002883163106162101
variant O 0 0.0003948519879486412
of O 0 1.4004246622789651e-05
FAP B-Disease 0 0.0008518231916241348
is O 0 2.1591384211205877e-05
attenuated B-Disease 0 0.12068292498588562
adenomatous I-Disease 1 0.9999983310699463
polyposis I-Disease 1 0.9999769926071167
coli I-Disease 1 0.9363350868225098
, O 0 1.8126715985999908e-06
which O 0 6.540447543557093e-07
results O 0 1.8858941075450275e-06
from O 0 3.423153316362004e-07
germ O 0 0.00010561189992586151
- O 0 0.00011270135291852057
line O 0 3.199137836418231e-06
mutations O 0 1.7194699921674328e-06
in O 0 1.426163862561225e-07
the O 0 1.5113454310267116e-07
5 O 0 1.864924286110181e-07
and O 0 1.1923320641926693e-07
3 O 0 2.6872638159147755e-07
regions O 0 2.595787407244643e-07
of O 0 1.726237854882129e-07
the O 0 1.8618796957525774e-06
APC B-Disease 0 7.186814764281735e-05
gene O 0 5.272256748867221e-05
. O 0 3.840025601675734e-05

Attenuated B-Disease 1 0.9994556307792664
adenomatous I-Disease 1 0.9999994039535522
polyposis I-Disease 1 0.9999992847442627
coli I-Disease 1 0.9999971389770508
patients O 1 0.9941605925559998
have O 0 1.5950790839269757e-05
" O 0 7.412326340272557e-06
multiple O 0 5.470214819069952e-05
" O 1 0.9885744452476501
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999988079071045
( O 0 1.9960464214818785e-06
typically O 0 5.277361196931452e-07
fewer O 0 3.228984439829219e-07
than O 0 1.565369842637665e-07
100 O 0 2.7169082272848755e-07
) O 0 2.2279557754245616e-07
without O 0 3.582100305266067e-07
the O 0 1.0321830359316664e-06
florid O 0 0.005490859970450401
phenotype O 0 0.002418647287413478
of O 0 2.364898818996153e-06
classical O 0 4.031095886602998e-05
FAP B-Disease 0 0.0009538952726870775
. O 0 6.553090497618541e-05

Another O 0 8.705531945452094e-05
group O 0 1.4977779756009113e-05
of O 0 1.6071135178208351e-06
patients O 0 1.8840637494577095e-05
with O 0 6.979028057685355e-07
multiple O 0 2.6171292120125145e-05
adenomas B-Disease 1 0.671109139919281
has O 0 1.661099531702348e-06
no O 0 6.909505145813455e-07
mutations O 0 1.5327684650401352e-06
in O 0 1.2872968113697425e-07
the O 0 2.48781674372367e-07
APC B-Disease 0 4.659338628698606e-06
gene O 0 9.198927273246227e-07
, O 0 1.5495869831738673e-07
and O 0 1.1411987799192502e-07
their O 0 4.0704483694753435e-07
phenotype O 0 0.018231447786092758
probably O 0 3.0340177090693032e-06
results O 0 1.0613921404001303e-06
from O 0 8.11805875855498e-08
variation O 0 4.3786297965198173e-07
at O 0 2.1971997909986385e-07
a O 0 2.2877875949234294e-07
locus O 0 7.799656486895401e-06
, O 0 2.206973590546113e-07
or O 0 2.846003042122902e-07
loci O 0 1.4959003920012037e-06
, O 0 3.274923301432864e-07
elsewhere O 0 7.475995289496495e-07
in O 0 4.5365149503595603e-07
the O 0 2.6013285605586134e-06
genome O 0 5.601051088888198e-05
. O 0 2.789993231999688e-05

Recently O 0 0.0006241656374186277
, O 0 1.0754146387625951e-05
however O 0 4.228785655868705e-06
, O 0 7.928413765512232e-07
a O 0 9.729893690746394e-07
missense O 0 1.8955419363919646e-05
variant O 0 1.7086933439713903e-05
of O 0 9.4297269015442e-07
APC B-Disease 0 2.9801831260556355e-05
( O 0 7.860505206735979e-07
I1307K O 0 1.2937896826770157e-05
) O 0 3.672013235700433e-07
was O 0 3.0618181767749775e-07
described O 0 3.86691453968524e-07
that O 0 9.573204096113841e-08
confers O 0 5.773730435976177e-07
an O 0 1.7806370067319222e-07
increased O 0 1.4747394061487284e-06
risk O 0 2.4116197891999036e-05
of O 0 0.000410683685913682
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 3.6410897337191273e-06
including O 0 1.2288011248529074e-06
multiple O 0 3.3852924389066175e-05
adenomas B-Disease 1 0.880624532699585
, O 0 3.92088122680434e-06
in O 0 1.0391459909442347e-05
Ashkenazim O 0 0.0013898356119170785
. O 0 7.138046930776909e-05

We O 0 4.1408464312553406e-05
have O 0 4.068906491738744e-06
studied O 0 2.5062104214157443e-06
a O 0 4.788335559169354e-07
set O 0 3.6682368431684154e-07
of O 0 2.514054813218536e-07
164 O 0 1.7309941540588625e-05
patients O 0 3.4185486583737656e-05
with O 0 2.038332468146109e-06
multiple O 1 0.9758033752441406
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999997615814209
and I-Disease 0 0.012757769785821438
/ I-Disease 1 0.7554613947868347
or I-Disease 0 0.005728725343942642
carcinoma I-Disease 1 0.9999998807907104
and O 0 2.168771516153356e-06
analyzed O 0 9.816791134653613e-06
codons O 0 2.0333258362370543e-05
1263 O 0 0.00047648046165704727
- O 0 5.336334288585931e-05
1377 O 0 0.00013261155982036144
( O 0 1.0343775329602067e-06
exon O 0 6.579675755347125e-06
15G O 0 8.075655387074221e-06
) O 0 1.9789864325048256e-07
of O 0 7.155544068382369e-08
the O 0 3.376232768914633e-07
APC B-Disease 0 3.91602316085482e-06
gene O 0 2.0708423562609823e-06
for O 0 7.441432785526558e-07
germ O 0 8.914771024137735e-05
- O 0 7.415978325298056e-05
line O 0 2.079609657812398e-05
variants O 0 5.326633618096821e-05
. O 0 4.444636215339415e-05

Three O 0 0.00010758320422610268
patients O 0 0.0003479630977381021
with O 0 1.7669294720690232e-06
the O 0 1.9153224002366187e-06
I1307K O 0 6.156448216643184e-05
allele O 0 1.759597762429621e-05
were O 0 1.342498308076756e-06
detected O 0 2.2596516373596387e-06
, O 0 2.919056782957341e-07
each O 0 4.621558105100121e-07
of O 0 1.6382842886741855e-06
Ashkenazi O 0 0.0009685067925602198
descent O 0 0.0016179342055693269
. O 0 7.411008118651807e-05

Four O 0 0.0003903777396772057
patients O 0 0.014450580812990665
had O 0 9.288569344789721e-06
a O 0 3.0825076464680023e-06
germ O 0 0.0046869670040905476
- O 0 0.0002695084549486637
line O 0 7.558996003353968e-06
E1317Q O 0 2.3336127924267203e-05
missense O 0 1.404155591444578e-05
variant O 0 3.1975212095858296e-06
of O 0 1.7937145457835868e-07
APC O 0 1.9184265056537697e-06
that O 0 9.957101809732194e-08
was O 0 2.086505759280044e-07
not O 0 6.408843944427645e-08
present O 0 9.386966581814704e-08
in O 0 9.757624752637639e-08
controls O 0 6.928086122570676e-07
; O 0 1.9576958720790572e-07
one O 0 4.002994558049977e-08
of O 0 3.893067201943268e-08
these O 0 9.956323054893801e-08
individuals O 0 2.0236342379575945e-07
had O 0 7.057834636725602e-07
an O 0 1.65161083032217e-07
unusually O 0 4.587916464515729e-06
large O 0 5.014683210902149e-07
number O 0 1.4892286515078013e-07
of O 0 4.619280105089274e-07
metaplastic B-Disease 0 0.043537966907024384
polyps I-Disease 0 0.0001250901259481907
of I-Disease 0 8.52164987463766e-07
the I-Disease 0 4.637068286683643e-06
colorectum I-Disease 0 0.001094885985367
. O 0 5.158732892596163e-05

There O 0 1.8680173525353894e-05
is O 0 2.3664351829211228e-06
increasing O 0 2.099665152854868e-06
evidence O 0 9.310397217632271e-07
that O 0 1.35990802618835e-07
there O 0 1.8509584265302692e-07
exist O 0 4.213449926737667e-07
germ O 0 1.5472329323529266e-05
- O 0 6.53808001516154e-06
line O 0 8.067120234045433e-07
variants O 0 5.632607553707203e-07
of O 0 5.594427321398143e-08
the O 0 1.864344483237801e-07
APC B-Disease 0 2.903757149397279e-06
gene O 0 6.678483828181925e-07
that O 0 1.5978218925738474e-07
predispose O 0 1.3252565622678958e-06
to O 0 1.306382131360806e-07
the O 0 1.2794026815754478e-07
development O 0 3.690909124998143e-07
of O 0 7.301017603822402e-07
multiple O 1 0.9918718934059143
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.990459680557251
carcinoma I-Disease 1 1.0
, O 0 1.5590991324643255e-06
but O 0 3.1466589689443936e-07
without O 0 1.4408929871478904e-07
the O 0 1.9883505331108609e-07
florid O 0 0.01577214151620865
phenotype O 0 0.0001817026932258159
of O 0 3.1817353374208324e-07
classical O 0 2.17026126847486e-06
FAP B-Disease 0 1.8461507352185436e-05
, O 0 2.2649497566362697e-07
and O 0 1.3059822379091202e-07
possibly O 0 4.0222127495326276e-07
with O 0 1.4714969154283608e-07
importance O 0 2.166076228604652e-06
for O 1 0.8907384872436523
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 0 0.0010425002546980977
in O 0 6.422415594897757e-07
the O 0 9.854862810243503e-07
general O 0 3.659508593045757e-06
population O 0 4.096229986316757e-06
. O 0 5.167710241948953e-06
. O 0 2.4685539756319486e-05

Genomic O 0 0.001363960443995893
structure O 0 8.740109478821978e-05
of O 0 6.731135272275424e-06
the O 0 1.419867476215586e-05
human O 0 0.00044462294317781925
congenital B-Disease 1 0.9999990463256836
chloride I-Disease 1 0.9999831914901733
diarrhea I-Disease 1 0.9999998807907104
( O 0 0.0005486204172484577
CLD B-Disease 1 0.9986403584480286
) O 0 3.35430413542781e-05
gene O 0 0.0001288486528210342
. O 0 6.110182584961876e-05

Congenital B-Disease 1 0.9999995231628418
chloride I-Disease 1 0.9999756813049316
diarrhea I-Disease 1 0.9999998807907104
( O 0 0.04528452083468437
CLD B-Disease 1 0.9999072551727295
) O 0 1.2082343346264679e-05
is O 0 6.933029794709e-07
caused O 0 2.6183927275269525e-06
by O 0 8.112608043120417e-07
mutations O 0 8.304316907015163e-06
in O 0 5.529723807740083e-07
a O 0 1.0755352377600502e-06
gene O 0 4.693662049248815e-06
which O 0 6.99541431004036e-07
encodes O 0 1.2910929399367888e-05
an O 0 4.980998710379936e-06
intestinal O 0 0.10299891233444214
anion O 0 0.05663749575614929
transporter O 0 0.001694875885732472
. O 0 8.676185098011047e-05

We O 0 9.661052172305062e-05
report O 0 1.1368041668902151e-05
here O 0 9.591751677362481e-07
the O 0 5.319030833561555e-07
complete O 0 1.32983200273884e-06
genomic O 0 5.7724869293451775e-06
organization O 0 8.809781775198644e-07
of O 0 1.9731783140741754e-07
the O 0 8.03056707354699e-07
human O 0 3.533049266479793e-06
CLD B-Disease 1 0.519316554069519
gene O 0 3.1980150652088923e-06
which O 0 3.21690805549224e-07
spans O 0 1.5692307897552382e-06
approximately O 0 8.683312557877798e-07
39kb O 0 1.909315869852435e-05
, O 0 5.278689627630229e-07
and O 0 4.910571647087636e-07
comprises O 0 2.1857269985048333e-06
21 O 0 7.901241588115226e-06
exons O 0 0.00011263904889347032
. O 0 4.43724165961612e-05

All O 0 6.011892401147634e-05
exon O 0 0.0003564725921023637
/ O 0 6.880892760818824e-05
intron O 0 0.00010642368579283357
boundaries O 0 9.491453056398313e-06
conform O 0 1.4233530237106606e-05
to O 0 2.6766467726702103e-06
the O 0 7.70512724557193e-06
GT O 0 0.1611626297235489
/ O 0 0.031533561646938324
AG O 1 0.9967542290687561
rule O 0 8.509717008564621e-05
. O 0 6.178956391522661e-05

An O 0 2.792176019283943e-05
analysis O 0 1.4410374205908738e-05
of O 0 1.3838249515174539e-06
the O 0 2.614056256788899e-06
putative O 0 2.9835529858246446e-05
promoter O 0 1.531164707557764e-05
region O 0 1.9377368971618125e-06
sequence O 0 9.83906829787884e-07
shows O 0 1.157283918473695e-06
a O 0 1.2914840681332862e-06
putative O 0 6.650899740634486e-05
TATA O 0 0.1043311208486557
box O 0 5.524571406567702e-06
and O 0 1.341322217740526e-06
predicts O 0 1.1124207048851531e-05
multiple O 0 4.96335906063905e-06
transcription O 0 1.4674493286293e-05
factor O 0 1.2829505067202263e-05
binding O 0 1.2144678294134792e-05
sites O 0 1.9416534996707924e-05
. O 0 2.8302280043135397e-05

The O 0 4.4541233364725485e-05
genomic O 0 0.00010605715942801908
structure O 0 8.88261365616927e-06
was O 0 1.7643347973717027e-06
determined O 0 1.4383643929249956e-06
using O 0 7.944550475258438e-07
DNA O 0 2.1172352262510685e-06
from O 0 1.6234763222655602e-07
several O 0 1.6280189640838216e-07
sources O 0 2.3375824298454972e-07
including O 0 1.7928542206391285e-07
multiple O 0 9.696009328763466e-07
large O 0 1.5546447684755549e-06
- O 0 5.7288951211376116e-05
insert O 0 7.254769116116222e-06
libaries O 0 2.0324712750152685e-05
and O 0 6.685168614239956e-07
genomic O 0 8.307707503263373e-06
DNA O 0 1.0110532457474619e-05
from O 0 2.730594587774249e-06
Finnish O 0 0.03543839603662491
CLD B-Disease 1 0.9998654127120972
patients O 0 0.0006382268620654941
and O 0 5.9227422752883285e-06
controls O 0 4.913443626719527e-05
. O 0 4.627741873264313e-05

Exon O 0 0.001073873951099813
- O 0 0.00021191949781496078
specific O 0 5.562258593272418e-06
primers O 0 3.052853935514577e-05
developed O 0 3.6316087062004954e-06
in O 0 3.535650705543958e-07
this O 0 2.0392840838212578e-07
study O 0 3.8644444089186436e-07
will O 0 1.7823461462285195e-07
facilitate O 0 8.244702485171729e-07
mutation O 0 3.0826661259197863e-06
screening O 0 2.6801665171660716e-06
studies O 0 1.5120936041057575e-06
of O 0 7.906743348939926e-07
patients O 0 5.7016444770852104e-05
with O 0 1.3826639815306407e-06
the O 0 9.905407205224037e-05
disease O 0 0.10885842144489288
. O 0 4.106727647013031e-05

Genomic O 0 0.0010239703115075827
sequencing O 0 0.0001975932391360402
of O 0 1.1313359209452756e-05
a O 0 1.3778155334875919e-05
BAC O 0 0.00022495409939438105
clone O 0 0.00057991809444502
H O 1 0.9954442977905273
_ O 0 7.046421160339378e-06
RG364P16 O 0 1.994630292756483e-05
revealed O 0 3.0206360861484427e-06
the O 0 2.3708959417945152e-07
presence O 0 2.3526068559931446e-07
of O 0 1.1374642383543687e-07
another O 0 3.141040281207097e-07
, O 0 2.706775319438748e-07
highly O 0 5.360503223528212e-07
homologous O 0 1.465040554649022e-06
gene O 0 1.054493054652994e-06
3 O 0 2.474782831995981e-07
of O 0 7.181440508929882e-08
the O 0 5.232912485553243e-07
CLD B-Disease 1 0.7500699162483215
gene O 0 3.3135629564640112e-06
, O 0 2.3110980862384167e-07
with O 0 1.1149042222768912e-07
a O 0 4.6084909399723983e-07
similar O 0 1.2191815130790928e-06
genomic O 0 1.2877901099273004e-05
structure O 0 3.1132892672758317e-06
, O 0 6.925351385689282e-07
recently O 0 4.567503310681786e-06
identified O 0 1.1329447033858742e-06
as O 0 7.536995099144406e-07
the O 0 0.0010496714385226369
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
gene O 0 0.00046346665476448834
( O 0 6.804947133787209e-06
PDS B-Disease 0 0.0341726616024971
) O 0 3.543330649335985e-06
. O 0 5.076174602436367e-06
. O 0 2.8007125365547836e-05

The O 0 4.9420661525800824e-05
APCI1307K O 0 0.0015459571732208133
allele O 0 0.00038784975185990334
and O 0 0.0010337820276618004
cancer B-Disease 1 0.996648371219635
risk O 0 4.81973729620222e-05
in O 0 6.752505328222469e-07
a O 0 1.2742583521685447e-06
community O 0 2.392732312728185e-06
- O 0 0.0009102069889195263
based O 0 4.079653535882244e-06
study O 0 2.8709951038763393e-06
of O 0 1.9778194655373227e-06
Ashkenazi O 0 0.0015901558799669147
Jews O 0 7.044849189696833e-05
. O 0 5.463802517624572e-05

Mutations O 0 0.0032399818301200867
in O 0 4.643603097065352e-05
APC O 0 0.00024286740517709404
are O 0 5.358670023269951e-06
classically O 0 0.00794821698218584
associated O 0 6.013710662955418e-05
with O 0 0.0002023338311119005
familial B-Disease 1 0.9999998807907104
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 0.0008291639969684184
FAP B-Disease 0 0.006667285226285458
) O 0 2.0302968550822698e-06
, O 0 5.753425966759096e-07
a O 0 3.049193992410437e-06
highly O 0 0.0024471564684063196
penetrant O 1 0.9999508857727051
autosomal B-Disease 1 0.9999984502792358
dominant I-Disease 1 0.9998069405555725
disorder I-Disease 1 0.9999955892562866
characterized O 0 0.00010047581599792466
by O 0 4.769076440425124e-06
multiple O 0 0.010280201211571693
intestinal O 1 0.9999480247497559
polyps B-Disease 0 0.37966611981391907
and O 0 7.091413749549247e-07
, O 0 3.805438950621465e-07
without O 0 5.405003093983396e-07
surgical O 0 0.0003008253697771579
intervention O 0 3.242780394430156e-06
, O 0 3.151310750126868e-07
the O 0 3.313469960630755e-07
development O 0 6.539414243889041e-06
of O 0 0.01844535768032074
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 6.631507858401164e-05
CRC B-Disease 0 0.011337846517562866
) O 0 1.497913763159886e-05
. O 0 3.450788790360093e-05

APC B-Disease 0 0.003339254530146718
is O 0 2.4377533918595873e-05
a O 0 2.933237010438461e-05
tumour O 1 0.9999432563781738
- O 0 0.0007826258079148829
suppressor O 0 5.429087104857899e-05
gene O 0 6.317393399513094e-06
, O 0 6.625159016948601e-07
and O 0 9.425537541574158e-07
somatic O 0 6.525279604829848e-05
loss O 0 0.0022444576025009155
occurs O 0 1.4257316252042074e-05
in O 0 9.054878319147974e-05
tumours B-Disease 1 0.9999909400939941
. O 0 0.0001563154364703223

The O 0 0.00010740668949438259
germline O 0 0.18109731376171112
T O 0 0.4280846416950226
- O 0 0.00013989515719003975
to O 0 3.077537712670164e-06
- O 0 1.3204262359067798e-05
A O 0 1.6713104287191527e-06
transversion O 0 2.2273099602898583e-05
responsible O 0 2.3375830551231047e-06
for O 0 3.3238222840736853e-07
the O 0 5.159808438293112e-07
APC O 0 5.917186626902549e-06
I1307K O 0 1.1887324944837019e-05
allele O 0 3.1377876439364627e-06
converts O 0 1.2158444633314502e-06
the O 0 3.1772717079547874e-07
wild O 0 6.033681074768538e-07
- O 0 3.0853543648845516e-06
type O 0 5.035697654420801e-07
sequence O 0 2.60865476775507e-07
to O 0 1.8172083571244002e-07
a O 0 6.892683472869976e-07
homopolymer O 0 0.0606570802628994
tract O 0 0.004619411192834377
( O 0 1.1641047876764787e-06
A8 O 0 0.0372203104197979
) O 0 3.486583182166214e-07
that O 0 1.4942834525299986e-07
is O 0 2.9773568144264573e-07
genetically O 0 2.799886942739249e-06
unstable O 0 3.129990000161342e-05
and O 0 1.2840247336498578e-06
prone O 0 1.9283614165033214e-05
to O 0 3.271500645496417e-06
somatic O 0 0.00017478565860074013
mutation O 0 0.00019693719514179975
. O 0 4.640486804419197e-05

The O 0 0.0001094542967621237
I1307K O 0 0.0005544860032387078
allele O 0 0.00030728281126357615
was O 0 1.8090267985826358e-05
found O 0 6.6792308643925935e-06
in O 0 4.394234565552324e-06
6 O 0 2.8453663617256097e-05
. O 0 2.8826038033002988e-05

1 O 0 0.00013872882118448615
% O 0 1.5160620932874735e-05
of O 0 1.8498656118026702e-06
unselected O 0 0.00030381977558135986
Ashkenazi O 0 0.0003034610999748111
Jews O 0 6.225415745575447e-06
and O 0 9.174396495836845e-07
higher O 0 1.8666642063180916e-06
proportions O 0 2.1844600723852636e-06
of O 0 3.1618074558537046e-07
Ashkenazim O 0 2.087985740217846e-05
with O 0 3.408513862268592e-07
family O 0 3.7000263546360657e-06
or O 0 9.077712661564874e-07
personal O 0 2.887448090405087e-06
histories O 0 6.96193774274434e-06
of O 0 1.1736199212464271e-06
CRC B-Disease 0 0.009855721145868301
( O 0 3.388168579476769e-06
ref O 0 0.0021785704884678125
. O 0 2.397247499175137e-06
2 O 0 6.9726884248666465e-06
) O 0 9.921809578372631e-06
. O 0 2.6080102543346584e-05

To O 0 4.9656679038889706e-05
evaluate O 0 4.1468134440947324e-05
the O 0 1.5833463749004295e-06
role O 0 1.7523333326607826e-06
of O 0 4.237855080191366e-07
I1307K O 0 6.054801633581519e-05
in O 0 4.93099469167646e-06
cancer B-Disease 0 0.0048937625251710415
, O 0 6.216002930159448e-07
we O 0 5.981384560982406e-07
genotyped O 0 1.4380076208908577e-05
5 O 0 1.0530881127124303e-06
, O 0 1.3389653759077191e-06
081 O 0 0.00011854896729346365
Ashkenazi O 0 8.506260928697884e-05
volunteers O 0 5.925623554503545e-06
in O 0 1.1873046332766535e-06
a O 0 3.278218400737387e-06
community O 0 1.7965039660339244e-05
survey O 0 8.660891762701795e-05
. O 0 4.5694614527747035e-05

Risk O 0 0.0009562000632286072
of O 0 1.3598417353932746e-05
developing O 0 0.0013945166720077395
colorectal B-Disease 1 0.9999995231628418
, I-Disease 0 4.942980740452185e-05
breast I-Disease 0 0.08137410134077072
and I-Disease 0 1.511655227659503e-06
other I-Disease 0 1.0378259958088165e-06
cancers I-Disease 0 0.009990090504288673
were O 0 2.9472190021806455e-07
compared O 0 4.596801943534956e-07
between O 0 2.1898905799844215e-07
genotyped O 0 1.4541396922140848e-05
I1307K O 0 1.3679294170287903e-05
carriers O 0 1.3145396451363922e-06
and O 0 2.0521603971701552e-07
non O 0 5.883442781851045e-07
- O 0 4.0448726394970436e-06
carriers O 0 4.653325618164672e-07
and O 0 1.132029581185634e-07
their O 0 2.406836188129091e-07
first O 0 1.1861706070703804e-06
- O 0 0.00012547695951070637
degree O 0 2.2969721612753347e-05
relatives O 0 7.493084558518603e-05
. O 0 5.011298708268441e-05

Sperm O 0 0.0019470395054668188
DNA O 0 0.0002528755576349795
analysis O 0 4.5031149056740105e-05
in O 0 5.1651682042574976e-06
a O 0 1.1853070645884145e-05
Friedreich B-Disease 0 0.4707909822463989
ataxia I-Disease 1 0.7822596430778503
premutation O 0 0.31960272789001465
carrier O 0 0.000284861569525674
suggests O 0 4.717036063084379e-06
both O 0 4.982429686606338e-07
meiotic O 0 1.801922917366028e-05
and O 0 7.196104547801951e-07
mitotic O 0 2.1616273443214595e-05
expansion O 0 5.942334610153921e-06
in O 0 1.6254234651569277e-06
the O 0 6.9175030148471706e-06
FRDA B-Disease 0 0.009824909269809723
gene O 0 0.00011078661918872967
. O 0 7.238185207825154e-05

Friedreich B-Disease 1 0.9990515112876892
ataxia I-Disease 1 0.9994118213653564
is O 0 5.906625301577151e-05
usually O 0 1.3099745046929456e-05
caused O 0 7.095186447259039e-06
by O 0 4.281026804164867e-07
an O 0 2.0363495423225686e-07
expansion O 0 9.400724820807227e-07
of O 0 2.931309097675694e-07
a O 0 1.7169955981444218e-06
GAA O 0 0.00013676861999556422
trinucleotide O 0 0.00032208836637437344
repeat O 0 1.5433735825354233e-05
in O 0 8.726256055524573e-07
intron O 0 1.71402825799305e-05
1 O 0 6.034429134160746e-07
of O 0 2.7901313615075196e-07
the O 0 2.154758703909465e-06
FRDA B-Disease 0 0.001308719045482576
gene O 0 7.116984488675371e-05
. O 0 4.036919926875271e-05

Occasionally O 0 0.00013903144281357527
, O 0 7.643657227163203e-06
a O 0 2.345421080462984e-06
fully O 0 2.141877985195606e-06
expanded O 0 1.4777128853893373e-06
allele O 0 7.832011760910973e-06
has O 0 6.478703085122106e-07
been O 0 3.2797427707009774e-07
found O 0 2.5652275326137897e-07
to O 0 1.927396056089492e-07
arise O 0 6.91659238327702e-07
from O 0 1.259558928268234e-07
a O 0 3.425347756547126e-07
premutation O 0 7.5730217758973595e-06
of O 0 2.900049480558664e-07
100 O 0 7.879508530095336e-07
or O 0 1.7503625713288784e-06
less O 0 4.149838332523359e-06
triplet O 0 0.0004919515922665596
repeats O 0 0.00016332603991031647
. O 0 5.112657163408585e-05

We O 0 5.813238749396987e-05
have O 0 7.441365141858114e-06
examined O 0 1.1533676115504932e-05
the O 0 1.310339143856254e-06
sperm O 0 1.2409343071340118e-05
DNA O 0 5.5641739891143516e-06
of O 0 7.552363854301802e-07
a O 0 7.643941899004858e-06
premutation O 0 0.06435154378414154
carrier O 0 0.0007753208628855646
. O 0 5.212695032241754e-05

This O 0 2.9606180760310963e-05
mans O 0 0.00012582128692883998
leucocyte O 0 0.0001997034123633057
DNA O 0 2.696415685932152e-05
showed O 0 4.272834303264972e-06
one O 0 7.326951845243457e-07
normal O 0 2.0949128156644292e-06
allele O 0 6.897358616697602e-06
and O 0 4.822430810236256e-07
one O 0 4.2100759856111836e-07
allele O 0 4.348361926531652e-06
of O 0 3.802094568072789e-07
approximately O 0 1.128626990976045e-06
100 O 0 3.964251845900435e-06
repeats O 0 4.421191260917112e-05
. O 0 3.796114833676256e-05

His O 0 0.00014555871894117445
sperm O 0 0.0003683167160488665
showed O 0 3.562973870430142e-05
an O 0 1.4172250075716875e-06
expanded O 0 3.945570369978668e-06
allele O 0 8.483575584250502e-06
in O 0 4.5691837158301496e-07
a O 0 5.521187631529756e-07
tight O 0 5.212031737755751e-06
range O 0 1.0543282087382977e-06
centering O 0 2.201584493377595e-06
on O 0 5.975802537250274e-07
a O 0 7.614044079673477e-07
size O 0 1.7394032738593523e-06
of O 0 8.194924703275319e-07
approximately O 0 3.353869487909833e-06
320 O 0 5.591450826614164e-05
trinucleotide O 0 0.0012907952768728137
repeats O 0 0.00018073091632686555
. O 0 7.600231765536591e-05

His O 0 0.00012809377221856266
affected O 0 0.00016382732428610325
son O 0 0.00027132706600241363
has O 0 4.261574304109672e-06
repeat O 0 1.3420652066997718e-05
sizes O 0 4.4394569158612285e-06
of O 0 1.0639317906679935e-06
1040 O 0 0.00010399711754871532
and O 0 6.373459655151237e-06
540 O 0 6.467973435064778e-05
. O 0 3.6640518374042585e-05

These O 0 1.598840935912449e-05
data O 0 1.1394959074095823e-05
suggest O 0 4.777748472406529e-06
that O 0 3.1559693525196053e-07
expansion O 0 9.650584615883417e-07
occurs O 0 3.434408313296444e-07
in O 0 9.8855153396471e-08
two O 0 1.1496218377260448e-07
stages O 0 1.3972370425108238e-06
, O 0 1.37328868277109e-07
the O 0 8.22361201358035e-08
first O 0 2.02146239303147e-07
during O 0 5.668701987815439e-07
meiosis O 0 2.0661002508859383e-06
followed O 0 1.069017116606119e-06
by O 0 3.4164088447141694e-07
a O 0 1.2867792520410148e-06
second O 0 5.883880476176273e-06
mitotic O 0 0.00018963981710840017
expansion O 0 8.754464943194762e-05
. O 0 5.85156049055513e-05

We O 0 4.755087138619274e-05
also O 0 3.929045305994805e-06
show O 0 1.606606360837759e-06
that O 0 1.681707857414949e-07
in O 0 9.041832527145743e-08
all O 0 6.619955428277535e-08
informative O 0 8.650350196148793e-07
carrier O 0 2.5885663035296602e-06
father O 0 1.3611280564873596e-06
to O 0 2.669842444902315e-07
affected O 0 7.704861673119012e-07
child O 0 1.5157767165874247e-06
transmissions O 0 1.957921313078259e-06
, O 0 9.249301058389392e-08
with O 0 4.389407948224289e-08
the O 0 8.770167880811641e-08
notable O 0 4.047578840982169e-07
exception O 0 2.889536858674546e-07
of O 0 9.39606721317432e-08
the O 0 4.40603315610133e-07
premutation O 0 0.008972623385488987
carrier O 0 1.2903938113595359e-05
, O 0 2.4231582074207836e-07
the O 0 2.3690471095960675e-07
expansion O 0 3.89481601814623e-06
size O 0 6.16819852439221e-06
decreases O 0 2.0448886061785743e-05
. O 0 7.553144769190112e-06
. O 0 1.8574122805148363e-05

The O 0 5.4810130677651614e-05
R496H O 0 0.0004403490456752479
mutation O 0 5.1857226935680956e-05
of O 0 1.9458591395959957e-06
arylsulfatase O 0 0.0001522011443739757
A O 0 7.810895112925209e-06
does O 0 6.379175374604529e-06
not O 0 1.1888957487826701e-05
cause O 0 0.0001891955325845629
metachromatic B-Disease 1 0.9999289512634277
leukodystrophy I-Disease 1 0.9999877214431763
. O 0 0.00031354257953353226

Deficiency B-Disease 1 0.9991132616996765
of I-Disease 0 3.753325654543005e-05
arylsulfatase I-Disease 0 0.0593741349875927
A I-Disease 0 0.00011043895210605115
( O 0 2.1593546989606693e-05
ARSA O 0 0.036126624792814255
) O 0 5.684472853317857e-06
enzyme O 0 2.104020313709043e-05
activity O 0 1.6282598153338768e-05
causes O 0 0.0003329945320729166
metachromatic B-Disease 1 0.9999902248382568
leukodystrophy I-Disease 1 0.9999984502792358
( O 0 0.00018150736286770552
MLD B-Disease 1 0.9998183846473694
) O 0 2.8526752430479974e-05
. O 0 3.8037174817873165e-05

A O 0 0.00011447160068200901
number O 0 9.865293577604461e-06
of O 0 5.770521966041997e-06
ARSA O 0 0.0038777808658778667
gene O 0 5.7803361414698884e-05
mutations O 0 4.301704029785469e-05
responsible O 0 1.0915040547843091e-05
for O 0 5.939292805123841e-06
MLD B-Disease 1 0.9999606609344482
have O 0 1.516599968454102e-05
been O 0 1.0659453437256161e-05
identified O 0 5.200639498070814e-05
. O 0 5.8204775996273383e-05

Recently O 0 0.0005735750892199576
, O 0 8.946979505708441e-06
the O 0 3.6188650938129285e-06
R496H O 0 4.2358875361969694e-05
mutation O 0 9.914923793985508e-06
of O 0 6.523964088955836e-07
ARSA O 0 0.008749758824706078
was O 0 1.06497134311212e-06
proposed O 0 6.395326863639639e-07
to O 0 2.0170428172150423e-07
be O 0 1.6402245250901615e-07
a O 0 2.7647774913930334e-07
cause O 0 1.8422234688841854e-06
of O 0 8.629899070911051e-07
MLD B-Disease 1 0.9999747276306152
( O 0 5.07374943481409e-06
Draghia O 0 0.0007139637600630522
et O 0 3.2026797271100804e-05
al O 0 5.351857907953672e-05
. O 0 1.1796389571827604e-06
, O 0 1.8707826257013949e-06
1997 O 0 1.618989699636586e-05
) O 0 7.545267635578057e-06
. O 0 2.0630681319744326e-05

We O 0 5.080744449514896e-05
have O 0 5.933427019044757e-06
investigated O 0 5.713822247344069e-06
the O 0 9.935206435329746e-07
R496H O 0 6.712885078741238e-05
mutation O 0 6.4742707763798535e-06
and O 0 4.447693413567322e-07
found O 0 2.937134979674738e-07
this O 0 1.8846235150249413e-07
mutation O 0 1.9008449498869595e-06
at O 0 1.7789584205729625e-07
a O 0 2.0390817212501133e-07
relatively O 0 6.410642185983306e-07
high O 0 4.869198733103985e-07
frequency O 0 8.177819381671725e-07
in O 0 1.8843323346118268e-07
an O 0 1.8969210202612885e-07
African O 0 5.182819791116344e-07
American O 0 5.364440198718512e-07
population O 0 3.690996948080283e-07
( O 0 3.71785318975526e-07
f O 0 2.4326636776095256e-06
= O 0 4.650983555620769e-06
0 O 0 7.347537689383898e-07
. O 0 2.1345277900763904e-07
09 O 0 2.9087739221722586e-06
, O 0 5.463216439238749e-07
n O 0 6.389013833540957e-06
= O 0 1.8061014998238534e-05
61 O 0 6.25494521955261e-06
subjects O 0 1.4689812815049663e-05
) O 0 6.409470643120585e-06
. O 0 1.9045583030674607e-05

The O 0 9.621273056836799e-05
ARSA O 0 0.004007273353636265
enzyme O 0 6.674548058072105e-05
activity O 0 6.5696053752617445e-06
in O 0 8.410201530750783e-07
subjects O 0 1.3046158073848346e-06
with O 0 1.5375690054497682e-07
and O 0 3.058409561162989e-07
without O 0 2.683202353637171e-07
the O 0 2.3791449166310485e-07
R496H O 0 4.9118742026621476e-05
mutation O 0 3.824674422503449e-06
was O 0 5.35111553290335e-07
determined O 0 5.404668286246306e-07
and O 0 2.586473897281394e-07
found O 0 3.5793411257145635e-07
to O 0 6.45430077383935e-07
be O 0 1.4387251212610863e-06
normal O 0 1.4807339539402165e-05
. O 0 2.7357833459973335e-05

It O 0 2.0878382201772183e-05
is O 0 2.776029759843368e-06
therefore O 0 2.0600443804141833e-06
concluded O 0 2.3799830159987323e-06
that O 0 2.3975670160325535e-07
the O 0 5.358734824767453e-07
R496H O 0 2.8710373953799717e-05
mutation O 0 6.02428417550982e-06
of O 0 5.646634235745296e-07
ARSA O 0 0.0072565507143735886
does O 0 1.2632596053663292e-06
not O 0 2.850099178886012e-07
negatively O 0 7.999365720934293e-07
influence O 0 4.926693577544938e-07
the O 0 2.106997527562271e-07
activity O 0 4.5463724518413073e-07
of O 0 3.0908333314982883e-07
ARSA O 0 0.02675897814333439
and O 0 8.957881618698593e-07
is O 0 6.375699967975379e-07
not O 0 1.388541704727686e-06
a O 0 6.3243078329833224e-06
cause O 0 5.547708133235574e-05
of O 0 4.0828446799423546e-05
MLD B-Disease 1 0.9999092817306519

Down O 0 0.0004908798728138208
- O 0 0.0003806340100709349
regulation O 0 5.173201861907728e-05
of O 0 3.879183623212157e-06
transmembrane O 0 6.505502824438736e-05
carbonic O 0 0.0001997897052206099
anhydrases O 0 0.0012932984391227365
in O 0 4.5073167711962014e-05
renal B-Disease 1 0.9999978542327881
cell I-Disease 1 0.9999778270721436
carcinoma I-Disease 1 1.0
cell O 0 0.00775900948792696
lines O 0 9.95953905658098e-06
by O 0 1.2950188192917267e-06
wild O 0 1.1183347851329017e-05
- O 0 0.020058147609233856
type O 0 0.00021438897238112986
von B-Disease 1 0.943493664264679
Hippel I-Disease 1 0.9963827133178711
- I-Disease 0 0.04651247337460518
Lindau I-Disease 0 0.17569275200366974
transgenes O 0 0.0019937220495194197
. O 0 0.00017518943059258163

To O 0 6.820287671871483e-05
discover O 0 9.162985224975273e-05
genes O 0 1.892948057502508e-05
involved O 0 5.430053533928003e-06
in O 0 5.666308879881399e-06
von B-Disease 1 0.9959524869918823
Hippel I-Disease 1 0.9999418258666992
- I-Disease 1 0.8553709983825684
Lindau I-Disease 1 0.9680662751197815
( O 0 6.103282885305816e-06
VHL B-Disease 0 0.0009762224508449435
) O 0 1.0731889688031515e-06
- O 0 3.971596925111953e-06
mediated O 0 5.138514097779989e-06
carcinogenesis O 0 3.345627192175016e-05
, O 0 5.158361773283104e-07
we O 0 5.836059813191241e-07
used O 0 1.0785081940412056e-05
renal B-Disease 1 0.9999943971633911
cell I-Disease 1 0.9999821186065674
carcinoma I-Disease 1 1.0
cell O 0 0.014233374036848545
lines O 0 2.4732620659051463e-05
stably O 0 5.030910688219592e-05
transfected O 0 0.00012888724450021982
with O 0 2.6179432097706012e-06
wild O 0 1.3061347999610007e-05
- O 0 0.002378130331635475
type O 0 8.89609000296332e-05
VHL O 0 0.17835953831672668
- O 0 0.000264383532339707
expressing O 0 9.478871652390808e-05
transgenes O 0 0.0008342590881511569
. O 0 0.0001265874016098678

Large O 0 0.00018402830755803734
- O 0 0.00018129531235899776
scale O 0 3.6884033761452883e-05
RNA O 0 8.231981155404355e-06
differential O 0 3.5392304198467173e-06
display O 0 1.0432778481117566e-06
technology O 0 2.2725382677890593e-06
applied O 0 5.549445631913841e-07
to O 0 1.4897898381605046e-07
these O 0 1.9041529242258548e-07
cell O 0 4.176901256869314e-06
lines O 0 3.0694593533553416e-06
identified O 0 7.879839358793106e-07
several O 0 3.4467458931430883e-07
differentially O 0 3.6198628095007734e-06
expressed O 0 6.449599823099561e-07
genes O 0 1.1412143976485822e-06
, O 0 2.6755159865388123e-07
including O 0 2.6815828846338263e-07
an O 0 7.099981189639948e-07
alpha O 0 1.671895370236598e-05
carbonic O 0 8.253996929852292e-05
anhydrase O 0 0.00014933888451196253
gene O 0 2.2916445232112892e-05
, O 0 7.356277365033748e-06
termed O 0 9.265638800570741e-05
CA12 O 0 0.007304856553673744
. O 0 9.408270852873102e-05

The O 0 2.7396292352932505e-05
deduced O 0 6.152345304144546e-05
protein O 0 1.1355061360518448e-05
sequence O 0 3.2894890864554327e-06
was O 0 1.3033499044468044e-06
classified O 0 1.4388431281986414e-06
as O 0 1.8250482014536829e-07
a O 0 2.979725479690387e-07
one O 0 3.334528457799024e-07
- O 0 1.799305755412206e-05
pass O 0 2.99310499940475e-06
transmembrane O 0 8.550779966753908e-06
CA O 0 5.9045823945780285e-06
possessing O 0 8.339995360984176e-07
an O 0 3.4296820672352624e-07
apparently O 0 2.714628863031976e-06
intact O 0 3.3200253710674588e-06
catalytic O 0 1.933089379235753e-06
domain O 0 1.4502941212413134e-06
in O 0 6.164090677884815e-07
the O 0 1.7781064798327861e-06
extracellular O 0 3.736515645869076e-05
CA O 0 0.0002529997727833688
module O 0 0.00014702786575071514
. O 0 4.3615666072582826e-05

Reintroduced O 0 0.001191497896797955
wild O 0 0.0001397682208335027
- O 0 0.0034987519029527903
type O 0 6.140359619166702e-05
VHL B-Disease 0 0.0029353017453104258
strongly O 0 9.02212195796892e-06
inhibited O 0 9.09652590053156e-06
the O 0 4.648872220514022e-07
overexpression O 0 2.8258455131435767e-06
of O 0 2.3664682657908997e-07
the O 0 4.347783999492094e-07
CA12 O 0 8.294931467389688e-05
gene O 0 1.895670948215411e-06
in O 0 5.099310556033743e-07
the O 0 2.4124440187733853e-06
parental O 0 0.31758007407188416
renal B-Disease 1 0.9999998807907104
cell I-Disease 1 0.9999978542327881
carcinoma I-Disease 1 1.0
cell O 1 0.7880518436431885
lines O 0 0.0007000347250141203
. O 0 0.00010094561730511487

Similar O 0 0.00011874538904521614
results O 0 5.390863589127548e-05
were O 0 2.6412203624204267e-06
obtained O 0 3.8071702874731272e-06
with O 0 1.9500241705827648e-06
CA9 O 0 0.2774522006511688
, O 0 8.908232871362998e-07
encoding O 0 3.196039415342966e-06
another O 0 2.319321311006206e-06
transmembrane O 0 2.8419282898539677e-05
CA O 0 8.248562153312378e-06
with O 0 3.5529163255887397e-07
an O 0 7.363250347225403e-07
intact O 0 1.7017720892908983e-05
catalytic O 0 2.263735223095864e-05
domain O 0 2.689019856916275e-05
. O 0 2.3923599655972794e-05

Although O 0 3.395324893062934e-05
both O 0 3.880756139551522e-06
domains O 0 2.7271410090179415e-06
of O 0 4.894105245512037e-07
the O 0 7.454011097252078e-07
VHL B-Disease 0 0.00043861489393748343
protein O 0 1.6532827658011229e-06
contribute O 0 4.590655464653537e-07
to O 0 2.1094544422339823e-07
regulation O 0 7.212573223114305e-07
of O 0 2.5469546471867943e-07
CA12 O 0 2.7334235710441135e-05
expression O 0 1.3440302382150549e-06
, O 0 2.902323785747285e-07
the O 0 4.942661462337128e-07
elongin O 0 2.1646636014338583e-05
binding O 0 1.7225686406163732e-06
domain O 0 2.3053842141962377e-06
alone O 0 3.834835297311656e-06
could O 0 2.8877013846795307e-06
effectively O 0 1.1956303751503583e-05
regulate O 0 3.520639438647777e-05
CA9 O 0 0.0015055699041113257
expression O 0 7.668959005968645e-05
. O 0 6.675203621853143e-05

We O 0 0.0001251297362614423
mapped O 0 0.00022756132239010185
CA12 O 0 0.0005131815560162067
and O 0 1.4304630894912407e-05
CA9 O 0 0.00833000149577856
loci O 0 4.456868191482499e-05
to O 0 3.328213779241196e-06
chromosome O 0 1.5622690625605173e-05
bands O 0 1.7244739865418524e-05
15q22 O 0 8.791700383881107e-05
and O 0 8.088944014161825e-06
17q21 O 0 0.0003546812804415822
. O 0 8.279205940198153e-05

2 O 0 0.00012658932246267796
respectively O 0 3.296201248303987e-05
, O 0 3.9914702938403934e-06
regions O 0 4.49370645583258e-06
prone O 0 1.0801147254824173e-05
to O 0 1.2212517503940035e-06
amplification O 0 1.2023101589875296e-05
in O 0 1.8083516124534071e-06
some O 0 2.145508915418759e-06
human O 0 2.4609244064777158e-05
cancers B-Disease 0 0.2767586410045624
. O 0 5.802648956887424e-05

Additional O 0 5.491089177667163e-05
experiments O 0 3.948334415326826e-05
are O 0 1.4336463891595486e-06
needed O 0 1.4864506283629453e-06
to O 0 2.029381960255705e-07
define O 0 6.133234933258791e-07
the O 0 1.8325371797800472e-07
role O 0 3.5362310768505267e-07
of O 0 2.995798240590375e-07
CA O 0 1.8974102204083465e-05
IX O 0 1.1084960533480626e-05
and O 0 7.090250733199355e-07
CA O 0 8.599537977715954e-06
XII O 0 1.2968978808203246e-05
enzymes O 0 1.571805341882282e-06
in O 0 1.1538087107965111e-07
the O 0 8.642305004968875e-08
regulation O 0 2.8370658355925116e-07
of O 0 1.120741899285349e-07
pH O 0 2.27882787839917e-06
in O 0 1.8076775631925557e-07
the O 0 1.937314237920873e-07
extracellular O 0 1.31504123146442e-06
microenvironment O 0 9.34148920350708e-06
and O 0 3.184728427640948e-07
its O 0 3.870249827286898e-07
potential O 0 1.9882720607711235e-06
impact O 0 4.08061077905586e-06
on O 0 6.8979375100752804e-06
cancer B-Disease 0 0.4220443069934845
cell O 0 0.0018363180570304394
growth O 0 0.00012639729538932443
. O 0 6.924851186340675e-05

A O 0 0.00013074124581180513
gene O 0 9.473684622207657e-05
encoding O 0 4.270542194717564e-05
a O 0 8.526091733074281e-06
transmembrane O 0 2.6414028980070725e-05
protein O 0 3.896450380125316e-06
is O 0 6.551035198754107e-07
mutated O 0 1.2110385796404444e-05
in O 0 3.1555650821246672e-06
patients O 0 0.0012137283338233829
with O 0 0.004595915786921978
diabetes B-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 0.6374755501747131
optic B-Disease 1 0.9999992847442627
atrophy I-Disease 1 0.9999924898147583
( O 1 0.8145808577537537
Wolfram B-Disease 1 0.9999998807907104
syndrome I-Disease 1 1.0
) O 0 7.072999869706109e-05
. O 0 6.436138937715441e-05

Wolfram B-Disease 1 0.9999998807907104
syndrome I-Disease 1 1.0
( O 0 0.08759555965662003
WFS B-Disease 1 0.9998600482940674
; O 0 0.007271137088537216
OMIM O 1 0.9927655458450317
222300 O 0 0.032977085560560226
) O 0 3.738204213732388e-06
is O 0 6.333580699902086e-07
an O 0 3.4228178265038878e-06
autosomal B-Disease 1 0.9972368478775024
recessive I-Disease 1 0.9999922513961792
neurodegenerative I-Disease 1 0.9999998807907104
disorder I-Disease 1 0.9439699649810791
defined O 0 5.540605798159959e-06
by O 0 2.347224381082924e-06
young O 0 2.408645741525106e-05
- O 0 0.01260535977780819
onset O 0 0.03180348500609398
non O 0 2.8429096346371807e-05
- O 0 0.027023734524846077
immune O 0 0.002616952871903777
insulin B-Disease 0 0.3011176586151123
- I-Disease 1 0.9386832118034363
dependent I-Disease 0 0.18282859027385712
diabetes I-Disease 1 0.9999998807907104
mellitus I-Disease 1 0.9999998807907104
and O 0 0.002009178278967738
progressive O 1 0.9018261432647705
optic B-Disease 1 0.9998144507408142
atrophy I-Disease 1 0.9483451843261719
. O 0 0.00021062203450128436

Linkage O 0 0.0005849285516887903
to O 0 1.6352547390852123e-05
markers O 0 2.032505835813936e-05
on O 0 2.6287762011634186e-06
chromosome O 0 2.0959256289643236e-05
4p O 0 0.03609059751033783
was O 0 6.690840564260725e-06
confirmed O 0 5.105307991470909e-06
in O 0 1.897848846965644e-06
five O 0 6.142603524494916e-06
families O 0 2.542127185733989e-05
. O 0 4.0574337617726997e-05

On O 0 1.2875641004939098e-05
the O 0 2.0478839815041283e-06
basis O 0 9.740571158545208e-07
of O 0 6.786178232687234e-07
meiotic O 0 0.00013831013347953558
recombinants O 0 0.18273839354515076
and O 0 0.0005866826977580786
disease O 0 0.11428309231996536
- O 0 0.025148451328277588
associated O 0 7.40407404009602e-06
haplotypes O 0 2.586370646895375e-05
, O 0 9.75743660092121e-07
the O 0 1.6241093589997035e-06
WFS B-Disease 1 0.5044657588005066
gene O 0 3.7587553833873244e-06
was O 0 1.0585930567685864e-06
localized O 0 3.298646561233909e-06
to O 0 6.672906920357491e-07
a O 0 1.9096737560175825e-06
BAC O 0 5.6152446632040665e-05
/ O 0 8.09152152214665e-06
P1 O 0 1.362758848699741e-05
contig O 0 9.101854629989248e-06
of O 0 4.598034024638764e-07
less O 0 1.3472795217239764e-06
than O 0 1.4002517900735256e-06
250 O 0 1.3590029993792996e-05
kb O 0 0.0014692917466163635
. O 0 4.630121111404151e-05

Mutations O 0 0.0029409383423626423
in O 0 2.5042989364010282e-05
a O 0 1.0144076441065408e-05
novel O 0 2.429060077702161e-05
gene O 0 1.9322751541039906e-05
( O 0 2.2700344288750784e-06
WFS1 O 0 3.970017496612854e-05
) O 0 4.146513390423934e-07
encoding O 0 1.0372530141466996e-06
a O 0 6.450504201893636e-07
putative O 0 7.1230520006793085e-06
transmembrane O 0 3.5211651265854016e-06
protein O 0 1.094480921892682e-06
were O 0 2.888644132781337e-07
found O 0 1.7327892010143842e-07
in O 0 9.222312513657016e-08
all O 0 9.920988475187187e-08
affected O 0 6.110197432462883e-07
individuals O 0 2.1011443607221736e-07
in O 0 2.3754404310238897e-07
six O 0 3.1004742595541757e-06
WFS B-Disease 1 0.9923827052116394
families O 0 2.969059096358251e-06
, O 0 2.2715560987762728e-07
and O 0 1.8430074533171137e-07
these O 0 3.186630408436031e-07
mutations O 0 2.99690373140038e-06
were O 0 2.8934911711075983e-07
associated O 0 8.739389159018174e-07
with O 0 9.358583952234767e-07
the O 0 0.0004964041872881353
disease O 1 0.7811447978019714
phenotype O 1 0.7762534022331238
. O 0 9.87206440186128e-05

WFS1 O 0 0.013376357965171337
appears O 0 6.383522122632712e-05
to O 0 3.2672974157321732e-06
function O 0 2.482200670783641e-06
in O 0 1.3395235782809323e-06
survival O 0 2.82720666291425e-05
of O 0 6.100672180764377e-07
islet O 0 0.00012490656808950007
beta O 0 6.582226342288777e-05
- O 0 0.0005556512041948736
cells O 0 1.299936502618948e-05
and O 0 2.195171418861719e-06
neurons O 0 2.4597886294941418e-05
. O 0 6.170622782519786e-06
. O 0 2.482444870111067e-05

Stable O 0 0.0003809074987657368
interaction O 0 2.013889024965465e-05
between O 0 1.4452215282290126e-06
the O 0 5.328769248080789e-07
products O 0 6.800910909987579e-07
of O 0 1.6844366257373622e-07
the O 0 1.2135878932895139e-06
BRCA1 O 0 0.0008190602529793978
and O 0 9.578274330124259e-06
BRCA2 O 0 0.20059607923030853
tumor B-Disease 0 0.0005247923545539379
suppressor O 0 6.394111551344395e-05
genes O 0 6.948909685888793e-06
in O 0 1.346909698440868e-06
mitotic O 0 6.630508869420737e-05
and O 0 1.4016884051670786e-05
meiotic O 0 0.003524032887071371
cells O 0 0.000535535451490432
. O 0 8.278968743979931e-05

BRCA1 O 0 0.1741546243429184
and O 0 8.444240665994585e-05
BRCA2 O 0 0.0016295817913487554
account O 0 9.089138075069059e-06
for O 0 8.022437896215706e-07
most O 0 4.577461822918849e-07
cases O 0 3.5571338230511174e-07
of O 0 2.391556677139306e-07
familial O 0 0.000175878667505458
, O 0 1.0517051123315468e-06
early O 0 1.196796256408561e-05
onset O 1 0.8300384879112244
breast B-Disease 1 0.8274413347244263
and I-Disease 0 6.718392251059413e-05
/ I-Disease 0 0.4383382201194763
or I-Disease 1 0.7079648375511169
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9998451471328735
and O 0 4.651808183098183e-07
encode O 0 1.3755028476225561e-06
products O 0 8.552897270419635e-07
that O 0 1.7717644595904858e-07
each O 0 3.372995251993416e-07
interact O 0 1.9113517737423535e-06
with O 0 3.2403195291408338e-06
hRAD51 O 0 0.0003796177334152162
. O 0 4.949320646119304e-05

Results O 0 0.00029114598874002695
presented O 0 2.2339980205288157e-05
here O 0 4.104089839529479e-06
show O 0 3.126413275822415e-06
that O 0 8.810932854430575e-07
BRCA1 O 0 5.272231646813452e-05
and O 0 2.2636590983893257e-06
BRCA2 O 0 0.0017806870164349675
coexist O 0 1.027650068863295e-05
in O 0 6.774732241865422e-07
a O 0 7.175743803600199e-07
biochemical O 0 1.8614111468195915e-05
complex O 0 1.639271999920311e-06
and O 0 6.079009153836523e-07
colocalize O 0 3.0483619411825202e-05
in O 0 5.698491918337822e-07
subnuclear O 0 3.0610863177571446e-05
foci O 0 7.73097690398572e-06
in O 0 5.42727036645374e-07
somatic O 0 8.998373232316226e-06
cells O 0 3.9690521589363925e-06
and O 0 2.581082299002446e-07
on O 0 2.0383235721510573e-07
the O 0 2.761696862307872e-07
axial O 0 4.61017043562606e-06
elements O 0 1.5777450244058855e-06
of O 0 1.5297864592866972e-06
developing O 0 4.065819302923046e-05
synaptonemal O 0 0.0021983981132507324
complexes O 0 0.0001716646656859666
. O 0 5.641835741698742e-05

Like O 0 0.00047178962267935276
BRCA1 O 0 0.00224379007704556
and O 0 5.2785348088946193e-05
RAD51 O 0 0.008027341216802597
, O 0 1.3528672752727289e-05
BRCA2 O 0 0.00017850975564215332
relocates O 0 4.9082540499512106e-05
to O 0 4.0854629332898185e-06
PCNA O 0 0.00014031319005880505
+ O 0 9.539239727018867e-06
replication O 0 2.962892494906555e-06
sites O 0 8.807277822597825e-07
following O 0 1.2231610071467003e-06
exposure O 0 4.285685918148374e-06
of O 0 4.350782774054096e-07
S O 0 0.0018072217935696244
phase O 0 1.069444897439098e-05
cells O 0 7.990071935637388e-06
to O 0 1.8421146705804858e-06
hydroxyurea O 0 0.00010771695815492421
or O 0 8.707013876119163e-06
UV O 0 0.0035549623426049948
irradiation O 0 0.00027084557223133743
. O 0 6.571853009518236e-05

Thus O 0 8.38648556964472e-05
, O 0 1.0425884283904452e-05
BRCA1 O 0 7.776291749905795e-05
and O 0 1.9673768747452414e-06
BRCA2 O 0 5.322743527358398e-05
participate O 0 9.290175171372539e-07
, O 0 2.101078280247748e-07
together O 0 2.2479754591131496e-07
, O 0 1.684259842704705e-07
in O 0 1.4721538832418446e-07
a O 0 4.277492564597196e-07
pathway O 0 4.329361217969563e-06
( O 0 6.849566034361487e-07
s O 0 0.00016179552767425776
) O 0 3.225777334137092e-07
associated O 0 1.7467361601575249e-07
with O 0 5.380498180329596e-08
the O 0 9.815602908247456e-08
activation O 0 5.730984753427038e-07
of O 0 1.0121853932787417e-07
double O 0 3.078183453908423e-06
- O 0 0.00014042601105757058
strand O 0 2.032447991950903e-05
break O 0 1.4959980944695417e-05
repair O 0 0.0013775941915810108
and O 0 1.661045644141268e-06
/ O 0 1.155712925537955e-05
or O 0 2.7363271328795236e-06
homologous O 0 3.517384175211191e-05
recombination O 0 0.0001125741982832551
. O 0 3.436365659581497e-05

Dysfunction O 0 0.030770273879170418
of O 0 8.076857739069965e-06
this O 0 3.0407929898501607e-06
pathway O 0 1.4978738363424782e-05
may O 0 3.2009838832891546e-06
be O 0 1.5168801326126413e-07
a O 0 2.0292813474043214e-07
general O 0 2.767452258467529e-07
phenomenon O 0 1.291263629354944e-06
in O 0 2.1142155048892164e-07
the O 0 2.90127218249836e-07
majority O 0 7.784873901073297e-07
of O 0 1.3021580969052593e-07
cases O 0 5.951954449301411e-07
of O 0 4.815859142581758e-07
hereditary B-Disease 1 0.9612608551979065
breast I-Disease 1 0.8623461127281189
and I-Disease 0 4.106265987502411e-05
/ I-Disease 1 0.6742388606071472
or I-Disease 1 0.965214192867279
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999991655349731
. O 0 3.449755604378879e-05
. O 0 4.043215449200943e-05

A O 0 0.000210016209166497
novel O 0 0.000141130352858454
Arg362Ser O 0 0.0005133508238941431
mutation O 0 6.111709808465093e-05
in O 0 3.3294836612185463e-06
the O 0 2.2866931885801023e-06
sterol O 0 7.86660602898337e-05
27 O 0 8.741625606489833e-06
- O 0 2.8076517992303707e-05
hydroxylase O 0 8.26552786747925e-05
gene O 0 6.17788873569225e-06
( O 0 6.535496481774317e-07
CYP27 O 0 1.4952107449062169e-05
) O 0 2.47671891884238e-07
: O 0 1.5737552416794642e-07
its O 0 2.3235934065723995e-07
effects O 0 1.5349903605965665e-06
on O 0 3.394985412796814e-07
pre O 0 1.2179369150544517e-05
- O 0 6.997855507506756e-06
mRNA O 0 5.378105015552137e-06
splicing O 0 1.3638133168569766e-05
and O 0 3.760196705115959e-06
enzyme O 0 2.6927151338895783e-05
activity O 0 2.5210147214238532e-05
. O 0 2.8545149689307436e-05

A O 0 0.00014608736091759056
novel O 0 8.722881466383114e-05
C O 0 6.672568270005286e-05
to O 0 1.4145191471470753e-06
A O 0 1.6665055682096863e-06
mutation O 0 3.92079891753383e-06
in O 0 4.713919565801916e-07
the O 0 7.603986205140245e-07
sterol O 0 0.00011704026110237464
27 O 0 8.605468792666215e-06
- O 0 5.765005334978923e-05
hydroxylase O 0 0.00015394444926641881
gene O 0 7.65245385991875e-06
( O 0 1.1505555903568165e-06
CYP27 O 0 5.03368501085788e-05
) O 0 6.004084980304469e-07
was O 0 4.177049959253054e-07
identified O 0 4.566143161355285e-07
by O 0 1.6254003298854514e-07
sequencing O 0 2.3897766823210986e-06
amplified O 0 4.803245701623382e-06
CYP27 O 0 3.752652992261574e-05
gene O 0 2.8385536552377744e-06
products O 0 9.857419627223862e-07
from O 0 3.346497408074356e-07
a O 0 1.3064833410680876e-06
patient O 0 5.526296081370674e-05
with O 0 9.151412996288855e-06
cerebrotendinous B-Disease 1 0.9999957084655762
xanthomatosis I-Disease 1 0.9999898672103882
( O 0 2.8827631467720494e-05
CTX B-Disease 1 0.9189550876617432
) O 0 2.212446452176664e-05
. O 0 2.347984627704136e-05

The O 0 8.954577060649171e-05
mutation O 0 0.00022582829114980996
changed O 0 2.174487781303469e-05
the O 0 3.458247192611452e-06
adrenodoxin O 0 6.247597775654867e-05
cofactor O 0 2.148064595530741e-05
binding O 0 7.432896836689906e-06
residue O 0 9.416423381480854e-06
362Arg O 0 1.8373830243945122e-05
to O 0 1.4958702649892075e-06
362Ser O 0 2.292914541612845e-05
( O 0 1.4608189076170675e-06
CGT O 0 1.2063391295669135e-05
362Arg O 0 1.4719570572196972e-05
to O 0 9.256612543140363e-07
AGT O 0 3.81038298655767e-05
362Ser O 0 1.2017095286864787e-05
) O 0 3.2786201131784765e-07
, O 0 9.85526114050117e-08
and O 0 1.280362056377271e-07
was O 0 5.622646312986035e-07
responsible O 0 2.7849816888192436e-06
for O 0 5.105307991470909e-06
deficiency O 0 0.005327495746314526
in O 0 2.5860521191134467e-07
the O 0 3.302576772057364e-07
sterol O 0 4.3682353862095624e-05
27 O 0 2.8824820219597314e-06
- O 0 1.0784773621708155e-05
hydroxylase O 0 1.772059295035433e-05
activity O 0 5.408401193562895e-07
, O 0 1.5369973027645756e-07
as O 0 1.3158776823729568e-07
confirmed O 0 5.286680107019492e-07
by O 0 1.4780115975554509e-07
expression O 0 4.688127148710919e-07
of O 0 2.0853640592122247e-07
mutant O 0 4.032262495456962e-06
cDNA O 0 4.841535883315373e-06
into O 0 2.8880099307571072e-06
COS O 0 0.0001461386273149401
- O 0 3.790912887779996e-05
1 O 0 6.704010957037099e-06
cells O 0 3.4846052585635334e-05
. O 0 2.4801542167551816e-05

Quantitative O 0 0.00038210206548683345
analysis O 0 7.611851469846442e-05
showed O 0 1.9166971469530836e-05
that O 0 9.04406363133603e-07
the O 0 5.445099873213621e-07
expression O 0 8.010129590729775e-07
of O 0 3.1778111519997765e-07
CYP27 O 0 2.5962181098293513e-05
gene O 0 2.3763336685078684e-06
mRNA O 0 1.529733822280832e-06
in O 0 5.185578402233659e-07
the O 0 8.995489224616904e-07
patient O 0 1.6054840671131387e-05
represented O 0 6.527638106490485e-06
52 O 0 5.24283605045639e-05
. O 0 3.6358440411277115e-05

5 O 0 0.00015204041847027838
% O 0 1.2802396668121219e-05
of O 0 1.172409497485205e-06
the O 0 3.2867296795302536e-06
normal O 0 1.573705412738491e-05
level O 0 3.067825673497282e-05
. O 0 5.148333730176091e-05

As O 0 2.628820584504865e-05
the O 0 7.300806373677915e-06
mutation O 0 1.609235187061131e-05
occurred O 0 2.181512172683142e-06
at O 0 4.3202854271839897e-07
the O 0 3.6915602663611935e-07
penultimate O 0 4.8203987716988195e-06
nucleotide O 0 2.4831572318362305e-06
of O 0 3.0985893317847513e-07
exon O 0 4.122109658055706e-06
6 O 0 9.069803468264581e-07
( O 0 2.6890558046943625e-07
- O 0 1.206487354465935e-06
2 O 0 2.1492266455425124e-07
position O 0 1.699964542467569e-07
of O 0 1.5021088017874717e-07
exon O 0 4.628536771633662e-06
6 O 0 1.0571653774604783e-06
- O 0 3.1017816581879742e-06
intron O 0 7.862013262638357e-06
6 O 0 6.193872081894369e-07
splice O 0 5.496860012499383e-06
site O 0 4.885869770987483e-07
) O 0 7.19944779348225e-08
of O 0 1.544404959474832e-08
the O 0 7.665015289148869e-08
gene O 0 6.941107244529121e-07
, O 0 1.8108886479240027e-07
we O 0 1.5349920090557134e-07
hypothesized O 0 5.326751875145419e-07
that O 0 6.771684013529011e-08
the O 0 1.9221241132072464e-07
mutation O 0 5.068342943559401e-06
may O 0 1.025048391056771e-06
partially O 0 1.2631162462639622e-06
affect O 0 2.937969725280709e-07
the O 0 8.3875519862886e-08
normal O 0 4.2950205170200206e-07
splicing O 0 3.0003898245922755e-06
efficiency O 0 2.112120910169324e-06
in O 0 3.975326308136573e-07
exon O 0 4.022694611194311e-06
6 O 0 7.167222406678775e-07
and O 0 2.0945762457813544e-07
cause O 0 9.61661044129869e-07
alternative O 0 8.657844432491402e-07
splicing O 0 3.7649620026058983e-06
elsewhere O 0 1.067707898982917e-06
, O 0 1.5285803556253086e-07
which O 0 1.5725656510312547e-07
resulted O 0 6.820304747634509e-07
in O 0 4.1581915866117924e-07
decreased O 0 5.212717951508239e-06
transcript O 0 2.0008868887089193e-05
in O 0 1.8745831766864285e-06
the O 0 5.306360890244832e-06
patient O 0 0.0009701853850856423
. O 0 7.68933750805445e-05

Transfection O 0 0.003289655316621065
of O 0 1.1982190699200146e-05
constructed O 0 2.6539848477113992e-05
minigenes O 0 0.00016360785230062902
, O 0 7.585126695630606e-07
with O 0 2.668004697170545e-07
or O 0 3.3862420423247386e-07
without O 0 2.961029395009973e-07
the O 0 2.3091020295851195e-07
mutation O 0 1.6530777884327108e-06
, O 0 1.6309063255448564e-07
into O 0 2.3781878155659797e-07
COS O 0 6.538110028486699e-05
- O 0 1.0659005965862889e-05
1 O 0 4.840741780753888e-07
cells O 0 1.231020405612071e-06
confirmed O 0 3.270881165917672e-07
that O 0 4.028638755926295e-08
the O 0 1.132604054987496e-07
mutant O 0 3.942188868677476e-06
minigene O 0 5.2540970500558615e-05
was O 0 7.019860390755639e-07
responsible O 0 6.147054136818042e-07
for O 0 1.4336502829337405e-07
a O 0 2.940413992291724e-07
mRNA O 0 1.095287075258966e-06
species O 0 3.5964976063951326e-07
alternatively O 0 1.2440176533345948e-06
spliced O 0 5.345073532225797e-06
at O 0 5.670291329806787e-07
an O 0 3.187767276813247e-07
activated O 0 2.8627653136936715e-06
cryptic O 0 4.8623583097651135e-06
5 O 0 7.557947014902311e-07
splice O 0 6.5661729422572535e-06
site O 0 1.3235614915174665e-06
88 O 0 1.7636433540246799e-06
bp O 0 5.05167554365471e-06
upstream O 0 1.1382134061932447e-06
from O 0 1.5999232516605844e-07
the O 0 2.726189620716468e-07
3 O 0 5.844448196512531e-07
end O 0 9.762127319845604e-07
of O 0 1.3136185543771717e-06
exon O 0 7.192190241767094e-05
6 O 0 3.3864744182210416e-05
. O 0 3.074526466662064e-05

Our O 0 4.433325375430286e-05
data O 0 1.398214681103127e-05
suggest O 0 3.257994194427738e-06
that O 0 3.0953111718190485e-07
the O 0 2.8723977152367297e-07
C O 0 5.69705298403278e-06
to O 0 3.034811300040019e-07
A O 0 6.855650553916348e-07
mutation O 0 2.121358420481556e-06
at O 0 2.939118530775886e-07
the O 0 2.1752330781055207e-07
penultimate O 0 3.6462151911109686e-06
nucleotide O 0 1.5309146874642465e-06
of O 0 1.7805147933813714e-07
exon O 0 2.2691579033562448e-06
6 O 0 3.2996018717312836e-07
of O 0 7.411170344084894e-08
the O 0 2.032535064699914e-07
CYP27 O 0 3.456321792327799e-05
gene O 0 1.3279590120873763e-06
not O 0 2.0073079554094875e-07
only O 0 2.5283296167799563e-07
causes O 0 2.4250452952401247e-06
the O 0 5.7490719882480334e-06
deficiency B-Disease 0 0.02176114171743393
in I-Disease 0 2.5177570250889403e-07
the I-Disease 0 4.054811313380924e-07
sterol I-Disease 0 3.967561133322306e-05
27 I-Disease 0 4.965792413713643e-06
- I-Disease 0 8.297873137053102e-06
hydroxylase I-Disease 0 1.5836052625672892e-05
activity I-Disease 0 5.946473606854852e-07
, O 0 1.6875864616849867e-07
but O 0 1.815981818253931e-07
also O 0 2.1342346201436158e-07
partially O 0 1.3282553936733166e-06
leads O 0 6.361821647260513e-07
to O 0 2.724627563566173e-07
alternative O 0 1.978727141249692e-06
pre O 0 5.706764568458311e-06
- O 0 3.07693017020938e-06
mRNA O 0 1.4649484683104674e-06
splicing O 0 4.244303909217706e-06
of O 0 6.749749559276097e-07
the O 0 3.3960166092583677e-06
gene O 0 4.8677713493816555e-05
. O 0 4.269027340342291e-05

To O 0 2.46998588409042e-05
our O 0 7.465703674824908e-06
knowledge O 0 2.9534080567827914e-06
, O 0 3.963057793043845e-07
this O 0 8.601406165098524e-08
is O 0 7.075876595763475e-08
the O 0 1.1446899605971339e-07
first O 0 4.063947471877327e-07
report O 0 5.844576094204967e-07
regarding O 0 4.150659549395641e-07
effects O 0 6.889259225317801e-07
on O 0 2.181948133284095e-07
pre O 0 3.42702810485207e-06
- O 0 1.0276637567585567e-06
mRNA O 0 3.799571572926652e-07
splicing O 0 9.036623964675528e-07
of O 0 7.853943628788329e-08
a O 0 1.8526256440054567e-07
mutation O 0 8.041779437917285e-07
at O 0 1.6986842865662766e-07
the O 0 1.516459207095977e-07
- O 0 5.417722150014015e-06
2 O 0 3.7598204016831005e-07
position O 0 3.8470736285489693e-07
of O 0 1.499392396908661e-07
a O 0 1.030014686875802e-06
5 O 0 2.5546469260007143e-06
splice O 0 0.00012338622764218599
site O 0 4.65261036879383e-05
. O 0 3.2151561754290015e-05

ATM O 0 0.011857596226036549
germline O 0 0.26990747451782227
mutations O 0 0.00040578225161880255
in O 0 2.502274583093822e-05
classical O 0 0.00014414395263884217
ataxia B-Disease 1 0.9999996423721313
- I-Disease 1 0.9999972581863403
telangiectasia I-Disease 1 0.9999997615814209
patients O 0 0.13195998966693878
in O 0 4.626855570677435e-06
the O 0 5.9544122450461145e-06
Dutch O 0 0.0014844706747680902
population O 0 3.437958730501123e-05
. O 0 5.390889054979198e-05

Germline O 1 0.9436498880386353
mutations O 0 0.0013304295716807246
in O 0 6.462908459070604e-06
the O 0 1.843884547270136e-06
ATM O 0 2.304722147528082e-05
gene O 0 5.240441623755032e-06
are O 0 3.7376833006419474e-07
responsible O 0 1.1319081067995285e-06
for O 0 2.3169516225607367e-06
the O 0 0.23162215948104858
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
( O 0 0.000548367912415415
A B-Disease 1 0.9845464825630188
- I-Disease 1 0.9999476671218872
T I-Disease 1 0.9999845027923584
) O 0 3.189652488799766e-05
. O 0 3.944250784115866e-05

In O 0 2.376574593654368e-05
our O 0 6.373277301463531e-06
study O 0 2.600961579446448e-06
, O 0 4.4795257281293743e-07
we O 0 2.4490830696777266e-07
have O 0 2.0078556417502114e-07
determined O 0 4.041715726543771e-07
the O 0 2.3191036291336786e-07
ATM O 0 7.3946325755969156e-06
mutation O 0 2.148285147995921e-06
spectrum O 0 1.1008203273377148e-06
in O 0 1.9164866671417258e-07
19 O 0 4.060243838921451e-07
classical O 0 1.6610773627689923e-06
A B-Disease 1 0.9630526900291443
- I-Disease 1 0.9999992847442627
T I-Disease 1 1.0
patients O 0 0.0012693473836407065
, O 0 2.1038773923010012e-07
including O 0 1.2604517962699902e-07
some O 0 1.60470619903208e-07
immigrant O 0 2.2051395717426203e-05
populations O 0 7.852727890167444e-07
, O 0 7.737017426734383e-08
as O 0 5.113184187166553e-08
well O 0 1.0082123935717391e-07
as O 0 1.1904800345519106e-07
12 O 0 2.625559147872991e-07
of O 0 2.439465447423572e-07
Dutch O 0 2.722268800425809e-05
ethnic O 0 7.045520305837272e-06
origin O 0 3.079474117839709e-05
. O 0 3.851137444144115e-05

Both O 0 2.7678754122462124e-05
the O 0 4.70234454041929e-06
protein O 0 5.891010459890822e-06
truncation O 0 2.348174893995747e-05
test O 0 1.0528900020290166e-05
( O 0 8.506215181114385e-07
PTT O 0 7.652811291336548e-06
) O 0 2.6645005846148706e-07
and O 0 1.0383986648321297e-07
the O 0 1.2398362514431938e-07
restriction O 0 7.336670933000278e-07
endonuclease O 0 7.685431228310335e-06
fingerprinting O 0 6.017939995217603e-06
( O 0 5.257213047116238e-07
REF O 0 1.2192606845928822e-05
) O 0 1.2165004648068134e-07
method O 0 1.5949416365401703e-07
were O 0 9.245772503163607e-08
used O 0 1.253252861488363e-07
and O 0 9.970233350031776e-08
compared O 0 2.312753792921285e-07
for O 0 6.518851591863495e-08
their O 0 1.780796736738921e-07
detection O 0 1.4013071449880954e-06
efficiency O 0 1.2626718444153084e-06
, O 0 2.3120637138163147e-07
identifying O 0 1.6494778947162558e-06
76 O 0 3.5858984119840898e-06
% O 0 2.7345637931830424e-07
and O 0 1.7173496758005058e-07
60 O 0 6.17375064848602e-07
% O 0 2.3960038220138813e-07
of O 0 9.3273037293784e-08
the O 0 1.0936389571725158e-06
mutations O 0 1.9762603187700734e-05
, O 0 3.365355951245874e-06
respectively O 0 2.4272445443784818e-05
. O 0 3.00478841381846e-05

Most O 0 0.0002076107048196718
patients O 0 0.002328285248950124
were O 0 6.205203135323245e-06
found O 0 2.919907956311363e-06
to O 0 1.5706472140664118e-06
be O 0 2.606846692287945e-06
compound O 0 4.0023478504735976e-05
heterozygote O 0 0.0009023301536217332
. O 0 7.983066461747512e-05

Seventeen O 0 0.00041958611109293997
mutations O 0 0.00025007539079524577
were O 0 3.290261247457238e-06
distinct O 0 1.568575385135773e-06
, O 0 2.2540505995038984e-07
of O 0 8.293566367001404e-08
which O 0 1.915868921287256e-07
10 O 0 2.098488920410091e-07
were O 0 4.157782882430183e-07
not O 0 1.1151014405186288e-06
reported O 0 1.431497457815567e-05
previously O 0 3.135846054647118e-05
. O 0 4.52308522653766e-05

Mutations O 0 0.002182033145800233
are O 0 1.0613946869852953e-05
small O 0 7.72601651988225e-06
deletions O 0 2.9242799428175204e-05
or O 0 3.909537554136477e-06
point O 0 6.603110250580357e-06
mutations O 0 2.272265737701673e-05
frequently O 0 9.32269267650554e-06
affecting O 0 2.0820321879000403e-05
splice O 0 0.0001892583240987733
sites O 0 5.108709228807129e-05
. O 0 6.113773997640237e-05

Moreover O 0 0.001068249810487032
, O 0 5.242816041572951e-05
a O 0 5.261368278297596e-05
16 O 0 5.383152165450156e-05
. O 0 5.483888526214287e-05

7 O 0 0.00024489316274411976
- O 0 0.00037478809827007353
kb O 0 0.000287344038952142
genomic O 0 2.5889496100717224e-05
deletion O 0 8.00086127128452e-06
of O 0 1.7233757887424872e-07
the O 0 1.8955429936795554e-07
3 O 0 2.0175180281967187e-07
end O 0 2.0369205344650254e-07
of O 0 5.462143803924846e-08
the O 0 1.443343791152074e-07
gene O 0 8.999230090012134e-07
, O 0 1.6250996281996777e-07
most O 0 1.6432917959718907e-07
likely O 0 4.7298965455411235e-07
a O 0 1.744538593584366e-07
result O 0 3.0490815561279305e-07
of O 0 7.74439996575893e-08
recombination O 0 9.532550961921515e-07
between O 0 1.2020871054119198e-07
two O 0 1.452864637485618e-07
LINE O 0 1.633979309190181e-06
elements O 0 7.351953286161006e-07
, O 0 9.871286010820768e-07
was O 0 4.793187599716475e-06
identified O 0 2.6054447516798973e-05
. O 0 3.239942452637479e-05

The O 0 2.7199124815524556e-05
most O 0 4.544904186332133e-06
frequently O 0 4.332260687078815e-06
found O 0 1.6140728575919638e-06
mutation O 0 4.277735570212826e-06
, O 0 3.8674161828566866e-07
identified O 0 8.172463026312471e-07
in O 0 2.423511773486098e-07
three O 0 3.237559553781466e-07
unrelated O 0 9.210434654960409e-06
Turkish O 0 7.795424608048052e-05
A B-Disease 1 0.9628453254699707
- I-Disease 1 0.9999501705169678
T I-Disease 1 0.9999755620956421
individuals O 0 7.738183285255218e-07
, O 0 2.7687721626534767e-07
was O 0 8.469602903460327e-07
previously O 0 7.408025908262061e-07
described O 0 8.989451885099697e-07
to O 0 1.6690059112534072e-07
be O 0 1.8499825671369763e-07
a O 0 5.44796705526096e-07
Turkish O 0 1.344854445051169e-05
A B-Disease 1 0.7268120646476746
- I-Disease 1 0.9991476535797119
T I-Disease 1 0.9998655319213867
founder O 0 0.000876358593814075
mutation O 0 0.0002690650289878249
. O 0 6.568500975845382e-05

The O 0 2.4546241547795944e-05
presence O 0 7.982623174029868e-06
of O 0 9.444739248465339e-07
a O 0 1.812768346098892e-06
founder O 0 3.480526720522903e-05
mutation O 0 1.0822356671269517e-05
among O 0 7.883996318014397e-07
relatively O 0 1.7042724493876449e-06
small O 0 5.453898097584897e-07
ethnic O 0 5.255307655716024e-07
population O 0 3.3351486194987956e-07
groups O 0 2.281055628827744e-07
in O 0 1.0550770213058058e-07
Western O 0 3.720570305176807e-07
Europe O 0 6.503750000774744e-07
could O 0 4.195582334887149e-07
indicate O 0 4.1393460037397745e-07
a O 0 1.7917979278081475e-07
high O 0 7.363798317783221e-07
carrier O 0 3.0963435619923985e-06
frequency O 0 1.963871909538284e-06
in O 0 6.538620596074907e-07
such O 0 1.405603484272433e-06
communities O 0 1.667780270508956e-05
. O 0 2.156002665287815e-05

In O 0 0.00019277888350188732
patients O 0 0.00024109735386446118
of O 0 1.6720374560463824e-06
Dutch O 0 2.814928302541375e-05
ethnic O 0 1.9484107269818196e-06
origin O 0 2.9553661988757085e-06
, O 0 5.314497570907406e-07
however O 0 5.066141284260084e-07
, O 0 2.9109338584021316e-07
no O 0 2.4691672706467216e-07
significant O 0 4.697610904713656e-07
founder O 0 6.764274985471275e-06
effect O 0 1.917211875479552e-06
could O 0 1.963272779903491e-06
be O 0 1.14757051505876e-06
identified O 0 1.4656339772045612e-05
. O 0 3.411429497646168e-05

The O 0 4.5547472836915404e-05
observed O 0 5.31944606336765e-05
genetic O 0 4.252628059475683e-05
heterogeneity O 0 1.998777406697627e-05
including O 0 1.5925901379887364e-06
the O 0 9.70460405369522e-07
relative O 0 4.97981591252028e-06
high O 0 3.316879428894026e-06
percentage O 0 2.9862590054108296e-06
of O 0 2.3997310449885845e-07
splice O 0 0.0004389842215459794
- O 0 0.0010547327110543847
site O 0 2.302121629327303e-06
mutations O 0 2.9123600597813493e-06
had O 0 7.939968327264069e-07
no O 0 3.1809949518901703e-07
reflection O 0 2.163833869417431e-06
on O 0 1.1339382126607234e-06
the O 0 7.920154530438595e-06
phenotype O 0 0.05151043459773064
. O 0 6.787839811295271e-05

All O 0 4.392999107949436e-05
patients O 0 0.00016646107542328537
manifested O 0 2.562367808423005e-05
classical O 0 1.8031605577562004e-05
A B-Disease 0 0.19329993426799774
- I-Disease 1 0.9793103337287903
T I-Disease 1 0.9907512068748474
and O 0 1.5028870166133856e-06
increased O 0 5.7961460697697476e-06
cellular O 0 4.1539773519616574e-05
radioresistant O 0 0.0003344554570503533
DNA O 0 9.576338925398886e-05
synthesis O 0 0.00014091856428422034
. O 0 6.939950253581628e-05

Determination O 0 0.00015916059783194214
of O 0 6.708845830871724e-06
the O 0 4.22610492023523e-06
genomic O 0 2.0123588910792023e-05
structure O 0 2.3961254100868246e-06
of O 0 3.361300286996993e-07
the O 0 8.793196002443437e-07
COL4A4 O 0 0.000114710237539839
gene O 0 3.2716502573748585e-06
and O 0 5.033930960962607e-07
of O 0 1.1002409792126855e-06
novel O 0 0.00606362521648407
mutations O 0 0.025866631418466568
causing O 0 0.038255348801612854
autosomal B-Disease 1 0.9998356103897095
recessive I-Disease 1 0.9999955892562866
Alport I-Disease 1 0.9999998807907104
syndrome I-Disease 1 0.999998927116394
. O 0 0.0002840877859853208

Autosomal B-Disease 1 0.9999904632568359
recessive I-Disease 1 0.9999991655349731
Alport I-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
is O 0 4.7447778342757374e-05
a O 0 3.730939351953566e-05
progressive O 0 0.4590274393558502
hematuric B-Disease 1 0.9989877343177795
glomerulonephritis I-Disease 1 0.9999986886978149
characterized O 0 0.0007175515638664365
by O 0 1.103833164961543e-05
glomerular B-Disease 1 0.9898430705070496
basement I-Disease 1 0.9806473851203918
membrane I-Disease 0 0.049319811165332794
abnormalities I-Disease 1 0.9376929998397827
and O 0 1.5854677712923149e-06
associated O 0 2.0955603758920915e-06
with O 0 4.4759045181308466e-07
mutations O 0 5.323696314007975e-06
in O 0 2.789104485145799e-07
either O 0 3.7827882692909043e-07
the O 0 4.308805614527955e-07
COL4A3 O 0 0.0038247958291321993
or O 0 7.21380445156683e-07
the O 0 4.108727864604589e-07
COL4A4 O 0 0.00015509960940107703
gene O 0 2.1203793494350975e-06
, O 0 2.2288271850356978e-07
which O 0 1.1125038668069465e-07
encode O 0 7.241209800668003e-07
the O 0 3.3412800348742167e-07
alpha3 O 0 1.0859897884074599e-05
and O 0 9.218591117132746e-07
alpha4 O 0 9.674327884567901e-05
type O 0 1.7171663785120472e-05
IV O 0 0.0004473220033105463
collagen O 0 8.632841490907595e-05
chains O 0 6.741625111317262e-05
, O 0 6.243454663490411e-06
respectively O 0 5.255114592728205e-05
. O 0 3.924381235265173e-05

To O 0 1.4522023775498383e-05
date O 0 5.081332346890122e-06
, O 0 1.0105358114742558e-06
mutation O 0 3.138883130304748e-06
screening O 0 1.5530711152678123e-06
in O 0 1.1385159126575672e-07
the O 0 8.353290326112983e-08
two O 0 1.3723447978009062e-07
genes O 0 9.00730128705618e-07
has O 0 4.0637999632053834e-07
been O 0 9.379626249028661e-07
hampered O 0 5.562057776842266e-05
by O 0 3.795884424562246e-07
the O 0 4.827815018870751e-07
lack O 0 1.4245696320358547e-06
of O 0 5.559080591410748e-07
genomic O 0 2.8735134037560783e-05
structure O 0 1.4835496585874353e-05
information O 0 1.419401633029338e-05
. O 0 2.4604949430795386e-05

We O 0 7.82049392000772e-05
report O 0 7.814895980118308e-06
here O 0 6.743598532921169e-07
the O 0 3.106364943050721e-07
complete O 0 7.65640834288206e-07
characterization O 0 2.669030209290213e-06
of O 0 1.4186217356382258e-07
the O 0 3.3897251228154346e-07
48 O 0 6.090498914090858e-07
exons O 0 9.950681487680413e-07
of O 0 9.00976075968174e-08
the O 0 2.469054436460283e-07
COL4A4 O 0 0.00017971293709706515
gene O 0 1.5023654214019189e-06
, O 0 1.5439579215126287e-07
a O 0 1.386319752327836e-07
comprehensive O 0 1.125052790484915e-06
gene O 0 1.8331645605940139e-06
screen O 0 1.8030546016234439e-06
, O 0 1.5488009807995695e-07
and O 0 8.320930078298261e-08
the O 0 1.3765234996299114e-07
subsequent O 0 9.063050470103917e-07
detection O 0 1.6346231177521986e-06
of O 0 1.5314928702991892e-07
10 O 0 3.854234762457054e-07
novel O 0 4.081455244886456e-06
mutations O 0 5.357352165447082e-06
in O 0 1.0233439979856485e-06
eight O 0 7.164452836150303e-05
patients O 1 0.9742096066474915
diagnosed O 1 0.9999368190765381
with O 0 0.002128833206370473
autosomal B-Disease 1 0.9999905824661255
recessive I-Disease 1 0.9999995231628418
Alport I-Disease 1 1.0
syndrome I-Disease 1 0.9999996423721313
. O 0 0.00040373604861088097

Furthermore O 0 0.0001949606667039916
, O 0 1.5785330106155016e-05
we O 0 3.0789615266257897e-06
identified O 0 2.699286369534093e-06
a O 0 6.79594450048171e-07
glycine O 0 3.2440918857901124e-06
to O 0 2.9910052035120316e-07
alanine O 0 2.7992248305963585e-06
substitution O 0 5.942176812823163e-07
in O 0 1.5611568926487962e-07
the O 0 1.6294806925998273e-07
collagenous O 0 4.2073119402630255e-05
domain O 0 6.706989097438054e-07
that O 0 1.5048446755372424e-07
is O 0 1.731358736378752e-07
apparently O 0 1.2009610372842872e-06
silent O 0 2.077862973237643e-06
in O 0 2.8594345735655224e-07
the O 0 4.7395053570653545e-07
heterozygous O 0 1.1402448762964923e-05
carriers O 0 4.809786787518533e-06
, O 0 1.2746120319206966e-06
in O 0 2.541914909670595e-06
11 O 0 1.3920704077463597e-05
. O 0 2.8734093575621955e-05

5 O 0 7.962394738569856e-05
% O 0 5.874836460861843e-06
of O 0 3.2941059657787264e-07
all O 0 2.616273491184984e-07
control O 0 1.0507105798751581e-06
individuals O 0 2.1272769856750529e-07
, O 0 1.288714344127584e-07
and O 0 1.0429899077735172e-07
in O 0 1.4542925441674015e-07
one O 0 2.370430109976951e-07
control O 0 1.5658313259336865e-06
individual O 0 6.830987331341021e-07
homozygous O 0 4.993116817786358e-06
for O 0 5.562293949878949e-07
this O 0 1.1008560250047594e-06
glycine O 0 3.328484308440238e-05
substitution O 0 6.200589996296912e-05
. O 0 5.751612116000615e-05

There O 0 2.1254661987768486e-05
has O 0 2.7126618533657165e-06
been O 0 6.215919370333722e-07
no O 0 2.418510689494724e-07
previous O 0 5.864262675459031e-07
finding O 0 3.6845855788669724e-07
of O 0 6.04160277362098e-08
a O 0 1.647765941470425e-07
glycine O 0 2.0206464341754327e-06
substitution O 0 7.557147227998939e-07
that O 0 2.230400610869765e-07
is O 0 1.442897854531111e-07
not O 0 1.685580599541936e-07
associated O 0 2.8279140451559215e-07
with O 0 1.1708759473094688e-07
any O 0 6.774706662326935e-07
obvious O 0 1.1417367204558104e-05
phenotype O 0 0.0030680163763463497
in O 0 4.845406692766119e-06
homozygous O 0 0.00023293345293495804
individuals O 0 2.0764149667229503e-05
. O 0 3.340912007843144e-05

Founder O 0 0.00236849975772202
BRCA1 O 0 0.01024705357849598
and O 0 4.5045195292914286e-05
BRCA2 O 0 0.001620485563762486
mutations O 0 5.70705124118831e-05
in O 0 4.369271209725412e-06
French O 0 2.1636813471559435e-05
Canadian O 0 0.00010692762589314952
breast B-Disease 1 0.9983036518096924
and I-Disease 1 0.9968664050102234
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.999998927116394
families O 0 0.0009465015027672052
. O 0 0.00013798118743579835

We O 0 4.470694329938851e-05
have O 0 5.325986421667039e-06
identified O 0 2.853601472452283e-06
four O 0 8.282625003630528e-07
mutations O 0 3.715329967235448e-06
in O 0 2.0315641791057715e-07
each O 0 1.1221194995414407e-07
of O 0 1.684208399410636e-07
the O 0 8.264062489615753e-05
breast B-Disease 1 0.9999747276306152
cancer I-Disease 1 0.996813952922821
- O 0 0.02208719588816166
susceptibility O 0 5.056104055256583e-05
genes O 0 4.493136657401919e-06
, O 0 1.413901372870896e-06
BRCA1 O 0 3.0537798011209816e-05
and O 0 1.46122295063833e-06
BRCA2 O 0 5.998240158078261e-05
, O 0 4.0459386241309403e-07
in O 0 3.483153534489247e-07
French O 0 4.349291430116864e-06
Canadian O 0 4.021504719275981e-05
breast B-Disease 1 0.9836792349815369
cancer I-Disease 0 0.4336826801300049
and O 0 0.0011894474737346172
breast B-Disease 1 0.9999957084655762
/ I-Disease 1 0.9999991655349731
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999992847442627
families O 0 3.9304635720327497e-05
from O 0 6.28747920927708e-06
Quebec O 0 0.00013226324517745525
. O 0 5.58395404368639e-05

To O 0 8.05756717454642e-05
identify O 0 6.298817606875673e-05
founder O 0 4.203983553452417e-05
effects O 0 1.6984176909318194e-05
, O 0 6.952781177460565e-07
we O 0 5.575587351813738e-07
examined O 0 3.0022160899534356e-06
independently O 0 1.2041998616041383e-06
ascertained O 0 4.469247869565152e-06
French O 0 3.8008288356650155e-06
Canadian O 0 2.818801840476226e-05
cancer B-Disease 0 0.028617456555366516
families O 0 1.0882423566727084e-06
for O 0 1.1483354001029511e-07
the O 0 1.904334538949115e-07
distribution O 0 3.4966961948157405e-07
of O 0 2.84422327467837e-07
these O 0 1.134592594098649e-06
eight O 0 1.3396613212535158e-05
mutations O 0 0.00018166008521802723
. O 0 5.76940001337789e-05

Mutations O 0 0.0022572490852326155
were O 0 2.8651156753767282e-05
found O 0 7.47810872780974e-06
in O 0 1.5467537650692975e-06
41 O 0 6.529132406285498e-06
of O 0 2.2802169041824527e-06
97 O 0 5.2619801863329485e-05
families O 0 6.427257903851569e-05
. O 0 5.227563815424219e-05

Six O 0 3.508188819978386e-05
of O 0 3.3858070764836157e-06
eight O 0 6.364707587636076e-06
mutations O 0 1.0224835023109335e-05
were O 0 1.2360600294414326e-06
observed O 0 2.5216936592187267e-06
at O 0 1.5656969480914995e-06
least O 0 2.8792153443646384e-06
twice O 0 2.655377465998754e-05
. O 0 5.15390929649584e-05

The O 0 0.00011488297604955733
BRCA1 O 0 0.0013451812556013465
C4446T O 0 0.0005029253079555929
mutation O 0 4.79422633361537e-05
was O 0 1.5743122503408813e-06
the O 0 6.069219580240315e-07
most O 0 8.596844054409303e-07
common O 0 2.4102914721879642e-06
mutation O 0 1.2399357729009353e-05
found O 0 7.286841423592705e-07
, O 0 2.42088304958088e-07
followed O 0 7.678358997509349e-07
by O 0 7.610777288391546e-07
the O 0 6.446127827075543e-06
BRCA2 O 0 0.02446063794195652
8765delAG O 0 0.0024078942369669676
mutation O 0 0.0002579461724963039
. O 0 6.25565808149986e-05

Together O 0 7.400605682050809e-05
, O 0 6.854722414573189e-06
these O 0 1.8972643829329172e-06
mutations O 0 4.978054221282946e-06
were O 0 5.610391440313833e-07
found O 0 4.799161388291395e-07
in O 0 2.100044582675764e-07
28 O 0 5.083321639176575e-07
of O 0 2.2165370694438025e-07
41 O 0 6.472999302786775e-06
families O 0 2.0970655896235257e-06
identified O 0 2.312020342287724e-06
to O 0 7.572867843919084e-07
have O 0 1.2641586408790317e-06
a O 0 6.211112122400664e-06
mutation O 0 0.00012611280544660985
. O 0 4.346991772763431e-05

The O 0 5.191828677197918e-05
odds O 0 0.00011958341201534495
of O 0 1.3376291008171393e-06
detection O 0 4.529055331659038e-06
of O 0 1.985625743827768e-07
any O 0 1.6740688124627923e-07
of O 0 1.1569434832381376e-07
the O 0 5.003390128877072e-07
four O 0 4.058009380969452e-06
BRCA1 O 0 0.02705918811261654
mutations O 0 3.359359106980264e-05
was O 0 7.281545549631119e-06
18 O 0 1.188776695926208e-05
. O 0 2.618914186314214e-05

7x O 0 0.004870508331805468
greater O 0 5.2036055421922356e-05
if O 0 4.842856924369698e-06
one O 0 5.837345611325873e-07
or O 0 3.789338052229141e-07
more O 0 1.7909573557517433e-07
cases O 0 1.0224766811006702e-06
of O 0 0.0003718988155014813
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999995231628418
were O 0 2.7094249617221067e-06
also O 0 5.988907787468634e-07
present O 0 4.486443003770546e-07
in O 0 8.243680440500611e-07
the O 0 3.7217453154880786e-06
family O 0 7.866005034884438e-05
. O 0 4.052618533023633e-05

The O 0 3.10835603158921e-05
odds O 0 6.142725760582834e-05
of O 0 1.0083178949571447e-06
detection O 0 2.7749817945732502e-06
of O 0 1.7942637953183294e-07
any O 0 1.5585743540214025e-07
of O 0 1.1106784114645052e-07
the O 0 6.199248900884413e-07
four O 0 7.877894859120715e-06
BRCA2 O 0 0.25535598397254944
mutations O 0 4.9981215852312744e-05
was O 0 9.180678716802504e-06
5 O 0 1.1492504199850373e-05
. O 0 2.6917856303043664e-05

3x O 0 0.0012243213132023811
greater O 0 3.758788079721853e-05
if O 0 3.922923497157171e-06
there O 0 5.179489903639478e-07
were O 0 3.0334049938574026e-07
at O 0 2.325393353430627e-07
least O 0 1.5834233124678576e-07
five O 0 1.79653412146763e-07
cases O 0 5.360677164389926e-07
of O 0 1.467823608436447e-06
breast B-Disease 1 0.9999665021896362
cancer I-Disease 1 0.9714810848236084
in O 0 1.8725944528341643e-06
the O 0 3.93757909478154e-06
family O 0 9.331457840744406e-05
. O 0 4.525366966845468e-05

Interestingly O 0 0.0002503996074665338
, O 0 4.761382569995476e-06
the O 0 5.923579351474473e-07
presence O 0 4.565315805393766e-07
of O 0 3.600615912091598e-07
a O 0 8.402182720601559e-05
breast B-Disease 1 0.9996898174285889
cancer I-Disease 0 0.29556721448898315
case O 0 3.705439667101018e-06
< O 0 7.28349050405086e-06
36 O 0 4.696481710197986e-07
years O 0 1.8679767777030065e-07
of O 0 7.132311452551221e-08
age O 0 4.806975653082191e-07
was O 0 3.806705706210778e-07
strongly O 0 4.3112717662552313e-07
predictive O 0 1.5111680795598659e-06
of O 0 5.515672896194701e-08
the O 0 9.385929189420494e-08
presence O 0 1.2555844364214863e-07
of O 0 5.5904486373492546e-08
any O 0 8.00619091023691e-08
of O 0 1.0319541132730592e-07
the O 0 6.36740537629521e-07
eight O 0 7.330688731599366e-06
mutations O 0 6.545983342221007e-05
screened O 0 5.5447824706789106e-05
. O 0 3.963549170293845e-05

Carriers O 0 0.00015476720000151545
of O 0 2.2396095573640196e-06
the O 0 1.001605255623872e-06
same O 0 9.939944902725983e-07
mutation O 0 3.2043162718764506e-06
, O 0 1.4037961193480442e-07
from O 0 1.1225112217516653e-07
different O 0 1.7362563653477991e-07
families O 0 9.830777116803802e-07
, O 0 1.7378533812006935e-07
shared O 0 3.6787676549465687e-07
similar O 0 8.885925808499451e-07
haplotypes O 0 1.1170876859978307e-05
, O 0 5.876332238585746e-07
indicating O 0 8.870176770869875e-07
that O 0 1.0646651560364262e-07
the O 0 2.00736920419331e-07
mutant O 0 2.732790790105355e-06
alleles O 0 2.285965138071333e-06
were O 0 2.561521341704065e-07
likely O 0 4.6834395561745623e-07
to O 0 6.754257242391759e-08
be O 0 7.924077038978794e-08
identical O 0 4.603970751304587e-07
by O 0 1.9052464494961896e-07
descent O 0 9.306898391514551e-06
for O 0 6.243724897103675e-07
a O 0 1.8872866576202796e-06
mutation O 0 1.2927994248457253e-05
in O 0 8.083246143542056e-07
the O 0 2.8484355425462127e-06
founder O 0 0.00034363724989816546
population O 0 2.091417263727635e-05
. O 0 3.294532871223055e-05

The O 0 2.2610294763580896e-05
identification O 0 1.2792841516784392e-05
of O 0 1.3588517049356597e-06
common O 0 6.223587206477532e-06
BRCA1 O 0 0.0005815155454911292
and O 0 4.874216301686829e-06
BRCA2 O 0 0.006469307001680136
mutations O 0 7.214593097160105e-06
will O 0 2.48646500722316e-07
facilitate O 0 4.542489193681831e-07
carrier O 0 3.570637545635691e-06
detection O 0 2.0367315300973132e-06
in O 0 2.982409057494806e-07
French O 0 4.067827831022441e-06
Canadian O 0 3.920251037925482e-05
breast B-Disease 1 0.9789741039276123
cancer I-Disease 1 0.9175074100494385
and O 0 0.019750045612454414
breast B-Disease 1 0.9999978542327881
/ I-Disease 1 0.9999985694885254
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999992847442627
families O 0 0.0005458705127239227
. O 0 7.97091779531911e-05

Are O 0 7.478701445506886e-05
Dp71 O 0 0.0005340093630366027
and O 0 2.0230092559359036e-05
Dp140 O 0 0.0009867016924545169
brain O 0 0.001214291318319738
dystrophin O 0 0.0006122621707618237
isoforms O 0 6.897946877870709e-05
related O 0 1.9593111574067734e-05
to O 0 8.870254532666877e-06
cognitive B-Disease 0 0.009421129710972309
impairment I-Disease 1 0.6175166964530945
in O 0 0.00031757718534208834
Duchenne B-Disease 1 0.9999004602432251
muscular I-Disease 1 0.9997958540916443
dystrophy I-Disease 1 0.9999357461929321
? O 0 0.003671462181955576

Molecular O 0 0.0014383298112079501
study O 0 4.938194251735695e-05
and O 0 5.3200624279270414e-06
neuropsychological O 0 8.131234062602744e-05
analysis O 0 4.9090681386587676e-06
were O 0 5.572807140197256e-07
performed O 0 5.124881568008277e-07
concurrently O 0 8.141175840137294e-07
on O 0 1.2113537195546087e-06
49 O 0 5.1855251513188705e-05
patients O 0 0.0002845545532181859
with O 0 1.2748763765557669e-05
Duchenne B-Disease 1 0.9999775886535645
muscular I-Disease 1 0.9999725818634033
dystrophy I-Disease 1 0.9999949932098389
( O 0 0.0002586487680673599
DMD B-Disease 1 0.9999988079071045
) O 0 1.0157627912121825e-06
in O 0 1.4477856780104048e-07
order O 0 2.497106095233903e-07
to O 0 1.6501624600095965e-07
find O 0 6.157550842544879e-07
a O 0 2.64078209966101e-07
molecular O 0 2.344338781767874e-06
explanation O 0 9.867577546174289e-07
for O 0 2.9599229378618475e-07
the O 0 1.2536620488390326e-06
cognitive B-Disease 0 0.006828384008258581
impairment I-Disease 0 0.022526146844029427
observed O 0 8.641851309221238e-06
in O 0 6.513037078548223e-06
most O 0 0.0004621863772626966
DMD B-Disease 1 1.0
patients O 1 0.9213552474975586
. O 0 0.00011383469245629385

Complete O 0 7.407016528304666e-05
analysis O 0 1.602023075975012e-05
of O 0 1.4623213928643963e-06
the O 0 1.6048912812038907e-06
dystrophin O 0 8.88286522240378e-05
gene O 0 5.571905148826772e-06
was O 0 1.0852171499209362e-06
performed O 0 5.66858318507002e-07
to O 0 2.2260316256961232e-07
define O 0 8.480982955916261e-07
the O 0 2.2001353272571578e-07
localization O 0 1.289286274186452e-06
of O 0 1.5044916779061168e-07
deletions O 0 2.057664460153319e-06
and O 0 4.119340815122996e-07
duplications O 0 4.13700399803929e-06
in O 0 4.5613208499162283e-07
relation O 0 1.3861945262760855e-06
to O 0 6.724576451233588e-07
the O 0 2.186773826906574e-06
different O 0 1.204633190354798e-05
DMD B-Disease 1 0.9999946355819702
promoters O 0 0.0010674059158191085
. O 0 9.190646233037114e-05

Qualitative O 0 0.0002208892401540652
analysis O 0 2.1252026272122748e-05
of O 0 1.0855515029106755e-06
the O 0 7.3967021307908e-07
Dp71 O 0 1.6086505638668314e-05
transcript O 0 7.17297189112287e-06
and O 0 5.900473638575932e-07
testing O 0 9.89007503449102e-07
for O 0 8.651425531525092e-08
the O 0 9.4107207360139e-08
specific O 0 1.9177336696429848e-07
first O 0 2.1070819400392793e-07
exon O 0 2.3755021629767725e-06
of O 0 1.8590306183341454e-07
Dp140 O 0 1.2421181963873096e-05
were O 0 7.052686896713567e-07
also O 0 6.028263328516914e-07
carried O 0 3.285034381406149e-06
out O 0 5.0256794565939344e-06
. O 0 3.086933065787889e-05

Neuropsychological O 0 0.013720906339585781
analysis O 0 0.00013591343304142356
assessed O 0 4.802847979590297e-05
verbal O 0 2.7257703550276347e-05
and O 0 4.563976290228311e-06
visuospatial O 0 0.0002605034096632153
intelligence O 0 2.6005893232650124e-05
, O 0 1.2577946790770511e-06
verbal O 0 9.46110776567366e-06
memory O 0 0.00017924678104463965
, O 0 2.4673013285791967e-06
and O 0 2.0299405605328502e-06
reading O 0 5.14585008204449e-05
skills O 0 0.00011727843957487494
. O 0 6.0975169617449865e-05

Comparison O 0 0.00018699619977269322
of O 0 6.839326033514226e-06
molecular O 0 4.837967571802437e-05
and O 0 4.544414423435228e-06
psychometric O 0 0.0010145724518224597
findings O 0 1.2125143257435411e-05
demonstrated O 0 2.2725969301973237e-06
that O 0 1.942831460155503e-07
deletions O 0 1.6795614783404744e-06
and O 0 2.767460216546169e-07
duplications O 0 2.519534746170393e-06
that O 0 2.1929000126874598e-07
were O 0 2.2252675080380868e-07
localized O 0 1.3675764876097674e-06
in O 0 2.1499276670056133e-07
the O 0 1.5812020137673244e-07
distal O 0 5.859717930434272e-06
part O 0 2.8096397386434546e-07
of O 0 8.131975448577577e-08
the O 0 3.237590249227651e-07
gene O 0 2.446651024001767e-06
seemed O 0 1.5789566987223225e-06
to O 0 1.619687424181393e-07
be O 0 1.5439314893228584e-07
preferentially O 0 1.985363724088529e-06
associated O 0 2.3328486804530257e-06
with O 0 2.6032544155896176e-06
cognitive B-Disease 0 0.03023001365363598
impairment I-Disease 0 0.14170680940151215
. O 0 5.572123336605728e-05

Two O 0 4.648361573345028e-05
altered O 0 9.537825098959729e-05
Dp71 O 0 7.973959145601839e-05
transcripts O 0 1.0473318070580717e-05
and O 0 7.426502861562767e-07
two O 0 4.2009514800156467e-07
deleted O 0 3.5551772725739283e-06
Dp140 O 0 6.85905797581654e-06
DNA O 0 1.3161001106709591e-06
sequences O 0 5.6678806004129e-07
were O 0 2.535646217438625e-07
found O 0 2.9615037533403665e-07
in O 0 2.616822314394085e-07
four O 0 3.6557030398398638e-06
patients O 0 0.0024960157461464405
with O 0 5.479423998622224e-05
severe O 1 0.9999921321868896
cerebral B-Disease 1 0.9999992847442627
dysfunction I-Disease 1 0.9998016953468323
. O 0 0.0003205502580385655

These O 0 3.5792181733995676e-05
findings O 0 3.235348412999883e-05
suggest O 0 5.51509037904907e-06
that O 0 3.5709334156308614e-07
some O 0 1.8913971189249423e-07
sequences O 0 5.468168637889903e-07
located O 0 2.3364056289665314e-07
in O 0 1.176570094685303e-07
the O 0 2.321515779613037e-07
distal O 0 4.552912287181243e-06
part O 0 2.5949458404284087e-07
of O 0 8.09160880521631e-08
the O 0 2.0484374374518666e-07
gene O 0 6.078649334995134e-07
and O 0 2.400101948296651e-07
, O 0 1.5496578953388962e-07
in O 0 1.2633978485609987e-07
particular O 0 2.526849698369915e-07
, O 0 2.3151305583724024e-07
some O 0 3.268876298534451e-07
DMD B-Disease 1 0.9998119473457336
isoforms O 0 6.595481863769237e-06
expressed O 0 6.178308922244469e-07
in O 0 2.942992125554156e-07
the O 0 2.551939132899861e-06
brain O 0 0.48720812797546387
may O 0 2.9571508548542624e-06
be O 0 1.293984013273075e-07
related O 0 3.2593257515145524e-07
to O 0 2.4473928306179005e-07
the O 0 1.7366285192110809e-06
cognitive B-Disease 0 0.07549672573804855
impairment I-Disease 0 0.2981049716472626
associated O 0 5.228655936662108e-05
with O 0 4.871067721978761e-05
DMD B-Disease 1 0.9999998807907104
. O 0 0.00013433019921649247
. O 0 9.361073898617178e-05

I1307K O 0 0.003794826800003648
APC O 0 0.0005862770485691726
and O 0 1.7750937331584282e-05
hMLH1 O 0 0.0001640430564293638
mutations O 0 2.125782339135185e-05
in O 0 1.0934251122307614e-06
a O 0 1.7589335357115488e-06
non O 0 5.8208070186083205e-06
- O 0 0.00019791566592175514
Jewish O 0 6.809049864386907e-06
family O 0 3.824681698461063e-06
with O 0 1.8097214251611149e-06
hereditary B-Disease 1 0.7812097668647766
non I-Disease 0 0.137619286775589
- I-Disease 1 0.9999860525131226
polyposis I-Disease 1 0.9999997615814209
colorectal I-Disease 1 1.0
cancer I-Disease 1 0.9999994039535522
. O 0 0.0003726266440935433

We O 0 7.74725413066335e-05
describe O 0 5.016548675484955e-05
a O 0 7.77948025643127e-06
French O 0 2.0625760953407735e-05
Canadian O 0 4.206505764159374e-05
hereditary B-Disease 1 0.523405134677887
non I-Disease 0 0.2608531415462494
- I-Disease 1 0.9999992847442627
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 0.00028835367993451655
HNPCC B-Disease 1 0.9975001215934753
) O 0 5.619110197585542e-06
kindred O 0 2.9352380806813017e-05
which O 0 6.103232408349868e-07
carries O 0 1.9313090433570324e-06
a O 0 1.42665510338702e-06
novel O 0 1.9189761587767862e-05
truncating O 0 0.00014915487554389983
mutation O 0 5.6588298321003094e-05
in O 0 1.1223607543797698e-05
hMLH1 O 0 0.0005124079762026668
. O 0 7.696460670558736e-05

Interestingly O 0 0.00044152853661216795
, O 0 1.700602297205478e-05
the O 0 6.407557521015406e-06
I1307K O 0 8.949489711085334e-05
APC O 0 2.43363028857857e-05
polymorphism O 0 2.4262169972644188e-05
, O 0 8.116631988741574e-07
associated O 0 3.068231251290854e-07
with O 0 1.4878686727115564e-07
an O 0 2.3842963514653093e-07
increased O 0 4.833370439882856e-06
risk O 0 0.00018068835197482258
of O 0 0.0013142838142812252
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 2.8779688818758586e-06
is O 0 3.991349615262152e-07
also O 0 5.071119630883913e-07
present O 0 6.358448558785312e-07
in O 0 1.5223755553961382e-06
this O 0 2.8313027087278897e-06
family O 0 4.9952766858041286e-05
. O 0 4.295149847166613e-05

The O 0 3.2767042284831405e-05
I1307K O 0 0.00019368500215932727
polymorphism O 0 5.924146535107866e-05
has O 0 1.4486159898297046e-06
previously O 0 9.62930243986193e-07
only O 0 2.396593288267468e-07
been O 0 5.181880737836764e-07
identified O 0 6.70231486310513e-07
in O 0 1.6908325051190332e-07
individuals O 0 2.686730624645861e-07
of O 0 2.7289522108731035e-07
self O 0 4.2921728891087696e-05
- O 0 0.12549927830696106
reported O 0 7.42730189813301e-05
Ashkenazi O 0 0.0003313622728455812
Jewish O 0 3.8874091842444614e-05
origins O 0 0.00011266076035099104
. O 0 6.180211494211107e-05

In O 0 1.9389166482142173e-05
addition O 0 6.901714641571743e-06
, O 0 6.417137683456531e-07
in O 0 2.307741482354686e-07
this O 0 1.88251988220145e-07
family O 0 1.4151370351100923e-06
, O 0 1.7757972159415658e-07
there O 0 8.64743228135012e-08
appears O 0 3.3720496617206663e-07
to O 0 1.1141220568333665e-07
be O 0 1.1216315698447943e-07
no O 0 1.2907857183108717e-07
relationship O 0 3.0670466344417946e-07
between O 0 1.0880352618869438e-07
the O 0 2.5932041580745135e-07
I1307K O 0 2.3800852432032116e-05
polymorphism O 0 6.960437531233765e-06
and O 0 1.67624946811884e-07
the O 0 1.4516042767809267e-07
presence O 0 4.254461885011551e-07
or O 0 4.2700909830273304e-07
absence O 0 2.628262336656917e-06
of O 0 2.1317134724085918e-06
cancer B-Disease 1 0.62821364402771
. O 0 9.371110536449123e-06
. O 0 3.1821909942664206e-05

Identification O 0 6.511231913464144e-05
of O 0 3.1534532354271505e-06
a O 0 3.0373757908819243e-06
novel O 0 8.209762199840043e-06
mutation O 0 3.884058969561011e-06
of O 0 2.6156970989177353e-07
the O 0 6.862178452138323e-07
CPO O 0 1.3905471860198304e-05
gene O 0 3.444843741817749e-06
in O 0 1.0423987077956554e-06
a O 0 2.6680706923798425e-06
Japanese O 0 5.973022052785382e-05
hereditary B-Disease 0 0.14608295261859894
coproporphyria I-Disease 1 0.6055192351341248
family O 0 0.0002706470841076225
. O 0 7.395780994556844e-05

Hereditary B-Disease 1 0.997940719127655
coproporphyria I-Disease 1 0.9806619882583618
( O 0 0.00013694817607756704
HCP B-Disease 0 0.382215678691864
) O 0 5.984391009405954e-06
is O 0 1.0486044175195275e-06
an O 0 2.71622388936521e-06
autosomal B-Disease 1 0.942284882068634
dominant I-Disease 1 0.9991995692253113
disease I-Disease 1 0.8558539748191833
characterized O 0 0.0001809623499866575
by O 0 7.037515842966968e-06
a O 0 0.0024259767960757017
deficiency B-Disease 0 0.4754249155521393
of I-Disease 0 1.0630606084305327e-06
coproporphyrinogen I-Disease 0 0.15429720282554626
oxidase I-Disease 0 0.0006684748223051429
( O 0 1.7020682889778982e-06
CPO O 0 9.172811587632168e-06
) O 0 6.578794682354783e-07
caused O 0 1.1900468734893366e-06
by O 0 3.3030397617039853e-07
a O 0 1.0591373893475975e-06
mutation O 0 8.559592060919385e-06
in O 0 1.0461352530910517e-06
the O 0 3.9458336686948314e-06
CPO O 0 0.00015687476843595505
gene O 0 9.229070565197617e-05
. O 0 6.578881584573537e-05

Only O 0 3.138571628369391e-05
11 O 0 1.664126102696173e-05
mutations O 0 9.419279194844421e-06
of O 0 3.7161166233090626e-07
the O 0 5.892056265111023e-07
gene O 0 3.0862668154441053e-06
have O 0 9.231549711330445e-07
been O 0 2.0737238628498744e-06
reported O 0 2.8301954444032162e-05
in O 0 2.2634867491433397e-05
HCP B-Disease 1 0.9965091347694397
patients O 0 0.017366277053952217
. O 0 6.0604863392654806e-05

We O 0 6.768951425328851e-05
report O 0 1.93501928151818e-05
another O 0 5.51318726138561e-06
mutation O 0 2.193097498093266e-05
in O 0 1.9339152004249627e-06
a O 0 4.041694865009049e-06
Japanese O 0 4.319046638556756e-05
family O 0 8.164901373675093e-05
. O 0 5.048385719419457e-05

Polymerase O 0 0.0018805409781634808
chain O 0 0.0007841764017939568
reaction O 0 0.00013609601592179388
- O 0 8.906699804356322e-05
single O 0 4.117441676498856e-06
strand O 0 1.3789787772111595e-05
conformational O 0 5.995329502184177e-06
polymorphism O 0 5.826983851875411e-06
and O 0 3.7199743019300513e-07
direct O 0 3.529704599714023e-07
sequence O 0 5.742002713304828e-07
analyses O 0 2.193154386986862e-06
demonstrated O 0 1.269501012757246e-06
a O 0 5.143021439835138e-07
C O 0 7.293965154531179e-06
to O 0 4.951030518896005e-07
T O 0 4.1723783397173975e-06
substitution O 0 6.509558261313941e-07
in O 0 2.6852501378016314e-07
exon O 0 1.8334302467337693e-06
1 O 0 1.766011905601772e-07
of O 0 5.82754502431726e-08
the O 0 1.7264353857626702e-07
CPO O 0 2.51079427471268e-06
gene O 0 6.769327001165948e-07
at O 0 2.4596491243755736e-07
nucleotide O 0 8.920865752770624e-07
position O 0 6.569628112629289e-07
85 O 0 7.694148393966316e-07
, O 0 1.4497724976081372e-07
which O 0 1.198607151309261e-07
lies O 0 5.279218271425634e-07
in O 0 3.153231773467269e-07
the O 0 5.255548103377805e-07
putative O 0 1.4679841115139425e-05
presequence O 0 2.5104898668359965e-05
for O 0 8.884603630576748e-07
targeting O 0 7.4398608376213815e-06
to O 0 6.49672256258782e-06
mitochondria O 0 0.00013953943562228233
. O 0 4.71092680527363e-05

This O 0 4.30026811955031e-05
mutation O 0 6.0112386563559994e-05
changes O 0 5.30718580193934e-06
the O 0 7.29792702713894e-07
codon O 0 3.7590743886539713e-06
for O 0 3.185117236625956e-07
glutamine O 0 2.8166091396997217e-06
to O 0 3.5819911659018544e-07
a O 0 8.881299891072558e-07
termination O 0 8.202076969610061e-06
codon O 0 7.459725111402804e-06
at O 0 1.8773096144286683e-06
amino O 0 4.793544576386921e-06
acid O 0 1.3929150554758962e-05
position O 0 1.073433941201074e-05
29 O 0 2.145157486665994e-05
. O 0 2.2139343855087645e-05

MaeI O 0 0.0017461865209043026
restriction O 0 0.00012708664871752262
analysis O 0 3.144776201224886e-05
showed O 0 8.66863592818845e-06
two O 0 6.573877726623323e-07
other O 0 5.993318268338044e-07
carriers O 0 4.606452421285212e-06
in O 0 1.5232964187816833e-06
the O 0 4.77716957902885e-06
family O 0 7.06581340637058e-05
. O 0 4.969031215296127e-05

The O 0 0.000156105263158679
C O 1 0.6069870591163635
- O 1 0.9051958918571472
T O 0 0.4047974944114685
mutation O 0 1.1211967830604408e-05
is O 0 2.435634485209448e-07
located O 0 2.8347724878585723e-07
within O 0 2.4138054754985205e-07
a O 0 4.6963921818132803e-07
recently O 0 2.324906290596118e-06
proposed O 0 2.1287025901983725e-06
putative O 0 9.166654308501165e-06
alternative O 0 1.9157296264893375e-06
translation O 0 3.287281288066879e-06
initiation O 0 3.030781726920395e-06
codon O 0 6.501444659079425e-06
( O 0 9.302374337494257e-07
TIC O 0 8.57730810821522e-06
- O 0 3.490260269245482e-06
1 O 0 2.2347589379023702e-07
) O 0 1.1243346165201729e-07
, O 0 5.1686043889276334e-08
supporting O 0 2.2177633240971772e-07
that O 0 1.5982060119767993e-07
TIC O 0 4.526726479525678e-05
- O 0 1.556994902784936e-05
1 O 0 2.997898889134376e-07
is O 0 6.864011936613679e-08
the O 0 1.5466902425487206e-07
real O 0 1.1085953701694962e-06
TIC O 0 1.3596006283478346e-05
rather O 0 7.523443628087989e-07
than O 0 6.422084197765798e-07
TIC O 0 5.325556776369922e-05
- O 0 3.0241062631830573e-05
2 O 0 3.224367219445412e-06
. O 0 3.9797182580514345e-06
. O 0 1.929019890667405e-05

Human B-Disease 0 0.0003078528097830713
complement I-Disease 0 0.0004945025430060923
factor I-Disease 0 0.1410311758518219
H I-Disease 1 0.9999995231628418
deficiency I-Disease 1 0.9997921586036682
associated O 0 0.00879405066370964
with O 1 0.7002640962600708
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
. O 0 0.0015266342088580132

This O 0 2.908965507231187e-05
study O 0 1.2882015653303824e-05
reports O 0 2.497935156497988e-06
on O 0 4.82358075259981e-07
six O 0 8.419623327426962e-07
cases O 0 8.150700523401611e-07
of O 0 1.3486859415934305e-06
deficiency B-Disease 0 0.210783451795578
in I-Disease 0 2.8574473276421486e-07
the I-Disease 0 3.234735572732461e-07
human I-Disease 0 5.879763307348185e-07
complement I-Disease 0 1.6089983319034218e-06
regulatory I-Disease 0 6.296954325080151e-06
protein I-Disease 0 5.179892923479201e-06
Factor I-Disease 0 1.1643972356978338e-05
H I-Disease 1 0.9900296330451965
( O 0 1.7327507748632343e-06
FH O 0 0.0003180128405801952
) O 0 3.0922544169698085e-07
in O 0 1.1587687254177581e-07
the O 0 1.6011473746857519e-07
context O 0 1.0450204399603535e-06
of O 0 1.3456912029141677e-06
an O 0 0.005468631628900766
acute B-Disease 1 0.9999992847442627
renal I-Disease 1 1.0
disease I-Disease 1 0.9999996423721313
. O 0 0.0004664577136281878

Five O 0 1.8141821783501655e-05
of O 0 1.3468364841173752e-06
the O 0 9.844173973760917e-07
cases O 0 1.0799661822602502e-06
were O 0 5.518124339687347e-07
observed O 0 1.1643267043837113e-06
in O 0 8.378819984500296e-07
children O 0 3.099918785665068e-06
presenting O 0 2.8615524570341222e-05
with O 0 0.29093044996261597
idiopathic O 1 1.0
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.028936145827174187
HUS B-Disease 1 0.999991774559021
) O 0 7.288400956895202e-05
. O 0 5.034847345086746e-05

Two O 0 1.3404102901404258e-05
of O 0 2.302672783116577e-06
the O 0 2.4603323254268616e-06
children O 0 2.743110144365346e-06
exhibited O 0 3.2167099561775103e-06
a O 0 1.2222792975080665e-05
homozygous O 1 0.9798184633255005
deficiency O 1 0.8560115694999695
characterized O 0 6.952224339329405e-06
by O 0 3.247430129249551e-07
the O 0 2.633669282658957e-07
absence O 0 8.080378961494716e-07
of O 0 1.1165556657033449e-07
the O 0 2.9935793577351433e-07
150 O 0 6.369360789904022e-07
- O 0 4.251263362675672e-06
kD O 0 7.729649951215833e-06
form O 0 1.66565712333977e-07
of O 0 1.1657918008722845e-07
Factor O 0 1.181681454909267e-06
H O 0 0.27554818987846375
and O 0 1.3675395393875078e-07
the O 0 9.490880614748676e-08
presence O 0 1.4101024703450094e-07
, O 0 8.08776619010132e-08
upon O 0 1.2526493264886085e-07
immunoblotting O 0 3.7700135635532206e-06
, O 0 6.461377211053332e-08
of O 0 3.667389592010295e-08
the O 0 1.8857183192722005e-07
42 O 0 2.297496166647761e-06
- O 0 1.000160955300089e-05
kD O 0 9.682690142653883e-05
Factor O 0 3.7798706671310356e-06
H O 0 0.45413893461227417
- O 0 4.664309017243795e-06
like O 0 6.093078468438762e-07
protein O 0 9.383222732139984e-07
1 O 0 6.478209115812206e-07
( O 0 3.9999193290896073e-07
FHL O 0 5.2489496738417074e-05
- O 0 7.616057700943202e-06
1 O 0 2.793246380861092e-07
) O 0 1.5220112459246593e-07
and O 0 1.2858292564033036e-07
other O 0 3.576393226012442e-07
FH O 0 0.1605743020772934
- O 0 0.00022144656395539641
related O 0 4.287537649361184e-06
protein O 0 5.867932486580685e-06
( O 0 3.2042582915892126e-06
FHR O 0 0.00011115633969893679
) O 0 4.9880054575623944e-06
bands O 0 2.344522908970248e-05
. O 0 3.815721356659196e-05

Southern O 0 0.00021281141380313784
blot O 0 0.00037804676685482264
and O 0 6.808972102589905e-06
PCR O 0 4.1728446376509964e-05
analysis O 0 2.515299911465263e-06
of O 0 2.438707156215969e-07
DNA O 0 1.3481986798069556e-06
of O 0 1.965796627700911e-07
one O 0 7.889584594522603e-07
patient O 0 4.0227550925919786e-05
with O 0 2.063221700154827e-06
homozygous O 1 0.9525366425514221
deficiency O 1 0.5328559279441833
ruled O 0 3.676365395222092e-06
out O 0 1.7623273151912144e-07
the O 0 1.1154978096783452e-07
presence O 0 1.2113348191178375e-07
of O 0 5.373032152533597e-08
a O 0 3.06050424114801e-07
large O 0 6.453137757489458e-07
deletion O 0 3.4580461942823604e-06
of O 0 2.4525800768060435e-07
the O 0 8.403001743317873e-07
FH O 0 0.05010109394788742
gene O 0 1.6864021290530218e-06
as O 0 1.8852956884529704e-07
the O 0 6.090103852329776e-07
underlying O 0 0.00033682934008538723
defect O 0 0.0007625630823895335
for O 0 5.685849828296341e-06
the O 0 0.00022135369363240898
deficiency O 1 0.920831561088562
. O 0 6.657841731794178e-05

The O 0 1.896087997010909e-05
other O 0 2.5460929009568645e-06
four O 0 1.4010546465215157e-06
children O 0 1.729382915982569e-06
presented O 0 1.612731239220011e-06
with O 0 2.8114297947468003e-06
heterozygous O 0 0.44167473912239075
deficiency O 0 0.19933363795280457
and O 0 9.419624689144257e-07
exhibited O 0 2.2438575797423255e-06
a O 0 8.312981094604766e-07
normal O 0 3.569561840777169e-06
immunoblotting O 0 3.6096087569603696e-05
pattern O 0 2.0112508991587674e-06
of O 0 3.8285247683234047e-07
proteins O 0 1.4055418660063879e-06
of O 0 6.726025958414539e-07
the O 0 1.1679583622026257e-05
FH O 1 0.9601173996925354
family O 0 0.00016130629228428006
. O 0 6.008087075315416e-05

Factor B-Disease 1 0.9991412162780762
H I-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9968332648277283
is O 0 3.1341062367573613e-06
the O 0 2.09560835173761e-06
only O 0 4.789710601471597e-06
complement B-Disease 1 0.9818483591079712
deficiency I-Disease 1 0.9999953508377075
associated O 0 6.55360272503458e-05
with O 0 2.5294919396401383e-05
HUS B-Disease 1 0.9999756813049316
. O 0 0.00021549093071371317

These O 0 4.1044728277483955e-05
observations O 0 4.152373367105611e-05
suggest O 0 1.228649853146635e-05
a O 0 1.7287053424297483e-06
role O 0 2.3962259092513705e-06
for O 0 1.5808974467290682e-06
FH O 0 0.16254155337810516
and O 0 2.5745357561390847e-06
/ O 0 3.937479050364345e-05
or O 0 2.2647645891993307e-06
FH O 0 0.04044333100318909
receptors O 0 4.047928541695001e-06
in O 0 4.462151252937474e-07
the O 0 1.5846469523239648e-06
pathogenesis O 0 0.0008910184842534363
of O 0 1.305085424974095e-05
idiopathic O 1 0.9999908208847046
HUS B-Disease 1 0.9999958276748657
. O 0 5.251582115306519e-05
. O 0 6.454676622524858e-05

Further O 0 7.44275821489282e-05
evidence O 0 1.730637450236827e-05
for O 0 1.4432545185627532e-06
a O 0 1.793984779396851e-06
major O 0 2.95224799629068e-06
ancient O 0 1.157016413344536e-05
mutation O 0 0.0015726956771686673
underlying O 1 0.6336387395858765
myotonic B-Disease 1 0.9999996423721313
dystrophy I-Disease 1 0.9999991655349731
from O 0 4.8215761125902645e-06
linkage O 0 9.972279076464474e-05
disequilibrium O 0 0.016234872862696648
studies O 0 1.2171752132417168e-05
in O 0 1.6405200540248188e-06
the O 0 3.297973535154597e-06
Japanese O 0 2.139698335668072e-05
population O 0 2.9083217668812722e-05
. O 0 5.144289752934128e-05

The O 0 0.001774919917806983
myotonic B-Disease 1 0.9999988079071045
dystrophy I-Disease 1 0.9999998807907104
( O 0 0.2050459384918213
DM B-Disease 1 0.9999998807907104
) O 0 2.2316431568469852e-05
mutation O 0 9.99472558760317e-06
is O 0 5.001205636290251e-07
an O 0 5.197574637350044e-07
unstable O 0 0.00042908554314635694
( O 0 1.5708702676420216e-06
CTG O 0 1.842144592956174e-05
) O 0 4.970531790604582e-07
n O 0 1.0315050076314947e-06
repeat O 0 1.5476036878681043e-06
, O 0 1.1619226114589765e-07
present O 0 1.18161892714852e-07
at O 0 1.1823087930906695e-07
a O 0 1.5727169966339716e-07
copy O 0 6.38803669517074e-07
number O 0 8.419625174838075e-08
of O 0 9.937862444076018e-08
5 O 0 4.026695705761085e-07
- O 0 2.4775108613539487e-06
37 O 0 4.847154286835575e-07
repeats O 0 6.22249103798822e-07
on O 0 1.64609460284737e-07
normal O 0 7.44618148473819e-07
chromosomes O 0 1.2125524335715454e-06
but O 0 2.380329675588655e-07
amplified O 0 1.012974166769709e-06
to O 0 1.9477180046578724e-07
50 O 0 6.412060429283883e-07
- O 0 6.2637673181598075e-06
3000 O 0 6.500564268208109e-06
copies O 0 3.4803817925421754e-06
on O 0 6.556574589922093e-06
DM B-Disease 1 0.9968511462211609
chromosomes O 0 0.00019397589494474232
. O 0 8.01615824457258e-05

Previous O 0 0.00038016351754777133
findings O 0 0.00010978104546666145
in O 0 5.347877504391363e-06
Caucasian O 0 3.40076549036894e-05
populations O 0 3.2289367482007947e-06
of O 0 5.05098796566017e-07
a O 0 1.7490592654212378e-05
DM B-Disease 1 0.9999991655349731
founder O 0 0.0008411413291469216
chromosome O 0 9.385663361172192e-06
raise O 0 2.0897286958643235e-06
a O 0 3.218810888938606e-07
question O 0 4.991161404177547e-07
about O 0 1.198540786617741e-07
the O 0 1.5726961066775402e-07
molecular O 0 2.0150464479229413e-06
events O 0 7.762277505207749e-07
involved O 0 8.918722187445383e-07
in O 0 4.431929880865937e-07
the O 0 1.7458413594795275e-06
expansion O 0 3.809413101407699e-05
mutation O 0 0.0001402207708451897
. O 0 6.90279048285447e-05

To O 0 4.802431067219004e-05
investigate O 0 4.603401248459704e-05
whether O 0 8.569671081204433e-06
a O 0 2.7525725272425916e-06
founder O 0 1.5669556887587532e-05
chromosome O 0 6.717654741805745e-06
for O 0 7.196592264335777e-07
the O 0 4.6716013457626104e-06
DM B-Disease 1 0.9999996423721313
mutation O 0 3.244852996431291e-05
exists O 0 5.439488859337871e-07
in O 0 1.388971924143334e-07
the O 0 1.4241958012917166e-07
Japanese O 0 7.855011858737271e-07
population O 0 3.5185564684070414e-07
, O 0 2.4125077402459283e-07
we O 0 2.552751823259314e-07
genotyped O 0 9.709069672680926e-06
families O 0 1.1023583965652506e-06
using O 0 6.376848773470556e-07
polymorphic O 0 1.0075670616060961e-05
markers O 0 2.083697154375841e-06
near O 0 9.335986419500841e-07
the O 0 8.220034715122893e-07
( O 0 1.5379312117147492e-06
CTG O 0 3.792952702497132e-05
) O 0 9.895699122353108e-07
n O 0 4.229072146699764e-06
repeat O 0 6.4002283579611685e-06
region O 0 2.6952350253850454e-06
and O 0 2.3492400487157283e-06
constructed O 0 3.349132384755649e-05
haplotypes O 0 0.0002582791494205594
. O 0 5.473575583891943e-05

Six O 0 8.015875209821388e-05
different O 0 1.0163686056330334e-05
haplotypes O 0 8.124893793137744e-05
were O 0 3.771185902223806e-06
found O 0 2.6118186724488623e-06
and O 0 5.773869361291872e-06
DM B-Disease 1 0.9999943971633911
alleles O 0 3.410821227589622e-05
were O 0 3.0748826702620136e-06
always O 0 6.59203624309157e-06
haplotype O 0 0.00014137278776615858
A O 0 4.348148650024086e-05
. O 0 7.37414593459107e-05

To O 0 3.258018477936275e-05
find O 0 1.1999435628240462e-05
an O 0 7.403766630886821e-07
origin O 0 7.037885438876401e-07
of O 0 1.6711433659111208e-07
the O 0 5.6705351880737e-07
( O 0 7.516057394241216e-07
CTG O 0 1.63271943165455e-05
) O 0 4.38469726304902e-07
n O 0 1.073279008778627e-06
repeat O 0 2.5632318738644244e-06
mutation O 0 1.2525304100563517e-06
and O 0 1.5690766019815783e-07
to O 0 1.483702902760342e-07
investigate O 0 4.858210331804003e-07
the O 0 9.031715109131255e-08
mechanism O 0 2.0761723362738849e-07
of O 0 4.2483918605285e-08
the O 0 9.744661610966432e-08
expansion O 0 1.2170057743787766e-06
mutation O 0 1.594772697899316e-06
in O 0 1.116660044431228e-07
the O 0 1.5239342587847204e-07
Japanese O 0 8.211705448957218e-07
population O 0 3.7583433254440024e-07
we O 0 1.723273754805632e-07
have O 0 1.8830064618668985e-07
studied O 0 1.2691257325059269e-06
90 O 0 1.1679801446007332e-06
Japanese O 0 1.3626899999508169e-05
DM B-Disease 1 0.999946117401123
families O 0 3.1820918593439274e-06
comprising O 0 1.0317627356926096e-06
190 O 0 3.3756221000658115e-06
affected O 0 3.7748632166767493e-06
and O 0 1.7203589095515781e-06
130 O 0 7.911987268016674e-06
unaffected O 0 7.925509271444753e-05
members O 0 1.92910447367467e-05
. O 0 5.0434966397006065e-05

The O 0 3.8687619962729514e-05
results O 0 5.143779344507493e-05
suggest O 0 5.048747425462352e-06
that O 0 4.2505564579187194e-07
a O 0 4.928004955218057e-07
few O 0 6.406766601685376e-07
common O 0 1.251361481990898e-06
ancestral O 0 1.6366948329959996e-05
mutations O 0 5.743597284890711e-06
in O 0 2.599542767711682e-07
both O 0 3.102303196556022e-07
Caucasian O 0 5.9144672377442475e-06
and O 0 5.181317419555853e-07
Japanese O 0 3.517721552270814e-06
populations O 0 1.0370206382503966e-06
have O 0 1.1685256140481215e-07
originated O 0 3.158793902002799e-07
by O 0 9.516421783928308e-08
expansion O 0 3.9157217202046013e-07
of O 0 1.0126604621518709e-07
an O 0 1.873752495384906e-07
ancestral O 0 4.2528167796263006e-06
n O 0 8.703942512511276e-06
= O 0 5.466642960527679e-06
5 O 0 4.973082923243055e-07
repeat O 0 3.4008874081337126e-06
to O 0 8.065919701039093e-07
n O 0 8.393868483835831e-06
= O 0 1.637255263631232e-05
19 O 0 2.0601266896846937e-06
- O 0 1.0574322914180811e-05
37 O 0 7.477032795577543e-06
copies O 0 1.5921124941087328e-05
. O 0 2.530760866648052e-05

These O 0 2.4937889975262806e-05
data O 0 1.6626319848001003e-05
support O 0 4.711070232588099e-06
multistep O 0 3.66983913409058e-05
models O 0 3.5274908896099078e-06
of O 0 3.826663146355713e-07
triplet O 0 5.637570939143188e-05
repeat O 0 7.607913175888825e-06
expansion O 0 1.7079300960176624e-06
that O 0 2.2832583113086002e-07
have O 0 1.9410016705023736e-07
been O 0 1.8860869488435128e-07
proposed O 0 5.590511591435643e-07
for O 0 3.394014527202671e-07
both O 0 2.516700988053344e-06
DM B-Disease 1 0.9999933242797852
and O 0 1.046840498020174e-05
Friedreichs B-Disease 0 0.0659695491194725
ataxia I-Disease 0 0.2381686121225357
. O 0 2.4893955924198963e-05
. O 0 3.303798439446837e-05

The O 0 4.0266004361910746e-05
molecular O 0 5.871475877938792e-05
basis O 0 7.877924872445874e-06
of O 0 1.0088785529660527e-05
C6 B-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9999936819076538
in O 0 1.2453660929168109e-06
the O 0 9.631680768507067e-07
western O 0 4.699103556049522e-06
Cape O 0 3.0644689104519784e-05
, O 0 1.7326616443824605e-06
South O 0 5.738439995184308e-06
Africa O 0 1.698963387752883e-05
. O 0 2.8790705982828513e-05

Deficiency B-Disease 1 0.9444807767868042
of I-Disease 0 7.004125109233428e-06
the I-Disease 0 3.127286845483468e-06
sixth I-Disease 0 6.1907462622912135e-06
component I-Disease 0 2.461644271534169e-06
of I-Disease 0 3.013026912412897e-07
human I-Disease 0 6.967025001358707e-07
complement I-Disease 0 2.2035087567928713e-06
( O 0 7.005087923062092e-07
C6 O 0 4.132286267122254e-05
) O 0 3.2804561556076806e-07
has O 0 1.252754486813501e-07
been O 0 1.7921739470239118e-07
reported O 0 2.750077499058534e-07
in O 0 6.453642242831847e-08
a O 0 1.4299800454864453e-07
number O 0 7.40095842388655e-08
of O 0 1.3011128885409562e-07
families O 0 5.611162237073586e-07
from O 0 1.5915547635358962e-07
the O 0 2.5410591319996456e-07
western O 0 1.3571823274105554e-06
Cape O 0 1.3425055840343703e-05
, O 0 8.708290692993614e-07
South O 0 2.6719565084931673e-06
Africa O 0 9.662901902629528e-06
. O 0 2.116495306836441e-05

Meningococcal B-Disease 1 0.999963641166687
disease I-Disease 1 0.9997355341911316
is O 0 1.661456008150708e-05
endemic O 0 1.0397267942607868e-05
in O 0 7.391308258775098e-07
the O 0 5.998819574415393e-07
Cape O 0 4.202043783152476e-06
and O 0 1.5001332087649644e-07
almost O 0 1.1087247742125328e-07
all O 0 1.3280053678954573e-07
pedigrees O 0 3.7527240692725172e-06
of O 0 5.185301574783807e-07
total O 0 0.00031600488000549376
C6 B-Disease 1 1.0
deficiency I-Disease 1 0.9999994039535522
( O 0 1.804936800908763e-06
C6Q0 O 0 0.001487733330577612
) O 0 5.938052254350623e-07
have O 0 3.125376792922907e-07
been O 0 7.590235213683627e-07
ascertained O 0 7.447697953466559e-06
because O 0 2.9567672754637897e-06
of O 0 5.475314537761733e-06
recurrent O 1 0.9786559343338013
disease O 1 0.8509184718132019
. O 0 0.00018824345897883177

We O 0 5.221012906986289e-05
have O 0 6.634594683418982e-06
sequenced O 0 1.245289695361862e-05
the O 0 1.2689756658801343e-06
expressed O 0 1.0704719670684426e-06
exons O 0 3.1971003409125842e-06
of O 0 2.681473176835425e-07
the O 0 5.024079996474029e-07
C6 O 0 1.7821432265918702e-05
gene O 0 9.809948551264824e-07
from O 0 1.3192550341045717e-07
selected O 0 3.141609568046988e-07
cases O 0 2.458511687564169e-07
and O 0 1.9641045412299718e-07
have O 0 2.1328042976165307e-07
found O 0 2.1875757738598622e-07
three O 0 4.6280899823614163e-07
molecular O 0 0.017786988988518715
defects O 0 0.10826627165079117
leading O 0 2.1154187379579525e-06
to O 0 4.6801801545370836e-07
total O 0 2.9976981750223786e-06
deficiency O 0 0.3303026854991913
879delG O 0 0.000524303934071213
, O 0 2.9582494676105853e-07
which O 0 9.682318591330841e-08
is O 0 6.065064184213043e-08
the O 0 1.7711967359446135e-07
common O 0 8.651158509564993e-07
defect O 0 1.1190176337549929e-05
in O 0 2.1862470589439909e-07
the O 0 3.7633108718182484e-07
Cape O 0 5.761471584264655e-06
and O 0 3.448031122843531e-07
hitherto O 0 3.386181788300746e-06
unreported O 0 1.6952417354332283e-06
, O 0 1.6759312870817666e-07
and O 0 1.8214106489722326e-07
1195delC O 0 2.2989995613897918e-06
and O 0 2.7829827331515844e-07
1936delG O 0 7.81624567025574e-06
, O 0 1.6830749416385515e-07
which O 0 8.737008982961925e-08
have O 0 1.6089508392269636e-07
been O 0 4.606048094046855e-07
previously O 0 2.099811354128178e-06
reported O 0 2.374555378992227e-06
in O 0 9.960955367205315e-07
African O 0 4.695586994785117e-06
- O 0 0.0005491914926096797
Americans O 0 2.100265737681184e-05
. O 0 2.9954100682516582e-05

We O 0 4.065687608090229e-05
also O 0 3.145163645967841e-06
show O 0 1.5464498801520676e-06
that O 0 2.6169098532591306e-07
the O 0 3.75203683233849e-07
879delG O 0 1.4909645869920496e-05
and O 0 1.5397569086417207e-06
1195delC O 0 0.22594307363033295
defects O 0 0.32048147916793823
are O 0 3.7426769949888694e-07
associated O 0 8.297092790598981e-07
with O 0 4.9282772351944e-07
characteristic O 0 3.0412422347581014e-05
C6 O 1 0.9191784262657166
/ O 0 0.00021859066328033805
C7 O 0 0.0005043791607022285
region O 0 2.463161081323051e-06
DNA O 0 7.5866555562242866e-06
marker O 0 6.410050900740316e-06
haplotypes O 0 1.1075048860220704e-05
, O 0 4.2824967749766074e-07
although O 0 7.063308657961898e-07
small O 0 9.925537369781523e-07
variations O 0 3.663045617940952e-06
were O 0 4.005792561656563e-06
observed O 0 1.601074473001063e-05
. O 0 2.7422849598224275e-05

The O 0 8.477424125885591e-05
1936delG O 0 0.0005487470189109445
defect O 0 0.0001337767025688663
was O 0 3.115816980425734e-06
observed O 0 1.8201203602075111e-06
only O 0 2.775587972791982e-07
once O 0 5.108431651024148e-07
in O 0 1.747822580000502e-07
the O 0 3.332560538638063e-07
Cape O 0 7.563740837213118e-06
, O 0 3.9636211113247555e-07
but O 0 3.518120479384379e-07
its O 0 7.136965223253355e-07
associated O 0 4.315403657528805e-06
haplotype O 0 8.217618596972898e-05
could O 0 8.4526927821571e-06
be O 0 2.9450377496686997e-06
deduced O 0 5.9120131481904536e-05
. O 0 2.654420313774608e-05

The O 0 1.8082506358041428e-05
data O 0 7.665331395401154e-06
from O 0 8.183841941900027e-07
the O 0 4.3170976482542756e-07
haplotypes O 0 9.718573892314453e-06
indicate O 0 1.2719928008664283e-06
that O 0 1.262263396029084e-07
these O 0 1.3216225625001243e-07
three O 0 2.965878991290083e-07
molecular O 0 0.002231392078101635
defects O 0 0.007782554253935814
account O 0 1.0788862709887326e-06
for O 0 2.895539239489153e-07
the O 0 1.0264521961289574e-06
defects O 0 0.004465394653379917
in O 0 1.5487979965200793e-07
all O 0 7.372329235977304e-08
the O 0 1.2450711039946327e-07
38 O 0 8.881096391633037e-07
unrelated O 0 3.7651129787263926e-06
C6Q0 O 0 0.001609938801266253
individuals O 0 5.596379537564644e-07
we O 0 2.876910230042995e-07
have O 0 2.590104770661128e-07
studied O 0 1.0340559128962923e-06
from O 0 8.538489169040986e-07
the O 0 2.687432697712211e-06
Cape O 0 0.0001718362618703395
. O 0 4.700444333138876e-05

We O 0 3.719191954587586e-05
have O 0 4.168043687968748e-06
also O 0 1.7567590475664474e-06
observed O 0 1.5444896916960715e-06
the O 0 8.423984354521963e-07
879delG O 0 3.461427695583552e-05
defect O 0 1.1265149623795878e-05
in O 0 4.1157991859108733e-07
two O 0 8.36827837247256e-07
Dutch O 1 0.7471472024917603
C6 B-Disease 1 0.9999991655349731
- I-Disease 1 0.9995477795600891
deficient I-Disease 1 0.9998220801353455
kindreds O 0 4.20785800088197e-05
, O 0 2.6292275379091734e-07
but O 0 1.298507328328924e-07
the O 0 1.934021014449172e-07
879delG O 0 2.634336669871118e-05
defect O 0 9.293567018175963e-06
in O 0 2.4982972490761313e-07
the O 0 2.8768445758942107e-07
Cape O 0 6.234874490473885e-06
probably O 0 1.149358013208257e-06
did O 0 3.619220194650552e-07
not O 0 2.086101886789038e-07
come O 0 4.151768280280521e-07
from O 0 2.3003016735856363e-07
The O 0 8.79892468219623e-07
Netherlands O 0 1.2196967873023823e-05
. O 0 5.681324182660319e-06
. O 0 2.4858274628059007e-05

Complement B-Disease 1 0.777103066444397
C7 I-Disease 1 0.9999997615814209
deficiency I-Disease 1 0.9999973773956299
: O 0 1.3016881894145627e-05
seven O 0 2.847829819074832e-06
further O 0 4.730744876724202e-06
molecular O 0 0.00944847334176302
defects O 1 0.5655115842819214
and O 0 4.566910774883581e-06
their O 0 7.630147592863068e-06
associated O 0 5.739651169278659e-05
marker O 0 0.00020267038780730218
haplotypes O 0 0.0011192646343261003
. O 0 9.720314847072586e-05

Seven O 0 6.525627395603806e-05
further O 0 1.7695365386316553e-05
molecular O 0 3.742464105016552e-05
bases O 0 1.5380473996629007e-05
of O 0 2.0494024283834733e-05
C7 B-Disease 1 1.0
deficiency I-Disease 1 0.9999995231628418
are O 0 1.3884166037314571e-05
described O 0 8.693909330759197e-05
. O 0 8.270084799733013e-05

All O 0 1.7144795492640696e-05
these O 0 3.828601165878354e-06
new O 0 4.5091010179021396e-06
molecular O 0 7.241837010951713e-05
defects O 0 0.00019120820797979832
involve O 0 1.7004734900183394e-06
single O 0 1.6225411627601716e-06
- O 0 8.319092557940166e-06
nucleotide O 0 1.469092467232258e-06
events O 0 2.575964970219502e-07
, O 0 1.0833056762749038e-07
deletions O 0 5.122658421896631e-07
and O 0 9.332588746246984e-08
substitutions O 0 3.93251696095831e-07
, O 0 8.173680754453017e-08
some O 0 3.972206741309492e-08
of O 0 7.920571221120554e-08
which O 0 4.0975717752189666e-07
alter O 0 7.160907898651203e-06
splice O 0 1.5145647921599448e-05
sites O 0 2.013190851357649e-06
, O 0 6.859260111014009e-07
and O 0 1.6410989474024973e-06
others O 0 7.019672011665534e-06
codons O 0 7.664096483495086e-05
. O 0 3.4762142604449764e-05

They O 0 2.9054332117084414e-05
are O 0 1.6621264649074874e-06
distributed O 0 8.613897648501734e-07
along O 0 4.736522782877728e-07
the O 0 8.816539320832817e-07
C7 O 0 9.841477731242776e-05
gene O 0 1.9957303720730124e-06
, O 0 2.2220991979793325e-07
but O 0 2.2372987018570711e-07
predominantly O 0 4.884947202299372e-07
towards O 0 3.8792367718087917e-07
the O 0 1.1121926490886835e-06
3 O 0 4.0537006498198025e-06
end O 0 1.5359819371951744e-05
. O 0 3.149127951473929e-05

All O 0 1.731650991132483e-05
were O 0 5.411257461673813e-06
found O 0 4.606224138115067e-06
in O 0 2.5836509394139284e-06
compound O 0 4.387460649013519e-05
heterozygous O 0 0.00014517585805151612
individuals O 0 2.363834937568754e-05
. O 0 4.2785319237736985e-05

The O 0 0.0002593940880615264
C6 O 0 0.03999468684196472
/ O 0 0.0005354435998015106
C7 O 0 0.001198535319417715
marker O 0 5.459062958834693e-05
haplotypes O 0 7.370040839305148e-05
associated O 0 7.496974376408616e-06
with O 0 1.3967121503810631e-06
most O 0 8.81956748344237e-06
C7 B-Disease 1 0.9996501207351685
defects I-Disease 1 0.9652979373931885
are O 0 3.550982455635676e-06
tabulated O 0 7.820762402843684e-05
. O 0 1.2430069546098821e-05
. O 0 3.946087235817686e-05

A O 0 0.00013879155449103564
genome O 0 0.00012412802607286721
- O 0 7.052665750961751e-05
wide O 0 5.444265752885258e-06
search O 0 4.9618347475188784e-06
for O 0 1.0528270877330215e-06
chromosomal O 0 2.6585090381558985e-05
loci O 0 2.099474659189582e-05
linked O 0 8.699663885636255e-05
to O 0 1.210582377098035e-05
mental O 1 0.7994713187217712
health O 0 0.0019783517345786095
wellness O 0 5.2549039537552744e-05
in O 0 9.509686833553133e-07
relatives O 0 5.719405180570902e-06
at O 0 1.5986953485480626e-06
high O 0 1.6839796444401145e-05
risk O 0 6.98360672686249e-05
for O 0 2.7531121304491535e-05
bipolar B-Disease 1 0.9999994039535522
affective I-Disease 1 0.9999850988388062
disorder I-Disease 1 0.9018355011940002
among O 0 1.3891590242565144e-06
the O 0 1.0998843436027528e-06
Old O 0 1.93501928151818e-05
Order O 0 1.4051724065211602e-05
Amish O 0 0.00016678139218129218
. O 0 4.642106796381995e-05

Bipolar B-Disease 1 0.9999995231628418
affective I-Disease 1 0.9999953508377075
disorder I-Disease 1 0.9999351501464844
( O 0 0.000313998491037637
BPAD B-Disease 1 0.9999948740005493
; O 0 0.1061827689409256
manic B-Disease 1 0.9999967813491821
- I-Disease 1 0.9999982118606567
depressive I-Disease 1 0.9999986886978149
illness I-Disease 1 0.9941535592079163
) O 0 1.7288289200223517e-06
is O 0 2.414588209376234e-07
characterized O 0 1.2566894156407216e-06
by O 0 2.766597333447862e-07
episodes O 0 1.2935006452607922e-06
of O 0 3.3838338708847004e-07
mania B-Disease 0 0.003257508622482419
and O 0 3.907323844032362e-06
/ O 0 3.535018186084926e-05
or O 0 1.8839706399376155e-06
hypomania B-Disease 0 0.0017002327367663383
interspersed O 0 6.77674324833788e-06
with O 0 9.924222013069084e-07
periods O 0 1.89565762411803e-05
of O 0 1.0235060472041368e-05
depression B-Disease 0 0.12510913610458374
. O 0 8.044299465836957e-05

Compelling O 0 0.0005775655154138803
evidence O 0 4.2179421143373474e-05
supports O 0 2.034313183685299e-05
a O 0 2.7226246857026126e-06
significant O 0 3.2477134936925722e-06
genetic O 0 5.167740255274111e-06
component O 0 2.872682216548128e-06
in O 0 5.735096806347428e-07
the O 0 1.4114843907009345e-06
susceptibility O 0 5.6257609685417265e-05
to O 0 8.939891813497525e-06
develop O 0 8.822472591418773e-05
BPAD B-Disease 1 0.999713122844696
. O 0 8.4110171883367e-05

To O 0 1.8411383280181326e-05
date O 0 6.043359917384805e-06
, O 0 6.668936975984252e-07
however O 0 4.093275549621467e-07
, O 0 2.5584697027625225e-07
linkage O 0 3.2111995551531436e-06
studies O 0 1.2454765965230763e-06
have O 0 1.6164067062618415e-07
attempted O 0 8.615195383754326e-07
only O 0 1.020517146343991e-07
to O 0 2.420019598048384e-07
identify O 0 2.2683527731715003e-06
chromosomal O 0 8.108098882075865e-06
loci O 0 3.6324818211141974e-06
that O 0 2.9220035457910853e-07
cause O 0 1.8946589079860132e-06
or O 0 5.229809403317631e-07
increase O 0 7.486283379876113e-07
the O 0 1.4635199931944953e-06
risk O 0 1.0231225132883992e-05
of O 0 2.9504183203243883e-06
developing O 0 0.0001905484386952594
BPAD B-Disease 1 0.999932050704956
. O 0 0.00010160823148908094

To O 0 1.677420732448809e-05
determine O 0 6.820020189479692e-06
whether O 0 8.311125725413149e-07
there O 0 2.49307049671188e-07
could O 0 3.7993325463503425e-07
be O 0 1.5734971725578362e-07
protective O 0 2.645722588567878e-06
alleles O 0 2.205093778684386e-06
that O 0 1.7222617998413625e-07
prevent O 0 9.844736723607639e-07
or O 0 4.0277978996527963e-07
reduce O 0 7.532849508606887e-07
the O 0 3.5877346249435504e-07
risk O 0 1.2647977882807027e-06
of O 0 1.2632315815608308e-07
developing O 0 6.327529263217002e-06
BPAD B-Disease 1 0.9999339580535889
, O 0 3.6468722441895807e-07
similar O 0 1.881843161299912e-07
to O 0 9.164220671209478e-08
what O 0 9.955639512782e-08
is O 0 5.8755254883635644e-08
observed O 0 2.322441332580638e-07
in O 0 1.339580677495178e-07
other O 0 2.544585413488676e-06
genetic B-Disease 1 0.9999759197235107
disorders I-Disease 1 0.9999915361404419
, O 0 1.2710783039437956e-06
we O 0 1.1253339380346006e-06
used O 0 5.368183337850496e-05
mental O 1 0.9892510175704956
health O 0 0.09609919041395187
wellness O 0 0.00013932645379099995
( O 0 4.1399778183404123e-07
absence O 0 5.074157911622024e-07
of O 0 1.7330238222257321e-07
any O 0 9.704099284135737e-06
psychiatric B-Disease 1 0.9997988343238831
disorder I-Disease 0 0.19834958016872406
) O 0 2.7360351850802545e-07
as O 0 1.3751090932601073e-07
the O 0 2.9072106144667487e-07
phenotype O 0 7.64378419262357e-05
in O 0 3.937391852559813e-07
our O 0 8.03093485046702e-07
genome O 0 2.605097279229085e-06
- O 0 4.17901264881948e-06
wide O 0 1.2044710047121043e-06
linkage O 0 7.0162386691663414e-06
scan O 0 1.2352902558632195e-05
of O 0 2.3453085873370583e-07
several O 0 4.0599459794066206e-07
large O 0 9.576050388204749e-07
multigeneration O 0 5.735137892770581e-05
Old O 0 6.243883490242297e-06
Order O 0 1.2941792419951526e-06
Amish O 0 1.2034102837787941e-05
pedigrees O 0 2.0811190552194603e-05
exhibiting O 0 2.58055320045969e-06
an O 0 7.854360433157126e-07
extremely O 0 7.278101747942856e-06
high O 0 1.5230758435791358e-05
incidence O 0 0.00021207777899689972
of O 0 1.8116685168934055e-05
BPAD B-Disease 1 0.9999653100967407
. O 0 0.0002544306335039437

We O 0 5.736494858865626e-05
have O 0 4.677276137954323e-06
found O 0 1.681377284512564e-06
strong O 0 9.924865480570588e-07
evidence O 0 9.118170964939054e-07
for O 0 3.7100187455507694e-07
a O 0 8.491277299071953e-07
locus O 0 2.2923921278561465e-05
on O 0 1.0347149554945645e-06
chromosome O 0 1.2303922630962916e-05
4p O 0 0.03801552578806877
at O 0 1.215453721670201e-06
D4S2949 O 0 1.0268555342918262e-05
( O 0 4.7371236178150866e-07
maximum O 0 8.519081688973529e-07
GENEHUNTER O 0 7.067646220093593e-05
- O 0 8.828824320517015e-06
PLUS O 0 2.0783525087608723e-06
nonparametric O 0 7.216313861135859e-06
linkage O 0 4.099583293282194e-06
score O 0 1.5334366025854251e-06
= O 0 2.6539203190623084e-06
4 O 0 3.047921666166076e-07
. O 0 2.2820501044407138e-07
05 O 0 2.081273851217702e-05
, O 0 5.571096153289545e-07
P O 0 5.0122067477786914e-05
= O 0 3.1930903787724674e-06
5 O 0 2.7554540338314837e-07
. O 0 1.468180386154927e-07
22 O 0 3.074300138905528e-07
x O 0 1.7138937664640252e-06
10 O 0 3.0275120366241026e-07
( O 0 1.952538468685816e-07
- O 0 2.2710717075824505e-06
4 O 0 4.005087532732432e-07
) O 0 2.032269605933834e-07
; O 0 3.934257790660922e-07
SIBPAL O 0 1.0865730473597068e-05
Pempirical O 0 6.826619028288405e-06
value O 0 4.0629242903378326e-07
< O 0 1.8082016595144523e-06
3 O 0 2.4508918272658775e-07
x O 0 9.020797619996301e-07
10 O 0 3.0833848541078623e-07
( O 0 1.977771404426676e-07
- O 0 2.104456370943808e-06
5 O 0 2.298474868211997e-07
) O 0 1.0217090817832286e-07
) O 0 6.800171803433841e-08
and O 0 8.48708552325661e-08
suggestive O 0 1.0815678024300723e-06
evidence O 0 3.179241900852503e-07
for O 0 1.3392356379426928e-07
a O 0 4.7667799663031474e-07
locus O 0 1.3413896340352949e-05
on O 0 1.6589464166827383e-06
chromosome O 0 2.54715505434433e-05
4q O 1 0.9793703556060791
at O 0 1.8261519016959937e-06
D4S397 O 0 2.2002574041835032e-05
( O 0 8.458398497168673e-07
maximum O 0 9.846370403465698e-07
GENEHUNTER O 0 4.4797292503062636e-05
- O 0 8.926286682253703e-06
PLUS O 0 1.6721680822229246e-06
nonparametric O 0 7.016472864052048e-06
linkage O 0 3.978883341915207e-06
score O 0 2.1367000044847373e-06
= O 0 3.3118224109784933e-06
3 O 0 3.0972125841799425e-07
. O 0 1.6327582841313415e-07
29 O 0 5.173940280656097e-07
, O 0 3.5186405966669554e-07
P O 0 5.421098830993287e-05
= O 0 2.059093731077155e-06
2 O 0 1.521697754469642e-07
. O 0 1.236359992162761e-07
57 O 0 7.304841460609168e-07
x O 0 2.7421160666563082e-06
10 O 0 4.2485908124945126e-07
( O 0 2.592877592633158e-07
- O 0 2.5033916699612746e-06
3 O 0 4.531585489075951e-07
) O 0 2.0128403832586628e-07
; O 0 2.661607823029044e-07
SIBPAL O 0 7.706053111178335e-06
Pempirical O 0 4.299264219298493e-06
value O 0 3.0616604362876387e-07
< O 0 1.3990197658131365e-06
1 O 0 2.3761111833664472e-07
x O 0 1.3136673260305542e-06
10 O 0 2.9999381467860076e-07
( O 0 2.1220654389253468e-07
- O 0 2.1782359453936806e-06
3 O 0 2.574378470399097e-07
) O 0 9.102534903604464e-08
) O 0 7.330139339956077e-08
that O 0 5.965501514992866e-08
are O 0 1.7573194099895773e-07
linked O 0 9.625633538234979e-06
to O 0 1.1295667718513869e-05
mental O 1 0.5334534645080566
health O 0 0.0010579308727756143
wellness O 0 0.0008752820431254804
. O 0 8.912612975109369e-05

These O 0 3.484352782834321e-05
findings O 0 2.7009811674361117e-05
are O 0 1.059816327142471e-06
consistent O 0 1.3726527186008752e-06
with O 0 1.850898456723371e-07
the O 0 3.380063446911663e-07
hypothesis O 0 3.435205144342035e-06
that O 0 1.0043277143267915e-07
certain O 0 1.839393775071585e-07
alleles O 0 1.613118797649804e-06
could O 0 4.78862318686879e-07
prevent O 0 6.201436804076366e-07
or O 0 2.42788871673838e-07
modify O 0 2.4226137611549348e-06
the O 0 4.407373808135162e-07
clinical O 0 6.078787464502966e-06
manifestations O 0 2.0408535874594236e-06
of O 0 4.504887556322501e-07
BPAD B-Disease 1 0.9998733997344971
and O 0 1.8251298570248764e-06
perhaps O 0 4.175487447355408e-06
other O 0 2.540572268117103e-06
related O 0 0.0029292681720107794
affective B-Disease 1 0.9997308850288391
disorders I-Disease 1 0.9987840056419373
. O 0 9.848125046119094e-05

Segregation O 0 0.008265799842774868
distortion O 0 0.00973489973694086
in O 0 0.002168351085856557
myotonic B-Disease 1 0.9999854564666748
dystrophy I-Disease 1 0.9999985694885254
. O 0 0.0027470653876662254

Myotonic B-Disease 1 0.9999991655349731
dystrophy I-Disease 1 1.0
( O 1 0.9851313233375549
DM B-Disease 1 1.0
) O 0 3.79571647499688e-05
is O 0 1.4706230331285042e-06
an O 0 1.3411814734354266e-06
autosomal B-Disease 0 0.21886764466762543
dominant I-Disease 1 0.8791753649711609
disease I-Disease 0 0.05349164456129074
which O 0 4.838166773879493e-07
, O 0 1.9025773667635804e-07
in O 0 1.3521216146727966e-07
the O 0 3.564897212982032e-07
typical O 0 7.823015948815737e-06
pedigree O 0 0.0016930904239416122
, O 0 4.3406620875430235e-07
shows O 0 5.031972705182852e-07
a O 0 6.284807909651136e-07
three O 0 1.9917526969948085e-06
generation O 0 4.1438561311224476e-05
anticipation O 0 0.0001062857627402991
cascade O 0 0.00038033819873817265
. O 0 7.32349362806417e-05

This O 0 8.553747466066852e-05
results O 0 0.00024238669720944017
in O 0 3.416485560592264e-05
infertility B-Disease 1 0.9957820177078247
and O 0 0.20666389167308807
congenital B-Disease 1 0.9999998807907104
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.0007112202001735568
CDM B-Disease 0 0.01285423245280981
) O 0 8.453689588350244e-07
with O 0 2.0055648519701208e-07
the O 0 4.022776920464821e-07
disappearance O 0 5.767188213212648e-06
of O 0 1.7219068695339956e-06
DM B-Disease 1 0.9999961853027344
in O 0 5.242221050139051e-06
that O 0 6.094373020459898e-06
pedigree O 0 0.0013049882836639881
. O 0 7.132719474611804e-05

The O 0 2.417210089333821e-05
concept O 0 1.2661056643992197e-05
of O 0 1.2040046613037703e-06
segregation O 0 1.029139821184799e-05
distortion O 0 9.077132745005656e-06
, O 0 6.234014335859683e-07
where O 0 2.807148860028974e-07
there O 0 1.503797335544732e-07
is O 0 1.0999183785997957e-07
preferential O 0 9.17724094051664e-07
transmission O 0 1.026475615617528e-06
of O 0 6.108553662897975e-08
the O 0 1.9228906467105844e-07
larger O 0 6.781067440897459e-07
allele O 0 3.2614946121611865e-06
at O 0 3.583877230539656e-07
the O 0 4.522501910741994e-07
DM B-Disease 1 0.9999639987945557
locus O 0 4.5284104999154806e-05
, O 0 3.797390775162057e-07
has O 0 1.6320079510023788e-07
been O 0 1.2915761260501313e-07
put O 0 2.3531454473868507e-07
forward O 0 2.492331248049595e-07
to O 0 1.860071563442034e-07
explain O 0 8.23374932679144e-07
partially O 0 7.869866180953977e-07
the O 0 2.7378777645026275e-07
maintenance O 0 2.0720101474580588e-06
of O 0 7.644901529602066e-07
DM B-Disease 1 0.99998939037323
in O 0 1.6320154827553779e-06
the O 0 3.0779308417550055e-06
population O 0 9.116796718444675e-06
. O 0 2.0340590708656237e-05

In O 0 4.8884812713367864e-05
a O 0 1.5114163943508174e-05
survey O 0 1.3428141755866818e-05
of O 0 1.4269190842242097e-06
DM B-Disease 1 0.9999362230300903
in O 0 1.4692451486553182e-06
Northern O 0 2.077876843031845e-06
Ireland O 0 3.864451628032839e-06
, O 0 1.7799761735659558e-06
59 O 0 7.347604878304992e-06
pedigrees O 0 7.426027150359005e-05
were O 0 1.2170463378424756e-05
ascertained O 0 0.00021388038294389844
. O 0 4.860395711148158e-05

Sibships O 0 0.0017112013883888721
where O 0 1.4080443179409485e-05
the O 0 1.602849238224735e-06
status O 0 6.652675210716552e-07
of O 0 9.999619976497343e-08
all O 0 6.98176521041205e-08
the O 0 1.6392863244618638e-07
members O 0 2.4935224018918234e-07
had O 0 5.97205939811829e-07
been O 0 2.690884741696209e-07
identified O 0 4.847838113164471e-07
were O 0 2.315951945774941e-07
examined O 0 8.598246381552599e-07
to O 0 1.26527893939965e-07
determine O 0 3.465347901965288e-07
the O 0 1.7117835682256555e-07
transmission O 0 8.170662795237149e-07
of O 0 1.1783173192725371e-07
the O 0 9.61358409767854e-07
DM B-Disease 1 0.9998602867126465
expansion O 0 1.9372489532543113e-06
from O 0 5.616686848952668e-07
affected O 0 2.4797516289254418e-06
parents O 0 2.616595565996249e-06
to O 0 1.088178009922558e-06
their O 0 5.765851256001042e-06
offspring O 0 0.00013752920494880527
. O 0 2.9503835321520455e-05

Where O 0 6.295171624515206e-05
the O 0 9.897766176436562e-06
transmitting O 0 9.724550909595564e-05
parent O 0 9.185302042169496e-05
was O 0 6.122381364548346e-06
male O 0 1.1886168977071065e-05
, O 0 5.383400093705859e-06
58 O 0 5.417977081378922e-05
. O 0 4.6528501115972176e-05

3 O 0 7.190434553194791e-05
% O 0 4.954194082529284e-06
of O 0 3.5019590427509684e-07
the O 0 6.056284860278538e-07
offspring O 0 3.170762283843942e-06
were O 0 3.484482533622213e-07
affected O 0 6.770275717826735e-07
, O 0 1.5649803231099213e-07
and O 0 9.240201848115248e-08
in O 0 1.0260875882295295e-07
the O 0 2.3066061771714885e-07
case O 0 5.277683499116392e-07
of O 0 1.5707743727944035e-07
a O 0 1.2511527529568411e-06
female O 0 8.614672879048157e-06
transmitting O 0 0.0003248719731345773
parent O 0 0.00010992047464242205
, O 0 4.505215201788815e-06
68 O 0 3.8967693399172276e-05
. O 0 3.219340942450799e-05

7 O 0 0.0008252453990280628
% O 0 0.00010817573638632894
were O 0 2.7425256121205166e-05
affected O 0 0.00010912175639532506
. O 0 7.189803727669641e-05

Studies O 0 0.0001652504870435223
on O 0 8.911825716495514e-06
meiotic O 0 0.00015389513282570988
drive O 0 2.9425136744976044e-05
in O 0 8.382580745092127e-06
DM B-Disease 1 0.9999922513961792
have O 0 1.564097146911081e-06
shown O 0 7.537145734204387e-07
increased O 0 6.915009294061747e-07
transmission O 0 1.0548119462328032e-06
of O 0 7.922702138785098e-08
the O 0 1.9777863258241268e-07
larger O 0 8.382176019949839e-07
allele O 0 4.457333943719277e-06
at O 0 7.20986349733721e-07
the O 0 1.5157738744164817e-06
DM B-Disease 1 0.9999760389328003
locus O 0 7.521197403548285e-05
in O 0 1.9746551060961792e-06
non O 0 1.3245604350231588e-05
- O 0 0.1892235279083252
DM O 1 0.9998664855957031
heterozygotes O 0 0.00012744100240524858
for O 0 9.570987458573654e-06
CTGn O 0 0.00045889956527389586
. O 0 4.7451216232730076e-05

This O 0 1.6929323464864865e-05
study O 0 1.2187502761662472e-05
provides O 0 1.321231025031011e-06
further O 0 4.930637373945501e-07
evidence O 0 6.234341753952322e-07
that O 0 2.5017541815941513e-07
the O 0 1.5289405155272107e-06
DM B-Disease 1 0.999909520149231
expansion O 0 5.494543529493967e-06
tends O 0 4.3389754864620045e-06
to O 0 8.539075224689441e-07
be O 0 1.0594706054689595e-06
transmitted O 0 1.2262758900760673e-05
preferentially O 0 5.166403570910916e-05
. O 0 3.7152462027734146e-05

Diagnosis O 1 0.9984958171844482
of O 0 0.001105746254324913
hemochromatosis B-Disease 1 0.9999818801879883
. O 0 0.0019871217664331198

If O 0 0.000410375272622332
untreated O 0 0.12699764966964722
, O 0 3.765446672332473e-05
hemochromatosis B-Disease 1 0.9999951124191284
can O 0 1.859656367741991e-05
cause O 0 0.00017764230142347515
serious O 0 0.0007008357206359506
illness O 0 0.020577410236001015
and O 0 8.755782232583442e-07
early B-Disease 0 6.45338013782748e-06
death I-Disease 0 3.11320363834966e-05
, O 0 1.0368684115746873e-06
but O 0 9.040304007612576e-07
the O 0 5.0996736717934255e-06
disease O 0 0.0005011977045796812
is O 0 5.115154522172816e-07
still O 0 2.6882223664870253e-06
substantially O 0 1.6542682715225965e-05
under O 0 2.6542886189417914e-05
- O 1 0.9975426197052002
diagnosed O 1 0.9757131338119507
. O 0 6.337909144349396e-05

The O 0 2.8651840693783015e-05
cornerstone O 0 4.19931166106835e-05
of O 0 1.6608967143838527e-06
screening O 0 6.03332819082425e-06
and O 0 7.159598567341163e-07
case O 0 1.8278541347171995e-06
detection O 0 2.8273957468627486e-06
is O 0 2.0227930974670016e-07
the O 0 2.9739769047409936e-07
measurement O 0 2.44648322222929e-06
of O 0 7.569864237666479e-07
serum O 0 3.471238960628398e-05
transferrin O 0 2.7794132620329037e-05
saturation O 0 1.110066023102263e-05
and O 0 1.1671417041725363e-06
the O 0 3.6248131891625235e-06
serum O 0 0.00014273014676291496
ferritin O 0 0.0006178171606734395
level O 0 3.888476931024343e-05
. O 0 3.6740064388141036e-05

Once O 0 0.0002473898930475116
the O 0 1.8572529370430857e-05
diagnosis O 0 0.17299124598503113
is O 0 1.877184331533499e-06
suspected O 0 1.5692510714870878e-05
, O 0 1.0643519772202126e-06
physicians O 0 3.8970083551248536e-06
must O 0 7.437204203597503e-07
use O 0 1.3055380350124324e-06
serum O 0 2.8278322133701295e-05
ferritin O 0 0.00022715464001521468
levels O 0 4.787249054061249e-06
and O 0 1.0590715646685567e-06
hepatic O 0 0.0013129876460880041
iron O 0 2.9123546482878737e-05
stores O 0 3.4083748232660582e-06
on O 0 1.5648818134650355e-06
liver O 0 0.0422869548201561
biopsy O 0 0.27405232191085815
specimens O 0 4.280996563466033e-06
to O 0 1.264340653506224e-06
assess O 0 0.00010464351362315938
patients O 0 9.643486919230781e-06
for O 0 2.016633118273603e-07
the O 0 6.491715680567722e-07
presence O 0 1.3891800563214929e-06
of O 0 1.90707669389667e-06
iron B-Disease 0 0.03509122133255005
overload I-Disease 0 0.01038074865937233
. O 0 5.0481838115956634e-05

Liver O 1 0.9999092817306519
biopsy O 1 0.9988141059875488
is O 0 7.627673767274246e-06
also O 0 1.2572874084071373e-06
used O 0 5.324903327164066e-07
to O 0 1.949805010781347e-07
establish O 0 3.796858436544426e-07
the O 0 1.5659090024655598e-07
presence O 0 2.684446087641845e-07
or O 0 1.6717777384656074e-07
absence O 0 7.063611633384426e-07
of O 0 4.5280862082108797e-07
cirrhosis B-Disease 1 0.5941112041473389
, O 0 6.647817372140707e-07
which O 0 5.025263476454711e-07
can O 0 1.5166718867476447e-06
affect O 0 1.7586582544026896e-05
prognosis O 1 0.9904787540435791
and O 0 1.620355214981828e-05
management O 0 0.0002775921020656824
. O 0 5.979324851068668e-05

A O 0 0.00010496771574253216
DNA O 0 0.00012076543498551473
- O 0 0.0001382051850669086
based O 0 2.4777918952167965e-06
test O 0 2.106022520820261e-06
for O 0 2.636700173752615e-07
the O 0 4.829141175832774e-07
HFE O 0 0.0006784964934922755
gene O 0 1.848458396125352e-06
is O 0 1.640299700511605e-07
commercially O 0 5.99230702391651e-07
available O 0 2.5851693408185383e-07
, O 0 8.530514605809003e-08
but O 0 5.889989296292697e-08
its O 0 8.42172909187866e-08
place O 0 1.6374549716147158e-07
in O 0 1.5456993196494295e-07
the O 0 9.54370193539944e-07
diagnosis O 1 0.5007928609848022
of O 0 2.2671786155115115e-06
hemochromatosis B-Disease 1 0.999998927116394
is O 0 3.385787749721203e-06
still O 0 5.6814378694980405e-06
being O 0 5.691296792065259e-06
evaluated O 0 6.566790398210287e-05
. O 0 2.8630372980842367e-05

Currently O 0 4.635152799892239e-05
, O 0 2.8380177354847547e-06
the O 0 3.8206795238693303e-07
most O 0 2.0810011847061105e-07
useful O 0 2.964436873753584e-07
role O 0 2.8815838959417306e-07
for O 0 1.445922919174336e-07
this O 0 1.8757602049390698e-07
test O 0 6.991912755438534e-07
is O 0 6.414212805339048e-08
in O 0 6.209426572922894e-08
the O 0 1.286475708184298e-07
detection O 0 1.4775268937228248e-06
of O 0 4.34858407061256e-07
hemochromatosis B-Disease 1 0.9999942779541016
in O 0 9.15636462650582e-07
the O 0 6.889193286951922e-07
family O 0 2.522742306609871e-06
members O 0 2.7599986651694053e-07
of O 0 4.043211561111093e-07
patients O 0 4.479870040086098e-05
with O 0 2.609321541058307e-07
a O 0 1.7318718619208084e-06
proven O 0 1.6965916074695997e-05
case O 0 1.5742762116133235e-06
of O 0 6.357720963023894e-07
the O 0 3.254428884247318e-05
disease O 0 0.07595859467983246
. O 0 8.333178993780166e-05

It O 0 1.7432295862818137e-05
is O 0 4.257495675119571e-06
crucial O 0 1.585511017765384e-05
to O 0 8.214728040911723e-06
diagnose O 1 0.9983229041099548
hemochromatosis B-Disease 1 0.9999954700469971
before O 0 0.0038165219593793154
hepatic B-Disease 1 0.9999450445175171
cirrhosis I-Disease 1 0.9999470710754395
develops O 0 0.0007489131530746818
because O 0 1.8273265595780686e-05
phlebotomy O 0 0.049884676933288574
therapy O 0 0.0004737106501124799
can O 0 7.338514933508122e-06
avert O 0 0.1434125155210495
serious O 1 0.9558183550834656
chronic O 1 0.9999991655349731
disease O 0 0.22490139305591583
and O 0 1.3084884358249838e-06
can O 0 5.024827487432049e-07
even O 0 5.773796942776244e-07
lead O 0 1.075666432370781e-06
to O 0 8.220661698032927e-07
normal O 0 4.181456461083144e-06
life O 0 5.517257704923395e-06
expectancy O 0 3.1018858862807974e-05
. O 0 7.997497050382663e-06
. O 0 4.033068398712203e-05

Prevalence O 0 0.001936554443091154
of O 0 8.951741619966924e-06
the O 0 6.140009190858109e-06
I1307K O 0 0.0001350709208054468
APC B-Disease 0 4.818326124222949e-05
gene O 0 9.68927542999154e-06
variant O 0 1.088132648874307e-05
in O 0 6.66706739593792e-07
Israeli O 0 2.7318656066199765e-06
Jews O 0 1.3344870239961892e-06
of O 0 1.9397731421122444e-07
differing O 0 1.2207486861370853e-06
ethnic O 0 9.61279624789313e-07
origin O 0 2.031207031905069e-06
and O 0 7.3342325777048245e-06
risk O 0 0.00323959207162261
for O 0 0.23467373847961426
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
. O 0 0.00020618307462427765

BACKGROUND O 0 0.0007098645437508821
& O 0 0.00027317836065776646
AIMS O 0 2.507910357962828e-05
Israeli O 0 8.292699021694716e-06
Jews O 0 2.359651944061625e-06
of O 0 1.7975281707549584e-07
European O 0 8.204621053664596e-07
birth O 0 2.529463472455973e-06
, O 0 3.8246713529588305e-07
i O 0 6.889482619953924e-07
. O 0 1.6932223445564887e-07
e O 0 7.954300258461444e-07
. O 0 1.1817519407486543e-07
, O 0 1.8663688194919814e-07
Ashkenazim O 0 4.682359758589882e-06
, O 0 2.1986502929394192e-07
have O 0 3.0209048418328166e-07
the O 0 1.924326625157846e-06
highest O 1 0.9935941100120544
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
incidence O 0 0.0009564341744408011
of O 0 7.369418426605989e-07
any O 0 2.274355210829526e-06
Israeli O 0 6.900025618961081e-05
ethnic O 0 2.030843825195916e-05
group O 0 0.00012090589734725654
. O 0 6.276930798776448e-05

The O 0 0.00010161616955883801
I1307K O 0 0.0006878386484459043
APC B-Disease 0 0.0001834253198467195
gene O 0 3.2478747016284615e-05
variant O 0 4.442889985512011e-05
was O 0 6.121237220213516e-06
found O 0 3.2589450711384416e-06
in O 0 3.922511950804619e-06
6 O 0 2.1565620045294054e-05
. O 0 4.849538890994154e-05

1 O 0 7.644732249900699e-05
% O 0 4.198414899292402e-06
of O 0 4.877899186794821e-07
American O 0 6.843931146249815e-07
Jews O 0 1.1592367172852391e-06
, O 0 2.1326151511402713e-07
28 O 0 5.366753157431958e-07
% O 0 2.087218149426917e-07
of O 0 1.5110659035144636e-07
their O 0 0.00011748326505767182
familial O 1 0.9999998807907104
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 6.97121276971302e-06
, O 0 5.880503408661752e-07
but O 0 5.26572307535389e-07
not O 0 4.550016114990285e-07
in O 0 8.561719369026832e-07
non O 0 8.068042916420382e-06
- O 0 0.0001562839897815138
Jews O 0 3.502105028019287e-05
. O 0 4.5539742131950334e-05

We O 0 8.349341078428552e-05
assessed O 0 5.90856398048345e-05
the O 0 7.656935849809088e-06
I1307K O 0 0.00017804655362851918
prevalence O 0 3.252536043873988e-05
in O 0 1.344799557045917e-06
Israeli O 0 6.237658453756012e-06
Jews O 0 2.460935320414137e-06
of O 0 1.9024720643301407e-07
differing O 0 1.070867142516363e-06
ethnic O 0 9.369720146423788e-07
origin O 0 2.4869682420103345e-06
and O 0 5.741166205552872e-06
risk O 0 0.0070416927337646484
for O 0 0.46507155895233154
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
. O 0 0.00027186519582755864

METHODS O 0 0.0002754747401922941
DNA O 0 9.35206189751625e-05
samples O 0 1.586395774211269e-05
from O 0 1.2267029205759172e-06
500 O 0 1.4536866501657641e-06
unrelated O 0 1.5112718756427057e-06
Jews O 0 9.285019473281864e-07
of O 0 8.704058274133786e-08
European O 0 5.221457399784413e-07
or O 0 4.2730076188490784e-07
non O 0 4.959395596415561e-07
- O 0 3.333245331305079e-06
European O 0 2.859677294964058e-07
origin O 0 2.5333935127491714e-07
, O 0 5.837268091113401e-08
with O 0 3.3532952414816464e-08
or O 0 1.591717193605291e-07
without O 0 1.5324410185257875e-07
a O 0 2.2646126751624251e-07
personal O 0 1.7196241515193833e-06
and O 0 1.7598412114239181e-06
/ O 0 8.510772022418678e-05
or O 0 5.7043860124395e-07
family O 0 5.652754566654039e-07
history O 0 2.552240516706661e-07
of O 0 2.3465614162887505e-07
neoplasia B-Disease 0 0.04698631539940834
, O 0 5.707139507649117e-07
were O 0 3.438154010382277e-07
examined O 0 2.569071057223482e-06
for O 0 1.757637875243745e-07
the O 0 3.7107758998899953e-07
I1307K O 0 3.678020220831968e-05
variant O 0 4.974618150299648e-06
by O 0 4.197531495719886e-07
the O 0 5.950768127149786e-07
allele O 0 1.919605529110413e-05
- O 0 2.6597670512273908e-05
specific O 0 2.981014858960407e-06
oligonucleotide O 0 0.00016371332458220422
( O 0 6.424917501135496e-06
ASO O 0 0.001100689172744751
) O 0 6.268781362450682e-06
method O 0 3.005330108862836e-05
. O 0 4.0821290895109996e-05

RESULTS O 0 0.0007391991093754768
In O 0 8.191648703359533e-06
persons O 0 5.2986856644565705e-06
at O 0 2.245263885924942e-06
average O 0 1.2974446690350305e-05
risk O 0 0.0013499631313607097
for O 1 0.5704026818275452
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
, O 0 3.8161051634233445e-06
I1307K O 0 0.0003441491862758994
was O 0 4.675220225180965e-06
found O 0 2.164874331356259e-06
in O 0 3.019895984834875e-06
5 O 0 1.4019370610185433e-05
. O 0 3.2948220905382186e-05

0 O 0 0.00019488020916469395
% O 0 1.4907157492416445e-05
of O 0 1.1565005024749553e-06
120 O 0 3.7707363844674546e-06
European O 0 6.977357315918198e-06
and O 0 4.369837824924616e-06
1 O 0 1.8874683519243263e-05
. O 0 2.8779179046978243e-05

6 O 0 0.0001658501714700833
% O 0 8.911009899748024e-06
of O 0 1.3250631809569313e-06
188 O 0 6.315863174677361e-06
non O 0 3.556052206477034e-06
- O 0 1.0819963790709153e-05
European O 0 1.869758762040874e-06
Jews O 0 4.001577508461196e-06
( O 0 1.512757080490701e-06
P O 0 0.00015221827197819948
= O 0 1.122977482737042e-05
0 O 0 1.6970535625659977e-06
. O 0 1.0387725524196867e-06
08 O 0 1.6807580323074944e-05
) O 0 6.034088073647581e-06
. O 0 1.1873593393829651e-05

It O 0 7.830053073121235e-05
occurred O 0 6.938421574886888e-05
in O 0 1.6352829334209673e-05
15 O 0 4.244686715537682e-05
. O 0 6.339129322441295e-05

4 O 0 0.0001381704059895128
% O 0 1.6595999113633297e-05
of O 0 1.5107704030015157e-06
52 O 0 1.2295617125346325e-05
Ashkenazi O 0 0.0001680308923823759
Israelis O 0 0.00012249186693225056
with O 0 8.083330612862483e-06
familial O 1 0.9989905953407288
cancer B-Disease 1 0.9973233342170715
( O 0 4.103889750695089e-06
P O 0 0.030539439991116524
= O 0 1.797719050955493e-05
0 O 0 7.856817774154479e-07
. O 0 2.1956078910534416e-07
02 O 0 3.976675543526653e-06
) O 0 8.590503597361021e-08
and O 0 5.883016740426683e-08
was O 0 1.7150729547665833e-07
not O 0 1.1503335883844557e-07
detected O 0 4.5828690531379834e-07
in O 0 1.5053814195198356e-07
51 O 0 9.283426152251195e-07
non O 0 7.028415325294191e-07
- O 0 2.9707696285186103e-06
European O 0 9.080457061827474e-07
Jews O 0 1.7409946622137795e-06
at O 0 2.2592830646317452e-06
increased O 0 3.343729258631356e-05
cancer B-Disease 1 0.6948739886283875
risk O 0 0.00019377624266780913
. O 0 6.044112524250522e-05

Colorectal B-Disease 1 0.9995821118354797
neoplasia I-Disease 1 0.5407485961914062
occurred O 0 0.00017836871847976
personally O 0 6.379251135513186e-05
or O 0 2.6026536943390965e-06
in O 0 4.721937330032233e-07
the O 0 4.3525423620849324e-07
families O 0 5.33939100932912e-07
of O 0 8.934004824823205e-08
13 O 0 2.8704482701868983e-07
of O 0 1.2366218982151622e-07
20 O 0 5.752772835876385e-07
Ashkenazi O 0 1.3260758350952528e-05
I1307K O 0 1.6522912119398825e-05
carriers O 0 1.0592443686618935e-06
, O 0 1.3360516959437518e-07
8 O 0 1.2459548770493711e-07
of O 0 7.426948656075183e-08
whom O 0 1.944439873113879e-06
also O 0 4.2540114009170793e-07
had O 0 5.915015321988903e-07
a O 0 3.411258546748286e-07
personal O 0 5.7862930589180905e-06
or O 0 2.2189658466231776e-06
family O 0 6.249567377381027e-06
history O 0 3.933210336981574e-06
of O 0 4.964788331562886e-06
noncolonic O 1 0.7832912802696228
neoplasia B-Disease 1 0.9373794794082642
. O 0 6.21534782112576e-05

CONCLUSIONS O 0 0.0003954688727390021
The O 0 2.598610990389716e-05
I1307K O 0 0.0002832828904502094
APC O 0 0.0001544372644275427
variant O 0 0.00010888922406593338
may O 0 4.0871927922125906e-06
represent O 0 7.677048188270419e-07
a O 0 8.864207075021113e-07
susceptibility O 0 1.1588273991947062e-05
gene O 0 4.662903847929556e-06
for O 0 4.005960818176391e-06
colorectal B-Disease 1 0.9999985694885254
, I-Disease 0 8.668410487189249e-07
or I-Disease 0 3.1201383876577893e-07
other I-Disease 0 2.0702881897705083e-07
, I-Disease 0 3.000352535309503e-06
cancers I-Disease 0 0.011323443613946438
in O 0 6.540896606566093e-07
Ashkenazi O 0 0.00031614743056707084
Jews O 0 2.9078807983751176e-06
, O 0 4.5706306650572515e-07
and O 0 3.5680196219800564e-07
partially O 0 3.1679030598752433e-06
explains O 0 2.1724497401010012e-06
the O 0 4.722153335023904e-07
higher O 0 5.205648449191358e-06
incidence O 0 0.0017894478514790535
of O 0 0.05392294377088547
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
in O 0 1.7142048818641342e-05
European O 0 6.12637450103648e-05
Israelis O 0 0.0008479736861772835
. O 0 0.00011933041241718456

Systematic O 0 0.00027146321372129023
analysis O 0 4.611199619830586e-05
of O 0 4.9979862524196506e-06
coproporphyrinogen O 0 0.0006670563016086817
oxidase O 0 0.0004449097323231399
gene O 0 0.00010483088408363983
defects O 0 0.025369010865688324
in O 0 3.597091563278809e-06
hereditary B-Disease 0 0.04043067246675491
coproporphyria I-Disease 0 0.21726621687412262
and O 0 1.7365129679092206e-05
mutation O 0 0.00015581201296299696
update O 0 0.00027398226666264236
. O 0 3.9486920286435634e-05

Hereditary B-Disease 1 0.9968510270118713
coproporphyria I-Disease 1 0.974927544593811
( O 0 8.952954522101209e-05
HC B-Disease 0 0.10053946077823639
) O 0 5.55137421542895e-06
is O 0 8.000655498108245e-07
an O 0 3.243547325837426e-06
acute O 1 0.9952834248542786
hepatic B-Disease 1 0.9999921321868896
porphyria I-Disease 1 0.9999847412109375
with O 0 0.0015843705041334033
autosomal O 1 0.9852011799812317
dominant O 0 0.12915727496147156
inheritance O 0 0.13452284038066864
caused O 0 0.0009661773801781237
by O 0 7.538995760114631e-06
deficient B-Disease 0 0.1707707643508911
activity I-Disease 0 2.2212018393474864e-06
of I-Disease 0 1.030274006552645e-06
coproporphyrinogen I-Disease 0 0.1480339765548706
III I-Disease 0 0.12704044580459595
oxidase I-Disease 0 0.00044318847358226776
( O 0 1.0267693141940981e-05
CPO O 0 6.498341826954857e-05
) O 0 1.1799352250818629e-05
. O 0 2.2841781174065545e-05

Clinical O 0 0.011805601418018341
manifestations O 0 0.00015232249279506505
of O 0 7.253862804645905e-06
the O 0 0.00010314460087101907
disease O 0 0.1899663358926773
are O 0 9.01699593214289e-07
characterized O 0 1.437892387912143e-05
by O 0 7.80766367824981e-06
acute O 1 0.9028324484825134
attacks O 0 0.08274166285991669
of O 0 0.0001959650544449687
neurological B-Disease 1 0.999998927116394
dysfunction I-Disease 1 0.982437789440155
often O 0 6.5528988670848776e-06
precipitated O 0 5.214773409534246e-05
by O 0 8.439157568318478e-07
drugs O 0 2.8621732326428173e-06
, O 0 3.6854606833003345e-07
fasting O 0 1.0221891898254398e-05
, O 0 1.5302591691579437e-06
cyclical O 0 0.0012341970577836037
hormonal O 0 6.535367720061913e-05
changes O 0 3.0505782433465356e-06
, O 0 2.947993834823137e-06
or O 0 1.8180928236688487e-05
infectious B-Disease 0 0.0144658163189888
diseases I-Disease 0 0.012786919251084328
. O 0 6.15468670730479e-05

Skin O 1 0.9995669722557068
photosensitivity O 1 0.9976812601089478
may O 0 0.0003043421311303973
also O 0 8.149121640599333e-06
be O 0 4.9671093620418105e-06
present O 0 1.5947476640576497e-05
. O 0 6.460113945649937e-05

The O 0 3.0828145099803805e-05
seven O 0 8.016189894988202e-06
exons O 0 2.38167467614403e-05
, O 0 1.2519033134594793e-06
the O 0 6.437868478315067e-07
exon O 0 1.1711194019881077e-05
/ O 0 4.365397671790561e-06
intron O 0 7.493793418689165e-06
boundaries O 0 8.485189937346149e-07
and O 0 2.416007305328094e-07
part O 0 2.1763619884040963e-07
of O 0 1.419422943627069e-07
3 O 0 7.858818662498379e-07
noncoding O 0 4.99430780109833e-06
sequence O 0 5.243533109933196e-07
of O 0 1.0408217576696188e-07
the O 0 2.4622448790978524e-07
CPO O 0 6.41098631604109e-06
gene O 0 3.181988631695276e-06
were O 0 5.128924840391846e-07
systematically O 0 2.7188573312741937e-06
analyzed O 0 1.6476352584504639e-06
by O 0 1.9360545877589175e-07
an O 0 2.7698021654032345e-07
exon O 0 8.575982974434737e-06
- O 0 9.575041985954158e-06
by O 0 9.216893772645562e-07
- O 0 9.778511412150692e-06
exon O 0 2.6774998332257383e-05
denaturing O 0 0.00013968467828817666
gradient O 0 6.486417260020971e-05
gel O 0 0.0002835117338690907
electrophoresis O 0 0.00011984620505245402
( O 0 2.1194371129240608e-06
DGGE O 0 2.3265090931090526e-05
) O 0 3.612919385886926e-07
strategy O 0 7.662529242224991e-07
followed O 0 3.135880035642913e-07
by O 0 8.568412113163504e-08
direct O 0 2.896914850225585e-07
sequencing O 0 1.475638441661431e-06
in O 0 3.639259773535741e-07
seven O 0 1.604374119779095e-06
unrelated O 0 2.9084048946970142e-05
heterozygous O 0 3.8567755836993456e-05
HC B-Disease 0 0.06930992007255554
patients O 0 3.8523900002473965e-05
from O 0 5.551526101044146e-07
France O 0 2.6376560526841786e-06
, O 0 5.976349939373904e-07
Holland O 0 1.0394986929895822e-05
, O 0 6.826669505244354e-07
and O 0 1.300171675211459e-06
Czech O 0 1.3740534996031784e-05
Republic O 0 1.4936701518308837e-05
. O 0 2.1518533685593866e-05

Seven O 0 7.784623448969796e-05
novel O 0 6.319284875644371e-05
mutations O 0 3.468211070867255e-05
and O 0 1.2897708074888214e-06
two O 0 7.199901119747665e-07
new O 0 3.2440052564197686e-06
polymorphisms O 0 5.291840716381557e-05
were O 0 6.248124918784015e-06
detected O 0 3.511740214889869e-05
. O 0 2.8876993383164518e-05

Among O 0 0.00010040456254500896
these O 0 1.13034811874968e-05
mutations O 0 2.6595487724989653e-05
two O 0 1.4170358326737187e-06
are O 0 1.0843584732356248e-06
missense O 0 1.8915981854661368e-05
( O 0 1.0971563142447849e-06
G197W O 0 1.351919308945071e-05
, O 0 4.63483900148276e-07
W427R O 0 1.1261668987572193e-05
) O 0 2.509979992737499e-07
, O 0 8.747630886318802e-08
two O 0 1.0765372593368738e-07
are O 0 1.3233680817847926e-07
nonsense O 0 2.635101509440574e-06
( O 0 3.995942563506105e-07
Q306X O 0 5.259326371742645e-06
, O 0 3.6532455283122545e-07
Q385X O 0 7.53791800889303e-06
) O 0 1.8920934508059872e-07
, O 0 6.949122877131231e-08
two O 0 5.3564964019869876e-08
are O 0 9.035212400476667e-08
small O 0 3.5230959838372655e-07
deletions O 0 3.411568059163983e-06
( O 0 6.340652021208371e-07
662de14bp O 0 7.855657713662367e-06
; O 0 7.414917604364746e-07
1168del3bp O 0 6.413450591935543e-06
removing O 0 8.352969871339155e-07
a O 0 2.579938040980778e-07
glycine O 0 1.8477463754607015e-06
at O 0 3.904095251527906e-07
position O 0 4.950861125507799e-07
390 O 0 1.124537789110036e-06
) O 0 2.8924264938723354e-07
, O 0 7.921070022121057e-08
and O 0 8.131215167850314e-08
one O 0 1.2751928579746163e-07
is O 0 1.437071119880784e-07
a O 0 5.328616339284054e-07
splicing O 0 1.538113247079309e-05
mutation O 0 9.7095698947669e-06
( O 0 1.16597141186503e-06
IVS1 O 0 4.48383652837947e-05
- O 0 3.475146877462976e-05
15c O 0 9.609737026039511e-05
- O 0 0.00023121724370867014
- O 0 4.068472117069177e-05
> O 0 1.9585375412134454e-05
g O 0 1.1529188668646384e-05
) O 0 3.3452846537329606e-07
which O 0 1.938046096938706e-07
creates O 0 7.916279969322204e-07
a O 0 9.59250314735982e-07
new O 0 3.575139089662116e-06
acceptor O 0 3.520069003570825e-05
splice O 0 0.00037013241671957076
site O 0 6.419380224542692e-05
. O 0 4.56551460956689e-05

The O 0 5.235911157797091e-05
pathological O 0 8.056544902501628e-05
significance O 0 6.776698228350142e-06
of O 0 6.866997068755154e-07
the O 0 6.507906959996035e-07
point O 0 1.6764058727858355e-06
mutations O 0 6.013980964780785e-06
G197W O 0 1.1717963388946373e-05
, O 0 3.582462682061305e-07
W427R O 0 7.300890047190478e-06
, O 0 2.0449610360628867e-07
and O 0 1.0985031906329823e-07
the O 0 1.3403460741301387e-07
in O 0 2.406900421192404e-07
- O 0 1.0836320143425837e-05
frame O 0 7.93403341958765e-06
deletion O 0 7.797782927809749e-06
390delGly O 0 1.1802279004768934e-05
were O 0 4.779092819262587e-07
assessed O 0 6.798064191571029e-07
by O 0 1.1415612277687615e-07
their O 0 1.5910949002773123e-07
respective O 0 3.4607111842888116e-07
expression O 0 4.912689064440201e-07
in O 0 1.840548407017195e-07
a O 0 4.3932567450610804e-07
prokaryotic O 0 5.116226475365693e-06
system O 0 1.937644356075907e-06
using O 0 1.7651913140070974e-06
site O 0 7.524859938712325e-06
- O 0 2.9158059987821616e-05
directed O 0 2.4765307898633182e-05
mutagenesis O 0 0.000370868161553517
. O 0 5.548702392843552e-05

These O 0 7.27078877389431e-05
mutations O 0 0.0001420658954884857
resulted O 0 1.3836804100719746e-05
in O 0 1.373226155010343e-06
the O 0 9.287251714340528e-07
absence O 0 5.157543455425184e-06
or O 0 1.4304642945717205e-06
a O 0 1.377825356030371e-06
dramatic O 0 3.313093111501075e-05
decrease O 0 1.3094024325255305e-05
of O 0 1.9463084299786715e-06
CPO O 0 0.00014283375639934093
activity O 0 4.220110713504255e-05
. O 0 5.173206591280177e-05

The O 0 2.4326396669493988e-05
two O 0 6.327818937279517e-06
polymorphisms O 0 4.79112786706537e-05
were O 0 1.513680786047189e-06
localized O 0 4.977826392860152e-06
in O 0 8.925298971007578e-07
noncoding O 0 9.051994311448652e-06
part O 0 3.251210500820889e-07
of O 0 1.0843186259990034e-07
the O 0 2.5220347765753104e-07
gene O 0 1.3998766235090443e-06
1 O 0 5.633735327137401e-07
) O 0 3.125585408270126e-07
a O 0 7.248913789226208e-07
C O 0 0.0004982613609172404
/ O 0 1.5060296391311567e-05
G O 0 3.0089464416960254e-05
polymorphism O 0 1.0083764209412038e-05
in O 0 3.5851695656674565e-07
the O 0 6.40593611933582e-07
promotor O 0 2.8363559977151453e-05
region O 0 1.497379003012611e-06
, O 0 5.085823886474827e-07
142 O 0 1.7015717048707302e-06
bp O 0 8.865645213518292e-06
upstream O 0 1.2237513828949886e-06
from O 0 1.419891333398482e-07
the O 0 1.4880873777656234e-07
transcriptional O 0 1.8375719719188055e-06
initiation O 0 1.5010649576652213e-06
site O 0 1.3787139323540032e-06
( O 0 4.170109093593055e-07
- O 0 3.4960235097969417e-06
142C O 0 1.3624015082314145e-05
/ O 0 3.632377456597169e-06
G O 0 7.661559720872901e-06
) O 0 1.520496653029113e-07
, O 0 7.464198858997406e-08
and O 0 7.591235373638483e-08
2 O 0 2.5917552193277515e-07
) O 0 1.7138188468379667e-07
a O 0 2.2780383801546122e-07
6 O 0 9.390169566358963e-07
bp O 0 1.534383227408398e-05
deletion O 0 5.187327133171493e-06
polymorphism O 0 6.2708681980439e-06
in O 0 2.2335849791943474e-07
the O 0 1.9272269469183811e-07
3 O 0 3.6503132605503197e-07
noncoding O 0 3.046647407245473e-06
part O 0 2.2916745479051315e-07
of O 0 1.0993247201440681e-07
the O 0 3.132060442112561e-07
CPO O 0 4.528653335000854e-06
gene O 0 1.989808652069769e-06
, O 0 4.072595345405716e-07
574 O 0 2.217586597907939e-06
bp O 0 3.5324528653291054e-06
downstream O 0 4.7668027036706917e-07
of O 0 4.512412132839927e-08
the O 0 1.285983870502605e-07
last O 0 4.201388321689592e-07
base O 0 2.351727630411915e-07
of O 0 1.0907385217251431e-07
the O 0 4.799820203515992e-07
normal O 0 4.485387307795463e-06
termination O 0 3.056845162063837e-05
codon O 0 2.613348260638304e-05
( O 0 4.161831384408288e-06
+ O 0 1.8577364244265482e-05
574 O 0 6.330328324111179e-05
delATTCTT O 0 0.00015092099783942103
) O 0 1.6985310139716603e-05
. O 0 2.8061851480742916e-05

Five O 0 6.346848385874182e-05
intragenic O 0 0.00042286847019568086
dimorphisms O 0 0.00034000654704868793
are O 0 1.8742131260296446e-06
now O 0 1.0734979696280789e-06
well O 0 4.7650982537561504e-07
characterized O 0 1.6736357792979106e-06
and O 0 4.281018561869132e-07
the O 0 4.433802587300306e-07
high O 0 1.175241663986526e-06
degree O 0 1.6225149011006579e-06
of O 0 3.093755935879017e-07
allelic O 0 1.399578195560025e-05
heterogeneity O 0 2.2888531020726077e-05
in O 0 1.0954437357213465e-06
HC B-Disease 0 0.0036768317222595215
is O 0 5.778103968623327e-07
demonstrated O 0 1.235136096511269e-06
with O 0 1.491628012217916e-07
seven O 0 3.75952652120759e-07
new O 0 3.214356922853767e-07
different O 0 2.3560600936889387e-07
mutations O 0 1.5573292557746754e-06
making O 0 2.830228993389028e-07
a O 0 1.8504607623981428e-07
total O 0 1.2450070130398672e-07
of O 0 1.5516987161845464e-07
nineteen O 0 7.351698059210321e-06
CPO O 0 0.00035212794318795204
gene B-Disease 0 0.00010825035860762
defects I-Disease 0 0.2367936372756958
reported O 0 7.074404493323527e-06
so O 0 1.1233277064093272e-06
far O 0 5.741801487602061e-06
. O 0 8.329603588208556e-06
. O 0 2.723691977735143e-05

Coincidence O 0 0.00020676184794865549
of O 0 5.724255970562808e-06
two O 0 2.9218965664767893e-06
novel O 0 1.5770134268677793e-05
arylsulfatase O 0 0.00015181847265921533
A O 0 4.835592790186638e-06
alleles O 0 1.3308952475199476e-05
and O 0 1.7829798935053986e-06
mutation O 0 1.5696043192292564e-05
459 O 0 3.117680535069667e-05
+ O 0 2.689974098757375e-05
1G O 0 0.0006858390406705439
> O 0 1.7577867765794508e-05
A O 0 6.908839509378595e-07
within O 0 4.4693956624541897e-07
a O 0 1.008398612611927e-06
family O 0 8.147334483510349e-06
with O 0 8.22366291686194e-06
metachromatic B-Disease 1 0.999998927116394
leukodystrophy I-Disease 1 0.9999970197677612
: O 0 6.018370186211541e-06
molecular O 0 1.3158392903278582e-05
basis O 0 2.868422370738699e-06
of O 0 4.086140506842639e-06
phenotypic O 0 0.0001447302638553083
heterogeneity O 0 0.0007858901517465711
. O 0 9.129746467806399e-05

In O 0 4.79524205729831e-05
a O 0 1.0739080607891083e-05
family O 0 5.689679255738156e-06
with O 0 4.549074503756856e-07
three O 0 1.3554090401157737e-06
siblings O 0 0.0005174335092306137
, O 0 5.201046064939874e-07
one O 0 4.3259996118649724e-07
developed O 0 2.6548673304205295e-06
classical O 0 6.903952453285456e-06
late O 0 0.0005675163120031357
infantile O 1 0.9884776473045349
metachromatic B-Disease 1 0.9999988079071045
leukodystrophy I-Disease 1 0.9999980926513672
( O 0 3.2927331631071866e-05
MLD B-Disease 1 0.9990302324295044
) O 0 1.3295531289259088e-06
, O 0 3.963919823490869e-07
fatal O 0 1.6431553376605734e-05
at O 0 7.217954021143669e-07
age O 0 6.13426436757436e-07
5 O 0 3.851478993510682e-07
years O 0 5.205219508752634e-07
, O 0 2.079888190564816e-07
with O 0 7.725337809461053e-07
deficient O 1 0.801070511341095
arylsulfatase O 0 0.05618087202310562
A O 0 3.152782483084593e-06
( O 0 1.3145922821422573e-06
ARSA O 0 0.0005374187603592873
) O 0 4.987069814887946e-07
activity O 0 4.382164036087488e-07
and O 0 5.563933882513084e-07
increased O 0 2.3913155473564984e-06
galactosylsulfatide O 0 0.014475221745669842
( O 0 7.639058821951039e-06
GS O 1 0.9997995495796204
) O 0 8.964590961113572e-06
excretion O 0 8.223740587709472e-05
. O 0 3.345381628605537e-05

The O 0 2.0580710042850114e-05
two O 0 4.056411398778437e-06
other O 0 1.8500774103813455e-06
siblings O 0 2.4014303562580608e-05
, O 0 1.0501386213945807e-06
apparently O 0 5.755781785410363e-06
healthy O 0 2.448135546728736e-06
at O 0 4.611445376667689e-07
12 O 0 3.0811861506663263e-07
( O 0 1.8688481873141427e-07
1 O 0 3.0479156976070954e-07
/ O 0 9.240295639756368e-07
2 O 0 1.390766612985317e-07
) O 0 6.242391492605748e-08
and O 0 5.65963844678663e-08
15 O 0 1.1028888025066408e-07
years O 0 1.5579739454096853e-07
, O 0 6.976786437462579e-08
respectively O 0 2.4448223712170147e-07
, O 0 7.97939065932951e-08
and O 0 7.820414538173281e-08
their O 0 2.4916442953326623e-07
father O 0 6.016419320076238e-06
, O 0 4.6953172727626225e-07
apparently O 0 4.199443992547458e-06
healthy O 0 1.2552975476864958e-06
as O 0 1.2347010169833084e-07
well O 0 2.1869395538942626e-07
, O 0 3.0783135684941954e-07
presented O 0 1.7444484683437622e-06
ARSA O 0 0.0032908183056861162
and O 0 2.1525631836993853e-06
GS O 1 0.9924065470695496
values O 0 1.2582818271766882e-06
within O 0 3.530768424298003e-07
the O 0 5.72069666304742e-07
range O 0 2.4147273052221863e-06
of O 0 4.964097115589539e-06
MLD B-Disease 1 0.9999923706054688
patients O 0 0.09536845982074738
. O 0 9.82501296675764e-05

Mutation O 0 0.001147668925113976
screening O 0 0.00010244159784633666
and O 0 3.7635907119693e-06
sequence O 0 4.061555955559015e-06
analysis O 0 4.294203336030478e-06
disclosed O 0 5.994987077428959e-06
the O 0 4.1699419739416044e-07
involvement O 0 1.3694728977498016e-06
of O 0 1.731031744611755e-07
three O 0 5.016304953642248e-07
different O 0 1.0946666861855192e-06
ARSA O 1 0.7960406541824341
mutations O 0 1.0352841854910366e-05
being O 0 5.870820132258814e-07
the O 0 3.523593647969392e-07
molecular O 0 3.530522690198268e-06
basis O 0 1.3793530797556741e-06
of O 0 1.999142114073038e-06
intrafamilial O 0 0.0009143492789007723
phenotypic O 0 0.00024406518787145615
heterogeneity O 0 0.0008215158013626933
. O 0 0.0001317512069363147

The O 0 6.26360924798064e-05
late O 0 0.0003478699072729796
infantile O 1 0.9487197995185852
patient O 1 0.5898028016090393
inherited O 0 0.05537056922912598
from O 0 1.3742978808295447e-06
his O 0 2.341619392609573e-06
mother O 0 2.6667717975215055e-05
the O 0 6.805867656112241e-07
frequent O 0 4.044702563987812e-06
0 O 0 9.636453796701971e-06
- O 0 9.03787586139515e-05
type O 0 5.77040054849931e-06
mutation O 0 9.033572496264242e-06
459 O 0 9.807004062167834e-06
+ O 0 9.83050722425105e-06
1G O 0 6.350904004648328e-05
> O 0 7.891670065873768e-06
A O 0 3.8291639725684945e-07
, O 0 1.0303197228722638e-07
and O 0 8.84647448629039e-08
from O 0 6.960902254604662e-08
his O 0 4.7380862611134944e-07
father O 0 9.297015822085086e-06
a O 0 5.887506517865404e-07
novel O 0 5.811411483591655e-06
, O 0 3.549394307356124e-07
single O 0 9.528415603199392e-07
basepair O 0 1.4071448276808951e-05
microdeletion O 0 7.471500794054009e-06
of O 0 2.323859291664121e-07
guanine O 0 1.8791778302329476e-06
at O 0 2.9375831900324556e-07
nucleotide O 0 1.4641411780758062e-06
7 O 0 9.694678055893746e-07
in O 0 5.282134338813194e-07
exon O 0 1.1091960914200172e-05
1 O 0 2.8403137548593804e-06
( O 0 2.9594418720080284e-06
7delG O 0 5.9315574617357925e-05
) O 0 1.0954699973808601e-05
. O 0 2.1604546418529935e-05

The O 0 2.3391366994474083e-05
two O 0 6.709837180096656e-06
clinically O 0 0.0002909356262534857
unaffected O 0 9.67997548286803e-05
siblings O 0 4.032030119560659e-05
carried O 0 1.8233796481581521e-06
the O 0 8.506004292030411e-07
maternal O 0 1.9823117327177897e-05
mutation O 0 1.2822776625398546e-05
459 O 0 1.4999150153016672e-05
+ O 0 1.4608475794375408e-05
1G O 0 7.572279719170183e-05
> O 0 8.751619134272914e-06
A O 0 4.1079402990362723e-07
and O 0 1.5326295965678582e-07
, O 0 1.231284016967038e-07
on O 0 1.2461592291401757e-07
their O 0 2.803622578539944e-07
paternal O 0 2.6979230824508704e-05
allele O 0 8.11882273410447e-06
, O 0 2.8244048166925495e-07
a O 0 4.7659753477091726e-07
novel O 0 3.199076672899537e-06
cytosine O 0 5.65307436772855e-06
to O 0 7.994431712177175e-07
thymidine O 0 1.4439318874792662e-05
transition O 0 5.173746103537269e-06
at O 0 1.3915268937125802e-06
nucleotide O 0 6.709485660394421e-06
2435 O 0 3.43052415701095e-05
in O 0 5.68704194847669e-07
exon O 0 7.25546078683692e-06
8 O 0 9.653770121076377e-07
, O 0 3.399119350433466e-07
resulting O 0 5.651601213685353e-07
in O 0 1.9233070247537398e-07
substitution O 0 1.136645892074739e-06
of O 0 6.016454108248581e-07
alanine O 0 4.850028926739469e-05
464 O 0 2.1586238290183246e-05
by O 0 4.317033472034382e-06
valine O 0 0.02343771792948246
( O 0 7.730984179943334e-06
A464V O 0 0.00017224047041963786
) O 0 1.3326250154932495e-05
. O 0 2.543994560255669e-05

The O 0 0.00011807716509792954
fathers O 0 0.0003805021697189659
genotype O 0 0.0007004590588621795
thus O 0 3.222212762921117e-05
was O 0 3.326421574456617e-05
7delG O 0 0.0007578459335491061
/ O 0 0.0002509770856704563
A464V O 0 0.0008885166025720537
. O 0 0.00012368954776320606

Mutation O 0 0.0012990289833396673
A464V O 0 0.0005733395228162408
was O 0 1.8710839867708273e-05
not O 0 1.9921972125303e-06
found O 0 1.6759390746301506e-06
in O 0 1.6341584796464304e-06
18 O 0 7.00393138686195e-06
unrelated O 0 0.002429222920909524
MLD B-Disease 1 0.999996542930603
patients O 0 0.009465949609875679
and O 0 5.7512384046276566e-06
50 O 0 1.2770241482940037e-05
controls O 0 4.9160262278746814e-05
. O 0 4.9590809794608504e-05

A464V O 0 0.0019977658521384
, O 0 2.734132795012556e-05
although O 0 9.796142876439262e-06
clearly O 0 7.1649519668426365e-06
modifying O 0 2.4278511773445643e-05
ARSA O 0 0.0024451445788145065
and O 0 5.946331384620862e-06
GS O 1 0.9998751878738403
levels O 0 5.36355810254463e-06
, O 0 1.025249730446376e-06
apparently O 0 3.527329454300343e-06
bears O 0 2.0310133095335914e-06
little O 0 9.186584293274791e-07
significance O 0 1.3172527815186186e-06
for O 0 9.056095109372109e-07
clinical O 0 1.9650895410450175e-05
manifestation O 0 8.07411561254412e-06
of O 0 2.1388079858297715e-06
MLD B-Disease 1 0.999925971031189
, O 0 4.580200766213238e-06
mimicking O 0 3.756007208721712e-05
the O 0 6.441101049858844e-06
frequent O 0 8.00214329501614e-05
ARSA O 1 0.5468189716339111
pseudodeficiency O 0 0.013762925751507282
allele O 0 0.000870192889124155
. O 0 0.00014379389176610857

Our O 0 0.00010275800741510466
results O 0 4.253090082784183e-05
demonstrate O 0 6.837225555500481e-06
that O 0 5.313859219313599e-07
in O 0 4.832209015148692e-07
certain O 0 1.283498249904369e-06
genetic O 0 2.65174858213868e-05
conditions O 0 0.0005412175669334829
MLD B-Disease 1 0.9999403953552246
- O 0 0.0011187316849827766
like O 0 2.9678815280931303e-06
ARSA O 0 0.005374234635382891
and O 0 1.6294276292683207e-06
GS O 1 0.9992479681968689
values O 0 1.1978567044934607e-06
need O 0 5.746177293985966e-07
not O 0 1.8845911142761906e-07
be O 0 1.1824869261545246e-07
paralleled O 0 2.4061230305960635e-06
by O 0 4.197901944280602e-06
clinical O 1 0.9881435036659241
disease O 0 0.03982530161738396
, O 0 6.472577069871477e-07
a O 0 7.488182518500253e-07
finding O 0 3.237144255763269e-06
with O 0 1.4133405557004153e-06
serious O 0 0.00014724239008501172
diagnostic O 0 0.013652590103447437
and O 0 2.7775320631917566e-05
prognostic O 0 0.35789671540260315
implications O 0 0.0002965457388199866
. O 0 6.817927351221442e-05

Moreover O 0 0.0005141566507518291
, O 0 2.3693577531958e-05
further O 0 1.4240414202504326e-05
ARSA O 0 0.012260559014976025
alleles O 0 5.701916597899981e-05
functionally O 0 2.798141213133931e-05
similar O 0 1.7460178014516714e-06
to O 0 5.705484795726079e-07
A464V O 0 2.286688868480269e-05
might O 0 9.335416280009667e-07
exist O 0 2.511933985260839e-07
which O 0 6.476874858662995e-08
, O 0 6.118255413412044e-08
together O 0 8.139765839132451e-08
with O 0 1.339859210247596e-07
0 O 0 1.0641728295013309e-05
- O 0 0.007265363819897175
type O 0 1.463503940613009e-05
mutations O 0 5.504403361555887e-06
, O 0 3.7548181808233494e-07
may O 0 1.2440033287930419e-06
cause O 0 1.0991187764375354e-06
pathological O 0 8.945989975472912e-06
ARSA O 0 0.20639364421367645
and O 0 3.6212852592143463e-06
GS O 1 0.9999924898147583
levels O 0 1.1647355222521583e-06
, O 0 1.529513582454456e-07
but O 0 1.9855195887430455e-07
not O 0 3.6290080629441945e-07
clinical O 0 1.7855521946330555e-05
outbreak O 0 6.0372822190402076e-06
of O 0 6.145928637124598e-07
the O 0 3.5267417842987925e-05
disease O 0 0.02185116522014141
. O 0 1.3499005035555456e-05
. O 0 4.179490861133672e-05

Human O 0 0.006628713570535183
MLH1 O 1 0.9993730187416077
deficiency O 1 0.9978724718093872
predisposes O 0 0.0025047161616384983
to O 0 0.0001297053968301043
hematological B-Disease 1 0.9819221496582031
malignancy I-Disease 1 0.9923940896987915
and O 0 0.0001637226960156113
neurofibromatosis B-Disease 1 0.9962571859359741
type I-Disease 0 0.0002341228973818943
1 I-Disease 0 4.784995689988136e-05
. O 0 6.09987837378867e-05

Heterozygous O 0 0.0015557848382741213
germ O 0 0.007376913446933031
- O 0 0.0032042660750448704
line O 0 6.170730193844065e-05
mutations O 0 1.9790346414083615e-05
in O 0 9.257574902221677e-07
the O 0 1.734883880999405e-06
DNA O 0 3.4312473871978e-05
mismatch O 0 0.012795590795576572
repair O 0 0.01829582080245018
genes O 0 3.2799303880892694e-05
lead O 0 1.7114409274654463e-05
to O 0 1.669693119765725e-05
hereditary B-Disease 1 0.9969191551208496
nonpolyposis I-Disease 1 0.9999985694885254
colorectal I-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
. O 0 0.0003351257764734328

The O 0 0.0004441658384166658
disease O 0 0.1666000932455063
susceptibility O 0 5.702884300262667e-05
of O 0 1.0952745697068167e-06
individuals O 0 1.645477709644183e-06
who O 0 2.6999894089385634e-06
constitutionally O 0 4.538350822258508e-06
lack O 0 1.6211801039389684e-06
both O 0 5.914237135584699e-07
wild O 0 3.4271718050149502e-06
- O 0 0.001725155976600945
type O 0 9.042977580975275e-06
alleles O 0 1.5727900972706266e-05
is O 0 3.5934845072915778e-06
unknown O 0 1.778492696757894e-05
. O 0 3.367059980519116e-05

We O 0 3.60426347469911e-05
have O 0 5.468488780024927e-06
identified O 0 3.677782160593779e-06
three O 0 9.088583396987815e-07
offspring O 0 5.116811735206284e-06
in O 0 8.390197763219476e-07
a O 0 6.805375960539095e-06
hereditary B-Disease 1 0.9999198913574219
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 0.10388368368148804
who O 0 0.0005151237710379064
developed O 0 0.0014857023488730192
hematological B-Disease 1 0.9986326098442078
malignancy I-Disease 1 0.8386012315750122
at O 0 6.649751185250352e-07
a O 0 2.989841618727951e-07
very O 0 2.905131850639009e-07
early O 0 1.1244916322539211e-06
age O 0 4.3615344225145236e-07
, O 0 1.1603169269847058e-07
and O 0 1.0793663562935762e-07
at O 0 1.008845202932207e-07
least O 0 4.585282198377172e-08
two O 0 2.8642290317293373e-08
of O 0 3.994132313778209e-08
them O 0 1.1919046016828361e-07
displayed O 0 4.619068647571112e-07
signs O 0 9.86825511972711e-07
of O 0 6.859953600724111e-07
neurofibromatosis B-Disease 1 0.9723881483078003
type I-Disease 0 7.050293061183766e-05
1 I-Disease 0 7.096201443346217e-06
( O 0 6.006793228152674e-06
NF1 B-Disease 0 0.001576942508108914
) O 0 1.6770818547229283e-05
. O 0 4.3140611523995176e-05

DNA O 0 0.0004574338672682643
sequence O 0 3.340669718454592e-05
analysis O 0 1.5616315067745745e-05
and O 0 3.222608711439534e-06
allele O 0 1.7514614228275605e-05
- O 0 1.0103804925165605e-05
specific O 0 1.1250634770476609e-06
amplification O 0 7.543944320786977e-06
in O 0 5.320644049788825e-07
two O 0 7.276779001585965e-07
siblings O 0 0.00021655003365594894
revealed O 0 1.4472694601863623e-05
a O 0 3.584110345400404e-06
homozygous O 0 0.00034966488601639867
MLH1 O 0 0.05962255224585533
mutation O 0 4.6100256440695375e-05
( O 0 3.466614543867763e-06
C676T O 0 0.00010344621114199981
- O 0 0.0013379392912611365
- O 0 0.00028578782803379
> O 0 8.710048132343218e-05
Arg226Stop O 0 0.00020529073663055897
) O 0 1.3714037777390331e-05
. O 0 2.028847848123405e-05

Thus O 0 0.00013581031817011535
, O 0 1.190081184176961e-05
a O 0 5.3765970733365975e-06
homozygous O 0 5.450053868116811e-05
germ O 0 0.0011256509460508823
- O 0 0.0005320304771885276
line O 0 2.9332959456951357e-05
MLH1 O 0 0.0048772068694233894
mutation O 0 1.9778100977418944e-05
and O 0 3.016418986589997e-06
consequent O 0 0.13643044233322144
mismatch O 1 0.9999643564224243
repair O 1 0.9999991655349731
deficiency O 1 0.9999334812164307
results O 0 0.0004373642150312662
in O 0 1.4230460010367096e-06
a O 0 7.447258212778252e-06
mutator O 1 0.9987339377403259
phenotype O 1 0.920216977596283
characterized O 0 0.00024648982798680663
by O 0 4.379797610454261e-05
leukemia B-Disease 1 0.9999430179595947
and O 0 0.0007069042767398059
/ O 1 0.8747955560684204
or O 0 0.3575936257839203
lymphoma B-Disease 1 1.0
associated O 0 6.901842425577343e-05
with O 0 8.557290129829198e-06
neurofibromatosis B-Disease 1 0.9974996447563171
type I-Disease 0 7.034496957203373e-05
1 I-Disease 0 7.467967861884972e-06
. O 0 5.304510068526724e-06
. O 0 3.2286781788570806e-05

Missense O 0 0.010912477970123291
mutations O 0 0.0007715967949479818
in O 0 7.671210369153414e-06
the O 0 1.2840444014727836e-06
most O 0 7.495921181543963e-07
ancient O 0 9.961230489352602e-07
residues O 0 1.0805605370478588e-06
of O 0 2.124345570564401e-07
the O 0 8.274974447886052e-07
PAX6 O 0 0.0006387599860318005
paired O 0 6.838451554358471e-06
domain O 0 4.555600753519684e-06
underlie O 0 1.6021238479879685e-05
a O 0 1.892055138341675e-06
spectrum O 0 1.0533701242820825e-05
of O 0 4.448560503078625e-06
human O 0 0.0005758461193181574
congenital B-Disease 1 0.9999972581863403
eye I-Disease 1 0.9997398257255554
malformations I-Disease 1 0.9996167421340942
. O 0 0.0003293645568192005

Mutations O 0 0.0008889637538231909
of O 0 6.2637673181598075e-06
the O 0 4.985090527043212e-06
human O 0 6.925279194547329e-06
PAX6 O 0 0.006640470586717129
gene O 0 0.00010267239849781618
underlie O 0 0.09159902483224869
aniridia B-Disease 1 0.9999991655349731
( O 0 0.0007518405909650028
congenital B-Disease 1 0.9981870055198669
absence I-Disease 0 5.595671609626152e-06
of I-Disease 0 3.6404398429112916e-07
the I-Disease 0 1.493902914262435e-06
iris I-Disease 1 0.5887746214866638
) O 0 1.37181518766738e-06
, O 0 3.8065641660978145e-07
a O 0 9.132338618655922e-07
rare O 0 1.0654757716110907e-05
dominant O 0 0.0029123416170477867
malformation B-Disease 1 0.938238263130188
of I-Disease 0 3.140191665806924e-06
the I-Disease 0 1.99547521333443e-05
eye I-Disease 0 0.1255446821451187
. O 0 0.0001174801291199401

The O 0 2.820108420564793e-05
spectrum O 0 4.819070818484761e-05
of O 0 5.033065917814383e-06
PAX6 O 0 0.02398153580725193
mutations O 0 0.00010120480146724731
in O 0 1.3386447790253442e-05
aniridia B-Disease 1 0.9999994039535522
patients O 0 0.06751171499490738
is O 0 4.7486216203651566e-07
highly O 0 8.696323448020848e-07
biased O 0 1.9972269456047798e-06
, O 0 1.4301735973276664e-07
with O 0 1.3541128396354907e-07
92 O 0 2.242635900984169e-06
% O 0 1.5073668180320965e-07
of O 0 5.889079091048188e-08
all O 0 2.0300845449128246e-07
reported O 0 4.387015906104352e-06
mutations O 0 2.6364941732026637e-06
leading O 0 1.0372975793870864e-06
to O 0 5.410536800809496e-07
premature O 0 6.339259016385768e-06
truncation O 0 4.055216322740307e-06
of O 0 1.6625212140297663e-07
the O 0 3.839094802060572e-07
protein O 0 1.2563347127070301e-06
( O 0 3.54237386090972e-07
nonsense O 0 1.1027789241779828e-06
, O 0 1.2740854060666607e-07
splicing O 0 1.6402070741605712e-06
, O 0 1.9686146401909355e-07
insertions O 0 1.2142940022386028e-06
and O 0 1.5672550546241837e-07
deletions O 0 7.095486012076435e-07
) O 0 1.4290500871538825e-07
and O 0 6.114534301104868e-08
just O 0 1.2953742611898633e-07
2 O 0 1.8282395330970758e-07
% O 0 1.095799433414868e-07
leading O 0 1.6619314635590854e-07
to O 0 6.220165715831172e-08
substitution O 0 2.944179584574158e-07
of O 0 1.0887453072427888e-07
one O 0 3.8604369478889566e-07
amino O 0 1.6292442523990758e-06
acid O 0 2.2737567633157596e-06
by O 0 3.9739768453728175e-07
another O 0 1.7725159295878257e-06
( O 0 3.5579791983764153e-06
missense O 0 7.492105942219496e-05
) O 0 1.1504477697599214e-05
. O 0 2.5822326279012486e-05

The O 0 3.209057467756793e-05
extraordinary O 0 1.8854227164410986e-05
conservation O 0 5.575504019361688e-06
of O 0 5.530404223463847e-07
the O 0 9.587838576408103e-07
PAX6 O 0 0.00014664353511761874
protein O 0 3.1327704164141323e-06
at O 0 4.847089485338074e-07
the O 0 3.5229584227636224e-07
amino O 0 1.9619906197476666e-06
acid O 0 4.699905730376486e-06
level O 0 6.248334898373287e-07
amongst O 0 8.786087164480705e-07
vertebrates O 0 7.151271802285919e-06
predicts O 0 2.0594570742105134e-05
that O 0 3.3641993013588944e-07
pathological O 0 6.901879260112764e-06
missense O 0 5.437263098428957e-05
mutations O 0 6.123210368969012e-06
should O 0 2.364406412880271e-07
in O 0 1.0294102992247645e-07
fact O 0 2.1893477253343008e-07
be O 0 1.139690226636958e-07
common O 0 1.9729185396499815e-07
even O 0 2.6892428195424145e-07
though O 0 3.5134664244651503e-07
they O 0 1.723342819559548e-07
are O 0 1.0472957256979498e-07
hardly O 0 1.6272939546979615e-06
ever O 0 2.3744853479001904e-06
seen O 0 3.7625532058882527e-06
in O 0 1.3828453120368067e-05
aniridia B-Disease 1 0.9999914169311523
patients O 0 0.12555915117263794
. O 0 8.17690888652578e-05

This O 0 2.548474549257662e-05
indicates O 0 1.5789531971677206e-05
that O 0 9.304414447797171e-07
there O 0 2.933724942977278e-07
is O 0 1.990661502304647e-07
a O 0 5.277426566863141e-07
heavy O 0 2.4803528503980488e-05
ascertainment O 0 0.00023862224770709872
bias O 0 9.912540917866863e-06
in O 0 3.880235510678176e-07
the O 0 2.4729922643018654e-07
selection O 0 7.627023705936153e-07
of O 0 4.510846167704585e-07
patients O 0 2.1881294742343016e-05
for O 0 5.95803157921182e-07
PAX6 O 0 0.06547851860523224
mutation O 0 9.225634130416438e-06
analysis O 0 1.3224588428784045e-06
and O 0 2.5415340587642277e-07
that O 0 1.9054026267895097e-07
the O 0 7.413036655634642e-07
missing O 0 1.6770050933700986e-05
PAX6 O 0 0.08654726296663284
missense O 0 0.0009429801721125841
mutations O 0 4.836998778046109e-05
frequently O 0 8.38286905491259e-06
may O 0 1.2473292372305878e-05
underlie O 0 0.0002885811554733664
phenotypes O 0 0.00018350439495407045
distinct O 0 1.0355350241297856e-05
from O 0 1.2746843822242226e-05
textbook O 0 0.020757848396897316
aniridia B-Disease 1 0.9998123049736023
. O 0 0.00014622617163695395

Here O 0 4.60561022919137e-05
we O 0 7.535934400948463e-06
present O 0 2.5581600766599877e-06
four O 0 1.884466655610595e-06
novel O 0 1.740561674523633e-05
PAX6 O 0 0.010966644622385502
missense O 0 0.0003908476501237601
mutations O 0 3.123072747257538e-05
, O 0 8.209473776332743e-07
two O 0 3.0898490877007134e-07
in O 0 8.410650593759783e-07
association O 0 3.02649823424872e-06
with O 0 1.2397432556099375e-06
atypical O 0 0.021664123982191086
phenotypes O 0 0.10495937615633011
ectopia B-Disease 0 0.1454324871301651
pupillae I-Disease 0 0.047270700335502625
( O 0 1.7698150713840732e-06
displaced B-Disease 0 3.947790901293047e-06
pupils I-Disease 0 6.7284645410836674e-06
) O 0 8.849864912008343e-07
and O 0 3.5003870380023727e-06
congenital B-Disease 1 0.9977344274520874
nystagmus I-Disease 0 0.0017031950410455465
( O 0 5.7592887969804e-07
searching B-Disease 0 9.66277752922906e-07
gaze I-Disease 0 2.761328005362884e-06
) O 0 1.739786910093244e-07
, O 0 7.713030925060593e-08
and O 0 9.547347445959531e-08
two O 0 1.257024564438325e-07
in O 0 3.9396491047227755e-07
association O 0 1.512387825641781e-06
with O 0 6.304582598204433e-07
more O 0 1.267161792384286e-06
recognizable O 0 0.00017072897753678262
aniridia B-Disease 1 0.999864935874939
phenotypes O 0 0.015985457226634026
. O 0 7.874305447330698e-05

Strikingly O 0 0.00036901942803524435
, O 0 8.512751264788676e-06
all O 0 6.37227742572577e-07
four O 0 1.0430908332637046e-06
mutations O 0 3.6428264138521627e-06
are O 0 1.5041129586279567e-07
located O 0 1.9461712952306698e-07
within O 0 1.2467012311390135e-07
the O 0 3.830354557976534e-07
PAX6 O 0 0.00021952533279545605
paired O 0 3.412095338717336e-06
domain O 0 8.233937478507869e-07
and O 0 2.7014473857889243e-07
affect O 0 5.482423262037628e-07
amino O 0 4.320297648519045e-07
acids O 0 4.705744629518449e-07
which O 0 6.197061708235196e-08
are O 0 6.823623976970339e-08
highly O 0 2.7912173550248554e-07
conserved O 0 2.932765710284002e-07
in O 0 1.0482310131010308e-07
all O 0 1.5190153135336004e-07
known O 0 1.0327707968826871e-06
paired O 0 6.1431310314219445e-06
domain O 0 7.106333214323968e-06
proteins O 0 1.594726199982688e-05
. O 0 2.1735753762186505e-05

Our O 0 7.673354411963373e-05
results O 0 3.551355257513933e-05
support O 0 3.598934199544601e-06
the O 0 1.3012385124966386e-06
hypothesis O 0 5.121459253132343e-06
that O 0 1.9301276665828482e-07
the O 0 1.9613698043485783e-07
under O 0 3.1426401392309344e-07
- O 0 2.2274214188655606e-06
representation O 0 6.216909582690278e-07
of O 0 3.7541022379627975e-07
missense O 0 0.0001043719457811676
mutations O 0 1.0895635568886064e-05
is O 0 3.499515344174142e-07
caused O 0 1.4916579402779462e-06
by O 0 3.475273047115479e-07
ascertainment O 0 5.4810443543829024e-05
bias O 0 1.2749786037602462e-05
and O 0 8.987823321149335e-07
suggest O 0 1.3022863640799187e-06
that O 0 1.7342424030175607e-07
a O 0 6.247179271667846e-07
substantial O 0 2.94586902782612e-06
burden O 0 9.74169779510703e-06
of O 0 7.648117730241211e-07
PAX6 B-Disease 1 0.9819424748420715
- I-Disease 1 0.9808444976806641
related I-Disease 0 0.003160809399560094
disease I-Disease 0 0.0008233872358687222
remains O 0 1.9892129330401076e-06
to O 0 5.257022053228866e-07
be O 0 6.937851821930963e-07
uncovered O 0 2.3048627554089762e-05
. O 0 6.410760306607699e-06
. O 0 2.9450906367856078e-05

The O 0 4.901509964838624e-05
chromosomal O 0 0.00016837396833579987
order O 0 4.67268864667858e-06
of O 0 7.169136324591818e-07
genes O 0 5.15381680088467e-06
controlling O 0 5.449933269119356e-06
the O 0 8.216907190217171e-07
major O 0 2.0904344637528993e-06
histocompatibility O 0 0.0003563840582501143
complex O 0 1.699631980045524e-06
, O 0 4.4647094910033047e-07
properdin O 0 1.2020453141303733e-05
factor O 0 2.033358441622113e-06
B O 0 7.0813971433381084e-06
, O 0 5.200882924327743e-07
and O 0 2.005414899031166e-06
deficiency B-Disease 0 2.5765013560885563e-05
of I-Disease 0 9.69771463132929e-08
the I-Disease 0 2.465012300945091e-07
second I-Disease 0 1.3354685961530777e-06
component I-Disease 0 2.75331308330351e-06
of I-Disease 0 1.7781370615921333e-06
complement I-Disease 0 3.6396257200976834e-05
. O 0 5.812756353407167e-05

The O 0 3.174728044541553e-05
relationship O 0 1.3037443750363309e-05
of O 0 1.4433371688937768e-06
the O 0 1.5853437389523606e-06
genes O 0 4.964059826306766e-06
coding O 0 8.543884177925065e-06
for O 0 9.391423532179033e-07
HLA O 0 1.884647826955188e-05
to O 0 2.4156938138730766e-07
those O 0 1.9337922196882573e-07
coding O 0 1.960393319677678e-06
for O 0 3.119599796264083e-07
properdin O 0 1.0267772267980035e-05
Factor O 0 9.631094144424424e-07
B O 0 2.3391930881189182e-06
allotypes O 0 4.940003236697521e-06
and O 0 3.764247935578169e-07
for O 0 1.20392883218301e-06
deficiency B-Disease 0 1.516903648735024e-05
of I-Disease 0 6.434038368752226e-08
the I-Disease 0 1.1728484139439388e-07
second I-Disease 0 3.169258206980885e-07
component I-Disease 0 4.68932114472409e-07
of I-Disease 0 1.0055505583750346e-07
complement I-Disease 0 1.002706198960368e-06
( O 0 5.991095690660586e-07
C2 O 0 4.6693046897416934e-05
) O 0 2.5368120759594603e-07
was O 0 2.314499170097406e-07
studied O 0 7.60809257371875e-07
in O 0 2.94204085093952e-07
families O 0 1.3921879826739314e-06
of O 0 8.446517085758387e-07
patients O 0 0.00027429431793279946
with O 0 2.4891724024200812e-05
connective O 1 0.9997962117195129
tissue O 1 0.999976396560669
disorders O 1 0.9994227886199951
. O 0 0.00018997499137185514

Patients O 0 0.10624372959136963
were O 0 6.675913027720526e-06
selected O 0 5.732767931476701e-06
because O 0 2.0576212591549847e-06
they O 0 1.241065774593153e-06
were O 0 1.3315110436451505e-06
heterozygous O 0 1.4441727216762956e-05
or O 0 7.307214673346607e-06
homozygous O 0 0.0004055463650729507
for O 0 0.0020524892024695873
C2 B-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9999980926513672
. O 0 0.00020637561101466417

12 O 0 0.00013226816372480243
families O 0 2.437794864817988e-05
with O 0 1.9611543393693864e-06
15 O 0 2.7682124255079543e-06
matings O 0 3.897222995874472e-05
informative O 0 3.812513023149222e-05
for O 0 0.002219701185822487
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999988079071045
were O 0 9.074848094314802e-06
found O 0 1.9320319552207366e-05
. O 0 4.756425187224522e-05

Of O 0 1.5825606169528328e-05
57 O 0 2.0386636606417596e-05
informative O 0 1.3139557268004864e-05
meioses O 0 3.0275659810286015e-05
, O 0 5.185113991501566e-07
two O 0 1.6583945239290188e-07
crossovers O 0 1.8582237544251257e-06
were O 0 2.9812375146320846e-07
noted O 0 3.5638944950733276e-07
between O 0 3.814035380855785e-07
the O 0 0.0015669380081817508
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9998769760131836
gene O 0 2.3147297270043055e-06
and O 0 3.5425023270363454e-07
the O 0 7.632495453435695e-07
HLA O 0 0.0013447520323097706
- O 0 0.0007969805155880749
B O 0 8.745244485908188e-06
gene O 0 1.4572150348612922e-06
, O 0 1.8038132054698508e-07
with O 0 1.394863033965521e-07
a O 0 5.549990760300716e-07
recombinant O 0 6.5478766373416875e-06
fraction O 0 4.35025367551134e-06
of O 0 3.3810540571721504e-06
0 O 0 3.651825318229385e-05
. O 0 3.466977796051651e-05

035 O 1 0.765313982963562
. O 0 0.004881910979747772

A O 0 0.0001116460480261594
lod O 0 0.0005220702732913196
score O 0 6.386632321664365e-06
of O 0 5.221108381192607e-07
13 O 0 1.1873306675624917e-06
was O 0 5.410825565377309e-07
calculated O 0 9.745347142597893e-07
for O 0 3.020524559360638e-07
linkage O 0 1.5001811334514059e-05
between O 0 5.7610872318036854e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999779462814331
and O 0 4.4577973312698305e-06
HLA O 0 0.0008578847046010196
- O 0 0.0003730713215190917
B O 0 6.6467159740568604e-06
at O 0 3.117684457265568e-07
a O 0 1.6070691799541237e-07
maximum O 0 5.846259796271625e-07
likelihood O 0 1.0508468903935864e-06
value O 0 1.8606357343742275e-07
of O 0 9.04578314475657e-08
the O 0 3.324846318264463e-07
recombinant O 0 3.652385657915147e-06
fraction O 0 3.3755354706954677e-06
of O 0 2.085094592985115e-06
0 O 0 2.2408259610529058e-05
. O 0 2.4469487470923923e-05

04 O 0 0.22084835171699524
. O 0 0.0026351306587457657

18 O 0 0.00010146405838895589
families O 0 1.6099858839879744e-05
with O 0 2.0321292595326668e-06
21 O 0 2.53752614298719e-06
informative O 0 4.022084794996772e-06
matings O 0 6.290862529567676e-06
for O 0 4.168661860148859e-07
both O 0 5.938658205195679e-07
properdin O 0 3.2416177418781444e-05
Factor O 0 5.1931974667240866e-06
B O 0 6.766236310795648e-06
allotype O 0 1.5508539945585653e-05
and O 0 1.8701084627537057e-06
HLA O 0 0.0006352614727802575
- O 0 0.0017076439689844847
B O 0 2.642509207362309e-05
were O 0 2.300925416420796e-06
found O 0 1.103050362871727e-05
. O 0 3.214840398868546e-05

Of O 0 2.245540963485837e-05
72 O 0 3.3834010537248105e-05
informative O 0 1.3802708053844981e-05
meioses O 0 4.7580084356013685e-05
, O 0 9.258705517822818e-07
three O 0 4.829348085877427e-07
recombinants O 0 2.2659167370875366e-05
were O 0 7.454530646100466e-07
found O 0 2.3077504351931566e-07
, O 0 1.5326486391131766e-07
giving O 0 4.810745508621039e-07
a O 0 7.855483659113816e-07
recombinant O 0 7.21665810488048e-06
fraction O 0 5.6630456128914375e-06
of O 0 3.226843318770989e-06
0 O 0 3.3013795473380014e-05
. O 0 3.0467021133517846e-05

042 O 0 0.054613061249256134
. O 0 0.0032056341879069805

A O 0 0.00010481548815732822
lod O 0 0.00030285704997368157
score O 0 4.999911652703304e-06
of O 0 5.858973963768221e-07
16 O 0 8.863412404025439e-07
between O 0 6.215896064531989e-07
HLA O 0 5.296152085065842e-05
- O 0 2.8337495677988045e-05
B O 0 2.2956978682486806e-06
and O 0 1.6144809933393844e-07
Factor O 0 6.372338248183951e-07
B O 0 9.93655248748837e-07
allotypes O 0 3.106719532297575e-06
was O 0 2.0280933199501305e-07
calculated O 0 3.292102235263883e-07
at O 0 1.1158914503539563e-07
a O 0 1.5657163032756216e-07
maximum O 0 3.8212516528801643e-07
likelihood O 0 1.1520993439262384e-06
value O 0 1.9989941790754528e-07
of O 0 1.0146305129410393e-07
the O 0 3.2378125069953967e-07
recombinant O 0 4.762267963087652e-06
fraction O 0 3.682927626869059e-06
of O 0 1.277114847653138e-06
0 O 0 2.019335443037562e-05
. O 0 2.3322043489315547e-05

04 O 0 0.3446919620037079
. O 0 0.004674579948186874

A O 0 5.961050192127004e-05
crossover O 0 4.522321614786051e-05
was O 0 5.8006080507766455e-06
shown O 0 1.736232775328972e-06
to O 0 4.69888760790127e-07
have O 0 2.2341986039009498e-07
occurred O 0 3.6156598071102053e-07
between O 0 1.2406901817030302e-07
genes O 0 5.140780103829456e-07
for O 0 2.062704709260288e-07
Factor O 0 9.616289844416315e-07
B O 0 2.2272515707300045e-06
and O 0 5.61167496471171e-07
HLA O 0 0.005541559774428606
- O 0 0.04239079728722572
D O 0 0.0048170508816838264
, O 0 1.4156242400531482e-07
in O 0 1.274152197083822e-07
which O 0 4.2697246271927725e-07
HLA O 0 0.001249752240255475
- O 0 0.011513677425682545
D O 0 0.00406779395416379
segregared O 0 9.870036592474207e-06
with O 0 8.142845331349235e-07
HLA O 0 0.00012190809502499178
- O 0 1.9109500499325804e-05
A O 0 2.0329493963799905e-06
and O 0 4.285060640540905e-06
B O 0 0.000128722153021954
. O 0 3.9665959775447845e-05

These O 0 3.538927558111027e-05
studies O 0 2.1979969460517168e-05
suggest O 0 5.659752787323669e-06
that O 0 2.3464271237116918e-07
the O 0 2.759961716947146e-07
genes O 0 5.81949223033007e-07
for O 0 2.4255604103018413e-07
Factor O 0 2.8709212074318202e-06
B O 0 0.0020509210880845785
and O 0 0.03040667064487934
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999920129776001
are O 0 1.1629746410335429e-07
located O 0 1.3987634872592025e-07
outside O 0 1.1679150446752828e-07
those O 0 1.0607571709897456e-07
for O 0 1.6261662949546007e-07
HLA O 0 5.861892714165151e-05
, O 0 1.6679716452472348e-07
that O 0 5.550340276272436e-08
the O 0 6.437660005076395e-08
order O 0 1.3139238319581636e-07
of O 0 1.1414937972631378e-07
genese O 0 4.432860077940859e-05
is O 0 3.866391011797532e-07
HLA O 0 3.255136471125297e-05
- O 0 3.5640443911688635e-06
A O 0 3.2116358283929003e-07
, O 0 3.338445253575628e-07
- O 0 1.1162442206114065e-05
B O 0 3.6406172512215562e-06
, O 0 3.85348499776228e-07
- O 0 4.737056224257685e-05
D O 0 0.00039185257628560066
, O 0 2.7776533784162893e-07
Factor O 0 1.0294510275343782e-06
B O 0 5.299271379044512e-06
allotype O 0 0.010844257660210133
, O 0 0.012612580321729183
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999743700027466
, O 0 1.62061766673105e-07
that O 0 5.942902703282016e-08
the O 0 1.2987845821044175e-07
genes O 0 1.4511989547827397e-06
coding O 0 5.1123210141668096e-05
for O 0 0.00029539220849983394
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9998646974563599
and O 0 5.408741685641871e-07
Factor O 0 1.5765479020046769e-06
B O 0 2.035942998190876e-06
allotypes O 0 3.910745817847783e-06
are O 0 9.990144178573246e-08
approximately O 0 1.514355005838297e-07
3 O 0 3.787567663948721e-07
- O 0 7.05486627339269e-06
- O 0 3.2173604722629534e-06
5 O 0 3.6676422610071313e-07
centimorgans O 0 1.8320215531275608e-06
from O 0 1.168764001135969e-07
the O 0 2.900608251366066e-07
HLA O 0 3.203241794835776e-05
- O 0 4.603554316418013e-06
A O 0 5.302762815517781e-07
and O 0 6.487618975370424e-07
HLA O 0 6.120646867202595e-05
- O 0 5.2857485570712015e-05
B O 0 2.8159699922980508e-06
loci O 0 1.156204916696879e-06
, O 0 1.2737051235944818e-07
and O 0 8.399382522839005e-08
that O 0 7.456273465322738e-08
the O 0 2.4101757389871636e-07
apparent O 0 2.5122408260358498e-06
lack O 0 5.203735327086179e-07
of O 0 9.73466711684523e-08
recombinants O 0 6.421676516765729e-06
between O 0 9.261640343538602e-08
the O 0 1.749932465600068e-07
Factor O 0 7.096982130860852e-07
B O 0 3.206217570550507e-06
gene O 0 2.7993742151011247e-06
and O 0 0.0009468379430472851
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999905824661255
gene O 0 2.940682179541909e-06
suggests O 0 7.816512948011223e-07
that O 0 6.6535385201405e-08
these O 0 6.821593956374272e-08
two O 0 1.3046241065239883e-07
genes O 0 1.0949319175779237e-06
lie O 0 1.1146719316457165e-06
in O 0 1.5387777807518432e-07
close O 0 4.812695806322154e-07
proximity O 0 1.5193849094430334e-06
to O 0 6.478925342889852e-07
one O 0 1.1067245395679493e-06
another O 0 8.259550668299198e-06
. O 0 2.927298737631645e-05

Distribution O 0 5.5411986977560446e-05
of O 0 5.581153800449101e-06
emerin O 0 0.00010296151594957337
and O 0 3.884973921230994e-06
lamins O 0 0.0001238044787896797
in O 0 1.0444306326462538e-06
the O 0 6.143977770989295e-07
heart O 0 1.036102094076341e-05
and O 0 1.0731623660831247e-06
implications O 0 1.444991175958421e-05
for O 0 3.995057340944186e-06
Emery B-Disease 0 0.21410755813121796
- I-Disease 1 0.9027705192565918
Dreifuss I-Disease 1 0.9985760450363159
muscular I-Disease 1 0.9957619309425354
dystrophy I-Disease 1 0.997657060623169
. O 0 0.0002716957242228091

Emerin O 0 0.002601286629214883
is O 0 1.8330179955228232e-05
a O 0 6.9389434429467656e-06
nuclear O 0 1.3358671822061297e-05
membrane O 0 5.744090685766423e-06
protein O 0 2.2392976006813115e-06
which O 0 2.983797173783387e-07
is O 0 2.289005323063975e-07
missing O 0 1.805766601137293e-06
or O 0 8.653386203150149e-07
defective O 0 2.3909093215479515e-05
in O 0 3.1298141038860194e-06
Emery B-Disease 0 0.26241034269332886
- I-Disease 1 0.9724129438400269
Dreifuss I-Disease 1 0.9997465014457703
muscular I-Disease 1 0.9996399879455566
dystrophy I-Disease 1 0.9999256134033203
( O 0 8.939271356211975e-05
EDMD B-Disease 1 0.9998811483383179
) O 0 4.047945185448043e-05
. O 0 5.51180201000534e-05

It O 0 2.246187796117738e-05
is O 0 2.783094032565714e-06
one O 0 6.767306217625446e-07
member O 0 7.942187494336395e-07
of O 0 1.8879873664445768e-07
a O 0 5.076229285805312e-07
family O 0 2.7792136734205997e-06
of O 0 4.86031865420955e-07
lamina O 1 0.9812257885932922
- O 0 0.0725460797548294
associated O 0 2.307638851561933e-06
proteins O 0 6.966267847019481e-07
which O 0 2.0008977230645542e-07
includes O 0 4.769121915160213e-07
LAP1 O 0 3.5289758670842275e-05
, O 0 9.721379683469422e-07
LAP2 O 0 6.292297621257603e-05
and O 0 5.046484602644341e-06
lamin O 0 0.07178864628076553
B O 0 0.0029397557955235243
receptor O 0 9.635843889554963e-05
( O 0 1.742248969094362e-05
LBR O 0 0.0016609193990007043
) O 0 1.3536775441025384e-05
. O 0 2.6140785848838277e-05

A O 0 0.00012827284808736295
panel O 0 4.7979134251363575e-05
of O 0 3.9841843317844905e-06
16 O 0 4.569681095745182e-06
monoclonal O 0 4.1023125959327444e-05
antibodies O 0 1.5960957171046175e-05
( O 0 1.8616044599184534e-06
mAbs O 0 2.3482150936615653e-05
) O 0 3.296261468221928e-07
has O 0 7.005308333418725e-08
been O 0 8.76518413406302e-08
mapped O 0 7.082397814883734e-07
to O 0 1.392039052916516e-07
six O 0 1.3842404200659075e-07
specific O 0 1.9233600312418275e-07
sites O 0 2.492903945494618e-07
throughout O 0 1.7267581142732524e-07
the O 0 1.8295790482625307e-07
emerin O 0 6.281869445956545e-06
molecule O 0 1.2048201369907474e-06
using O 0 4.927417194267036e-07
phage O 0 4.635114237316884e-06
- O 0 1.1248113196415943e-06
displayed O 0 3.0845143328406266e-07
peptide O 0 8.360158290088293e-07
libraries O 0 3.38912059305585e-07
and O 0 1.3552212863032764e-07
has O 0 1.7428207854663924e-07
been O 0 1.4823395133589656e-07
used O 0 2.2659477849629184e-07
to O 0 4.145797731780476e-07
localize O 0 1.4943981113901827e-05
emerin O 0 4.0211441955761984e-05
in O 0 1.0189178283326328e-06
human O 0 1.4087033832765883e-06
and O 0 3.817692231677938e-06
rabbit O 0 0.0043947575613856316
heart O 0 0.015769336372613907
. O 0 0.00010197483788942918

Several O 0 7.399250898743048e-05
mAbs O 0 0.0006349962786771357
against O 0 1.3577658137364779e-05
different O 0 4.526921657088678e-06
emerin O 0 9.822052379604429e-05
epitopes O 0 5.8000816352432594e-05
did O 0 2.307676368218381e-06
not O 0 4.5907867729511054e-07
recognize O 0 9.692311095932382e-07
intercalated O 0 6.221160674613202e-06
discs O 0 1.7669632370598265e-06
in O 0 2.032056443113106e-07
the O 0 3.2455909604323097e-07
heart O 0 3.268474756623618e-05
, O 0 2.309965481117615e-07
though O 0 2.4438080004074436e-07
they O 0 1.8994553840911976e-07
recognized O 0 4.344670969658182e-07
cardiomyocyte O 0 5.459380190586671e-06
nuclei O 0 1.2514271929831011e-06
strongly O 0 6.151869342829741e-07
, O 0 1.2722678377485863e-07
both O 0 1.4480274046491104e-07
at O 0 1.955430661837454e-07
the O 0 1.4104992374086578e-07
rim O 0 1.3213519878263469e-06
and O 0 5.73654574509419e-07
in O 0 9.145132935373113e-07
intranuclear O 0 0.00014877122885081917
spots O 0 1.4435669072554447e-05
or O 0 5.0082203415513504e-06
channels O 0 3.58603720087558e-05
. O 0 3.618272967287339e-05

A O 0 0.00023256173881236464
polyclonal O 0 0.0012782721314579248
rabbit O 0 0.0005520614795386791
antiserum O 0 0.00047021848149597645
against O 0 1.472751591791166e-05
emerin O 0 0.00021995045244693756
did O 0 5.111836799187586e-06
recognize O 0 2.0400634639372583e-06
both O 0 4.988320370102883e-07
nuclear O 0 2.972189349748078e-06
membrane O 0 1.773889152900665e-06
and O 0 4.841564305024804e-07
intercalated O 0 8.398328645853326e-06
discs O 0 1.983465608645929e-06
but O 0 2.6022465249297966e-07
, O 0 1.1337257888044405e-07
after O 0 4.1224143387808e-07
affinity O 0 1.0773029543997836e-06
purification O 0 1.701383553154301e-06
against O 0 4.091741914180602e-07
a O 0 3.0929649597055686e-07
pure O 0 1.8883165466831997e-06
- O 0 4.0040544263320044e-05
emerin O 0 2.1231484424788505e-05
band O 0 9.139299663729616e-07
on O 0 1.29188904907096e-07
a O 0 2.1708063968617353e-07
western O 0 9.623913683753926e-07
blot O 0 7.677468238398433e-05
, O 0 9.444018473914184e-07
it O 0 5.645551937050186e-07
stained O 0 2.953914190584328e-05
only O 0 7.333718485824647e-07
the O 0 2.065524995487067e-06
nuclear O 0 3.14944663841743e-05
membrane O 0 6.75625997246243e-05
. O 0 5.183498069527559e-05

These O 0 1.9106875697616488e-05
results O 0 1.4244000340113416e-05
would O 0 8.072399282355036e-07
not O 0 3.3545560995662527e-07
be O 0 1.4940567893972911e-07
expected O 0 3.3755955541892035e-07
if O 0 2.180525200401462e-07
immunostaining O 0 3.194412101947819e-06
at O 0 1.9438694209839014e-07
intercalated O 0 2.8274064334254945e-06
discs O 0 1.3762323760602158e-06
were O 0 1.7080704139971203e-07
due O 0 2.131578185071703e-07
to O 0 6.495876903045428e-08
a O 0 1.0905242930903114e-07
product O 0 2.8740035418195475e-07
of O 0 7.801493495662726e-08
the O 0 3.0735202471987577e-07
emerin O 0 3.449360519880429e-05
gene O 0 1.7164815062642447e-06
and O 0 2.732499240210018e-07
, O 0 2.919557857694599e-07
therefore O 0 2.5796131808419887e-07
, O 0 1.3912838880969502e-07
cast O 0 4.051007920224947e-07
some O 0 1.0174793629857959e-07
doubt O 0 5.890471470593184e-07
upon O 0 2.1950677364657167e-07
the O 0 4.004453728612134e-07
hypothesis O 0 2.630415474413894e-05
that O 0 2.3561956368212122e-06
cardiac B-Disease 1 0.9965404868125916
defects I-Disease 1 0.9689059257507324
in O 0 1.0615516657708213e-05
EDMD B-Disease 1 0.9999963045120239
are O 0 8.765198344917735e-07
caused O 0 1.86477814168029e-06
by O 0 3.0212794399631093e-07
absence O 0 1.010848109217477e-06
of O 0 4.3154963691449666e-07
emerin O 0 0.0003693421895150095
from O 0 3.626548959800857e-06
intercalated O 0 0.0006197365000844002
discs O 0 7.383582124020904e-05
. O 0 3.9437320083379745e-05

Although O 0 9.899863653117791e-05
emerin O 0 0.00035549161839298904
was O 0 4.058249032823369e-06
abundant O 0 1.919784608617192e-06
in O 0 3.598899240842002e-07
the O 0 3.123052749742783e-07
membranes O 0 2.1144485344848363e-06
of O 0 2.0642791298541852e-07
cardiomyocyte O 0 1.7728285456541926e-05
nuclei O 0 2.405542545602657e-06
, O 0 1.6776230893356114e-07
it O 0 7.333257912023328e-08
was O 0 3.6002450087835314e-07
absent O 0 8.759615752751415e-07
from O 0 1.6864666463334288e-07
many O 0 3.899272655871755e-07
non O 0 2.295608283020556e-06
- O 0 5.301174314809032e-05
myocyte O 0 0.0023628338240087032
cells O 0 1.901215910038445e-05
in O 0 1.624223955332127e-06
the O 0 7.055391051835613e-06
heart O 0 0.002175715286284685
. O 0 6.697819480905309e-05

This O 0 1.3693351320398506e-05
distribution O 0 6.733844202244654e-06
of O 0 9.378409231430851e-07
emerin O 0 7.236729288706556e-05
was O 0 9.381200243296917e-07
similar O 0 6.175411044750945e-07
to O 0 2.0517474297321314e-07
that O 0 1.3985300029162318e-07
of O 0 2.2054503290291905e-07
lamin O 0 0.0015878599369898438
A O 0 1.5070088466018206e-06
, O 0 4.0954466840048553e-07
a O 0 4.9173246452483e-07
candidate O 0 3.116012976533966e-06
gene O 0 1.6290998701151693e-06
for O 0 4.180369330697431e-07
an O 0 6.510936145787127e-07
autosomal O 0 0.00010551224113442004
form O 0 8.359349521924742e-06
of O 0 9.878944183583371e-06
EDMD B-Disease 1 0.9999651908874512
. O 0 0.00011986710160272196

In O 0 0.00011503600399009883
contrast O 0 0.00012327275180723518
, O 0 1.8506583728594705e-05
lamin O 0 0.030030928552150726
B1 O 0 0.03575899451971054
was O 0 2.5744618596945656e-06
absent O 0 2.320463181604282e-06
from O 0 2.1641339742473065e-07
cardiomyocyte O 0 5.786469955637585e-06
nuclei O 0 2.570419155745185e-06
, O 0 4.0518580135540105e-07
showing O 0 1.6187314031412825e-06
that O 0 7.799616810189036e-07
lamin O 0 0.037470873445272446
B1 O 0 0.0021100230515003204
is O 0 2.570972981175146e-07
not O 0 1.2662603410262818e-07
essential O 0 2.0121763100178214e-07
for O 0 1.431753986480544e-07
localization O 0 1.5684857999076485e-06
of O 0 2.472272910836182e-07
emerin O 0 1.236714069818845e-05
to O 0 7.486869435524568e-07
the O 0 2.3748609692120226e-06
nuclear O 0 4.141707540838979e-05
lamina O 0 0.00793393887579441
. O 0 4.1003335354616866e-05

Lamin O 1 0.9938831329345703
B1 O 1 0.9221994876861572
is O 0 1.822427293518558e-05
also O 0 4.678886398323812e-06
almost O 0 2.6452785277797375e-06
completely O 0 7.566943622805411e-06
absent O 0 1.2053019418090116e-05
from O 0 3.4355557545495685e-06
skeletal O 0 0.0020162775181233883
muscle O 0 0.0005618331488221884
nuclei O 0 0.0003369948535691947
. O 0 8.876834908733144e-05

In O 0 0.000134008310851641
EDMD B-Disease 1 0.999224066734314
, O 0 3.6706478567793965e-06
the O 0 6.860025791866065e-07
additional O 0 6.146122473182913e-07
absence O 0 1.3525540225600707e-06
of O 0 6.579472824341792e-07
lamin O 0 0.2959067225456238
B1 O 0 0.2152102291584015
from O 0 6.424430694096372e-07
heart O 0 1.2873356354248244e-05
and O 0 7.710175395914121e-07
skeletal O 0 0.004523174371570349
muscle O 0 5.523113941308111e-05
nuclei O 0 8.821948540571611e-06
which O 0 6.150050921860384e-07
already O 0 1.9610758954513585e-06
lack O 0 1.6276570704576443e-06
emerin O 0 0.024776767939329147
may O 0 1.902165081446583e-06
offer O 0 4.1112167536994093e-07
an O 0 6.597656465601176e-08
alternative O 0 3.9879631685835193e-07
explanation O 0 4.6793323349447746e-07
of O 0 9.718657167923084e-08
why O 0 7.355530442509917e-07
these O 0 2.578990745405463e-07
tissues O 0 5.798357960884459e-06
are O 0 3.5956608712695015e-07
particularly O 0 2.140816150131286e-06
affected O 0 7.540059868915705e-06
. O 0 6.342124834191054e-06
. O 0 3.151507189613767e-05

Genetic O 0 0.0007283911108970642
mapping O 0 7.194988575065508e-05
of O 0 5.015873284719419e-06
the O 0 5.500058250618167e-06
copper B-Disease 0 0.00012140323087805882
toxicosis I-Disease 0 0.07356252521276474
locus O 0 6.0288399254204705e-05
in O 0 2.2934987100597937e-06
Bedlington O 0 6.922394095454365e-05
terriers O 0 0.00010048750118585303
to O 0 1.7698876035865396e-06
dog O 0 9.675756700744387e-06
chromosome O 0 4.106172127649188e-06
10 O 0 3.970411910358962e-07
, O 0 2.1816005357777613e-07
in O 0 1.642546010316437e-07
a O 0 4.3600039134616964e-07
region O 0 1.676730335020693e-06
syntenic O 0 0.00011230229574721307
to O 0 1.157827000497491e-06
human O 0 3.924233169527724e-06
chromosome O 0 1.4526539416692685e-05
region O 0 1.2643379704968538e-05
2p13 O 0 0.00046488476800732315
- O 0 0.0005004623089917004
p16 O 0 0.00040791230276227
. O 0 6.954206764930859e-05

Abnormal O 1 0.9161955118179321
hepatic B-Disease 1 0.9994761347770691
copper I-Disease 0 0.06398241966962814
accumulation I-Disease 0 9.306442370871082e-05
is O 0 1.7689527567199548e-06
recognized O 0 1.7157680076707038e-06
as O 0 1.072280497282918e-06
an O 0 9.914582733472344e-06
inherited B-Disease 1 1.0
disorder I-Disease 1 0.9999974966049194
in O 0 3.482845386315603e-06
man O 0 6.726508581778035e-05
, O 0 1.2479875977078336e-06
mouse O 0 3.896104681189172e-05
, O 0 3.6691499190055765e-06
rat O 0 0.001800046768039465
and O 0 8.891537618183065e-06
dog O 0 0.00028071875567547977
. O 0 6.995670264586806e-05

The O 0 3.555038711056113e-05
major O 0 1.6541611330467276e-05
cause O 0 1.1751536476367619e-05
of O 0 1.4591897752325167e-06
hepatic B-Disease 1 0.8915402293205261
copper I-Disease 0 0.012295075692236423
accumulation I-Disease 0 1.4139191989670508e-05
in O 0 1.2550258361443412e-06
man O 0 9.000723366625607e-06
is O 0 5.250438448456407e-07
a O 0 1.6728635046092677e-06
dysfunctional O 0 0.00033862830605357885
ATP7B O 0 0.002333661075681448
gene O 0 1.1500507753225975e-05
, O 0 2.797100705720368e-06
causing O 0 0.000135155045427382
Wilson B-Disease 1 0.7375856041908264
disease I-Disease 0 0.1715642362833023
( O 0 2.3735030481475405e-05
WD B-Disease 1 0.995617151260376
) O 0 2.070765185635537e-05
. O 0 3.0046394385863096e-05

Mutations O 0 0.0008166361949406564
in O 0 8.568297744204756e-06
the O 0 2.8638523872359656e-06
ATP7B O 0 0.0007092633168213069
genes O 0 8.42615008878056e-06
have O 0 7.012928335825563e-07
also O 0 6.397864922291774e-07
been O 0 5.883611038370873e-07
demonstrated O 0 2.928200956375804e-06
in O 0 1.7027226704158238e-06
mouse O 0 9.881425648927689e-05
and O 0 2.0302917619119398e-05
rat O 0 0.017559435218572617
. O 0 4.983020335203037e-05

The O 0 4.0230464946944267e-05
ATP7B O 0 0.0010748421773314476
gene O 0 4.455363887245767e-05
has O 0 3.152271574435872e-06
been O 0 9.100344868784305e-07
excluded O 0 1.9076151147601195e-06
in O 0 1.695308213811586e-07
the O 0 1.8138460688987834e-07
much O 0 7.817713481017563e-07
rarer O 0 5.987827535136603e-05
human O 0 3.004349764523795e-06
copper B-Disease 0 0.10723526030778885
overload I-Disease 1 0.7847254276275635
disease O 0 0.0017423550598323345
non B-Disease 0 4.711780547950184e-06
- I-Disease 0 0.00012767089356202632
Indian I-Disease 0 6.907390343258157e-06
childhood I-Disease 0 0.007099546492099762
cirrhosis I-Disease 1 0.9740172624588013
, O 0 1.0064511116070207e-05
indicating O 0 6.632159784203395e-05
genetic O 0 0.00018488202476873994
heterogeneity O 0 0.0011108076432719827
. O 0 0.00010966919944621623

By O 0 8.298223838210106e-05
investigating O 0 0.00014760563499294221
the O 0 2.522031900298316e-05
common O 0 0.00014697543520014733
autosomal O 1 0.9050096869468689
recessive O 1 0.9453427791595459
copper B-Disease 1 0.6479256749153137
toxicosis I-Disease 1 0.9965440630912781
( O 0 1.3085897990094963e-05
CT B-Disease 1 0.8683304786682129
) O 0 1.1575443750189152e-06
in O 0 6.982469926697377e-07
Bedlington O 0 5.7810204452835023e-05
terriers O 0 0.0004890348645858467
, O 0 7.091873612807831e-07
we O 0 2.981612681196566e-07
have O 0 2.4695347633496567e-07
identified O 0 5.033220986661036e-07
a O 0 2.6403185415802e-07
new O 0 1.03720060451451e-06
locus O 0 2.6358118702773936e-05
involved O 0 4.690547484642593e-06
in O 0 3.8591297197854146e-05
progressive O 1 0.9999853372573853
liver B-Disease 1 1.0
disease I-Disease 1 0.9999967813491821
. O 0 0.00026319618336856365

We O 0 7.945366087369621e-05
examined O 0 7.951604493428022e-05
whether O 0 7.70005863159895e-06
the O 0 4.986883141100407e-06
WD B-Disease 1 0.6599346399307251
gene O 0 1.615088331163861e-05
ATP7B O 0 0.001423086505383253
was O 0 2.049509475909872e-06
also O 0 4.644892612759577e-07
causative O 0 3.2125533380167326e-06
for O 0 7.092570513123064e-07
CT B-Disease 0 0.18010026216506958
by O 0 5.359628971746133e-07
investigating O 0 4.243073817633558e-06
the O 0 1.3487270962286857e-06
chromosomal O 0 0.0001556022180011496
co O 0 9.088590741157532e-05
- O 0 1.0644682333804667e-05
localization O 0 2.094481260428438e-06
of O 0 2.2032050139841886e-07
ATP7B O 0 5.81960630370304e-05
and O 0 4.150928702983947e-07
C04107 O 0 5.5811005950090475e-06
, O 0 2.124843945239263e-07
using O 0 3.9294167208936415e-07
fluorescence O 0 5.4874162742635235e-06
in O 0 9.792319133339333e-07
situ O 0 1.0765003025881015e-05
hybridization O 0 1.4877942703606095e-05
( O 0 2.9521240776375635e-06
FISH O 0 8.127406545099802e-06
) O 0 5.7040656429308e-06
. O 0 1.8237993572256528e-05

C04107 O 0 0.004011623561382294
is O 0 3.0067289117141627e-05
an O 0 7.5343823482398875e-06
anonymous O 0 2.938850775535684e-05
microsatellite O 0 0.00023284506460186094
marker O 0 3.948857920477167e-05
closely O 0 2.788790880003944e-05
linked O 0 5.616198541247286e-05
to O 0 2.817355743900407e-05
CT B-Disease 1 0.995941162109375
. O 0 0.0001046892284648493

However O 0 0.00018381646077614278
, O 0 2.860954737116117e-05
BAC O 0 0.00020220634178258479
clones O 0 2.5230903702322394e-05
containing O 0 3.883584668074036e-06
ATP7B O 0 4.305344555177726e-05
and O 0 1.202967041535885e-06
C04107 O 0 1.2783267266058829e-05
mapped O 0 4.71208613816998e-06
to O 0 6.552646709678811e-07
the O 0 7.525754313064681e-07
canine O 0 2.328730988665484e-05
chromosome O 0 6.468087121902499e-06
regions O 0 1.7277478718824568e-06
CFA22q11 O 0 1.7210815713042393e-05
and O 0 6.928515290383075e-07
CFA10q26 O 0 1.6828525986056775e-05
, O 0 3.749414645426441e-07
respectively O 0 1.045861949933169e-06
, O 0 3.1435544656233105e-07
demonstrating O 0 1.1962425787714892e-06
that O 0 6.321626528915658e-07
WD B-Disease 0 0.28096678853034973
cannot O 0 2.444125584588619e-06
be O 0 6.099671168158238e-07
homologous O 0 1.470991537644295e-05
to O 0 7.289563200174598e-06
CT B-Disease 1 0.9306755661964417
. O 0 4.69084334326908e-05

The O 0 5.883139601792209e-05
copper O 0 9.523629705654457e-05
transport O 0 2.7155971110914834e-05
genes O 0 1.204628551931819e-05
CTR1 O 0 4.309998621465638e-05
and O 0 9.818315902521135e-07
CTR2 O 0 7.641743286512792e-05
were O 0 3.976421965035115e-07
also O 0 1.981006789719686e-07
excluded O 0 6.596020512006362e-07
as O 0 1.0009580364567228e-07
candidate O 0 7.783195314914337e-07
genes O 0 3.978902611834201e-07
for O 0 3.0213655577426834e-07
CT B-Disease 1 0.8397036194801331
since O 0 1.0600709856589674e-06
they O 0 2.8153689868304355e-07
both O 0 4.345251340964751e-07
mapped O 0 6.90744309395086e-06
to O 0 2.858995003407472e-06
canine O 0 0.00013271225907374173
chromosome O 0 9.227582631865516e-05
region O 0 3.3511802030261606e-05
CFA11q22 O 0 0.0005892320768907666
. O 0 6.445861799875274e-05

2 O 0 0.0010505708632990718
- O 0 0.0022332442458719015
22 O 0 0.00035187305184081197
. O 0 0.00014396112237591296

5 O 0 0.00545497564598918
. O 0 0.0014687868533656001

A O 0 9.125829092226923e-05
transcribed O 0 4.8524765588808805e-05
sequence O 0 1.3535459402191918e-05
identified O 0 4.905693458567839e-06
from O 0 5.012584551877808e-07
the O 0 5.616730049951002e-07
C04107 O 0 2.568253876233939e-05
- O 0 8.101435923890676e-06
containing O 0 6.170288884277397e-07
BAC O 0 7.026932962617138e-06
was O 0 4.5699025008616445e-07
found O 0 2.255099929016069e-07
to O 0 1.0267552141840497e-07
be O 0 8.864260081509201e-08
homologous O 0 6.69090866267652e-07
to O 0 1.2247957670297183e-07
a O 0 2.85181727122108e-07
gene O 0 1.1303052360744914e-06
expressed O 0 5.348304057406494e-07
from O 0 3.883311876506923e-07
human O 0 7.296994226635434e-07
chromosome O 0 4.6977279453130905e-06
2p13 O 0 5.716948362533003e-05
- O 0 8.897209772840142e-05
p16 O 0 1.3082840268907603e-05
, O 0 4.6163825118128443e-07
a O 0 4.7070687969608116e-07
region O 0 7.627518812114431e-07
devoid O 0 1.793272986105876e-06
of O 0 2.952170348180516e-07
any O 0 1.2028363016725052e-06
positional O 0 3.9793190808268264e-05
candidate O 0 8.835960761643946e-05
genes O 0 6.0340975323924795e-05
. O 0 5.0593549531186e-05

Molecular O 0 0.00036749214632436633
analysis O 0 3.154778460157104e-05
of O 0 2.496484967196011e-06
the O 0 1.6072056041593896e-06
APC B-Disease 0 1.9329054339323193e-05
gene O 0 2.928843287008931e-06
in O 0 6.018325393597479e-07
205 O 0 3.39284747497004e-06
families O 0 1.6459500784549164e-06
: O 0 6.36977404155914e-07
extended O 0 2.354147227379144e-06
genotype O 0 0.03087957762181759
- O 0 0.016219139099121094
phenotype O 0 0.00012544584751594812
correlations O 0 8.615955266577657e-06
in O 0 6.34413595435035e-07
FAP B-Disease 0 6.5106833062600344e-06
and O 0 2.639663989612018e-07
evidence O 0 3.104475467807788e-07
for O 0 1.2040375452215812e-07
the O 0 1.7287106857111212e-07
role O 0 5.198055532673607e-07
of O 0 2.548669897350919e-07
APC B-Disease 0 1.135943784902338e-05
amino O 0 3.299587433502893e-06
acid O 0 9.447726370126475e-06
changes O 0 1.828864151320886e-05
in O 0 0.08175603300333023
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
predisposition O 1 0.7678412199020386
. O 0 0.0001639761176193133

BACKGROUND O 0 0.0017310625407844782
/ O 0 0.0005333853769116104
AIMS O 0 2.9259594157338142e-05
The O 0 2.065820581265143e-06
development O 0 2.8873682822450064e-06
of O 0 7.71246268413961e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
and O 0 2.658175844771904e-06
a O 0 9.440632879886834e-07
variable O 0 2.4347664293600246e-06
range O 0 1.0468647815287113e-06
of O 0 4.40833645143357e-07
extracolonic O 0 0.004813106264919043
manifestations O 0 0.0003002989396918565
in O 0 0.0035474183969199657
familial B-Disease 1 0.9999998807907104
adenomatous I-Disease 1 0.9999998807907104
polyposis I-Disease 1 1.0
( O 0 4.60384035250172e-05
FAP B-Disease 0 0.00023958884412422776
) O 0 9.116258183894388e-07
is O 0 1.3001454135519452e-07
the O 0 1.5325916535857687e-07
result O 0 3.434087432196975e-07
of O 0 9.666246825190683e-08
the O 0 8.186784725694451e-07
dominant O 0 6.217582267709076e-05
inheritance O 0 0.0030179305467754602
of O 0 4.4055683247279376e-05
adenomatous B-Disease 1 1.0
polyposis I-Disease 1 0.9999992847442627
coli I-Disease 1 0.9999256134033203
( O 0 2.0114284779992886e-05
APC B-Disease 0 7.591916801175103e-05
) O 0 7.064965757308528e-06
gene O 0 2.647667861310765e-05
mutations O 0 0.00010009692778112367
. O 0 5.0341459427727386e-05

In O 0 3.542699050740339e-05
this O 0 3.335636847623391e-06
study O 0 3.498678324831417e-06
, O 0 4.4389133790900814e-07
direct O 0 8.067996759564267e-07
mutation O 0 2.793161002045963e-06
analysis O 0 5.520450372387131e-07
of O 0 9.979918047520187e-08
the O 0 3.8504211374856823e-07
APC B-Disease 0 5.365696779335849e-06
gene O 0 1.111500296246959e-06
was O 0 4.739496262118337e-07
performed O 0 5.174009629627108e-07
to O 0 4.252380847447057e-07
determine O 0 2.3855982362874784e-06
genotype O 0 0.0014259183080866933
- O 0 0.0004879315383732319
phenotype O 0 3.9647886296734214e-05
correlations O 0 3.1802655939827673e-06
for O 0 2.391702480508684e-07
nine O 0 6.142917072793352e-07
extracolonic O 0 1.75462118932046e-05
manifestations O 0 1.8117833633368718e-06
and O 0 2.4673360599081207e-07
to O 0 2.182472513823086e-07
investigate O 0 1.3950028687759186e-06
the O 0 4.96506459057855e-07
incidence O 0 8.458870070171542e-06
of O 0 6.738924867022433e-07
APC B-Disease 0 3.36610282829497e-05
mutations O 0 1.5114149391592946e-05
in O 0 2.4751705041126115e-06
non O 0 7.646642916370183e-05
- O 1 0.9985640645027161
FAP O 1 0.9998364448547363
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999978542327881
. O 0 0.000197505098185502

METHODS O 0 0.00019978664931841195
The O 0 1.2194048395031132e-05
APC B-Disease 0 3.872047091135755e-05
gene O 0 1.2380121916066855e-05
was O 0 2.31730723498913e-06
analysed O 0 5.329136911313981e-06
in O 0 6.773402105864079e-07
190 O 0 4.000268745585345e-06
unrelated O 0 6.990785095695173e-06
FAP B-Disease 0 1.191568844660651e-05
and O 0 6.959919005566917e-07
15 O 0 1.3425443512460333e-06
non O 0 1.1316229574731551e-05
- O 1 0.9987016916275024
FAP O 1 0.9999727010726929
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
patients O 0 0.00011298112804070115
using O 0 2.468327465976472e-06
denaturing O 0 0.0009904229082167149
gradient O 0 0.00013060217315796763
gel O 0 0.0011572084622457623
electrophoresis O 0 4.0676262869965285e-05
, O 0 5.168678285372152e-07
the O 0 3.5580228541221004e-07
protein O 0 1.4078868844080716e-06
truncation O 0 8.213896762754302e-06
test O 0 3.207024974472006e-06
, O 0 5.323852292349329e-07
and O 0 1.2176163863841793e-06
direct O 0 6.622387900279136e-06
sequencing O 0 8.922680717660114e-05
. O 0 5.703308852389455e-05

RESULTS O 0 0.0004603403795044869
Chain O 0 7.021448982413858e-05
terminating O 0 3.029920299013611e-05
signals O 0 1.093122955353465e-05
were O 0 7.271430035871163e-07
only O 0 3.915654360753251e-07
identified O 0 1.21566483812785e-06
in O 0 9.055879104380438e-07
patients O 0 2.5186311177094467e-05
belonging O 0 1.887387384158501e-06
to O 0 3.571315119188512e-07
the O 0 1.0699421864046599e-06
FAP B-Disease 0 0.0010913194855675101
group O 0 5.986937139823567e-06
( O 0 1.4874616454108036e-06
105 O 0 1.011834592645755e-05
patients O 0 9.809144830796868e-05
) O 0 1.0560384907876141e-05
. O 0 2.1674606614396907e-05

Amino O 0 0.0004024744557682425
acid O 0 0.00014782507787458599
changes O 0 1.0719598321884405e-05
were O 0 7.856458523747278e-07
identified O 0 8.23547679829062e-07
in O 0 1.9413313623317663e-07
four O 0 6.727514119120315e-07
patients O 0 1.9063865693169646e-05
, O 0 1.5130846975353052e-07
three O 0 1.2923203485115664e-07
of O 0 9.928407962433994e-08
whom O 0 2.5475160327914637e-06
belonged O 0 1.1652977036646917e-06
to O 0 2.693698775146913e-07
the O 0 7.433339987983345e-07
non O 0 6.0968254729232285e-06
- O 0 0.0019397498108446598
FAP O 0 0.0001368507946608588
group O 0 2.5060453481273726e-05
of O 0 0.0008372574811801314
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 1 0.8244547843933105
. O 0 0.00011297078162897378

Genotype O 1 0.992999792098999
- O 1 0.9780069589614868
phenotype O 0 0.04534432291984558
correlations O 0 0.0001313455286435783
identified O 0 1.0765033039206173e-05
significant O 0 1.975613713511848e-06
differences O 0 3.5111797842546366e-06
in O 0 6.407720434253861e-07
the O 0 3.9416110553247563e-07
nature O 0 5.718395073017746e-07
of O 0 1.377495379983884e-07
certain O 0 6.607920681744872e-07
extracolonic O 0 0.00012456710101105273
manifestations O 0 1.0045984708995093e-05
in O 0 3.8719513213436585e-06
FAP B-Disease 0 0.010329830460250378
patients O 0 2.1290283257258125e-05
belonging O 0 1.7122044937423198e-06
to O 0 7.329124969146505e-07
three O 0 2.394859620835632e-06
mutation O 0 5.3696938266512007e-05
subgroups O 0 8.871572936186567e-05
. O 0 3.312000262667425e-05

CONCLUSIONS O 0 0.00042644134373404086
Extended O 0 0.0001313112152274698
genotype O 0 0.011756738647818565
- O 0 0.0033409483730793
phenotype O 0 7.10891981725581e-05
correlations O 0 5.986389169265749e-06
made O 0 5.900935207137081e-07
in O 0 2.2501374985495204e-07
this O 0 2.293362371119656e-07
study O 0 9.985398037315463e-07
may O 0 5.350186711439164e-07
have O 0 7.472517893347685e-08
the O 0 5.715767770197999e-08
potential O 0 1.7194128076880588e-07
to O 0 9.606383599702895e-08
determine O 0 1.8745996044344793e-07
the O 0 5.0981483923351334e-08
most O 0 1.0612306766688562e-07
appropriate O 0 2.2780253061682743e-07
surveillance O 0 7.049963528515946e-07
and O 0 3.325518775909586e-07
prophylactic O 0 6.446642510127276e-05
treatment O 0 4.1135557694360614e-05
regimens O 0 2.9678036298719235e-05
for O 0 3.761176117222931e-07
those O 0 1.2467600072341156e-06
patients O 0 1.9127202904201113e-05
with O 0 7.548288181169482e-07
mutations O 0 1.4493660273728892e-05
associated O 0 1.3216166507845628e-06
with O 0 8.009250791474187e-07
life O 0 0.00011281857587164268
threatening O 0 0.031958915293216705
conditions O 0 0.0037303962744772434
. O 0 6.924058106960729e-05

This O 0 2.40186091104988e-05
study O 0 1.5144637472985778e-05
also O 0 1.5721382169431308e-06
provided O 0 1.008100525723421e-06
evidence O 0 8.479478310619015e-07
for O 0 3.7954140452711727e-07
the O 0 5.259028057480464e-07
pathological O 0 9.382020834891591e-06
nature O 0 6.888470807098201e-07
of O 0 1.9841152720800892e-07
amino O 0 2.0546369796647923e-06
acid O 0 6.6092461565858684e-06
changes O 0 1.9057312101722346e-06
in O 0 7.665613566132379e-07
APC O 0 8.972690920927562e-06
associated O 0 8.304383527502068e-07
with O 0 2.653738420121954e-07
both O 0 1.1230534937567427e-06
FAP B-Disease 0 2.2737849576515146e-05
and O 0 2.196748482674593e-06
non O 0 5.7928074966184795e-05
- O 1 0.9988724589347839
FAP O 1 0.9999589920043945
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 0.4110085070133209
. O 0 2.7817841328214854e-05
. O 0 5.580770084634423e-05

Inherited B-Disease 1 0.9999856948852539
colorectal I-Disease 1 1.0
polyposis I-Disease 1 0.9999966621398926
and O 1 0.9825888872146606
cancer B-Disease 1 0.9999362230300903
risk O 0 8.683485793881118e-05
of O 0 1.431392320228042e-06
the O 0 7.081370313244406e-06
APC O 0 0.0003509394300635904
I1307K O 0 0.0006493725813925266
polymorphism O 0 0.0006915392004884779
. O 0 9.292679169448093e-05

Germ O 0 0.2103787362575531
- O 0 0.0013385153142735362
line O 0 1.6053998479037546e-05
and O 0 2.5962306153815007e-06
somatic O 0 2.2401080059353262e-05
truncating O 0 6.830396159784868e-05
mutations O 0 8.774767593422439e-06
of O 0 2.2109087183252996e-07
the O 0 4.880942583440628e-07
APC B-Disease 0 5.683995823346777e-06
gene O 0 1.6290547364405938e-06
are O 0 2.0404493739079044e-07
thought O 0 1.1517852271936135e-06
to O 0 1.4447363128056168e-06
initiate O 0 0.003269695909693837
colorectal B-Disease 1 0.9999997615814209
tumor I-Disease 0 0.20643772184848785
formation O 0 4.60796472907532e-05
in O 0 0.0006764111458323896
familial B-Disease 1 0.9999997615814209
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
syndrome I-Disease 1 0.9999996423721313
and O 0 0.0001662861177464947
sporadic O 1 0.8560603260993958
colorectal O 1 1.0
carcinogenesis O 1 0.9987934827804565
, O 0 3.8560403481824324e-05
respectively O 0 0.00014933489728718996
. O 0 7.481838838430122e-05

Recently O 0 0.00045282061910256743
, O 0 1.5199531844700687e-05
an O 0 6.457301878981525e-06
isoleucine O 0 0.006154429633170366
- O 0 0.017351126298308372
- O 0 0.00012779854296240956
> O 0 2.4214348741224967e-05
lysine O 0 1.1400546100048814e-05
polymorphism O 0 1.0918247426161543e-05
at O 0 1.0671856216504239e-06
codon O 0 5.1847064241883345e-06
1307 O 0 3.007216400874313e-05
( O 0 7.050548447296023e-07
I1307K O 0 3.580332077035564e-06
) O 0 1.2836875384891755e-07
of O 0 4.8399208196769905e-08
the O 0 2.55858907394213e-07
APC B-Disease 0 3.84490203941823e-06
gene O 0 1.2640525710594375e-06
has O 0 1.7565989196555165e-07
been O 0 2.2070705085752707e-07
identified O 0 4.1136877371172886e-07
in O 0 1.5084252424912847e-07
6 O 0 7.120092391232902e-07
% O 0 5.993798595227418e-07
- O 0 1.5203939256025478e-05
7 O 0 7.189429993559315e-07
% O 0 2.5841339379439887e-07
of O 0 1.3618209493415634e-07
the O 0 1.2461086953408085e-06
Ashkenazi O 0 0.00046018962166272104
Jewish O 0 3.832723086816259e-05
population O 0 2.1160654796403833e-05
. O 0 3.951506005250849e-05

To O 0 5.6232616771012545e-05
assess O 0 8.725502993911505e-05
the O 0 5.2409609452297445e-06
risk O 0 6.1368427850538865e-06
of O 0 3.6333091202322976e-07
this O 0 6.588438736798707e-07
common O 0 4.673669081967091e-06
APC B-Disease 0 1.3768317330686841e-05
allelic O 0 2.879018211388029e-05
variant O 0 6.347109592752531e-05
in O 0 1.554847949591931e-05
colorectal O 1 0.9999980926513672
carcinogenesis O 0 0.12058860808610916
, O 0 1.952003913174849e-06
we O 0 4.891800244877231e-07
have O 0 2.7752307119044417e-07
analyzed O 0 1.326796905232186e-06
a O 0 5.036937409386155e-07
large O 0 1.2232087556185434e-06
cohort O 0 2.0515533833531663e-05
of O 0 6.372678740262927e-07
unselected O 0 0.000838165869936347
Ashkenazi O 0 0.00017479463713243604
Jewish O 0 5.213811618887121e-06
subjects O 0 3.7665063246095087e-06
with O 0 1.4909724086464848e-06
adenomatous B-Disease 1 0.6369901299476624
polyps I-Disease 0 0.0005072460044175386
and O 0 1.2224892316226033e-06
. O 0 5.691470050805947e-06
or O 0 0.34212636947631836
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999994039535522
, I-Disease 0 1.2095241572751547e-06
for O 0 8.447032087133266e-07
the O 0 3.98930887968163e-06
APC O 0 0.0001810023677535355
I1307K O 0 0.00047413402353413403
polymorphism O 0 0.0006565955118276179
. O 0 6.869262142572552e-05

The O 0 5.6799373851390556e-05
APC O 0 0.00015237365732900798
I1307K O 0 9.525118366582319e-05
allele O 0 4.603304842021316e-05
was O 0 3.992955043941038e-06
identified O 0 2.0899401533824857e-06
in O 0 4.063250003127905e-07
48 O 0 1.5730665836599655e-06
( O 0 3.895426061717444e-07
10 O 0 2.3561972284369403e-07
. O 0 2.987202663007338e-07
1 O 0 6.122370450611925e-07
% O 0 7.05982017734641e-07
) O 0 5.765240871369315e-07
of O 0 1.2414706134222797e-06
476 O 0 0.0021085557527840137
patients O 0 0.0012981019681319594
. O 0 5.998560300213285e-05

Compared O 0 0.00011880336387548596
with O 0 1.9170838641002774e-06
the O 0 8.482309681312472e-07
frequency O 0 2.0724348814837867e-06
in O 0 3.0798759098615847e-07
two O 0 1.9965173692071403e-07
separate O 0 8.359281196135271e-07
population O 0 4.4660976072918857e-07
control O 0 1.050321884576988e-06
groups O 0 2.579372164746019e-07
, O 0 1.0914773440617864e-07
the O 0 2.3645687008411187e-07
APC O 0 5.918411716265837e-06
I1307K O 0 2.7570746169658378e-05
allele O 0 6.838731678726617e-06
is O 0 2.065826976149765e-07
associated O 0 3.898908289556857e-07
with O 0 1.6399805247147015e-07
an O 0 2.8055379175384587e-07
estimated O 0 1.8451967207511188e-06
relative O 0 1.4983823348302394e-05
risk O 0 9.799992767511867e-06
of O 0 1.6894283589863335e-06
1 O 0 1.039385733747622e-05
. O 0 3.14070020976942e-05

5 O 0 0.0007161934627220035
- O 0 0.0020784917287528515
1 O 0 0.00011712175910361111
. O 0 8.818822243483737e-05

7 O 0 0.0005491958581842482
for O 0 0.00021974417904857546
colorectal B-Disease 1 0.9999992847442627
neoplasia I-Disease 1 0.9749400019645691
( O 0 1.6868261809577234e-05
both O 0 6.170128017402021e-06
P O 1 0.7553226351737976
= O 0 0.0014315149746835232
. O 0 6.429625045711873e-06
01 O 0 0.0003766813315451145
) O 0 1.1816558981081471e-05
. O 0 2.7906558898393996e-05

Furthermore O 0 0.0002548533084336668
, O 0 1.1425536285969429e-05
compared O 0 6.382948413374834e-06
with O 0 9.290715752285905e-07
noncarriers O 0 6.90682718413882e-05
, O 0 1.4228397731130826e-06
APC O 0 8.13781389297219e-06
I1307K O 0 1.5432529835379682e-05
carriers O 0 2.604247811177629e-06
had O 0 4.0118922584042593e-07
increased O 0 3.516168476380699e-07
numbers O 0 3.951916767164221e-07
of O 0 3.20784607765745e-07
adenomas B-Disease 0 0.08618678897619247
and O 0 0.007504278793931007
colorectal B-Disease 1 1.0
cancers I-Disease 1 0.9527378678321838
per O 0 4.8252372835122515e-06
patient O 0 0.0003866403712891042
( O 0 2.579728970886208e-06
P O 0 0.09290598332881927
= O 0 1.2587099263328128e-05
. O 0 2.9913078947174654e-07
03 O 0 6.2284561863634735e-06
) O 0 1.169435179804168e-07
, O 0 5.8925735402226564e-08
as O 0 4.444860834951214e-08
well O 0 9.509835052767812e-08
as O 0 1.843119861177911e-07
a O 0 5.410299763752846e-07
younger O 0 1.1821936823253054e-05
age O 0 6.662950454483507e-06
at O 0 1.2711614544969052e-05
diagnosis O 0 0.4458375871181488
. O 0 7.704524614382535e-05

We O 0 3.9544349419884384e-05
conclude O 0 2.1306694179656915e-05
that O 0 1.2376287941151531e-06
the O 0 1.1985903256572783e-06
APC O 0 1.1494027603475843e-05
I1307K O 0 2.3181375581771135e-05
variant O 0 1.3082316399959382e-05
leads O 0 3.0307326142064994e-06
to O 0 8.168753993231803e-07
increased O 0 6.387156190612586e-06
adenoma B-Disease 1 0.996220052242279
formation O 0 3.2189072953769937e-06
and O 0 4.2540358435871894e-07
directly O 0 4.224103804517654e-07
contributes O 0 5.199790962251427e-07
to O 0 2.8759009751411213e-07
3 O 0 5.343894144971273e-07
% O 0 4.847329932999855e-07
- O 0 4.635839104594197e-06
4 O 0 4.927986196889833e-07
% O 0 1.8419706293570925e-07
of O 0 1.8183386885084474e-07
all O 0 1.3284719670991763e-06
Ashkenazi O 1 0.5447172522544861
Jewish O 1 0.9985407590866089
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999991655349731
. O 0 0.00016447817324660718

The O 0 3.557538366294466e-05
estimated O 0 1.5842246284591965e-05
relative O 0 1.7372285583405755e-05
risk O 0 1.117273041018052e-05
for O 0 7.520688996009994e-07
carriers O 0 3.823485712928232e-06
may O 0 8.898832675185986e-07
justify O 0 1.5679668194934493e-06
specific O 0 5.752789888902043e-07
clinical O 0 9.172365025733598e-06
screening O 0 1.361886234008125e-06
for O 0 8.57789643760043e-08
the O 0 1.0121700455556493e-07
360 O 0 5.307832680045976e-07
, O 0 1.4935524461634486e-07
000 O 0 2.8229129611645476e-07
Americans O 0 2.2279006373082666e-07
expected O 0 1.9866864420237107e-07
to O 0 1.2800202853213705e-07
harbor O 0 8.312188128911657e-07
this O 0 7.791278022750703e-08
allele O 0 8.785014529166801e-07
, O 0 1.082780940464545e-07
and O 0 1.7347667835565517e-07
genetic O 0 1.2592397524713306e-06
testing O 0 5.698274776477774e-07
in O 0 9.578099025020492e-08
the O 0 1.0671760009017817e-07
setting O 0 2.0481660101268062e-07
of O 0 1.2074687560925668e-07
long O 0 5.963550393062178e-06
- O 0 0.0010926889954134822
term O 0 1.8861834178096615e-05
- O 0 2.5773812012630515e-05
outcome O 0 3.004676500495407e-06
studies O 0 2.3571508336317493e-06
may O 0 1.32995126023161e-06
impact O 0 2.2617471131525235e-06
significantly O 0 9.23069819691591e-05
on O 0 0.21887557208538055
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
prevention O 0 7.924104284029454e-05
in O 0 1.6139250647029257e-06
this O 0 2.7149912966706324e-06
population O 0 1.4336205822473858e-05
. O 0 2.3645925466553308e-05

Localization O 0 0.00022232644550967962
of O 0 7.269944489962654e-06
human O 0 9.695505468698684e-06
BRCA1 O 0 9.170879638986662e-05
and O 0 1.1017026508852723e-06
its O 0 6.316118970062234e-07
loss O 0 1.055739357980201e-05
in O 0 5.963272542430786e-07
high O 0 3.977722371928394e-06
- O 0 0.0003809560148511082
grade O 0 1.0501343240321148e-05
, O 0 1.6042546349126496e-06
non B-Disease 0 1.301204065384809e-05
- I-Disease 1 0.7518715858459473
inherited I-Disease 1 0.9873348474502563
breast I-Disease 1 0.9991579055786133
carcinomas I-Disease 1 0.999988317489624
. O 0 0.00014815060421824455

Although O 0 6.963457417441532e-05
the O 0 4.6350082811841276e-06
link O 0 1.0600734640320297e-05
between O 0 1.1996309012829443e-06
the O 0 4.585991973726777e-06
BRCA1 O 1 0.9688403010368347
tumour B-Disease 1 0.99997878074646
- O 0 0.00013173487968742847
suppressor O 0 3.054962508031167e-05
gene O 0 4.123595772398403e-06
and O 0 1.612525011296384e-06
hereditary B-Disease 0 0.45228633284568787
breast I-Disease 1 0.9999120235443115
and I-Disease 1 0.9997487664222717
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
is O 0 4.7012721893224807e-07
established O 0 2.1287280560500221e-07
, O 0 7.748094077442147e-08
the O 0 9.029631087287271e-08
role O 0 3.2206224886977e-07
, O 0 1.4394206004908483e-07
if O 0 6.966866550328632e-08
any O 0 5.1294282599201324e-08
, O 0 6.049917544714845e-08
of O 0 1.2902835067052365e-07
BRCA1 O 0 8.774146408541128e-05
in O 0 1.5533821624558186e-06
non B-Disease 0 2.2456608348875307e-05
- I-Disease 1 0.8583807349205017
familial I-Disease 1 0.9772565364837646
cancers I-Disease 1 0.936699628829956
is O 0 4.9549971663509496e-06
unclear O 0 3.205093162250705e-05
. O 0 3.638417547335848e-05

BRCA1 O 1 0.9003564119338989
mutations O 0 0.0014913651393726468
are O 0 7.311676199606154e-06
rare O 0 6.620954081881791e-06
in O 0 1.6128680044857902e-06
sporadic B-Disease 0 0.0012856690445914865
cancers I-Disease 1 0.9813057780265808
, O 0 1.216430177919392e-06
but O 0 1.1082391893069143e-06
loss O 0 4.972882379661314e-06
of O 0 3.324541921756463e-07
BRCA1 O 0 0.0007861568010412157
resulting O 0 3.797223826040863e-06
from O 0 5.60824048534414e-07
reduced O 0 1.6061866290328908e-06
expression O 0 1.2176558357168688e-06
or O 0 4.234324251228827e-07
incorrect O 0 1.8349276160734007e-06
subcellular O 0 9.860618774837349e-06
localization O 0 4.486063517106231e-06
is O 0 1.9588574673434778e-07
postulated O 0 1.3215915259934263e-06
to O 0 1.7812858743582183e-07
be O 0 9.022176783446412e-08
important O 0 2.0018177337988163e-07
in O 0 3.6868704000880825e-07
non B-Disease 0 3.378820338184596e-06
- I-Disease 0 0.006341270636767149
familial I-Disease 1 0.6620945334434509
breast I-Disease 1 0.9998238682746887
and I-Disease 1 0.9958368539810181
ovarian I-Disease 1 1.0
cancers I-Disease 1 0.9999980926513672
. O 0 0.00019247180898673832

Epigenetic O 0 0.0021025643218308687
loss O 0 0.012710602954030037
, O 0 5.363179752748692e-06
however O 0 2.057619440165581e-06
, O 0 4.6757725158386165e-07
has O 0 2.571811705820437e-07
not O 0 1.7862225831777323e-07
received O 0 4.31284263413545e-07
general O 0 4.029745923617156e-07
acceptance O 0 2.0705622318928363e-06
due O 0 6.365729632307193e-07
to O 0 2.029354817523199e-07
controversy O 0 6.164960382193385e-07
regarding O 0 2.951398982986575e-07
the O 0 1.4824017569026182e-07
subcellular O 0 4.588441697706003e-06
localization O 0 2.5975382413889747e-06
of O 0 2.4911358309509524e-07
BRCA1 O 0 1.7210750229423866e-05
proteins O 0 5.551409572035482e-07
, O 0 1.3137133691998315e-07
reports O 0 1.4412613325021084e-07
of O 0 3.437842011067005e-08
which O 0 8.823960229165095e-08
have O 0 9.037384529619885e-08
ranged O 0 4.0872839690564433e-07
from O 0 9.067981210364451e-08
exclusively O 0 2.0906865927372564e-07
nuclear O 0 1.067224388862087e-06
, O 0 7.443711780297235e-08
to O 0 1.2170411878287268e-07
conditionally O 0 2.7166981908521848e-06
nuclear O 0 1.2069662034264184e-06
, O 0 1.2547715755317768e-07
to O 0 1.9331616840645438e-07
the O 0 5.101903184367984e-07
ER O 0 0.0002116797841154039
/ O 0 7.597110197821166e-06
golgi O 0 0.0001507337437942624
, O 0 3.921996665212646e-07
to O 0 4.147161689616041e-07
cytoplasmic O 0 5.834946932736784e-06
invaginations O 0 2.2793714379076846e-05
into O 0 2.1326468413462862e-06
the O 0 3.55660176865058e-06
nucleus O 0 4.591966717271134e-05
. O 0 4.2482501157792285e-05

In O 0 2.0437775674508885e-05
an O 0 2.2166900635056663e-06
attempt O 0 6.194892193889245e-06
to O 0 8.6380998709501e-07
resolve O 0 1.5877373016337515e-06
this O 0 1.5098011374448106e-07
issue O 0 2.954716364911292e-07
, O 0 1.420311122046769e-07
we O 0 2.5361831035297655e-07
have O 0 4.0508803067496046e-07
comprehensively O 0 1.50472314999206e-05
characterized O 0 1.1457649634394329e-05
19 O 0 4.7236940190487076e-06
anti O 0 2.7757683710660785e-05
- O 0 0.0007804682245478034
BRCA1 O 0 0.0005742194480262697
antibodies O 0 0.00016193535702768713
. O 0 5.214713382883929e-05

These O 0 6.479949661297724e-05
reagents O 0 0.00021492605446837842
detect O 0 7.475021993741393e-05
a O 0 3.401620233489666e-06
220 O 0 7.434101917169755e-06
- O 0 2.179836155846715e-05
kD O 0 6.859823042759672e-05
protein O 0 2.630873041198356e-06
localized O 0 3.412817704884219e-06
in O 0 4.781162488143309e-07
discrete O 0 2.5602421374060214e-06
nuclear O 0 3.925045348296408e-06
foci O 0 3.6315948364062933e-06
in O 0 3.125168177575688e-07
all O 0 2.007131882919566e-07
epithelial O 0 8.353770681424066e-06
cell O 0 1.2841574971389491e-05
lines O 0 1.9134017748001497e-06
, O 0 2.3810515870081872e-07
including O 0 2.3839326956931473e-07
those O 0 4.4092112716498377e-07
derived O 0 3.324011004224303e-06
from O 0 6.544130883412436e-06
breast B-Disease 1 0.940915584564209
malignancies I-Disease 1 0.9262394309043884
. O 0 8.56986443977803e-05

Immunohistochemical O 0 0.031537771224975586
staining O 0 0.0036900434643030167
of O 0 2.0434345060493797e-05
human O 0 4.644368891604245e-05
breast O 0 0.3278942406177521
specimens O 0 1.3306236724019982e-05
also O 0 1.8511327652959153e-06
revealed O 0 1.903835618577432e-05
BRCA1 O 0 0.00025218285736627877
nuclear O 0 1.6457634046673775e-05
foci O 0 3.1877978472039104e-05
in O 0 5.489588147611357e-06
benign O 1 0.6047553420066833
breast O 1 0.5549309849739075
, O 0 7.228208687592996e-06
invasive B-Disease 0 0.0011010854505002499
lobular I-Disease 1 0.9998270869255066
cancers I-Disease 0 0.47996655106544495
and O 0 5.97492453380255e-06
low B-Disease 0 0.0021408223547041416
- I-Disease 1 0.8487875461578369
grade I-Disease 0 0.09265439212322235
ductal I-Disease 1 0.9995744824409485
carcinomas I-Disease 1 0.9999953508377075
. O 0 0.00017678389849606901

Conversely O 0 0.0005927056772634387
, O 0 1.847579187597148e-05
BRCA1 O 0 0.00012722682731691748
expression O 0 4.761582204082515e-06
was O 0 1.468308028051979e-06
reduced O 0 1.439738070985186e-06
or O 0 5.292082505548024e-07
undetectable O 0 4.8317574510292616e-06
in O 0 1.8060060824609536e-07
the O 0 2.2609140160056995e-07
majority O 0 6.32855176263547e-07
of O 0 9.851164151086778e-08
high O 0 4.037064627482323e-06
- O 0 0.000952141301240772
grade O 0 1.0729702808021102e-05
, O 0 1.8199536953034112e-06
ductal B-Disease 1 0.8368105888366699
carcinomas I-Disease 1 0.999994158744812
, O 0 6.751944852112501e-07
suggesting O 0 1.0591231784928823e-06
that O 0 1.0602231981238219e-07
absence O 0 4.38651653666966e-07
of O 0 1.8008945801284426e-07
BRCA1 O 0 0.0007965299300849438
may O 0 1.3207371694079484e-06
contribute O 0 1.9863870193148614e-07
to O 0 1.1211481876216567e-07
the O 0 1.304479866348629e-07
pathogenesis O 0 2.9960006031615194e-06
of O 0 9.470880968365236e-08
a O 0 4.353696283487807e-07
significant O 0 1.028932842928043e-06
percentage O 0 3.222790155632538e-06
of O 0 1.0251442290609702e-06
sporadic B-Disease 0 0.033515553921461105
breast I-Disease 1 0.9999881982803345
cancers I-Disease 1 0.9967843294143677
. O 0 2.6217754566459917e-05
. O 0 4.167889346717857e-05

